{"source_ent": {"research_entity_id": "HPO:HP:0001621", "canonical_name": "Weak voice", "aliases": ["weak voice", "hypophonia", "soft voice"], "definition": "Weak artificial intelligence (weak AI), also known as narrow AI, is artificial intelligence that is focused on one narrow task.", "other_contexts": [], "par_relations": ["Abnormality of the voice"], "chd_relations": [], "syn_relations": ["Weak voice", "Weak voice"], "sib_relations": ["Weak voice", "Loss of voice", "Hoarse voice", "Weak cry", "Cat cry", "High pitched voice", "Nasal speech", "Dysphonia", "Speech articulation difficulties", "Hyponasal speech", "Abnormally low-pitched voice", "Weak voice"], "wiki_entities": ["Weak AI", "Arabic verbs", "Pronoun", "Cadence (music)", "Agnosticism", "Speech recognition", "Germanic weak verb", "Adjective", "Land of the Lustrous", "English grammar"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "MSH:C043295", "canonical_name": "paromomycin phosphotransferase", "aliases": ["paromomycin phosphotransferase"], "definition": "Neomycin is an aminoglycoside antibiotic found in many topical medications such as creams, ointments, and eyedrops.", "other_contexts": [], "par_relations": ["Phosphotransferases (Alcohol Group Acceptor)"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Neomycin"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "CPT:82024", "canonical_name": "Adrenocorticotropic hormone (ACTH)", "aliases": ["adrenocorticotropic hormone acth", "assay of acth", "adrenocorticotropic hormone (acth)", "adrenocorticotropic hormone (acth) level", "measurement of adrenocorticotropic hormone (acth)"], "definition": "Adrenocorticotropic hormone (ACTH, also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced and secreted by the anterior pituitary gland.", "other_contexts": [], "par_relations": ["Chemistry Procedures"], "chd_relations": [], "syn_relations": ["Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)"], "sib_relations": ["Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)", "ACTH stimulation panel; for adrenal insufficiency This panel must include the following: Cortisol (82533 x 2)", "Corticotropic releasing hormone (CRH) stimulation panel This panel must include the following: Cortisol (82533 x 6) Adrenocorticotropic hormone (ACTH) (82024 x 6)", "Combined rapid anterior pituitary evaluation panel This panel must include the following: Adrenocorticotropic hormone (ACTH) (82024 x 4) Luteinizing hormone (LH) (83002 x 4) Follicle stimulating hormone (FSH) (83001 x 4) Prolactin (84146 x 4) Human growth hormone (HGH) (83003 x 4) Cortisol (82533 x 4) Thyroid stimulating hormone (TSH) (84443 x 4)", "Irrigation of implanted venous access device for drug delivery systems", "Androsterone", "Bradykinin", "Methemalbumin", "Pregnenolone", "Sialic acid", "Vitamin K", "17-hydroxypregnenolone", "Mucin, synovial fluid (Ropes test)", "Alpha-fetoprotein (AFP)", "Unlisted chemistry procedure", "Chemiluminescent assay", "Osmolality", "Acetylcholinesterase", "Phosphatase, acid", "Albumin", "Aldolase", "Vasopressin (antidiuretic hormone, ADH)", "Phosphatase, alkaline", "Alpha-1-antitrypsin", "Ammonia", "Amniotic fluid scan (spectrophotometric)", "Amylase", "Angiotensin I - converting enzyme (ACE)", "Ascorbic acid (Vitamin C), blood", "Glucosidase, beta", "Beta-2 microglobulin", "Bilirubin", "Biotinidase, each specimen", "Calcitonin", "Calcium", "Carbon dioxide (bicarbonate)", "Carboxyhemoglobin", "Carcinoembryonic antigen (CEA)", "Myelin basic protein, cerebrospinal fluid", "Chloride", "Citrate", "Cortisol", "Deoxycortisol, 11-", "Creatinine", "Dehydroepiandrosterone-sulfate (DHEA-S)", "Aminolevulinic acid, delta (ALA)", "Dibucaine number", "Erythropoietin", "Estrogens", "Etiocholanolone", "Fat differential, feces, quantitative", "Galactokinase, RBC", "Glutamyltransferase, gamma (GGT)", "Gastrin", "Phosphohexose isomerase", "Glutathione", "Growth hormone, human (HGH) (somatotropin)", "Histamine", "Homovanillic acid (HVA)", "Hydroxyprogesterone, 17-d", "Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit)", "Insulin", "C-peptide", "Transferrin", "Lactate dehydrogenase (LD), (LDH)", "Lactate (lactic acid)", "Leucine aminopeptidase (LAP)", "Nucleotidase 5'-", "Oxalate", "Parathormone (parathyroid hormone)", "pH", "Phosphatidylglycerol", "Urobilinogen, feces, quantitative", "Potassium", "Protein", "Oligoclonal immune (oligoclonal bands)", "Cholinesterase", "Serotonin", "Sex hormone binding globulin (SHBG)", "Thyroid stimulating hormone (TSH)", "Thyroxine", "Thyroxine binding globulin (TBG)", "Triglycerides", "Uric acid", "Vasoactive intestinal peptide (VIP)", "Pyridoxal phosphate (Vitamin B-6)", "Cyanocobalamin (Vitamin B-12)", "Chlorinated hydrocarbons, screen", "Alcohol (ethanol), breath", "Aluminum", "Chloramphenicol", "Cyanide", "Ethylene glycol", "Fluoride", "Quinine", "Silica", "Estrone", "Cryofibrinogen", "Creatine", "Glutamate dehydrogenase", "Isocitric dehydrogenase (IDH)", "Metanephrines", "Pyruvate", "Thiocyanate", "Androstenedione", "Estradiol", "Estriol", "Galactose", "Glucagon", "Glucose", "Iron", "Prealbumin", "Pregnanediol", "Sodium", "Thyroglobulin", "Tyrosine", "Glucagon tolerance test", "Adenosine, 5-monophosphate, cyclic (cyclic AMP)", "Aldosterone", "Angiotensin II", "Arsenic", "Atomic absorption spectroscopy, each analyte", "Cadmium", "Carotene", "Ceruloplasmin", "Cholesterol, serum or whole blood, total", "Chondroitin B sulfate, quantitative", "Chromium", "Copper", "Corticosterone", "Cystine and homocystine, urine, qualitative", "Dehydroepiandrosterone (DHEA)", "Desoxycorticosterone, 11-", "Electrophoretic technique, not elsewhere specified", "Fatty acids, nonesterified", "Ferritin", "Gases, blood, pH only", "Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)", "Gases, blood, O2 saturation only, by direct measurement, except pulse oximetry", "Hemoglobin-oxygen affinity (pO2 for 50% hemoglobin saturation with oxygen)", "Gastrin after secretin stimulation", "Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use", "Glutathione reductase, RBC", "Glycated protein", "Hemosiderin, qualitative", "Hydroxycorticosteroids, 17- (17-OHCS)", "Intrinsic factor", "Iron binding capacity", "Ketogenic steroids, fractionation", "Lactogen, human placental (HPL) human chorionic somatomammotropin", "Lactose, urine, qualitative", "Lipase", "Luteinizing releasing factor (LRH)", "Magnesium", "Malate dehydrogenase", "Manganese", "Mucopolysaccharides, acid, quantitative", "Myoglobin", "Nephelometry, each analyte not elsewhere specified", "Nickel", "Osteocalcin (bone g1a protein)", "Phenylalanine (PKU), blood", "Phosphogluconate, 6-, dehydrogenase, RBC", "Pregnanetriol", "Progesterone", "Prolactin", "Prostaglandin, each", "Protein, total, by refractometry, any source", "Proinsulin", "Pyruvate kinase", "Renin", "Riboflavin (Vitamin B-2)", "Selenium", "Somatomedin", "Somatostatin", "Spectrophotometry, analyte not elsewhere specified", "Sugars, chromatographic, TLC or paper chromatography", "Thiamine (Vitamin B-1)", "Thyroid stimulating immune globulins (TSI)", "Transcortin (cortisol binding globulin)", "Urea nitrogen, urine", "Vitamin A", "Volatiles (eg, acetic anhydride, diethylether)", "Xylose absorption test, blood and/or urine", "Zinc", "Ovulation tests, by visual color comparison methods for human luteinizing hormone", "Urobilinogen, urine", "Mercury, quantitative", "Vanillylmandelic acid (VMA), urine", "Porphobilinogen, urine", "Very long chain fatty acids", "Porphyrins, feces, quantitative", "Hemoglobin", "Collagen cross links, any method", "Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR)", "Troponin, quantitative", "Troponin, qualitative", "Hydroxyprogesterone, 20-", "Acylcarnitines", "Apolipoprotein, each", "Androstanediol glucuronide", "Bile acids", "Cathepsin-D", "Folic acid", "Hydroxyindolacetic acid, 5-(HIAA)", "Phenylketones, qualitative", "Phosphorus inorganic (phosphate)", "Specific gravity (except urine)", "Sulfate, urine", "Testosterone", "Urea nitrogen, clearance", "Lead", "Catecholamines", "Gonadotropin", "Amino acids, 2 to 5 amino acids, quantitative, each specimen", "Amino acids, 6 or more amino acids, quantitative, each specimen", "Carnitine (total and free), quantitative, each specimen", "Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen", "Fetal fibronectin, cervicovaginal secretions, semi-quantitative", "b-Hexosaminidase, each assay", "Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen", "Amines, vaginal fluid, qualitative", "Glucose, body fluid, other than blood", "Organic acid, single, quantitative", "Vitamin, not otherwise specified", "Carbohydrate deficient transferrin", "Vitamin D", "Haptoglobin", "Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations", "Lipoprotein (a)", "Tocopherol alpha (Vitamin E)", "Fructose, semen", "Hydroxyproline", "Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative", "Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (eg, C-13)", "Procalcitonin (PCT)", "Cystatin C", "Blood, occult, by peroxidase activity (eg, guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening", "Lipoprotein-associated phospholipase A2 (Lp-PLA2)", "Calprotectin, fecal", "Pregnancy-associated plasma protein-A (PAPP-A)", "Homocysteine", "Natriuretic peptide", "Myeloperoxidase (MPO)", "Thromboxane metabolite(s), including thromboxane if performed, urine", "Gastric acid analysis, includes pH if performed, each specimen", "Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity", "Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-fetoprotein), qualitative, each specimen", "Galectin-3", "Fetal lung maturity assessment", "Receptor assay", "Calculus", "Urea nitrogen", "Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate)", "Blood, occult, by peroxidase activity (eg, guaiac), qualitative", "Creatine kinase (CK), (CPK)", "Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified", "Fat or lipids, feces", "Gammaglobulin (immunoglobulin)", "Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury)", "Hemoglobin fractionation and quantitation", "Lipoprotein, blood", "Lipoprotein, direct measurement", "Porphyrins, urine", "Protein, total, except by refractometry", "Protoporphyrin, RBC", "Sugars (mono-, di-, and oligosaccharides)", "Lactoferrin, fecal", "Immunoassay for analyte other than infectious agent antibody or infectious agent antigen", "Ketosteroids, 17- (17-KS)", "Amino acids", "Glucose-6-phosphate dehydrogenase (G6PD)", "Galactose-1-phosphate uridyl transferase", "Transferase", "Triiodothyronine T3", "Trypsin", "Oncoprotein", "Helicobacter pylori", "Prostate specific antigen (PSA)", "Gonadotropin, chorionic (hCG)", "Organic acids", "Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)", "Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)"], "wiki_entities": ["Adrenocorticotropic hormone", "ACTH stimulation test", "Adrenocorticotropic hormone (medication)", "Melanocyte-stimulating hormone", "Adrenocorticotropic hormone deficiency", "Peptide hormone", "Anterior pituitary", "Trophic hormone", "Alpha-Melanocyte-stimulating hormone", "Tropic hormone"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "GO:GO:0051460", "canonical_name": "negative regulation of corticotropin secretion", "aliases": ["downregulation of adrenocorticotropin secretion", "down-regulation of adrenocorticotropin secretion", "down regulation of adrenocorticotropin secretion", "negative regulation of acth secretion", "negative regulation of adrenocorticotropic hormone secretion", "inhibition of adrenocorticotropin secretion", "negative regulation of adrenotropic hormone secretion", "negative regulation of adrenotropin secretion", "negative regulation of corticotropic hormone secretion", "negative regulation of adrenocorticotropin secretion", "negative regulation of corticotropin secretion"], "definition": "Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of corticotropic hormone from a cell. [GOC:ai]", "other_contexts": [], "par_relations": ["regulation of corticotropin secretion", "negative regulation of multicellular organismal process", "negative regulation of peptide hormone secretion", "biological regulation", "negative regulation of corticotropin secretion"], "chd_relations": ["negative regulation of corticotropin secretion"], "syn_relations": ["negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion"], "sib_relations": ["corticotropin secretion", "corticotropin secretion", "negative regulation of circadian sleep/wake cycle, sleep", "negative regulation of insulin secretion", "negative regulation of isotype switching", "negative regulation of muscle contraction", "negative regulation of juvenile hormone secretion", "negative regulation of retinal cell programmed cell death", "negative regulation of embryonic development", "negative regulation of multicellular organism growth", "negative regulation of organ growth", "negative regulation of eclosion", "negative regulation of odontogenesis", "negative regulation of salivary gland boundary specification", "negative regulation of ossification", "negative regulation of antipodal cell differentiation", "negative regulation of embryo sac central cell differentiation", "negative regulation of embryo sac egg cell differentiation", "negative regulation of synergid differentiation", "negative regulation of spermatid nuclear differentiation", "negative regulation of atrichoblast fate specification", "negative regulation of trichoblast fate specification", "negative regulation of cuticle pigmentation", "negative regulation of female pigmentation", "negative regulation of male pigmentation", "negative regulation of cytokine production", "negative regulation of hair cycle", "negative regulation of epidermis development", "negative regulation of terminal cell fate specification, open tracheal system", "negative regulation of fusion cell fate specification", "negative regulation of multicellular organismal metabolic process", "negative regulation of heat generation", "negative regulation of neurological system process", "negative regulation of heat dissipation", "negative regulation of corticotropin-releasing hormone secretion", "positive regulation of corticotropin secretion", "negative regulation of post-embryonic development", "negative regulation of cardioblast differentiation", "negative regulation of border follicle cell delamination", "negative regulation of fusion of sperm to egg plasma membrane", "negative regulation of chitin-based cuticle tanning", "negative regulation of nervous system development", "negative regulation of tolerance induction", "negative regulation of gonadotropin secretion", "negative regulation of inhibin secretion", "negative regulation of neurotrophin production", "negative regulation of mammary gland epithelial cell proliferation", "negative regulation of tissue remodeling", "negative regulation of compound eye cone cell fate specification", "negative regulation of nurse cell apoptotic process", "negative regulation of muscle organ development", "negative regulation of glomerular filtration", "negative regulation of growth hormone secretion", "negative regulation of muscle hypertrophy", "negative regulation of muscle adaptation", "negative regulation of ovulation", "negative regulation of oocyte development", "negative regulation of penile erection", "negative regulation of digestive system process", "negative regulation of glucagon secretion", "negative regulation of adiponectin secretion", "negative regulation of biomineral tissue development", "negative regulation of mucus secretion", "negative regulation of hepatocyte differentiation", "negative regulation of spore-bearing organ development", "negative regulation of epithelial cell migration", "negative regulation of epithelial to mesenchymal transition", "negative regulation of very-low-density lipoprotein particle remodeling", "negative regulation of mammary gland development in males by androgen receptor signaling pathway", "negative regulation of epithelial cell proliferation involved in prostate gland development", "negative regulation of canonical Wnt signaling pathway involved in neural plate anterior/posterior pattern formation", "negative regulation of cartilage development", "negative regulation of branching involved in lung morphogenesis", "negative regulation of Wnt signaling pathway involved in heart development", "negative regulation of mesenchymal cell proliferation involved in ureter development", "negative regulation of kidney development", "negative regulation of somatostatin secretion", "negative regulation of lipoprotein particle clearance", "negative regulation of coagulation", "negative regulation of respiratory burst involved in inflammatory response", "negative regulation of stomach neuroendocrine cell differentiation", "negative regulation of canonical Wnt signaling pathway involved in neural crest cell differentiation", "negative regulation of determination of dorsal identity", "negative regulation of male gonad development", "negative regulation of cardiac cell fate specification", "negative regulation of Wnt signaling pathway involved in dorsal/ventral axis specification", "negative regulation of Wnt signaling pathway involved in digestive tract morphogenesis", "negative regulation of ureter smooth muscle cell differentiation", "negative regulation of type B pancreatic cell development", "negative regulation of mammary stem cell proliferation", "negative regulation of cell proliferation involved in heart morphogenesis", "negative regulation of female gonad development", "negative regulation of pancreatic A cell differentiation", "negative regulation of male germ cell proliferation", "negative regulation of defecation", "negative regulation of fibroblast growth factor receptor signaling pathway involved in neural plate anterior/posterior pattern formation", "negative regulation of hepatocyte proliferation", "negative regulation of cell proliferation involved in compound eye morphogenesis", "negative regulation of energy homeostasis", "negative regulation of renal albumin absorption", "negative regulation of thyroid-stimulating hormone secretion", "negative regulation of leukotriene production involved in inflammatory response", "negative regulation of renal sodium excretion", "negative regulation of trichome patterning", "negative regulation of hemostasis", "negative regulation of leaf senescence", "negative regulation of nodal signaling pathway involved in determination of left/right asymmetry", "negative regulation of bone trabecula formation", "negative regulation of beta-amyloid clearance", "negative regulation of mesenchymal cell proliferation involved in lung development", "negative regulation of epithelial cell proliferation involved in lung morphogenesis", "negative regulation of amniotic stem cell differentiation", "negative regulation of parathyroid hormone secretion", "negative regulation of steroid hormone secretion", "negative regulation of lens epithelial cell proliferation", "negative regulation of renal water transport", "negative regulation of adrenergic receptor signaling pathway involved in heart process", "negative regulation of oviposition", "negative regulation of sclerotium development", "negative regulation of vasculature development", "negative regulation of lung goblet cell differentiation", "negative regulation of lung ciliated cell differentiation", "negative regulation of cardiac chamber morphogenesis", "negative regulation of trophoblast cell migration", "negative regulation of relaxation of muscle", "negative regulation of cartilage homeostasis", "negative regulation of shoot apical meristem development", "negative regulation of apoptotic process involved in outflow tract morphogenesis", "negative regulation of male mating behavior", "negative regulation of stem cell population maintenance", "negative regulation of sperm capacitation", "negative regulation of prolactin secretion", "negative regulation of lens fiber cell differentiation", "negative regulation of renal amino acid absorption", "negative regulation of BMP signaling pathway involved in determination of lateral mesoderm left/right asymmetry", "negative regulation of retina development in camera-type eye", "negative regulation of root hair elongation", "negative regulation of bone development", "negative regulation of insulin receptor signaling pathway involved in determination of adult lifespan", "negative regulation of tube lumen cavitation", "negative regulation of vitellogenesis", "negative regulation of fear response", "negative regulation of renal phosphate excretion", "negative regulation of lactation", "negative regulation of blood circulation", "negative regulation of histamine secretion by mast cell", "negative regulation of epithelial cell-cell adhesion involved in epithelium migration", "negative regulation of hemopoiesis", "negative regulation of cardiac conduction", "negative regulation of collecting lymphatic vessel constriction", "negative regulation of respiratory gaseous exchange", "negative regulation of apical ectodermal ridge formation", "negative regulation of male germ-line stem cell asymmetric division", "negative regulation of lung alveolus development", "negative regulation of substance P secretion", "negative regulation of thyroid gland epithelial cell proliferation", "negative regulation of cardiac ventricle development", "negative regulation of calcitonin secretion", "negative regulation of maternal process involved in parturition", "negative regulation of adipose tissue development"], "wiki_entities": ["Corticotropin-releasing hormone", "Anterior pituitary", "UCN3", "Vasopressin", "Neuroendocrinology", "Hypothalamic–pituitary–adrenal axis", "CRHBP", "Corticotropin-releasing hormone receptor 1", "Negative feedback", "Hypothalamus"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HPO:HP:0002902", "canonical_name": "Hyponatremia", "aliases": ["hyponatremia", "low blood sodium levels"], "definition": "Hyponatremia is a low sodium level in the blood.", "other_contexts": ["involved in gait function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by", "2 [ 1.18 - 1.48 ; 95% CIs ] ; P < .000 ) . A meta - regression analysis showed that the hyponatremia - related length of hospital stay was higher in males ( Slope = 0.09 [ 0.05 - 0.12 ; 95% CIs ] ; P", "RESULTS Dose, age, baseline serum sodium level and kidney function, according to estimated GFR clearance, were significant risk factors for hyponatraemia in both sexes; similar to the known risk factors associated with hyponatraemia in the general population.", "codes and administrative variables of heart failure patients with and without hyponatremia . The chi - square test was used for qualitative variables and the Student 's t test for", "MEASUREMENTS AND MAIN RESULTS Three hundred nineteen patients were placed in three exclusive groups based on the lowest serum sodium measurement during admission : 1 ) severe hyponatremia : serum sodium less than or equal to 130 mEq / L ; 2 ) mild hyponatremia : 131 - 135 mEq / L ; and 3 ) normal sodium : more than 135 mEq / L. Timing and severity of sodium perturbations were assessed within each group .", "patients with osteoporosis or assessing bone mineral density ( BMD ) in patients with hyponatremia ? The answers to these questions have not been established . Definitive answers will require", "Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95% confidence interval , 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar .", "function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone", "the cost of normonatremic subjects . CONCLUSIONS This meta - analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission . These", "SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs significantly .", "all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients ( 40.9% ; n=27 versus 21.1% ; n=75 ) , translating into a 2.", "function , according to estimated GFR clearance , were significant risk factors for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general", "This is worrisome not only because hyponatremia counts as the most common electrolyte disorder in hospitalized patients but also because it is associated with increased mortality .", "Across various disciplines, hyponatremia is associated with increased mortality and longer hospital stay, yet in intracerebral hemorrhage (ICH) no data are available.", "Hyponatremia maintained statistical significance in the regression model after adjusting for gender, OR 0.919 (95% CI 0.902-0.936); age, OR 1.061 (95% CI 1.060-1.062); and Charlson index, OR 1.388 (95% CI 1.361-1.461).", "condition that is linked to worse outcome due to greater comorbidity . Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", ". In men , arthritis and use of drugs for bone disease were also predictive of hyponatraemia , while in women , raised monocytes and absence of lipid - modifying drugs increased the risk of", "published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was performed including all", ". This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH . METHODS This observational study included all consecutive spontaneous ICH", "and fractures has become more established . This study evaluates the prevalence of hyponatraemia ( plasma sodium<135mmol / l ) in 3897 patients undergoing operative treatment for hip fracture and", "mortality with a fairly high prevalence in spontaneous ICH patients . The presence of hyponatremia at hospital admission is related to an increased short - term mortality in patients surviving", "A meta-regression analysis showed that the hyponatremia-related length of hospital stay was higher in males (Slope = 0.09 [0.05-0.12; 95% CIs]; P = .000 and Intercept = -1.36 [-3.03-0.32; 95% CIs]; P = .11) and in elderly patients (Slope = 0.002 [0.001-0.003; 95% CIs]; P", "study was the evaluation of frequency , potential causes , and risk factors of hyponatraemia in patients with tick - borne encephalitis ( TBE ) . A total of 61 patients ( 22 women , 39 men )", "increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly . Hyponatremia appears to contribute to falls and fractures by two mechanisms . First , it produces mild", "Do patients die with or from hyponatremia ? ”", "patients were appropriately screened out , only mild , non - clinically significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the", "In the hyponatremia group, the mean survival time of corrected hyponatremia patients was 0.91±0.42 years, which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years (t=2.75, p<0.05) after symptomatic treatment.", "Does the patient have hypovolemic , euvolemic , or hypervolemic hyponatremia ?", "within 12 months of discharge . Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003", "admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with", "In men, arthritis and use of drugs for bone disease were also predictive of hyponatraemia, while in women, raised monocytes and absence of lipid-modifying drugs increased the risk of hyponatraemia.", "Hyponatremia appears to contribute to falls and fractures by two mechanisms.", "and 20% of patients at discharge . There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited", "Finally, when only US studies (n = 8) were considered, hyponatremia was associated with up to around $3000 higher hospital costs/patient when compared with the cost of normonatremic subjects.", "Every effort should be made to identify and correct hyponatraemia in hip fracture patients .", "BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice.", "of hospital stay and of hospital resource utilization . To clarify the impact of hyponatremia on the length of hospitalization and costs , we performed a meta - analysis based on published", "active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD , thereby reducing the risk of fractures . Until", "Importantly, hyponatremia’s most dangerous and potentially fatal complications, cerebral edema and the osmotic demeylination syndrome, were rarely observed.", "These disorders were largely absent in survivors, whose more severe hyponatremia was largely attributed to the use of thiazides and antidepressants.", "A sodium monitoring plan is proposed whereby baseline sodium must be ≥135 mmol / L ( especially important in the elderly ) , with additional monitoring at week 1 and month 1 for those at elevated risk because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia .", "Hyponatremia at 1- and 3-year follow - up was associated with worse survival rates ( p<0.05 ) .", "In this vulnerable patient group, hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post-operative mortality.", "Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.", "After surgery , sodium decreased in all groups with lower averaged concentrations during postoperative days 0 - 1 and 5 - 6 , although patients with severe hyponatremia had the greatest decline .", "1.060 - 1.062 ) ; and Charlson index , OR 1.388 ( 95% CI 1.361 - 1.461 ) . CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute", "Should we be screening for low serum sodium in patients with osteoporosis or assessing bone mineral density ( BMD ) in patients with hyponatremia ?", "abnormality observed in clinical practice . Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization . To", "duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia . RESULTS Of 444 retrieved articles , 46 studies satisfied the inclusion criteria , encompassing a", "is common in hospitalised patients . In recent years the relationship between hyponatraemia and bone metabolism , falls and fractures has become more established . This study evaluates the", "Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", "hyponatremia may represent one important determinant of the hospitalization costs .", "Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria.", "will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether", "when 125 - 129 mmol / l , and severe when < 125 mmol / l . Among the 61 patients , hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% )", "patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "042 patients ; among these , 757,763 ( 19.2% ) were hyponatremic . Across all studies , hyponatremia was associated with a significantly longer duration of hospitalization ( 3.30 [ 2.90 - 3.71 ; 95%", "This monitoring plan would help to prevent some at-risk patients developing hyponatraemia; retrospective application of the monitoring plan showed that, once at-risk patients were appropriately screened out, only mild, non-clinically significant hyponatraemia was observed, within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population.", "CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender-specific dosing with the ODT formulation of desmopressin (25 μg in women, 50 μg in men).", "to retrieve all studies published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was", "METHODS An extensive Medline , Embase , and Cochrane search was performed to retrieve all studies published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \"", "variables , and age , gender , comorbidity according to the Charlson index and hyponatremia as independent variables . RESULTS A total of 504,860 patients with acute heart failure were", "for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general population . In men , arthritis and use of drugs for bone disease were also", "Young children with hydrocephalus have increased risk of severe hyponatremia.", "Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD ,", "CONCLUSION Hyponatremia developed in just over half of children .", "The Economic Burden of Hyponatremia : Systematic Review and Meta - Analysis .", "Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival, especially in the uncorrected group.", "Those with severe hyponatremia need frequent and prolonged monitoring because of risk for repeat sodium changes.", "Finally , elderly patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "Nine patients had initial severe hyponatremia between days 6 and 20 after surgery.", "Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours.", "main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs", "RESULTS The incidence rate of hyponatremia in SCLC was 46.56% (149/320).", "Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003 ) .", ", 39 men ) aged 18 - 80 years , with a history of TBE was included in the study . Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild", "Therefore , two possibilities remain ( Figure 1 ) : ( 1 ) Hyponatremia is a direct cause of death , or ( 2 ) severe underlying disease is the cause of death and hyponatremia is merely another complication of this underlying disease .", "operative mortality on multivariate analysis . Median age at admission was 83 years . Hyponatraemia was present in 19.1% of patients with hip fracture on admission , 29.5% of patients in the first 24", "an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636", "- up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure", "For those who are not electrolyte enthusiasts, hyponatremia can be a frustrating disorder.", "These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs.", ", in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients ,", "most frequent electrolyte disturbance in critical care . Across various disciplines , hyponatremia is associated with increased mortality and longer hospital stay , yet in intracerebral hemorrhage (", "The probability of readmission for patients with hyponatremia was 22% versus 17% in the non-hyponatremic group.", "First, it produces mild cognitive impairment, resulting in unsteady gait and falls; this is probably due to the loss of glutamate (a neurotransmitter involved in gait function) as an osmolyte during brain adaptation to chronic hyponatremia.", "desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced", "Hundred thirty - seven patients ( 43% ) had mild hyponatremia , 39 ( 12% ) had severe hyponatremia , and 143 ( 45% ) had normal sodium .", "Little is known about the effects of hyponatremia on other organs, such as the heart, although a recent study identified hyponatremia as an independent predictor of myocardial infarction in community patients (16).", "with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia , and if present , treatment should be initiated . Finally , elderly patients presenting with an", "morbidities was observed . Finally , when only US studies ( n = 8) were considered , hyponatremia was associated with up to around $ 3000 higher hospital costs / patient when compared with the", ", hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe", "fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post - operative mortality on multivariate analysis .", "differs significantly . Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe .", "length of stay , associated comorbidities , readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set ( MBDS ) .", ". This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ; retrospective application of the monitoring plan showed that , once at - risk patients were", "/ L ) . Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital", "post - operative mortality . Every effort should be made to identify and correct hyponatraemia in hip fracture patients .", "Analysis of hyponatraemia associated post - operative mortality in 3897 hip fracture patients .", "A descriptive data analysis was conducted comparing the diagnosis codes and administrative variables of heart failure patients with and without hyponatremia .", "In - hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients ( 40.9% ; n=27 versus 21.1% ; n=75 ) , translating into a 2.5-fold increased odds ratio ( P<0.001 ) .", "patients ( 53,820 patients ) . The probability of readmission for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate", "Among hyponatremic patients , obstructive hydrocephalus and age less than 3.5 years were significant independent risk factors for severe hyponatremia .", "Across all studies , hyponatremia was associated with a significantly longer duration of hospitalization ( 3.30 [ 2.90 - 3.71 ; 95% CIs ] mean days ; P < .000 ) .", "Patients with severe hyponatremia had greater sodium variability with significantly lower nadirs , greater maximum values , and larger decreases within 24-hour periods compared with other sodium groups .", "Further study is needed to evaluate ideal monitoring and treatment of severe hyponatremia after intracranial tumor surgery.", "Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization .", "heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) . Hyponatremia maintained statistical significance in the regression model after adjusting for gender , OR 0.919 (", "This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH .", "Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model.", "functional outcome ( 90 days and 1 year ) were analyzed to determine the effects of hyponatremia ( Na<135 mEq / L ) . Multivariable regression analyses were calculated for factors associated with", "at initial presentation and during admission . In this vulnerable patient group , hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post -", "differences as far as gender or clinical form of the disease are concerned . Hyponatraemia , usually mild , is a common disorder in the course of TBE , although it is not significantly more", "Until such studies are conducted , physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders .", "A multivariate logistic regression analysis was performed, taking intrahospital mortality and hospital readmissions as dependent variables, and age, gender, comorbidity according to the Charlson index and hyponatremia as independent variables.", "The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients younger than 60 years old.", "Following elimination of other independent variables associated with increased mortality , hyponatraemia on admission was associated with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) .", ", 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar . CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high", "This study evaluates the prevalence of hyponatraemia ( plasma sodium<135mmol / l ) in 3897 patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients .", "However, hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "This is an interesting conclusion that will definitely stir debate on the value of actively treating hyponatremia.", "for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with", "The presence of hyponatremia at hospital admission is related to an increased short-term mortality in patients surviving acute care, possibly reflecting a preexisting condition that is linked to worse outcome due to greater comorbidity.", "Evaluation of hyponatraemia in patients with tick-borne encephalitis--a preliminary study.", "patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post -", "association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The mean survival time was 1.10±0.42 years in patients with", "Dehydration seems to be the main cause of hyponatraemia in the course of TBE .", "serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia", "than in other hospitalized patients . Dehydration seems to be the main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE ,", "Use of the proposed monitoring scheme and the minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment.", "SNS hospitals . Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity", "with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post - operative hyponatraemia was also associated with an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends", "Median time to death for patients with and without hyponatraemia within 24h post - operatively was 35 months ( SE 2.5 months ) and 42 months ( SE 1.7 months ) respectively ( p=0.004 ) .", "Second, hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone resorption to mobilize sodium stores in bone.", "L was recorded by age , sex and dose . Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model . RESULTS Dose ,", "Thus , the authors conclude that patients die with and not from hyponatremia .", "and prognosis of elderly small cell lung cancer ( SCLC ) patients complicated with hyponatremia , thus providing increased attention for appropriate intervention and improving outcomes in", "The investigators first show mortality rates in a large sample of hospitalized patients with hyponatremia ( serum sodium 135 mmol / L ) .", "disorder . Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate", "(10) elegantly rephrase the issue of hyponatremia and mortality as, “", "During the defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "into a 2.5-fold increased odds ratio ( P<0.001 ) . Multivariable analyses identified hyponatremia as an independent predictor of in - hospital mortality ( odds ratio , 2.2 ; 95% confidence", "to decrease when compared to another group of patients younger than 60 years old . Hyponatremia at 1- and 3-year follow - up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The", "formulate an interesting hypothesis ( 10 ) : That patients with moderate hyponatremia have more severe underlying disease than those with severe hyponatremia and therefore higher mortality rates .", ", physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders . As serum sodium is a readily available , simple , and affordable biochemical", "These challenges may be the reason that the management of hyponatremia is still suboptimal (1– 3).", "Hyponatremia and bone disease Hip fractures represent a serious health risk in the elderly, causing substantial morbidity and mortality.", "length of stay and higher risk of readmission . These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs .", "Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) .", "with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic", "For example, emerging data implicate hyponatremia in falls (11), osteoporosis (12), and fractures (13–15), suggesting an effect on the nervous system and bone.", "Hyponatremia and mortality : how innocent is the bystander ?", "of hyponatraemia in patients with tick - borne encephalitis -- a preliminary study . Hyponatraemia is one of the most frequently observed , but sometimes overlooked , electrolyte disorder .", "in elderly patients , especially in those receiving medications that can cause hyponatremia . Furthermore , elderly patients with an unsteady gait and/or confusion should be evaluated for", "Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality .", "Hyponatremia in hospitalised patients with heart failure in internal medicine : Analysis of the Spanish national minimum basic data set ( MBDS ) ( 2005 - 2011 ) .", "women , raised monocytes and absence of lipid - modifying drugs increased the risk of hyponatraemia . Use of the proposed monitoring scheme and the minimum effective dose would have omitted all", "Does this study prove hyponatremia to be an innocent bystander in mortality ?", "It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided .", "Timing , duration , and severity of hyponatremia following pediatric brain tumor surgery*. OBJECTIVE To describe the time course , variability , and magnitude of serum sodium changes among children undergoing intracranial tumor surgery .", "hyponatraemia associated post - operative mortality in 3897 hip fracture patients . Hyponatraemia is common in hospitalised patients . In recent years the relationship between hyponatraemia and", "Among the 61 patients, hyponatraemia was observed in 41% (25 patients).", ") respectively ( p=0.003 ) . Median time to death for patients with and without hyponatraemia within 24h post - operatively was 35 months ( SE 2.5 months ) and 42 months ( SE 1.7 months )", "was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) . Hyponatraemia is common in elderly patients with hip fractures both at initial presentation and during admission", "CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high prevalence in spontaneous ICH patients .", "Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia.", "A gradual year - on - year increase of hyponatremia codification ( both primary and secondary diagnosis ) was observed at discharge throughout the study period ( from 1.6% in 2005 to 2.8% in 2011 ; p<0.0001 ) .", "hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all", "Multivariable analyses identified hyponatremia as an independent predictor of in-hospital mortality (odds ratio, 2.2; 95% confidence interval, 1.05-4.62; P=0.037).", ", 2.2 ; 95% confidence interval , 1.05 - 4.62 ; P=0.037 ) . Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95%", "A meta - analysis was performed including all studies comparing duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia .", "The objective of this study is to assess the incidence, average length of stay, associated comorbidities, readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set (MBDS).", "mortality . There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia . This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ;", "survival , especially in the uncorrected group . It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided .", "patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years ( t=2.75 , p<0.05 ) after symptomatic", "Seventy-five percent of patients manifest mild hyponatremia within two postoperative days; however, severe hyponatremia developed later with 75% of patients manifesting severe hyponatremia within six postoperative days.", "Economic Burden of Hyponatremia : Systematic Review and Meta - Analysis . BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice . Several studies have", "elimination of other independent variables associated with increased mortality , hyponatraemia on admission was associated with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post -", "The prognosis and possible association with hyponatremia was investigated .", "Nearly 80% of hyponatremic patients had mild hyponatremia prior to development of severe hyponatremia; median time between mild hyponatremia and severe hyponatremia was 1.6 days (interquartile range, 0.4-5.6).", "BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care.", "RESULTS The prevalence of hyponatremia on hospital admission was 15.6% ( n=66 ) .", "Hyponatremia is an independent predictor of in - hospital mortality in spontaneous intracerebral hemorrhage .", "Overall mortality due to any cause in patients with hyponatremia was 17% (1937 patients) versus 11% in non-hyponatremic patients (53,820 patients).", "Seventy-five percent of children with severe hyponatremia spent more than 4 days with abnormally low sodium values.", "OBJECTIVE To explore risk factors for desmopressin-induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan.", "OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice.", "The nuance comes from a third possibility ( Figure 1 ) : Hyponatremia may contribute to organ dysfunction and therefore indirectly contribute to mortality .", "of the Spanish national minimum basic data set ( MBDS ) ( 2005 - 2011 ) . OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice . Numerous studies have reported", "Furthermore, elderly patients with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia, and if present, treatment should be initiated.", "significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender - specific dosing with the ODT formulation of", "and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia : A Retrospective Analysis . AIM This study was designed to evaluate the clinical characteristics", "The patients with severe hyponatremia , they argue , were likely admitted because their serum sodium was so low , not because they were so ill .", "treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan . SUBJECTS AND METHODS This was a meta -", "Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) .", "There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "normal values and 0.83±0.35 years in patients with subnormal serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was", "In recent years the relationship between hyponatraemia and bone metabolism, falls and fractures has become more established.", "significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population .", "and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients , sodium concentration normalized", "Post-operative hyponatraemia was also associated with an increased risk of death (adjusted HR 1.15, p=0.006).", "0.05 ) after symptomatic treatment . The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients", "CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute heart failure in SNS hospitals.", "There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer.", "AIM This study was designed to evaluate the clinical characteristics and prognosis of elderly small cell lung cancer (SCLC) patients complicated with hyponatremia, thus providing increased attention for appropriate intervention and improving outcomes in symptomatic subjects.", ", simple , and affordable biochemical measurement , clinicians should look for hyponatremia in elderly patients , especially in those receiving medications that can cause hyponatremia .", "- hospital mortality in spontaneous intracerebral hemorrhage . BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care . Across various disciplines ,", "The aim of the present study was the evaluation of frequency , potential causes , and risk factors of hyponatraemia in patients with tick - borne encephalitis ( TBE ) .", "that compared hospital length of stay and cost between patients with and without hyponatremia . METHODS An extensive Medline , Embase , and Cochrane search was performed to retrieve all", "Low - dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia .", "To clarify the impact of hyponatremia on the length of hospitalization and costs, we performed a meta-analysis based on published studies that compared hospital length of stay and cost between patients with and without hyponatremia.", "defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity index .", ". Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild when sodium concentration was 130 - 134 mmol / l , moderate when 125 - 129", "Definitive answers will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia, to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD, thereby reducing the risk of fractures.", "hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission .", "Patient characteristics, in-hospital measures, mortality, and functional outcome (90 days and 1 year) were analyzed to determine the effects of hyponatremia (Na<135 mEq/L).", "The association between hyponatremia and mortality has been demonstrated in numerous studies (4 –9), but causality has been difficult to prove.", "minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using", ", of whom 11,095 ( 2.2% ) presented with HNa . A gradual year - on - year increase of hyponatremia codification ( both primary and secondary diagnosis ) was observed at discharge throughout the", "and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer . The median follow - up time was 863 ( range 0 - 4352 ) days . There were 2460", "As serum sodium is a readily available, simple, and affordable biochemical measurement, clinicians should look for hyponatremia in elderly patients, especially in those receiving medications that can cause hyponatremia.", "2005 to 2.8% in 2011 ; p<0.0001 ) . Overall mortality due to any cause in patients with hyponatremia was 17% ( 1937 patients ) versus 11% in non - hyponatremic patients ( 53,820 patients ) . The", "CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts .", "Dealing with hyponatremia means considering various and often opposite scenarios.", "1st , 2012 , were studied retrospectively . The prognosis and possible association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The", "of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival , especially in the"], "par_relations": ["Abnormality of sodium homeostasis"], "chd_relations": [], "syn_relations": ["Hyponatremia", "Hyponatremia"], "sib_relations": ["Hypernatremia", "Increased intracellular sodium"], "wiki_entities": ["Hyponatremia", "Hypotonic hyponatremia", "Isotonic hyponatremia", "Water intoxication", "Exercise-associated hyponatremia", "Exercise-induced nausea", "Syndrome of inappropriate antidiuretic hormone secretion", "Central pontine myelinolysis", "Potomania", "Vasopressin receptor antagonist"], "mesh_synonynms": ["hyponatremias"], "dbpedia_synonyms": ["hypovolemic hyponatremia", "hyponatermia", "sodium deficiency", "hyponaetraemia", "salt deficiency", "hyponetremia", "hyponatrimia", "hyponatremic encephalopathy", "low sodium", "hyponatraemia"]}, "target_ent": {"research_entity_id": "MSH:D007010", "canonical_name": "Hyponatremia", "aliases": ["hyponatremia", "hyponatremias"], "definition": "Hyponatremia is a low sodium level in the blood.", "other_contexts": ["In men , arthritis and use of drugs for bone disease were also predictive of hyponatraemia , while in women , raised monocytes and absence of lipid - modifying drugs increased the risk of hyponatraemia .", "2 [ 1.18 - 1.48 ; 95% CIs ] ; P < .000 ) . A meta - regression analysis showed that the hyponatremia - related length of hospital stay was higher in males ( Slope = 0.09 [ 0.05 - 0.12 ; 95% CIs ] ; P", "involved in gait function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by", "codes and administrative variables of heart failure patients with and without hyponatremia . The chi - square test was used for qualitative variables and the Student 's t test for", "patients with osteoporosis or assessing bone mineral density ( BMD ) in patients with hyponatremia ? The answers to these questions have not been established . Definitive answers will require", "Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95% confidence interval , 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar .", "Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia.", "Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone resorption to mobilize sodium stores in bone .", "function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone", "the cost of normonatremic subjects . CONCLUSIONS This meta - analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission . These", "SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs significantly .", "all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients ( 40.9% ; n=27 versus 21.1% ; n=75 ) , translating into a 2.", "RESULTS Dose , age , baseline serum sodium level and kidney function , according to estimated GFR clearance , were significant risk factors for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general population .", "function , according to estimated GFR clearance , were significant risk factors for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general", "This is worrisome not only because hyponatremia counts as the most common electrolyte disorder in hospitalized patients but also because it is associated with increased mortality .", "condition that is linked to worse outcome due to greater comorbidity . Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", ". In men , arthritis and use of drugs for bone disease were also predictive of hyponatraemia , while in women , raised monocytes and absence of lipid - modifying drugs increased the risk of", "published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was performed including all", "The aim of the present study was the evaluation of frequency, potential causes, and risk factors of hyponatraemia in patients with tick-borne encephalitis (TBE).", ". This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH . METHODS This observational study included all consecutive spontaneous ICH", "Further study is needed to evaluate ideal monitoring and treatment of severe hyponatremia after intracranial tumor surgery .", "and fractures has become more established . This study evaluates the prevalence of hyponatraemia ( plasma sodium<135mmol / l ) in 3897 patients undergoing operative treatment for hip fracture and", "mortality with a fairly high prevalence in spontaneous ICH patients . The presence of hyponatremia at hospital admission is related to an increased short - term mortality in patients surviving", "A meta-regression analysis showed that the hyponatremia-related length of hospital stay was higher in males (Slope = 0.09 [0.05-0.12; 95% CIs]; P = .000 and Intercept = -1.36 [-3.03-0.32; 95% CIs]; P = .11) and in elderly patients (Slope = 0.002 [0.001-0.003; 95% CIs]; P", "study was the evaluation of frequency , potential causes , and risk factors of hyponatraemia in patients with tick - borne encephalitis ( TBE ) . A total of 61 patients ( 22 women , 39 men )", "increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly . Hyponatremia appears to contribute to falls and fractures by two mechanisms . First , it produces mild", "Do patients die with or from hyponatremia ? ”", "patients were appropriately screened out , only mild , non - clinically significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the", "within 12 months of discharge . Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003", "admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with", "Should we be screening for low serum sodium in patients with osteoporosis or assessing bone mineral density (BMD) in patients with hyponatremia?", "and 20% of patients at discharge . There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited", "of hospital stay and of hospital resource utilization . To clarify the impact of hyponatremia on the length of hospitalization and costs , we performed a meta - analysis based on published", "< length of stay and higher risk of readmission . These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs .", "active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD , thereby reducing the risk of fractures . Until", "Importantly, hyponatremia’s most dangerous and potentially fatal complications, cerebral edema and the osmotic demeylination syndrome, were rarely observed.", "These disorders were largely absent in survivors, whose more severe hyponatremia was largely attributed to the use of thiazides and antidepressants.", "Analysis of hyponatraemia associated post-operative mortality in 3897 hip fracture patients.", "Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization.", "A sodium monitoring plan is proposed whereby baseline sodium must be ≥135 mmol / L ( especially important in the elderly ) , with additional monitoring at week 1 and month 1 for those at elevated risk because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia .", "MEASUREMENTS AND MAIN RESULTS Three hundred nineteen patients were placed in three exclusive groups based on the lowest serum sodium measurement during admission: 1) severe hyponatremia: serum sodium less than or equal to 130 mEq/L; 2) mild hyponatremia: 131-135 mEq/L; and 3) normal sodium: more than 135 mEq/L. Timing and severity of sodium perturbations were assessed within each group.", "In this vulnerable patient group, hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post-operative mortality.", "Median time to death for patients with and without hyponatraemia within 24h post-operatively was 35 months (SE 2.5 months) and 42 months (SE 1.7 months) respectively (p=0.004).", "Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.", "After surgery , sodium decreased in all groups with lower averaged concentrations during postoperative days 0 - 1 and 5 - 6 , although patients with severe hyponatremia had the greatest decline .", "1.060 - 1.062 ) ; and Charlson index , OR 1.388 ( 95% CI 1.361 - 1.461 ) . CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute", "abnormality observed in clinical practice . Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization . To", "duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia . RESULTS Of 444 retrieved articles , 46 studies satisfied the inclusion criteria , encompassing a", "A multivariate logistic regression analysis was performed , taking intrahospital mortality and hospital readmissions as dependent variables , and age , gender , comorbidity according to the Charlson index and hyponatremia as independent variables .", "Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", "is common in hospitalised patients . In recent years the relationship between hyponatraemia and bone metabolism , falls and fractures has become more established . This study evaluates the", "CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts.", "will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether", "Definitive answers will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD , thereby reducing the risk of fractures .", "patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "when 125 - 129 mmol / l , and severe when < 125 mmol / l . Among the 61 patients , hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% )", "042 patients ; among these , 757,763 ( 19.2% ) were hyponatremic . Across all studies , hyponatremia was associated with a significantly longer duration of hospitalization ( 3.30 [ 2.90 - 3.71 ; 95%", "In-hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients (40.9%; n=27 versus 21.1%; n=75), translating into a 2.5-fold increased odds ratio (P<0.001).", "Little is known about the effects of hyponatremia on other organs , such as the heart , although a recent study identified hyponatremia as an independent predictor of myocardial infarction in community patients ( 16 ) .", "to retrieve all studies published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was", "CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender-specific dosing with the ODT formulation of desmopressin (25 μg in women, 50 μg in men).", "variables , and age , gender , comorbidity according to the Charlson index and hyponatremia as independent variables . RESULTS A total of 504,860 patients with acute heart failure were", "A descriptive data analysis was conducted comparing the diagnosis codes and administrative variables of heart failure patients with and without hyponatremia.", "Young children with hydrocephalus have increased risk of severe hyponatremia.", "Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD ,", "for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general population . In men , arthritis and use of drugs for bone disease were also", "CONCLUSION Hyponatremia developed in just over half of children .", "Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival, especially in the uncorrected group.", "Those with severe hyponatremia need frequent and prolonged monitoring because of risk for repeat sodium changes.", "Following elimination of other independent variables associated with increased mortality, hyponatraemia on admission was associated with an increased risk of death (adjusted HR 1.15, p=0.005).", "It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided.", "Finally , elderly patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "Nine patients had initial severe hyponatremia between days 6 and 20 after surgery.", "main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs", "Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours.", "Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003 ) .", "Among hyponatremic patients, obstructive hydrocephalus and age less than 3.5 years were significant independent risk factors for severe hyponatremia.", ", 39 men ) aged 18 - 80 years , with a history of TBE was included in the study . Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild", "operative mortality on multivariate analysis . Median age at admission was 83 years . Hyponatraemia was present in 19.1% of patients with hip fracture on admission , 29.5% of patients in the first 24", "Therefore , two possibilities remain ( Figure 1 ) : ( 1 ) Hyponatremia is a direct cause of death , or ( 2 ) severe underlying disease is the cause of death and hyponatremia is merely another complication of this underlying disease .", "an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636", "- up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure", "RESULTS The prevalence of hyponatremia on hospital admission was 15.6% (n=66).", "For those who are not electrolyte enthusiasts, hyponatremia can be a frustrating disorder.", "METHODS An extensive Medline, Embase, and Cochrane search was performed to retrieve all studies published up to April 1, 2015 using the following words: \"hyponatremia\" or \"hyponatraemia\" AND \"hospitalization\" or \"hospitalisation.\"", ", in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients ,", "most frequent electrolyte disturbance in critical care . Across various disciplines , hyponatremia is associated with increased mortality and longer hospital stay , yet in intracerebral hemorrhage (", "Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model .", "First, it produces mild cognitive impairment, resulting in unsteady gait and falls; this is probably due to the loss of glutamate (a neurotransmitter involved in gait function) as an osmolyte during brain adaptation to chronic hyponatremia.", "Post - operative hyponatraemia was also associated with an increased risk of death ( adjusted HR 1.15 , p=0.006 ) .", "desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced", "The patients with severe hyponatremia, they argue, were likely admitted because their serum sodium was so low, not because they were so ill.", "morbidities was observed . Finally , when only US studies ( n = 8) were considered , hyponatremia was associated with up to around $ 3000 higher hospital costs / patient when compared with the", "A gradual year-on-year increase of hyponatremia codification (both primary and secondary diagnosis) was observed at discharge throughout the study period (from 1.6% in 2005 to 2.8% in 2011; p<0.0001).", "with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia , and if present , treatment should be initiated . Finally , elderly patients presenting with an", "fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post - operative mortality on multivariate analysis .", ", hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe", "differs significantly . Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "length of stay , associated comorbidities , readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set ( MBDS ) .", "In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe .", ". This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ; retrospective application of the monitoring plan showed that , once at - risk patients were", "/ L ) . Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital", "post - operative mortality . Every effort should be made to identify and correct hyponatraemia in hip fracture patients .", "This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ; retrospective application of the monitoring plan showed that , once at - risk patients were appropriately screened out , only mild , non - clinically significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population .", "patients ( 53,820 patients ) . The probability of readmission for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate", "Hyponatremia maintained statistical significance in the regression model after adjusting for gender , OR 0.919 ( 95% CI 0.902 - 0.936 ) ; age , OR 1.061 ( 95% CI 1.060 - 1.062 ) ; and Charlson index , OR 1.388 ( 95% CI 1.361 - 1.461 ) .", "Does the patient have hypovolemic, euvolemic, or hypervolemic hyponatremia?", "heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) . Hyponatremia maintained statistical significance in the regression model after adjusting for gender , OR 0.919 (", "Patients with severe hyponatremia had greater sodium variability with significantly lower nadirs , greater maximum values , and larger decreases within 24-hour periods compared with other sodium groups .", "The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis.", "This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH .", "Across various disciplines , hyponatremia is associated with increased mortality and longer hospital stay , yet in intracerebral hemorrhage ( ICH ) no data are available .", "BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice .", "functional outcome ( 90 days and 1 year ) were analyzed to determine the effects of hyponatremia ( Na<135 mEq / L ) . Multivariable regression analyses were calculated for factors associated with", "at initial presentation and during admission . In this vulnerable patient group , hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post -", "differences as far as gender or clinical form of the disease are concerned . Hyponatraemia , usually mild , is a common disorder in the course of TBE , although it is not significantly more", "The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients younger than 60 years old.", ", 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar . CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high", "However, hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "The investigators first show mortality rates in a large sample of hospitalized patients with hyponatremia (serum sodium 135 mmol/L).", "RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) .", "This is an interesting conclusion that will definitely stir debate on the value of actively treating hyponatremia.", "for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with", "The presence of hyponatremia at hospital admission is related to an increased short-term mortality in patients surviving acute care, possibly reflecting a preexisting condition that is linked to worse outcome due to greater comorbidity.", "Evaluation of hyponatraemia in patients with tick-borne encephalitis--a preliminary study.", "patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post -", "association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The mean survival time was 1.10±0.42 years in patients with", "Dehydration seems to be the main cause of hyponatraemia in the course of TBE .", "serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia", "than in other hospitalized patients . Dehydration seems to be the main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE ,", "with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post - operative hyponatraemia was also associated with an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends", "SNS hospitals . Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity", "L was recorded by age , sex and dose . Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model . RESULTS Dose ,", "Thus , the authors conclude that patients die with and not from hyponatremia .", "and prognosis of elderly small cell lung cancer ( SCLC ) patients complicated with hyponatremia , thus providing increased attention for appropriate intervention and improving outcomes in", "Hundred thirty-seven patients (43%) had mild hyponatremia, 39 (12%) had severe hyponatremia, and 143 (45%) had normal sodium.", "This study evaluates the prevalence of hyponatraemia (plasma sodium<135mmol/l) in 3897 patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients.", "disorder . Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate", "< , of whom 11,095 ( 2.2% ) presented with HNa . A gradual year - on - year increase of hyponatremia codification ( both primary and secondary diagnosis ) was observed at discharge throughout the", "These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs .", "(10) elegantly rephrase the issue of hyponatremia and mortality as, “", "During the defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "These challenges may be the reason that the management of hyponatremia is still suboptimal ( 1– 3 ) .", "into a 2.5-fold increased odds ratio ( P<0.001 ) . Multivariable analyses identified hyponatremia as an independent predictor of in - hospital mortality ( odds ratio , 2.2 ; 95% confidence", "formulate an interesting hypothesis ( 10 ) : That patients with moderate hyponatremia have more severe underlying disease than those with severe hyponatremia and therefore higher mortality rates .", ", physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders . As serum sodium is a readily available , simple , and affordable biochemical", "Hyponatremia in hospitalised patients with heart failure in internal medicine: Analysis of the Spanish national minimum basic data set (MBDS) (2005-2011).", "to decrease when compared to another group of patients younger than 60 years old . Hyponatremia at 1- and 3-year follow - up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The", "Hyponatremia and bone disease Hip fractures represent a serious health risk in the elderly, causing substantial morbidity and mortality.", "For example, emerging data implicate hyponatremia in falls (11), osteoporosis (12), and fractures (13–15), suggesting an effect on the nervous system and bone.", "Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) .", "with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic", "Hyponatremia and mortality : how innocent is the bystander ?", "of hyponatraemia in patients with tick - borne encephalitis -- a preliminary study . Hyponatraemia is one of the most frequently observed , but sometimes overlooked , electrolyte disorder .", "in elderly patients , especially in those receiving medications that can cause hyponatremia . Furthermore , elderly patients with an unsteady gait and/or confusion should be evaluated for", "Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality .", "women , raised monocytes and absence of lipid - modifying drugs increased the risk of hyponatraemia . Use of the proposed monitoring scheme and the minimum effective dose would have omitted all", "Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria .", "Does this study prove hyponatremia to be an innocent bystander in mortality?", "hyponatraemia associated post - operative mortality in 3897 hip fracture patients . Hyponatraemia is common in hospitalised patients . In recent years the relationship between hyponatraemia and", ") respectively ( p=0.003 ) . Median time to death for patients with and without hyponatraemia within 24h post - operatively was 35 months ( SE 2.5 months ) and 42 months ( SE 1.7 months )", "Timing, duration, and severity of hyponatremia following pediatric brain tumor surgery*. OBJECTIVE To describe the time course, variability, and magnitude of serum sodium changes among children undergoing intracranial tumor surgery.", "Use of the proposed monitoring scheme and the minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment .", "CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high prevalence in spontaneous ICH patients .", "was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) . Hyponatraemia is common in elderly patients with hip fractures both at initial presentation and during admission", "Until such studies are conducted, physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders.", "Overall mortality due to any cause in patients with hyponatremia was 17% ( 1937 patients ) versus 11% in non - hyponatremic patients ( 53,820 patients ) .", "Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia.", "hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all", "The probability of readmission for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group .", "Among the 61 patients , hyponatraemia was observed in 41% ( 25 patients ) .", "Multivariable analyses identified hyponatremia as an independent predictor of in-hospital mortality (odds ratio, 2.2; 95% confidence interval, 1.05-4.62; P=0.037).", ", 2.2 ; 95% confidence interval , 1.05 - 4.62 ; P=0.037 ) . Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95%", "A meta - analysis was performed including all studies comparing duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia .", "The objective of this study is to assess the incidence, average length of stay, associated comorbidities, readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set (MBDS).", "mortality . There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia . This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ;", "survival , especially in the uncorrected group . It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided .", "Finally , when only US studies ( n = 8) were considered , hyponatremia was associated with up to around $ 3000 higher hospital costs / patient when compared with the cost of normonatremic subjects .", "Economic Burden of Hyponatremia : Systematic Review and Meta - Analysis . BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice . Several studies have", "elimination of other independent variables associated with increased mortality , hyponatraemia on admission was associated with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post -", "patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years ( t=2.75 , p<0.05 ) after symptomatic", "The prognosis and possible association with hyponatremia was investigated .", "CONCLUSIONS This meta - analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission .", "The nuance comes from a third possibility (Figure 1): Hyponatremia may contribute to organ dysfunction and therefore indirectly contribute to mortality.", "Hyponatremia is an independent predictor of in - hospital mortality in spontaneous intracerebral hemorrhage .", "Seventy-five percent of children with severe hyponatremia spent more than 4 days with abnormally low sodium values.", "OBJECTIVE To explore risk factors for desmopressin-induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan.", "Hyponatremia at 1- and 3-year follow-up was associated with worse survival rates (p<0.05).", "OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice.", "Nearly 80% of hyponatremic patients had mild hyponatremia prior to development of severe hyponatremia ; median time between mild hyponatremia and severe hyponatremia was 1.6 days ( interquartile range , 0.4 - 5.6 ) .", "of the Spanish national minimum basic data set ( MBDS ) ( 2005 - 2011 ) . OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice . Numerous studies have reported", "Furthermore, elderly patients with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia, and if present, treatment should be initiated.", "significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender - specific dosing with the ODT formulation of", "and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia : A Retrospective Analysis . AIM This study was designed to evaluate the clinical characteristics", "BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care .", "Across all studies, hyponatremia was associated with a significantly longer duration of hospitalization (3.30 [2.90-3.71; 95% CIs] mean days; P < .000).", "treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan . SUBJECTS AND METHODS This was a meta -", "Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) .", "normal values and 0.83±0.35 years in patients with subnormal serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was", "There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population .", "and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients , sodium concentration normalized", "0.05 ) after symptomatic treatment . The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients", "There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer.", "CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute heart failure in SNS hospitals.", "AIM This study was designed to evaluate the clinical characteristics and prognosis of elderly small cell lung cancer (SCLC) patients complicated with hyponatremia, thus providing increased attention for appropriate intervention and improving outcomes in symptomatic subjects.", ", simple , and affordable biochemical measurement , clinicians should look for hyponatremia in elderly patients , especially in those receiving medications that can cause hyponatremia .", "- hospital mortality in spontaneous intracerebral hemorrhage . BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care . Across various disciplines ,", "that compared hospital length of stay and cost between patients with and without hyponatremia . METHODS An extensive Medline , Embase , and Cochrane search was performed to retrieve all", "Seventy - five percent of patients manifest mild hyponatremia within two postoperative days ; however , severe hyponatremia developed later with 75% of patients manifesting severe hyponatremia within six postoperative days .", "defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity index .", ". Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild when sodium concentration was 130 - 134 mmol / l , moderate when 125 - 129", "To clarify the impact of hyponatremia on the length of hospitalization and costs, we performed a meta-analysis based on published studies that compared hospital length of stay and cost between patients with and without hyponatremia.", "Every effort should be made to identify and correct hyponatraemia in hip fracture patients.", "of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival , especially in the", "Patient characteristics, in-hospital measures, mortality, and functional outcome (90 days and 1 year) were analyzed to determine the effects of hyponatremia (Na<135 mEq/L).", "Hyponatremia appears to contribute to falls and fractures by two mechanisms .", "The association between hyponatremia and mortality has been demonstrated in numerous studies (4 –9), but causality has been difficult to prove.", "minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using", "and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer . The median follow - up time was 863 ( range 0 - 4352 ) days . There were 2460", "As serum sodium is a readily available, simple, and affordable biochemical measurement, clinicians should look for hyponatremia in elderly patients, especially in those receiving medications that can cause hyponatremia.", "2005 to 2.8% in 2011 ; p<0.0001 ) . Overall mortality due to any cause in patients with hyponatremia was 17% ( 1937 patients ) versus 11% in non - hyponatremic patients ( 53,820 patients ) . The", "Dealing with hyponatremia means considering various and often opposite scenarios.", "1st , 2012 , were studied retrospectively . The prognosis and possible association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The", "In recent years the relationship between hyponatraemia and bone metabolism, falls and fractures has become more established.", "In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years ( t=2.75 , p<0.05 ) after symptomatic treatment ."], "par_relations": ["Water-Electrolyte Imbalance"], "chd_relations": [], "syn_relations": ["Hyponatremia", "Hyponatremia"], "sib_relations": ["Sodium", "Dehydration", "Hypercalcemia", "Hyperkalemia", "Hypernatremia", "Hypocalcemia", "Hypokalemia", "Inappropriate ADH Syndrome", "Water Intoxication"], "wiki_entities": ["Hyponatremia", "Hypotonic hyponatremia", "Isotonic hyponatremia", "Water intoxication", "Exercise-associated hyponatremia", "Exercise-induced nausea", "Syndrome of inappropriate antidiuretic hormone secretion", "Central pontine myelinolysis", "Potomania", "Vasopressin receptor antagonist"], "mesh_synonynms": ["hyponatremias", "hyponatremia"], "dbpedia_synonyms": ["hypovolemic hyponatremia", "hyponatermia", "sodium deficiency", "hyponaetraemia", "salt deficiency", "hyponetremia", "hyponatrimia", "hyponatremic encephalopathy", "low sodium", "hyponatraemia"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0006650", "canonical_name": "Thickening of the lateral border of the scapula", "aliases": ["thickening of the lateral border of the scapula", "thickening of the lateral border of the shoulder blade"], "definition": "In anatomy, the scapula (plural scapulae or scapulas; also known as shoulder blade or wing bone) is the bone that connects the humerus (upper arm bone) with the clavicle (collar bone).", "other_contexts": [], "par_relations": ["Abnormality of the scapula"], "chd_relations": [], "syn_relations": ["Thickening of the lateral border of the scapula", "Thickening of the lateral border of the scapula"], "sib_relations": ["Sprengel anomaly", "Scapular winging", "Sclerotic scapulae", "Scapular exostoses", "Scapulohumeral synostosis", "Abnormality of the glenoid fossa", "Aplasia/Hypoplasia of the scapulae"], "wiki_entities": ["Scapula", "Triangular interval", "Impingement syndrome", "List of skeletal muscles of the human body", "Osteochondritis dissecans", "Elbow", "Bone", "Ampelosaurus", "List of eponymously named medical signs", "Glossary of bird terms"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU016833", "canonical_name": "Thickening of the lateral border of the scapula", "aliases": ["thickening of the lateral border of the scapula"], "definition": "In anatomy, the scapula (plural scapulae or scapulas; also known as shoulder blade or wing bone) is the bone that connects the humerus (upper arm bone) with the clavicle (collar bone).", "other_contexts": [], "par_relations": ["Ribs, sternum, clavicles, and scapulae"], "chd_relations": [], "syn_relations": [], "sib_relations": ["NAIL-PATELLA SYNDROME"], "wiki_entities": ["Scapula", "Triangular interval", "Impingement syndrome", "List of skeletal muscles of the human body", "Osteochondritis dissecans", "Elbow", "Bone", "Ampelosaurus", "List of eponymously named medical signs", "Glossary of bird terms"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0012722", "canonical_name": "Heart block", "aliases": ["heart block"], "definition": "Heart block is a disease or inherited condition that causes a fault within the heart's natural pacemaker due to some kind of obstruction (or \"block\") in the electrical conduction system of the heart.", "other_contexts": [], "par_relations": ["Arrhythmia"], "chd_relations": ["Atrioventricular block", "Bundle branch block", "Sick sinus syndrome", "Sinoatrial block"], "syn_relations": [], "sib_relations": ["Cardiac arrest", "Palpitations", "Tachycardia", "Ventricular arrhythmia", "Supraventricular arrhythmia", "Bradycardia", "Abnormal electrophysiology of sinoatrial node origin", "Abnormal atrioventricular conduction"], "wiki_entities": ["Heart block", "Second-degree atrioventricular block", "Third-degree atrioventricular block", "First-degree atrioventricular block", "Beta blocker", "Atrioventricular block", "Heart", "Bundle branch block", "Trifascicular block", "Left bundle branch block"], "mesh_synonynms": ["dissociations, atrioventricular", "a-v dissociation", "dissociations, a-v", "atrioventricular dissociation", "atrioventricular dissociations", "dissociation, a-v", "dissociation, atrioventricular", "block, heart", "blocks, heart", "dissociations, auriculo-ventricular", "dissociation, auriculo-ventricular", "a-v dissociations", "a v dissociation", "auriculo-ventricular dissociations", "auriculo-ventricular dissociation", "heart blocks", "auriculo ventricular dissociation"], "dbpedia_synonyms": ["sinoatrial heart block", "heartblock", "hemiblock", "conduction block", "sino-auricular heart block"]}, "target_ent": {"research_entity_id": "OMIM:MTHU007927", "canonical_name": "Block vertebrae", "aliases": ["block vertebrae"], "definition": "Congenital vertebral anomalies are a collection of malformations of the spine.", "other_contexts": [], "par_relations": ["Spine"], "chd_relations": [], "syn_relations": [], "sib_relations": ["AICARDI SYNDROME", "SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME", "SPONDYLOCOSTAL DYSOSTOSIS WITH ANAL ATRESIA AND UROGENITAL ANOMALIES", "SPONDYLOCOSTAL DYSOSTOSIS 4, AUTOSOMAL RECESSIVE", "HEMIFACIAL MICROSOMIA"], "wiki_entities": ["Congenital vertebral anomaly", "Lumbar vertebrae", "Vertebra", "Scalene muscles", "Corpectomy", "Volta (album)", "Facet joint", "Ken Block", "Hatzegopteryx", "Somite"], "mesh_synonynms": [], "dbpedia_synonyms": ["congenital vertebral anomaly"]}, "label": 0}
{"source_ent": {"research_entity_id": "MSH:D020936", "canonical_name": "Epilepsy, Benign Neonatal", "aliases": ["benign familial infantile convulsions", "epilepsy, benign neonatal", "familial benign neonatal convulsions", "benign familial neonatal infantile seizures", "non familial benign neonatal epilepsy", "neonatal convulsions, benign", "non familial benign neonatal convulsions", "benign non-familial neonatal convulsions", "non-familial benign neonatal convulsions", "epilepsy, benign neonatal, nonfamilial", "benign neonatal-infantile epilepsy", "benign neonatal epilepsy", "benign neonatal convulsions", "benign neonatal epilepsy, nonfamilial", "benign familial neonatal-infantile seizures", "benign familial infantile convulsions syndrome", "convulsion, benign neonatal", "benign familial neonatal convulsions", "neonatal epilepsies, benign", "convulsions, benign familial infantile, 3", "convulsions, benign neonatal, non-familial", "epilepsies, benign neonatal", "benign familial neonatal epilepsy", "neonatal-infantile epilepsy, benign", "benign neonatal non familial convulsions", "neonatal convulsion, benign", "non-familial benign neonatal epilepsy", "seizures, benign familial neonatal-infantile", "benign neonatal-infantile epilepsies", "convulsions, benign familial infantile, 1", "convulsions, benign neonatal", "neonatal epilepsy, benign", "familial benign neonatal epilepsy", "seizures, benign familial infantile, 3", "benign neonatal convulsion", "epilepsy, benign neonatal, non-familial", "seizures, benign familial neonatal infantile", "convulsions, benign neonatal, familial", "benign infantile familial convulsions", "convulsions benign familial neonatal", "neonatal-infantile epilepsies, benign", "epilepsy, benign neonatal, familial", "epilepsies, benign neonatal-infantile", "benign neonatal epilepsies", "epilepsy, benign neonatal infantile", "benign non familial neonatal convulsions", "epilepsy, benign neonatal-infantile", "benign neonatal non-familial convulsions", "benign neonatal nonfamilial epilepsy", "seizures, benign familial infantile, 1"], "definition": "Benign familial neonatal seizures (BFNS), formerly called benign familial neonatal convulsions (BFNC), is a rare autosomal dominant inherited form of seizures.", "other_contexts": [], "par_relations": ["Epilepsy, Benign Neonatal", "Epilepsy", "Infant, Newborn, Diseases", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal"], "chd_relations": ["Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal, 3", "Epilepsy, Benign Neonatal, Autosomal Recessive", "Convulsions benign familial neonatal dominant form", "Epilepsy, Benign Neonatal, 1", "Infantile convulsions and paroxysmal choreoathetosis, familial", "Convulsions, Benign Familial Infantile, 4", "Myokymia with neonatal epilepsy", "Convulsions, Benign Familial Neonatal, 1, Atypical Severe", "Convulsions, Benign Familial Neonatal, 1, And-Or Myokymia", "Epilepsy, Benign Neonatal, 1, Atypical Severe"], "syn_relations": ["Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal"], "sib_relations": ["Amniotic Band Syndrome", "Anemia, Neonatal", "Asphyxia Neonatorum", "Birth Injuries", "Seizures, Febrile", "Cystic Fibrosis", "Epilepsies, Partial", "Epilepsy, Generalized", "Epilepsies, Myoclonic", "Epilepsy, Post-Traumatic", "Erythroblastosis, Fetal", "Hydrophthalmos", "Hyperostosis, Cortical, Congenital", "Ichthyosis", "Infant, Premature, Diseases", "Meconium Aspiration Syndrome", "Neonatal Abstinence Syndrome", "Persistent Fetal Circulation Syndrome", "Rothmund-Thomson Syndrome", "Sclerema Neonatorum", "Seizures", "Status Epilepticus", "Syphilis, Congenital", "Thanatophoric Dysplasia", "Toxoplasmosis, Congenital", "Wolman Disease", "Severe Combined Immunodeficiency", "Mobius Syndrome", "Colic", "Lennox Gastaut Syndrome", "Epilepsy, Reflex", "Landau-Kleffner Syndrome", "Ophthalmia Neonatorum", "Neonatal Sepsis", "Nystagmus, Congenital", "Hyperbilirubinemia, Neonatal", "Drug Resistant Epilepsy", "Hernia, Umbilical", "Vitamin K Deficiency Bleeding", "Thrombocytopenia, Neonatal Alloimmune", "Congenital Hyperinsulinism"], "wiki_entities": ["Benign familial neonatal seizures", "Benign familial infantile epilepsy", "Benign neonatal seizures", "Neonatal seizure", "List of diseases (E)", "Epilepsy syndromes", "KvLQT3", "KvLQT2", "Epilepsy and employment", "ICD-10 Chapter VI: Diseases of the nervous system"], "mesh_synonynms": ["convulsions, benign neonatal", "neonatal epilepsies, benign", "benign non-familial neonatal convulsions", "convulsions, benign neonatal, non-familial", "benign neonatal-infantile epilepsies", "seizures, benign familial infantile, 1", "non familial benign neonatal convulsions", "benign neonatal non familial convulsions", "neonatal-infantile epilepsies, benign", "benign familial neonatal infantile seizures", "non familial benign neonatal epilepsy", "benign neonatal-infantile epilepsy", "benign familial neonatal epilepsy", "seizures, benign familial neonatal-infantile", "epilepsies, benign neonatal", "familial benign neonatal epilepsy", "benign familial infantile convulsions syndrome", "convulsions, benign neonatal, familial", "benign neonatal convulsions", "benign neonatal epilepsy, nonfamilial", "epilepsy, benign neonatal, nonfamilial", "benign neonatal nonfamilial epilepsy", "neonatal convulsion, benign", "epilepsy, benign neonatal infantile", "benign neonatal non-familial convulsions", "benign familial neonatal convulsions", "convulsions, benign familial infantile, 3", "convulsions, benign familial infantile, 1", "neonatal epilepsy, benign", "epilepsy, benign neonatal-infantile", "epilepsy, benign neonatal", "benign familial infantile convulsions", "benign neonatal epilepsy", "convulsion, benign neonatal", "benign non familial neonatal convulsions", "seizures, benign familial infantile, 3", "seizures, benign familial neonatal infantile", "convulsions benign familial neonatal", "benign neonatal convulsion", "non-familial benign neonatal convulsions", "benign neonatal epilepsies", "epilepsy, benign neonatal, familial", "familial benign neonatal convulsions", "neonatal convulsions, benign", "non-familial benign neonatal epilepsy", "epilepsies, benign neonatal-infantile", "neonatal-infantile epilepsy, benign", "benign familial neonatal-infantile seizures", "benign infantile familial convulsions", "epilepsy, benign neonatal, non-familial"], "dbpedia_synonyms": ["benign familial neonatal seizures"]}, "target_ent": {"research_entity_id": "OMIM:607745", "canonical_name": "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "aliases": ["bfnis", "bfis3", "seizures, benign familial neonatal-infantile", "seizures, benign familial infantile, 3", "convulsions, benign familial infantile, 3", "bfic3"], "definition": "Hypotonia, commonly known as floppy baby syndrome, is a state of low muscle tone (the amount of tension or resistance to stretch in a muscle), often involving reduced muscle strength.", "other_contexts": ["In most recent years a new form of benign epilepsy has been proposed, with an intermediate onset between the neonatal and infantile age, which was defined with the term benign familial neonatal-infantile seizures (BFNIS).", "In addition to those included in the classification of the International League Against Epilepsy , new epilepsy syndromes comprise febrile seizures plus , benign familial neonatal - infantile seizures ( BFNIS ) , benign infantile focal epilepsy with midline spikes and waves during sleep ( BFIS ) , malignant migrating partial seizures in infancy , devastating epilepsy in school age children and late onset cryptogenic spasms .", "SCN2A was analyzed in 2 families with probable BFNIS, 9 with possible BFNIS, 10 with benign familial infantile seizures, and in 93 additional families with various early childhood epilepsies.", "Mutations of the gene encoding the alpha2 subunit of the neuronal sodium channel, SCN2A, have been found in benign familial neonatal-infantile seizures (BFNIS).", "To dissect the genetics of benign familial epilepsies of the first year of life and to assess the extent of the genetic overlap between benign familial neonatal seizures (BFNS), benign familial neonatal-infantile seizures (BFNIS), and benign familial infantile seizures (BFIS).", "Biochemical experiments demonstrated that all three BFNIS mutations exhibited a significant reduction in cell surface expression compared to WT.", "The observation of benign and severe phenotypes due to an identical mutation within one family contradicts the hypothesis of different modes of inheritance as a mandatory feature discriminating BFNIS from SCN2A encephalopathy .", "The onset of BFNIS lies in between BFNS and BFIS, so that seizures can occur in the neonatal and early infantile period.", "Mutations effecting changes in conserved amino acids were found in two of two probable BFNIS families, in four of nine possible BFNIS families, and in none of the others.", "However, there were striking differences in the spectrum of clinical presentations, ranging from BFNIS to OS.", "Henceforth, in this discussion BFNS, BFNIS, and BFIS will be referred to as BFNE, BFNIE, and BFIE, respectively, distinguished by ascending average ages of seizure onset (mean age at onset of 2–3 days; 11 weeks; and 6 months, respectively) but with overlapping distributions of seizure age at onset (1 day to 6 months; 3 days to 6 months; and 2–20 months, respectively) (Berkovic et al.", "In this paper we report a patient presenting with an atypical epileptic syndrome whose phenotype partially overlaps both Dravet syndrome and benign familial neonatal - infantile seizures ( BFNIS ) ."], "par_relations": [], "chd_relations": [], "syn_relations": ["SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3"], "sib_relations": ["Cyanosis", "Autosomal dominant", "Normal psychomotor development", "Seizures, partial, afebrile", "Normal interictal EEG", "Onset ranges from 2 days to 7 months (most at 2-3 months)", "Seizures are easily controlled by medications", "See also benign familial infantile convulsions (BFIC1, 601764)", "See also benign neonatal epilepsy (EBN1, 121200)", "Secondary generalized tonic-clonic seizures may occur", "Seizures occur in clusters over 1 or several days", "Seizures often begin focally with head and eye deviation", "Rigidity during seizures", "Staring episodes during seizures", "Ictal EEG shows focal onset, often posterior region of brain", "Spontaneous resolution by 12 months of age with no recurrence later in life", "Caused by mutation in the alpha-1-subunit of the voltage-gated type II sodium channel gene (SCN2A, 182390.0002)", "Apnea during seizure spells"], "wiki_entities": ["Hypotonia", "Infantile convulsions and choreoathetosis", "Nav1.2", "Cavernous hemangioma", "Progressive myoclonus epilepsy", "ICD-10 Chapter VI: Diseases of the nervous system", "List of diseases (S)", "Paroxysmal kinesigenic choreoathetosis", "Hyperglycerolemia", "List of genetic disorders"], "mesh_synonynms": ["convulsions, benign neonatal", "neonatal epilepsies, benign", "benign non-familial neonatal convulsions", "convulsions, benign neonatal, non-familial", "benign neonatal-infantile epilepsies", "seizures, benign familial infantile, 1", "non familial benign neonatal convulsions", "benign neonatal non familial convulsions", "neonatal-infantile epilepsies, benign", "benign familial neonatal infantile seizures", "non familial benign neonatal epilepsy", "benign neonatal-infantile epilepsy", "benign familial neonatal epilepsy", "seizures, benign familial neonatal-infantile", "epilepsies, benign neonatal", "familial benign neonatal epilepsy", "benign familial infantile convulsions syndrome", "convulsions, benign neonatal, familial", "benign neonatal convulsions", "benign neonatal epilepsy, nonfamilial", "epilepsy, benign neonatal, nonfamilial", "benign neonatal nonfamilial epilepsy", "neonatal convulsion, benign", "epilepsy, benign neonatal infantile", "benign neonatal non-familial convulsions", "benign familial neonatal convulsions", "convulsions, benign familial infantile, 3", "convulsions, benign familial infantile, 1", "neonatal epilepsy, benign", "epilepsy, benign neonatal-infantile", "epilepsy, benign neonatal", "benign familial infantile convulsions", "benign neonatal epilepsy", "convulsion, benign neonatal", "benign non familial neonatal convulsions", "seizures, benign familial infantile, 3", "seizures, benign familial neonatal infantile", "convulsions benign familial neonatal", "benign neonatal convulsion", "non-familial benign neonatal convulsions", "benign neonatal epilepsies", "epilepsy, benign neonatal, familial", "familial benign neonatal convulsions", "neonatal convulsions, benign", "non-familial benign neonatal epilepsy", "epilepsies, benign neonatal-infantile", "neonatal-infantile epilepsy, benign", "benign familial neonatal-infantile seizures", "benign infantile familial convulsions", "epilepsy, benign neonatal, non-familial"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C562880", "canonical_name": "Amelogenesis Imperfecta, Type III", "aliases": ["adhcai", "amelogenesis imperfecta, type iii", "amelogenesis imperfecta, hypomineralization type", "amelogenesis imperfecta, hypocalcification type, autosomal dominant"], "definition": "Dentin sialophosphoprotein is a precursor protein for other proteins found in the teeth.", "other_contexts": ["Truncation mutations in FAM83H ( family with sequence similarity 83 , member H ) cause autosomal dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) , but little is known about FAM83H function and the pathogenesis of ADHCAI .", "Fam83h is associated with intracellular vesicles and ADHCAI .", "This study tested the hypothesis that there are phenotype and genotype associations in families with FAM83H - associated ADHCAI .", "Laboratory and field evaluation of the repellents deet , CIC-4 , and AI3 - 37220 against Anopheles farauti ( Diptera : Culicidae ) in Australia . Laboratory and", "ADHCAI is likely caused by gain - of - function effects mediated by truncated FAM83H , which potentially mislocalizes CK1 as part of its pathological mechanism .", "FAM83H mutations cause ADHCAI and alter intracellular protein localization .", "Affected individuals having truncating FAMH3H mutations of 677 or fewer amino acids presented a generalized ADHCAI phenotype , while those having mutations capable of producing a protein of at least 694 amino acids had a unique and previously unreported phenotype affecting primarily the cervical enamel .", "All FAM83H ADHCAI - causing mutations terminate translation or shift the reading frame within the specific exon 5 segment that encodes from Ser(287 ) to Glu(694 ) .", "Seven families segregating ADHCAI ( 147 individuals ) were evaluated .", "We here report novel FAM83H mutations in four kindreds with ADHCAI .", "The present study is designed to evaluate AI3 by measuring background and induced aniseikonia in children aged 5 to 13 years .", "The original mutation in the amidase gene of strain AI3 appeared responsible for the differences between the two groups of Ph mutants and the binding interactions with acetanilide that it determined were eliminated in AI3-Ph mutants .", "FAM83H gene mutations are associated with autosomal - dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) , which is typically characterized by enamel having normal thickness and a markedly decreased mineral content .", "Fam83h null mice support a neomorphic mechanism for human ADHCAI .", "Trials of AI3 were performed in the vertical direction only , using the 12-point test , and two trials were recorded .", "Adaptation to phenylacetamide as a growth substrate by an acetanilide - utilizing mutant of Pseudomonas aeruginosa Mutants able to utilize phenylacetamide as sole nitrogen source were isolated from the acetanilide ( N - phenylacetamide)-utilizing Pseudomonas aeruginosa mutant strain AI3 and from its parent strain L10 .", "Laboratory and field evaluation of deet , CIC-4 , and AI3 - 37220 against Anopheles dirus ( Diptera : Culicidae ) in Thailand . Laboratory and", "No FAM83H coding - region or splice - junction mutations were identified in three probands with autosomal - dominant hypocalcification AI ( ADHCAI ) , suggesting that a second gene may contribute to the aetiology of ADHCAI .", "Q398X ) families with ADHCAI .", "We recruited three ADHCAI families and identified two novel ( p .", "dirus was more sensitive to CIC-4 than either AI3 - 37220 or deet .", "Defects in FAM83H on human chromosome 8q24.3 cause autosomal - dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) .", "The AI3 group had a high level of activity towards 4-nitrophenylacetamide , activity towards phenylacetyl-4-nitroaniline but , unlike strain AI3 , no activity towards acetyl-4-nitroaniline ; the L10 group had a low activity towards 4-nitrophenylacetamide , no activity towards phenylacetyl-4-nitroaniline but retained the low level of activity towards acetyl-4-nitroaniline exhibited by strain L10 .", "Recently we identified mutations in FAM83H that caused autosomal dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) .", "CONCLUSIONS Most children were able to complete aniseikonia testing with AI3 .", "In contrast to the laboratory tests , protection provided by AI3 - 37220 was significantly better than that by either deet or CIC-4 , and there was no difference between protection by deet and CIC-4 .", "We identified disease - causing FAM83H mutations in two families with ADHCAI : family 1 ( g.3115C > T , c.1993 C > T , p ."], "par_relations": ["Amelogenesis Imperfecta"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Dentin sialophosphoprotein", "Human tooth", "List of genetic disorders", "Neonatal teeth", "List of diseases (C)", "Phenobarbital", "Temporomandibular joint dysfunction", "Oral mucosa", "Attrition (dental)", "Tooth decay"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:104500", "canonical_name": "AMELOGENESIS IMPERFECTA, TYPE IB", "aliases": ["aih2", "amelogenesis imperfecta, type ib", "amelogenesis imperfecta, hypoplastic local, autosomal dominant", "ai1b", "enamel hypoplasia, hereditary localized"], "definition": "Herpes simplex is a viral disease caused by the herpes simplex virus.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB"], "sib_relations": ["Amelogenesis imperfecta, hypoplastic", "Autosomal dominant", "Enamel has horizontal row of pits or linear depressions", "Incisal edge or occlusal surface not usually involved", "Caused by mutation in the enamelin gene (ENAM, 606585.0001)"], "wiki_entities": ["Herpes simplex", "List of genetic disorders", "Temporomandibular joint dysfunction"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:6364", "canonical_name": "kallikrein related peptidase 3", "aliases": ["klk3 gene", "kallikrein related peptidase 3", "psa", "klk3"], "definition": "Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["kallikrein related peptidase 3", "kallikrein related peptidase 3", "kallikrein related peptidase 3", "kallikrein related peptidase 3"], "sib_relations": [], "wiki_entities": ["Prostate-specific antigen", "Kallikrein", "KLK1", "KLK14", "KLK4", "KLK9", "KLK12", "KLK6", "KLK5", "KLK7"], "mesh_synonynms": [], "dbpedia_synonyms": ["piscis austrinus", "prostate-specific antigen", "psa", "p.s.a.", "psa (disambiguation)"]}, "target_ent": {"research_entity_id": "OMIM:176820", "canonical_name": "KALLIKREIN-RELATED PEPTIDASE 3", "aliases": ["antigen, prostate-specific", "kallikrein-related peptidase 3", "psa", "klk3", "kallikrein 3", "aps", "prostate-specific antigen"], "definition": "Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["aps", "aps (disambiguation)", "piscis austrinus", "prostate-specific antigen", "psa", "anpartsselskab", "p.s.a.", "psa (disambiguation)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D008127", "canonical_name": "Lofepramine", "aliases": ["deftan", "gamonil", "lofepramine", "ethanone, 1-(4-chlorophenyl)-2-((3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)methylamino)-", "ashbourne brand of lofepramine hydrochloride", "merck brand of lofepramine hydrochloride", "lopramine", "rosemont brand of lofepramine hydrochloride", "hydrochloride, lofepramine", "lofepramine hydrochloride", "gamanil", "feprapax", "lomont", "leo 640"], "definition": "Lofepramine, sold under the brand names Gamanil, Lomont, and Tymelyt among others, is a tricyclic antidepressant (TCA) which is used to treat depression.", "other_contexts": ["Pharmacokinetics of 3 doses (70 mg, 105 mg and 140 mg) of lofepramine were compared with amitriptyline (50 mg) in 6 healthy drug free elderly subjects aged between 65 and 72 years.", "Lofepramine , ( N - methyl - N-[4-chlorobenzoylmethyl]-3-[10,11-dihydro-5H - dibenz(b , f)-azepin-5-yl]-propylamine hydrochloride ) , is a new antidepressant with low toxicity and no peripheral anticholinergic activity .", "A double - blind randomised controlled trial of the effect of low dose lofepramine ( 70 mg once daily ) against placebo was carried out on depressed elderly inpatients on general medical wards for the elderly , comparing measures of depression and side - effects between the randomised groups .", "These results suggest that lofepramine is qualitatively similar to desipramine with respect to preferential inhibition of noradrenaline uptake into central noradrenergic neurons.", "Peak plasma lofepramine and amitriptyline concentrations were achieved at about 1 h and 3 h of dosing respectively .", "The incidence of subjective side - effects with amitryptyline was also higher than that of lofepramine or placebo .", "Pharmacokinetics of lofepramine in man: Relationship to inhibition of noradrenaline uptake The pharmacokinetics of lofepramine, an imipramine analogue, have been studied by administering single oral doses to volunteers, determination of plasma levels of lofepramine and desmethylimipramine after ten days of oral administration to patients, and by relating plasma levels to the effect on uptake of noradrenaline by isolated rat irides and brain slices of plasma samples collected during treatment.", "Imipramine and amitriptyline ( 1 - 5 mg / kg ) also elicited similar EEG changes but were much more potent than lopramine in this effect .", "A double - blind comparison of the pharmacodynamic effects of single doses of lofepramine , amitryptyline and placebo in elderly subjects In a double - blind five - way cross - over study , six drug free healthy elderly subjects received single oral doses of lofepramine ( 70 mg , 105 mg and 140 mg ) , amitriptyline ( 50 mg ) and matched placebo tablets .", "A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review.", "Elimination half-life of lofepramine was 2.5 h and that of amitriptyline was 31 h. A 24-fold inter-individual variation in peak plasma lofepramine concentrations was observed, but amitriptyline levels in plasma showed less variation.", "No effect was seen on the uptake of 5-hydroxytryptamine in brain slices incubated in patients' plasma which suggests that neither lofepramine nor its metabolites formedin vivo in man affect neuronal uptake of this amine.", "With regard to reported side effects, however, a statistically significant lower number of severe and/or moderate side effects were reported for the lofepramine group than for the imipramine group.", "Lofepramine has not been associated with adverse effects on cardiac function even in cases of attempted suicide by overdose.", "Lofepramine is a tricyclic antidepressant that is structurally similar to imipramine and is extensively metabolised to desipramine.", "Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects .", "After treatment with either active drug , lofepramine or imipramine , the clinical outcome was significantly greater than with placebo .", "BASDEC and GDS were administered on day 8 post - admission , and depressed patients were randomised double - blind to either low dose lofepramine ( 70 mg daily ) ( n = 23 ) or placebo ( n = 23 ) .", "Lofepramine.", "Pharmacokinetics of lofepramine in the elderly appear to be similar to young adults as published before.", "Both lofepramine and desipramine inhibited intraventricular noradrenaline uptake into synaptosomes without any effect on 5-HT uptake .", "A double blind comparison of lofepramine , imipramine and placebo in patients with depression .", "Electroencephalographic ( EEG ) effects of lopramine , a new antidepressant , were investigated in rabbits with chronic electrode implants , and compared with those of imipramine and amitriptyline .", "The results of double blind trial in which 139 patients with primary depression were randomly assigned to either lofepramine (46), imipramine (48), or placebo (45) are discussed.", "In particular, for severe and/or moderate occurrences of dry mouth, the statistically significant lower incidence in favor of lofepramine is by almost a factor of 3 (8 lofepramine vs 21 imipramine patients).", "[ Electroencephalographic effects of lopramine ] .", "injection of physostigmine 0.1 mg/kg showed no change after lopramine (20 mg/kg), while the response was significantly suppressed by imipramine (2, 5 mg/kg) and amitriptyline (1, 2 mg/kg).", "Dry mouth is the most commonly reported side effect of usual therapeutic doses of lofepramine , but the incidence of this and other anticholinergic side effects is less among patients treated with lofepramine than with imipramine .", "Lofepramine ( 140 mg ) improved psychomotor performance ( choice reaction time and letter cancellation ) , but no such change was seen with lower dose regimes or placebo .", "3. Pretreatment of rats with lofepramine or DMI did not alter the rate of aniline hydroxylation, aminopyrine demethylation or lofepramine metabolism per mg microsomal protein.", "Lopramine (10, 20 mg/kg) failed to suppress the EEG arousal responses induced by not only auditory stimulation but also electrical stimulation of the mesencephalic reticular formation, centromedian thalamus and posterior hypothalamus, whereas imipramine and amitriptyline (1 approximately 5 mg/kg) markedly inhibited these responses.", "No significant differences were found in clinical responses between lofepramine and imipramine.", "Low dose lofepramine may prove useful in moderately or severely depressed patients treated for only 4 weeks.", "Lopramine ( 10 , 20 mg / kg ) induced a drowsy pattern of spontaneous EEG consisted of high voltage slow waves in the cortex and amygdala , and desynchronization of hippocampal thetha waves .", "On the other hand , subjects who were less depressed ( i.e. GDS < 18 ) improved more on placebo than lofepramine .", "Lofepramine tended to be more effective than placebo in those patients who were more depressed ( GDS > or = 18 ) .", "Lopramine showed no effect on the recruiting response induced by electrical stimulation (8 Hz) of the centromedian thalamus and slightly enhanced the limbic afterdischarges elicited by either hippocampal or amygdaloid stimulation, while imipramine (2, 5 mg/kg) and amitriptyline (1--5 mg/kg) caused an initial depression followed by sustained enhancement of these afterdischarges.", "Thus the acute toxicity of lofepramine is approximately one - fifth that of its metabolite ; lofepramine is a less potent muscarinic receptor antagonist than desipramine ( verified by clinical studies in volunteers and depressed patients ) ; lofepramine is less likely to produce conduction defects than desipramine .", "Pretreatment with SKF 525A ( i.p . ) did not diminish the effect of lofepramine , but rather potentiated it .", "Lofepramine belongs to the group of tricyclic anti - depressants which preferentially inhibit noradrenaline uptake .", "The metabolism of lofepramine in vitro by rat liver microsomes was studied.", "The effect of low dose lofepramine in depressed elderly patients in general medical wards .", "Therefore it is suggested that the formation of desipramine is not necessary for lofepramine to exhibit , the effect on amine uptake in vivo .", "Thus , providing its apparent favourable side effect profile is confirmed in practice , lofepramine may be a valuable alternative for treatment of the depressed patient where a tricyclic is indicated .", "Neurochemical studies show that both lofepramine and its metabolite are potent noradrenaline uptake inhibitors in vitro and evidence is presented to suggest that lofepramine may release this amine following chronic administration in vivo ; both drugs slightly increase serotonin turnover under these conditions and down - regulate cortical beta - adrenoceptor function .", "During steady-state conditions the plasma level of lofepramine fluctuates considerably between doses.", "The results indicate that lofepramine undergoes pronounced first pass elimination and that desmethylimipramine is a major metabolite of it .", "Compared to placebo and lofepramine , amitriptyline produced drowsiness and dry mouth , reduced salivary volume and increased movement reaction time .", "In double - bind clinical trials , lofepramine has been shown to be as effective as desipramine and other comparator tricyclic antidepressants in the treatment of endogenous and reactive depression , but there are some differences between them .", "Metabolism of lofepramine by rat liver microsomes. 1.", "The overall therapeutic efficacy of lofepramine is comparable to that of imipramine , amitriptyline , clomipramine , maprotiline and mianserin in patients with depression of varying severity , and coexisting anxiety .", "Noradrenaline uptake was also preferentially inhibited in synaptosomes from brain of rats treated previously with lofepramine or desipramine (i.p.).", "However, low dose lofepramine is not indicated for mild (GDS 15-18) depression.", "No significant differences between lofepramine and placebo were observed in other parameters measured .", "4. Lofepramine, imipramine and DMI inhibited competitively the microsomal hydroxylation of aniline in vitro.", "These results demonstrate lopramine to be an antidepressant of a new type which has no effect on the ascending reticular activating system and no central anticholinergic action .", "In the dosage used, lofepramine exhibited no deleterious effect on the peripheral cholinergic system or psychomotor performance.", "Lofepramine was the most potent inhibitor , which probably reflects the higher lipophilicity of this compound .", "Lofepramine inhibited both 5-HT and noradrenaline uptake into synaptosomal fractions in vitro but was 4 times more potent in inhibiting noradrenaline than 5-HT uptake, indicating the effect resembles that of desipramine.", "Microsomes from rats pretreated with phenobarbital or 3-methylcholanthrene showed enhanced lofepramine metabolizing activity .", "From such tests it appears unlikely that the active metabolite, desipramine, is formed in the brain in sufficient concentrations after chronic lofepramine administration to make a substantial contribution towards the pharmacological activity of the parent compound.", "The effects of the novel tricyclic antidepressant lofepramine were compared with that of its principal metabolite desipramine.", "A dose related increase in plasma drug levels and pharmacological effects of lofepramine was observed .", "Effect of lofepramine and other antidepressants on the uptake of 5-hydroxytryptamine and noradrenaline into rat brain monoaminergic neurons.", "Unlike desipramine and most clinically effective antidepressants, lofepramine was inactive in attenuating the hyperactivity of olfactory bulbectomized rats in the \"open field\" apparatus, and in reversing acute clonidine induced hypomotility."], "par_relations": ["Lofepramine", "Dibenzazepines", "Antidepressive Agents, Tricyclic", "Lofepramine", "Lofepramine", "Lofepramine", "Lofepramine"], "chd_relations": ["Lofepramine", "Lofepramine", "Lofepramine", "Lofepramine", "Lofepramine"], "syn_relations": ["Lofepramine", "Lofepramine"], "sib_relations": ["Carbamazepine", "Clomipramine", "Clozapine", "Desipramine", "Imipramine", "Mianserin", "Opipramol", "Trimipramine"], "wiki_entities": ["Lofepramine", "List of drugs: Lo", "Desipramine", "List of antidepressants", "Otilonium bromide", "Tricyclic antidepressant", "Schedule H", "List of adrenergic drugs", "Atypical antidepressant", "Purple drank"], "mesh_synonynms": ["lofepramine", "deftan", "gamanil", "feprapax", "rosemont brand of lofepramine hydrochloride", "ashbourne brand of lofepramine hydrochloride", "gamonil", "leo 640", "lofepramine hydrochloride", "lopramine", "lomont", "hydrochloride, lofepramine", "merck brand of lofepramine hydrochloride"], "dbpedia_synonyms": ["atcvet code qn06aa07", "lofepramine", "lopramine", "atc code n06aa07"]}, "target_ent": {"research_entity_id": "RXNORM:6294", "canonical_name": "Lofepramine Hydrochloride", "aliases": ["lofepramine hydrochloride"], "definition": "Lofepramine, sold under the brand names Gamanil, Lomont, and Tymelyt among others, is a tricyclic antidepressant (TCA) which is used to treat depression.", "other_contexts": [], "par_relations": ["Lofepramine"], "chd_relations": ["Lomont", "Gamanil"], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Lofepramine", "Schedule H", "Desipramine", "Bupropion", "Ziprasidone", "Cyclobenzaprine", "Imipramine", "Tramadol", "Promethazine", "Dosulepin"], "mesh_synonynms": ["lofepramine", "deftan", "gamanil", "feprapax", "rosemont brand of lofepramine hydrochloride", "ashbourne brand of lofepramine hydrochloride", "gamonil", "leo 640", "lopramine", "lomont", "hydrochloride, lofepramine", "merck brand of lofepramine hydrochloride"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:13233", "canonical_name": "acidic nuclear phosphoprotein 32 family member A", "aliases": ["acidic nuclear phosphoprotein 32 family member a", "mapmodulin", "mapm", "i1pp2a", "anp32a", "pp32", "phapi", "anp32a gene", "lanp"], "definition": "Acidic leucine-rich nuclear phosphoprotein 32 family member A is a protein that in humans is encoded by the ANP32A gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A"], "sib_relations": [], "wiki_entities": ["Acidic leucine-rich nuclear phosphoprotein 32 family member A", "ANP32C", "ANP32D", "ANP32E", "ANP32B", "Protein SET", "MAP1B", "Rev-ErbA alpha", "IκB kinase", "Chromosome 12 (human)"], "mesh_synonynms": [], "dbpedia_synonyms": ["acidic leucine-rich nuclear phosphoprotein 32 family member a"]}, "target_ent": {"research_entity_id": "OMIM:600832", "canonical_name": "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "aliases": ["phap1", "anp32a", "acidic leucine-rich nuclear phosphoprotein 32 family, member a", "leucine-rich acidic nuclear protein", "phap i", "lanp", "putative human hla class ii-associated protein"], "definition": "Acidic leucine-rich nuclear phosphoprotein 32 family member A is a protein that in humans is encoded by the ANP32A gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["acidic leucine-rich nuclear phosphoprotein 32 family member a"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0001621", "canonical_name": "Weak voice", "aliases": ["weak voice", "hypophonia", "soft voice"], "definition": "Weak artificial intelligence (weak AI), also known as narrow AI, is artificial intelligence that is focused on one narrow task.", "other_contexts": [], "par_relations": ["Abnormality of the voice"], "chd_relations": [], "syn_relations": ["Weak voice", "Weak voice"], "sib_relations": ["Weak voice", "Loss of voice", "Hoarse voice", "Weak cry", "Cat cry", "High pitched voice", "Nasal speech", "Dysphonia", "Speech articulation difficulties", "Hyponasal speech", "Abnormally low-pitched voice", "Weak voice"], "wiki_entities": ["Weak AI", "Arabic verbs", "Cadence (music)", "Pronoun", "Agnosticism", "Speech recognition", "Germanic weak verb", "Adjective", "Land of the Lustrous", "English grammar"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "MSH:C043295", "canonical_name": "paromomycin phosphotransferase", "aliases": ["paromomycin phosphotransferase"], "definition": "Neomycin is an aminoglycoside antibiotic found in many topical medications such as creams, ointments, and eyedrops.", "other_contexts": [], "par_relations": ["Phosphotransferases (Alcohol Group Acceptor)"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Neomycin"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "CPT:82024", "canonical_name": "Adrenocorticotropic hormone (ACTH)", "aliases": ["adrenocorticotropic hormone acth", "assay of acth", "adrenocorticotropic hormone (acth)", "adrenocorticotropic hormone (acth) level", "measurement of adrenocorticotropic hormone (acth)"], "definition": "Adrenocorticotropic hormone (ACTH, also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced and secreted by the anterior pituitary gland.", "other_contexts": [], "par_relations": ["Chemistry Procedures"], "chd_relations": [], "syn_relations": ["Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)"], "sib_relations": ["Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)", "ACTH stimulation panel; for adrenal insufficiency This panel must include the following: Cortisol (82533 x 2)", "Corticotropic releasing hormone (CRH) stimulation panel This panel must include the following: Cortisol (82533 x 6) Adrenocorticotropic hormone (ACTH) (82024 x 6)", "Combined rapid anterior pituitary evaluation panel This panel must include the following: Adrenocorticotropic hormone (ACTH) (82024 x 4) Luteinizing hormone (LH) (83002 x 4) Follicle stimulating hormone (FSH) (83001 x 4) Prolactin (84146 x 4) Human growth hormone (HGH) (83003 x 4) Cortisol (82533 x 4) Thyroid stimulating hormone (TSH) (84443 x 4)", "Irrigation of implanted venous access device for drug delivery systems", "Androsterone", "Bradykinin", "Methemalbumin", "Pregnenolone", "Sialic acid", "Vitamin K", "17-hydroxypregnenolone", "Mucin, synovial fluid (Ropes test)", "Alpha-fetoprotein (AFP)", "Unlisted chemistry procedure", "Chemiluminescent assay", "Osmolality", "Acetylcholinesterase", "Phosphatase, acid", "Albumin", "Aldolase", "Vasopressin (antidiuretic hormone, ADH)", "Phosphatase, alkaline", "Alpha-1-antitrypsin", "Ammonia", "Amniotic fluid scan (spectrophotometric)", "Amylase", "Angiotensin I - converting enzyme (ACE)", "Ascorbic acid (Vitamin C), blood", "Glucosidase, beta", "Beta-2 microglobulin", "Bilirubin", "Biotinidase, each specimen", "Calcitonin", "Calcium", "Carbon dioxide (bicarbonate)", "Carboxyhemoglobin", "Carcinoembryonic antigen (CEA)", "Myelin basic protein, cerebrospinal fluid", "Chloride", "Citrate", "Cortisol", "Deoxycortisol, 11-", "Creatinine", "Dehydroepiandrosterone-sulfate (DHEA-S)", "Aminolevulinic acid, delta (ALA)", "Dibucaine number", "Erythropoietin", "Estrogens", "Etiocholanolone", "Fat differential, feces, quantitative", "Galactokinase, RBC", "Glutamyltransferase, gamma (GGT)", "Gastrin", "Phosphohexose isomerase", "Glutathione", "Growth hormone, human (HGH) (somatotropin)", "Histamine", "Homovanillic acid (HVA)", "Hydroxyprogesterone, 17-d", "Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit)", "Insulin", "C-peptide", "Transferrin", "Lactate dehydrogenase (LD), (LDH)", "Lactate (lactic acid)", "Leucine aminopeptidase (LAP)", "Nucleotidase 5'-", "Oxalate", "Parathormone (parathyroid hormone)", "pH", "Phosphatidylglycerol", "Urobilinogen, feces, quantitative", "Potassium", "Protein", "Oligoclonal immune (oligoclonal bands)", "Cholinesterase", "Serotonin", "Sex hormone binding globulin (SHBG)", "Thyroid stimulating hormone (TSH)", "Thyroxine", "Thyroxine binding globulin (TBG)", "Triglycerides", "Uric acid", "Vasoactive intestinal peptide (VIP)", "Pyridoxal phosphate (Vitamin B-6)", "Cyanocobalamin (Vitamin B-12)", "Chlorinated hydrocarbons, screen", "Alcohol (ethanol), breath", "Aluminum", "Chloramphenicol", "Cyanide", "Ethylene glycol", "Fluoride", "Quinine", "Silica", "Estrone", "Cryofibrinogen", "Creatine", "Glutamate dehydrogenase", "Isocitric dehydrogenase (IDH)", "Metanephrines", "Pyruvate", "Thiocyanate", "Androstenedione", "Estradiol", "Estriol", "Galactose", "Glucagon", "Glucose", "Iron", "Prealbumin", "Pregnanediol", "Sodium", "Thyroglobulin", "Tyrosine", "Glucagon tolerance test", "Adenosine, 5-monophosphate, cyclic (cyclic AMP)", "Aldosterone", "Angiotensin II", "Arsenic", "Atomic absorption spectroscopy, each analyte", "Cadmium", "Carotene", "Ceruloplasmin", "Cholesterol, serum or whole blood, total", "Chondroitin B sulfate, quantitative", "Chromium", "Copper", "Corticosterone", "Cystine and homocystine, urine, qualitative", "Dehydroepiandrosterone (DHEA)", "Desoxycorticosterone, 11-", "Electrophoretic technique, not elsewhere specified", "Fatty acids, nonesterified", "Ferritin", "Gases, blood, pH only", "Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)", "Gases, blood, O2 saturation only, by direct measurement, except pulse oximetry", "Hemoglobin-oxygen affinity (pO2 for 50% hemoglobin saturation with oxygen)", "Gastrin after secretin stimulation", "Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use", "Glutathione reductase, RBC", "Glycated protein", "Hemosiderin, qualitative", "Hydroxycorticosteroids, 17- (17-OHCS)", "Intrinsic factor", "Iron binding capacity", "Ketogenic steroids, fractionation", "Lactogen, human placental (HPL) human chorionic somatomammotropin", "Lactose, urine, qualitative", "Lipase", "Luteinizing releasing factor (LRH)", "Magnesium", "Malate dehydrogenase", "Manganese", "Mucopolysaccharides, acid, quantitative", "Myoglobin", "Nephelometry, each analyte not elsewhere specified", "Nickel", "Osteocalcin (bone g1a protein)", "Phenylalanine (PKU), blood", "Phosphogluconate, 6-, dehydrogenase, RBC", "Pregnanetriol", "Progesterone", "Prolactin", "Prostaglandin, each", "Protein, total, by refractometry, any source", "Proinsulin", "Pyruvate kinase", "Renin", "Riboflavin (Vitamin B-2)", "Selenium", "Somatomedin", "Somatostatin", "Spectrophotometry, analyte not elsewhere specified", "Sugars, chromatographic, TLC or paper chromatography", "Thiamine (Vitamin B-1)", "Thyroid stimulating immune globulins (TSI)", "Transcortin (cortisol binding globulin)", "Urea nitrogen, urine", "Vitamin A", "Volatiles (eg, acetic anhydride, diethylether)", "Xylose absorption test, blood and/or urine", "Zinc", "Ovulation tests, by visual color comparison methods for human luteinizing hormone", "Urobilinogen, urine", "Mercury, quantitative", "Vanillylmandelic acid (VMA), urine", "Porphobilinogen, urine", "Very long chain fatty acids", "Porphyrins, feces, quantitative", "Hemoglobin", "Collagen cross links, any method", "Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR)", "Troponin, quantitative", "Troponin, qualitative", "Hydroxyprogesterone, 20-", "Acylcarnitines", "Apolipoprotein, each", "Androstanediol glucuronide", "Bile acids", "Cathepsin-D", "Folic acid", "Hydroxyindolacetic acid, 5-(HIAA)", "Phenylketones, qualitative", "Phosphorus inorganic (phosphate)", "Specific gravity (except urine)", "Sulfate, urine", "Testosterone", "Urea nitrogen, clearance", "Lead", "Catecholamines", "Gonadotropin", "Amino acids, 2 to 5 amino acids, quantitative, each specimen", "Amino acids, 6 or more amino acids, quantitative, each specimen", "Carnitine (total and free), quantitative, each specimen", "Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen", "Fetal fibronectin, cervicovaginal secretions, semi-quantitative", "b-Hexosaminidase, each assay", "Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen", "Amines, vaginal fluid, qualitative", "Glucose, body fluid, other than blood", "Organic acid, single, quantitative", "Vitamin, not otherwise specified", "Carbohydrate deficient transferrin", "Vitamin D", "Haptoglobin", "Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations", "Lipoprotein (a)", "Tocopherol alpha (Vitamin E)", "Fructose, semen", "Hydroxyproline", "Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative", "Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (eg, C-13)", "Procalcitonin (PCT)", "Cystatin C", "Blood, occult, by peroxidase activity (eg, guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening", "Lipoprotein-associated phospholipase A2 (Lp-PLA2)", "Calprotectin, fecal", "Pregnancy-associated plasma protein-A (PAPP-A)", "Homocysteine", "Natriuretic peptide", "Myeloperoxidase (MPO)", "Thromboxane metabolite(s), including thromboxane if performed, urine", "Gastric acid analysis, includes pH if performed, each specimen", "Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity", "Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-fetoprotein), qualitative, each specimen", "Galectin-3", "Fetal lung maturity assessment", "Receptor assay", "Calculus", "Urea nitrogen", "Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate)", "Blood, occult, by peroxidase activity (eg, guaiac), qualitative", "Creatine kinase (CK), (CPK)", "Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified", "Fat or lipids, feces", "Gammaglobulin (immunoglobulin)", "Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury)", "Hemoglobin fractionation and quantitation", "Lipoprotein, blood", "Lipoprotein, direct measurement", "Porphyrins, urine", "Protein, total, except by refractometry", "Protoporphyrin, RBC", "Sugars (mono-, di-, and oligosaccharides)", "Lactoferrin, fecal", "Immunoassay for analyte other than infectious agent antibody or infectious agent antigen", "Ketosteroids, 17- (17-KS)", "Amino acids", "Glucose-6-phosphate dehydrogenase (G6PD)", "Galactose-1-phosphate uridyl transferase", "Transferase", "Triiodothyronine T3", "Trypsin", "Oncoprotein", "Helicobacter pylori", "Prostate specific antigen (PSA)", "Gonadotropin, chorionic (hCG)", "Organic acids", "Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)", "Adrenocorticotropic hormone (ACTH)", "Adrenocorticotropic hormone (ACTH)"], "wiki_entities": ["Adrenocorticotropic hormone", "ACTH stimulation test", "Adrenocorticotropic hormone (medication)", "Melanocyte-stimulating hormone", "Adrenocorticotropic hormone deficiency", "Trophic hormone", "Peptide hormone", "Anterior pituitary", "Alpha-Melanocyte-stimulating hormone", "Tropic hormone"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "GO:GO:0051460", "canonical_name": "negative regulation of corticotropin secretion", "aliases": ["downregulation of adrenocorticotropin secretion", "down-regulation of adrenocorticotropin secretion", "down regulation of adrenocorticotropin secretion", "negative regulation of acth secretion", "negative regulation of adrenocorticotropic hormone secretion", "inhibition of adrenocorticotropin secretion", "negative regulation of adrenotropic hormone secretion", "negative regulation of adrenotropin secretion", "negative regulation of corticotropic hormone secretion", "negative regulation of adrenocorticotropin secretion", "negative regulation of corticotropin secretion"], "definition": "Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of corticotropic hormone from a cell. [GOC:ai]", "other_contexts": [], "par_relations": ["regulation of corticotropin secretion", "negative regulation of multicellular organismal process", "negative regulation of peptide hormone secretion", "biological regulation", "negative regulation of corticotropin secretion"], "chd_relations": ["negative regulation of corticotropin secretion"], "syn_relations": ["negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion", "negative regulation of corticotropin secretion"], "sib_relations": ["corticotropin secretion", "corticotropin secretion", "negative regulation of circadian sleep/wake cycle, sleep", "negative regulation of insulin secretion", "negative regulation of isotype switching", "negative regulation of muscle contraction", "negative regulation of juvenile hormone secretion", "negative regulation of retinal cell programmed cell death", "negative regulation of embryonic development", "negative regulation of multicellular organism growth", "negative regulation of organ growth", "negative regulation of eclosion", "negative regulation of odontogenesis", "negative regulation of salivary gland boundary specification", "negative regulation of ossification", "negative regulation of antipodal cell differentiation", "negative regulation of embryo sac central cell differentiation", "negative regulation of embryo sac egg cell differentiation", "negative regulation of synergid differentiation", "negative regulation of spermatid nuclear differentiation", "negative regulation of atrichoblast fate specification", "negative regulation of trichoblast fate specification", "negative regulation of cuticle pigmentation", "negative regulation of female pigmentation", "negative regulation of male pigmentation", "negative regulation of cytokine production", "negative regulation of hair cycle", "negative regulation of epidermis development", "negative regulation of terminal cell fate specification, open tracheal system", "negative regulation of fusion cell fate specification", "negative regulation of multicellular organismal metabolic process", "negative regulation of heat generation", "negative regulation of neurological system process", "negative regulation of heat dissipation", "negative regulation of corticotropin-releasing hormone secretion", "positive regulation of corticotropin secretion", "negative regulation of post-embryonic development", "negative regulation of cardioblast differentiation", "negative regulation of border follicle cell delamination", "negative regulation of fusion of sperm to egg plasma membrane", "negative regulation of chitin-based cuticle tanning", "negative regulation of nervous system development", "negative regulation of tolerance induction", "negative regulation of gonadotropin secretion", "negative regulation of inhibin secretion", "negative regulation of neurotrophin production", "negative regulation of mammary gland epithelial cell proliferation", "negative regulation of tissue remodeling", "negative regulation of compound eye cone cell fate specification", "negative regulation of nurse cell apoptotic process", "negative regulation of muscle organ development", "negative regulation of glomerular filtration", "negative regulation of growth hormone secretion", "negative regulation of muscle hypertrophy", "negative regulation of muscle adaptation", "negative regulation of ovulation", "negative regulation of oocyte development", "negative regulation of penile erection", "negative regulation of digestive system process", "negative regulation of glucagon secretion", "negative regulation of adiponectin secretion", "negative regulation of biomineral tissue development", "negative regulation of mucus secretion", "negative regulation of hepatocyte differentiation", "negative regulation of spore-bearing organ development", "negative regulation of epithelial cell migration", "negative regulation of epithelial to mesenchymal transition", "negative regulation of very-low-density lipoprotein particle remodeling", "negative regulation of mammary gland development in males by androgen receptor signaling pathway", "negative regulation of epithelial cell proliferation involved in prostate gland development", "negative regulation of canonical Wnt signaling pathway involved in neural plate anterior/posterior pattern formation", "negative regulation of cartilage development", "negative regulation of branching involved in lung morphogenesis", "negative regulation of Wnt signaling pathway involved in heart development", "negative regulation of mesenchymal cell proliferation involved in ureter development", "negative regulation of kidney development", "negative regulation of somatostatin secretion", "negative regulation of lipoprotein particle clearance", "negative regulation of coagulation", "negative regulation of respiratory burst involved in inflammatory response", "negative regulation of stomach neuroendocrine cell differentiation", "negative regulation of canonical Wnt signaling pathway involved in neural crest cell differentiation", "negative regulation of determination of dorsal identity", "negative regulation of male gonad development", "negative regulation of cardiac cell fate specification", "negative regulation of Wnt signaling pathway involved in dorsal/ventral axis specification", "negative regulation of Wnt signaling pathway involved in digestive tract morphogenesis", "negative regulation of ureter smooth muscle cell differentiation", "negative regulation of type B pancreatic cell development", "negative regulation of mammary stem cell proliferation", "negative regulation of cell proliferation involved in heart morphogenesis", "negative regulation of female gonad development", "negative regulation of pancreatic A cell differentiation", "negative regulation of male germ cell proliferation", "negative regulation of defecation", "negative regulation of fibroblast growth factor receptor signaling pathway involved in neural plate anterior/posterior pattern formation", "negative regulation of hepatocyte proliferation", "negative regulation of cell proliferation involved in compound eye morphogenesis", "negative regulation of energy homeostasis", "negative regulation of renal albumin absorption", "negative regulation of thyroid-stimulating hormone secretion", "negative regulation of leukotriene production involved in inflammatory response", "negative regulation of renal sodium excretion", "negative regulation of trichome patterning", "negative regulation of hemostasis", "negative regulation of leaf senescence", "negative regulation of nodal signaling pathway involved in determination of left/right asymmetry", "negative regulation of bone trabecula formation", "negative regulation of beta-amyloid clearance", "negative regulation of mesenchymal cell proliferation involved in lung development", "negative regulation of epithelial cell proliferation involved in lung morphogenesis", "negative regulation of amniotic stem cell differentiation", "negative regulation of parathyroid hormone secretion", "negative regulation of steroid hormone secretion", "negative regulation of lens epithelial cell proliferation", "negative regulation of renal water transport", "negative regulation of adrenergic receptor signaling pathway involved in heart process", "negative regulation of oviposition", "negative regulation of sclerotium development", "negative regulation of vasculature development", "negative regulation of lung goblet cell differentiation", "negative regulation of lung ciliated cell differentiation", "negative regulation of cardiac chamber morphogenesis", "negative regulation of trophoblast cell migration", "negative regulation of relaxation of muscle", "negative regulation of cartilage homeostasis", "negative regulation of shoot apical meristem development", "negative regulation of apoptotic process involved in outflow tract morphogenesis", "negative regulation of male mating behavior", "negative regulation of stem cell population maintenance", "negative regulation of sperm capacitation", "negative regulation of prolactin secretion", "negative regulation of lens fiber cell differentiation", "negative regulation of renal amino acid absorption", "negative regulation of BMP signaling pathway involved in determination of lateral mesoderm left/right asymmetry", "negative regulation of retina development in camera-type eye", "negative regulation of root hair elongation", "negative regulation of bone development", "negative regulation of insulin receptor signaling pathway involved in determination of adult lifespan", "negative regulation of tube lumen cavitation", "negative regulation of vitellogenesis", "negative regulation of fear response", "negative regulation of renal phosphate excretion", "negative regulation of lactation", "negative regulation of blood circulation", "negative regulation of histamine secretion by mast cell", "negative regulation of epithelial cell-cell adhesion involved in epithelium migration", "negative regulation of hemopoiesis", "negative regulation of cardiac conduction", "negative regulation of collecting lymphatic vessel constriction", "negative regulation of respiratory gaseous exchange", "negative regulation of apical ectodermal ridge formation", "negative regulation of male germ-line stem cell asymmetric division", "negative regulation of lung alveolus development", "negative regulation of substance P secretion", "negative regulation of thyroid gland epithelial cell proliferation", "negative regulation of cardiac ventricle development", "negative regulation of calcitonin secretion", "negative regulation of maternal process involved in parturition", "negative regulation of adipose tissue development"], "wiki_entities": ["Corticotropin-releasing hormone", "Anterior pituitary", "UCN3", "Vasopressin", "CRHBP", "Hypothalamic–pituitary–adrenal axis", "Neuroendocrinology", "Corticotropin-releasing hormone receptor 1", "Ghrelin", "Hypothalamus"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HPO:HP:0002902", "canonical_name": "Hyponatremia", "aliases": ["hyponatremia", "low blood sodium levels"], "definition": "Hyponatremia is a low sodium level in the blood.", "other_contexts": ["involved in gait function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by", "2 [ 1.18 - 1.48 ; 95% CIs ] ; P < .000 ) . A meta - regression analysis showed that the hyponatremia - related length of hospital stay was higher in males ( Slope = 0.09 [ 0.05 - 0.12 ; 95% CIs ] ; P", "RESULTS Dose, age, baseline serum sodium level and kidney function, according to estimated GFR clearance, were significant risk factors for hyponatraemia in both sexes; similar to the known risk factors associated with hyponatraemia in the general population.", "codes and administrative variables of heart failure patients with and without hyponatremia . The chi - square test was used for qualitative variables and the Student 's t test for", "MEASUREMENTS AND MAIN RESULTS Three hundred nineteen patients were placed in three exclusive groups based on the lowest serum sodium measurement during admission : 1 ) severe hyponatremia : serum sodium less than or equal to 130 mEq / L ; 2 ) mild hyponatremia : 131 - 135 mEq / L ; and 3 ) normal sodium : more than 135 mEq / L. Timing and severity of sodium perturbations were assessed within each group .", "patients with osteoporosis or assessing bone mineral density ( BMD ) in patients with hyponatremia ? The answers to these questions have not been established . Definitive answers will require", "Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95% confidence interval , 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar .", "function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone", "the cost of normonatremic subjects . CONCLUSIONS This meta - analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission . These", "SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs significantly .", "all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients ( 40.9% ; n=27 versus 21.1% ; n=75 ) , translating into a 2.", "function , according to estimated GFR clearance , were significant risk factors for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general", "This is worrisome not only because hyponatremia counts as the most common electrolyte disorder in hospitalized patients but also because it is associated with increased mortality .", "Across various disciplines, hyponatremia is associated with increased mortality and longer hospital stay, yet in intracerebral hemorrhage (ICH) no data are available.", "Hyponatremia maintained statistical significance in the regression model after adjusting for gender, OR 0.919 (95% CI 0.902-0.936); age, OR 1.061 (95% CI 1.060-1.062); and Charlson index, OR 1.388 (95% CI 1.361-1.461).", "condition that is linked to worse outcome due to greater comorbidity . Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", ". In men , arthritis and use of drugs for bone disease were also predictive of hyponatraemia , while in women , raised monocytes and absence of lipid - modifying drugs increased the risk of", "published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was performed including all", ". This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH . METHODS This observational study included all consecutive spontaneous ICH", "and fractures has become more established . This study evaluates the prevalence of hyponatraemia ( plasma sodium<135mmol / l ) in 3897 patients undergoing operative treatment for hip fracture and", "mortality with a fairly high prevalence in spontaneous ICH patients . The presence of hyponatremia at hospital admission is related to an increased short - term mortality in patients surviving", "A meta-regression analysis showed that the hyponatremia-related length of hospital stay was higher in males (Slope = 0.09 [0.05-0.12; 95% CIs]; P = .000 and Intercept = -1.36 [-3.03-0.32; 95% CIs]; P = .11) and in elderly patients (Slope = 0.002 [0.001-0.003; 95% CIs]; P", "study was the evaluation of frequency , potential causes , and risk factors of hyponatraemia in patients with tick - borne encephalitis ( TBE ) . A total of 61 patients ( 22 women , 39 men )", "increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly . Hyponatremia appears to contribute to falls and fractures by two mechanisms . First , it produces mild", "Do patients die with or from hyponatremia ? ”", "patients were appropriately screened out , only mild , non - clinically significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the", "In the hyponatremia group, the mean survival time of corrected hyponatremia patients was 0.91±0.42 years, which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years (t=2.75, p<0.05) after symptomatic treatment.", "Does the patient have hypovolemic , euvolemic , or hypervolemic hyponatremia ?", "within 12 months of discharge . Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003", "admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with", "In men, arthritis and use of drugs for bone disease were also predictive of hyponatraemia, while in women, raised monocytes and absence of lipid-modifying drugs increased the risk of hyponatraemia.", "Hyponatremia appears to contribute to falls and fractures by two mechanisms.", "and 20% of patients at discharge . There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited", "Finally, when only US studies (n = 8) were considered, hyponatremia was associated with up to around $3000 higher hospital costs/patient when compared with the cost of normonatremic subjects.", "Every effort should be made to identify and correct hyponatraemia in hip fracture patients .", "BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice.", "of hospital stay and of hospital resource utilization . To clarify the impact of hyponatremia on the length of hospitalization and costs , we performed a meta - analysis based on published", "active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD , thereby reducing the risk of fractures . Until", "Importantly, hyponatremia’s most dangerous and potentially fatal complications, cerebral edema and the osmotic demeylination syndrome, were rarely observed.", "These disorders were largely absent in survivors, whose more severe hyponatremia was largely attributed to the use of thiazides and antidepressants.", "A sodium monitoring plan is proposed whereby baseline sodium must be ≥135 mmol / L ( especially important in the elderly ) , with additional monitoring at week 1 and month 1 for those at elevated risk because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia .", "Hyponatremia at 1- and 3-year follow - up was associated with worse survival rates ( p<0.05 ) .", "In this vulnerable patient group, hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post-operative mortality.", "Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.", "After surgery , sodium decreased in all groups with lower averaged concentrations during postoperative days 0 - 1 and 5 - 6 , although patients with severe hyponatremia had the greatest decline .", "1.060 - 1.062 ) ; and Charlson index , OR 1.388 ( 95% CI 1.361 - 1.461 ) . CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute", "Should we be screening for low serum sodium in patients with osteoporosis or assessing bone mineral density ( BMD ) in patients with hyponatremia ?", "abnormality observed in clinical practice . Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization . To", "duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia . RESULTS Of 444 retrieved articles , 46 studies satisfied the inclusion criteria , encompassing a", "is common in hospitalised patients . In recent years the relationship between hyponatraemia and bone metabolism , falls and fractures has become more established . This study evaluates the", "Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", "hyponatremia may represent one important determinant of the hospitalization costs .", "Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria.", "will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether", "when 125 - 129 mmol / l , and severe when < 125 mmol / l . Among the 61 patients , hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% )", "patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "042 patients ; among these , 757,763 ( 19.2% ) were hyponatremic . Across all studies , hyponatremia was associated with a significantly longer duration of hospitalization ( 3.30 [ 2.90 - 3.71 ; 95%", "This monitoring plan would help to prevent some at-risk patients developing hyponatraemia; retrospective application of the monitoring plan showed that, once at-risk patients were appropriately screened out, only mild, non-clinically significant hyponatraemia was observed, within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population.", "CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender-specific dosing with the ODT formulation of desmopressin (25 μg in women, 50 μg in men).", "to retrieve all studies published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was", "METHODS An extensive Medline , Embase , and Cochrane search was performed to retrieve all studies published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \"", "variables , and age , gender , comorbidity according to the Charlson index and hyponatremia as independent variables . RESULTS A total of 504,860 patients with acute heart failure were", "for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general population . In men , arthritis and use of drugs for bone disease were also", "Young children with hydrocephalus have increased risk of severe hyponatremia.", "Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD ,", "CONCLUSION Hyponatremia developed in just over half of children .", "The Economic Burden of Hyponatremia : Systematic Review and Meta - Analysis .", "Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival, especially in the uncorrected group.", "Those with severe hyponatremia need frequent and prolonged monitoring because of risk for repeat sodium changes.", "Finally , elderly patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "Nine patients had initial severe hyponatremia between days 6 and 20 after surgery.", "Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours.", "main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs", "RESULTS The incidence rate of hyponatremia in SCLC was 46.56% (149/320).", "Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003 ) .", ", 39 men ) aged 18 - 80 years , with a history of TBE was included in the study . Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild", "Therefore , two possibilities remain ( Figure 1 ) : ( 1 ) Hyponatremia is a direct cause of death , or ( 2 ) severe underlying disease is the cause of death and hyponatremia is merely another complication of this underlying disease .", "operative mortality on multivariate analysis . Median age at admission was 83 years . Hyponatraemia was present in 19.1% of patients with hip fracture on admission , 29.5% of patients in the first 24", "an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636", "- up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure", "For those who are not electrolyte enthusiasts, hyponatremia can be a frustrating disorder.", "These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs.", ", in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients ,", "most frequent electrolyte disturbance in critical care . Across various disciplines , hyponatremia is associated with increased mortality and longer hospital stay , yet in intracerebral hemorrhage (", "The probability of readmission for patients with hyponatremia was 22% versus 17% in the non-hyponatremic group.", "First, it produces mild cognitive impairment, resulting in unsteady gait and falls; this is probably due to the loss of glutamate (a neurotransmitter involved in gait function) as an osmolyte during brain adaptation to chronic hyponatremia.", "desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced", "Hundred thirty - seven patients ( 43% ) had mild hyponatremia , 39 ( 12% ) had severe hyponatremia , and 143 ( 45% ) had normal sodium .", "Little is known about the effects of hyponatremia on other organs, such as the heart, although a recent study identified hyponatremia as an independent predictor of myocardial infarction in community patients (16).", "with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia , and if present , treatment should be initiated . Finally , elderly patients presenting with an", "morbidities was observed . Finally , when only US studies ( n = 8) were considered , hyponatremia was associated with up to around $ 3000 higher hospital costs / patient when compared with the", ", hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe", "fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post - operative mortality on multivariate analysis .", "differs significantly . Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe .", "length of stay , associated comorbidities , readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set ( MBDS ) .", ". This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ; retrospective application of the monitoring plan showed that , once at - risk patients were", "/ L ) . Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital", "post - operative mortality . Every effort should be made to identify and correct hyponatraemia in hip fracture patients .", "Analysis of hyponatraemia associated post - operative mortality in 3897 hip fracture patients .", "A descriptive data analysis was conducted comparing the diagnosis codes and administrative variables of heart failure patients with and without hyponatremia .", "In - hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients ( 40.9% ; n=27 versus 21.1% ; n=75 ) , translating into a 2.5-fold increased odds ratio ( P<0.001 ) .", "patients ( 53,820 patients ) . The probability of readmission for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate", "Among hyponatremic patients , obstructive hydrocephalus and age less than 3.5 years were significant independent risk factors for severe hyponatremia .", "Across all studies , hyponatremia was associated with a significantly longer duration of hospitalization ( 3.30 [ 2.90 - 3.71 ; 95% CIs ] mean days ; P < .000 ) .", "Patients with severe hyponatremia had greater sodium variability with significantly lower nadirs , greater maximum values , and larger decreases within 24-hour periods compared with other sodium groups .", "Further study is needed to evaluate ideal monitoring and treatment of severe hyponatremia after intracranial tumor surgery.", "Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization .", "heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) . Hyponatremia maintained statistical significance in the regression model after adjusting for gender , OR 0.919 (", "This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH .", "Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model.", "functional outcome ( 90 days and 1 year ) were analyzed to determine the effects of hyponatremia ( Na<135 mEq / L ) . Multivariable regression analyses were calculated for factors associated with", "at initial presentation and during admission . In this vulnerable patient group , hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post -", "differences as far as gender or clinical form of the disease are concerned . Hyponatraemia , usually mild , is a common disorder in the course of TBE , although it is not significantly more", "Until such studies are conducted , physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders .", "A multivariate logistic regression analysis was performed, taking intrahospital mortality and hospital readmissions as dependent variables, and age, gender, comorbidity according to the Charlson index and hyponatremia as independent variables.", "The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients younger than 60 years old.", "Following elimination of other independent variables associated with increased mortality , hyponatraemia on admission was associated with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) .", ", 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar . CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high", "This study evaluates the prevalence of hyponatraemia ( plasma sodium<135mmol / l ) in 3897 patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients .", "However, hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "This is an interesting conclusion that will definitely stir debate on the value of actively treating hyponatremia.", "for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with", "The presence of hyponatremia at hospital admission is related to an increased short-term mortality in patients surviving acute care, possibly reflecting a preexisting condition that is linked to worse outcome due to greater comorbidity.", "Evaluation of hyponatraemia in patients with tick-borne encephalitis--a preliminary study.", "patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post -", "association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The mean survival time was 1.10±0.42 years in patients with", "Dehydration seems to be the main cause of hyponatraemia in the course of TBE .", "serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia", "than in other hospitalized patients . Dehydration seems to be the main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE ,", "Use of the proposed monitoring scheme and the minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment.", "SNS hospitals . Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity", "with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post - operative hyponatraemia was also associated with an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends", "Median time to death for patients with and without hyponatraemia within 24h post - operatively was 35 months ( SE 2.5 months ) and 42 months ( SE 1.7 months ) respectively ( p=0.004 ) .", "Second, hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone resorption to mobilize sodium stores in bone.", "L was recorded by age , sex and dose . Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model . RESULTS Dose ,", "Thus , the authors conclude that patients die with and not from hyponatremia .", "and prognosis of elderly small cell lung cancer ( SCLC ) patients complicated with hyponatremia , thus providing increased attention for appropriate intervention and improving outcomes in", "The investigators first show mortality rates in a large sample of hospitalized patients with hyponatremia ( serum sodium 135 mmol / L ) .", "disorder . Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate", "(10) elegantly rephrase the issue of hyponatremia and mortality as, “", "During the defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "into a 2.5-fold increased odds ratio ( P<0.001 ) . Multivariable analyses identified hyponatremia as an independent predictor of in - hospital mortality ( odds ratio , 2.2 ; 95% confidence", "to decrease when compared to another group of patients younger than 60 years old . Hyponatremia at 1- and 3-year follow - up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The", "formulate an interesting hypothesis ( 10 ) : That patients with moderate hyponatremia have more severe underlying disease than those with severe hyponatremia and therefore higher mortality rates .", ", physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders . As serum sodium is a readily available , simple , and affordable biochemical", "These challenges may be the reason that the management of hyponatremia is still suboptimal (1– 3).", "Hyponatremia and bone disease Hip fractures represent a serious health risk in the elderly, causing substantial morbidity and mortality.", "length of stay and higher risk of readmission . These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs .", "Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) .", "with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic", "For example, emerging data implicate hyponatremia in falls (11), osteoporosis (12), and fractures (13–15), suggesting an effect on the nervous system and bone.", "Hyponatremia and mortality : how innocent is the bystander ?", "of hyponatraemia in patients with tick - borne encephalitis -- a preliminary study . Hyponatraemia is one of the most frequently observed , but sometimes overlooked , electrolyte disorder .", "in elderly patients , especially in those receiving medications that can cause hyponatremia . Furthermore , elderly patients with an unsteady gait and/or confusion should be evaluated for", "Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality .", "Hyponatremia in hospitalised patients with heart failure in internal medicine : Analysis of the Spanish national minimum basic data set ( MBDS ) ( 2005 - 2011 ) .", "women , raised monocytes and absence of lipid - modifying drugs increased the risk of hyponatraemia . Use of the proposed monitoring scheme and the minimum effective dose would have omitted all", "Does this study prove hyponatremia to be an innocent bystander in mortality ?", "It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided .", "Timing , duration , and severity of hyponatremia following pediatric brain tumor surgery*. OBJECTIVE To describe the time course , variability , and magnitude of serum sodium changes among children undergoing intracranial tumor surgery .", "hyponatraemia associated post - operative mortality in 3897 hip fracture patients . Hyponatraemia is common in hospitalised patients . In recent years the relationship between hyponatraemia and", "Among the 61 patients, hyponatraemia was observed in 41% (25 patients).", ") respectively ( p=0.003 ) . Median time to death for patients with and without hyponatraemia within 24h post - operatively was 35 months ( SE 2.5 months ) and 42 months ( SE 1.7 months )", "was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) . Hyponatraemia is common in elderly patients with hip fractures both at initial presentation and during admission", "CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high prevalence in spontaneous ICH patients .", "Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia.", "A gradual year - on - year increase of hyponatremia codification ( both primary and secondary diagnosis ) was observed at discharge throughout the study period ( from 1.6% in 2005 to 2.8% in 2011 ; p<0.0001 ) .", "hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all", "Multivariable analyses identified hyponatremia as an independent predictor of in-hospital mortality (odds ratio, 2.2; 95% confidence interval, 1.05-4.62; P=0.037).", ", 2.2 ; 95% confidence interval , 1.05 - 4.62 ; P=0.037 ) . Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95%", "A meta - analysis was performed including all studies comparing duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia .", "The objective of this study is to assess the incidence, average length of stay, associated comorbidities, readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set (MBDS).", "mortality . There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia . This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ;", "survival , especially in the uncorrected group . It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided .", "patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years ( t=2.75 , p<0.05 ) after symptomatic", "Seventy-five percent of patients manifest mild hyponatremia within two postoperative days; however, severe hyponatremia developed later with 75% of patients manifesting severe hyponatremia within six postoperative days.", "Economic Burden of Hyponatremia : Systematic Review and Meta - Analysis . BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice . Several studies have", "elimination of other independent variables associated with increased mortality , hyponatraemia on admission was associated with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post -", "The prognosis and possible association with hyponatremia was investigated .", "Nearly 80% of hyponatremic patients had mild hyponatremia prior to development of severe hyponatremia; median time between mild hyponatremia and severe hyponatremia was 1.6 days (interquartile range, 0.4-5.6).", "BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care.", "RESULTS The prevalence of hyponatremia on hospital admission was 15.6% ( n=66 ) .", "Hyponatremia is an independent predictor of in - hospital mortality in spontaneous intracerebral hemorrhage .", "Overall mortality due to any cause in patients with hyponatremia was 17% (1937 patients) versus 11% in non-hyponatremic patients (53,820 patients).", "Seventy-five percent of children with severe hyponatremia spent more than 4 days with abnormally low sodium values.", "OBJECTIVE To explore risk factors for desmopressin-induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan.", "OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice.", "The nuance comes from a third possibility ( Figure 1 ) : Hyponatremia may contribute to organ dysfunction and therefore indirectly contribute to mortality .", "of the Spanish national minimum basic data set ( MBDS ) ( 2005 - 2011 ) . OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice . Numerous studies have reported", "Furthermore, elderly patients with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia, and if present, treatment should be initiated.", "significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender - specific dosing with the ODT formulation of", "and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia : A Retrospective Analysis . AIM This study was designed to evaluate the clinical characteristics", "The patients with severe hyponatremia , they argue , were likely admitted because their serum sodium was so low , not because they were so ill .", "treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan . SUBJECTS AND METHODS This was a meta -", "Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) .", "There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "normal values and 0.83±0.35 years in patients with subnormal serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was", "In recent years the relationship between hyponatraemia and bone metabolism, falls and fractures has become more established.", "significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population .", "and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients , sodium concentration normalized", "Post-operative hyponatraemia was also associated with an increased risk of death (adjusted HR 1.15, p=0.006).", "0.05 ) after symptomatic treatment . The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients", "CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute heart failure in SNS hospitals.", "There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer.", "AIM This study was designed to evaluate the clinical characteristics and prognosis of elderly small cell lung cancer (SCLC) patients complicated with hyponatremia, thus providing increased attention for appropriate intervention and improving outcomes in symptomatic subjects.", ", simple , and affordable biochemical measurement , clinicians should look for hyponatremia in elderly patients , especially in those receiving medications that can cause hyponatremia .", "- hospital mortality in spontaneous intracerebral hemorrhage . BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care . Across various disciplines ,", "The aim of the present study was the evaluation of frequency , potential causes , and risk factors of hyponatraemia in patients with tick - borne encephalitis ( TBE ) .", "that compared hospital length of stay and cost between patients with and without hyponatremia . METHODS An extensive Medline , Embase , and Cochrane search was performed to retrieve all", "Low - dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia .", "To clarify the impact of hyponatremia on the length of hospitalization and costs, we performed a meta-analysis based on published studies that compared hospital length of stay and cost between patients with and without hyponatremia.", "defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity index .", ". Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild when sodium concentration was 130 - 134 mmol / l , moderate when 125 - 129", "Definitive answers will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia, to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD, thereby reducing the risk of fractures.", "hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission .", "Patient characteristics, in-hospital measures, mortality, and functional outcome (90 days and 1 year) were analyzed to determine the effects of hyponatremia (Na<135 mEq/L).", "The association between hyponatremia and mortality has been demonstrated in numerous studies (4 –9), but causality has been difficult to prove.", "minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using", ", of whom 11,095 ( 2.2% ) presented with HNa . A gradual year - on - year increase of hyponatremia codification ( both primary and secondary diagnosis ) was observed at discharge throughout the", "and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer . The median follow - up time was 863 ( range 0 - 4352 ) days . There were 2460", "As serum sodium is a readily available, simple, and affordable biochemical measurement, clinicians should look for hyponatremia in elderly patients, especially in those receiving medications that can cause hyponatremia.", "2005 to 2.8% in 2011 ; p<0.0001 ) . Overall mortality due to any cause in patients with hyponatremia was 17% ( 1937 patients ) versus 11% in non - hyponatremic patients ( 53,820 patients ) . The", "CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts .", "Dealing with hyponatremia means considering various and often opposite scenarios.", "1st , 2012 , were studied retrospectively . The prognosis and possible association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The", "of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival , especially in the"], "par_relations": ["Abnormality of sodium homeostasis"], "chd_relations": [], "syn_relations": ["Hyponatremia", "Hyponatremia"], "sib_relations": ["Hypernatremia", "Increased intracellular sodium"], "wiki_entities": ["Hyponatremia", "Hypotonic hyponatremia", "Isotonic hyponatremia", "Water intoxication", "Exercise-associated hyponatremia", "Exercise-induced nausea", "Syndrome of inappropriate antidiuretic hormone secretion", "Central pontine myelinolysis", "Potomania", "Vasopressin receptor antagonist"], "mesh_synonynms": ["hyponatremias"], "dbpedia_synonyms": ["hypovolemic hyponatremia", "sodium deficiency", "hyponaetraemia", "low sodium", "hyponatermia", "hyponatraemia", "salt deficiency", "hyponatrimia", "hyponetremia", "hyponatremic encephalopathy"]}, "target_ent": {"research_entity_id": "MSH:D007010", "canonical_name": "Hyponatremia", "aliases": ["hyponatremia", "hyponatremias"], "definition": "Hyponatremia is a low sodium level in the blood.", "other_contexts": ["In men , arthritis and use of drugs for bone disease were also predictive of hyponatraemia , while in women , raised monocytes and absence of lipid - modifying drugs increased the risk of hyponatraemia .", "2 [ 1.18 - 1.48 ; 95% CIs ] ; P < .000 ) . A meta - regression analysis showed that the hyponatremia - related length of hospital stay was higher in males ( Slope = 0.09 [ 0.05 - 0.12 ; 95% CIs ] ; P", "involved in gait function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by", "codes and administrative variables of heart failure patients with and without hyponatremia . The chi - square test was used for qualitative variables and the Student 's t test for", "patients with osteoporosis or assessing bone mineral density ( BMD ) in patients with hyponatremia ? The answers to these questions have not been established . Definitive answers will require", "Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95% confidence interval , 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar .", "Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia.", "Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone resorption to mobilize sodium stores in bone .", "function ) as an osmolyte during brain adaptation to chronic hyponatremia . Second , hyponatremia directly contributes to osteoporosis and increased bone fragility by inducing increased bone", "the cost of normonatremic subjects . CONCLUSIONS This meta - analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission . These", "SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs significantly .", "all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients ( 40.9% ; n=27 versus 21.1% ; n=75 ) , translating into a 2.", "RESULTS Dose , age , baseline serum sodium level and kidney function , according to estimated GFR clearance , were significant risk factors for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general population .", "function , according to estimated GFR clearance , were significant risk factors for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general", "This is worrisome not only because hyponatremia counts as the most common electrolyte disorder in hospitalized patients but also because it is associated with increased mortality .", "condition that is linked to worse outcome due to greater comorbidity . Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", ". In men , arthritis and use of drugs for bone disease were also predictive of hyponatraemia , while in women , raised monocytes and absence of lipid - modifying drugs increased the risk of", "published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was performed including all", "The aim of the present study was the evaluation of frequency, potential causes, and risk factors of hyponatraemia in patients with tick-borne encephalitis (TBE).", ". This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH . METHODS This observational study included all consecutive spontaneous ICH", "Further study is needed to evaluate ideal monitoring and treatment of severe hyponatremia after intracranial tumor surgery .", "and fractures has become more established . This study evaluates the prevalence of hyponatraemia ( plasma sodium<135mmol / l ) in 3897 patients undergoing operative treatment for hip fracture and", "mortality with a fairly high prevalence in spontaneous ICH patients . The presence of hyponatremia at hospital admission is related to an increased short - term mortality in patients surviving", "A meta-regression analysis showed that the hyponatremia-related length of hospital stay was higher in males (Slope = 0.09 [0.05-0.12; 95% CIs]; P = .000 and Intercept = -1.36 [-3.03-0.32; 95% CIs]; P = .11) and in elderly patients (Slope = 0.002 [0.001-0.003; 95% CIs]; P", "study was the evaluation of frequency , potential causes , and risk factors of hyponatraemia in patients with tick - borne encephalitis ( TBE ) . A total of 61 patients ( 22 women , 39 men )", "increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly . Hyponatremia appears to contribute to falls and fractures by two mechanisms . First , it produces mild", "Do patients die with or from hyponatremia ? ”", "patients were appropriately screened out , only mild , non - clinically significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the", "within 12 months of discharge . Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003", "admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours . In - hospital mortality was roughly doubled in hyponatremia compared with", "Should we be screening for low serum sodium in patients with osteoporosis or assessing bone mineral density (BMD) in patients with hyponatremia?", "and 20% of patients at discharge . There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited", "of hospital stay and of hospital resource utilization . To clarify the impact of hyponatremia on the length of hospitalization and costs , we performed a meta - analysis based on published", "< length of stay and higher risk of readmission . These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs .", "active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD , thereby reducing the risk of fractures . Until", "Importantly, hyponatremia’s most dangerous and potentially fatal complications, cerebral edema and the osmotic demeylination syndrome, were rarely observed.", "These disorders were largely absent in survivors, whose more severe hyponatremia was largely attributed to the use of thiazides and antidepressants.", "Analysis of hyponatraemia associated post-operative mortality in 3897 hip fracture patients.", "Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization.", "A sodium monitoring plan is proposed whereby baseline sodium must be ≥135 mmol / L ( especially important in the elderly ) , with additional monitoring at week 1 and month 1 for those at elevated risk because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia .", "MEASUREMENTS AND MAIN RESULTS Three hundred nineteen patients were placed in three exclusive groups based on the lowest serum sodium measurement during admission: 1) severe hyponatremia: serum sodium less than or equal to 130 mEq/L; 2) mild hyponatremia: 131-135 mEq/L; and 3) normal sodium: more than 135 mEq/L. Timing and severity of sodium perturbations were assessed within each group.", "In this vulnerable patient group, hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post-operative mortality.", "Median time to death for patients with and without hyponatraemia within 24h post-operatively was 35 months (SE 2.5 months) and 42 months (SE 1.7 months) respectively (p=0.004).", "Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.", "After surgery , sodium decreased in all groups with lower averaged concentrations during postoperative days 0 - 1 and 5 - 6 , although patients with severe hyponatremia had the greatest decline .", "1.060 - 1.062 ) ; and Charlson index , OR 1.388 ( 95% CI 1.361 - 1.461 ) . CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute", "abnormality observed in clinical practice . Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization . To", "duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia . RESULTS Of 444 retrieved articles , 46 studies satisfied the inclusion criteria , encompassing a", "A multivariate logistic regression analysis was performed , taking intrahospital mortality and hospital readmissions as dependent variables , and age , gender , comorbidity according to the Charlson index and hyponatremia as independent variables .", "Correction of hyponatremia does not seem to compensate its influence on mortality , which strongly warrants future research .", "is common in hospitalised patients . In recent years the relationship between hyponatraemia and bone metabolism , falls and fractures has become more established . This study evaluates the", "CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts.", "will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether", "Definitive answers will require randomized controlled studies that allocate elderly individuals with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD , thereby reducing the risk of fractures .", "patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "when 125 - 129 mmol / l , and severe when < 125 mmol / l . Among the 61 patients , hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% )", "042 patients ; among these , 757,763 ( 19.2% ) were hyponatremic . Across all studies , hyponatremia was associated with a significantly longer duration of hospitalization ( 3.30 [ 2.90 - 3.71 ; 95%", "In-hospital mortality was roughly doubled in hyponatremia compared with nonhyponatremia patients (40.9%; n=27 versus 21.1%; n=75), translating into a 2.5-fold increased odds ratio (P<0.001).", "Little is known about the effects of hyponatremia on other organs , such as the heart , although a recent study identified hyponatremia as an independent predictor of myocardial infarction in community patients ( 16 ) .", "to retrieve all studies published up to April 1 , 2015 using the following words : \" hyponatremia \" or \" hyponatraemia \" AND \" hospitalization \" or \" hospitalisation . \" A meta - analysis was", "CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender-specific dosing with the ODT formulation of desmopressin (25 μg in women, 50 μg in men).", "variables , and age , gender , comorbidity according to the Charlson index and hyponatremia as independent variables . RESULTS A total of 504,860 patients with acute heart failure were", "A descriptive data analysis was conducted comparing the diagnosis codes and administrative variables of heart failure patients with and without hyponatremia.", "Young children with hydrocephalus have increased risk of severe hyponatremia.", "Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "with mild hyponatremia to receive either active treatment or no treatment for hyponatremia , to determine whether correction of hyponatremia prevents gait disturbances and changes in BMD ,", "for hyponatraemia in both sexes ; similar to the known risk factors associated with hyponatraemia in the general population . In men , arthritis and use of drugs for bone disease were also", "CONCLUSION Hyponatremia developed in just over half of children .", "Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival, especially in the uncorrected group.", "Those with severe hyponatremia need frequent and prolonged monitoring because of risk for repeat sodium changes.", "Following elimination of other independent variables associated with increased mortality, hyponatraemia on admission was associated with an increased risk of death (adjusted HR 1.15, p=0.005).", "It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided.", "Finally , elderly patients presenting with an orthopedic injury should have serum sodium checked and hyponatremia corrected , if present .", "Nine patients had initial severe hyponatremia between days 6 and 20 after surgery.", "main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE , although it should be taken into consideration as the treatment differs", "Normonatremia was achieved and maintained in almost all hyponatremia patients<48 hours.", "Median time to death for patients with and without hyponatraemia on admission was 34 months ( SE 1.7 months ) and 41 months ( SE 2.5 months ) respectively ( p=0.003 ) .", "Among hyponatremic patients, obstructive hydrocephalus and age less than 3.5 years were significant independent risk factors for severe hyponatremia.", ", 39 men ) aged 18 - 80 years , with a history of TBE was included in the study . Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild", "operative mortality on multivariate analysis . Median age at admission was 83 years . Hyponatraemia was present in 19.1% of patients with hip fracture on admission , 29.5% of patients in the first 24", "Therefore , two possibilities remain ( Figure 1 ) : ( 1 ) Hyponatremia is a direct cause of death , or ( 2 ) severe underlying disease is the cause of death and hyponatremia is merely another complication of this underlying disease .", "an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636", "- up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The severity of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure", "RESULTS The prevalence of hyponatremia on hospital admission was 15.6% (n=66).", "For those who are not electrolyte enthusiasts, hyponatremia can be a frustrating disorder.", "METHODS An extensive Medline, Embase, and Cochrane search was performed to retrieve all studies published up to April 1, 2015 using the following words: \"hyponatremia\" or \"hyponatraemia\" AND \"hospitalization\" or \"hospitalisation.\"", ", in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients ,", "most frequent electrolyte disturbance in critical care . Across various disciplines , hyponatremia is associated with increased mortality and longer hospital stay , yet in intracerebral hemorrhage (", "Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model .", "First, it produces mild cognitive impairment, resulting in unsteady gait and falls; this is probably due to the loss of glutamate (a neurotransmitter involved in gait function) as an osmolyte during brain adaptation to chronic hyponatremia.", "Post - operative hyponatraemia was also associated with an increased risk of death ( adjusted HR 1.15 , p=0.006 ) .", "desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced", "The patients with severe hyponatremia, they argue, were likely admitted because their serum sodium was so low, not because they were so ill.", "morbidities was observed . Finally , when only US studies ( n = 8) were considered , hyponatremia was associated with up to around $ 3000 higher hospital costs / patient when compared with the", "A gradual year-on-year increase of hyponatremia codification (both primary and secondary diagnosis) was observed at discharge throughout the study period (from 1.6% in 2005 to 2.8% in 2011; p<0.0001).", "with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia , and if present , treatment should be initiated . Finally , elderly patients presenting with an", "fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post - operative mortality on multivariate analysis .", ", hyponatraemia was observed in 41% ( 25 patients ) . In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe . Two patients with severe", "differs significantly . Patients > 60 years of age with TBE are more susceptible to hyponatraemia than younger patients .", "length of stay , associated comorbidities , readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set ( MBDS ) .", "In 20 patients ( 33% ) , hyponatraemia was mild , in 3 ( 5% ) it was moderate , and in 2 ( 3% ) severe .", ". This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ; retrospective application of the monitoring plan showed that , once at - risk patients were", "/ L ) . Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital", "post - operative mortality . Every effort should be made to identify and correct hyponatraemia in hip fracture patients .", "This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ; retrospective application of the monitoring plan showed that , once at - risk patients were appropriately screened out , only mild , non - clinically significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population .", "patients ( 53,820 patients ) . The probability of readmission for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate", "Hyponatremia maintained statistical significance in the regression model after adjusting for gender , OR 0.919 ( 95% CI 0.902 - 0.936 ) ; age , OR 1.061 ( 95% CI 1.060 - 1.062 ) ; and Charlson index , OR 1.388 ( 95% CI 1.361 - 1.461 ) .", "Does the patient have hypovolemic, euvolemic, or hypervolemic hyponatremia?", "heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) . Hyponatremia maintained statistical significance in the regression model after adjusting for gender , OR 0.919 (", "Patients with severe hyponatremia had greater sodium variability with significantly lower nadirs , greater maximum values , and larger decreases within 24-hour periods compared with other sodium groups .", "The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis.", "This the first study that investigated the prevalence and clinical associations of hyponatremia in patients with ICH .", "Across various disciplines , hyponatremia is associated with increased mortality and longer hospital stay , yet in intracerebral hemorrhage ( ICH ) no data are available .", "BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice .", "functional outcome ( 90 days and 1 year ) were analyzed to determine the effects of hyponatremia ( Na<135 mEq / L ) . Multivariable regression analyses were calculated for factors associated with", "at initial presentation and during admission . In this vulnerable patient group , hyponatraemia may delay time to definitive surgery and is a potentially reversible cause of increased post -", "differences as far as gender or clinical form of the disease are concerned . Hyponatraemia , usually mild , is a common disorder in the course of TBE , although it is not significantly more", "The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients younger than 60 years old.", ", 2.1 - 10.6 ; P<0.001 ) ; thereafter , mortality rates were similar . CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high", "However, hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "The investigators first show mortality rates in a large sample of hospitalized patients with hyponatremia (serum sodium 135 mmol/L).", "RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) .", "This is an interesting conclusion that will definitely stir debate on the value of actively treating hyponatremia.", "for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group . Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with", "The presence of hyponatremia at hospital admission is related to an increased short-term mortality in patients surviving acute care, possibly reflecting a preexisting condition that is linked to worse outcome due to greater comorbidity.", "Evaluation of hyponatraemia in patients with tick-borne encephalitis--a preliminary study.", "patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients . Hyponatraemia was an independent risk factor for increased post -", "association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The mean survival time was 1.10±0.42 years in patients with", "Dehydration seems to be the main cause of hyponatraemia in the course of TBE .", "serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia", "than in other hospitalized patients . Dehydration seems to be the main cause of hyponatraemia in the course of TBE . SIADH is a less common cause of hyponatraemia in the course of TBE ,", "with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post - operative hyponatraemia was also associated with an increased risk of death ( adjusted HR 1.15 , p=0.006 ) . Trends", "SNS hospitals . Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity", "L was recorded by age , sex and dose . Potential predictors of clinically significant hyponatraemia were identified using multivariate analysis in a Cox proportional hazards model . RESULTS Dose ,", "Thus , the authors conclude that patients die with and not from hyponatremia .", "and prognosis of elderly small cell lung cancer ( SCLC ) patients complicated with hyponatremia , thus providing increased attention for appropriate intervention and improving outcomes in", "Hundred thirty-seven patients (43%) had mild hyponatremia, 39 (12%) had severe hyponatremia, and 143 (45%) had normal sodium.", "This study evaluates the prevalence of hyponatraemia (plasma sodium<135mmol/l) in 3897 patients undergoing operative treatment for hip fracture and the relationship between hyponatraemia and mortality in these patients.", "disorder . Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate", "< , of whom 11,095 ( 2.2% ) presented with HNa . A gradual year - on - year increase of hyponatremia codification ( both primary and secondary diagnosis ) was observed at discharge throughout the", "These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs .", "(10) elegantly rephrase the issue of hyponatremia and mortality as, “", "During the defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "These challenges may be the reason that the management of hyponatremia is still suboptimal ( 1– 3 ) .", "into a 2.5-fold increased odds ratio ( P<0.001 ) . Multivariable analyses identified hyponatremia as an independent predictor of in - hospital mortality ( odds ratio , 2.2 ; 95% confidence", "formulate an interesting hypothesis ( 10 ) : That patients with moderate hyponatremia have more severe underlying disease than those with severe hyponatremia and therefore higher mortality rates .", ", physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders . As serum sodium is a readily available , simple , and affordable biochemical", "Hyponatremia in hospitalised patients with heart failure in internal medicine: Analysis of the Spanish national minimum basic data set (MBDS) (2005-2011).", "to decrease when compared to another group of patients younger than 60 years old . Hyponatremia at 1- and 3-year follow - up was associated with worse survival rates ( p<0.05 ) . CONCLUSION The", "Hyponatremia and bone disease Hip fractures represent a serious health risk in the elderly, causing substantial morbidity and mortality.", "For example, emerging data implicate hyponatremia in falls (11), osteoporosis (12), and fractures (13–15), suggesting an effect on the nervous system and bone.", "Hyponatremia was associated to a higher rate of mortality during hospitalisation for acute heart failure with an odds ratio ( OR ) of 1.58 , 95% CI , 1.50 - 1.66 ( p<0.05 ) .", "with meningitis are predisposed to develop hypovolaemic hyponatraemia . However , hyponatraemia in meningitis may also be caused by the syndrome of inappropriate secretion of antidiuretic", "Hyponatremia and mortality : how innocent is the bystander ?", "of hyponatraemia in patients with tick - borne encephalitis -- a preliminary study . Hyponatraemia is one of the most frequently observed , but sometimes overlooked , electrolyte disorder .", "in elderly patients , especially in those receiving medications that can cause hyponatremia . Furthermore , elderly patients with an unsteady gait and/or confusion should be evaluated for", "Multivariable regression analyses were calculated for factors associated with hyponatremia and predictors of in - hospital mortality .", "women , raised monocytes and absence of lipid - modifying drugs increased the risk of hyponatraemia . Use of the proposed monitoring scheme and the minimum effective dose would have omitted all", "Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria .", "Does this study prove hyponatremia to be an innocent bystander in mortality?", "hyponatraemia associated post - operative mortality in 3897 hip fracture patients . Hyponatraemia is common in hospitalised patients . In recent years the relationship between hyponatraemia and", ") respectively ( p=0.003 ) . Median time to death for patients with and without hyponatraemia within 24h post - operatively was 35 months ( SE 2.5 months ) and 42 months ( SE 1.7 months )", "Timing, duration, and severity of hyponatremia following pediatric brain tumor surgery*. OBJECTIVE To describe the time course, variability, and magnitude of serum sodium changes among children undergoing intracranial tumor surgery.", "Use of the proposed monitoring scheme and the minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment .", "CONCLUSIONS Hyponatremia was identified as an independent predictor of in - hospital mortality with a fairly high prevalence in spontaneous ICH patients .", "was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) . Hyponatraemia is common in elderly patients with hip fractures both at initial presentation and during admission", "Until such studies are conducted, physicians caring for elderly patients must be aware of the association between hyponatremia and bone disorders.", "Overall mortality due to any cause in patients with hyponatremia was 17% ( 1937 patients ) versus 11% in non - hyponatremic patients ( 53,820 patients ) .", "Patients with meningitis are predisposed to develop hypovolaemic hyponatraemia.", "hyponatremia and predictors of in - hospital mortality . RESULTS The prevalence of hyponatremia on hospital admission was 15.6% ( n=66 ) . Normonatremia was achieved and maintained in almost all", "The probability of readmission for patients with hyponatremia was 22% versus 17% in the non - hyponatremic group .", "Among the 61 patients , hyponatraemia was observed in 41% ( 25 patients ) .", "Multivariable analyses identified hyponatremia as an independent predictor of in-hospital mortality (odds ratio, 2.2; 95% confidence interval, 1.05-4.62; P=0.037).", ", 2.2 ; 95% confidence interval , 1.05 - 4.62 ; P=0.037 ) . Within 90 days after ICH , hyponatremia patients surviving hospital stay were also at greater risk of death ( odds ratio , 4.8 ; 95%", "A meta - analysis was performed including all studies comparing duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia .", "The objective of this study is to assess the incidence, average length of stay, associated comorbidities, readmissions and mortality caused by hyponatremia in admissions for acute heart failure from the Spanish national minimum basic data set (MBDS).", "mortality . There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "because they are aged ≥65 years or receiving concomitant medication associated with hyponatraemia . This monitoring plan would help to prevent some at - risk patients developing hyponatraemia ;", "survival , especially in the uncorrected group . It is important that the cause of the hyponatremia is diagnosed at an early stage and precise medical treatment is provided .", "Finally , when only US studies ( n = 8) were considered , hyponatremia was associated with up to around $ 3000 higher hospital costs / patient when compared with the cost of normonatremic subjects .", "Economic Burden of Hyponatremia : Systematic Review and Meta - Analysis . BACKGROUND Hyponatremia is the most common electrolyte abnormality observed in clinical practice . Several studies have", "elimination of other independent variables associated with increased mortality , hyponatraemia on admission was associated with an increased risk of death ( adjusted HR 1.15 , p=0.005 ) . Post -", "patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years ( t=2.75 , p<0.05 ) after symptomatic", "The prognosis and possible association with hyponatremia was investigated .", "CONCLUSIONS This meta - analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission .", "The nuance comes from a third possibility (Figure 1): Hyponatremia may contribute to organ dysfunction and therefore indirectly contribute to mortality.", "Hyponatremia is an independent predictor of in - hospital mortality in spontaneous intracerebral hemorrhage .", "Seventy-five percent of children with severe hyponatremia spent more than 4 days with abnormally low sodium values.", "OBJECTIVE To explore risk factors for desmopressin-induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan.", "Hyponatremia at 1- and 3-year follow-up was associated with worse survival rates (p<0.05).", "OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice.", "Nearly 80% of hyponatremic patients had mild hyponatremia prior to development of severe hyponatremia ; median time between mild hyponatremia and severe hyponatremia was 1.6 days ( interquartile range , 0.4 - 5.6 ) .", "of the Spanish national minimum basic data set ( MBDS ) ( 2005 - 2011 ) . OBJECTIVE Hyponatremia is the most common electrolyte disorder seen in clinical practice . Numerous studies have reported", "Furthermore, elderly patients with an unsteady gait and/or confusion should be evaluated for the presence of mild hyponatremia, and if present, treatment should be initiated.", "significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using minimum effective gender - specific dosing with the ODT formulation of", "and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia : A Retrospective Analysis . AIM This study was designed to evaluate the clinical characteristics", "BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care .", "Across all studies, hyponatremia was associated with a significantly longer duration of hospitalization (3.30 [2.90-3.71; 95% CIs] mean days; P < .000).", "treated for nocturia . OBJECTIVE To explore risk factors for desmopressin - induced hyponatraemia and evaluate the impact of a serum sodium monitoring plan . SUBJECTS AND METHODS This was a meta -", "Trends suggested that hyponatraemia within 48h of discharge was associated with an increased risk of death ( adjusted HR 1.15 , p=0.636 ) .", "normal values and 0.83±0.35 years in patients with subnormal serum sodium . In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was", "There is now a considerable volume of literature suggesting that chronic hyponatremia increases the adjusted odds ratio ( OR ) for both falls and fractures in the elderly .", "significant hyponatraemia was observed , within ranges of other drugs associated with hyponatraemia and similar to the background prevalence in the treatment population .", "and in 2 ( 3% ) severe . Two patients with severe hyponatraemia and one with moderate hyponatraemia fulfilled the SIADH criteria . In the non - SIADH patients , sodium concentration normalized", "0.05 ) after symptomatic treatment . The mean survival time of the normal group and the hyponatremia group in elderly patients had a tendency to decrease when compared to another group of patients", "There was a significant association between hyponatraemia and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer.", "CONCLUSIONS Hyponatremia is associated to an increased rate of mortality and readmission in patients admitted for acute heart failure in SNS hospitals.", "AIM This study was designed to evaluate the clinical characteristics and prognosis of elderly small cell lung cancer (SCLC) patients complicated with hyponatremia, thus providing increased attention for appropriate intervention and improving outcomes in symptomatic subjects.", ", simple , and affordable biochemical measurement , clinicians should look for hyponatremia in elderly patients , especially in those receiving medications that can cause hyponatremia .", "- hospital mortality in spontaneous intracerebral hemorrhage . BACKGROUND AND PURPOSE Hyponatremia is the most frequent electrolyte disturbance in critical care . Across various disciplines ,", "that compared hospital length of stay and cost between patients with and without hyponatremia . METHODS An extensive Medline , Embase , and Cochrane search was performed to retrieve all", "Seventy - five percent of patients manifest mild hyponatremia within two postoperative days ; however , severe hyponatremia developed later with 75% of patients manifesting severe hyponatremia within six postoperative days .", "defined follow - up period the discharge reports showed an increased codification of hyponatremia .", "Our study identified a statistically significant association between hyponatremia and increased intrahospital mortality independent of age , gender and the Charlson comorbidity index .", ". Hyponatraemia was diagnosed when sodium concentration was below 135 mmol / l . Hyponatraemia was considered mild when sodium concentration was 130 - 134 mmol / l , moderate when 125 - 129", "To clarify the impact of hyponatremia on the length of hospitalization and costs, we performed a meta-analysis based on published studies that compared hospital length of stay and cost between patients with and without hyponatremia.", "Every effort should be made to identify and correct hyponatraemia in hip fracture patients.", "of hyponatremia has unfavorable prognostic impacts . Elderly SCLC patients with hyponatremia are difficult to cure and associated with significantly shorter survival , especially in the", "Patient characteristics, in-hospital measures, mortality, and functional outcome (90 days and 1 year) were analyzed to determine the effects of hyponatremia (Na<135 mEq/L).", "Hyponatremia appears to contribute to falls and fractures by two mechanisms .", "The association between hyponatremia and mortality has been demonstrated in numerous studies (4 –9), but causality has been difficult to prove.", "minimum effective dose would have omitted all patients with clinically significant hyponatraemia from further treatment . CONCLUSIONS The incidence of hyponatraemia can be reduced by using", "and time from admission to surgery indicating that patients admitted with hyponatraemia waited longer . The median follow - up time was 863 ( range 0 - 4352 ) days . There were 2460", "As serum sodium is a readily available, simple, and affordable biochemical measurement, clinicians should look for hyponatremia in elderly patients, especially in those receiving medications that can cause hyponatremia.", "2005 to 2.8% in 2011 ; p<0.0001 ) . Overall mortality due to any cause in patients with hyponatremia was 17% ( 1937 patients ) versus 11% in non - hyponatremic patients ( 53,820 patients ) . The", "Dealing with hyponatremia means considering various and often opposite scenarios.", "1st , 2012 , were studied retrospectively . The prognosis and possible association with hyponatremia was investigated . RESULTS The incidence rate of hyponatremia in SCLC was 46.56% ( 149/320 ) . The", "In recent years the relationship between hyponatraemia and bone metabolism, falls and fractures has become more established.", "In the hyponatremia group , the mean survival time of corrected hyponatremia patients was 0.91±0.42 years , which was significantly longer than uncorrected hyponatremia patients whose mean survival time was 0.68±0.26 years ( t=2.75 , p<0.05 ) after symptomatic treatment ."], "par_relations": ["Water-Electrolyte Imbalance"], "chd_relations": [], "syn_relations": ["Hyponatremia", "Hyponatremia"], "sib_relations": ["Sodium", "Dehydration", "Hypercalcemia", "Hyperkalemia", "Hypernatremia", "Hypocalcemia", "Hypokalemia", "Inappropriate ADH Syndrome", "Water Intoxication"], "wiki_entities": ["Hyponatremia", "Hypotonic hyponatremia", "Isotonic hyponatremia", "Water intoxication", "Exercise-associated hyponatremia", "Exercise-induced nausea", "Syndrome of inappropriate antidiuretic hormone secretion", "Central pontine myelinolysis", "Potomania", "Vasopressin receptor antagonist"], "mesh_synonynms": ["hyponatremias", "hyponatremia"], "dbpedia_synonyms": ["hypovolemic hyponatremia", "sodium deficiency", "hyponaetraemia", "low sodium", "hyponatermia", "hyponatraemia", "salt deficiency", "hyponatrimia", "hyponetremia", "hyponatremic encephalopathy"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0006650", "canonical_name": "Thickening of the lateral border of the scapula", "aliases": ["thickening of the lateral border of the scapula", "thickening of the lateral border of the shoulder blade"], "definition": "In anatomy, the scapula (plural scapulae or scapulas; also known as shoulder blade or wing bone) is the bone that connects the humerus (upper arm bone) with the clavicle (collar bone).", "other_contexts": [], "par_relations": ["Abnormality of the scapula"], "chd_relations": [], "syn_relations": ["Thickening of the lateral border of the scapula", "Thickening of the lateral border of the scapula"], "sib_relations": ["Sprengel anomaly", "Scapular winging", "Sclerotic scapulae", "Scapular exostoses", "Scapulohumeral synostosis", "Abnormality of the glenoid fossa", "Aplasia/Hypoplasia of the scapulae"], "wiki_entities": ["Scapula", "Triangular interval", "Impingement syndrome", "List of skeletal muscles of the human body", "Osteochondritis dissecans", "Elbow", "Bone", "Ampelosaurus", "List of eponymously named medical signs", "Glossary of bird terms"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU016833", "canonical_name": "Thickening of the lateral border of the scapula", "aliases": ["thickening of the lateral border of the scapula"], "definition": "In anatomy, the scapula (plural scapulae or scapulas; also known as shoulder blade or wing bone) is the bone that connects the humerus (upper arm bone) with the clavicle (collar bone).", "other_contexts": [], "par_relations": ["Ribs, sternum, clavicles, and scapulae"], "chd_relations": [], "syn_relations": [], "sib_relations": ["NAIL-PATELLA SYNDROME"], "wiki_entities": ["Scapula", "Triangular interval", "Impingement syndrome", "List of skeletal muscles of the human body", "Osteochondritis dissecans", "Elbow", "Bone", "Ampelosaurus", "List of eponymously named medical signs", "Glossary of bird terms"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0012722", "canonical_name": "Heart block", "aliases": ["heart block"], "definition": "Heart block is a disease or inherited condition that causes a fault within the heart's natural pacemaker due to some kind of obstruction (or \"block\") in the electrical conduction system of the heart.", "other_contexts": [], "par_relations": ["Arrhythmia"], "chd_relations": ["Atrioventricular block", "Bundle branch block", "Sick sinus syndrome", "Sinoatrial block"], "syn_relations": [], "sib_relations": ["Cardiac arrest", "Palpitations", "Tachycardia", "Ventricular arrhythmia", "Supraventricular arrhythmia", "Bradycardia", "Abnormal electrophysiology of sinoatrial node origin", "Abnormal atrioventricular conduction"], "wiki_entities": ["Heart block", "Third-degree atrioventricular block", "Second-degree atrioventricular block", "First-degree atrioventricular block", "Beta blocker", "Atrioventricular block", "Heart", "Bundle branch block", "Left bundle branch block", "Trifascicular block"], "mesh_synonynms": ["dissociation, a-v", "auriculo ventricular dissociation", "dissociations, atrioventricular", "a-v dissociation", "dissociation, atrioventricular", "blocks, heart", "atrioventricular dissociations", "heart blocks", "a-v dissociations", "atrioventricular dissociation", "auriculo-ventricular dissociation", "auriculo-ventricular dissociations", "dissociation, auriculo-ventricular", "dissociations, auriculo-ventricular", "dissociations, a-v", "block, heart", "a v dissociation"], "dbpedia_synonyms": ["sinoatrial heart block", "hemiblock", "heartblock", "conduction block", "sino-auricular heart block"]}, "target_ent": {"research_entity_id": "OMIM:MTHU007927", "canonical_name": "Block vertebrae", "aliases": ["block vertebrae"], "definition": "Congenital vertebral anomalies are a collection of malformations of the spine.", "other_contexts": [], "par_relations": ["Spine"], "chd_relations": [], "syn_relations": [], "sib_relations": ["AICARDI SYNDROME", "SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME", "SPONDYLOCOSTAL DYSOSTOSIS WITH ANAL ATRESIA AND UROGENITAL ANOMALIES", "SPONDYLOCOSTAL DYSOSTOSIS 4, AUTOSOMAL RECESSIVE", "HEMIFACIAL MICROSOMIA"], "wiki_entities": ["Congenital vertebral anomaly", "Lumbar vertebrae", "Vertebra", "Scalene muscles", "Corpectomy", "Volta (album)", "Facet joint", "Ken Block", "Hatzegopteryx", "Somite"], "mesh_synonynms": [], "dbpedia_synonyms": ["congenital vertebral anomaly"]}, "label": 0}
{"source_ent": {"research_entity_id": "MSH:D020936", "canonical_name": "Epilepsy, Benign Neonatal", "aliases": ["benign familial infantile convulsions", "epilepsy, benign neonatal", "familial benign neonatal convulsions", "benign familial neonatal infantile seizures", "non familial benign neonatal epilepsy", "neonatal convulsions, benign", "non familial benign neonatal convulsions", "benign non-familial neonatal convulsions", "non-familial benign neonatal convulsions", "epilepsy, benign neonatal, nonfamilial", "benign neonatal-infantile epilepsy", "benign neonatal epilepsy", "benign neonatal convulsions", "benign neonatal epilepsy, nonfamilial", "benign familial neonatal-infantile seizures", "benign familial infantile convulsions syndrome", "convulsion, benign neonatal", "benign familial neonatal convulsions", "neonatal epilepsies, benign", "convulsions, benign familial infantile, 3", "convulsions, benign neonatal, non-familial", "epilepsies, benign neonatal", "benign familial neonatal epilepsy", "neonatal-infantile epilepsy, benign", "benign neonatal non familial convulsions", "neonatal convulsion, benign", "non-familial benign neonatal epilepsy", "seizures, benign familial neonatal-infantile", "benign neonatal-infantile epilepsies", "convulsions, benign familial infantile, 1", "convulsions, benign neonatal", "neonatal epilepsy, benign", "familial benign neonatal epilepsy", "seizures, benign familial infantile, 3", "benign neonatal convulsion", "epilepsy, benign neonatal, non-familial", "seizures, benign familial neonatal infantile", "convulsions, benign neonatal, familial", "benign infantile familial convulsions", "convulsions benign familial neonatal", "neonatal-infantile epilepsies, benign", "epilepsy, benign neonatal, familial", "epilepsies, benign neonatal-infantile", "benign neonatal epilepsies", "epilepsy, benign neonatal infantile", "benign non familial neonatal convulsions", "epilepsy, benign neonatal-infantile", "benign neonatal non-familial convulsions", "benign neonatal nonfamilial epilepsy", "seizures, benign familial infantile, 1"], "definition": "Benign familial neonatal seizures (BFNS), formerly called benign familial neonatal convulsions (BFNC), is a rare autosomal dominant inherited form of seizures.", "other_contexts": [], "par_relations": ["Epilepsy, Benign Neonatal", "Epilepsy", "Infant, Newborn, Diseases", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal"], "chd_relations": ["Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal, 3", "Epilepsy, Benign Neonatal, Autosomal Recessive", "Convulsions benign familial neonatal dominant form", "Epilepsy, Benign Neonatal, 1", "Infantile convulsions and paroxysmal choreoathetosis, familial", "Convulsions, Benign Familial Infantile, 4", "Myokymia with neonatal epilepsy", "Convulsions, Benign Familial Neonatal, 1, Atypical Severe", "Convulsions, Benign Familial Neonatal, 1, And-Or Myokymia", "Epilepsy, Benign Neonatal, 1, Atypical Severe"], "syn_relations": ["Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal", "Epilepsy, Benign Neonatal"], "sib_relations": ["Amniotic Band Syndrome", "Anemia, Neonatal", "Asphyxia Neonatorum", "Birth Injuries", "Seizures, Febrile", "Cystic Fibrosis", "Epilepsies, Partial", "Epilepsy, Generalized", "Epilepsies, Myoclonic", "Epilepsy, Post-Traumatic", "Erythroblastosis, Fetal", "Hydrophthalmos", "Hyperostosis, Cortical, Congenital", "Ichthyosis", "Infant, Premature, Diseases", "Meconium Aspiration Syndrome", "Neonatal Abstinence Syndrome", "Persistent Fetal Circulation Syndrome", "Rothmund-Thomson Syndrome", "Sclerema Neonatorum", "Seizures", "Status Epilepticus", "Syphilis, Congenital", "Thanatophoric Dysplasia", "Toxoplasmosis, Congenital", "Wolman Disease", "Severe Combined Immunodeficiency", "Mobius Syndrome", "Colic", "Lennox Gastaut Syndrome", "Epilepsy, Reflex", "Landau-Kleffner Syndrome", "Ophthalmia Neonatorum", "Neonatal Sepsis", "Nystagmus, Congenital", "Hyperbilirubinemia, Neonatal", "Drug Resistant Epilepsy", "Hernia, Umbilical", "Vitamin K Deficiency Bleeding", "Thrombocytopenia, Neonatal Alloimmune", "Congenital Hyperinsulinism"], "wiki_entities": ["Benign familial neonatal seizures", "Benign familial infantile epilepsy", "Benign neonatal seizures", "Neonatal seizure", "Epilepsy syndromes", "List of diseases (E)", "KvLQT3", "KvLQT2", "Epilepsy and employment", "ICD-10 Chapter VI: Diseases of the nervous system"], "mesh_synonynms": ["seizures, benign familial neonatal-infantile", "benign neonatal convulsions", "benign familial infantile convulsions", "benign familial neonatal infantile seizures", "seizures, benign familial infantile, 3", "convulsion, benign neonatal", "benign neonatal epilepsy", "convulsions, benign neonatal", "convulsions, benign neonatal, non-familial", "epilepsies, benign neonatal-infantile", "benign neonatal-infantile epilepsies", "convulsions, benign familial infantile, 3", "epilepsy, benign neonatal infantile", "neonatal-infantile epilepsies, benign", "epilepsy, benign neonatal-infantile", "non familial benign neonatal convulsions", "neonatal epilepsy, benign", "neonatal epilepsies, benign", "neonatal convulsions, benign", "benign neonatal nonfamilial epilepsy", "benign non-familial neonatal convulsions", "familial benign neonatal convulsions", "benign neonatal non-familial convulsions", "benign familial neonatal convulsions", "benign non familial neonatal convulsions", "convulsions, benign neonatal, familial", "epilepsy, benign neonatal, nonfamilial", "epilepsy, benign neonatal", "neonatal convulsion, benign", "non-familial benign neonatal convulsions", "epilepsy, benign neonatal, non-familial", "benign familial infantile convulsions syndrome", "benign familial neonatal epilepsy", "neonatal-infantile epilepsy, benign", "epilepsies, benign neonatal", "non-familial benign neonatal epilepsy", "benign neonatal epilepsies", "convulsions benign familial neonatal", "seizures, benign familial neonatal infantile", "benign neonatal epilepsy, nonfamilial", "seizures, benign familial infantile, 1", "benign familial neonatal-infantile seizures", "non familial benign neonatal epilepsy", "benign neonatal non familial convulsions", "familial benign neonatal epilepsy", "benign infantile familial convulsions", "convulsions, benign familial infantile, 1", "epilepsy, benign neonatal, familial", "benign neonatal convulsion", "benign neonatal-infantile epilepsy"], "dbpedia_synonyms": ["benign familial neonatal seizures"]}, "target_ent": {"research_entity_id": "OMIM:607745", "canonical_name": "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "aliases": ["bfnis", "bfis3", "seizures, benign familial neonatal-infantile", "seizures, benign familial infantile, 3", "convulsions, benign familial infantile, 3", "bfic3"], "definition": "Infantile convulsions and choreoathetosis (ICCA) syndrome is a neurological genetic disorder with an autosomal dominant mode of inheritance.", "other_contexts": ["In most recent years a new form of benign epilepsy has been proposed, with an intermediate onset between the neonatal and infantile age, which was defined with the term benign familial neonatal-infantile seizures (BFNIS).", "In addition to those included in the classification of the International League Against Epilepsy , new epilepsy syndromes comprise febrile seizures plus , benign familial neonatal - infantile seizures ( BFNIS ) , benign infantile focal epilepsy with midline spikes and waves during sleep ( BFIS ) , malignant migrating partial seizures in infancy , devastating epilepsy in school age children and late onset cryptogenic spasms .", "SCN2A was analyzed in 2 families with probable BFNIS, 9 with possible BFNIS, 10 with benign familial infantile seizures, and in 93 additional families with various early childhood epilepsies.", "Mutations of the gene encoding the alpha2 subunit of the neuronal sodium channel, SCN2A, have been found in benign familial neonatal-infantile seizures (BFNIS).", "To dissect the genetics of benign familial epilepsies of the first year of life and to assess the extent of the genetic overlap between benign familial neonatal seizures (BFNS), benign familial neonatal-infantile seizures (BFNIS), and benign familial infantile seizures (BFIS).", "Biochemical experiments demonstrated that all three BFNIS mutations exhibited a significant reduction in cell surface expression compared to WT.", "The observation of benign and severe phenotypes due to an identical mutation within one family contradicts the hypothesis of different modes of inheritance as a mandatory feature discriminating BFNIS from SCN2A encephalopathy .", "The onset of BFNIS lies in between BFNS and BFIS, so that seizures can occur in the neonatal and early infantile period.", "Mutations effecting changes in conserved amino acids were found in two of two probable BFNIS families, in four of nine possible BFNIS families, and in none of the others.", "However, there were striking differences in the spectrum of clinical presentations, ranging from BFNIS to OS.", "Henceforth, in this discussion BFNS, BFNIS, and BFIS will be referred to as BFNE, BFNIE, and BFIE, respectively, distinguished by ascending average ages of seizure onset (mean age at onset of 2–3 days; 11 weeks; and 6 months, respectively) but with overlapping distributions of seizure age at onset (1 day to 6 months; 3 days to 6 months; and 2–20 months, respectively) (Berkovic et al.", "In this paper we report a patient presenting with an atypical epileptic syndrome whose phenotype partially overlaps both Dravet syndrome and benign familial neonatal - infantile seizures ( BFNIS ) ."], "par_relations": [], "chd_relations": [], "syn_relations": ["SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3", "SEIZURES, BENIGN FAMILIAL INFANTILE, 3"], "sib_relations": ["Cyanosis", "Autosomal dominant", "Normal psychomotor development", "Seizures, partial, afebrile", "Normal interictal EEG", "Onset ranges from 2 days to 7 months (most at 2-3 months)", "Seizures are easily controlled by medications", "See also benign familial infantile convulsions (BFIC1, 601764)", "See also benign neonatal epilepsy (EBN1, 121200)", "Secondary generalized tonic-clonic seizures may occur", "Seizures occur in clusters over 1 or several days", "Seizures often begin focally with head and eye deviation", "Rigidity during seizures", "Staring episodes during seizures", "Ictal EEG shows focal onset, often posterior region of brain", "Spontaneous resolution by 12 months of age with no recurrence later in life", "Caused by mutation in the alpha-1-subunit of the voltage-gated type II sodium channel gene (SCN2A, 182390.0002)", "Apnea during seizure spells"], "wiki_entities": ["Infantile convulsions and choreoathetosis", "Nav1.2", "Hypotonia", "Cavernous hemangioma", "Progressive myoclonus epilepsy", "ICD-10 Chapter VI: Diseases of the nervous system", "List of diseases (S)", "Paroxysmal kinesigenic choreoathetosis", "Hyperglycerolemia", "List of genetic disorders"], "mesh_synonynms": ["seizures, benign familial neonatal-infantile", "benign neonatal convulsions", "benign familial infantile convulsions", "benign familial neonatal infantile seizures", "seizures, benign familial infantile, 3", "convulsion, benign neonatal", "benign neonatal epilepsy", "convulsions, benign neonatal", "convulsions, benign neonatal, non-familial", "epilepsies, benign neonatal-infantile", "benign neonatal-infantile epilepsies", "convulsions, benign familial infantile, 3", "epilepsy, benign neonatal infantile", "neonatal-infantile epilepsies, benign", "epilepsy, benign neonatal-infantile", "non familial benign neonatal convulsions", "neonatal epilepsy, benign", "neonatal epilepsies, benign", "neonatal convulsions, benign", "benign neonatal nonfamilial epilepsy", "benign non-familial neonatal convulsions", "familial benign neonatal convulsions", "benign neonatal non-familial convulsions", "benign familial neonatal convulsions", "benign non familial neonatal convulsions", "convulsions, benign neonatal, familial", "epilepsy, benign neonatal, nonfamilial", "epilepsy, benign neonatal", "neonatal convulsion, benign", "non-familial benign neonatal convulsions", "epilepsy, benign neonatal, non-familial", "benign familial infantile convulsions syndrome", "benign familial neonatal epilepsy", "neonatal-infantile epilepsy, benign", "epilepsies, benign neonatal", "non-familial benign neonatal epilepsy", "benign neonatal epilepsies", "convulsions benign familial neonatal", "seizures, benign familial neonatal infantile", "benign neonatal epilepsy, nonfamilial", "seizures, benign familial infantile, 1", "benign familial neonatal-infantile seizures", "non familial benign neonatal epilepsy", "benign neonatal non familial convulsions", "familial benign neonatal epilepsy", "benign infantile familial convulsions", "convulsions, benign familial infantile, 1", "epilepsy, benign neonatal, familial", "benign neonatal convulsion", "benign neonatal-infantile epilepsy"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C562880", "canonical_name": "Amelogenesis Imperfecta, Type III", "aliases": ["adhcai", "amelogenesis imperfecta, type iii", "amelogenesis imperfecta, hypomineralization type", "amelogenesis imperfecta, hypocalcification type, autosomal dominant"], "definition": "Dentin sialophosphoprotein is a precursor protein for other proteins found in the teeth.", "other_contexts": ["Truncation mutations in FAM83H ( family with sequence similarity 83 , member H ) cause autosomal dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) , but little is known about FAM83H function and the pathogenesis of ADHCAI .", "Fam83h is associated with intracellular vesicles and ADHCAI .", "This study tested the hypothesis that there are phenotype and genotype associations in families with FAM83H - associated ADHCAI .", "Laboratory and field evaluation of the repellents deet , CIC-4 , and AI3 - 37220 against Anopheles farauti ( Diptera : Culicidae ) in Australia . Laboratory and", "ADHCAI is likely caused by gain - of - function effects mediated by truncated FAM83H , which potentially mislocalizes CK1 as part of its pathological mechanism .", "FAM83H mutations cause ADHCAI and alter intracellular protein localization .", "Affected individuals having truncating FAMH3H mutations of 677 or fewer amino acids presented a generalized ADHCAI phenotype , while those having mutations capable of producing a protein of at least 694 amino acids had a unique and previously unreported phenotype affecting primarily the cervical enamel .", "All FAM83H ADHCAI - causing mutations terminate translation or shift the reading frame within the specific exon 5 segment that encodes from Ser(287 ) to Glu(694 ) .", "Seven families segregating ADHCAI ( 147 individuals ) were evaluated .", "We here report novel FAM83H mutations in four kindreds with ADHCAI .", "The present study is designed to evaluate AI3 by measuring background and induced aniseikonia in children aged 5 to 13 years .", "The original mutation in the amidase gene of strain AI3 appeared responsible for the differences between the two groups of Ph mutants and the binding interactions with acetanilide that it determined were eliminated in AI3-Ph mutants .", "FAM83H gene mutations are associated with autosomal - dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) , which is typically characterized by enamel having normal thickness and a markedly decreased mineral content .", "Fam83h null mice support a neomorphic mechanism for human ADHCAI .", "Trials of AI3 were performed in the vertical direction only , using the 12-point test , and two trials were recorded .", "Adaptation to phenylacetamide as a growth substrate by an acetanilide - utilizing mutant of Pseudomonas aeruginosa Mutants able to utilize phenylacetamide as sole nitrogen source were isolated from the acetanilide ( N - phenylacetamide)-utilizing Pseudomonas aeruginosa mutant strain AI3 and from its parent strain L10 .", "Laboratory and field evaluation of deet , CIC-4 , and AI3 - 37220 against Anopheles dirus ( Diptera : Culicidae ) in Thailand . Laboratory and", "No FAM83H coding - region or splice - junction mutations were identified in three probands with autosomal - dominant hypocalcification AI ( ADHCAI ) , suggesting that a second gene may contribute to the aetiology of ADHCAI .", "Q398X ) families with ADHCAI .", "We recruited three ADHCAI families and identified two novel ( p .", "dirus was more sensitive to CIC-4 than either AI3 - 37220 or deet .", "Defects in FAM83H on human chromosome 8q24.3 cause autosomal - dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) .", "The AI3 group had a high level of activity towards 4-nitrophenylacetamide , activity towards phenylacetyl-4-nitroaniline but , unlike strain AI3 , no activity towards acetyl-4-nitroaniline ; the L10 group had a low activity towards 4-nitrophenylacetamide , no activity towards phenylacetyl-4-nitroaniline but retained the low level of activity towards acetyl-4-nitroaniline exhibited by strain L10 .", "Recently we identified mutations in FAM83H that caused autosomal dominant hypocalcified amelogenesis imperfecta ( ADHCAI ) .", "CONCLUSIONS Most children were able to complete aniseikonia testing with AI3 .", "In contrast to the laboratory tests , protection provided by AI3 - 37220 was significantly better than that by either deet or CIC-4 , and there was no difference between protection by deet and CIC-4 .", "We identified disease - causing FAM83H mutations in two families with ADHCAI : family 1 ( g.3115C > T , c.1993 C > T , p ."], "par_relations": ["Amelogenesis Imperfecta"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Dentin sialophosphoprotein", "Human tooth", "List of genetic disorders", "Neonatal teeth", "List of diseases (C)", "Temporomandibular joint dysfunction", "Attrition (dental)", "Oral mucosa", "Phenobarbital", "Tooth decay"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:104500", "canonical_name": "AMELOGENESIS IMPERFECTA, TYPE IB", "aliases": ["aih2", "amelogenesis imperfecta, type ib", "amelogenesis imperfecta, hypoplastic local, autosomal dominant", "ai1b", "enamel hypoplasia, hereditary localized"], "definition": "Herpes simplex is a viral disease caused by the herpes simplex virus.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB", "AMELOGENESIS IMPERFECTA, TYPE IB"], "sib_relations": ["Amelogenesis imperfecta, hypoplastic", "Autosomal dominant", "Enamel has horizontal row of pits or linear depressions", "Incisal edge or occlusal surface not usually involved", "Caused by mutation in the enamelin gene (ENAM, 606585.0001)"], "wiki_entities": ["Herpes simplex", "List of genetic disorders", "Temporomandibular joint dysfunction"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:6364", "canonical_name": "kallikrein related peptidase 3", "aliases": ["klk3 gene", "kallikrein related peptidase 3", "psa", "klk3"], "definition": "Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["kallikrein related peptidase 3", "kallikrein related peptidase 3", "kallikrein related peptidase 3", "kallikrein related peptidase 3"], "sib_relations": [], "wiki_entities": ["Prostate-specific antigen", "Kallikrein", "KLK1", "KLK14", "KLK4", "KLK9", "KLK12", "KLK6", "KLK5", "KLK7"], "mesh_synonynms": [], "dbpedia_synonyms": ["piscis austrinus", "p.s.a.", "prostate-specific antigen", "psa", "psa (disambiguation)"]}, "target_ent": {"research_entity_id": "OMIM:176820", "canonical_name": "KALLIKREIN-RELATED PEPTIDASE 3", "aliases": ["antigen, prostate-specific", "kallikrein-related peptidase 3", "psa", "klk3", "kallikrein 3", "aps", "prostate-specific antigen"], "definition": "Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3", "KALLIKREIN-RELATED PEPTIDASE 3"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["piscis austrinus", "aps (disambiguation)", "p.s.a.", "prostate-specific antigen", "aps", "anpartsselskab", "psa", "psa (disambiguation)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D008127", "canonical_name": "Lofepramine", "aliases": ["deftan", "gamonil", "lofepramine", "ethanone, 1-(4-chlorophenyl)-2-((3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)methylamino)-", "ashbourne brand of lofepramine hydrochloride", "merck brand of lofepramine hydrochloride", "lopramine", "rosemont brand of lofepramine hydrochloride", "hydrochloride, lofepramine", "lofepramine hydrochloride", "gamanil", "feprapax", "lomont", "leo 640"], "definition": "Lofepramine, sold under the brand names Gamanil, Lomont, and Tymelyt among others, is a tricyclic antidepressant (TCA) which is used to treat depression.", "other_contexts": ["Pharmacokinetics of 3 doses (70 mg, 105 mg and 140 mg) of lofepramine were compared with amitriptyline (50 mg) in 6 healthy drug free elderly subjects aged between 65 and 72 years.", "Lofepramine , ( N - methyl - N-[4-chlorobenzoylmethyl]-3-[10,11-dihydro-5H - dibenz(b , f)-azepin-5-yl]-propylamine hydrochloride ) , is a new antidepressant with low toxicity and no peripheral anticholinergic activity .", "A double - blind randomised controlled trial of the effect of low dose lofepramine ( 70 mg once daily ) against placebo was carried out on depressed elderly inpatients on general medical wards for the elderly , comparing measures of depression and side - effects between the randomised groups .", "These results suggest that lofepramine is qualitatively similar to desipramine with respect to preferential inhibition of noradrenaline uptake into central noradrenergic neurons.", "Peak plasma lofepramine and amitriptyline concentrations were achieved at about 1 h and 3 h of dosing respectively .", "The incidence of subjective side - effects with amitryptyline was also higher than that of lofepramine or placebo .", "Pharmacokinetics of lofepramine in man: Relationship to inhibition of noradrenaline uptake The pharmacokinetics of lofepramine, an imipramine analogue, have been studied by administering single oral doses to volunteers, determination of plasma levels of lofepramine and desmethylimipramine after ten days of oral administration to patients, and by relating plasma levels to the effect on uptake of noradrenaline by isolated rat irides and brain slices of plasma samples collected during treatment.", "Imipramine and amitriptyline ( 1 - 5 mg / kg ) also elicited similar EEG changes but were much more potent than lopramine in this effect .", "A double - blind comparison of the pharmacodynamic effects of single doses of lofepramine , amitryptyline and placebo in elderly subjects In a double - blind five - way cross - over study , six drug free healthy elderly subjects received single oral doses of lofepramine ( 70 mg , 105 mg and 140 mg ) , amitriptyline ( 50 mg ) and matched placebo tablets .", "A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review.", "Elimination half-life of lofepramine was 2.5 h and that of amitriptyline was 31 h. A 24-fold inter-individual variation in peak plasma lofepramine concentrations was observed, but amitriptyline levels in plasma showed less variation.", "No effect was seen on the uptake of 5-hydroxytryptamine in brain slices incubated in patients' plasma which suggests that neither lofepramine nor its metabolites formedin vivo in man affect neuronal uptake of this amine.", "With regard to reported side effects, however, a statistically significant lower number of severe and/or moderate side effects were reported for the lofepramine group than for the imipramine group.", "Lofepramine has not been associated with adverse effects on cardiac function even in cases of attempted suicide by overdose.", "Lofepramine is a tricyclic antidepressant that is structurally similar to imipramine and is extensively metabolised to desipramine.", "Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects .", "After treatment with either active drug , lofepramine or imipramine , the clinical outcome was significantly greater than with placebo .", "BASDEC and GDS were administered on day 8 post - admission , and depressed patients were randomised double - blind to either low dose lofepramine ( 70 mg daily ) ( n = 23 ) or placebo ( n = 23 ) .", "Lofepramine.", "Pharmacokinetics of lofepramine in the elderly appear to be similar to young adults as published before.", "Both lofepramine and desipramine inhibited intraventricular noradrenaline uptake into synaptosomes without any effect on 5-HT uptake .", "A double blind comparison of lofepramine , imipramine and placebo in patients with depression .", "Electroencephalographic ( EEG ) effects of lopramine , a new antidepressant , were investigated in rabbits with chronic electrode implants , and compared with those of imipramine and amitriptyline .", "The results of double blind trial in which 139 patients with primary depression were randomly assigned to either lofepramine (46), imipramine (48), or placebo (45) are discussed.", "In particular, for severe and/or moderate occurrences of dry mouth, the statistically significant lower incidence in favor of lofepramine is by almost a factor of 3 (8 lofepramine vs 21 imipramine patients).", "[ Electroencephalographic effects of lopramine ] .", "injection of physostigmine 0.1 mg/kg showed no change after lopramine (20 mg/kg), while the response was significantly suppressed by imipramine (2, 5 mg/kg) and amitriptyline (1, 2 mg/kg).", "Dry mouth is the most commonly reported side effect of usual therapeutic doses of lofepramine , but the incidence of this and other anticholinergic side effects is less among patients treated with lofepramine than with imipramine .", "Lofepramine ( 140 mg ) improved psychomotor performance ( choice reaction time and letter cancellation ) , but no such change was seen with lower dose regimes or placebo .", "3. Pretreatment of rats with lofepramine or DMI did not alter the rate of aniline hydroxylation, aminopyrine demethylation or lofepramine metabolism per mg microsomal protein.", "Lopramine (10, 20 mg/kg) failed to suppress the EEG arousal responses induced by not only auditory stimulation but also electrical stimulation of the mesencephalic reticular formation, centromedian thalamus and posterior hypothalamus, whereas imipramine and amitriptyline (1 approximately 5 mg/kg) markedly inhibited these responses.", "No significant differences were found in clinical responses between lofepramine and imipramine.", "Low dose lofepramine may prove useful in moderately or severely depressed patients treated for only 4 weeks.", "Lopramine ( 10 , 20 mg / kg ) induced a drowsy pattern of spontaneous EEG consisted of high voltage slow waves in the cortex and amygdala , and desynchronization of hippocampal thetha waves .", "On the other hand , subjects who were less depressed ( i.e. GDS < 18 ) improved more on placebo than lofepramine .", "Lofepramine tended to be more effective than placebo in those patients who were more depressed ( GDS > or = 18 ) .", "Lopramine showed no effect on the recruiting response induced by electrical stimulation (8 Hz) of the centromedian thalamus and slightly enhanced the limbic afterdischarges elicited by either hippocampal or amygdaloid stimulation, while imipramine (2, 5 mg/kg) and amitriptyline (1--5 mg/kg) caused an initial depression followed by sustained enhancement of these afterdischarges.", "Thus the acute toxicity of lofepramine is approximately one - fifth that of its metabolite ; lofepramine is a less potent muscarinic receptor antagonist than desipramine ( verified by clinical studies in volunteers and depressed patients ) ; lofepramine is less likely to produce conduction defects than desipramine .", "Pretreatment with SKF 525A ( i.p . ) did not diminish the effect of lofepramine , but rather potentiated it .", "Lofepramine belongs to the group of tricyclic anti - depressants which preferentially inhibit noradrenaline uptake .", "The metabolism of lofepramine in vitro by rat liver microsomes was studied.", "The effect of low dose lofepramine in depressed elderly patients in general medical wards .", "Therefore it is suggested that the formation of desipramine is not necessary for lofepramine to exhibit , the effect on amine uptake in vivo .", "Thus , providing its apparent favourable side effect profile is confirmed in practice , lofepramine may be a valuable alternative for treatment of the depressed patient where a tricyclic is indicated .", "Neurochemical studies show that both lofepramine and its metabolite are potent noradrenaline uptake inhibitors in vitro and evidence is presented to suggest that lofepramine may release this amine following chronic administration in vivo ; both drugs slightly increase serotonin turnover under these conditions and down - regulate cortical beta - adrenoceptor function .", "During steady-state conditions the plasma level of lofepramine fluctuates considerably between doses.", "The results indicate that lofepramine undergoes pronounced first pass elimination and that desmethylimipramine is a major metabolite of it .", "Compared to placebo and lofepramine , amitriptyline produced drowsiness and dry mouth , reduced salivary volume and increased movement reaction time .", "In double - bind clinical trials , lofepramine has been shown to be as effective as desipramine and other comparator tricyclic antidepressants in the treatment of endogenous and reactive depression , but there are some differences between them .", "Metabolism of lofepramine by rat liver microsomes. 1.", "The overall therapeutic efficacy of lofepramine is comparable to that of imipramine , amitriptyline , clomipramine , maprotiline and mianserin in patients with depression of varying severity , and coexisting anxiety .", "Noradrenaline uptake was also preferentially inhibited in synaptosomes from brain of rats treated previously with lofepramine or desipramine (i.p.).", "However, low dose lofepramine is not indicated for mild (GDS 15-18) depression.", "No significant differences between lofepramine and placebo were observed in other parameters measured .", "4. Lofepramine, imipramine and DMI inhibited competitively the microsomal hydroxylation of aniline in vitro.", "These results demonstrate lopramine to be an antidepressant of a new type which has no effect on the ascending reticular activating system and no central anticholinergic action .", "In the dosage used, lofepramine exhibited no deleterious effect on the peripheral cholinergic system or psychomotor performance.", "Lofepramine was the most potent inhibitor , which probably reflects the higher lipophilicity of this compound .", "Lofepramine inhibited both 5-HT and noradrenaline uptake into synaptosomal fractions in vitro but was 4 times more potent in inhibiting noradrenaline than 5-HT uptake, indicating the effect resembles that of desipramine.", "Microsomes from rats pretreated with phenobarbital or 3-methylcholanthrene showed enhanced lofepramine metabolizing activity .", "From such tests it appears unlikely that the active metabolite, desipramine, is formed in the brain in sufficient concentrations after chronic lofepramine administration to make a substantial contribution towards the pharmacological activity of the parent compound.", "The effects of the novel tricyclic antidepressant lofepramine were compared with that of its principal metabolite desipramine.", "A dose related increase in plasma drug levels and pharmacological effects of lofepramine was observed .", "Effect of lofepramine and other antidepressants on the uptake of 5-hydroxytryptamine and noradrenaline into rat brain monoaminergic neurons.", "Unlike desipramine and most clinically effective antidepressants, lofepramine was inactive in attenuating the hyperactivity of olfactory bulbectomized rats in the \"open field\" apparatus, and in reversing acute clonidine induced hypomotility."], "par_relations": ["Lofepramine", "Dibenzazepines", "Antidepressive Agents, Tricyclic", "Lofepramine", "Lofepramine", "Lofepramine", "Lofepramine"], "chd_relations": ["Lofepramine", "Lofepramine", "Lofepramine", "Lofepramine", "Lofepramine"], "syn_relations": ["Lofepramine", "Lofepramine"], "sib_relations": ["Carbamazepine", "Clomipramine", "Clozapine", "Desipramine", "Imipramine", "Mianserin", "Opipramol", "Trimipramine"], "wiki_entities": ["Lofepramine", "List of drugs: Lo", "List of antidepressants", "Desipramine", "Otilonium bromide", "Tricyclic antidepressant", "Schedule H", "List of adrenergic drugs", "Atypical antidepressant", "Purple drank"], "mesh_synonynms": ["gamonil", "gamanil", "lopramine", "deftan", "lofepramine", "rosemont brand of lofepramine hydrochloride", "lomont", "merck brand of lofepramine hydrochloride", "ashbourne brand of lofepramine hydrochloride", "hydrochloride, lofepramine", "lofepramine hydrochloride", "leo 640", "feprapax"], "dbpedia_synonyms": ["atcvet code qn06aa07", "lofepramine", "lopramine", "atc code n06aa07"]}, "target_ent": {"research_entity_id": "RXNORM:6294", "canonical_name": "Lofepramine Hydrochloride", "aliases": ["lofepramine hydrochloride"], "definition": "Lofepramine, sold under the brand names Gamanil, Lomont, and Tymelyt among others, is a tricyclic antidepressant (TCA) which is used to treat depression.", "other_contexts": [], "par_relations": ["Lofepramine"], "chd_relations": ["Lomont", "Gamanil"], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Lofepramine", "Schedule H", "Desipramine", "Bupropion", "Ziprasidone", "Cyclobenzaprine", "Imipramine", "Tramadol", "Promethazine", "Dosulepin"], "mesh_synonynms": ["gamonil", "gamanil", "lopramine", "deftan", "lofepramine", "rosemont brand of lofepramine hydrochloride", "lomont", "merck brand of lofepramine hydrochloride", "ashbourne brand of lofepramine hydrochloride", "hydrochloride, lofepramine", "leo 640", "feprapax"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:13233", "canonical_name": "acidic nuclear phosphoprotein 32 family member A", "aliases": ["acidic nuclear phosphoprotein 32 family member a", "mapmodulin", "mapm", "i1pp2a", "anp32a", "pp32", "phapi", "anp32a gene", "lanp"], "definition": "Acidic leucine-rich nuclear phosphoprotein 32 family member A is a protein that in humans is encoded by the ANP32A gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A", "acidic nuclear phosphoprotein 32 family member A"], "sib_relations": [], "wiki_entities": ["Acidic leucine-rich nuclear phosphoprotein 32 family member A", "ANP32C", "ANP32D", "ANP32E", "ANP32B", "Protein SET", "MAP1B", "Rev-ErbA alpha", "IκB kinase", "Chromosome 2 (human)"], "mesh_synonynms": [], "dbpedia_synonyms": ["acidic leucine-rich nuclear phosphoprotein 32 family member a"]}, "target_ent": {"research_entity_id": "OMIM:600832", "canonical_name": "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "aliases": ["phap1", "anp32a", "acidic leucine-rich nuclear phosphoprotein 32 family, member a", "leucine-rich acidic nuclear protein", "phap i", "lanp", "putative human hla class ii-associated protein"], "definition": "Acidic leucine-rich nuclear phosphoprotein 32 family member A is a protein that in humans is encoded by the ANP32A gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A", "ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["acidic leucine-rich nuclear phosphoprotein 32 family member a"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:8775", "canonical_name": "phosphodiesterase 1B", "aliases": ["phosphodiesterase 1b", "pde1b", "pde1b gene"], "definition": "A phosphodiesterase (PDE) is an enzyme that breaks a phosphodiester bond.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["phosphodiesterase 1B", "phosphodiesterase 1B"], "sib_relations": [], "wiki_entities": ["Phosphodiesterase", "Phosphodiesterase inhibitor", "CGMP-specific phosphodiesterase type 5", "Sphingomyelin phosphodiesterase 1", "Phosphodiesterase-4 inhibitor", "PDE5 inhibitor", "Cyclic nucleotide phosphodiesterase", "Spleen exonuclease", "Ectonucleotide pyrophosphatase/phosphodiesterase 1", "PDE1"], "mesh_synonynms": [], "dbpedia_synonyms": ["pde1b (gene)"]}, "target_ent": {"research_entity_id": "OMIM:171891", "canonical_name": "PHOSPHODIESTERASE 1B", "aliases": ["pde1b", "pde1b1", "phosphodiesterase 1b"], "definition": "A phosphodiesterase (PDE) is an enzyme that breaks a phosphodiester bond.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["PHOSPHODIESTERASE 1B", "PHOSPHODIESTERASE 1B", "PHOSPHODIESTERASE 1B", "PHOSPHODIESTERASE 1B"], "sib_relations": [], "wiki_entities": ["Phosphodiesterase", "Phosphodiesterase inhibitor", "CGMP-specific phosphodiesterase type 5", "Sphingomyelin phosphodiesterase 1", "Phosphodiesterase-4 inhibitor", "PDE5 inhibitor", "Cyclic nucleotide phosphodiesterase", "Spleen exonuclease", "Ectonucleotide pyrophosphatase/phosphodiesterase 1", "PDE1"], "mesh_synonynms": [], "dbpedia_synonyms": ["pde1b (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:7415", "canonical_name": "mitochondrially encoded ATP synthase 8", "aliases": ["mt-atp8", "mitochondrially encoded atp synthase 8", "a6l", "mt-atp8 gene", "atp8"], "definition": "ATP synthase is an enzyme that creates the energy storage molecule adenosine triphosphate (ATP).", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["mitochondrially encoded ATP synthase 8", "mitochondrially encoded ATP synthase 8", "mitochondrially encoded ATP synthase 8", "mitochondrially encoded ATP synthase 8", "mitochondrially encoded ATP synthase 8", "mitochondrially encoded ATP synthase 8"], "sib_relations": [], "wiki_entities": ["ATP synthase", "Oxidative phosphorylation", "ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 1", "MT-ATP6", "Mitochondrion", "MT-ATP8", "Proton pump", "Adenosine triphosphate", "Human mitochondrial genetics", "Citric acid cycle"], "mesh_synonynms": [], "dbpedia_synonyms": ["mt-atp8"]}, "target_ent": {"research_entity_id": "OMIM:516070", "canonical_name": "ATP SYNTHASE 8", "aliases": ["complex v, atp synthase, subunit atpase 8", "cardiomyopathy, infantile hypertrophic", "mc5dm2", "atp synthase 8", "brain pseudoatrophy, reversible, valproate-induced, susceptibility to", "mitochondrial complex v (atp synthase) deficiency, mitochondrial type 2", "cardiomyopathy, apical hypertrophic, and neuropathy", "atp8", "mtatp8"], "definition": "ATP synthase is an enzyme that creates the energy storage molecule adenosine triphosphate (ATP).", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["ATP SYNTHASE 8", "ATP SYNTHASE 8", "MTATP8, 8393C-T", "MTATP8, TRP55TER", "MTATP8, TRP55ARG", "ATP SYNTHASE 8", "ATP SYNTHASE 8", "ATP SYNTHASE 8", "ATP SYNTHASE 8", "ATP SYNTHASE 8", "ATP SYNTHASE 8"], "sib_relations": ["MTATP8, TRP55ARG", "MTATP8, TRP55TER", "MTATP8, 8393C-T"], "wiki_entities": ["ATP synthase", "ATP synthase gamma subunit", "ATPase", "MT-ATP8", "Oxidative phosphorylation", "Electron transport chain", "MT-ATP6", "Adenosine triphosphate", "ATP citrate synthase", "Chemiosmosis"], "mesh_synonynms": [], "dbpedia_synonyms": ["mt-atp8"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:7797", "canonical_name": "NFKB inhibitor alpha", "aliases": ["ikba", "nfkb inhibitor alpha", "nfkbia", "nfkbia gene", "nf-kappa-b inhibitor alpha", "ikappabalpha", "mad-3"], "definition": "IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) is one member of a family of cellular proteins that function to inhibit the NF-κB transcription factor.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["NFKB inhibitor alpha", "NFKB inhibitor alpha", "NFKB inhibitor alpha", "NFKB inhibitor alpha", "NFKB inhibitor alpha", "NFKB inhibitor alpha", "NFKB inhibitor alpha", "NFKB inhibitor alpha"], "sib_relations": [], "wiki_entities": ["IκBα", "NFKB2", "NFKB1", "TANK-binding kinase 1", "NFKBIB", "NFKBIE", "NF-κB", "REL", "RELB", "BCL3"], "mesh_synonynms": ["major histocompatibility complex enhancer-binding protein mad3", "inhibitor alpha, nf-kappab", "nf-kappab inhibitor alpha", "nf kappab inhibitor alpha", "ikappab alpha", "p40 protein (ikappab-alpha)", "i kappa b-alpha protein", "major histocompatibility complex enhancer binding protein mad3", "alpha, nf-kappab inhibitor", "i kappa b alpha protein", "ikappab-alpha"], "dbpedia_synonyms": ["iκbα"]}, "target_ent": {"research_entity_id": "OMIM:164008", "canonical_name": "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "aliases": ["nuclear factor kappa-b inhibitor", "ikba", "nfkbia", "nuclear factor of kappa light chain gene enhancer in b cells inhibitor, alpha", "ectodermal dysplasia, anhidrotic, with t-cell immunodeficiency, autosomal dominant", "inhibitor of kappa light chain gene enhancer in b cells, alpha", "nuclear factor of kappa light chain gene enhancer in b cells inhibitor", "nfkbi", "i-kappa-b-alpha"], "definition": "NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls transcription of DNA, cytokine production and cell survival.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NFKBIA, SER32ILE", "NFKBIA, TRP11TER", "NFKBIA, GLU14TER", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA", "NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA"], "sib_relations": ["NFKBIA, SER32ILE", "NFKBIA, TRP11TER", "NFKBIA, GLU14TER"], "wiki_entities": ["NF-κB", "IKBKG", "IκB kinase", "IKK2", "Actin", "C-jun", "TP53", "Proteasome", "Protein kinase R", "IKBKE"], "mesh_synonynms": ["major histocompatibility complex enhancer-binding protein mad3", "inhibitor alpha, nf-kappab", "nf-kappab inhibitor alpha", "nf kappab inhibitor alpha", "ikappab alpha", "p40 protein (ikappab-alpha)", "i kappa b-alpha protein", "major histocompatibility complex enhancer binding protein mad3", "alpha, nf-kappab inhibitor", "i kappa b alpha protein", "ikappab-alpha"], "dbpedia_synonyms": ["iκbα"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:10149", "canonical_name": "small nucleolar RNA, C/D box 27", "aliases": ["snord27 gene", "snord27", "u27", "small nucleolar rna, c/d box 27"], "definition": "Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules that primarily guide chemical modifications of other RNAs, mainly ribosomal RNAs, transfer RNAs and small nuclear RNAs.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["small nucleolar RNA, C/D box 27", "small nucleolar RNA, C/D box 27", "small nucleolar RNA, C/D box 27", "small nucleolar RNA, C/D box 27"], "sib_relations": [], "wiki_entities": ["Small nucleolar RNA", "Small nucleolar RNA SNORD27", "Pyrococcus C/D box small nucleolar RNA", "Small nucleolar RNA U3", "Small nucleolar RNA SNORD113", "Small nucleolar RNA SNORD67", "Small nucleolar RNA SNORD116", "Small nucleolar RNA SNORD92", "Small nucleolar RNA SNORA76", "Small nucleolar RNA SNORA11"], "mesh_synonynms": [], "dbpedia_synonyms": ["german submarine u-27"]}, "target_ent": {"research_entity_id": "OMIM:613117", "canonical_name": "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "aliases": ["snord50a", "small nucleolar rna, c/d box, 50a", "snorna, u50", "rna, u50 small nucleolar", "rnu50"], "definition": "Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules that primarily guide chemical modifications of other RNAs, mainly ribosomal RNAs, transfer RNAs and small nuclear RNAs.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A", "SMALL NUCLEOLAR RNA, C/D BOX, 50A"], "sib_relations": [], "wiki_entities": ["Small nucleolar RNA", "Small nucleolar RNA Z50", "Small nucleolar RNA SNORD50", "Non-coding RNA", "Pyrococcus C/D box small nucleolar RNA", "Small nucleolar RNA U3", "Small nucleolar RNA SNORD67", "Small nucleolar RNA SNORD113", "Small nucleolar RNA SNORA76", "Small nucleolar RNA SNORD116"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HPO:HP:0000505", "canonical_name": "Visual impairment", "aliases": ["visual impairment", "poor vision", "impaired vision"], "definition": "Visual impairment, also known as vision impairment or vision loss, is a decreased ability to see to a degree that causes problems not fixable by usual means, such as glasses.", "other_contexts": [], "par_relations": ["Abnormality of vision"], "chd_relations": ["Blindness", "Severe visual impairment", "Moderate visual impairment", "Congenital visual impairment", "Cortical visual impairment"], "syn_relations": ["Visual impairment", "Visual impairment", "Visual impairment", "Visual impairment"], "sib_relations": ["Vitreous floaters", "Hemeralopia", "Nyctalopia", "Photopsia", "Photophobia", "Amaurosis fugax", "Abnormality of color vision", "Reduced visual acuity", "Metamorphopsia", "Blurred vision", "Bradyopsia", "Visual loss", "Visual field defect", "Abnormality of binocular vision", "Difficulty adjusting to changes in luminance"], "wiki_entities": ["Visual impairment", "Cortical visual impairment", "Visual impairment due to intracranial pressure", "Visual agnosia", "Computer accessibility", "Physical disability", "Cortical blindness", "Special education in the United States", "Associative visual agnosia", "Accessibility"], "mesh_synonynms": ["vision disability", "vision disabilities", "disorder, visual", "hemeralopias", "metamorphopsia", "impairments, visual", "blindness, day", "hemeralopia", "visual disorders", "disability, vision", "impairment, visual", "micropsias", "vision disorder", "macropsias", "day blindness", "visual impairments", "micropsia", "vision disorders", "disabilities, vision", "metamorphopsias", "disorders, visual", "macropsia", "visual disorder"], "dbpedia_synonyms": ["ablepsy", "poor vision", "blind people", "low-vision", "blind sports", "vision problem", "vision defect", "visual impairment", "purblind", "blindly", "dimsightedness", "loss of sight", "problems seeing", "blindest", "visually impared", "unseeing", "visual imparement", "blindness", "low vision", "unseeingly", "no light perception", "visually-impaired", "vision loss", "visually impaired", "blindism", "ablepsia", "loss of vision", "totally blind", "visual disabilities", "visually challenged", "visual impairments", "impaired vision", "can't see", "visually impaired community", "legally blind", "blindnesses", "visually impaired people", "visually disabled", "vision impairment", "decreased vision", "vision, low", "legally-blind", "partially sighted", "vision problems", "visual loss", "problems with vision", "vision impaired", "legal blindness", "sight loss", "amaurotic"]}, "target_ent": {"research_entity_id": "OMIM:MTHU031431", "canonical_name": "Micrognathia (57%)", "aliases": ["micrognathia (57%)"], "definition": "Marden–Walker syndrome (MWS) is a rare autosomal recessive congenital disorder.", "other_contexts": [], "par_relations": ["Face"], "chd_relations": [], "syn_relations": [], "sib_relations": ["ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1"], "wiki_entities": ["Marden–Walker syndrome", "Coloboma", "Möbius syndrome", "Marfan syndrome", "Crohn's disease", "List of genetic disorders", "Oral allergy syndrome", "Shingles", "Herpes simplex", "Aphthous stomatitis"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "CPT:1009733", "canonical_name": "Enucleation of eye", "aliases": ["enucleation of eye"], "definition": "Enucleation is the removal of the eye that leaves the eye muscles and remaining orbital contents intact.", "other_contexts": [], "par_relations": ["Removal Procedures of Eye Contents"], "chd_relations": ["Enucleation of eye; with implant, muscles attached to implant", "Enucleation of eye; with implant, muscles not attached to implant", "Enucleation of eye; without implant"], "syn_relations": [], "sib_relations": ["Evisceration of ocular contents", "Exenteration of orbit (does not include skin graft), removal of orbital contents"], "wiki_entities": ["Enucleation of the eye", "Enucleation", "Phantom eye syndrome", "Enucleation (surgery)", "Ocular prosthesis", "Evisceration (ophthalmology)", "Eye-gouging", "Phthisis bulbi", "Exophthalmos", "Sympathetic ophthalmia"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "MSH:D015353", "canonical_name": "Eye Enucleation", "aliases": ["eye enucleations", "enucleation, eye", "eye enucleation", "enucleations, eye"], "definition": "Enucleation is the removal of the eye that leaves the eye muscles and remaining orbital contents intact.", "other_contexts": [], "par_relations": ["Ophthalmologic Surgical Procedures"], "chd_relations": [], "syn_relations": ["Eye Enucleation", "Eye Enucleation", "Eye Enucleation", "Eye Enucleation", "Eye Enucleation", "Eye Enucleation"], "sib_relations": ["Eye Evisceration", "Dacryocystorhinostomy", "Light Coagulation", "Scleral Buckling", "Vitrectomy", "Orbit Evisceration", "Eye Evisceration", "Blepharoplasty", "Iridectomy", "Filtering Surgery", "Refractive Surgical Procedures", "Vitreoretinal Surgery"], "wiki_entities": ["Enucleation of the eye", "Enucleation", "Enucleation (surgery)", "Phantom eye syndrome", "Ocular prosthesis", "Evisceration (ophthalmology)", "Eye-gouging", "Phthisis bulbi", "Exophthalmos", "Sympathetic ophthalmia"], "mesh_synonynms": ["eye enucleations", "enucleation, eye", "enucleations, eye", "eye enucleation"], "dbpedia_synonyms": ["enucleation of the eye"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D060825", "canonical_name": "Cognitive Dysfunction", "aliases": ["impairment, cognitive", "deterioration, mental", "mild cognitive impairments", "mild cognitive impairment", "cognitive impairments, mild", "mental deterioration", "cognitive dysfunction", "deteriorations, mental", "disorder, mild neurocognitive", "decline, cognitive", "mental deteriorations", "disorders, mild neurocognitive", "cognitive dysfunctions", "cognitive impairment", "mild neurocognitive disorder", "cognitive declines", "dysfunctions, cognitive", "impairment, mild cognitive", "cognitive decline", "mild neurocognitive disorders", "impairments, mild cognitive", "cognitive impairment, mild", "impairments, cognitive", "neurocognitive disorders, mild", "neurocognitive disorder, mild", "dysfunction, cognitive", "cognitive impairments", "declines, cognitive"], "definition": "Neurocognitive disorders (NCDs), also known as cognitive disorders, are a category of mental health disorders that primarily affect cognitive abilities including learning, memory, perception, and problem solving.", "other_contexts": [], "par_relations": ["Cognitive Dysfunction", "Cognition Disorders", "Cognitive Dysfunction"], "chd_relations": ["Cognitive Dysfunction", "Cognitive Dysfunction"], "syn_relations": ["Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction", "Cognitive Dysfunction"], "sib_relations": ["Auditory Perceptual Disorders", "Huntington Disease"], "wiki_entities": ["Cognitive disorder", "Postoperative cognitive dysfunction", "Canine cognitive dysfunction", "Cognitive dysfunction syndrome", "Feline cognitive dysfunction", "Executive dysfunction", "Erectile dysfunction", "Sexual dysfunction", "Cognitive science", "Delirium"], "mesh_synonynms": ["mild cognitive impairments", "declines, cognitive", "impairments, cognitive", "disorder, mild neurocognitive", "cognitive declines", "deterioration, mental", "neurocognitive disorders, mild", "neurocognitive disorder, mild", "dysfunction, cognitive", "cognitive impairments", "deteriorations, mental", "dysfunctions, cognitive", "mild cognitive impairment", "impairments, mild cognitive", "disorders, mild neurocognitive", "mild neurocognitive disorder", "cognitive impairments, mild", "cognitive dysfunctions", "mental deteriorations", "decline, cognitive", "cognitive impairment", "cognitive dysfunction", "mental deterioration", "cognitive impairment, mild", "impairment, cognitive", "mild neurocognitive disorders", "impairment, mild cognitive", "cognitive decline"], "dbpedia_synonyms": ["mild cognitive impairment", "dementia", "mild cognitive disorder", "incipient dementia", "delirium", "cognitive disorder", "hiv-associated neurocognitive disorder", "cognitive deficit"]}, "target_ent": {"research_entity_id": "OMIM:MTHU000616", "canonical_name": "Cognitive impairment, mild", "aliases": ["cognitive impairment, mild"], "definition": "Mild cognitive impairment (MCI, also known as incipient dementia, or isolated memory impairment) is a brain function syndrome involving the onset and evolution of cognitive impairments beyond those expected based on the age and education of the individual, but which are not significant enough to interfere with their daily activities.", "other_contexts": [], "par_relations": ["Central nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["SPINOCEREBELLAR ATAXIA 1", "SPASTIC PARAPLEGIA 23", "DANON DISEASE", "SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS", "JOUBERT SYNDROME 4", "SPINOCEREBELLAR ATAXIA 29", "MYOPATHY, CENTRONUCLEAR, 4", "PEROXISOME BIOGENESIS DISORDER 8B", "MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 12"], "wiki_entities": ["Mild cognitive impairment", "Post-chemotherapy cognitive impairment", "Montreal Cognitive Assessment", "Cognitive disorder", "Severe cognitive impairment", "Dementia", "Cingulum (brain)", "Mini–Mental State Examination", "Vascular dementia", "Donepezil"], "mesh_synonynms": ["mild cognitive impairments", "declines, cognitive", "impairments, cognitive", "disorder, mild neurocognitive", "cognitive declines", "deterioration, mental", "neurocognitive disorders, mild", "neurocognitive disorder, mild", "dysfunction, cognitive", "cognitive impairments", "deteriorations, mental", "dysfunctions, cognitive", "mild cognitive impairment", "impairments, mild cognitive", "disorders, mild neurocognitive", "mild neurocognitive disorder", "cognitive impairments, mild", "cognitive dysfunctions", "mental deteriorations", "decline, cognitive", "cognitive impairment", "cognitive dysfunction", "mental deterioration", "impairment, cognitive", "mild neurocognitive disorders", "impairment, mild cognitive", "cognitive decline"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0006961", "canonical_name": "Jerky head movements", "aliases": ["jerky head movements", "jerking head movements"], "definition": "Tom and Jerry is an American animated series of short films created in 1940, by William Hanna and Joseph Barbera.", "other_contexts": [], "par_relations": ["Abnormal head movements"], "chd_relations": [], "syn_relations": ["Jerky head movements", "Jerky head movements"], "sib_relations": ["Head titubation"], "wiki_entities": ["Kronichthys subteres", "Popping", "Jerk (dance)", "Saccade", "Cardiac examination", "Angelman syndrome", "Schizolecis guntheri", "Infantile convulsions and choreoathetosis", "Tripod head", "Dandy–Walker syndrome"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU011933", "canonical_name": "Jerky head movements", "aliases": ["jerky head movements"], "definition": "Tom and Jerry is an American animated series of short films created in 1940, by William Hanna and Joseph Barbera.", "other_contexts": [], "par_relations": ["Central nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["PYRUVATE DEHYDROGENASE E2 DEFICIENCY"], "wiki_entities": ["Kronichthys subteres", "Popping", "Jerk (dance)", "Saccade", "Cardiac examination", "Angelman syndrome", "Schizolecis guntheri", "Infantile convulsions and choreoathetosis", "Tripod head", "Dandy–Walker syndrome"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "CPT:98925", "canonical_name": "Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "aliases": ["osteopathic manipulative tx 1-2 body regions", "osteopath manj 1-2 regions", "osteopathic manipulative treatment to 1-2 body regions", "osteopathic manipulative treatment (omt); 1-2 body regions involved", "osteopathic manipulative treatment"], "definition": "Osteopathic medicine is a branch of the medical profession in the United States.", "other_contexts": [], "par_relations": ["Osteopathic manipulative treatment (OMT)"], "chd_relations": [], "syn_relations": ["Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "Osteopathic manipulative treatment (OMT); 1-2 body regions involved"], "sib_relations": ["Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "Irrigation of implanted venous access device for drug delivery systems", "Osteopathic manipulative treatment (OMT); 3-4 body regions involved", "Osteopathic manipulative treatment (OMT); 5-6 body regions involved", "Osteopathic manipulative treatment (OMT); 7-8 body regions involved", "Osteopathic manipulative treatment (OMT); 9-10 body regions involved", "Osteopathic manipulative treatment (OMT); 1-2 body regions involved", "Osteopathic manipulative treatment (OMT); 1-2 body regions involved"], "wiki_entities": ["Osteopathic medicine in the United States"], "mesh_synonynms": ["osteopathic manipulative treatments", "osteopathic manipulation", "treatment, osteopathic manipulative", "treatments, osteopathic manipulative", "manipulation, osteopathic"], "dbpedia_synonyms": ["osteopathic manipulative medicine"]}, "target_ent": {"research_entity_id": "MSH:D026301", "canonical_name": "Manipulation, Osteopathic", "aliases": ["osteopathic manipulative treatment", "treatment, osteopathic manipulative", "manipulation, osteopathic", "osteopathic manipulative treatments", "treatments, osteopathic manipulative", "osteopathic manipulation"], "definition": "Osteopathic manipulation or osteopathic manipulative medicine is a core set of techniques of osteopathy and osteopathic medicine distinguishing these fields from the rest of medicine.", "other_contexts": [], "par_relations": ["Musculoskeletal Manipulations"], "chd_relations": [], "syn_relations": ["Manipulation, Osteopathic", "Manipulation, Osteopathic", "Manipulation, Osteopathic", "Manipulation, Osteopathic", "Manipulation, Osteopathic", "Manipulation, Osteopathic"], "sib_relations": ["Manipulation, Orthopedic", "Manipulation, Chiropractic", "Manipulation, Orthopedic", "Motion Therapy, Continuous Passive", "Manipulation, Spinal", "Kinesiology, Applied", "Manipulation, Chiropractic", "Therapy, Soft Tissue"], "wiki_entities": ["Osteopathic manipulation", "Osteopathic medicine in the United States", "Osteopathy", "Doctor of Osteopathic Medicine", "Comparison of MD and DO in the United States", "Neck manipulation", "Craniosacral therapy", "Manual therapy", "Manipulation under anesthesia", "Rocky Vista University College of Osteopathic Medicine"], "mesh_synonynms": ["osteopathic manipulative treatments", "osteopathic manipulation", "osteopathic manipulative treatment", "treatment, osteopathic manipulative", "treatments, osteopathic manipulative", "manipulation, osteopathic"], "dbpedia_synonyms": ["osteopathic manipulative medicine"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:16156", "canonical_name": "neuralized E3 ubiquitin protein ligase 2", "aliases": ["neuralized e3 ubiquitin protein ligase 2", "neurl2 gene", "ozz-e3", "ozz", "dj337o18.6", "flj30259", "neurl2"], "definition": "Ubiquitin is a small (8.5 kDa) regulatory protein found in most tissues of eukaryotic organisms i.e.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2", "neuralized E3 ubiquitin protein ligase 2"], "sib_relations": [], "wiki_entities": ["Ubiquitin", "Neuralized e3 ubiquitin protein ligase 3", "Parkin (ligase)", "Proteasome", "Ubiquitin C", "NEDD8", "MIB1 (gene)", "Cell division control protein 4", "NEDD4", "NUMB (gene)"], "mesh_synonynms": [], "dbpedia_synonyms": ["ouarzazate airport", "neurl2 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:608597", "canonical_name": "NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2", "aliases": ["neuralized-like 2", "neuralized e3 ubiquitin protein ligase 2", "ozz", "neurl2"], "definition": "Ubiquitin is a small (8.5 kDa) regulatory protein found in most tissues of eukaryotic organisms i.e.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2", "NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2", "NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2", "NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2", "NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2", "NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2"], "sib_relations": [], "wiki_entities": ["Ubiquitin", "Neuralized e3 ubiquitin protein ligase 3", "Parkin (ligase)", "Proteasome", "Ubiquitin C", "NEDD8", "MIB1 (gene)", "Cell division control protein 4", "NEDD4", "NUMB (gene)"], "mesh_synonynms": [], "dbpedia_synonyms": ["ouarzazate airport", "neurl2 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C567267", "canonical_name": "Niemann-Pick Disease, Intermediate, With Visceral Involvement And Rapid Progression", "aliases": ["niemann-pick disease, intermediate, with visceral involvement and rapid progression"], "definition": "Many conditions affect the human integumentary system—the organ system covering the entire surface of the body and composed of skin, hair, nails, and related muscle and glands.", "other_contexts": [], "par_relations": ["Niemann-Pick Diseases"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:607616", "canonical_name": "NIEMANN-PICK DISEASE, TYPE B", "aliases": ["niemann-pick disease, intermediate, with visceral involvement and rapid progression", "niemann-pick disease, type b", "niemann-pick disease, type e", "niemann-pick disease, type f"], "definition": "Niemann–Pick disease ( nee-mən-PIK) is a group of inherited, severe metabolic disorders in which sphingomyelin accumulates in lysosomes in cells.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": [], "sib_relations": ["Dyspnea", "Hepatomegaly", "Splenomegaly", "Decreased HDL cholesterol", "'Sea blue' histiocytes", "Decreased platelets", "Autosomal recessive", "Increased LDL cholesterol", "Increased triglycerides", "Variable phenotype", "Absence of neurologic manifestations", "Short stature (less common)", "Cherry-red maculae (less common)", "Decreased acid sphingomyelinase activity", "Multiple visceral organs (lung, liver, spleen, kidney) contain foamy resident cells and histiocytes", "Electron microscopy of foam cells shows lamellar inclusions", "Decreased pulmonary diffusion secondary to alveolar infiltration", "Diffuse reticular or finely nodular infiltrations", "Caused by mutations in the acid lysosomal sphingomyelin phosphodiesterase-1 gene (SMPD1, 607608.0002)", "More common in Ashkenazi Jews", "Allelic disorder to Niemann-Pick disease type A (257200)", "Onset in infancy or childhood", "Large vacuolated foam cells ('NP cells') on bone marrow biopsy", "Frequent respiratory infections"], "wiki_entities": ["Niemann–Pick disease", "Niemann–Pick disease, type C"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:20764", "canonical_name": "pleckstrin homology and FYVE domain containing 1", "aliases": ["appd", "phafin1", "plekhf1", "mgc4090", "zfyve15", "plekhf1 gene", "pleckstrin homology and fyve domain containing 1"], "definition": "Pleckstrin homology domain (PH domain) is a protein domain of approximately 120 amino acids that occurs in a wide range of proteins involved in intracellular signaling or as constituents of the cytoskeleton.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1", "pleckstrin homology and FYVE domain containing 1"], "sib_relations": [], "wiki_entities": ["Pleckstrin homology domain", "Phosphoinositide 3-kinase", "PLEKHF2", "FGD1", "BMX (gene)", "Akt/PKB signaling pathway", "Peripheral membrane protein", "Apoptosis"], "mesh_synonynms": [], "dbpedia_synonyms": ["appd (disambiguation)"]}, "target_ent": {"research_entity_id": "OMIM:615200", "canonical_name": "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "aliases": ["lapf", "phafin1", "plekhf1", "pleckstrin homology domain-containing protein, family f, member 1", "ph and fyve domains-containing protein 1", "lysosome-associated apoptosis-inducing protein containing ph and fyve domains", "phafin 1"], "definition": "Protein–protein interactions (PPIs) are the physical contacts of high specificity established between two or more protein molecules as a result of biochemical events steered by electrostatic forces including the hydrophobic effect.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1", "PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["link access procedure for frame relay"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0005914", "canonical_name": "Aplasia/Hypoplasia involving the metacarpal bones", "aliases": ["absent/small long bones of hand", "hypoplastic/absent metacarpals", "absent/underdeveloped long bones of hand", "metacarpal aplasia/hypoplasia", "aplastic/hypoplastic metacarpals", "aplasia/hypoplasia involving the metacarpal bones", "hypoplastic/absent metacarpal bones", "hypoplastic metacarpals", "absent or hypoplastic metacarpals"], "definition": "Ectrodactyly, split hand, cleft hand, derived from the Greek ektroma (abortion) and daktylos (finger) involves the deficiency or absence of one or more central digits of the hand or foot and is also known as split hand/split foot malformation (SHFM).", "other_contexts": [], "par_relations": ["Aplasia/hypoplasia involving bones of the hand", "Abnormal metacarpal morphology"], "chd_relations": ["Short metacarpal", "Aplasia of metacarpal bones", "Aplasia/Hypoplasia of the 5th metacarpal", "Aplasia/Hypoplasia of the 4th metacarpal", "Aplasia/Hypoplasia of the 3rd metacarpal", "Aplasia/Hypoplasia of the 2nd metacarpal", "Aplasia/Hypoplasia of the 1st metacarpal"], "syn_relations": ["Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones", "Aplasia/Hypoplasia involving the metacarpal bones"], "sib_relations": ["Absent hand", "Small hand", "Metacarpal diaphyseal endosteal sclerosis", "Broad metacarpals", "Short palm", "Widened metacarpal shaft", "Thin metacarpal cortices", "Proximal tapering of metacarpals", "Tubular metacarpal bones", "Y-shaped metacarpals", "Distal widening of metacarpals", "Expanded metacarpals with widened medullary cavities", "Long metacarpals", "Metacarpal synostosis", "Flattened metacarpal heads", "Aplasia/Hypoplasia involving the carpal bones", "Aplasia/Hypoplasia of fingers", "Slender metacarpals", "Irregular metacarpals", "Tapered metacarpals"], "wiki_entities": ["Ectrodactyly", "Congenital disorder", "List of genetic disorders"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU014824", "canonical_name": "Absent or hypoplastic metacarpals", "aliases": ["absent or hypoplastic metacarpals"], "definition": "Thumb hypoplasia is a spectrum of congenital abnormalities of the thumb varying from small defects to absolute retardation of the thumb.", "other_contexts": [], "par_relations": ["Hands"], "chd_relations": [], "syn_relations": [], "sib_relations": ["CHONDRODYSPLASIA, GREBE TYPE"], "wiki_entities": ["Thumb hypoplasia", "Pollicization", "Polydactyly", "Radial dysplasia", "Brachydactyly", "List of diseases (M)", "Congenital disorder"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "MSH:C009679", "canonical_name": "VoSoL", "aliases": ["vosol"], "definition": "In phonetics, a vowel is a sound in spoken language, with two complementary definitions.", "other_contexts": [], "par_relations": ["Acetic Acid", "Benzethonium", "Drug Combinations", "Propylene Glycols"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Acetic acid/hydrocortisone", "List of drugs: Vf-Vz", "Cortisol"], "mesh_synonynms": [], "dbpedia_synonyms": ["acetic acid/hydrocortisone"]}, "target_ent": {"research_entity_id": "RXNORM:42240", "canonical_name": "VoSoL", "aliases": ["vosol"], "definition": "In phonetics, a vowel is a sound in spoken language, with two complementary definitions.", "other_contexts": [], "par_relations": ["Acetic Acid"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Acetic Acid Otic Solution [VoSoL]", "VoSol 2 % Otic Solution", "Acetic Acid 20 MG/ML [VoSoL]", "VoSoL Otic Product"], "wiki_entities": ["Acetic acid/hydrocortisone", "List of drugs: Vf-Vz", "Cortisol"], "mesh_synonynms": [], "dbpedia_synonyms": ["acetic acid/hydrocortisone"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D009464", "canonical_name": "Neuroma, Acoustic", "aliases": ["schwannoma, acoustic", "schwannoma, melanocytic vestibular", "tumors, angle", "acoustic neuroma, cerebellopontine angle", "neuromas, acoustic", "acoustic neurilemmoma", "acoustic tumors", "schwannomas, melanocytic vestibular", "melanocytic vestibular schwannoma", "angle tumors, cerebellopontine", "tumors, cerebellopontine angle", "schwannoma, vestibular", "acoustic neurilemmomas", "vestibular schwannomas", "neurilemoma, acoustic", "vestibular schwannoma", "cerebellopontine angle acoustic neuroma", "acoustic neurilemoma", "neuroma, acoustic", "acoustic neuromas", "acoustic tumor", "neurilemmomas, acoustic", "neurilemmoma, acoustic", "cerebellopontine angle tumor", "tumor, angle", "melanocytic vestibular schwannomas", "neurinoma, acoustic", "tumor, acoustic", "tumor, cerebellopontine angle", "vestibular schwannomas, melanocytic", "schwannomas, acoustic", "acoustic schwannoma", "cerebellopontine angle tumors", "vestibular schwannoma, melanocytic", "angle tumor", "acoustic neuroma", "angle tumors", "neurinomas, acoustic", "neurilemomas, acoustic", "acoustic schwannomas", "angle tumor, cerebellopontine", "acoustic neurinomas", "neurinoma of the acoustic nerve", "tumors, acoustic", "acoustic neurinoma", "schwannomas, vestibular", "neuroma, acoustic, unilateral", "acoustic neurilemomas"], "definition": "A vestibular schwannoma (VS) is a benign primary intracranial tumor of the myelin-forming cells of the vestibulocochlear nerve (8th cranial nerve).", "other_contexts": [], "par_relations": ["Vestibulocochlear Nerve Diseases", "Cranial Nerve Neoplasms", "Neurilemmoma", "Otorhinolaryngologic Neoplasms", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic"], "chd_relations": ["Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neurofibromatosis 2"], "syn_relations": ["Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic", "Neuroma, Acoustic"], "sib_relations": ["Ear Neoplasms", "Laryngeal Neoplasms", "Nose Neoplasms", "Pharyngeal Neoplasms", "Vestibulocochlear Nerve Injuries", "Cogan Syndrome", "Optic Nerve Neoplasms", "Vestibular Neuronitis"], "wiki_entities": ["Vestibular schwannoma", "Neuroma", "Neurofibromatosis type II", "Cerebellopontine angle syndrome", "Cerebellopontine angle", "Translabyrinthine approach", "Acoustic reflex", "Otology", "Jugular foramen syndrome", "Neurotology"], "mesh_synonynms": ["cerebellopontine angle tumor", "acoustic neurilemmomas", "acoustic neuroma", "tumors, cerebellopontine angle", "acoustic neuroma, cerebellopontine angle", "neurinoma, acoustic", "neuroma, acoustic", "vestibular schwannoma", "neurilemmomas, acoustic", "schwannoma, vestibular", "acoustic neurilemomas", "acoustic schwannomas", "acoustic neurinoma", "acoustic neuromas", "neurilemoma, acoustic", "acoustic neurilemoma", "vestibular schwannomas, melanocytic", "acoustic neurilemmoma", "schwannoma, acoustic", "melanocytic vestibular schwannoma", "acoustic schwannoma", "cerebellopontine angle acoustic neuroma", "acoustic tumors", "schwannomas, vestibular", "acoustic tumor", "vestibular schwannomas", "angle tumors", "vestibular schwannoma, melanocytic", "schwannomas, acoustic", "neurinomas, acoustic", "melanocytic vestibular schwannomas", "angle tumor", "angle tumor, cerebellopontine", "schwannoma, melanocytic vestibular", "acoustic neurinomas", "tumor, angle", "neurinoma of the acoustic nerve", "tumors, acoustic", "neuroma, acoustic, unilateral", "cerebellopontine angle tumors", "angle tumors, cerebellopontine", "neurilemmoma, acoustic", "tumor, acoustic", "neuromas, acoustic", "tumors, angle", "tumor, cerebellopontine angle", "schwannomas, melanocytic vestibular", "neurilemomas, acoustic"], "dbpedia_synonyms": ["acoustic neurinoma", "acusticus neurinoma", "acoustic schwannomas", "acoustic neuroma", "acoustic neuromas", "neuroma, acoustic", "acoustic schwannoma", "vestibular schwannoma"]}, "target_ent": {"research_entity_id": "OMIM:MTHU043236", "canonical_name": "Vestibular Schwannoma", "aliases": ["vestibular schwannoma"], "definition": "A vestibular schwannoma (VS) is a benign primary intracranial tumor of the myelin-forming cells of the vestibulocochlear nerve (8th cranial nerve).", "other_contexts": [], "par_relations": ["NEOPLASIA"], "chd_relations": [], "syn_relations": [], "sib_relations": ["CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B"], "wiki_entities": ["Vestibular schwannoma", "Schwannoma", "Neurofibromatosis type II", "Schwannomatosis", "Bruns nystagmus", "Cerebellopontine angle", "Vertigo", "Cerebellopontine angle syndrome", "Ménière's disease", "Neurotology"], "mesh_synonynms": ["cerebellopontine angle tumor", "acoustic neurilemmomas", "acoustic neuroma", "tumors, cerebellopontine angle", "acoustic neuroma, cerebellopontine angle", "neurinoma, acoustic", "neuroma, acoustic", "neurilemmomas, acoustic", "schwannoma, vestibular", "acoustic neurilemomas", "acoustic schwannomas", "acoustic neurinoma", "acoustic neuromas", "neurilemoma, acoustic", "acoustic neurilemoma", "vestibular schwannomas, melanocytic", "acoustic neurilemmoma", "schwannoma, acoustic", "melanocytic vestibular schwannoma", "acoustic schwannoma", "cerebellopontine angle acoustic neuroma", "acoustic tumors", "schwannomas, vestibular", "acoustic tumor", "vestibular schwannomas", "angle tumors", "vestibular schwannoma, melanocytic", "schwannomas, acoustic", "neurinomas, acoustic", "melanocytic vestibular schwannomas", "angle tumor", "angle tumor, cerebellopontine", "schwannoma, melanocytic vestibular", "acoustic neurinomas", "tumor, angle", "neurinoma of the acoustic nerve", "tumors, acoustic", "neuroma, acoustic, unilateral", "cerebellopontine angle tumors", "angle tumors, cerebellopontine", "neurilemmoma, acoustic", "tumor, acoustic", "neuromas, acoustic", "tumors, angle", "tumor, cerebellopontine angle", "schwannomas, melanocytic vestibular", "neurilemomas, acoustic"], "dbpedia_synonyms": ["acoustic neurinoma", "acusticus neurinoma", "acoustic schwannomas", "acoustic neuroma", "acoustic neuromas", "neuroma, acoustic", "acoustic schwannoma"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C536343", "canonical_name": "Posterior column ataxia with retinitis pigmentosa", "aliases": ["posterior column ataxia with retinitis pigmentosa"], "definition": "Subacute combined degeneration of spinal cord, also known as Lichtheim's disease, refers to degeneration of the posterior and lateral columns of the spinal cord as a result of vitamin B12 deficiency (most common), vitamin E deficiency, and copper deficiency.", "other_contexts": [], "par_relations": ["Ataxia", "Retinitis Pigmentosa"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Subacute combined degeneration of spinal cord", "Abetalipoproteinemia", "Hemicentin 1", "Major facilitator superfamily"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:609144", "canonical_name": "FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 1", "aliases": ["feline leukemia virus subgroup c receptor 1", "flvcr1", "flvcr", "posterior column ataxia with retinitis pigmentosa"], "definition": "Feline leukemia virus (FeLV) is a retrovirus that infects cats.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 1", "FLVCR1, ASN121ASP", "FLVCR1, ALA241THR", "FLVCR1, CYS192ARG", "FLVCR1, GLY493ARG", "FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 1", "FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 1", "FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 1"], "sib_relations": ["FLVCR1, ASN121ASP", "FLVCR1, ALA241THR", "FLVCR1, CYS192ARG", "FLVCR1, GLY493ARG"], "wiki_entities": ["Feline leukemia virus", "FLVCR2", "SLC20A1", "FLVCR1", "Inorganic phosphate transporter family", "Lymphoma in animals"], "mesh_synonynms": [], "dbpedia_synonyms": ["flvcr1 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:48926", "canonical_name": "CDR1 antisense RNA", "aliases": ["circular rna sponge for mir-7", "cirs-7", "cdr1nat", "cdr1-as gene", "cdr1 natural antisense transcript", "cdr1as", "cdr1-as", "cdr1 antisense rna"], "definition": "CD81 molecule, also known as CD81 (Cluster of Differentiation 81), is a protein which in humans is encoded by the CD81 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["CDR1 antisense RNA", "CDR1 antisense RNA", "CDR1 antisense RNA", "CDR1 antisense RNA", "CDR1 antisense RNA", "CDR1 antisense RNA", "CDR1 antisense RNA", "CDR1 antisense RNA"], "sib_relations": [], "wiki_entities": ["CDR1-AS", "Mir-671 microRNA precursor family", "Circular RNA"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:300898", "canonical_name": "CIRCULAR RNA SPONGE FOR MIR7", "aliases": ["circular rna sponge for mir7", "cdr1as", "cirs7", "cdr1 antisense transcript", "cerebellar degeneration-related autoantigen 1, antisense"], "definition": "Bacteria ( ( listen); common noun bacteria, singular bacterium) constitute a large domain of prokaryotic microorganisms.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7", "CIRCULAR RNA SPONGE FOR MIR7"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C535662", "canonical_name": "Acromicric dysplasia", "aliases": ["geleophysic dysplasia", "acmicd", "acromicric skeletal dysplasia", "geleophysic dwarfism", "acromicric dysplasia"], "definition": "Acromicric dysplasia is an extremely rare inherited disorder characterized by abnormally short hands and feet, growth retardation and delayed bone maturation leading to short stature.", "other_contexts": [], "par_relations": ["Bone Diseases, Developmental", "Limb Deformities, Congenital"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Acromicric dysplasia", "Acromicric dysplasia"], "wiki_entities": ["Acromicric dysplasia", "Martin Klebba", "List of diseases (A)"], "mesh_synonynms": [], "dbpedia_synonyms": ["geleophysic dwarfism", "acromicric dysplasia"]}, "target_ent": {"research_entity_id": "OMIM:134797", "canonical_name": "FIBRILLIN 1", "aliases": ["fibrillin 1", "marfan syndrome, autosomal recessive", "marfan syndrome, atypical", "marfan syndrome, classic", "marfan syndrome, severe classic", "weill-marchesani syndrome 2", "geleophysic dysplasia 2", "mass syndrome", "stiff skin syndrome", "marfan syndrome, neonatal", "reclassified - variant of unknown significance", "acromicric dysplasia", "fnb1 polymorphism", "fbn", "fbn1", "fibrillin", "marfan syndrome, mild", "marfan lipodystrophy syndrome", "marfan syndrome, mild variable", "marfan syndrome", "ectopia lentis 1, isolated, autosomal dominant"], "definition": "Fibrillin-1 is a protein that in humans is encoded by the FBN1 gene, located on chromosome 15.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["FIBRILLIN 1", "FBN1, ARG1137PRO", "FBN1, CYS2307SER", "FBN1, 366-BP DEL", "FBN1, G8268A, TRP2756TER", "FBN1, CYS1249SER", "FBN1, CYS1663ARG", "FBN1, CYS2221SER", "FBN1, TYR2113TER, EX51DEL", "FBN1, ASN2144SER", "FBN1, ASN548ILE", "FBN1, ASP723ALA", "FBN1, 4-BP INS, NT5138", "FBN1, 83-BP DEL", "FBN1, IVS54DS, G-C, +1, 123-BP DEL", "FBN1, GLU2447LYS", "FBN1, CYS1074ARG", "FBN1, ARG2776TER", "FBN1, ARG122CYS", "FBN1, IVS31AS, A-T, -2", "FBN1, IVS32DS, G-A, +1", "FBN1, GLY1127SER", "FBN1, CYS1223TYR", "FBN1, ARG2726TRP", "FBN1, CYS1117TYR", "FBN1, CYS1242TYR", "FBN1, LYS1043ARG", "FBN1, ASN1131TYR", "FBN1, 1-BP DEL, 3192A", "FBN1, 6354C-T, EX51DEL, ILE2118ILE", "FBN1, CYS1265ARG", "FBN1, ARG1170HIS", "FBN1, ARG529TER", "FBN1, GLY985GLU", "FBN1, IVS2DS, G-A, +1", "FBN1, GLY1013ARG", "FBN1, 33-BP INS, IVS46, G-A, +1", "FBN1, GLU1073LYS", "FBN1, IVS46+5G-A", "FBN1, 24-BP DEL", "FBN1, TYR754CYS", "FBN1, ARG240CYS", "FBN1, CYS1032TYR", "FBN1, CYS1129TYR", "FBN1, CYS1221TYR", "FBN1, CYS1086TYR", "FBN1, ARG485CYS", "FBN1, 302.5-KB DEL", "FBN1, TRP1570CYS, 4710G-T", "FBN1, TRP1570CYS, 4710G-C", "FBN1, CYS1564SER", "FBN1, CYS1577GLY", "FBN1, TYR1699CYS", "FBN1, GLY1762SER", "FBN1, ALA1728THR", "FBN1, TYR1696CYS", "FBN1, SER1750ARG", "FBN1, TYR1700CYS", "FBN1, 3-BP DUP, NT5202", "FBN1, PRO1148ALA", "FBN1, ARG974CYS", "FBN1, 2-BP DEL, 8155AA", "FBN1, 20-BP DEL, NT8156", "FBN1, 7-BP DEL, NT4253", "FBN1, EX13-49DEL", "FBN1, GLY1594ASP", "FBN1, ARG2576CYS (dbSNP rs147195031)", "FBN1, IVS64, G-A, +1", "FBN1, 8-BP DEL, NT8175", "FBN1, IVS64DS, G-T, +1", "FIBRILLIN 1", "FIBRILLIN 1", "FIBRILLIN 1", "FIBRILLIN 1", "FIBRILLIN 1"], "sib_relations": ["FBN1, 366-BP DEL", "FBN1, G8268A, TRP2756TER", "FBN1, CYS1249SER", "FBN1, CYS1663ARG", "FBN1, CYS2221SER", "FBN1, TYR2113TER, EX51DEL", "FBN1, ASN2144SER", "FBN1, ASN548ILE", "FBN1, ASP723ALA", "FBN1, 83-BP DEL", "FBN1, IVS54DS, G-C, +1, 123-BP DEL", "FBN1, ARG2776TER", "FBN1, CYS1223TYR", "FBN1, CYS1117TYR", "FBN1, CYS1242TYR", "FBN1, 1-BP DEL, 3192A", "FBN1, 6354C-T, EX51DEL, ILE2118ILE", "FBN1, ARG529TER", "FBN1, IVS2DS, G-A, +1", "FBN1, GLY1013ARG", "FBN1, 33-BP INS, IVS46, G-A, +1", "FBN1, IVS46+5G-A", "FBN1, TYR754CYS", "FBN1, ARG240CYS", "FBN1, CYS1129TYR", "FBN1, CYS1221TYR", "FBN1, 302.5-KB DEL", "FBN1, ARG974CYS", "FBN1, 7-BP DEL, NT4253", "FBN1, EX13-49DEL", "FBN1, SER1750ARG", "FBN1, TYR1700CYS", "FBN1, 3-BP DUP, NT5202", "FBN1, TYR1699CYS", "FBN1, ALA1728THR", "FBN1, 4-BP INS, NT5138", "FBN1, ARG1170HIS", "FBN1, TRP1570CYS, 4710G-T", "FBN1, TRP1570CYS, 4710G-C", "FBN1, CYS1564SER", "FBN1, CYS1577GLY", "FBN1, GLY1594ASP", "FBN1, 24-BP DEL", "FBN1, TYR1699CYS", "FBN1, GLY1762SER", "FBN1, ALA1728THR", "FBN1, TYR1696CYS", "FBN1, GLU2447LYS", "FBN1, ARG240CYS", "FBN1, ARG974CYS", "FBN1, ARG2726TRP", "FBN1, ARG1137PRO", "FBN1, CYS2307SER", "FBN1, CYS1074ARG", "FBN1, IVS31AS, A-T, -2", "FBN1, IVS32DS, G-A, +1", "FBN1, LYS1043ARG", "FBN1, ASN1131TYR", "FBN1, GLU1073LYS", "FBN1, CYS1032TYR", "FBN1, CYS1086TYR", "FBN1, ARG122CYS", "FBN1, GLY985GLU", "FBN1, GLY1127SER", "FBN1, CYS1265ARG", "FBN1, ARG485CYS", "FBN1, ARG2576CYS (dbSNP rs147195031)", "FBN1, PRO1148ALA", "FBN1, 2-BP DEL, 8155AA", "FBN1, 20-BP DEL, NT8156", "FBN1, IVS64, G-A, +1", "FBN1, 8-BP DEL, NT8175", "FBN1, IVS64DS, G-T, +1"], "wiki_entities": ["Fibrillin 1", "Fibrillin", "MASS phenotype", "Arachnodactyly", "Basement membrane", "Zonule of Zinn", "Elastic fiber", "Asprosin", "Marfan syndrome", "Reticular connective tissue"], "mesh_synonynms": ["profibrillin 1", "marfan's syndrome", "syndrome, marfan's", "marfans syndrome", "fibrillins", "profibrillin-1", "syndrome, marfan", "fibrillin-1", "marfan syndrome, type i"], "dbpedia_synonyms": ["marfan syndrome", "marfan's syndrome", "stiff-skin syndrome", "marfan's disease", "ghent criteria", "fbn3", "marfin syndrome", "tapering fingers", "fox business network", "marfan's", "marfans syndrome", "marfans", "fbn2", "mass phenotype", "fibrillin 1", "mfs1", "fbn1 (gene)", "geleophysic dwarfism", "congenital fascial dystrophy", "fbn1", "marfan", "fibrillin-1"]}, "label": 1}
{"source_ent": {"research_entity_id": "ICD10CM:E46", "canonical_name": "Unspecified protein-calorie malnutrition", "aliases": ["malnutrition nos", "unspecified protein-calorie malnutrition", "protein-calorie imbalance nos"], "definition": "Protein–energy malnutrition (PEM) refers to a form of malnutrition which is defined as a range of pathological conditions arising from coincident lack of protein and/or energy in varying proportions.The condition vary in forms ranging from mild through moderate to severe degrees.", "other_contexts": [], "par_relations": ["Malnutrition (E40-E46)"], "chd_relations": [], "syn_relations": ["Unspecified protein-calorie malnutrition", "Unspecified protein-calorie malnutrition", "Unspecified protein-calorie malnutrition", "Unspecified protein-calorie malnutrition", "Unspecified protein-calorie malnutrition", "Unspecified protein-calorie malnutrition"], "sib_relations": ["Kwashiorkor", "Nutritional marasmus", "Marasmic kwashiorkor", "Unspecified severe protein-calorie malnutrition", "Protein-calorie malnutrition of moderate and mild degree", "Retarded development following protein-calorie malnutrition"], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "LNC:LA18401-2", "canonical_name": "Malnutrition", "aliases": ["malnutrition"], "definition": "Malnutrition is a condition that results from eating a diet in which nutrients are either not enough or are too much such that the diet causes health problems.", "other_contexts": ["The Indigenous Australian Malnutrition Project : the burden and impact of malnutrition in Aboriginal Australian and Torres Strait Islander hospital inpatients , and validation of a malnutrition screening tool for use in hospitals — study rationale and protocol BACKGROUND Malnutrition is associated with adverse outcomes for hospital inpatients and is a significant economic burden on hospitals .", "OBJECTIVE The aim of this study was to define the prevalence of malnutrition diagnosis reported among inpatient hospitalizations.", ": findings from the Multiple Indicator Cluster Surveys , 2000–2011 Background Child malnutrition is not only a major contributor to child mortality and morbidity , but it can also determine", "between age groups . There were 7 ( 1.4% ) children with coexistent acute and chronic malnutrition . The STRONGkids tool revealed that 35.7% of patients were either in the moderate or high risk", ", ESPEN diagnostic criteria for malnutrition and ESPEN diagnostic criteria for malnutrition without FFMI criterion . The association between malnutrition and three - months and one - year", "The prevalence of malnutrition was significantly (p 0.05) higher among the children with a history of infection (81.8%) and worm infestation (77.0%) in comparison to those without history of infection (13.1%) and worm infestation (61.9%), respectively.", "65.0% among females compared to 61.9% in males ( p 0.05 ) . However , higher grades of malnutrition ( III+IV ) were 13.12% among females in comparison to 7.87% among males ( p 0.05 ) ; whereas lower", ". We also intend to take into account the different methodologies used to evaluate undernutrition risk and undernutrition in this population . Pubmed , ISI - Web of Science , and Scopus were", ", contrary to the estimates for undernutrition prevalence . Undernutrition risk and undernutrition prevalence at hospital admission are high among pulmonology inpatients , but the heterogeneity", "Asses sment - Dialysis Malnutrition Score and correlate it with standard indicators of malnutrition like anthropometric and biochemical parameters of the study population by Pearson 's correlation .", "We also intend to take into account the different methodologies used to evaluate undernutrition risk and undernutrition in this population.", "CONCLUSIONS Missing a malnutrition diagnosis appears to be a universal issue because the rate of malnutrition diagnosis was consistently low across academic medical centers .", "between birth interval and grades of malnutrition ( p 0.05 ) . The prevalence of malnutrition was significantly higher among those children whose fathers were illiterate ( p 0.05 ) . In", "The assessment of undernutrition must always be preceded by nutritional screening, in accordance with guidelines, which did not occur in some of the analyzed studies.", "significantly associated with three - months survival for the Dutch definition for malnutrition ( HR:2.25 , p = 0.04 ) and the ESPEN diagnostic criteria for malnutrition ( HR:2.76 , p = 0.02 ) .", "[ Malnutrition and poverty in Colombia ] .", "Even though cardiac patients are at risk of malnutrition , data on the prevalence of malnutrition among cardiology inpatients is limited .", ", the prevalence of malnutrition among children decreased . The prevalence of malnutrition had a positive association ( p 0.05 ) with children 's family size : 3 members ( 47.0% ) , 4 - 6", "Undernutrition Risk and Undernutrition in Pulmonology Department Inpatients: A Systematic Review and Meta-Analysis.", "Malnutrition among children in an urban Indian slum and its associations.", "using a fully quantitative scoring system Subjective Global Assessment - Dialysis Malnutrition Score which is simple , reliable and dynamic . The primary objective of the study was to assess", "in the qualitative analysis and 21 in meta - analysis . The overall prevalence of undernutrition risk ( 32.73% ; 95% confidence interval [ CI ] , 31.29%-34.17% , I2 = 97.6% ) was lower than", "The prevalence of malnutrition was significantly higher among those children whose fathers were illiterate ( p 0.05 ) .", "malnutrition , respectively . The STRONGkids NRS tool was used to determine risk for malnutrition . RESULTS Malnutrition was detected in 13.4% in this group of pediatric surgical patients . Acute", ". Studies conducted in non - pulmonology departments showed lower prevalence of undernutrition risk than those from pulmonology departments , contrary to the estimates for undernutrition", ". Data on height for age indicated that 43% were normal , 32% had mild chronic malnutrition , 17% had moderate chronic malnutrition , and 8% had severe chronic malnutrition . The prevalence", "and meta - analysis was to investigate the prevalence of undernutrition risk and undernutrition on hospital admission in pulmonology department inpatients . We also intend to take into account", "the inequality was decomposed to understand the contributions of determinants to child malnutrition . The total differential decomposition was used to identify and explore factors contributing to", "population and the criteria used for diagnosis . Identifying early those who are malnourished and at risk of malnutrition and intervening at an early stage will improve patients overall", "cohort and diagnostic validation methodologies to assess the burden and impact of malnutrition and to validate a malnutrition screening tool . A target of 752 adult Indigenous and non -", "assessed and used to assess institutional variables associated with higher rates of malnutrition diagnosis . OBJECTIVE The aim of this study was to define the prevalence of malnutrition diagnosis", "and dynamic . The primary objective of the study was to assess the severity of malnutrition in patients with end stage renal disease and undergoing hemodialysis in a tertiary care teaching", "p 0.05 ) . In general , as the literacy status of father increased , the prevalence of malnutrition among children decreased . The prevalence of malnutrition had a positive association ( p 0.05 )", "-2002 . The studies using only anthropometric parameters for the assessment of undernutrition reported lower prevalence of undernutrition than the studies that used Subjective Global", "Assessment Questionnaire categorized 5.0% and 17.7% patients to be moderately malnourished and severely malnourished correspondingly . In conclusion , Although malnutrition was prevalent", "Australian and Torres Strait Islander hospital inpatients , and validation of a malnutrition screening tool for use in hospitals — study rationale and protocol BACKGROUND Malnutrition is", "was used to identify and explore factors contributing to changes in child malnutrition inequalities . Results Inequality in child malnutrition increased between 2000 and 2011 , even", "relevant ministries and sectors , may be necessary to reduce inequalities in childhood malnutrition .", "( 9.4% ) , fluorine deficiency ( 2.9% ) , and anemia ( 7.2% ) . The prevalence of malnutrition was 65.0% among females compared to 61.9% in males ( p 0.05 ) . However , higher grades of", "on Hemodialysis Malnutrition is widely prevalent among patients on hemodialysis . Malnutrition can be estimated using a fully quantitative scoring system Subjective Global Assessment - Dialysis", "larger samples reported a prevalence estimate similar to the overall prevalence for undernutrition risk and undernutrition . Studies conducted in non - pulmonology departments showed lower", "By institution , median rate of malnutrition diagnosis during hospitalization was 4.0% , whereas the rate of severe malnutrition diagnosis was 0.9% .", "The concentration index was calculated to see the magnitude of child malnutrition , and the inequality was decomposed to understand the contributions of determinants to child malnutrition .", "0.05 ) . The birth order of the children was positively associated with their grades of malnutrition ( p 0.05 ) . On the other hand , an inverse relationship was observed between birth interval and", "2014 and 2015 ( P<0.01 ) . Institutional factors associated with increased diagnosis of malnutrition were higher hospital volume , hospital ranking , and patient satisfaction scores ( P<0.01 ) .", "malnutrition , 17% had moderate chronic malnutrition , and 8% had severe chronic malnutrition . The prevalence of acute malnutrition in the poor population measured by the ratio of weight to", "35.7% of patients were either in the moderate or high risk group for malnutrition . Malnutrition , as revealed by anthropometric measurements , was more likely in the presence of gastrointestinal", "into account the different methodologies used to evaluate undernutrition risk and undernutrition in this population . Pubmed , ISI - Web of Science , and Scopus were searched until January 2015 .", "Trends in socioeconomic inequalities in child malnutrition in Vietnam : findings from the Multiple Indicator Cluster Surveys , 2000–2011 Background Child malnutrition is not only a major contributor to child mortality and morbidity , but it can also determine socioeconomic status in adult life .", "The STRONGkids NRS tool was used to determine risk for malnutrition.", "guidelines , which did not take place in some analyzed studies . Teaching Points • Undernutrition risk and undernutrition prevalence are high among pulmonology inpatients . • The heterogeneity", "DISCUSSION Indigenous Australians continue to experience poorer levels of health than non-Indigenous Australians and issues such as food insecurity, poor diet, and a disproportionate burden of chronic disease play a key contributing role for malnutrition in Indigenous Australians.", "Patterns of malnutrition in children of the poorest 30% of the Colombian population were quite similar in the 11 departments included in the 1977 survey.", "BACKGROUND Malnutrition is a significant problem for hospitalized patients.", "% among females in comparison to 7.87% among males ( p 0.05 ) ; whereas lower grades of malnutrition ( I+II ) were 54.04% among males and 51.87% among females ( p0.05 ) . The birth order of the", "status assessment in these patients . • Timely screening and identification of undernutrition is of the utmost relevance in earlier nutritional interventions and implementation of nutritional", "- five children . The concentration index was calculated to see the magnitude of child malnutrition , and the inequality was decomposed to understand the contributions of determinants to child", "largely unrecognised by healthcare workers . AIMS To determine the prevalence of malnutrition and effectiveness of STRONGkids nutritional risk screening ( NRS ) tool in the identification of", "published by the World Health Organization clearly demonstrates the pattern of overall malnutrition indicated by weight for age figures . It can be concluded at 33% of children in the poorest 30% of", "and a wide variability in the estimates of frequency of undernutrition risk and undernutrition is found in the literature . The aim of this systematic review and meta - analysis was to", ". Nutritional status was greatly influenced by age , with the lowest rates of malnutrition occurring in children under 1 . Mortality among children aged 1 - 2 years probably was responsible", "females almost matched in age and birth order . The prevalence of various nutritional deficiency diseases comprised : protein calorie malnutrition ( 63.4% ) , vitamin A deficiency ( 23.4% ) ,", "January 2015 . The evidence regarding the prevalence of undernutrition risk and undernutrition was summarized . Twenty - two studies were included in the qualitative analysis and 21 in meta -", "measured by the ratio of weight to height was less than that of chronic or overall malnutrition . 21% were considered to show mild , 4% moderate , and 1% severe acute malnutrition . Nutritional", "negative correlation between modified Subjective Global Assessment - Dialysis Malnutrition Score and anthropometric measures such as triceps skin fold thickness , mid arm circumference ,", "the STRONGkids tool among pediatric surgical patients to identify patients at risk for malnutrition and to increase the physician 's awareness of nutritional assessment among hospitalised patients", "diagnosis . OBJECTIVE The aim of this study was to define the prevalence of malnutrition diagnosis reported among inpatient hospitalizations . DESIGN The University Health System", "The subtotal prevalence of undernutrition risk was similar using the Malnutrition Universal Screening Tool and Nutritional Risk Screening-2002.", "On the other hand, an inverse correlation was observed between socioeconomic status and the prevalence of malnutrition (p 0.05).", "The association between malnutrition and three-months and one-year overall survival was analyzed by log rank tests and Cox regression.", "Malnutrition classification followed the Harvard classification (weight in relation to the age of the child) modified by the Indian Academy of Pediatrics.", "parameters for the assessment of undernutrition reported lower prevalence of undernutrition than the studies that used Subjective Global Assessment . Cross - sectional studies reported", "methods to assess nutritional status in this population . The assessment of undernutrition must always be preceded by nutritional screening , according to guidelines , which did not take", "methodologies to assess the burden and impact of malnutrition and to validate a malnutrition screening tool . A target of 752 adult Indigenous and non - Indigenous Australian inpatients will", "was improved in Vietnam , there were significant differences in under - five child malnutrition that favored those who were more advantaged in socioeconomic terms . The impact of socioeconomic", "advantaged in socioeconomic terms . The impact of socioeconomic inequalities in child malnutrition has increased over time . Multifaceted approaches , connecting several relevant ministries and", "12% were considered to have severe and 23% moderate malnutrition.", "an inverse correlation was observed between socioeconomic status and the prevalence of malnutrition ( p 0.05 ) . The prevalence of malnutrition was significantly ( p 0.05 ) higher among the children", "The aim of this study is to determine the burden of malnutrition , understand its impact , and validate a malnutrition screening tool for Indigenous Australian inpatients .", "Australian Nutrition Tool , will be assessed against an existing screening tool , the malnutrition screening tool , used in these settings and the malnutrition reference standard , the Subjective", "are normal , 31% have mild malnutrition , 23% moderate malnutrition , and 12% severe malnutrition . Data on height for age indicated that 43% were normal , 32% had mild chronic malnutrition , 17%", "Malnutrition Screening Tool 47.9% to be at risk of malnutrition .", "a prevalence estimate similar to the overall prevalence for undernutrition risk and undernutrition . Studies conducted in non - pulmonology departments showed lower prevalence of undernutrition", "The aim of this systematic review and meta - analysis was to investigate the prevalence of undernutrition risk and undernutrition on hospital admission in pulmonology department inpatients .", "medical centers . Institutional variables were associated with the prevalence of malnutrition diagnosis , which suggests that institutional culture influences malnutrition diagnosis . Quality", "The evidence regarding the prevalence of undernutrition risk and undernutrition was summarized .", "that 43% were normal , 32% had mild chronic malnutrition , 17% had moderate chronic malnutrition , and 8% had severe chronic malnutrition . The prevalence of acute malnutrition in the poor", "patients aged ≤60 months than aged > 60 months ( 13.4 vs. 6.6% , p=0.012 ) . Chronic malnutrition was identified in 23 ( 4.6% ) of patients with no significant difference between age groups .", "The total differential decomposition was used to identify and explore factors contributing to changes in child malnutrition inequalities.", "and to stratify participants based on the International Consensus Guideline Committee malnutrition aetiology - diagnostic framework . Subjects will then be followed prospectively to measure short", "Multiple regression analysis was performed to assess the association between these variables and reported rates of malnutrition .", "of malnutrition diagnosis , which suggests that institutional culture influences malnutrition diagnosis . Quality improvement efforts aimed at improved structure and process appear to be", "Screening Tool categorized 20.4% and 19.6% subjects as at medium risk and high risk of malnutrition respectively . Nutritional Risk Screening detected 6.3% , 25.1% and 24.9% patients to be mildly ,", "using a validated screening tool . It is also imperative that the burden and impact of malnutrition is properly understood , and fully appreciated , so that early and appropriate nutritional", "can also determine socioeconomic status in adult life . The rate of under - five child malnutrition in Vietnam has significantly decreased , but associated inequality issues still need attention .", "Consortium ( Vizient ) database was retrospectively reviewed for reported rates of malnutrition diagnosis . PARTICIPANTS / SETTING All adult inpatient hospitalization at 105 member institutions", "In general, as the literacy status of father increased, the prevalence of malnutrition among children decreased.", "SD - scores < -2 for Body Mass Index ( BMI ) for age or weight - for - height ( WFH ) and height - for - age ( HFA ) were considered to indicate acute and chronic malnutrition , respectively .", "institutions during fiscal years 2014 and 2015 were evaluated . MAIN OUTCOME MEASURES Malnutrition diagnosis based on the presence of an International Classification of Diseases - Ninth Revision", "Short Nutrition Assessment Questionnaire categorized 5.0% and 17.7% patients to be moderately malnourished and severely malnourished correspondingly .", "Prediction of Malnutrition Using Modified Subjective Global Assessment - dialysis Malnutrition Score in Patients on Hemodialysis Malnutrition is widely prevalent among patients on hemodialysis .", "was responsible for a decline in malnutrition rates in children over 2 . Patterns of malnutrition in children of the poorest 30% of the Colombian population were quite similar in the 11", "A Systematic Review and Meta - Analysis . Pulmonology patients are predisposed to be undernourished and a wide variability in the estimates of frequency of undernutrition risk and undernutrition is", "revealed that 35.7% of patients were either in the moderate or high risk group for malnutrition . Malnutrition , as revealed by anthropometric measurements , was more likely in the presence of", "problem for hospitalized patients . However , the true prevalence of reported malnutrition diagnosis in real - world clinical practice is largely unknown . Using a large collaborative multi", "detected 6.3% , 25.1% and 24.9% patients to be mildly , moderately and severely malnourished respectively . Short Nutrition Assessment Questionnaire categorized 5.0% and 17.7% patients to be", "Institutional factors associated with increased diagnosis of malnutrition were higher hospital volume , hospital ranking , and patient satisfaction scores ( P<0.01 ) .", "21% were considered to show mild, 4% moderate, and 1% severe acute malnutrition.", ". The STRONGkids NRS tool was used to determine risk for malnutrition . RESULTS Malnutrition was detected in 13.4% in this group of pediatric surgical patients . Acute malnutrition was", "Providing data on the prevalence of malnutrition and risk of malnutrition in a prospectively recruited group of hospitalised pediatric surgical patients , the data acquired in the present study emphasise the need to raise clinician 's awareness about the importance of nutritional status assessment among hospitalised pediatric patients and the benefits of identifying patients at the risk of nutritional depletion before malnutrition occurs .", ". Even though cardiac patients are at risk of malnutrition , data on the prevalence of malnutrition among cardiology inpatients is limited . The aim of the study was to assess malnutrition status of", "Most of the inequality in malnutrition was due to ethnicity and socioeconomic status .", "Teaching Points • Undernutrition risk and undernutrition prevalence are high among pulmonology inpatients. •", "In 2015 the European Society for Clinical Nutrition and Metabolism (ESPEN) presented new consensus criteria for the diagnosis of malnutrition.", "and creatinine . Based on the scores , of the 66 patients , 91% were moderately malnourished . There was a significant negative correlation between modified Subjective Global Assessment -", "Data on height for age indicated that 43% were normal, 32% had mild chronic malnutrition, 17% had moderate chronic malnutrition, and 8% had severe chronic malnutrition.", "screening tool , the malnutrition screening tool , used in these settings and the malnutrition reference standard , the Subjective Global Assessment . DISCUSSION Indigenous Australians continue", "Malnutrition is frequently under-recognised in this setting and valid screening and early diagnosis are important for timely nutritional management.", "The prevalence of malnutrition had a positive association ( p 0.05 ) with children 's family size : 3 members ( 47.0% ) , 4 - 6 members ( 63.9% ) , and 7 members and above ( 70.6% ) .", "Subjective Global Assessments categorized only 4.2% as malnourished on the other hand Malnutrition Universal Screening Tool categorized 20.4% and 19.6% subjects as at medium risk and high risk of malnutrition respectively.", "anthropometric and biochemical assessment . may be integrated in regular assessment of malnutrition in patients on maintenance hemodialysis .", "Scopus were searched until January 2015 . The evidence regarding the prevalence of undernutrition risk and undernutrition was summarized . Twenty - two studies were included in the qualitative", "Similarly, nonimmunized children experienced more malnutrition (66.4%) in comparison to immunized children (57.0%).", ", hospital ranking , and patient satisfaction scores ( P<0.01 ) . CONCLUSIONS Missing a malnutrition diagnosis appears to be a universal issue because the rate of malnutrition diagnosis was", ". Cross - sectional studies reported higher prevalence of undernutrition risk and undernutrition than cohort studies . Studies including larger samples reported a prevalence estimate similar to", "Malnutrition can be estimated using a fully quantitative scoring system Subjective Global Assessment-Dialysis Malnutrition Score which is simple, reliable and dynamic.", "The data obtained from this study confirm that a high degree of malnutrition was prevalent in patients on hemodialysis, as shown by anthropometric assessment, biochemical markers of malnutrition and Subjective Global Assessment-Dialysis Malnutrition Score.", "criteria for malnutrition ( HR:2.17 , p < 0.02 ) and the ESPEN diagnostic criteria for malnutrition without FFMI ( HR:2.66 , p < 0.01 ) . CONCLUSION The new ESPEN definition for malnutrition is", "were used to study the predictive value for survival : Dutch definition for malnutrition , ESPEN diagnostic criteria for malnutrition and ESPEN diagnostic criteria for malnutrition", "Three sets of criteria for malnutrition were used to study the predictive value for survival: Dutch definition for malnutrition, ESPEN diagnostic criteria for malnutrition and ESPEN diagnostic criteria for malnutrition without FFMI criterion.", "Finally, the utility of a new screening tool, the Australian Nutrition Tool, will be assessed against an existing screening tool, the malnutrition screening tool, used in these settings and the malnutrition reference standard, the Subjective Global Assessment.", "On the other hand , an inverse relationship was observed between birth interval and grades of malnutrition ( p 0.05 ) .", "of STRONGkids nutritional risk screening ( NRS ) tool in the identification of malnutrition risk among pediatric surgical patients . STUDY DESIGN Cross - sectional study . METHODS A total of", "not take place in some analyzed studies . Teaching Points • Undernutrition risk and undernutrition prevalence are high among pulmonology inpatients . • The heterogeneity between the analyzed", "After adjustments , malnutrition remained significantly associated with three - months survival for the Dutch definition for malnutrition ( HR:2.25 , p = 0.04 ) and the ESPEN diagnostic criteria for malnutrition ( HR:2.76 , p = 0.02 ) .", "Multi - Institutional Collaborative Database of Academic Medical Centers . BACKGROUND Malnutrition is a significant problem for hospitalized patients . However , the true prevalence of reported", "RESULTS Ninety patients (27%) were classified as malnourished by any of the sets of criteria; malnourished patients had significant lower survival rates than non-malnourished patients at three months (84% vs 94%; p = 0.01) and one year (76% vs 87%; p = 0.02).", "METHODS This project involves cross-sectional, prospective cohort and diagnostic validation methodologies to assess the burden and impact of malnutrition and to validate a malnutrition screening tool.", "to inequalities in stunting . Conclusions Although the overall level of child malnutrition was improved in Vietnam , there were significant differences in under - five child malnutrition", "of this systematic review and meta - analysis was to investigate the prevalence of undernutrition risk and undernutrition on hospital admission in pulmonology department inpatients . We also", "determinants of income distribution in Colombia . This work analyzes the extent of malnutrition among the poorest 30% of the Colombian population . The National Plan for Feeding and Nutrition (", "However, higher grades of malnutrition (III+IV) were 13.12% among females in comparison to 7.87% among males (p 0.05); whereas lower grades of malnutrition (I+II) were 54.04% among males and 51.87% among females (p0.05).", "91% were moderately malnourished.", "Pulmonology patients are predisposed to be undernourished and a wide variability in the estimates of frequency of undernutrition risk and undernutrition is found in the literature .", "Malnutrition Score is a useful and reliable index for identifying patients at risk for malnutrition and it correlates well with anthropometric and biochemical assessment . may be integrated in", "Malnutrition remained significantly associated with one - year survival for the ESPEN diagnostic criteria for malnutrition ( HR:2.17 , p < 0.02 ) and the ESPEN diagnostic criteria for malnutrition without FFMI ( HR:2.66 , p < 0.01 ) .", "Undernutrition risk and undernutrition prevalence at hospital admission are high among pulmonology inpatients, but the heterogeneity between the studies illustrates the lack of standardized methods to assess nutritional status in this population.", "According to Mini Nutritional Assessment tool 69.6% were having possible malnutrition.", "DESIGN The University Health System Consortium (Vizient) database was retrospectively reviewed for reported rates of malnutrition diagnosis.", "without FFMI ( HR:2.66 , p < 0.01 ) . CONCLUSION The new ESPEN definition for malnutrition is predictive for both three - months and one - year survival in a general hospital population ,", ". BACKGROUND High prevalence of malnutrition along with the risk for the development of malnutrition in hospitalised children has been reported . However , this problem remains largely unrecognised", "Prevalence of hospital malnutrition among cardiac patients: results from six nutrition screening tools Malnutrition is highly prevalent among hospitalized patients, ranging from 30% to 50% depending on the patient population and the criteria used for diagnosis.", "of Malnutrition and Effectiveness of STRONGkids Tool in the Identification of Malnutrition Risks among Pediatric Surgical Patients . BACKGROUND High prevalence of malnutrition along with", "to changes in child malnutrition inequalities . Results Inequality in child malnutrition increased between 2000 and 2011 , even though the overall rate declined . Most of the inequality", "Nutritional Risk Screening detected 6.3%, 25.1% and 24.9% patients to be mildly, moderately and severely malnourished respectively.", ". Subjective Global Assessments categorized only 4.2% as malnourished on the other hand Malnutrition Universal Screening Tool categorized 20.4% and 19.6% subjects as at medium risk and high risk of", "and the benefits of identifying patients at the risk of nutritional depletion before malnutrition occurs . Our findings support the use of the STRONGkids tool among pediatric surgical patients to", "( 61.9% ) , respectively . Similarly , nonimmunized children experienced more malnutrition ( 66.4% ) in comparison to immunized children ( 57.0% ) .", ", biochemical markers of malnutrition and Subjective Global Assessment - Dialysis Malnutrition Score . Nutritional status as determined by Subjective Global Assessment - Dialysis Malnutrition", "chronic and acute malnutrition . 12% were considered to have severe and 23% moderate malnutrition . 8% had severe and 17% had moderate problems of height for age . 26% had deficient weight for", "Among patients categorized as low risk for malnutrition , there were more outpatients than inpatients ( 89.3 vs. 10.7% , p<0.001 ) and more elective surgery cases than emergency surgery cases ( 93.4 vs. 6.6% , p<0.001 ) .", "Although the overall level of child malnutrition was improved in Vietnam , there were significant differences in under - five child malnutrition that favored those who were more advantaged in socioeconomic terms .", "Using a large collaborative multi - institutional database , the rate of malnutrition diagnosis was assessed and used to assess institutional variables associated with higher rates of malnutrition diagnosis .", "outcomes for hospital inpatients and is a significant economic burden on hospitals . Malnutrition is frequently under - recognised in this setting and valid screening and early diagnosis are", "In conclusion, Although malnutrition was prevalent among this population, a wide variation in the nutritional status when assessed by widely used internationally recognized tools was observed.", "001 ) and inpatient admissions ( p=0.014 ) . Among patients categorized as low risk for malnutrition , there were more outpatients than inpatients ( 89.3 vs. 10.7% , p<0.001 ) and more elective", "screening tool for use in hospitals — study rationale and protocol BACKGROUND Malnutrition is associated with adverse outcomes for hospital inpatients and is a significant economic burden", "Nutritional status was greatly influenced by age, with the lowest rates of malnutrition occurring in children under 1.", "on hemodialysis , as shown by anthropometric assessment , biochemical markers of malnutrition and Subjective Global Assessment - Dialysis Malnutrition Score . Nutritional status as determined", "Mortality among children aged 1-2 years probably was responsible for a decline in malnutrition rates in children over 2.", "risk than those from pulmonology departments , contrary to the estimates for undernutrition prevalence . Undernutrition risk and undernutrition prevalence at hospital admission are high", "Multifaceted approaches , connecting several relevant ministries and sectors , may be necessary to reduce inequalities in childhood malnutrition .", "Cross - sectional studies reported higher prevalence of undernutrition risk and undernutrition than cohort studies .", "Malnutrition, as revealed by anthropometric measurements, was more likely in the presence of gastrointestinal (26.9%, p=0.004) and inguinoscrotal/penile surgery (4.0%, p=0.031), co-morbidities affecting nutritional status (p<0.001) and inpatient admissions (p=0.014).", "BACKGROUND High prevalence of malnutrition along with the risk for the development of malnutrition in hospitalised children has been reported.", "During study period , 322 ( 61.22% ) males and 204 ( 38.78% ) females were recruited . Malnutrition status assessed by each screening tool had a wide variation . According to Mini Nutritional", "The prevalence of various nutritional deficiency diseases comprised : protein calorie malnutrition ( 63.4% ) , vitamin A deficiency ( 23.4% ) , vitamin B deficiency ( 16.2% ) , vitamin C deficiency ( 2.6% ) , vitamin D deficiency ( 9.4% ) , fluorine deficiency ( 2.9% ) , and anemia ( 7.2% ) .", "and Metabolism ( ESPEN ) presented new consensus criteria for the diagnosis of malnutrition . Whereas most previous definitions were based on involuntary weight loss and/or a low BMI , the", "for malnutrition ( HR:2.25 , p = 0.04 ) and the ESPEN diagnostic criteria for malnutrition ( HR:2.76 , p = 0.02 ) . Malnutrition remained significantly associated with one - year survival", "used for diagnosis . Identifying early those who are malnourished and at risk of malnutrition and intervening at an early stage will improve patients overall prognosis and will reduce the", "AIM To study the predictive value of the new ESPEN diagnostic criteria for malnutrition on survival , with specific focus on the additional value of FFMI .", ", and a disproportionate burden of chronic disease play a key contributing role for malnutrition in Indigenous Australians . To improve the health and hospital outcomes of Indigenous and non -", "The impact of socioeconomic inequalities in child malnutrition has increased over time .", "other hand , an inverse relationship was observed between birth interval and grades of malnutrition ( p 0.05 ) . The prevalence of malnutrition was significantly higher among those children whose", "was detected in 13.4% in this group of pediatric surgical patients . Acute malnutrition was identified in 10.1% of patients and more commonly in patients aged ≤60 months than aged > 60", "of malnutrition diagnosis during hospitalization was 4.0% , whereas the rate of severe malnutrition diagnosis was 0.9% . There was a statistically significant increase in malnutrition diagnosis from", "detect nutritional deficiency diseases . Anthropometric measurements were also taken . Malnutrition classification followed the Harvard classification ( weight in relation to the age of the child )", "malnutrition . 21% were considered to show mild , 4% moderate , and 1% severe acute malnutrition . Nutritional status was greatly influenced by age , with the lowest rates of malnutrition", "to Mini Nutritional Assessment tool 69.6% were having possible malnutrition . Malnutrition Screening Tool 47.9% to be at risk of malnutrition . Subjective Global Assessments categorized", "value for survival : Dutch definition for malnutrition , ESPEN diagnostic criteria for malnutrition and ESPEN diagnostic criteria for malnutrition without FFMI criterion . The association between", "malnourished and severely malnourished correspondingly . In conclusion , Although malnutrition was prevalent among this population , a wide variation in the nutritional status when assessed by", "Comparison of the data to normal values published by the World Health Organization clearly demonstrates the pattern of overall malnutrition indicated by weight for age figures.", "Medical Center Amsterdam ( 60% female , age 58 ± 18 y ) . Three sets of criteria for malnutrition were used to study the predictive value for survival : Dutch definition for malnutrition , ESPEN", "The prevalence of acute malnutrition in the poor population measured by the ratio of weight to height was less than that of chronic or overall malnutrition .", "MAIN OUTCOME MEASURES Malnutrition diagnosis based on the presence of an International Classification of Diseases-Ninth Revision diagnosis code.", "at improved structure and process appear to be needed to improve the identification of malnutrition .", "The assessment of undernutrition must always be preceded by nutritional screening, according to guidelines, which did not take place in some analyzed studies.", "There was a significant negative correlation between modified Subjective Global Assessment-Dialysis Malnutrition Score and anthropometric measures such as triceps skin fold thickness, mid arm circumference, mid arm muscle circumference; biochemical markers such as albumin, transferrin and ferritin.", "It can be concluded at 33% of children in the poorest 30% of the population are normal , 31% have mild malnutrition , 23% moderate malnutrition , and 12% severe malnutrition .", "Subjective Global Assessment - dialysis Malnutrition Score in Patients on Hemodialysis Malnutrition is widely prevalent among patients on hemodialysis . Malnutrition can be estimated using a fully", "The Prevalence of Malnutrition and Effectiveness of STRONGkids Tool in the Identification of Malnutrition Risks among Pediatric Surgical Patients .", "children examined had low weight for age caused by a combination of chronic and acute malnutrition . 12% were considered to have severe and 23% moderate malnutrition . 8% had severe and 17% had", "There was a statistically significant increase in malnutrition diagnosis from 4.0% to 4.9% between 2014 and 2015 (P<0.01).", "diagnostic criteria for malnutrition without FFMI criterion . The association between malnutrition and three - months and one - year overall survival was analyzed by log rank tests and Cox", "Chronic malnutrition was identified in 23 (4.6%) of patients with no significant difference between age groups.", "A 1977 survey stratified by socioeconomic levels indicated that among the poorest 30% of the population , 67% of the children examined had low weight for age caused by a combination of chronic and acute malnutrition .", "In a cross-sectional study in Bhopal, India, mothers and other family members were surveyed by questionnaire, then 1000 randomly selected slum children were clinically examined, to detect nutritional deficiency diseases.", "unknown . Using a large collaborative multi - institutional database , the rate of malnutrition diagnosis was assessed and used to assess institutional variables associated with higher rates of", "interventions and implementation of nutritional support . • The assessment of undernutrition must always be preceded by nutritional screening , in accordance with guidelines , which did not", "Timely screening and identification of undernutrition is of the utmost relevance in earlier nutritional interventions and implementation of nutritional support. •", "were having possible malnutrition . Malnutrition Screening Tool 47.9% to be at risk of malnutrition . Subjective Global Assessments categorized only 4.2% as malnourished on the other hand", "Malnutrition Risks among Pediatric Surgical Patients . BACKGROUND High prevalence of malnutrition along with the risk for the development of malnutrition in hospitalised children has been reported", "Studies including larger samples reported a prevalence estimate similar to the overall prevalence for undernutrition risk and undernutrition.", "care teaching hospital in Chennai , using Subjective Global Asses sment - Dialysis Malnutrition Score and correlate it with standard indicators of malnutrition like anthropometric and", ". The prevalence of various nutritional deficiency diseases comprised : protein calorie malnutrition ( 63.4% ) , vitamin A deficiency ( 23.4% ) , vitamin B deficiency ( 16.2% ) , vitamin C deficiency", "The primary objective of the study was to assess the severity of malnutrition in patients with end stage renal disease and undergoing hemodialysis in a tertiary care teaching hospital in Chennai, using Subjective Global Asses sment-Dialysis Malnutrition Score and correlate it with standard indicators of malnutrition like anthropometric and biochemical parameters of the study population by Pearson's correlation.", "Identifying early those who are malnourished and at risk of malnutrition and intervening at an early stage will improve patients overall prognosis and will reduce the costs to the state .", "categorized 5.0% and 17.7% patients to be moderately malnourished and severely malnourished correspondingly . In conclusion , Although malnutrition was prevalent among this population , a", "Acute malnutrition was identified in 10.1% of patients and more commonly in patients aged ≤60 months than aged > 60 months ( 13.4 vs. 6.6% , p=0.012 ) .", "of chronic diseases . Despite this increased risk , the burden and impact of malnutrition in Indigenous Australians is poorly understood . Furthermore , a suitable screening tool has not", "complexity and length of stay . RESULTS Ninety patients ( 27% ) were classified as malnourished by any of the sets of criteria ; malnourished patients had significant lower survival rates than", "( 36.95% ; 95% CI , 34.80%-39.10% , I2 = 99.7% ) . The subtotal prevalence of undernutrition risk was similar using the Malnutrition Universal Screening Tool and Nutritional Risk Screening-200", "cases ( 93.4 vs. 6.6% , p<0.001 ) . CONCLUSION Providing data on the prevalence of malnutrition and risk of malnutrition in a prospectively recruited group of hospitalised pediatric surgical", "AIMS To determine the prevalence of malnutrition and effectiveness of STRONGkids nutritional risk screening ( NRS ) tool in the identification of malnutrition risk among pediatric surgical patients .", "This work analyzes the extent of malnutrition among the poorest 30% of the Colombian population.", "malnutrition among cardiac patients : results from six nutrition screening tools Malnutrition is highly prevalent among hospitalized patients , ranging from 30% to 50% depending on the patient", "pulmonology departments , contrary to the estimates for undernutrition prevalence . Undernutrition risk and undernutrition prevalence at hospital admission are high among pulmonology inpatients ,", "( WFH ) and height - for - age ( HFA ) were considered to indicate acute and chronic malnutrition , respectively . The STRONGkids NRS tool was used to determine risk for malnutrition . RESULTS", "trends , contributing factors , and changes in inequalities for under - five child malnutrition in Vietnam between 2000 and 2011 . Design Data were drawn from the Viet Nam Multiple Indicator", "2000 and 2011 , even though the overall rate declined . Most of the inequality in malnutrition was due to ethnicity and socioeconomic status . The total differential decomposition showed that", "% , p<0.001 ) . CONCLUSION Providing data on the prevalence of malnutrition and risk of malnutrition in a prospectively recruited group of hospitalised pediatric surgical patients , the data acquired", "and will reduce the costs to the state . Even though cardiac patients are at risk of malnutrition , data on the prevalence of malnutrition among cardiology inpatients is limited . The aim of the", "this vulnerable patient group . The aim of this study is to determine the burden of malnutrition , understand its impact , and validate a malnutrition screening tool for Indigenous Australian", "Missing a malnutrition diagnosis appears to be a universal issue because the rate of malnutrition diagnosis was consistently low across academic medical centers . Institutional variables were", "The birth order of the children was positively associated with their grades of malnutrition (p 0.05).", "is to determine the burden of malnutrition , understand its impact , and validate a malnutrition screening tool for Indigenous Australian inpatients . METHODS This project involves cross -", "It was found that 292,754 patients ( 5.0% ) had a malnutrition diagnosis during their hospital stay .", "Objective This study aims to explore trends, contributing factors, and changes in inequalities for under-five child malnutrition in Vietnam between 2000 and 2011.", "The new ESPEN diagnostic criteria for malnutrition predict overall survival in hospitalised patients.", "Malnutrition Diagnosis during Adult Inpatient Hospitalizations: Analysis of a Multi-Institutional Collaborative Database of Academic Medical Centers.", "to be undernourished and a wide variability in the estimates of frequency of undernutrition risk and undernutrition is found in the literature . The aim of this systematic review and meta -", "at 33% of children in the poorest 30% of the population are normal , 31% have mild malnutrition , 23% moderate malnutrition , and 12% severe malnutrition . Data on height for age indicated that 4", "during the 2-year period . It was found that 292,754 patients ( 5.0% ) had a malnutrition diagnosis during their hospital stay . By institution , median rate of malnutrition diagnosis", "RESULTS Malnutrition was detected in 13.4% in this group of pediatric surgical patients.", "The aim of the study was to assess malnutrition status of the newly admitted patients in a specialist cardiology institution in Sri Lanka by internationally recommended nutrition screening and assessment tools.", "32.73% ; 95% confidence interval [ CI ] , 31.29%-34.17% , I2 = 97.6% ) was lower than undernutrition prevalence ( 36.95% ; 95% CI , 34.80%-39.10% , I2 = 99.7% ) . The subtotal prevalence of", "to be at risk of malnutrition . Subjective Global Assessments categorized only 4.2% as malnourished on the other hand Malnutrition Universal Screening Tool categorized 20.4% and 19.6% subjects as at", "The rate of under-five child malnutrition in Vietnam has significantly decreased, but associated inequality issues still need attention.", "Islander peoples ( Indigenous Australians ) are likely to be at increased risk of malnutrition due to their disproportionate burden , pattern and age - distribution of chronic diseases .", "Our findings support the use of the STRONGkids tool among pediatric surgical patients to identify patients at risk for malnutrition and to increase the physician's awareness of nutritional assessment among hospitalised patients upon admission.", "and ferritin . The data obtained from this study confirm that a high degree of malnutrition was prevalent in patients on hemodialysis , as shown by anthropometric assessment , biochemical", "Institutional variables were associated with the prevalence of malnutrition diagnosis , which suggests that institutional culture influences malnutrition diagnosis .", "p = 0.04 ) and the ESPEN diagnostic criteria for malnutrition ( HR:2.76 , p = 0.02 ) . Malnutrition remained significantly associated with one - year survival for the ESPEN diagnostic criteria for", "1000 randomly selected slum children were clinically examined , to detect nutritional deficiency diseases . Anthropometric measurements were also taken . Malnutrition classification followed the", "CONCLUSION The new ESPEN definition for malnutrition is predictive for both three - months and one - year survival in a general hospital population , whereas definitions without FFMI are predictive for either three - months or one year survival .", "1 . Mortality among children aged 1 - 2 years probably was responsible for a decline in malnutrition rates in children over 2 . Patterns of malnutrition in children of the poorest 30% of the", "among cardiology inpatients is limited . The aim of the study was to assess malnutrition status of the newly admitted patients in a specialist cardiology institution in Sri Lanka by", "Quality improvement efforts aimed at improved structure and process appear to be needed to improve the identification of malnutrition .", "variation . According to Mini Nutritional Assessment tool 69.6% were having possible malnutrition . Malnutrition Screening Tool 47.9% to be at risk of malnutrition . Subjective Global Assessments", "was performed to assess the association between these variables and reported rates of malnutrition . RESULTS A total of 5,896,792 hospitalizations were identified from 105 institutions during the 2-", "malnutrition , and 8% had severe chronic malnutrition . The prevalence of acute malnutrition in the poor population measured by the ratio of weight to height was less than that of chronic or", "socioeconomic status and the prevalence of malnutrition ( p 0.05 ) . The prevalence of malnutrition was significantly ( p 0.05 ) higher among the children with a history of infection ( 81.8% ) and", "Global Assessment . Cross - sectional studies reported higher prevalence of undernutrition risk and undernutrition than cohort studies . Studies including larger samples reported a", "Results Inequality in child malnutrition increased between 2000 and 2011 , even though the overall rate declined .", "The studies using only anthropometric parameters for the assessment of undernutrition reported lower prevalence of undernutrition than the studies that used Subjective Global Assessment.", "associated with one - year survival for the ESPEN diagnostic criteria for malnutrition ( HR:2.17 , p < 0.02 ) and the ESPEN diagnostic criteria for malnutrition without FFMI ( HR:2.66 ,", "poorest 30% of the population are normal , 31% have mild malnutrition , 23% moderate malnutrition , and 12% severe malnutrition . Data on height for age indicated that 43% were normal , 32% had", "However, the true prevalence of reported malnutrition diagnosis in real-world clinical practice is largely unknown.", "Studies conducted in non - pulmonology departments showed lower prevalence of undernutrition risk than those from pulmonology departments , contrary to the estimates for undernutrition prevalence .", "of criteria ; malnourished patients had significant lower survival rates than non - malnourished patients at three months ( 84% vs 94% ; p = 0.01 ) and one year ( 76% vs 87% ; p = 0.02 ) . After", "malnutrition diagnosis was 0.9% . There was a statistically significant increase in malnutrition diagnosis from 4.0% to 4.9% between 2014 and 2015 ( P<0.01 ) . Institutional factors associated", "The prevalence of malnutrition was 65.0% among females compared to 61.9% in males (p 0.05).", "Aboriginal Australian and/or Torres Strait Islander peoples ( Indigenous Australians ) are likely to be at increased risk of malnutrition due to their disproportionate burden , pattern and age - distribution of chronic diseases .", "It is also imperative that the burden and impact of malnutrition is properly understood, and fully appreciated, so that early and appropriate nutritional management can be provided to this group of hospital patients.", "a malnutrition diagnosis during their hospital stay . By institution , median rate of malnutrition diagnosis during hospitalization was 4.0% , whereas the rate of severe malnutrition diagnosis was 0", "patients ( 27% ) were classified as malnourished by any of the sets of criteria ; malnourished patients had significant lower survival rates than non - malnourished patients at three months ( 84", "% , I2 = 99.7% ) . The subtotal prevalence of undernutrition risk was similar using the Malnutrition Universal Screening Tool and Nutritional Risk Screening-2002 . The studies using only", "Despite this increased risk , the burden and impact of malnutrition in Indigenous Australians is poorly understood .", "criteria . AIM To study the predictive value of the new ESPEN diagnostic criteria for malnutrition on survival , with specific focus on the additional value of FFMI . METHODS Included were 335", "( 84% vs 94% ; p = 0.01 ) and one year ( 76% vs 87% ; p = 0.02 ) . After adjustments , malnutrition remained significantly associated with three - months survival for the Dutch definition for", "Cross - sectional data collection will be used to determine the prevalence of malnutrition using the Subjective Global Assessment and to stratify participants based on the International Consensus Guideline Committee malnutrition aetiology - diagnostic framework .", "The STRONGkids tool revealed that 35.7% of patients were either in the moderate or high risk group for malnutrition .", "The overall prevalence of undernutrition risk (32.73%; 95% confidence interval [CI], 31.29%-34.17%, I2 = 97.6%) was lower than undernutrition prevalence (36.95%; 95% CI, 34.80%-39.10%, I2 = 99.7%).", "Score . Nutritional status as determined by Subjective Global Assessment - Dialysis Malnutrition Score is a useful and reliable index for identifying patients at risk for malnutrition and it", "Malnutrition status assessed by each screening tool had a wide variation.", "There were 7 ( 1.4% ) children with coexistent acute and chronic malnutrition .", "Nutritional status as determined by Subjective Global Assessment - Dialysis Malnutrition Score is a useful and reliable index for identifying patients at risk for malnutrition and it correlates well with anthropometric and biochemical assessment . may be integrated in regular assessment of malnutrition in patients on maintenance hemodialysis .", ". Cross - sectional data collection will be used to determine the prevalence of malnutrition using the Subjective Global Assessment and to stratify participants based on the International"], "par_relations": [], "chd_relations": [], "syn_relations": [], "sib_relations": ["Active diagnoses based on review of patient records:Find:Pt:^Patient:Nom:CARE"], "wiki_entities": ["Malnutrition", "Malnutrition in India", "Protein–energy malnutrition", "Malnutrition in children", "Epidemiology of malnutrition", "Global Acute Malnutrition", "Malnutrition in Zimbabwe", "List of causes of death by rate", "List of types of malnutrition", "Malnutrition in South Africa"], "mesh_synonynms": ["undernutrition", "malnourishments", "nutritional deficiencies", "nutritional deficiency", "malnourishment"], "dbpedia_synonyms": ["malnutritions", "nutrient deficiencies", "under-feed", "underfeed", "mal nutrition", "nutritional defiency", "fetal malnutrition", "malnutrition", "list of illnesses caused by poor nutrition", "malnourish", "nutritional deficiency", "malnutrient", "malnourishment", "dietary diversity", "under feeding", "nutritional disease", "under feed", "under-feeding", "deficiency disease", "undernourished", "nutrition disorder", "undernourishment", "diet-deficiency disease", "under-fed", "under fed", "hunger (malnutrition)", "list of illnesses related to poor nutrition", "undernutrition", "hypoalimentation", "deficiency diseases", "malnourished children", "underfeeds", "malnourished", "undernourish", "underfed", "child malnutrition", "underfeeding", "nutritional deficiencies", "nutrition disorders", "illnesses related to poor nutrition", "malnutritiousness", "world hunger", "under feeds", "under-feeds", "poor nutrition", "malnutrients", "malnutritious", "deficiency states"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D000068257", "canonical_name": "Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination", "aliases": ["efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination", "atripla"], "definition": "Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals.", "other_contexts": [], "par_relations": ["Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination", "Drug Combinations", "Oxazines", "Tenofovir", "Emtricitabine", "Reverse Transcriptase Inhibitors", "Anti-HIV Agents"], "chd_relations": ["Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination"], "syn_relations": [], "sib_relations": ["Antiretroviral Therapy, Highly Active", "Aminophylline", "Contraceptives, Oral, Combined", "Dimenhydrinate", "Ifosfamide", "Morpholines", "Trimethoprim, Sulfamethoxazole Drug Combination", "Biphasic Insulins", "Benzoxazines", "Albuterol, Ipratropium Drug Combination", "Aspirin, Dipyridamole Drug Combination", "Buprenorphine, Naloxone Drug Combination", "Ezetimibe, Simvastatin Drug Combination", "Fluticasone Propionate, Salmeterol Xinafoate Drug Combination", "Amlodipine, Valsartan Drug Combination", "Amlodipine Besylate, Olmesartan Medoxomil Drug Combination", "Adapalene, Benzoyl Peroxide Drug Combination", "Multi-Ingredient Cold, Flu, and Allergy Medications", "Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination", "Budesonide, Formoterol Fumarate Drug Combination", "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination", "Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination", "Mometasone Furoate, Formoterol Fumarate Drug Combination", "Emtricitabine, Rilpivirine, Tenofovir Drug Combination", "Brimonidine Tartrate, Timolol Maleate Drug Combination"], "wiki_entities": ["Tenofovir disoproxil", "Management of HIV/AIDS", "WHO Model List of Essential Medicines", "Reverse-transcriptase inhibitor", "John C. Martin (businessman)"], "mesh_synonynms": ["atripla", "efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination"], "dbpedia_synonyms": ["efavirenz/emtricitabine/tenofovir"]}, "target_ent": {"research_entity_id": "RXNORM:643067", "canonical_name": "Atripla", "aliases": ["atripla"], "definition": "Attila (; fl.", "other_contexts": ["This study assessed the clinical and economic trade - offs involved in using Atripla compared with Stribild as first - line antiretroviral therapy in HIV - infected US adults .", "METHODS A Markov cohort model was developed to project lifetime health - related outcomes , costs , quality - adjusted life years ( QALYs ) , and cost - effectiveness of Stribild compared with Atripla as first - line antiretroviral therapy in HIV-1-infected US patients .", "Study shows people can safely switch to Atripla .", "The total number of patients receiving ART at the time of review was 142 , of which 47 ( 33% ) were currently taking Atripla .", "In addition , there were a further 34 cases ( 36% ) where Atripla had never been offered to the patient for appropriate reasons and documentation of 8 instances in which Atripla had been declined by the patient .", "Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects : final results of a 24-week , randomized study Background Dyslipidemia in persons with HIV contributes significantly to cardiovascular ( CV ) risk .", "inhibitory effect on HIV replication ( P=0.0001 ) . CONCLUSION The result showed that atripla - TMC conjugate does not have a significant cytotoxicity effect . Due to the higher inhibitory", "We aimed to describe the outcomes of individuals commencing Atripla ( Gilead Sciences Inc , Foster City , California ; Bristol - Myers Squibb Co , Princeton , New Jersey , USA ) as a first - line regimen .", "There remained , however , 28 cases ( 29% ) where there was no documentation of Atripla having been considered or offered , and no apparent contraindications to the STR or its components .", "Discontinuation of Atripla as first - line therapy in HIV-1 infected individuals .", "-1.35±0.04 mv for nano - conjugate and -7.69±0.3 mv for drug . Conjugation efficiency of atripla with trimethyl chitosan was 5.27% . Measured cellular uptake with spectrophotometry for nano -", "We describe a patient with acute renal failure and irreversible kidney damage after an overdose with the fixed dose combination of efavirenz / tenofovir disoproxil fumarate / emtricitabine ( Atripla ) .", "At a societal willingness to pay of $ 100,000/QALY , Stribild was not cost - effective in the base case compared with Atripla for first - line HIV treatment .", "All consecutive patients who initiated TDF+FTC+EFV coformulated ( Atripla ) as a first regim were compared to patients who initiated TDF + FTC ( Truvada ) plus EFV ( Sustiva ) .", "Atripla is currently the only available single - tablet regimen ( STR ) for the treatment of HIV which contains a combination of BHIVA preferred first - line antiretrovirals ( tenofovir , emtricitabine and efavirenz ) .", "METHODS We performed a retrospective case - based analysis of all individuals within our HIV cohort who had received Atripla as their first antiretroviral combination .", "We investigated the change in fasting lipid parameters in hypercholesterolemic subjects switching from KVX + Efavirenz [ EFV ] to Atripla [ ATR ] .", "Of the remaining 95 patients , 30 ( 32% ) had taken Atripla or some of its components in the past and been changed from this for valid clinical or virological reasons .", "Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART ; an observational study comparing Atripla Vs Truvada / Sustiva exposure Methods This prospective and observational study was conducted at a referral outclinic in Madrid .", "Trimethyl Chitosan Improves Anti - HIV Effects of Atripla as a New Nanoformulated Drug .", "RESULTS Compared with patients initiating Atripla , patients initiating Stribild were estimated to have higher lifetime costs .", "Short Communication : The Impact of Switching from Atripla to Darunavir / Ritonavir Monotherapy on Neurocognition , Quality of Life , and Sleep : Results from a Randomized Controlled Study .", "The purpose was to ascertain the proportion of patients receiving BHIVA preferred ART in its simplest dosing format ( in this case Atripla ) and to investigate whether there were clinically or virologically appropriate reasons why patients not on Atripla were prescribed more complex drug regimens .", "Acute Kidney Injury After Efavirenz / Tenofovir Disoproxil Fumarate / Emtricitabine ( Atripla ) Overdose .", "When equivalent efficacy was assumed , Atripla dominated Stribild with lower costs and greater QALYs .", "In conclusion , switching to DRV / r monotherapy did not affect neurocognitive function or quality of life but improved anxiety , and sleep quality was significantly better than in continued Atripla .", "the drug carriers which has been introduced recently . MATERIALS AND METHODS the conjugated atripla - trimethyl chitosan was designed and characterized by zetasizer , AFM and FTIR techniques . The", "The commonest reason for switch in our cohort was CNS toxicity , which although it may develop shortly after initiation may persist , ultimately leading to discontinuation of Atripla months or years later .", "was about twice of the free drug in examined concentrations ( P=0.007 ) . Compared to atripla , the nano - conjugate showed a higher inhibitory effect on HIV replication ( P=0.0001 ) ."], "par_relations": ["efavirenz", "emtricitabine", "tenofovir disoproxil", "Tenofovir disoproxil fumarate"], "chd_relations": [], "syn_relations": [], "sib_relations": ["efavirenz 600 MG / emtricitabine 200 MG / Tenofovir disoproxil fumarate 300 MG [Atripla]", "efavirenz / emtricitabine / tenofovir disoproxil Oral Tablet [Atripla]", "Atripla 600/200/300 Oral Tablet", "Atripla Oral Product", "Atripla Pill"], "wiki_entities": ["Efavirenz/emtricitabine/tenofovir", "Elvitegravir/cobicistat/emtricitabine/tenofovir", "Abacavir/dolutegravir/lamivudine", "Fixed-dose combination (antiretroviral)", "John C. Martin (businessman)", "List of antiviral drugs", "Tony Mills (physician)", "Management of HIV/AIDS", "Rilpivirine", "Emtricitabine"], "mesh_synonynms": ["efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination"], "dbpedia_synonyms": ["efavirenz/emtricitabine/tenofovir"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:6370", "canonical_name": "kallikrein related peptidase 9", "aliases": ["kallikrein related peptidase 9", "klk-l3", "klk9 gene", "klk9"], "definition": "Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["kallikrein related peptidase 9", "kallikrein related peptidase 9", "kallikrein related peptidase 9", "kallikrein related peptidase 9"], "sib_relations": [], "wiki_entities": ["Kallikrein", "Prostate-specific antigen", "KLK9", "KLK14", "KLK4", "KLK1", "KLK12", "KLK5", "KLK6", "KLK11"], "mesh_synonynms": [], "dbpedia_synonyms": ["klk9 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:605504", "canonical_name": "KALLIKREIN-RELATED PEPTIDASE 9", "aliases": ["kallikrein-like 3", "kallikrein 9", "klk9", "klkl3", "kallikrein-related peptidase 9"], "definition": "Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9", "KALLIKREIN-RELATED PEPTIDASE 9"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["klk9 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0000020", "canonical_name": "Urinary incontinence", "aliases": ["bladder incontinence", "urinary incontinence", "loss of bladder control"], "definition": "Urinary incontinence (UI), also known as involuntary urination, is any leakage of urine.", "other_contexts": [], "par_relations": ["Functional abnormality of the bladder"], "chd_relations": ["Stress urinary incontinence"], "syn_relations": ["Urinary incontinence", "Urinary incontinence", "Urinary incontinence", "Urinary incontinence"], "sib_relations": ["Neurogenic bladder", "Dysuria", "Enuresis", "Nocturia", "Pollakisuria", "Vesicoureteral reflux", "Urinary retention", "Urinary urgency", "Urinary hesitancy", "Spastic/hyperactive bladder", "Urinary bladder sphincter dysfunction"], "wiki_entities": ["Urinary incontinence", "Overflow incontinence", "Stress incontinence", "Urinary system", "Incontinence", "Athletic incontinence", "Functional incontinence", "Fecal incontinence", "Urinary urgency", "Incontinence pad"], "mesh_synonynms": ["incontinence, urinary"], "dbpedia_synonyms": ["involuntary urination", "bladder control", "bladder incontinence", "urine, incontinence", "male urinary incontinence", "peeing in pants", "effort incontinence", "pissing oneself", "marshall-marchetti-krantz", "urinal incontinence", "light bladder leakage", "urinary incontinence", "urine incontinence", "mixed incontinence", "urinary continence", "pee in pants", "coital incontinence", "bladder leakage"]}, "target_ent": {"research_entity_id": "MSH:D014549", "canonical_name": "Urinary Incontinence", "aliases": ["incontinence, urinary", "urinary incontinence"], "definition": "Urinary incontinence (UI), also known as involuntary urination, is any leakage of urine.", "other_contexts": ["BACKGROUND Urinary incontinence is prevalent among women , but few seek treatment .", "Two randomised controlled trials selected their sample on the criteria of existing post - partum urinary incontinence .", "RESULTS Epidemiological studies demonstrate that obesity is a strong and independent risk factor for prevalent and incident urinary incontinence .", "Then another group (111 without urinary incontinence and 100 with urinary continence were asked about the number of instrumental deliveries they had undegone.", "Case series and clinical trials reporting the effect of surgical , behavioral , and/or pharmacological weight loss on urinary incontinence are summarized .", "notion . Thus , the present study was conducted to evaluate the correlation of urinary incontinence developed in women under different modes of delivery that have been used during childbirth . The", "Of the urinary incontinence episodes without urgency 82% occurred after a stress activity ( eg coughing or sneezing ) .", "on urinary incontinence has an odds ratio of 4 - 5 . The odds of incident urinary incontinence over 5 - 10 years increase by approximately 30%-60% for each 5-unit increase in body mass index .", "BACKGROUND Nurses must have adequate knowledge to manage the complexities of urinary incontinence.", "OBJECTIVE The aim was to assess the impact of lifestyle factors such as body mass index, smoking, and delivery mode (vaginal/cesarean) on the incidence and remission of urinary incontinence after hysterectomy.", "or remission of urinary incontinence after the hysterectomy . Residual urinary incontinence and de novo urinary incontinence significantly reduced satisfaction with surgery 1 year", "Residual urinary incontinence and de novo urinary incontinence significantly reduced satisfaction with surgery 1 year postoperatively compared with women without urinary incontinence .", "TYPES OF OUTCOME MEASURES Outcomes that were of interest : • non - occurrence of urinary incontinence following childbirth ; • a change in the frequency , duration or severity ( as appropriate ) of urinary incontinence up to 12 months following childbirth . •", "validated questionnaires , the Urinary Incontinence Knowledge Scale and the Urinary Incontinence Attitude Scale , to access students ' knowledge and attitudes toward urinary incontinence .", "from NIH ( National Institutes of Health ) funded clinical research on urinary incontinence in women and discussed the future of urinary incontinence research . MATERIALS AND METHODS The", "' knowledge and attitudes toward urinary incontinence . RESULTS Overall urinary incontinence knowledge was poor ( 49.9% , 15.0/30 ) and attitudes about urinary incontinence were generally", "prolapse surgery in women with potential stress urinary incontinence . The Urinary Incontinence Treatment Network study found that fascial slings were better than colposuspension , and that", "was to determine the core reasons as to why women tend to develop some urinary incontinence after delivery . First 111 women without urinary incontinence and 100 women with urinary", "of body mass index , smoking , and mode of delivery on the occurrence of urinary incontinence after hysterectomy are required to provide women with information about how these factors", "Urinary incontinence is a stigmatised attribute .", "CONCLUSION Women with 5 or more vaginal deliveries as well as instrumental deliveries were more liable to develop urinary incontinence in this study .", ". Nursing students are the nurses of the future , yet little is known about urinary incontinence education in undergraduate nursing programs . OBJECTIVES The aim of this study was ( a ) to assess", "San Pedro in La Rioja , Spain . PARTICIPANTS 402 pregnant women without urinary incontinence at the start of pregnancy . MEASUREMENTS AND FINDINGS the dependent variable was urinary", "55% of them complain of lower urinary symptoms . The most prevalent form of urinary incontinence is associated with stress , followed by mixed urinary incontinence and urge urinary incontinence .", "MEASUREMENTS AND FINDINGS the dependent variable was urinary incontinence , assessed using the Urogenital Distress Inventory - Short Form questionnaire .", "transobturator mid urethral polypropylene slings were equivalent for stress urinary incontinence . In patients with stress urinary incontinence a preoperative urodynamic study was noninferior to", "CONCLUSIONS Women with mixed urinary incontinence express a heterogeneous set of bladder control episodes with stress induced urgency urinary incontinence as the dominant type.", "RESULTS Having five or more vaginal births had a significantly (p<0.001) high risk for development of urinary incontinence (n=74, 66.67%) as compared to no urinary incontinence (n=8, 8.0%).", "of urinary incontinence : A possible link is demonstrated . BACKGROUND Urinary incontinence is a major problem faced by many mothers and has been traditionally linked to diverse ways of", "Data were collected on socio - demographic characteristics , urinary incontinence symptoms , stigma and attitudes towards seeking treatment for urinary incontinence using a self - reported questionnaire .", "RESULTS De novo urinary incontinence was reported by 8.5% , remission of urinary incontinence by 13.3% , and residual urinary incontinence by 16.1% after the hysterectomy .", "Relationship between mode of delivery and development of urinary incontinence : A possible link is demonstrated .", "after the hysterectomy . Residual urinary incontinence and de novo urinary incontinence significantly reduced satisfaction with surgery 1 year postoperatively compared with women without", "The Pelvic Floor Disorders Network study found that anticholinergic medications and onabotulinumtoxinA are efficacious for treating urge urinary incontinence , and Burch colposuspension and retropubic mid urethral polypropylene slings are efficacious for decreasing stress urinary incontinence following pelvic organ prolapse surgery in women with potential stress urinary incontinence .", "Future Directions of Research and Care for Urinary Incontinence: Findings from the National Institute of Diabetes and Digestive and Kidney Diseases Summit on Urinary Incontinence Clinical Research in Women. PURPOSE Female urinary incontinence is prevalent, costly and morbid.", "whether and how stigma influences attitudes towards seeking treatment for urinary incontinence , and whether its effect varies by symptom severity . BACKGROUND Urinary incontinence is prevalent", "incontinence knowledge was poor ( 49.9% , 15.0/30 ) and attitudes about urinary incontinence were generally positive ( 71.7% , 43.0/60 ) . A high level of interest in learning more about", "Summit on Urinary Incontinence Clinical Research in Women . PURPOSE Female urinary incontinence is prevalent , costly and morbid . Participants in a NIDDK ( National Institute of Diabetes and", ". BACKGROUND Nurses must have adequate knowledge to manage the complexities of urinary incontinence . Nursing students are the nurses of the future , yet little is known about urinary incontinence", "Urinary incontinence episodes were further defined as stress urinary incontinence , urgency urinary incontinence , stress induced urgency urinary incontinence and other .", "showing that women who never had cesarean section were more likely to report urinary incontinence .", "BACKGROUND Urinary incontinence is a major problem faced by many mothers and has been traditionally linked to diverse ways of delivery .", "CONCLUSION Vaginal delivery, obesity, and daily urge symptoms without incontinence prior to surgery increased de novo urinary incontinence and had a negative influence on the rate of remission of urinary incontinence after hysterectomy, which in turn influenced patients' satisfaction with surgery.", "urinary incontinence and had a negative influence on the rate of remission of urinary incontinence after hysterectomy , which in turn influenced patients ' satisfaction with surgery .", "analysed using path analysis . RESULTS Attitudes towards seeking treatment for urinary incontinence were generally negative . For the total sample , all the stigma domains of social rejection ,", "The maximum effect of weight on urinary incontinence has an odds ratio of 4 - 5 .", "hysterectomy with regard to de novo urinary incontinence or remission of urinary incontinence after the hysterectomy . Residual urinary incontinence and de novo urinary incontinence", "weight loss decreases the risk of urinary incontinence , even if other urinary incontinence risk factors co - exist . IMPLICATIONS FOR PRACTICE primary care midwifes can make a major", "understanding of precursors , incidence , prevalence and natural history of urinary incontinence in a diverse group of women . The Pelvic Floor Disorders Network study found that anticholinergic", "of this research was review the epidemiology of the association of obesity and urinary incontinence , and to summarize the published data on the effect of weight loss on urinary incontinence .", "• Pay particular attention to women with antenatal and post - natal urinary incontinence in providing advice and PFME instruction ( E1 ) .", "satisfaction with surgery 1 year postoperatively compared with women without urinary incontinence . CONCLUSION Vaginal delivery , obesity , and daily urge symptoms without incontinence prior to", "There was no effect of age or smoking or a difference between total and subtotal hysterectomy with regard to de novo urinary incontinence or remission of urinary incontinence after the hysterectomy.", "A subgroup analysis of these studies showed that post-natal PFME also have a significant effect on reducing or resolving urinary incontinence in women with existing post-partum urinary incontinence.", "There was a weak correlation between urinary incontinence knowledge and attitudes (r=0.135, p<0.01).", "of life . Nowadays , it is assumed that urinary incontinence , especially urge urinary incontinence , promotes anxiety and several self - esteem damages in women . The odour and the fear of", "the start of pregnancy to six months post partum . The association between urinary incontinence and the main independent variables was measured using Student 's t - test . Three simple logistic", "positive ( 71.7% , 43.0/60 ) . A high level of interest in learning more about urinary incontinence was found . There was a weak correlation between urinary incontinence knowledge and attitudes ( r=0", "in each group in terms of number of women that developed or experienced urinary incontinence with those who have no problem at all or have minor problems . METHODS The study was conducted at", "A total of 24 women ( 69% ) reported at least 1 episode of stress induced urgency urinary incontinence , which was the most prevalent urinary incontinence subtype episode , followed by urgency urinary incontinence and stress urinary incontinence ( 29% vs 27% and 16% , respectively ) .", "Individualised advice about eating and exercise habits to avoid weight retention after pregnancy may have a considerable impact on decreasing the risk of urinary incontinence .", "Weight loss by both surgical and more conservative approaches is effective in reducing urinary incontinence symptoms and should be strongly considered as a first line treatment for overweight and obese women with urinary incontinence .", "Female urinary incontinence and sexuality Urinary incontinence is a common problem among women and it is estimated that between 15 and 55% of them complain of lower urinary symptoms .", "In most of these studies women were selected randomly and therefore included women without urinary incontinence and women with urinary incontinence.", "attitudes towards urinary incontinence treatment inhibit from seeking care . Urinary incontinence is a stigmatised attribute . However , the relationship between stigma and attitudes towards", "IMPLICATIONS FOR PRACTICE primary care midwifes can make a major contribution towards the prevention and rehabilitation of urinary incontinence in women .", "• Health professionals working with women in the post-partum period should ask about symptoms of incontinence to ensure assistance is offered to those experiencing urinary incontinence (E4).", "is prevalent among women , but few seek treatment . Negative attitudes towards urinary incontinence treatment inhibit from seeking care . Urinary incontinence is a stigmatised attribute . However ,", "of vaginal deliveries they had underwent . Then another group ( 111 without urinary incontinence and 100 with urinary continence were asked about the number of instrumental deliveries they had", "The association between urinary incontinence and the main independent variables was measured using Student's t-test.", "The addition of behavioral intervention did not allow female patients to discontinue antimuscarinics for urge urinary incontinence.", "Weight loss studies indicate that both surgical and nonsurgical weight loss leads to significant improvements in prevalence, frequency, and/or symptoms of urinary incontinence. CONCLUSION Epidemiological studies document overweight and obesity as important risk factors for urinary incontinence.", "by both surgical and more conservative approaches is effective in reducing urinary incontinence symptoms and should be strongly considered as a first line treatment for overweight and obese", "incontinence , and whether its effect varies by symptom severity . BACKGROUND Urinary incontinence is prevalent among women , but few seek treatment . Negative attitudes towards urinary", "The most prevalent form of urinary incontinence is associated with stress , followed by mixed urinary incontinence and urge urinary incontinence .", "There is a clear dose - response effect of weight on urinary incontinence , with each 5-unit increase in body mass index associated with a 20%-70% increase in risk of urinary incontinence .", "OBJECTIVES The aim of this study was (a) to assess the knowledge and attitudes of urinary incontinence held by undergraduate nursing students in China and (b) to explore the relationship between knowledge, attitudes and socio-demographic characteristics.", "of urinary incontinence , whereas postpartum weight loss decreases the risk of urinary incontinence , even if other urinary incontinence risk factors co - exist . IMPLICATIONS FOR PRACTICE primary", "incontinence research . MATERIALS AND METHODS The NIDDK convened the Summit on Urinary Incontinence Clinical Research in Women on March 14 , 2014 . Participants representing a broad range of", "or a difference between total and subtotal hysterectomy with regard to de novo urinary incontinence or remission of urinary incontinence after the hysterectomy . Residual urinary incontinence and de", "considered as a first line treatment for overweight and obese women with urinary incontinence .", "The association of urinary incontinence with these variables was significant , and remained stable in both simple and multiple regression analyses with BMI at six months post partum [ odds ratio ( OR ) 1.09 versus 1.08 ] , weight loss from delivery to six months post partum ( OR 0.88 versus 0.88 ) , and retained weight from the beginning of pregnancy until six months post partum ( OR 1.23 versus 1.19 ) .", "A uterine weight > 300 g ( odds ratio , 1.98 , 95% confidence interval , 1.69 - 2.33 ) , body mass index < 25 kg / m2 ( odds ratio , 1.22 , 95% confidence interval , 1.01 - 1.47 ) , prolapse ( odds ratio , 2.25 , 95% confidence interval , 1.60 - 3.18 ) , or fibroids ( odds ratio , 1.33 , 95% confidence interval , 1.09 - 1.62 ) as indication for surgery and the absence of daily urge without incontinence preoperatively ( odds ratio , 1.51 , 95% confidence interval , 1.29 - 1.76 ) were associated with an increased remission of urinary incontinence .", "form of urinary incontinence is associated with stress , followed by mixed urinary incontinence and urge urinary incontinence . It is a symptom with several effects on quality of life of women", "toward urinary incontinence . This study suggests there is a need to examine urinary incontinence content throughout undergraduate nursing curricula in China .", ". METHODS We enrolled a sample of 305 women aged 40 - 65 years with stress urinary incontinence from three communities in a Chinese city between May - October in 2011 . Data were collected on", "to significant improvements in prevalence , frequency , and/or symptoms of urinary incontinence . CONCLUSION Epidemiological studies document overweight and obesity as important risk factors for", "following pelvic organ prolapse surgery in women with potential stress urinary incontinence . The Urinary Incontinence Treatment Network study found that fascial slings were better than", "Thus, the present study was conducted to evaluate the correlation of urinary incontinence developed in women under different modes of delivery that have been used during childbirth.", "Multivariable logistic regression analyses were used to identify independent risk factors for de novo urinary incontinence and postoperative remission of urinary incontinence, presented as adjusted odds ratios with 95% confidence intervals.", "each of the independent variables that showed a significant association with urinary incontinence ( p<0.05 ) , and three multiple regression models that included the possible variable effect", "This study suggests there is a need to examine urinary incontinence content throughout undergraduate nursing curricula in China.", "Two studies found that women receiving the intervention (a PFME program) and who were performing PFME regularly in the month before data collection were significantly less likely to have any incontinence.", "Interventions should specifically target the self-stigma domains of social isolation and internalised shame in women with urinary incontinence to most efficiently increase their use of health care.", "to develop some urinary incontinence after delivery . First 111 women without urinary incontinence and 100 women with urinary incontinence were asked retrospectively about the number of vaginal", "impact on global and sexual quality of life . Nowadays , it is assumed that urinary incontinence , especially urge urinary incontinence , promotes anxiety and several self - esteem damages in", "The results were compared in each group in terms of number of women that developed or experienced urinary incontinence with those who have no problem at all or have minor problems .", "Urinary incontinence and weight changes during pregnancy and post partum: a pending challenge. OBJECTIVE to analyse the association between urinary incontinence and maternal weight, and its variations in pregnancy and post partum.", "MATERIALS AND METHODS A random sample of women 40 years old or older with mixed urinary incontinence on GLOBE - UI ( General Longitudinal Overactive Bladder Evaluation - Urinary Incontinence ) was recruited in a digital daily diary study using a smartphone application .", "the effect of surgical , behavioral , and/or pharmacological weight loss on urinary incontinence are summarized . RESULTS Epidemiological studies demonstrate that obesity is a strong and", ", and delivery mode ( vaginal / cesarean ) on the incidence and remission of urinary incontinence after hysterectomy . STUDY DESIGN This was a cohort study based on pre- , per- , and postoperative", "Notably, a stress activity also occurred just before 52.5% of the urgency urinary incontinence episodes (p <0.001).", "Both conservative and surgical treatments have been studied about its benefit in urinary incontinence and also the impact among female sexual function.", "high BMI and weight retention at six months post partum increase the risk of urinary incontinence , whereas postpartum weight loss decreases the risk of urinary incontinence , even if other", "PURPOSE We sought to understand variations in the expression and temporal relation of bladder control episodes among women with mixed urinary incontinence .", "clinical research on urinary incontinence in women and discussed the future of urinary incontinence research . MATERIALS AND METHODS The NIDDK convened the Summit on Urinary Incontinence Clinical", "First 111 women without urinary incontinence and 100 women with urinary incontinence were asked retrospectively about the number of vaginal deliveries they had underwent .", "Unfortunately, there are sparse articles that evaluate the benefits of female sexual function with drug management of incontinence.", "The mean (±standard deviation) retained weight was 2 (±3.1) kg. Postpartum urinary incontinence was associated with BMI at six months post partum, postpartum weight loss and retained weight at six months post partum (p<0.05).", "decreased urinary incontinence . CONCLUSIONS Strategies for future research on urinary incontinence should include a focus on early disease , risk factor identification , better phenotyping ,", "There appears to be a stronger association between increasing weight and prevalent and incident stress incontinence (including mixed incontinence) than for urge incontinence.", "-70% increase in risk of urinary incontinence . The maximum effect of weight on urinary incontinence has an odds ratio of 4 - 5 . The odds of incident urinary incontinence over 5 - 10 years increase", "after pregnancy may have a considerable impact on decreasing the risk of urinary incontinence .", "Three simple logistic regression models were used to assess the strength of this association, one for each of the independent variables that showed a significant association with urinary incontinence (p<0.05), and three multiple regression models that included the possible variable effect modifiers were also used.", "The odds of incident urinary incontinence over 5 - 10 years increase by approximately 30%-60% for each 5-unit increase in body mass index .", "Of the 950 bladder control episodes reported 25% were urgency only, 55% were urinary incontinence with urgency and 19% were urinary incontinence without urgency.", "EXCLUSIONS • women who delivered by elective caesarean section; • women experiencing post-partum overflow urinary incontinence.", "vaginal births had a significantly ( p<0.001 ) high risk for development of urinary incontinence ( n=74 , 66.67% ) as compared to no urinary incontinence ( n=8 , 8.0% ) . In the group who had no", ". PRIDE showed that modest weight reductions significantly decreased urinary incontinence . CONCLUSIONS Strategies for future research on urinary incontinence should include a focus on", "studies document overweight and obesity as important risk factors for urinary incontinence . Weight loss by both surgical and more conservative approaches is effective in reducing urinary", "Effects of stigma on Chinese women's attitudes towards seeking treatment for urinary incontinence. AIMS AND OBJECTIVES To examine whether and how stigma influences attitudes towards seeking treatment for urinary incontinence, and whether its effect varies by symptom severity.", "The results of this review indicate that antenatal PFME and post - natal PFME are effective in resolving or reducing urinary incontinence following childbirth .", "function in females . This article is a review of both the concepts of female urinary incontinence and its impact on global and sexual quality of life . Nowadays , it is assumed that urinary", "mid urethral polypropylene slings are efficacious for decreasing stress urinary incontinence following pelvic organ prolapse surgery in women with potential stress urinary incontinence . The", "Effect of weight loss on urinary incontinence in women BACKGROUND The purpose of this research was review the epidemiology of the association of obesity and urinary incontinence , and to summarize the published data on the effect of weight loss on urinary incontinence .", "mean ( ±standard deviation ) retained weight was 2 ( ±3.1 ) kg . Postpartum urinary incontinence was associated with BMI at six months post partum , postpartum weight loss and retained weight at", "RESULTS Attitudes towards seeking treatment for urinary incontinence were generally negative.", "incontinence symptoms , stigma and attitudes towards seeking treatment for urinary incontinence using a self - reported questionnaire . Effects of stigma were analysed using path analysis .", "poor urinary incontinence knowledge but generally positive attitudes toward urinary incontinence . This study suggests there is a need to examine urinary incontinence content throughout", "r=0.135 , p<0.01 ) . There was also a significant positive correlation between urinary incontinence knowledge and attitudes and nursing students ' year of study , urinary incontinence education and", "deliveries as well as instrumental deliveries were more liable to develop urinary incontinence in this study . This may be because vaginal deliveries and instrumental deliveries lead to", "Nowadays, it is assumed that urinary incontinence, especially urge urinary incontinence, promotes anxiety and several self-esteem damages in women.", "RESULTS Overall urinary incontinence knowledge was poor ( 49.9% , 15.0/30 ) and attitudes about urinary incontinence were generally positive ( 71.7% , 43.0/60 ) .", "Effectiveness of a pelvic floor muscle exercise program on urinary incontinence following childbirth.", "conservative and surgical treatments have been studied about its benefit in urinary incontinence and also the impact among female sexual function . Unfortunately , there are sparse articles that", "Participants representing a broad range of clinical expertise reviewed completed NIH sponsored urinary incontinence related studies , including results from community based epidemiological studies such as the BACH ( Boston Area Community Health ) Survey and from randomized clinical trials such as PRIDE ( Program to Reduce Incontinence by Diet and Exercise ) , and studies conducted by the Pelvic Floor Disorders Network and the Urinary Incontinence Treatment Network .", "obesity is a strong and independent risk factor for prevalent and incident urinary incontinence . There is a clear dose - response effect of weight on urinary incontinence , with each 5-unit", "The aim of this study was ( a ) to assess the knowledge and attitudes of urinary incontinence held by undergraduate nursing students in China and ( b ) to explore the relationship between", "Vaginal compared with abdominal hysterectomy was associated with a decreased remission of urinary incontinence (odds ratio, 0.70, 95% confidence interval, 0.57-0.87).", "Self - reported data were collected using two validated questionnaires , the Urinary Incontinence Knowledge Scale and the Urinary Incontinence Attitude Scale , to access students ' knowledge and", "KEY CONCLUSIONS high BMI and weight retention at six months post partum increase the risk of urinary incontinence , whereas postpartum weight loss decreases the risk of urinary incontinence , even if other urinary incontinence risk factors co - exist .", "with abdominal hysterectomy was associated with a decreased remission of urinary incontinence ( odds ratio , 0.70 , 95% confidence interval , 0.57 - 0.87 ) . There was no effect of age or", "delivery . First 111 women without urinary incontinence and 100 women with urinary incontinence were asked retrospectively about the number of vaginal deliveries they had underwent . Then", "Participants in a NIDDK ( National Institute of Diabetes and Digestive and Kidney Diseases ) sponsored summit reviewed findings from NIH ( National Institutes of Health ) funded clinical research on urinary incontinence in women and discussed the future of urinary incontinence research .", "PRIDE showed that modest weight reductions significantly decreased urinary incontinence .", "can make a major contribution towards the prevention and rehabilitation of urinary incontinence in women . It is important for the midwife and the woman to keep in contact in the first six", "October in 2011 . Data were collected on socio - demographic characteristics , urinary incontinence symptoms , stigma and attitudes towards seeking treatment for urinary incontinence using a self -", "with the unpredictability and the chronicity of incontinence , namely urge urinary incontinence . Female urinary incontinence management involves conservative ( pelvic floor muscle training ) ,", "There was insufficient evidence to conclude that PFME can prevent urinary incontinence in post - partum women .", "self - stigma domains of social isolation and internalised shame in women with urinary incontinence to most efficiently increase their use of health care .", "BACKGROUND Studies on the influence of body mass index , smoking , and mode of delivery on the occurrence of urinary incontinence after hysterectomy are required to provide women with information about how these factors influence continence after a hysterectomy .", "UNLABELLED EXECUTIVE SUMMARY : Objectives The primary objective of this review was to determine , from the available evidence , the effectiveness of an antenatal and/or a post - natal program of pelvic floor muscle exercises ( PFME ) compared with usual care on preventing , reducing or resolving the incidence and severity of stress incontinence , urge incontinence or mixed stress and urge urinary incontinence following childbirth .", "A body mass index ≥30 kg / m2 ( odds ratio , 1.63 , 95% confidence interval , 1.37 - 1.94 ) , having undergone a vaginal delivery ( odds ratio , 1.40 , 95% confidence interval , 1.14 - 1.86 ) , the presence of daily urge without incontinence prior to surgery ( odds ratio , 1.77 , 95% confidence interval , 1.47 - 2.13 ) , and a uterine weight < 500 g ( odds ratio , 2.46 , 95% confidence interval , 1.96 - 3.09 ) were associated with an increased risk of de novo urinary incontinence .", "Mixed Incontinence Masked as Stress Induced Urgency Urinary Incontinence .", "risk factors for de novo urinary incontinence and postoperative remission of urinary incontinence , presented as adjusted odds ratios with 95% confidence intervals . RESULTS De novo urinary", "-unit increase in body mass index associated with a 20%-70% increase in risk of urinary incontinence . The maximum effect of weight on urinary incontinence has an odds ratio of 4 - 5 . The odds of", "enhances the formation of negative attitudes towards seeking treatment for urinary incontinence ; public stigma affects treatment - seeking attitudes through internalisation of social messages .", "daily urge symptoms without incontinence prior to surgery increased de novo urinary incontinence and had a negative influence on the rate of remission of urinary incontinence after hysterectomy ,", ", and to summarize the published data on the effect of weight loss on urinary incontinence . METHODS A literature review of the association between urinary incontinence and overweight /", "RESULTS BACH Survey results improved our understanding of precursors , incidence , prevalence and natural history of urinary incontinence in a diverse group of women .", "There was also a significant positive correlation between urinary incontinence knowledge and attitudes and nursing students' year of study, urinary incontinence education and training, and formal clinical practicum experience in urology (p<0.05).", "paths : the effect of internalised shame was higher in women with more severe urinary incontinence . CONCLUSIONS Stigma enhances the formation of negative attitudes towards seeking treatment for", "regression analyses were used to identify independent risk factors for de novo urinary incontinence and postoperative remission of urinary incontinence , presented as adjusted odds ratios with 95%", "Attitude Scale , to access students ' knowledge and attitudes toward urinary incontinence . RESULTS Overall urinary incontinence knowledge was poor ( 49.9% , 15.0/30 ) and attitudes about", "reported by 8.5% , remission of urinary incontinence by 13.3% , and residual urinary incontinence by 16.1% after the hysterectomy . A body mass index ≥30 kg / m2 ( odds ratio , 1.63 , 95%", "METHODS We enrolled a sample of 305 women aged 40-65 years with stress urinary incontinence from three communities in a Chinese city between May-October in 2011.", "as adjusted odds ratios with 95% confidence intervals . RESULTS De novo urinary incontinence was reported by 8.5% , remission of urinary incontinence by 13.3% , and residual urinary", "urinary incontinence . METHODS A literature review of the association between urinary incontinence and overweight / obesity in women was performed . Case series and clinical trials reporting the", "medications and onabotulinumtoxinA are efficacious for treating urge urinary incontinence , and Burch colposuspension and retropubic mid urethral polypropylene slings are efficacious for", "did not allow female patients to discontinue antimuscarinics for urge urinary incontinence . PRIDE showed that modest weight reductions significantly decreased urinary incontinence .", "METHODS Self-reported data were collected using two validated questionnaires, the Urinary Incontinence Knowledge Scale and the Urinary Incontinence Attitude Scale, to access students' knowledge and attitudes toward urinary incontinence.", "deliveries they had undegone . The same was repeated ( 111 women without urinary incontinence and 100 with urinary incontinence ) for women with cesarean section . RESULTS Having five or more", "a broad range of clinical expertise reviewed completed NIH sponsored urinary incontinence related studies , including results from community based epidemiological studies such as the BACH (", "is associated with stress , followed by mixed urinary incontinence and urge urinary incontinence . It is a symptom with several effects on quality of life of women mainly in their social ,", "MATERIALS AND METHODS The NIDDK convened the Summit on Urinary Incontinence Clinical Research in Women on March 14, 2014.", "the start of pregnancy . MEASUREMENTS AND FINDINGS the dependent variable was urinary incontinence , assessed using the Urogenital Distress Inventory - Short Form questionnaire . The main", "Negative attitudes towards urinary incontinence treatment inhibit from seeking care .", "were equivalent for stress urinary incontinence . In patients with stress urinary incontinence a preoperative urodynamic study was noninferior to basic office examinations for surgical outcome .", "PARTICIPANTS 402 pregnant women without urinary incontinence at the start of pregnancy.", "CONCLUSIONS Strategies for future research on urinary incontinence should include a focus on early disease , risk factor identification , better phenotyping , incorporation of new technologies , patient centered research and prevention .", ". RESULTS De novo urinary incontinence was reported by 8.5% , remission of urinary incontinence by 13.3% , and residual urinary incontinence by 16.1% after the hysterectomy . A body mass index ≥3", "This is further supported by the results of this study showing that women who never had cesarean section were more likely to report urinary incontinence .", "interval , 1.29 - 1.76 ) were associated with an increased remission of urinary incontinence . Vaginal compared with abdominal hysterectomy was associated with a decreased remission of", "METHODS A literature review of the association between urinary incontinence and overweight / obesity in women was performed .", "CONCLUSIONS Stigma enhances the formation of negative attitudes towards seeking treatment for urinary incontinence; public stigma affects treatment-seeking attitudes through internalisation of social messages.", ") , and studies conducted by the Pelvic Floor Disorders Network and the Urinary Incontinence Treatment Network . RESULTS BACH Survey results improved our understanding of precursors ,", "in urology ( p<0.05 ) . CONCLUSIONS Chinese nursing students showed poor urinary incontinence knowledge but generally positive attitudes toward urinary incontinence . This study suggests there", "Female urinary incontinence management involves conservative (pelvic floor muscle training), surgical and pharmacological treatment.", "interval , 1.96 - 3.09 ) were associated with an increased risk of de novo urinary incontinence . A uterine weight > 300 g ( odds ratio , 1.98 , 95% confidence interval , 1.69 - 2.33 ) , body", "partum : a pending challenge . OBJECTIVE to analyse the association between urinary incontinence and maternal weight , and its variations in pregnancy and post partum . DESIGN observational study", "about urinary incontinence was found . There was a weak correlation between urinary incontinence knowledge and attitudes ( r=0.135 , p<0.01 ) . There was also a significant positive correlation", "INCLUSION CRITERIA TYPES OF STUDIES: Randomised controlled trials and non-randomised controlled trials were included in the review if, in relation to urinary incontinence, and/or adherence to a PFME program, and/or pelvic floor muscle strength, the following had been explored: • antenatal PFME compared with usual care; • post-natal PFME compared with usual care; • a PFME program compared with usual care.", "The same was repeated (111 women without urinary incontinence and 100 with urinary incontinence) for women with cesarean section.", "CONCLUSIONS Chinese nursing students showed poor urinary incontinence knowledge but generally positive attitudes toward urinary incontinence .", "In patients with stress urinary incontinence a preoperative urodynamic study was noninferior to basic office examinations for surgical outcome.", "incontinence knowledge and attitudes and nursing students ' year of study , urinary incontinence education and training , and formal clinical practicum experience in urology ( p<0.05 ) .", "Symptom severity influenced the strength of paths: the effect of internalised shame was higher in women with more severe urinary incontinence.", "This article is a review of both the concepts of female urinary incontinence and its impact on global and sexual quality of life.", "However , the relationship between stigma and attitudes towards seeking treatment for urinary incontinence has not been well understood .", ", the relationship between stigma and attitudes towards seeking treatment for urinary incontinence has not been well understood . DESIGN This was a cross - sectional community - based study .", "for development of urinary incontinence ( n=74 , 66.67% ) as compared to no urinary incontinence ( n=8 , 8.0% ) . In the group who had no cesarean section , there was a significantly ( p < 0 .001", "Nursing students are the nurses of the future , yet little is known about urinary incontinence education in undergraduate nursing programs .", "and the chronicity of incontinence , namely urge urinary incontinence . Female urinary incontinence management involves conservative ( pelvic floor muscle training ) , surgical and pharmacological", "urinary incontinence . There is a clear dose - response effect of weight on urinary incontinence , with each 5-unit increase in body mass index associated with a 20%-70% increase in risk of", "Nursing students' knowledge and attitudes toward urinary incontinence: A cross-sectional survey.", "Implications for practice In terms of the effectiveness of PFME programs, the results of this review indicate that urinary incontinence following childbirth can be improved by performing PFME and that any form of a specific PFME program appears to improve exercising frequency.", "A high level of interest in learning more about urinary incontinence was found .", "the National Institute of Diabetes and Digestive and Kidney Diseases Summit on Urinary Incontinence Clinical Research in Women . PURPOSE Female urinary incontinence is prevalent , costly and morbid .", "Factors influencing the incidence and remission of urinary incontinence after hysterectomy.", "The odour and the fear of incontinence during sexual intercourse affect female sexual function and this is related with the unpredictability and the chronicity of incontinence , namely urge urinary incontinence .", ". The same was repeated ( 111 women without urinary incontinence and 100 with urinary incontinence ) for women with cesarean section . RESULTS Having five or more vaginal births had a significantly", "Episodes were defined as urgency , and urinary incontinence with and urinary incontinence without urgency .", "and retained weight at six months post partum ( p<0.05 ) . The association of urinary incontinence with these variables was significant , and remained stable in both simple and multiple regression", "The objective was to determine the core reasons as to why women tend to develop some urinary incontinence after delivery .", "The Urinary Incontinence Treatment Network study found that fascial slings were better than colposuspension , and that retropubic and transobturator mid urethral polypropylene slings were equivalent for stress urinary incontinence .", "A number of studies reported a high percentage of women lost to follow-up and the data collected in most of the studies relied on self-reports relating to urinary incontinence and/or frequency of exercising."], "par_relations": ["Urination Disorders", "Lower Urinary Tract Symptoms"], "chd_relations": ["Urinary Incontinence, Stress", "Urinary Incontinence, Urge"], "syn_relations": ["Urinary Incontinence", "Urinary Incontinence"], "sib_relations": ["Incontinence Pads", "Urinary Sphincter, Artificial", "Anuria", "Dysuria", "Enuresis", "Glycosuria", "Hematuria", "Nocturia", "Oliguria", "Polyuria", "Proteinuria", "Urinary Retention", "Prostatism", "Urinary Bladder, Overactive"], "wiki_entities": ["Urinary incontinence", "Overflow incontinence", "Stress incontinence", "Urinary system", "Incontinence", "Athletic incontinence", "Functional incontinence", "Fecal incontinence", "Urinary urgency", "Incontinence pad"], "mesh_synonynms": ["incontinence, urinary", "urinary incontinence"], "dbpedia_synonyms": ["involuntary urination", "bladder control", "bladder incontinence", "urine, incontinence", "male urinary incontinence", "peeing in pants", "effort incontinence", "pissing oneself", "marshall-marchetti-krantz", "urinal incontinence", "light bladder leakage", "urinary incontinence", "urine incontinence", "mixed incontinence", "urinary continence", "pee in pants", "coital incontinence", "bladder leakage"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0030404", "canonical_name": "Glucagonoma", "aliases": ["glucagonoma"], "definition": "A glucagonoma is a rare tumor of the alpha cells of the pancreas that results in the overproduction of the hormone glucagon.", "other_contexts": ["Glucagonoma is a rare islet cell tumor of pancreas.", "rash , glucose intolerance , hypoaminoacidemia , hyperglucagonaemia and pancreatic glucagonoma . The clinical case of a 45-year - old woman is presented . She had been experiencing weight loss ,", "CONCLUSION Glucagonoma is a rare pancreatic NET that has significant malignant potential .", "OBJECTIVE To report the diagnostic difficulties encountered in a case of glucagonoma.", "Phenylalanine hydroxylation was moderately higher only in the male patient with glucagonoma ( + & 30 % , d > 2 SD ) .", "Presentation of diffuse malignant glucagonoma with tumor emboli but no metastasis or NME is unusual .", "Malignant glucagonoma metastasizes frequently to liver.", "Glucagonoma is often found in the pancreatic body and/or tail and is usually large enough to be localized by computed tomography .", "CT examination found a space-occupying lesion in the pancreas, and an elevated serum glucagon level indicate the diagnosis of glucagonoma, which was confirmed postoperatively by pathological examination of the tumor tissue.", "the first documented case of a non - secreting benign pancreatic neuroendocrine tumor ( glucagonoma ) associated with TTP that is refractory to standard treatment .", "of necrolytic migratory erythema . A suggestion was made to investigate a pancreatic glucagonoma . Laboratory tests showed moderate anemia , hyperglycemia and marked hyperglucagonaemia .", "An evaluation for possible glucagonoma may be considered in a patient with the characteristic eczematous dermatitis, glossitis or stomatitis and glucose intolerance, an unusual or atypical history of diabetes mellitus, or hepatomegaly with other characteristics of glucagonoma.", "Necrolytic migratory erythema and pancreatic glucagonoma.", "is a rare paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome , a disorder characterized by mucocutaneous rash , glucose intolerance ,", "Extreme fasting hyperglucagonemia, and a paradoxical rise in plasma glucagon concentrations after glucose ingestion should strongly suggest the presence of glucagonoma.", "Early detection of pancreatic glucagonoma.", "This is the first case of a pancreatic glucagonoma metastasising to the ovary 5 years after radical distal pancreatosplenectomy.", "The pathological diagnosis was benign glucagonoma.", "The patient was hospitalized, and because of the dermatologic findings suggestive of necrolytic migratory erythema, the presence of a glucagonoma was suspected.", "These alterations could contribute to the determination of the catabolic state of the glucagonoma syndrome .", "CONTEXT Glucagonomas of the pancreas are neuroendocrine tumours (NETs) that arise from well-differentiated neuroendocrine cells within the pancreatic islets.", "A suggestion was made to investigate a pancreatic glucagonoma .", "Plasma leucine, phenylalanine and tyrosine rates of appearance in patients with glucagonoma were similar to values in the control subjects, except leucine rate of appearence in the female patient with glucagonoma ( + &30 %, d > 2 SD).", "Possible early detection of glucagonoma was discussed in this report .", "In conclusion , whole - body protein breakdown is enhanced in patients with glucagonoma compared with healthy control subjects .", "Suspicion of glucagonoma is based on characteristic presentations known as \"glucagonoma syndrome\".", "Necrolytic Migratory Erythema: First Symptom of a Glucagonoma A Case Report.", "Glucagonoma is one form of islet cell neoplasm and involves pancreatic alpha cells .", "Surgical resection is an effective means for treatment of glucagonoma .", "Rare presentation of endocrine pancreatic tumor: a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema.", "to an acrodermatitis enteropathica due to zinc deficiency . We describe a case of a glucagonoma with its classic features , diagnosis and treatment .", "Clinicians should be aware of the unusual initial manifestations of this tumor and the potential for less than a full spectrum of the characteristic features of the glucagonoma syndrome .", "To our knowledge, this represents the first documented case of a non-secreting benign pancreatic neuroendocrine tumor (glucagonoma) associated with TTP that is refractory to standard treatment.", "The average size of clinically detected glucagonomas was 5.8 cm , and 54.7% of them exhibited metastasis .", "When confronted with a xerosis cutis one should always exclude the possibility of a NME caused by a glucagonoma as demonstrated in this case report where the rash was wrongly attributed to an acrodermatitis enteropathica due to zinc deficiency .", "We describe a case of a glucagonoma with its classic features, diagnosis and treatment.", "CASE REPORT The authors present a case of a glucagonoma that initially presented with classical necrolytic migratory erythema and a large solitary mass in the body and tail of the pancreas that was surgically resected .", "We report a case of diffuse glucagonoma necrolytic migratory erythema ( NME ) in a 45-year - old man with mild diabetes mellitus , mild anemia , and weight loss over 1.5 years .", "Protein metabolism in glucagonoma Although protein wasting and reduced amino acid concentrations are common findings in glucagonoma patients, the mechanisms underlying these alterations are unclear.", "with blisters that heal with hyperpigmentation . NME is a pathognomonic feature of a glucagonoma . When confronted with a xerosis cutis one should always exclude the possibility of a NME caused", "Necrolytic migratory erythema is a rare paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome , a disorder characterized by mucocutaneous rash , glucose intolerance , hypoaminoacidemia , hyperglucagonaemia and pancreatic glucagonoma .", "A definite diagnosis of glucagonoma relies on pathological report , and so far no standard treatment strategy has been available for this tumor .", "Rarely, glucagonoma with massive destruction of the pancreas or other factors may induce severe glucose intolerance.", "Clinical and metabolic aspects of glucagonoma .", "We describe the case of a 0.7-cm asymptomatic pancreatic glucagonoma.", "OBJECTIVE glucagonoma is a rare islet alpha - cell tumor .", "At diagnosis , most glucagonomas are malignant and often metastatic .", "Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report.", "Diagnostic challenge of glucagonoma : case report and literature review .", "In contrast localised glucagonoma without metastatic spread may have prolonged disease free survival with radical resectional surgery .", "paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome , a disorder characterized by mucocutaneous rash , glucose intolerance , hypoaminoacidemia ,", "Glucagonoma is a model for studying the importance of glucagon in causing the hyperglycemia of diabetes mellitus.", "Therefore, we studied basal postabsorptive leucine, phenylalanine and tyrosine turnover following L-[D3]-Leucine, L-[D5]-Phenylalanine and L-[D2]-Tyrosine i. v. infusions in one male and one female patient with glucagonoma, compared with healthy control volunteers.", "Treatment for the various dermatologic or metabolic complications of glucagonoma which include glucose intolerance , hypoproteinemia , hypocholesterolemia and anemia may not be satisfactory .", "with a xerosis cutis one should always exclude the possibility of a NME caused by a glucagonoma as demonstrated in this case report where the rash was wrongly attributed to an acrodermatitis", "Pathology of the resected ovary after oophorectomy identified this as an isolated metastatic glucagonoma.", "The histologic appearance and immunohistochemical staining results confirmed the diagnosis of a glucagonoma .", "CONCLUSION The diagnosis of glucagonoma is often delayed.", "which was resected . The histopathological findings were compatible with a diagnosis of glucagonoma , as confirmed by immunohistochemistry . Skin symptoms disappeared 10 days after the tumor", "This may be the smallest glucagonoma detected by image diagnostics that has been reported in the English literature.", "and splenopancreatectomy was performed . The pathological diagnosis was benign glucagonoma . The hematological symptoms resolved completely after the procedure and 3 years later , the", "pattern of vacuolation and epidermal necrosis should arouse suspicion of pancreatic glucagonoma .", "procedure and 3 years later , the patient is well with no sign of recurrence of TTP or glucagonoma . To our knowledge , this represents the first documented case of a non - secreting benign", "Study of patients with glucagonoma does suggest that glucagon has some role in the etiology of hyperglycemia in diabetic states ; however , as in studies on diabetes , investigations on glucagonoma do not demonstrate that glucagon has a primary role in producing severe glucose intolerance .", "NME is a pathognomonic feature of a glucagonoma.", "The hematological symptoms resolved completely after the procedure and 3 years later, the patient is well with no sign of recurrence of TTP or glucagonoma.", "[Diagnosis and treatment of glucagonoma: report of one case].", "Glucagonoma is a very rare endocrine pancreatic tumor.", "METHODS We provide a literature review and present the clinical findings , pertinent laboratory data , and results of related studies in a patient with a glucagonoma .", "The histopathological findings were compatible with a diagnosis of glucagonoma , as confirmed by immunohistochemistry .", "Diagnosis of glucagonoma has usually been delayed.", "Non-secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura: report of a case Thrombotic thrombocytopenic purpura (TTP) is a rare hematologic disorder, which may be idiopathic or secondary to a variety of diseases.", "We report a case of glucagonoma in a 55-year - old male patient with such clinical findings of necrolytic migratory erythema , diabetes mellitus , body weight loss , and anemia .", "Radiographic demonstration of pancreatic glucagonoma is best carried out by celiac arteriography.", "The histological pattern of vacuolation and epidermal necrosis should arouse suspicion of pancreatic glucagonoma .", "The features of 41 proven or suspected cases of pancreatic glucagonoma and one possible case of renal glucagonoma have been reviewed."], "par_relations": ["Pancreatic endocrine tumor"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Pancreatic islet cell adenoma"], "wiki_entities": ["Glucagonoma", "Necrolytic migratory erythema", "Alpha cell", "Endocrine oncology", "NME (disambiguation)", "Endocrine disease", "Chancre", "Angular cheilitis", "Marie Antoinette syndrome", "Thrombotic thrombocytopenic purpura"], "mesh_synonynms": ["alpha cell tumor", "syndrome, glucagonoma", "syndromes, glucagonoma", "alpha-cell tumor", "alpha-cell adenoma", "adenoma, alpha-cell", "adenoma, alpha cell", "adenomas, alpha-cell", "tumors, alpha-cell", "glucagonoma syndrome", "glucagonoma syndromes", "tumor, alpha-cell", "alpha-cell adenomas", "alpha-cell tumors", "glucagonomas"], "dbpedia_synonyms": ["pseudoglucagonoma syndrome"]}, "target_ent": {"research_entity_id": "MSH:D005935", "canonical_name": "Glucagonoma", "aliases": ["glucagonomas", "syndromes, glucagonoma", "tumors, alpha-cell", "glucagonoma", "syndrome, glucagonoma", "alpha-cell tumor", "tumor, alpha-cell", "glucagonoma syndromes", "alpha-cell adenomas", "alpha-cell adenoma", "alpha cell tumor", "adenomas, alpha-cell", "adenoma, alpha-cell", "adenoma, alpha cell", "alpha-cell tumors", "glucagonoma syndrome"], "definition": "A glucagonoma is a rare tumor of the alpha cells of the pancreas that results in the overproduction of the hormone glucagon.", "other_contexts": ["rash , glucose intolerance , hypoaminoacidemia , hyperglucagonaemia and pancreatic glucagonoma . The clinical case of a 45-year - old woman is presented . She had been experiencing weight loss ,", "CONCLUSION Glucagonoma is a rare pancreatic NET that has significant malignant potential .", "The patient was hospitalized , and because of the dermatologic findings suggestive of necrolytic migratory erythema , the presence of a glucagonoma was suspected .", "Phenylalanine hydroxylation was moderately higher only in the male patient with glucagonoma ( + & 30 % , d > 2 SD ) .", "OBJECTIVE To report the diagnostic difficulties encountered in a case of glucagonoma.", "Presentation of diffuse malignant glucagonoma with tumor emboli but no metastasis or NME is unusual .", "Malignant glucagonoma metastasizes frequently to liver.", "Radiographic demonstration of pancreatic glucagonoma is best carried out by celiac arteriography.", "An evaluation for possible glucagonoma may be considered in a patient with the characteristic eczematous dermatitis, glossitis or stomatitis and glucose intolerance, an unusual or atypical history of diabetes mellitus, or hepatomegaly with other characteristics of glucagonoma.", "of necrolytic migratory erythema . A suggestion was made to investigate a pancreatic glucagonoma . Laboratory tests showed moderate anemia , hyperglycemia and marked hyperglucagonaemia .", "Pathology of the resected ovary after oophorectomy identified this as an isolated metastatic glucagonoma .", "the first documented case of a non - secreting benign pancreatic neuroendocrine tumor ( glucagonoma ) associated with TTP that is refractory to standard treatment .", "The histopathological findings were compatible with a diagnosis of glucagonoma, as confirmed by immunohistochemistry.", "At diagnosis, most glucagonomas are malignant and often metastatic.", "is a rare paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome , a disorder characterized by mucocutaneous rash , glucose intolerance ,", "Extreme fasting hyperglucagonemia, and a paradoxical rise in plasma glucagon concentrations after glucose ingestion should strongly suggest the presence of glucagonoma.", "Possible early detection of glucagonoma was discussed in this report.", "These alterations could contribute to the determination of the catabolic state of the glucagonoma syndrome .", "CONTEXT Glucagonomas of the pancreas are neuroendocrine tumours (NETs) that arise from well-differentiated neuroendocrine cells within the pancreatic islets.", "This may be the smallest glucagonoma detected by image diagnostics that has been reported in the English literature .", "We describe the case of a 0.7-cm asymptomatic pancreatic glucagonoma .", "A suggestion was made to investigate a pancreatic glucagonoma .", "In conclusion , whole - body protein breakdown is enhanced in patients with glucagonoma compared with healthy control subjects .", "Necrolytic Migratory Erythema: First Symptom of a Glucagonoma A Case Report.", "Glucagonoma is one form of islet cell neoplasm and involves pancreatic alpha cells .", "When confronted with a xerosis cutis one should always exclude the possibility of a NME caused by a glucagonoma as demonstrated in this case report where the rash was wrongly attributed to an acrodermatitis enteropathica due to zinc deficiency.", "Clinicians should be aware of the unusual initial manifestations of this tumor and the potential for less than a full spectrum of the characteristic features of the glucagonoma syndrome .", "Surgical resection is an effective means for treatment of glucagonoma .", "To our knowledge , this represents the first documented case of a non - secreting benign pancreatic neuroendocrine tumor ( glucagonoma ) associated with TTP that is refractory to standard treatment .", "Early detection of pancreatic glucagonoma .", "to an acrodermatitis enteropathica due to zinc deficiency . We describe a case of a glucagonoma with its classic features , diagnosis and treatment .", "CT examination found a space - occupying lesion in the pancreas , and an elevated serum glucagon level indicate the diagnosis of glucagonoma , which was confirmed postoperatively by pathological examination of the tumor tissue .", "We describe a case of a glucagonoma with its classic features, diagnosis and treatment.", "Non - secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura : report of a case Thrombotic thrombocytopenic purpura ( TTP ) is a rare hematologic disorder , which may be idiopathic or secondary to a variety of diseases .", "We report a case of diffuse glucagonoma necrolytic migratory erythema ( NME ) in a 45-year - old man with mild diabetes mellitus , mild anemia , and weight loss over 1.5 years .", "CASE REPORT The authors present a case of a glucagonoma that initially presented with classical necrolytic migratory erythema and a large solitary mass in the body and tail of the pancreas that was surgically resected .", "with blisters that heal with hyperpigmentation . NME is a pathognomonic feature of a glucagonoma . When confronted with a xerosis cutis one should always exclude the possibility of a NME caused", "Necrolytic migratory erythema is a rare paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome , a disorder characterized by mucocutaneous rash , glucose intolerance , hypoaminoacidemia , hyperglucagonaemia and pancreatic glucagonoma .", "Rarely, glucagonoma with massive destruction of the pancreas or other factors may induce severe glucose intolerance.", "Glucagonoma is a rare islet cell tumor of pancreas .", "Clinical and metabolic aspects of glucagonoma .", "[ Diagnosis and treatment of glucagonoma : report of one case ] .", "The histological pattern of vacuolation and epidermal necrosis should arouse suspicion of pancreatic glucagonoma .", "Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report.", "Rare presentation of endocrine pancreatic tumor : a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema .", "Suspicion of glucagonoma is based on characteristic presentations known as \" glucagonoma syndrome \" .", "paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome , a disorder characterized by mucocutaneous rash , glucose intolerance , hypoaminoacidemia ,", "Glucagonoma is a model for studying the importance of glucagon in causing the hyperglycemia of diabetes mellitus.", "OBJECTIVE glucagonoma is a rare islet alpha-cell tumor.", "Treatment for the various dermatologic or metabolic complications of glucagonoma which include glucose intolerance, hypoproteinemia, hypocholesterolemia and anemia may not be satisfactory.", "We report a case of glucagonoma in a 55-year-old male patient with such clinical findings of necrolytic migratory erythema, diabetes mellitus, body weight loss, and anemia.", "A definite diagnosis of glucagonoma relies on pathological report , and so far no standard treatment strategy has been available for this tumor .", "with a xerosis cutis one should always exclude the possibility of a NME caused by a glucagonoma as demonstrated in this case report where the rash was wrongly attributed to an acrodermatitis", "Protein metabolism in glucagonoma Although protein wasting and reduced amino acid concentrations are common findings in glucagonoma patients , the mechanisms underlying these alterations are unclear .", "The histologic appearance and immunohistochemical staining results confirmed the diagnosis of a glucagonoma .", "Therefore , we studied basal postabsorptive leucine , phenylalanine and tyrosine turnover following L-[D3]-Leucine , L-[D5]-Phenylalanine and L-[D2]-Tyrosine i. v. infusions in one male and one female patient with glucagonoma , compared with healthy control volunteers .", "which was resected . The histopathological findings were compatible with a diagnosis of glucagonoma , as confirmed by immunohistochemistry . Skin symptoms disappeared 10 days after the tumor", "CONCLUSION The diagnosis of glucagonoma is often delayed.", "procedure and 3 years later , the patient is well with no sign of recurrence of TTP or glucagonoma . To our knowledge , this represents the first documented case of a non - secreting benign", "and splenopancreatectomy was performed . The pathological diagnosis was benign glucagonoma . The hematological symptoms resolved completely after the procedure and 3 years later , the", "pattern of vacuolation and epidermal necrosis should arouse suspicion of pancreatic glucagonoma .", "The pathological diagnosis was benign glucagonoma .", "Study of patients with glucagonoma does suggest that glucagon has some role in the etiology of hyperglycemia in diabetic states ; however , as in studies on diabetes , investigations on glucagonoma do not demonstrate that glucagon has a primary role in producing severe glucose intolerance .", "Glucagonoma is often found in the pancreatic body and/or tail and is usually large enough to be localized by computed tomography.", "NME is a pathognomonic feature of a glucagonoma.", "The hematological symptoms resolved completely after the procedure and 3 years later, the patient is well with no sign of recurrence of TTP or glucagonoma.", "The features of 41 proven or suspected cases of pancreatic glucagonoma and one possible case of renal glucagonoma have been reviewed.", "Glucagonoma is a very rare endocrine pancreatic tumor.", "The average size of clinically detected glucagonomas was 5.8 cm, and 54.7% of them exhibited metastasis.", "METHODS We provide a literature review and present the clinical findings , pertinent laboratory data , and results of related studies in a patient with a glucagonoma .", "Diagnosis of glucagonoma has usually been delayed.", "Diagnostic challenge of glucagonoma : case report and literature review .", "Plasma leucine , phenylalanine and tyrosine rates of appearance in patients with glucagonoma were similar to values in the control subjects , except leucine rate of appearence in the female patient with glucagonoma ( + & 30 % , d > 2 SD ) .", "This is the first case of a pancreatic glucagonoma metastasising to the ovary 5 years after radical distal pancreatosplenectomy.", "Necrolytic migratory erythema and pancreatic glucagonoma .", "In contrast localised glucagonoma without metastatic spread may have prolonged disease free survival with radical resectional surgery."], "par_relations": ["Carcinoma, Islet Cell"], "chd_relations": [], "syn_relations": ["Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma", "Glucagonoma"], "sib_relations": ["Necrolytic Migratory Erythema", "Vipoma", "Gastrinoma", "Somatostatinoma"], "wiki_entities": ["Glucagonoma", "Necrolytic migratory erythema", "Alpha cell", "Endocrine oncology", "NME (disambiguation)", "Endocrine disease", "Chancre", "Angular cheilitis", "Marie Antoinette syndrome", "Thrombotic thrombocytopenic purpura"], "mesh_synonynms": ["alpha cell tumor", "syndrome, glucagonoma", "syndromes, glucagonoma", "alpha-cell tumor", "alpha-cell adenoma", "adenoma, alpha-cell", "adenoma, alpha cell", "adenomas, alpha-cell", "tumors, alpha-cell", "glucagonoma syndrome", "glucagonoma syndromes", "tumor, alpha-cell", "alpha-cell adenomas", "alpha-cell tumors", "glucagonomas", "glucagonoma"], "dbpedia_synonyms": ["pseudoglucagonoma syndrome", "necrolytic migratory erythema"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0001387", "canonical_name": "Joint stiffness", "aliases": ["joint stiffness", "stiff joints", "stiff joint"], "definition": "Joint stiffness may be either the symptom of pain on moving a joint, the symptom of loss of range of motion or the physical sign of reduced range of motion.", "other_contexts": ["Passive resistive torque (PRT) of the ankle joint was measured to evaluate joint stiffness.", "CONCLUSIONS Joint stiffness is associated with HRQOL.", "Joint stiffness was assessed at the neck, low back, shoulder, elbow, hand or wrist, hip, knee, and ankle or feet; the duration of joint stiffness was also evaluated.", "There was a significant positive correlation between the ankle joint stiffness during the eccentric phase and ankle joint torque at midpoint in rebound jumps.", "Passive tension of the exposed gastrocnemius muscle was also measured when the maximum value of joint stiffness was obtained.", "Joint stiffness at two or more sites and at each site had a meaningful impact on PCS.", "Simulation studies of a stiffness model, whose parameters varied with time as is expected during walking, demonstrated that the new algorithm accurately tracked the changes in dynamic joint stiffness using as little as 40 gait cycles.", "These results suggested that for the rebound jumps to be effective, it may be important to enhance the ankle joint torque at midpoint by greater ankle joint stiffness during the eccentric phase.", "OBJECTIVES To measure passive knee joint stiffness and pain in participants with and without patellofemoral pain syndrome (PFPS) and to determine the relationship between mechanical knee joint stiffness, self-reported stiffness, and pain.", "We calculated the physical component summary scores (PCS) and mental component summary scores (MCS) from SF-12 and the EQ-5D index from EQ-5D. RESULTS The prevalence of joint stiffness was 54.0%.", "No significant relationships were observed between walking knee joint stiffness and quadriceps strength, knee joint laxity or varus knee malalignment.", "Dynamic joint stiffness is composed of intrinsic and reflex mechanisms that act and change together, so that nonlinear, mathematical models and specialized system identification techniques are necessary to estimate their relative contributions to overall joint stiffness.", "However, ankle joint stiffness is possibly increased in 5RJ because the restraint to defend the tendomuscular system is reduced by prediction or adaptation to the stretch load because it is a continuous jump.", "This study examined the effects of an imposed forefoot strike (FFS) on RE and ankle and knee joint stiffness before and after a long run in habitual rearfoot strike (RFS) runners.", "Measurement of gastrocnemius muscle elasticity by shear wave elastography: association with passive ankle joint stiffness and sex differences Passive joint stiffness is an important quantitative measure of flexibility, but is affected by muscle volume and all of the anatomical structures located within and over the joint.", "Further investigations of the temporal relationship between self-reported knee joint instability and walking knee joint stiffness are warranted.", "The MG elasticity was not significantly associated with joint stiffness in PF or NE, but it was significantly associated with joint stiffness in DF.", "Knee flexion range of motion, knee extensor moment and ankle joint stiffness were lower while plantarflexor moment and knee joint stiffness were greater during imposed FFS compared with RFS.", "Joint stiffness that lasted for 30min or more was meaningfully associated with low PCS and EQ-5D scores (PCS, 30-60min: beta=-6.122, P<0.05; >60min: beta=-5.962, P<0.01; EQ-5D index, 30-60min: beta=-0.068, P<0.01; >60min: beta=-0.070, P<0.01).", "Consequently, during movement, when joint position and torque change rapidly, dynamic joint stiffness will be Time-Varying (TV).", "Research has focused on the effects of acute strike pattern modifications on lower extremity joint stiffness and running economy (RE).", "When compared with RDJ30 and RDJ50, 5RJ displayed significantly higher jumping height, ankle joint torque at midpoint, ankle joint stiffness during the eccentric phase, and integrated EMG (IEMG) of GAS and SOL.", "In addition to kinematic and kinetic variables, dynamic hip joint stiffness which was calculated as an angular coefficient of linear regression of the plot of the hip flexion moment vs. hip extension angle during the late stance of gait, was measured.", "Muscle elasticity, measured independent of the confounding effects of muscle volume and the other nearby anatomical structures, is associated with passive joint stiffness in the joint position where the muscle is sufficiently lengthened, but does not vary by sex in any joint position tested.", "The results show that when gravity and joint stiffness forces were adaptively compensated the reachable workspace of the user was increased more than 50% compared to the workspace reached when only constant gravity compensation was provided.", "Further, joint stiffness that lasted over 60min extended over MCS (MCS, >60min: beta=-3.212, P<0.05).", "We propose two simple, effective and adaptive methods for the compensation of forces resulting from gravity and joint stiffness.", "Quasi-stationary experiments have demonstrated that dynamic joint stiffness is heavily modulated by joint position and voluntary torque.", "Application to the Ankle Joint Dynamic joint stiffness determines the relation between joint position and torque, and plays a vital role in the control of posture and movement.", "FINDINGS Dynamic hip joint stiffness was 47% higher on the side with the more pronounced limp in patients with bilateral arthroplasty than in healthy controls.", "The purposes of this study were to investigate firstly, the ankle joint stiffness during the eccentric phase in rebound jumps, and secondly, the effect of ankle joint stiffness during the eccentric phase on ankle joint torque at midpoint.", "OBJECTIVE This study aimed to examine the association between joint stiffness and health-related quality of life (HRQOL) in community-dwelling older adults. METHODS Participants in this cross-sectional study were 530 Japanese community-dwelling older adults (mean age, 73.9 years; women, 64.3%).", "Knee joint stiffness was calculated during the weight-acceptance phase of gait as the change in the external knee joint moment divided by the change in the knee flexion angle.", "Individuals with PFPS perceive increased knee stiffness after sitting, but may misinterpret the sensation of pain as joint stiffness.", "The effects of altering hip joint stiffness on gait biomechanics need to be explored.", "Joint stiffness and pain in individuals with patellofemoral syndrome.", "Association between joint stiffness and health-related quality of life in community-dwelling older adults.", "Increased walking knee joint stiffness has been reported in patients with knee osteoarthritis (OA) as a compensatory strategy to improve knee joint stability.", "Effect of ankle joint stiffness during eccentric phase in rebound jumps on ankle joint torque at midpoint.", "The unstable group walked with lower knee joint stiffness (p=0.01), mainly due to smaller heel-contact knee flexion angles (p<0.01) and greater knee flexion excursions (p<0.01) compared to their knee stable counterparts.", "The sensation of joint stiffness is frequently observed after eccentric contractions (ECs) in human, but the joint stiffness of animals after ECs has not been examined previously.", "Due to the disuse of the arms, passive joint stiffness increases and providing only gravity compensation becomes insufficient to support the arm function.", "Model- and calibration-based strategies for the estimation of gravity and joint stiffness forces lack adaptability and are time consuming since they are measurement dependent.", "A critical aspect of force-based interfaces, to properly detect the movement intention of the user, is the ability to distinguish the voluntary forces from any other force, such as gravity or joint stiffness forces.", "The passive ankle joint stiffness and tissue elasticity of the medial gastrocnemius (MG) were quantified with the ankle in 30° plantar flexion (PF), a neutral anatomical position (NE), and 20° dorsiflexion (DF).", "Effects of acute eccentric contractions on rat ankle joint stiffness.", "This study tested whether a bout of ECs affects rat ankle joint stiffness.", "INTERPRETATION We found that dynamic hip joint stiffness was an important factor in assessing relationships between hip impairments and dynamics in other joints, especially in patients with bilateral total hip arthroplasty.", "Dynamic hip joint stiffness in individuals with total hip arthroplasty: relationships between hip impairments and dynamics of the other joints.", "Hence, joint stiffness compensation is also required, for which the use of active arm supports is essential.", "The long run did not influence the difference in ankle and knee joint stiffness between strike patterns.", "We determined how muscle elasticity, as measured using shear wave elastography, is associated with passive joint stiffness and patient sex.", "We also evaluate muscle passive tension in the rat hindlimb to examine the relationships of ankle joint stiffness with muscle passive tension.", "BACKGROUND Little is known about hip joint stiffness during walking (dynamic joint stiffness) and the effect of hip impairments on biomechanical alterations of other joints in patients with total hip arthroplasty.", "The algorithm combines ensemble and deterministic approaches for estimation of TV systems; and uses a TV, parallel-cascade, nonlinear system identification technique to separate overall dynamic joint stiffness into intrinsic and reflex components from position and torque records.", "However, presence of episodic self-reported knee instability in a large subgroup of patients with knee OA may be a sign of inadequate walking knee joint stiffness.", "This paper introduces a new method to quantify the TV intrinsic and reflex components of dynamic joint stiffness during movement.", "RESULTS Sitting for 20 minutes did not induce significant changes in mechanical knee joint stiffness.", "In the same patients, increased dynamic hip joint stiffness was significantly associated especially with increased ankle plantarflexion moment on the ipsilateral side.", "Alterations in walking knee joint stiffness in individuals with knee osteoarthritis and self-reported knee instability.", "Mechanical passive knee joint stiffness was calculated using the damped natural frequency of oscillation of the lower leg while sitting.", "The changes in joint stiffness and muscle passive tension after ECs have been examined independently and the direct relationships have not been examined previously.", "Adaptive gravity and joint stiffness compensation methods for force-controlled arm supports People with muscular weakness can benefit from arm supports that compensate the weight of their arms.", "Assessing joint stiffness and intervention could be beneficial for HRQOL.", "A significant correlation (r = 0.70, P<.01) was found between self-reported stiffness and pain in participants with PFPS; however, no significant relationship was observed between mechanical and self-reported knee joint stiffness.", "BACKGROUND Patients with PFPS complain of knee joint stiffness and pain, but no research has quantified both of these characteristics in this population.", "The objective of this work was to evaluate the differences in walking knee joint stiffness in patients with knee OA with and without self-reported instability and examine the relationship between walking knee joint stiffness with quadriceps strength, knee joint laxity, and varus knee malalignment.", "Dynamic joint stiffness can be quantified during quasi-stationary conditions using disturbance experiments, where small position perturbations are applied to the joint and the torque response is recorded.", "Estimation of Time-Varying, Intrinsic and Reflex Dynamic Joint Stiffness during Movement.", "CONCLUSIONS Despite frequent complaints of joint stiffness, the knees of individuals with PFPS do not appear physiologically stiffer than those of control subjects.", "Joint stiffness and running economy during imposed forefoot strike before and after a long run in rearfoot strike runners.", "No significant difference in passive joint stiffness by sex was observed with the ankle in PF, but significantly greater passive ankle joint stiffness in men than in women was observed in NE and DF.", "Reduced walking knee joint stiffness appears to be associated with episodic knee instability and independent of quadriceps muscle weakness, knee joint laxity or varus malalignment.", "These results also suggested that compared to 5RJ, RDJ30 and RDJ50 may reduce ankle joint stiffness in order to protect the tendomuscular system from the stretch load."], "par_relations": ["Limitation of joint mobility"], "chd_relations": ["Stiff shoulders", "Stiff interphalangeal joints", "Generalized morning stiffness"], "syn_relations": ["Joint stiffness", "Joint stiffness", "Joint stiffness", "Joint stiffness"], "sib_relations": ["Elbow ankylosis", "Decreased movement range in interphalangeal joints", "Limited wrist movement", "Limited interphalangeal movement", "Limited elbow movement", "Limited shoulder movement", "Limited hip movement", "Scapulohumeral synostosis", "Limitation of knee mobility", "Limitation of movement at ankles", "Ankylosis of feet small joints", "Restricted chest movement", "Restricted large joint movement"], "wiki_entities": ["Joint stiffness", "Osteoarthritis", "Arthritis", "Hallux rigidus", "Anti-roll bar", "Neural control of limb stiffness", "Knee effusion", "Range of motion", "Spondylitis", "Tenosynovitis"], "mesh_synonynms": [], "dbpedia_synonyms": ["morning stiffness", "stiffness of joint", "loss of range of motion of a joint"]}, "target_ent": {"research_entity_id": "OMIM:MTHU020682", "canonical_name": "Joint stiffness (neck, shoulder, elbow, hips)", "aliases": ["joint stiffness (neck, shoulder, elbow, hips)"], "definition": "The elbow includes prominent landmarks such as the olecranon (the bony prominence at the very tip of the elbow), the elbow pit, the lateral and medial epicondyles, and the elbow joint.", "other_contexts": [], "par_relations": ["SKELETAL"], "chd_relations": [], "syn_relations": [], "sib_relations": ["KNIEST-LIKE DYSPLASIA WITH PURSED LIPS AND ECTOPIA LENTIS"], "wiki_entities": ["Elbow", "Equine conformation", "GALS screen", "Professional wrestling attacks", "Ultimate Soldier", "Jumping position", "Index of trauma & orthopaedics articles", "Orthopedic surgery", "Back (horse)", "List of ICD-9 codes 710–739: diseases of the musculoskeletal system and connective tissue"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "MSH:D010996", "canonical_name": "Pleural Effusion", "aliases": ["pleural effusion", "effusions, pleural", "effusion, pleural", "pleural effusions"], "definition": "A pleural effusion is excess fluid that accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs.", "other_contexts": [], "par_relations": ["Pleural Diseases"], "chd_relations": ["Pleural Effusion, Malignant"], "syn_relations": ["Pleural Effusion", "Pleural Effusion", "Pleural Effusion", "Pleural Effusion", "Pleural Effusion", "Pleural Effusion"], "sib_relations": ["Exudates and Transudates", "Thoracentesis", "Yellow Nail Syndrome", "Chylothorax", "Empyema, Pleural", "Hemopneumothorax", "Hemothorax", "Hydropneumothorax", "Hydrothorax", "Pleural Neoplasms", "Pleurisy", "Pneumothorax", "Tuberculosis, Pleural"], "wiki_entities": ["Pleural effusion", "Malignant pleural effusion", "Pleural empyema", "Pleural cavity", "Thoracentesis", "Parapneumonic effusion", "Yellow nail syndrome", "Effusion", "Costodiaphragmatic recess", "Hemothorax"], "mesh_synonynms": ["effusions, pleural", "effusion, pleural", "pleural effusion", "pleural effusions"], "dbpedia_synonyms": ["light's criteria", "pleural hemorrhage", "pulmonary effusion", "plural effusion"]}, "target_ent": {"research_entity_id": "OMIM:MTHU012521", "canonical_name": "Pleural effusion", "aliases": ["pleural effusion"], "definition": "A pleural effusion is excess fluid that accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs.", "other_contexts": [], "par_relations": ["Lung"], "chd_relations": [], "syn_relations": [], "sib_relations": ["MALIGNANT ATROPHIC PAPULOSIS", "HEMOCHROMATOSIS, TYPE 1", "OSTEOCHONDRODYSPLASIA, COMPLEX LETHAL, SYMOENS-BARNES-GISTELINCK TYPE"], "wiki_entities": ["Pleural effusion", "Malignant pleural effusion", "Pleural empyema", "Pleural cavity", "Thoracentesis", "Parapneumonic effusion", "Yellow nail syndrome", "Effusion", "Costodiaphragmatic recess", "Hemothorax"], "mesh_synonynms": ["effusions, pleural", "effusion, pleural", "pleural effusions"], "dbpedia_synonyms": ["light's criteria", "pleural hemorrhage", "pulmonary effusion", "plural effusion"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0012724", "canonical_name": "Upper eyelid edema", "aliases": ["puffiness of upper eyelid", "swelling of upper eyelid", "cellulitis of upper eyelid", "upper eyelid edema", "fullness of upper eyelid"], "definition": "An eyelid is a thin fold of skin that covers and protects the human eye.", "other_contexts": [], "par_relations": ["Palpebral edema"], "chd_relations": [], "syn_relations": ["Upper eyelid edema", "Upper eyelid edema", "Upper eyelid edema", "Upper eyelid edema", "Upper eyelid edema", "Upper eyelid edema", "Upper eyelid edema", "Upper eyelid edema"], "sib_relations": ["Blepharochalasis", "Lower eyelid edema"], "wiki_entities": ["Eyelid", "Ptosis (eyelid)", "Periorbital puffiness", "Blepharochalasis", "Persistent edema of rosacea", "Lid lag", "Ascher's syndrome", "Graves' ophthalmopathy", "Bimatoprost", "GM1 gangliosidoses"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU010689", "canonical_name": "Puffiness of hands", "aliases": ["puffiness of hands"], "definition": "\"The Puffy Shirt\" is the second episode of the fifth season of the American NBC sitcom Seinfeld.", "other_contexts": [], "par_relations": ["Hands"], "chd_relations": [], "syn_relations": [], "sib_relations": ["NEU-LAXOVA SYNDROME 1"], "wiki_entities": ["The Puffy Shirt", "Charles Puffy", "Hi Hi Puffy AmiYumi: The Genie and the Amp", "Sean Combs", "Turner syndrome", "Mike Bordin", "List of Hi Hi Puffy AmiYumi episodes", "Thyroiditis", "Accounting (video game)", "The Poor of New York"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HPO:HP:0002140", "canonical_name": "Ischemic stroke", "aliases": ["ischemic stroke"], "definition": "Stroke is a medical condition in which poor blood flow to the brain results in cell death.", "other_contexts": ["acid and homovanillic acid in the urine as potential prognostic biomarkers in ischaemic stroke patients . BACKGROUND Suitable biomarkers that have prognostic values are one of the key points of", "biomarkers that have prognostic values are one of the key points of interest in ischaemic stroke . Increased sympathetic nervous system activity in ischaemic stroke causes multiple local and", "There has been a substantial and significant increase in patients hospitalized for ischaemic stroke with co - existing HIV infection . However , little is known about the mechanism of stroke in", "infarct topography of naturally occurring ischaemic stroke in pet dogs with human ischaemic stroke . METHODS Medical records and magnetic resonance imaging ( MRI ) of 27 dogs with spontaneous", "+ ve ischaemic stroke patients with HIV - ve and HIV + ve patients with and without ischaemic stroke respectively . METHODS A matched case control study in which a total of 52 HIV + ve patients with", "and with multiple risk factors , non - AF patients may have a risk of incident ischaemic stroke that is comparable or even higher than patients with AF , suggesting that the incremental stroke", "association for LRP6 rs2075241 was observed at a similar magnitude across ischaemic stroke subtypes , whilst the effects of rs23022685 , rs10492120 and rs10743980 were most apparent for", "After Ischaemic Stroke OBJECTIVES To determine the incidence of brain edema after ischaemic stroke and its impact on the outcome of patients in the acute phase of ischaemic stroke . PATIENTS AND", "and homovanillic acids positively correlated with functional outcome of ischaemic stroke . Favorable outcomes correlated with decreased values , on contrary to increased values , which", "METHODS A matched case control study in which a total of 52 HIV + ve patients with ischaemic stroke were prospectively compared with control groups for the presence of protein S , protein C", "of interest in ischaemic stroke . Increased sympathetic nervous system activity in ischaemic stroke causes multiple local and systemic effects that can be detrimental to the outcome . The mechanism", "the association between serum 25-hydroxyvitamin D levels and clinical outcomes of ischaemic stroke in the 3-month period of follow - up in all patients and in different lipid - level subgroups .", "ischaemic stroke . RESULTS In the Caucasian series , significant associations with ischaemic stroke were observed for LRP6 rs2075241 [ odds ratio ( OR ) 0.42 , P = 0.023 ] , rs2302685 ( OR 0.44 , P =", "ischaemic stroke . PATIENTS AND METHODS We retrospectively analyzed 114 patients . Ischaemic stroke and brain edema are verified by computed tomography . The severity of stroke was determined by", "Medical records and magnetic resonance imaging ( MRI ) of 27 dogs with spontaneous ischaemic stroke were retrospectively investigated with respect to clinical symptoms and infarct topography .", "37months . The future symptomatic ICH rate was 1.6% ( 16/990 ) , while recurrent ischaemic stroke rate was 5.9% ( 58/990 ) . Baseline CMB presence was associated with increased risk of symptomatic", "therapy . Amongst patients with no antithrombotic therapy , annual incidence of ischaemic stroke in PD patients was comparable with those non - CKD counterparts ( 9.32 vs. 9.30%/year ) . Similar", "cardiovascular risk factors ( besides AF ) contributes to a greater risk for ischaemic stroke , especially in the elderly population . If elderly and with multiple risk factors , non - AF", "ischaemic stroke was calculated amongst the individuals with no prior history of ischaemic stroke , in relation to age groups ( aged < 65 , 65 - 74 , ≥ 75 years old ; n = 348,431 , n = 56,952 , n =", "Spontaneously occurring ischaemic stroke in dogs share characteristics with human ischaemic stroke in terms of clinical symptoms and infarct topography . Investigating pet dogs with spontaneous", "Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation.", "According to multivariate Cox analysis, the strong independent risk factor for ischemic strokes in HCM was AF (p < 0.01), whereas in patients with AF they were HCM (p < 0.01) and age (p < 0.01).", "risk factors is unclear . In an individual patient with AF the mechanism of ischaemic stroke may be related directly to AF itself or to risk factors associated with AF . It was this study 's", "A total of 3181 ischaemic patients from China Antihypertensive Trial in Acute Ischaemic Stroke were included in this study and their baseline serum 25-hydroxyvitamin D levels were tested . They", ",242 ( 3.1% ) ischaemic strokes after 64,834 person - years follow - up . Overall , ischaemic stroke incidence ( per 100 person - years ) was 0.35 ( 95%CI 0.34 - 0.35 ) in the non - AF population and", "up for death , major disability and vascular events for 3 months after acute ischaemic stroke . A multivariable logistic model was used to evaluate the association between serum 25-", "of LRP1 and LRP6 gene variants with risk of ischaemic stroke as part of the Ischemic Stroke Genetics Study ( ISGS ) . METHODS A Caucasian series ( 434 stroke patients , 319 controls ) and an", "Primary endpoints (ischemic strokes or cardiac death, whichever occurred first) and ischemic strokes were examined by Kaplan-Meier curves.", "( 9.32 vs. 9.30%/year ) . Similar to non - CKD patients , annual incidence of ischaemic stroke increased with increasing CHA2DS2-VASc score ( CHA2DS2-VASc = 0 - 1 : 5.76 vs. 5.70%/year , P = 1.0", "- analysis of cohorts and anticoagulation decision schema . INTRODUCTION Whether ischaemic stroke patients with atrial fibrillation ( AF ) and cerebral microbleeds ( CMBs ) on MRI can be safely", "The clinical outcome and the incidence of ischemic strokes in patients with hypertrophic cardiomyopathy (HCM) with and without atrial fibrillation (AF) were examined.", "the effect of serum vitamin D especially its deficiency on the global outcome of ischaemic stroke stratified by individual lipid component level . METHODS A total of 3181 ischaemic patients from", "hyperhomocysteinaemia or protein S deficiency in HIV + ve patients with or without ischaemic stroke . Protein C deficiency was not noted to be significantly different between the cases and the two", "These results suggest that incidence of ischemic strokes in HCM is markedly increased if complicated by AF as compared with that in patients with AF alone.", "Similarly, the frequency of ischemic strokes in HCM was also much higher with AF than without AF (23.0% vs 5.9% at 5 years, p < 0.01).", "of these compounds in the urine is an easily available prognostic tool for the ischaemic stroke outcome , while also influencing potential therapeutic changes .", "whether these compounds can be used as potential prognostic biomarkers in ischaemic stroke , as a unique insight into the activity of the sympathetic nervous system . METHODS Urine samples", "atrial fibrillation ( AF ) . Our objective was to determine the risk of ischaemic stroke in a ' real - world ' cohort of PD patients with AF , and clinical benefit or harm of aspirin and", "in LRP1 and LRP6 has been linked with various factors that are related to risk of ischaemic stroke . The aim of this study was to examine the association of LRP1 and LRP6 gene variants with risk of", "to explore the association of hypercoagulability state in HIV + ve patients with ischaemic stroke . This was achieved by comparing hypercoagulability state markers between HIV + ve ischaemic", "no effect on survival in the acute phase . The existence of brain edema in acute ischaemic stroke significantly influence the degree of neurological deficit .", "associated with AF . It was this study 's objective to investigate incident ischaemic stroke in relation to age and increasing cardiovascular risk factor(s ) , and the incremental impact of", ". This was achieved by comparing hypercoagulability state markers between HIV + ve ischaemic stroke patients with HIV - ve and HIV + ve patients with and without ischaemic stroke respectively .", "approaches are therefore desirable . As humans , pet dogs suffer from spontaneous ischaemic stroke and may hence offer new ways of studying genuine stroke injury mechanisms . AIMS The objective of", "- up . RESULTS Four studies , with slightly heterogeneous design , including 990 ischaemic stroke patients were pooled in a meta - analysis ( crude CMBs prevalence : 25% ; 95%CI : 17%-33% ) . The", "was to compare clinical symptoms and infarct topography of naturally occurring ischaemic stroke in pet dogs with human ischaemic stroke . METHODS Medical records and magnetic resonance imaging (", "6 variants and three LRP1 variants were genotyped and assessed for association with ischaemic stroke . RESULTS In the Caucasian series , significant associations with ischaemic stroke were observed", "of the sympathetic nervous system . METHODS Urine samples of 96 patients with ischaemic stroke and transitory ischaemic attacks were analysed . Values of vanillylmandelic and homovanillic acids", "were reported in 15 of 27 cases ( 56% ) . CONCLUSIONS Spontaneously occurring ischaemic stroke in dogs share characteristics with human ischaemic stroke in terms of clinical symptoms and", "a higher risk of ICH . CONCLUSION In CKD patients on PD with AF , who had similar ischaemic stroke risk as non - CKD counterparts , warfarin therapy is associated with reduction in risk of", "matched for age and sex HIV - ve and HIV + ve patients with and without ischaemic stroke respectively . Data was analysed in contingency tables using Paired t- test , Chi square and", "( hypertension , vascular disease , diabetic , or heart failure ) had ischaemic stroke rates similar to an AF population with CHA2DS2-VASc ≥ 4 . In both non - AF and AF populations ,", "using Paired t- test , Chi square and conditional logistic regression . RESULTS Ischaemic stroke of undetermined aetiology occurred more frequently in HIV + ve compared to HIV - ve patients ( p <", "age 60 years ; 880 with AF , vs 424,720 non - AF ] , there were 13,242 ( 3.1% ) ischaemic strokes after 64,834 person - years follow - up . Overall , ischaemic stroke incidence ( per 100 person -", "non - CKD counterparts , warfarin therapy is associated with reduction in risk of ischaemic stroke without a higher risk of ICH .", "10492120 ( OR 0.62 , P = 0.036 ) and rs10743980 ( OR 0.66 , P = 0.037 ) . Risk of ischaemic stroke was significantly lower for carriers of any of these five protective LRP6 variants ( 24.0% of", "AF on warfarin , is associated with a 4-fold increase in subsequent ICH ( but not ischaemic stroke ) risk ( Class III evidence ) . These pooled estimates are useful for future trials design . We", ". RESULTS Vitamin D deficiency was associated with poor clinical outcomes only in ischaemic stroke patients with high density lipoprotein cholesterol ( HDLC ) < 1.04 mmol / l rather than all", "- 11.25 ; p=0.005 ) . There was no association between CMBs presence and recurrent ischaemic stroke risk . CONCLUSION We have shown that the presence of CMBs in cohorts of ischaemic stroke patients ,", "study provide evidence that LRP6 and LRP1 variants may be associated with risk of ischaemic stroke . Validation in larger studies is warranted .", "Vitamin D deficiency may be merely an independent risk factor of poor prognosis in ischaemic stroke patients with low HDLC level .", "significant correlation between brain edema and survival in patients after acute ischaemic stroke . Patients with brain edema had a significantly higher degree of neurological deficit as at", "clinical symptoms and infarct topography . Investigating pet dogs with spontaneous ischaemic stroke may provide an alternative approach to the research of stroke injury mechanisms as they occur", "( p = 0.04 , p = 0.004 ) . CONCLUSION The cerebral edema is common after acute ischaemic stroke and no effect on survival in the acute phase . The existence of brain edema in acute ischaemic", "factors . How atrial fibrillation ( AF ) incrementally contributes to the risk for ischaemic stroke with increasing age and multiple cardiovascular risk factors is unclear . In an individual patient", "fibrillation . An analysis of 425,600 Chinese individuals without prior stroke . Ischaemic stroke risk rises with the increasing cardiovascular risk factors . How atrial fibrillation ( AF )", "study was to examine the association of LRP1 and LRP6 gene variants with risk of ischaemic stroke as part of the Ischemic Stroke Genetics Study ( ISGS ) . METHODS A Caucasian series ( 434 stroke", "to investigated the association between CMBs presence at baseline MRI and ICH or ischaemic stroke during follow - up . RESULTS Four studies , with slightly heterogeneous design , including 990", "indicate that a lower vitamin D level is associated with a higher risk of poor ischaemic stroke prognosis . Whether this association is affected by lipid levels is unclear . Our aim was to", "stroke risk . CONCLUSION We have shown that the presence of CMBs in cohorts of ischaemic stroke patients , most with AF on warfarin , is associated with a 4-fold increase in subsequent ICH ( but", "study of Chinese patients with non - valvular AF . Hospitalizations with ischaemic stroke and intracranial haemorrhage ( ICH ) were recorded . Of 9810 patients from a hospital - based AF", "ischaemic stroke and its impact on the outcome of patients in the acute phase of ischaemic stroke . PATIENTS AND METHODS We retrospectively analyzed 114 patients . Ischaemic stroke and brain edema", "more than 10 million individuals , for the years 2001 to 2012 . The rate of ischaemic stroke was calculated amongst the individuals with no prior history of ischaemic stroke , in relation to", "kidney disease undergoing peritoneal dialysis . AIMS Little is known about the ischaemic stroke risk and benefit of warfarin therapy for stroke prevention in chronic kidney disease ( CKD )", "= 0.78 ) . Amongst PD patients , warfarin therapy was associated with lower risk of ischaemic stroke compared with aspirin [ Hazard ratio ( HR ) : 0.16 , 95% confidence interval ( CI ) : 0.04 - 0.66 ,", "deficiency and Hyperhomocysteinaemia were more prominent in HIV + ve than HIV - ve ischaemic stroke patients ( P = 0.011 ) . There was no difference in the presence of hyperhomocysteinaemia or"], "par_relations": ["Stroke", "Cerebral ischemia"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Transient ischemic attack", "Stroke-like episodes"], "wiki_entities": ["Stroke", "Transient ischemic attack", "Animal model of ischemic stroke", "Ischemia", "Tissue plasminogen activator", "Cerebral hypoxia", "National Institutes of Health Stroke Scale", "Watershed stroke", "Silent stroke", "Ischemic cascade"], "mesh_synonynms": [], "dbpedia_synonyms": ["stroke"]}, "target_ent": {"research_entity_id": "OMIM:MTHU000098", "canonical_name": "Ischemic stroke", "aliases": ["ischemic stroke"], "definition": "Stroke is a medical condition in which poor blood flow to the brain results in cell death.", "other_contexts": ["biomarkers that have prognostic values are one of the key points of interest in ischaemic stroke . Increased sympathetic nervous system activity in ischaemic stroke causes multiple local and", "acid and homovanillic acid in the urine as potential prognostic biomarkers in ischaemic stroke patients . BACKGROUND Suitable biomarkers that have prognostic values are one of the key points of", "There has been a substantial and significant increase in patients hospitalized for ischaemic stroke with co - existing HIV infection . However , little is known about the mechanism of stroke in", "infarct topography of naturally occurring ischaemic stroke in pet dogs with human ischaemic stroke . METHODS Medical records and magnetic resonance imaging ( MRI ) of 27 dogs with spontaneous", "+ ve ischaemic stroke patients with HIV - ve and HIV + ve patients with and without ischaemic stroke respectively . METHODS A matched case control study in which a total of 52 HIV + ve patients with", "association for LRP6 rs2075241 was observed at a similar magnitude across ischaemic stroke subtypes , whilst the effects of rs23022685 , rs10492120 and rs10743980 were most apparent for", "and with multiple risk factors , non - AF patients may have a risk of incident ischaemic stroke that is comparable or even higher than patients with AF , suggesting that the incremental stroke", "After Ischaemic Stroke OBJECTIVES To determine the incidence of brain edema after ischaemic stroke and its impact on the outcome of patients in the acute phase of ischaemic stroke . PATIENTS AND", "and homovanillic acids positively correlated with functional outcome of ischaemic stroke . Favorable outcomes correlated with decreased values , on contrary to increased values , which", "METHODS A matched case control study in which a total of 52 HIV + ve patients with ischaemic stroke were prospectively compared with control groups for the presence of protein S , protein C", "Similarly , the frequency of ischemic strokes in HCM was also much higher with AF than without AF ( 23.0% vs 5.9% at 5 years , p < 0.01 ) .", "of interest in ischaemic stroke . Increased sympathetic nervous system activity in ischaemic stroke causes multiple local and systemic effects that can be detrimental to the outcome . The mechanism", "ischaemic stroke . RESULTS In the Caucasian series , significant associations with ischaemic stroke were observed for LRP6 rs2075241 [ odds ratio ( OR ) 0.42 , P = 0.023 ] , rs2302685 ( OR 0.44 , P =", "These results suggest that incidence of ischemic strokes in HCM is markedly increased if complicated by AF as compared with that in patients with AF alone .", "Medical records and magnetic resonance imaging ( MRI ) of 27 dogs with spontaneous ischaemic stroke were retrospectively investigated with respect to clinical symptoms and infarct topography .", "37months . The future symptomatic ICH rate was 1.6% ( 16/990 ) , while recurrent ischaemic stroke rate was 5.9% ( 58/990 ) . Baseline CMB presence was associated with increased risk of symptomatic", "cardiovascular risk factors ( besides AF ) contributes to a greater risk for ischaemic stroke , especially in the elderly population . If elderly and with multiple risk factors , non - AF", "therapy . Amongst patients with no antithrombotic therapy , annual incidence of ischaemic stroke in PD patients was comparable with those non - CKD counterparts ( 9.32 vs. 9.30%/year ) . Similar", "ischaemic stroke . PATIENTS AND METHODS We retrospectively analyzed 114 patients . Ischaemic stroke and brain edema are verified by computed tomography . The severity of stroke was determined by", "Spontaneously occurring ischaemic stroke in dogs share characteristics with human ischaemic stroke in terms of clinical symptoms and infarct topography . Investigating pet dogs with spontaneous", "According to multivariate Cox analysis, the strong independent risk factor for ischemic strokes in HCM was AF (p < 0.01), whereas in patients with AF they were HCM (p < 0.01) and age (p < 0.01).", "A total of 3181 ischaemic patients from China Antihypertensive Trial in Acute Ischaemic Stroke were included in this study and their baseline serum 25-hydroxyvitamin D levels were tested . They", "risk factors is unclear . In an individual patient with AF the mechanism of ischaemic stroke may be related directly to AF itself or to risk factors associated with AF . It was this study 's", "up for death , major disability and vascular events for 3 months after acute ischaemic stroke . A multivariable logistic model was used to evaluate the association between serum 25-", "ischaemic stroke was calculated amongst the individuals with no prior history of ischaemic stroke , in relation to age groups ( aged < 65 , 65 - 74 , ≥ 75 years old ; n = 348,431 , n = 56,952 , n =", ",242 ( 3.1% ) ischaemic strokes after 64,834 person - years follow - up . Overall , ischaemic stroke incidence ( per 100 person - years ) was 0.35 ( 95%CI 0.34 - 0.35 ) in the non - AF population and", "of LRP1 and LRP6 gene variants with risk of ischaemic stroke as part of the Ischemic Stroke Genetics Study ( ISGS ) . METHODS A Caucasian series ( 434 stroke patients , 319 controls ) and an", "Primary endpoints (ischemic strokes or cardiac death, whichever occurred first) and ischemic strokes were examined by Kaplan-Meier curves.", "( 9.32 vs. 9.30%/year ) . Similar to non - CKD patients , annual incidence of ischaemic stroke increased with increasing CHA2DS2-VASc score ( CHA2DS2-VASc = 0 - 1 : 5.76 vs. 5.70%/year , P = 1.0", "- analysis of cohorts and anticoagulation decision schema . INTRODUCTION Whether ischaemic stroke patients with atrial fibrillation ( AF ) and cerebral microbleeds ( CMBs ) on MRI can be safely", "the effect of serum vitamin D especially its deficiency on the global outcome of ischaemic stroke stratified by individual lipid component level . METHODS A total of 3181 ischaemic patients from", "hyperhomocysteinaemia or protein S deficiency in HIV + ve patients with or without ischaemic stroke . Protein C deficiency was not noted to be significantly different between the cases and the two", "of these compounds in the urine is an easily available prognostic tool for the ischaemic stroke outcome , while also influencing potential therapeutic changes .", "whether these compounds can be used as potential prognostic biomarkers in ischaemic stroke , as a unique insight into the activity of the sympathetic nervous system . METHODS Urine samples", "atrial fibrillation ( AF ) . Our objective was to determine the risk of ischaemic stroke in a ' real - world ' cohort of PD patients with AF , and clinical benefit or harm of aspirin and", "in LRP1 and LRP6 has been linked with various factors that are related to risk of ischaemic stroke . The aim of this study was to examine the association of LRP1 and LRP6 gene variants with risk of", "to explore the association of hypercoagulability state in HIV + ve patients with ischaemic stroke . This was achieved by comparing hypercoagulability state markers between HIV + ve ischaemic", "no effect on survival in the acute phase . The existence of brain edema in acute ischaemic stroke significantly influence the degree of neurological deficit .", "associated with AF . It was this study 's objective to investigate incident ischaemic stroke in relation to age and increasing cardiovascular risk factor(s ) , and the incremental impact of", "approaches are therefore desirable . As humans , pet dogs suffer from spontaneous ischaemic stroke and may hence offer new ways of studying genuine stroke injury mechanisms . AIMS The objective of", ". This was achieved by comparing hypercoagulability state markers between HIV + ve ischaemic stroke patients with HIV - ve and HIV + ve patients with and without ischaemic stroke respectively .", "was to compare clinical symptoms and infarct topography of naturally occurring ischaemic stroke in pet dogs with human ischaemic stroke . METHODS Medical records and magnetic resonance imaging (", "The clinical outcome and the incidence of ischemic strokes in patients with hypertrophic cardiomyopathy ( HCM ) with and without atrial fibrillation ( AF ) were examined .", "6 variants and three LRP1 variants were genotyped and assessed for association with ischaemic stroke . RESULTS In the Caucasian series , significant associations with ischaemic stroke were observed", "- up . RESULTS Four studies , with slightly heterogeneous design , including 990 ischaemic stroke patients were pooled in a meta - analysis ( crude CMBs prevalence : 25% ; 95%CI : 17%-33% ) . The", "of the sympathetic nervous system . METHODS Urine samples of 96 patients with ischaemic stroke and transitory ischaemic attacks were analysed . Values of vanillylmandelic and homovanillic acids", "were reported in 15 of 27 cases ( 56% ) . CONCLUSIONS Spontaneously occurring ischaemic stroke in dogs share characteristics with human ischaemic stroke in terms of clinical symptoms and", "Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation .", "a higher risk of ICH . CONCLUSION In CKD patients on PD with AF , who had similar ischaemic stroke risk as non - CKD counterparts , warfarin therapy is associated with reduction in risk of", "matched for age and sex HIV - ve and HIV + ve patients with and without ischaemic stroke respectively . Data was analysed in contingency tables using Paired t- test , Chi square and", "( hypertension , vascular disease , diabetic , or heart failure ) had ischaemic stroke rates similar to an AF population with CHA2DS2-VASc ≥ 4 . In both non - AF and AF populations ,", "using Paired t- test , Chi square and conditional logistic regression . RESULTS Ischaemic stroke of undetermined aetiology occurred more frequently in HIV + ve compared to HIV - ve patients ( p <", "age 60 years ; 880 with AF , vs 424,720 non - AF ] , there were 13,242 ( 3.1% ) ischaemic strokes after 64,834 person - years follow - up . Overall , ischaemic stroke incidence ( per 100 person -", "non - CKD counterparts , warfarin therapy is associated with reduction in risk of ischaemic stroke without a higher risk of ICH .", "10492120 ( OR 0.62 , P = 0.036 ) and rs10743980 ( OR 0.66 , P = 0.037 ) . Risk of ischaemic stroke was significantly lower for carriers of any of these five protective LRP6 variants ( 24.0% of", "AF on warfarin , is associated with a 4-fold increase in subsequent ICH ( but not ischaemic stroke ) risk ( Class III evidence ) . These pooled estimates are useful for future trials design . We", ". RESULTS Vitamin D deficiency was associated with poor clinical outcomes only in ischaemic stroke patients with high density lipoprotein cholesterol ( HDLC ) < 1.04 mmol / l rather than all", "- 11.25 ; p=0.005 ) . There was no association between CMBs presence and recurrent ischaemic stroke risk . CONCLUSION We have shown that the presence of CMBs in cohorts of ischaemic stroke patients ,", "significant correlation between brain edema and survival in patients after acute ischaemic stroke . Patients with brain edema had a significantly higher degree of neurological deficit as at", "clinical symptoms and infarct topography . Investigating pet dogs with spontaneous ischaemic stroke may provide an alternative approach to the research of stroke injury mechanisms as they occur", "study provide evidence that LRP6 and LRP1 variants may be associated with risk of ischaemic stroke . Validation in larger studies is warranted .", "Vitamin D deficiency may be merely an independent risk factor of poor prognosis in ischaemic stroke patients with low HDLC level .", "( p = 0.04 , p = 0.004 ) . CONCLUSION The cerebral edema is common after acute ischaemic stroke and no effect on survival in the acute phase . The existence of brain edema in acute ischaemic", "factors . How atrial fibrillation ( AF ) incrementally contributes to the risk for ischaemic stroke with increasing age and multiple cardiovascular risk factors is unclear . In an individual patient", "deficiency and Hyperhomocysteinaemia were more prominent in HIV + ve than HIV - ve ischaemic stroke patients ( P = 0.011 ) . There was no difference in the presence of hyperhomocysteinaemia or", "fibrillation . An analysis of 425,600 Chinese individuals without prior stroke . Ischaemic stroke risk rises with the increasing cardiovascular risk factors . How atrial fibrillation ( AF )", "stroke risk . CONCLUSION We have shown that the presence of CMBs in cohorts of ischaemic stroke patients , most with AF on warfarin , is associated with a 4-fold increase in subsequent ICH ( but", "study was to examine the association of LRP1 and LRP6 gene variants with risk of ischaemic stroke as part of the Ischemic Stroke Genetics Study ( ISGS ) . METHODS A Caucasian series ( 434 stroke", "indicate that a lower vitamin D level is associated with a higher risk of poor ischaemic stroke prognosis . Whether this association is affected by lipid levels is unclear . Our aim was to", "to investigated the association between CMBs presence at baseline MRI and ICH or ischaemic stroke during follow - up . RESULTS Four studies , with slightly heterogeneous design , including 990", "study of Chinese patients with non - valvular AF . Hospitalizations with ischaemic stroke and intracranial haemorrhage ( ICH ) were recorded . Of 9810 patients from a hospital - based AF", "ischaemic stroke and its impact on the outcome of patients in the acute phase of ischaemic stroke . PATIENTS AND METHODS We retrospectively analyzed 114 patients . Ischaemic stroke and brain edema", "more than 10 million individuals , for the years 2001 to 2012 . The rate of ischaemic stroke was calculated amongst the individuals with no prior history of ischaemic stroke , in relation to", "kidney disease undergoing peritoneal dialysis . AIMS Little is known about the ischaemic stroke risk and benefit of warfarin therapy for stroke prevention in chronic kidney disease ( CKD )", "= 0.78 ) . Amongst PD patients , warfarin therapy was associated with lower risk of ischaemic stroke compared with aspirin [ Hazard ratio ( HR ) : 0.16 , 95% confidence interval ( CI ) : 0.04 - 0.66 ,", "the association between serum 25-hydroxyvitamin D levels and clinical outcomes of ischaemic stroke in the 3-month period of follow - up in all patients and in different lipid - level subgroups ."], "par_relations": ["Central nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER", "TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 2", "TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 4", "ARTERIAL TORTUOSITY SYNDROME", "PORENCEPHALY 1"], "wiki_entities": ["Stroke", "Transient ischemic attack", "Animal model of ischemic stroke", "Ischemia", "Tissue plasminogen activator", "Cerebral hypoxia", "National Institutes of Health Stroke Scale", "Watershed stroke", "Silent stroke", "Ischemic cascade"], "mesh_synonynms": [], "dbpedia_synonyms": ["stroke"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:7587", "canonical_name": "myosin light chain 6", "aliases": ["myl6 gene", "mlc3nm", "esmlc", "myl6", "myosin light chain 6", "mlc1sm"], "definition": "Myosin light-chain kinase also known as MYLK or MLCK is a serine/threonine-specific protein kinase that phosphorylates a specific myosin light chain, namely, the regulatory light chain of myosin II.\n\n\n== Isoforms ==\nFour different MLCK isoforms exist:\nMYLK – smooth muscle\nMYLK2 – skeletal\nMYLK3 – cardiac\nMYLK4 – novel\n\n\n== Function ==\nThese enzymes are important in the mechanism of contraction in muscle.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["myosin light chain 6", "myosin light chain 6", "myosin light chain 6", "myosin light chain 6", "myosin light chain 6", "myosin light chain 6", "myosin light chain 6", "myosin light chain 6"], "sib_relations": [], "wiki_entities": ["Myosin light-chain kinase", "Myosin-light-chain phosphatase", "Myosin light chain", "Myosin", "Smooth muscle tissue", "MYL9", "Myosin-heavy-chain kinase", "MYL6", "MYL6B", "Myosin head"], "mesh_synonynms": [], "dbpedia_synonyms": ["myl6 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:609931", "canonical_name": "MYOSIN LIGHT CHAIN 6, ALKALI, SMOOTH MUSCLE AND NONMUSCLE", "aliases": ["myl6", "myosin light chain 6, alkali, smooth muscle and nonmuscle"], "definition": "Myosin light polypeptide 6 is a protein that in humans is encoded by the MYL6 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["MYOSIN LIGHT CHAIN 6, ALKALI, SMOOTH MUSCLE AND NONMUSCLE", "MYOSIN LIGHT CHAIN 6, ALKALI, SMOOTH MUSCLE AND NONMUSCLE"], "sib_relations": [], "wiki_entities": ["MYL6", "MYL6B"], "mesh_synonynms": [], "dbpedia_synonyms": ["myl6 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0010547", "canonical_name": "Muscle flaccidity", "aliases": ["muscle flaccidity"], "definition": "Flaccid paralysis is an illness characterized by weakness or paralysis and reduced muscle tone without other obvious cause (e.g., trauma).", "other_contexts": [], "par_relations": ["Muscle weakness"], "chd_relations": ["Episodic flaccid weakness"], "syn_relations": [], "sib_relations": ["Proximal muscle weakness", "Intercostal muscle weakness", "Progressive muscle weakness", "Neck muscle weakness", "Facial palsy", "Distal muscle weakness", "Diaphragmatic weakness", "Limb muscle weakness", "Generalized muscle weakness", "Fatigable weakness", "Poor head control", "Weakness of orbicularis oculi muscle", "Scapuloperoneal weakness", "Axial muscle weakness", "Limb-girdle muscle weakness", "Abdominal wall muscle weakness", "Weakness of muscles of respiration", "Bulbar palsy"], "wiki_entities": ["Flaccid paralysis", "Muscle tone", "Flaccid dysarthria", "Cholinergic crisis", "Flaccid paralysis (shooting)", "Rigor mortis", "Erection", "Lower motor neuron lesion", "Lower motor neuron", "Tetraplegia"], "mesh_synonynms": ["flaccid muscle tone", "hypotonia, muscular", "hypotonia", "neonatal hypotonia", "floppy muscle", "flaccidity, muscle", "hypotony, muscle", "muscle tone atonic", "flaccidity, muscular", "muscle hypotony", "muscle tone, decreased", "muscle hypotonia", "muscle tone, flaccid", "muscular hypotonia", "hypotonia, muscle", "muscular flaccidity", "neonatal hypotonias", "floppy muscles", "hypomyotonia", "hypotonias, neonatal", "hypotonia, neonatal", "muscular flaccidities", "muscle, floppy", "muscle tone atonics", "muscles, floppy", "decreased muscle tone", "tone atonic, muscle", "muscle tone poor", "hypotonias, unilateral", "unilateral hypotonia", "tone poor, muscle", "hypotonia, unilateral"], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "MSH:D009123", "canonical_name": "Muscle Hypotonia", "aliases": ["hypotony, muscle", "hypotonias, unilateral", "muscle tone poor", "muscular flaccidity", "floppy muscle", "muscle hypotony", "muscle tone, flaccid", "hypotonia, neonatal", "flaccid muscle tone", "hypotonia, muscle", "muscle hypotonia", "hypotonia", "hypomyotonia", "muscle tone atonics", "neonatal hypotonia", "muscle flaccidity", "muscular hypotonia", "tone poor, muscle", "hypotonia, unilateral", "hypotonia, muscular", "flaccidity, muscular", "hypotonias, neonatal", "muscles, floppy", "unilateral hypotonia", "flaccidity, muscle", "muscle, floppy", "decreased muscle tone", "muscle tone atonic", "muscular flaccidities", "muscle tone, decreased", "floppy muscles", "tone atonic, muscle", "neonatal hypotonias"], "definition": "Hypotonia, commonly known as floppy baby syndrome, is a state of low muscle tone (the amount of tension or resistance to stretch in a muscle), often involving reduced muscle strength.", "other_contexts": [], "par_relations": ["Muscle Hypotonia", "Neuromuscular Manifestations", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia"], "chd_relations": ["Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Opitz-Kaveggia syndrome", "Cohen syndrome", "Ethanolaminosis", "Allan-Herndon-Dudley syndrome", "Carnitine Acetyltransferase Deficiency", "Emanuel syndrome", "Joubert syndrome 3", "Midface Hypoplasia, Obesity, Developmental Delay, and Neonatal Hypotonia", "Hypotonia-Cystinuria Syndrome", "Miller-McKusick-Malvaux-Syndrome (3M Syndrome)", "Radioulnar Synostosis, Unilateral, with Developmental Retardation and Hypotonia", "Ketoadipicaciduria", "Joubert syndrome 5", "Hydronephrosis, Congenital, with Cleft Palate, Characteristic Facies, Hypotonia, and Mental Retardation", "Atonic-Astatic Syndrome of Foerster", "Axenfeld-Rieger Anomaly with Partially Absent Eye Muscles, Distinctive Face, Hydrocephaly, and Skeletal Abnormalities", "Combined Oxidative Phosphorylation Deficiency 3", "Creases, Infra-Auricular Cutaneous, with Tall Stature and Advanced Bone Age", "Scalp ear nipple syndrome", "Hypotonia, congenital nystagmus, ataxia and abnormal auditory brainstem response", "Birk-Barel Mental Retardation Dysmorphism Syndrome", "Hypotonia, Seizures, And Precocious Puberty", "Joubert Syndrome 10", "Three M Syndrome 2", "Qazi Markouizos syndrome", "Grubben de Cock Borghgraef syndrome", "Der Kaloustian Mcintosh Silver syndrome", "Fumaric aciduria", "German Syndrome"], "syn_relations": ["Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia", "Muscle Hypotonia"], "sib_relations": ["Muscle Tonus", "Fasciculation", "Muscle Cramp", "Muscle Hypertonia", "Muscular Atrophy", "Myotonia", "Spasm", "Tetany", "Muscle Weakness", "Myokymia"], "wiki_entities": ["Hypotonia", "Muscle tone", "Myalgia", "Lower motor neuron lesion", "Atony", "Congenital myopathy", "Classification of Ehlers–Danlos syndrome", "Paresis", "Wiedemann-Steiner syndrome", "Hypertonia"], "mesh_synonynms": ["flaccid muscle tone", "hypotonia, muscular", "hypotonia", "neonatal hypotonia", "floppy muscle", "flaccidity, muscle", "hypotony, muscle", "muscle tone atonic", "flaccidity, muscular", "muscle hypotony", "muscle tone, decreased", "muscle hypotonia", "muscle tone, flaccid", "muscular hypotonia", "hypotonia, muscle", "muscular flaccidity", "neonatal hypotonias", "floppy muscles", "hypomyotonia", "hypotonias, neonatal", "hypotonia, neonatal", "muscular flaccidities", "muscle, floppy", "muscle tone atonics", "muscles, floppy", "decreased muscle tone", "tone atonic, muscle", "muscle tone poor", "hypotonias, unilateral", "unilateral hypotonia", "tone poor, muscle", "muscle flaccidity", "hypotonia, unilateral"], "dbpedia_synonyms": ["poor muscle tone", "benign congenital hypotonia", "amytonia congenita", "muscle hypotonia", "floppy baby", "infantile hypotonia", "low muscle tone", "hypotonia", "floppy baby syndrome", "congenital hypotonia", "amyotonia congenita", "floppy infant", "congenital muscle hypotonia", "congenital muscle weakness", "floppy infant syndrome"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0003448", "canonical_name": "Decreased sensory nerve conduction velocity", "aliases": ["decreased sensory nerve conduction velocity", "decreased sensory ncv", "decreased sensory nerve conduction velocities"], "definition": "Nerve conduction velocity is an important aspect of nerve conduction studies.", "other_contexts": [], "par_relations": ["Decreased nerve conduction velocity", "Abnormal sensory nerve conduction velocity"], "chd_relations": [], "syn_relations": ["Decreased sensory nerve conduction velocity", "Decreased sensory nerve conduction velocity", "Decreased sensory nerve conduction velocity", "Decreased sensory nerve conduction velocity"], "sib_relations": ["Decreased motor nerve conduction velocity", "Motor conduction block"], "wiki_entities": ["Nerve conduction velocity", "Axon", "Ulnar neuropathy", "Action potential", "Zenker's paralysis", "Acute motor axonal neuropathy", "Median nerve palsy", "Thermoreceptor", "Rheobase", "Electromyoneurography"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU009396", "canonical_name": "Decreased sensory nerve conduction velocities (NCV)", "aliases": ["decreased sensory nerve conduction velocities (ncv)"], "definition": "Ulnar neuropathy is a disorder involving the ulnar nerve.", "other_contexts": [], "par_relations": ["Peripheral nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE", "NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA"], "wiki_entities": ["Ulnar neuropathy", "Amyotrophic lateral sclerosis", "Physical therapy"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:995", "canonical_name": "BCL2 like 2", "aliases": ["ppp1r51", "bcl2l2", "bcl-w", "bcl2 like 2", "bcl2l2 gene", "protein phosphatase 1, regulatory subunit 51", "kiaa0271"], "definition": "Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inducing (pro-apoptotic) or inhibiting (anti-apoptotic) apoptosis.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["BCL2 like 2", "BCL2 like 2", "BCL2 like 2", "BCL2 like 2", "BCL2 like 2", "BCL2 like 2", "BCL2 like 2", "BCL2 like 2"], "sib_relations": [], "wiki_entities": ["Bcl-2", "BCL2-like 1 (gene)", "Bcl-2-associated X protein", "Bcl-2 family", "BCL2L11", "BCL2L2", "BCL6", "Bcl-xL", "BCL2L14", "Bcl-2 homologous antagonist killer"], "mesh_synonynms": [], "dbpedia_synonyms": ["bcl-w", "bcl2l2 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:601931", "canonical_name": "BCL2-LIKE 2", "aliases": ["bcl2-like 2", "bcl2l2", "bclw"], "definition": "Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inducing (pro-apoptotic) or inhibiting (anti-apoptotic) apoptosis.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["BCL2-LIKE 2", "BCL2-LIKE 2", "BCL2-LIKE 2", "BCL2-LIKE 2"], "sib_relations": [], "wiki_entities": ["Bcl-2", "BCL2-like 1 (gene)", "Bcl-2-associated X protein", "BCL2L2", "Bcl-2 family", "BCL2L11", "BCL6", "Bcl-2 homologous antagonist killer", "Bcl-xL", "BCL2L12"], "mesh_synonynms": [], "dbpedia_synonyms": ["bcl-w", "bcl2l2 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C564480", "canonical_name": "Fg Syndrome 5", "aliases": ["fgs5", "fg syndrome 5"], "definition": "FG syndrome (FGS; also known as Opitz–Kaveggia syndrome) is a rare genetic syndrome caused by one or more recessive genes located on the X chromosome and causing physical anomalies and developmental delays.", "other_contexts": [], "par_relations": ["Constipation", "Craniofacial Abnormalities", "Genetic Diseases, X-Linked", "Intellectual Disability"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["FG syndrome", "Marfan syndrome", "Wiedemann–Rautenstrauch syndrome", "Marfanoid–progeroid–lipodystrophy syndrome", "Kim Peek", "Asperger syndrome", "Loin pain hematuria syndrome", "Hemolytic-uremic syndrome", "Diabetes mellitus", "Endometrial cancer"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:300581", "canonical_name": "FG SYNDROME 5", "aliases": ["fgs5", "fg syndrome 5"], "definition": "FG syndrome (FGS; also known as Opitz–Kaveggia syndrome) is a rare genetic syndrome caused by one or more recessive genes located on the X chromosome and causing physical anomalies and developmental delays.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["FG SYNDROME 5", "FG SYNDROME 5"], "sib_relations": [], "wiki_entities": ["FG syndrome", "Marfan syndrome", "Wiedemann–Rautenstrauch syndrome", "Marfanoid–progeroid–lipodystrophy syndrome", "Kim Peek", "Asperger syndrome", "Loin pain hematuria syndrome", "Hemolytic-uremic syndrome", "Diabetes mellitus", "Endometrial cancer"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D008619", "canonical_name": "Mepivacaine", "aliases": ["astra brand of mepivacaine hydrochloride", "mecain", "mepivacain injektopas", "mepivacaine hydrochloride", "novocol brand of mepivacaine hydrochloride", "aventis brand of mepivacaine hydrochloride", "isogaine", "dentsply brand of mepivacaine hydrochloride", "monohydrochloride, mepivacaine", "braun brand of mepivicaine hydrochloride", "curasan brand of mepivacaine hydrochloride", "hexal brand of mepivacaine hydrochloride", "mepihexal", "polocaine", "isocaine", "mepivastesin", "astrazeneca brand of mepivacaine hydrochloride", "inibsa brand of mepivacaine hydrochloride", "carbocaïne", "pascoe brand of mepivacaine hydrochloride", "mepivacaina braun", "mepivacain-injektopas", "abbott brand of mepivacaine hydrochloride", "scandicain", "2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl-", "hydrochloride, mepivacaine", "mepivacaine monohydrochloride", "sanofi brand of mepivacaine hydrochloride", "meaverin", "mepivacaine", "scandinibsa", "carbocaine", "braun, mepivacaina", "scandonest", "scandicaine", "clarben brand of mepivacaine hydrochloride", "3m brand of mepivacaine hydrochloride"], "definition": "Mepivacaine  is a local anesthetic of the amide type.", "other_contexts": ["Mepivacaine was found in all synovial structures adjacent to the injected DFTS and in the contralateral MCP / MTP joints , but concentrations were low , with a maximum value of only 3.2 mg / l .", "Diffusion of mepivacaine to adjacent synovial structures after intrasynovial analgesia of the digital flexor tendon sheath .", "On a 50% effective dose (ED₅₀) basis, the spinal block effect of nisoxetine in motor function, proprioception, and nociception [0.99 (0.91-1.10), 0.85 (0.76-0.95), 0.82 (0.74-0.89)] was more potent (P < 0.05) than that of mepivacaine [1.28 (1.21-1.34), 1.14 (1.07-1.22), 0.99 (0.93-1.05)], respectively.", "Following written informed consent , subjects undergoing outpatient knee arthroscopy were prospectively randomized into one of four groups : mepivacaine 37.5 mg ( M37.5 ) ; mepivacaine 30 mg plus fentanyl 10 μg ( M30/F10 ) ; mepivacaine 27 mg plus fentanyl 10 μg ( M27/F10 ) ; and mepivacaine 24 mg plus fentanyl 10 μg ( M24/F10 ) .", "Mepivacaine and glibenclamide, alone or in combination, attenuated levcromakalim-induced membrane hyperpolarization.", "buccal infiltration and 2% mepivacaine IANB ( articaine regimen ) and another with 2% mepivacaine buccal infiltration supplemented to 2% mepivacaine IANB ( mepivacaine regimen ) . Pulp testing of", "For needle placement into the incisive canal , 54% of the subjects reported moderate / severe pain with the lidocaine solution and 58% reported moderate / severe pain with the mepivacaine solution .", "Taken together, these results indicate that mepivacaine-induced contraction involves increased calcium sensitization mediated by Rho kinase and PKC.", "and 4% articaine with 1:100,000 adrenaline buccal infiltration following 2% mepivacaine with 1:100,000 adrenaline inferior alveolar nerve block ( IANB ) for testing pulp anesthesia of", "Pretreatment with Y-27632 or GF 109203X shifted the mepivacaine-induced [Ca(2+)]i-tension curve to the lower right.", "outpatient knee arthroscopy were prospectively randomized into one of four groups : mepivacaine 37.5 mg ( M37.5 ) ; mepivacaine 30 mg plus fentanyl 10 μg ( M30/F10 ) ; mepivacaine 27 mg plus", "Interestingly, volunteers in the articaine regimen provided faster onset and longer duration (means 2.78 min, 42.22 min, respectively) than mepivacaine regimen (means 4.26 min, 40.74 min, respectively) for first molar pulp anesthesia (P < 0.001).", "108 mg with epinephrine 54 μg ) and group II ( four third molars ; submaximal dose of mepivacaine 216 mg with epinephrine 108 μg ) . Blood samples were collected before anaesthesia , and 5 , 10 , 1", "- induced vasodilation were assessed in the isolated aortas . The effects of mepivacaine or combined treatment with a protein kinase C ( PKC ) inhibitor , GF109203X , and mepivacaine on", "and JNK phosphorylation , respectively . Taken together , these results indicate that mepivacaine - induced contraction involves increased calcium sensitization mediated by Rho kinase and PKC .", "to be mediated primarily by calcium influx in rat aorta without endothelium BACKGROUND Mepivacaine induces contraction or decreased blood flow both in vivo and in vitro . Vasoconstriction is", "There were significant differences in the meantime of first numbness to associated lip and tooth of volunteers between mepivacaine and articaine BI groups P = 0.03 and 0.002.", "Mepivacaine - induced intracellular calcium increase appears to be mediated primarily by calcium influx in rat aorta without endothelium BACKGROUND Mepivacaine induces contraction or decreased blood flow both in vivo and in vitro .", "right . Pretreatment with Y-27632 , GF 109203X , PD 98059 , or SP600125 attenuated mepivacaine - induced contraction in a concentration - dependent manner . Y-27632 and GF 109203X attenuated", ": mepivacaine 37.5 mg ( M37.5 ) ; mepivacaine 30 mg plus fentanyl 10 μg ( M30/F10 ) ; mepivacaine 27 mg plus fentanyl 10 μg ( M27/F10 ) ; and mepivacaine 24 mg plus fentanyl 10 μg ( M24/F10 ) .", "value of only 3.2 mg / l . With the exception of the navicular bursa samples , the mepivacaine concentrations in the adjacent synovial structures were significantly higher at T60 than at T15 (", "were significantly higher at T60 than at T15 ( P<0.03 ) . Significantly higher mepivacaine concentrations were found in the ipsilateral than the contralateral MCP / MTP joints at T60 ( P<0.0", "BIs . Earlier lip and teeth numbness were recorded in articaine group . Articaine and mepivacaine BIs were more comfortable than mepivacaine IANB injections .", "RESULTS Mepivacaine produced vasoconstriction and increased [ Ca(2+)]i .", "Four patients obtained plasma levels of mepivacaine above the threshold for toxicity ( 5 μg / mL ) .", "blood samples were obtained at T0 , T15 and T60 to evaluate systemic distribution of mepivacaine . After a 2-week washout period , the procedure was repeated using the same limbs but reversing", "the effect of verapamil on the mepivacaine - evoked [ Ca(2+)]i increment . RESULTS Mepivacaine produced vasoconstriction and increased [ Ca(2+)]i . Nifedipine , 2-APB and low calcium attenuated", "regimen ) and another with 2% mepivacaine buccal infiltration supplemented to 2% mepivacaine IANB ( mepivacaine regimen ) . Pulp testing of first molar tooth was electronically measured twice", ". This randomized controlled trial compared plain mepivacaine to three reduced doses of mepivacaine with 10 μg fentanyl for spinal anesthesia . Following written informed consent , subjects", "limbs but reversing the time of sampling ( front vs. hindlimbs ) . The concentration of mepivacaine in samples was measured with a commercial ELISA kit . RESULTS Mepivacaine concentrations in the", "We hypothesized that intraoral injection of submaximal doses of mepivacaine does not lead to toxic levels of this drug in blood .", "RESULTS Mepivacaine concentrations in the DFTS samples , at both T15 ( 5077 mg / l ) and T60 ( 3503 mg / l ) , exceeded those estimated sufficient to produce synovial analgesia ( 100 mg / l or 300 mg / l ) .", "fentanyl 10 μg ( M30/F10 ) ; mepivacaine 27 mg plus fentanyl 10 μg ( M27/F10 ) ; and mepivacaine 24 mg plus fentanyl 10 μg ( M24/F10 ) . The spinal was evaluated by the blinded anesthetist and", "PURPOSE The purpose of this prospective, randomized, double-blind study was to compare injection pain and postinjection pain of 2% lidocaine with 1:100,000 epinephrine and 3% mepivacaine using the computer-assisted Wand Plus injection system to administer the palatal-anterior superior alveolar (P-ASA) injection.", "Plasma mepivacaine concentrations in patients undergoing third molar surgery.", "Intrathecal nisoxetine elicited more potent spinal anesthesia than mepivacaine .", "Therefore, the objective of this in vitro study was to examine the mechanism responsible for the mepivacaine-evoked [Ca(2+)]i increment in isolated rat aorta.", "The concentration of mepivacaine in samples was measured with a commercial ELISA kit .", "Further, the effects of mepivacaine and glibenclamide on levcromakalim-induced hyperpolarization were assessed in rat aortic vascular smooth muscle cells.", "contraction in a concentration - dependent manner . Y-27632 and GF 109203X attenuated mepivacaine - induced Rho kinase membrane translocation and PKC phosphorylation , respectively . PD 98059 and", "mediated via Rho kinase and protein kinase C in endothelium - denuded rat aorta . Mepivacaine is an aminoamide local anesthetic that produces vasoconstriction in vivo and in vitro . The goals", "Pretreatment with Y-27632, GF 109203X, PD 98059, or SP600125 attenuated mepivacaine-induced contraction in a concentration-dependent manner.", "in rat aorta . The goal of this in vitro study was to investigate the effect of mepivacaine on vasodilation induced by the ATP - sensitive potassium ( KATP ) channel opener levcromakalim in", ", mepivacaine . Intrathecal nisoxetine elicited more potent spinal anesthesia than mepivacaine .", "Articaine and mepivacaine buccal infiltration in securing mandibular first molar pulp anesthesia following mepivacaine inferior alveolar nerve block : A randomized , double - blind crossover study AIMS A crossover double - blind , randomized study was designed to explore the efficacy of 2% mepivacaine with 1:100,000 adrenaline buccal infiltration and 4% articaine with 1:100,000 adrenaline buccal infiltration following 2% mepivacaine with 1:100,000 adrenaline inferior alveolar nerve block ( IANB ) for testing pulp anesthesia of mandibular first molar teeth in adult volunteers .", "Postinjection, 12% and 18% of the subjects experienced temporary numbness/paresthesia of the incisive papilla with the lidocaine and mepivacaine solutions, respectively.", "The mepivacaine - evoked [ Ca(2+)]i increment , which contributes to mepivacaine - evoked contraction , appears to be mediated mainly by calcium influx and partially by calcium released from the sarcoplasmic reticulum .", "( 267 vs. 250 episodes , respectively , P < 0.001 ) , however , both articaine and mepivacaine buccal infiltrations are equally effective in securing anesthetic success for first molar pulp", "action of mepivacaine . We compared nisoxetine with an established local anesthetic mepivacaine for spinal anesthesia after rats were intrathecally injected with drugs . The drugs were spinally", "higher mepivacaine concentrations at T15 and T60 than at T0 ( P<0.001 ) . CONCLUSIONS Mepivacaine injected into the DFTS of horses diffuses towards adjacent synovial structures without achieving", "satisfaction was 10/10 for all groups . Adding fentanyl 10 μg to a lower dose of mepivacaine 1.5% can lead to quicker recovery profiles . However , this advantage of a quicker recovery must", "reliable anesthesia for knee arthroscopy with a more rapid recovery profile than 45 mg mepivacaine . This randomized controlled trial compared plain mepivacaine to three reduced doses of", "in securing anesthetic success for first molar pulp anesthesia when supplemented to mepivacaine IANB injections ( P > 0.05 ) . Interestingly , volunteers in the articaine regimen provided faster", ", the DFTS of one front and one hindlimb of 8 horses were injected simultaneously with mepivacaine . Synovial fluid samples of the injected DFTS , the adjacent metacarpo-/metatarsophalangeal ( MCP /", "Furthermore , the nociceptive / sensory blockade ( ED₅₀ ) was greater than the motor blockade in both nisoxetine and mepivacaine groups ( P < 0.05 ) .", "CONCLUSIONS Supplementary mepivacaine and articaine buccal infiltrations produced similar successful first molar pulp anesthesia following mepivacaine IANB injections in volunteers .", "Mepivacaine attenuated levcromakalim - induced vasodilation , whereas it had no effect on this vasodilation in isolated aortas pretreated with glibenclamide .", "Venous blood samples were obtained at T0, T15 and T60 to evaluate systemic distribution of mepivacaine.", "/ sensory blockade ( ED₅₀ ) was greater than the motor blockade in both nisoxetine and mepivacaine groups ( P < 0.05 ) . Saline group ( vehicle ) produced no spinal anesthesia . Coadministration of", "regimens with at least 1-week apart ; one with 4% articaine buccal infiltration and 2% mepivacaine IANB ( articaine regimen ) and another with 2% mepivacaine buccal infiltration supplemented to 2%", "This randomized controlled trial compared plain mepivacaine to three reduced doses of mepivacaine with 10 μg fentanyl for spinal anesthesia .", "However, the mechanism responsible for the mepivacaine-evoked [Ca(2+)]i increase remains to be determined.", "- induced membrane hyperpolarization . Taken together , these results suggest that mepivacaine attenuates vasodilation induced by KATP channels , which appears to be partly mediated by PKC .", "Blood samples had significantly higher mepivacaine concentrations at T15 and T60 than at T0 (P<0.001).", "]i increment in fura-2 loaded aortic strips . We assessed the effect of verapamil on the mepivacaine - evoked [ Ca(2+)]i increment . RESULTS Mepivacaine produced vasoconstriction and increased [ Ca(2+", "faster onset and longer duration ( means 2.78 min , 42.22 min , respectively ) than mepivacaine regimen ( means 4.26 min , 40.74 min , respectively ) for first molar pulp anesthesia ( P < 0.001 )", "0.85 ( 0.76 - 0.95 ) , 0.82 ( 0.74 - 0.89 ) ] was more potent ( P < 0.05 ) than that of mepivacaine [ 1.28 ( 1.21 - 1.34 ) , 1.14 ( 1.07 - 1.22 ) , 0.99 ( 0.93 - 1.05 ) ] , respectively .", "isolated aortas pretreated with glibenclamide . Combined treatment with GF109203X and mepivacaine enhanced levcromakalim - induced vasodilation compared with pretreatment with mepivacaine alone .", "buccal infiltrations produced similar successful first molar pulp anesthesia following mepivacaine IANB injections in volunteers . Articaine buccal infiltration produced faster onset and longer", "volunteers in the post IANB and postbuccal injection groups ( t - test : P < 0.001 ) . Mepivacaine IANB injection was significantly more painful than articaine / mepivacaine buccal injection .", "translocation and PKC phosphorylation , respectively . PD 98059 and SP600125 attenuated mepivacaine - induced ERK and JNK phosphorylation , respectively . Taken together , these results indicate", "The incidence of postinjection pain , temporary numbness / paresthesia , and incisive papilla swelling or soreness would indicate that some pain and problems occur with the P - ASA technique , regardless of whether 2% lidocaine with 1:100,000 epinephrine or 3% mepivacaine is used .", "STUDY DESIGN Using a crossover design, 40 subjects randomly received, in a double-blind manner, P-ASA injections of 1.4 mL of 2% lidocaine with 1:100,000 epinephrine and 1.4 mL of 3% mepivacaine, at 2 separate appointments.", "group ( vehicle ) produced no spinal anesthesia . Coadministration of nisoxetine with mepivacaine displayed an additive effect . Our data reported nisoxetine produced significant anesthesia at", "- response curves and isobolographic analysis . We showed that nisoxetine , as well as mepivacaine elicited spinal anesthesia in dose - dependent manners . On a 50% effective dose ( ED₅₀ ) basis ,", "profile than 45 mg mepivacaine . This randomized controlled trial compared plain mepivacaine to three reduced doses of mepivacaine with 10 μg fentanyl for spinal anesthesia . Following", "Regarding postinjection pain , when anesthesia wore off on the day of the injection , 20% of the subjects reported moderate / severe pain with the lidocaine solution and 14% reported moderate / severe pain with the mepivacaine solution .", "Mepivacaine is an aminoamide local anesthetic that produces vasoconstriction in vivo and in vitro.", "or a PKC activator , phorbol 12,13-dibutyrate ( PDBu ) . Further , the effects of mepivacaine and glibenclamide on levcromakalim - induced hyperpolarization were assessed in rat aortic", "METHODS Twenty - one patients were randomly assigned into two groups : group I ( two unilateral third molars ; submaximal dose of mepivacaine 108 mg with epinephrine 54 μg ) and group II ( four third molars ; submaximal dose of mepivacaine 216 mg with epinephrine 108 μg ) .", "We showed that nisoxetine, as well as mepivacaine elicited spinal anesthesia in dose-dependent manners.", "For needle insertion, 30% of the subjects reported moderate/severe pain with the lidocaine solution and 43% reported moderate/severe pain with the mepivacaine solution.", "We compared nisoxetine with an established local anesthetic mepivacaine for spinal anesthesia after rats were intrathecally injected with drugs.", "Significantly higher mepivacaine concentrations were found in the ipsilateral than the contralateral MCP/MTP joints at T60 (P<0.001).", "are possible , even when a submaximal dose is used . A twofold increase in the dose of mepivacaine caused the mean peak plasma concentration to increase proportionally , indicating that they may be", "The effects of mepivacaine and potassium chloride on intracellular calcium concentrations ([Ca(2+)]i) and tension in the presence or absence of Y-27632 or GF 109203X were measured simultaneously using the acetoxymethyl ester of fura-2-loaded aortic strips.", "CONCLUSIONS The P - ASA injection of 1.4 mL of 2% lidocaine with 1:100,000 epinephrine or 3% mepivacaine , administered with the Wand Plus , has the potential to be a painful injection .", "Isobolographic analysis of interaction between nisoxetine- and mepivacaine-induced spinal blockades in rats.", "Combined treatment with GF109203X and mepivacaine enhanced levcromakalim - induced vasodilation compared with pretreatment with mepivacaine alone .", "With the exception of the navicular bursa samples , the mepivacaine concentrations in the adjacent synovial structures were significantly higher at T60 than at T15 ( P<0.03 ) .", "Mepivacaine - induced contraction involves increased calcium sensitization mediated via Rho kinase and protein kinase C in endothelium - denuded rat aorta .", ") supplemented with either articaine 4% with epinephrine 1:100,000 ( septocaine ) or mepivacaine 2% buccal infiltration ( BI ) injection on two visits . The time of first numbness to associated", "The slope of the mepivacaine-induced [Ca(2+)]i-tension curve was higher than that of the KCl-induced [Ca(2+)]i-tension curve.", "in the meantime of first numbness to associated lip and tooth of volunteers between mepivacaine and articaine BI groups P = 0.03 and 0.002 . Volunteers in articaine group recorded earlier lip", "lead to toxic levels of this drug in blood . This study evaluated the plasma levels of mepivacaine in third molars surgeries . METHODS Twenty - one patients were randomly assigned into two groups :", "were detected in vascular smooth muscle cells by Western blotting . The slope of the mepivacaine - induced [ Ca(2+)]i - tension curve was higher than that of the KCl - induced [ Ca(2+)]i -", "Lower-Dose Mepivacaine Plus Fentanyl May Improve Spinal Anesthesia for Knee Arthroscopy Previous work indicates that 30 mg isobaric mepivacaine 1.5% plus 10 μg fentanyl produces reliable anesthesia for knee arthroscopy with a more rapid recovery profile than 45 mg mepivacaine.", "The effects of mepivacaine or combined treatment with a protein kinase C (PKC) inhibitor, GF109203X, and mepivacaine on this vasodilation were also investigated.", "recorded in articaine group . Articaine and mepivacaine BIs were more comfortable than mepivacaine IANB injections .", "crossover double - blind , randomized study was designed to explore the efficacy of 2% mepivacaine with 1:100,000 adrenaline buccal infiltration and 4% articaine with 1:100,000 adrenaline buccal", "hexahydrate ( Gd(3 + ) ) , low calcium level and Krebs solution without calcium on the mepivacaine - evoked contraction in isolated rat aorta and on the mepivacaine - evoked [ Ca(2+)]i increment in", "CONCLUSIONS Mepivacaine injected into the DFTS of horses diffuses towards adjacent synovial structures without achieving clinically relevant concentrations .", "spinal anesthesia of nisoxetine and its influence on the antinociceptive action of mepivacaine . We compared nisoxetine with an established local anesthetic mepivacaine for spinal anesthesia", "1.88 ± 0.12 mg / kg ( group I ) to 3.35 ± 0.17 mg / kg ( group II ) increased the mean mepivacaine peak plasma levels from 2.33 ± 0.58 to 4.01 ± 0.69 μg / mL , respectively . Four patients obtained", "We assessed the effect of verapamil on the mepivacaine - evoked [ Ca(2+)]i increment .", "Y-27632 and GF 109203X attenuated mepivacaine - induced Rho kinase membrane translocation and PKC phosphorylation , respectively .", "anesthesia at spinal level , and additive interaction with the local anesthetic , mepivacaine . Intrathecal nisoxetine elicited more potent spinal anesthesia than mepivacaine .", "using the acetoxymethyl ester of fura-2-loaded aortic strips . Cumulative mepivacaine concentration - response curves were generated in the presence or absence of the following", "buccal infiltration in securing mandibular first molar pulp anesthesia following mepivacaine inferior alveolar nerve block : A randomized , double - blind crossover study AIMS A crossover", "Our data reported nisoxetine produced significant anesthesia at spinal level, and additive interaction with the local anesthetic, mepivacaine.", "PD 98059 and SP600125 attenuated mepivacaine-induced ERK and JNK phosphorylation, respectively.", "The goal of this in vitro study was to investigate the effect of mepivacaine on vasodilation induced by the ATP-sensitive potassium (KATP) channel opener levcromakalim in isolated endothelium-denuded rat aortas.", "Injection pain and postinjection pain of the palatal - anterior superior alveolar injection , administered with the Wand Plus system , comparing 2% lidocaine with 1:100,000 epinephrine to 3% mepivacaine .", "Volunteers in articaine group recorded earlier lip and teeth numbness than those in mepivacaine group .", "mepivacaine - induced [ Ca(2+)]i increment . Calcium - free solution almost abolished mepivacaine - induced contraction and strongly attenuated the mepivacaineinduced [ Ca(2+)]i increase . Gd(3 + )", "We investigated the effects of nifedipine, 2-aminoethoxydiphenylborate (2-APB), gadolinium chloride hexahydrate (Gd(3+)), low calcium level and Krebs solution without calcium on the mepivacaine-evoked contraction in isolated rat aorta and on the mepivacaine-evoked [Ca(2+)]i increment in fura-2 loaded aortic strips.", "Articaine buccal infiltration produced faster onset and longer duration than mepivacaine buccal infiltration following mepivacaine IANB injections .", "Comparison of speed of action and injection discomfort of 4% articaine and 2% mepivacaine for pulpal anesthesia in mandibular teeth: A randomized, double-blind cross-over trial OBJECTIVE To compare the injection pain and speed of local anesthetic effect induced by tissue infiltration of mepivacaine 2% with epinephrine 1:100,000 versus articaine 4% with epinephrine 1:100,000 in securing mandibular first molar pulp anesthesia.", ". CONCLUSIONS The mepivacaine - evoked [ Ca(2+)]i increment , which contributes to mepivacaine - evoked contraction , appears to be mediated mainly by calcium influx and partially by calcium", "Adding fentanyl 10 μg to a lower dose of mepivacaine 1.5% can lead to quicker recovery profiles .", "Each subject received injections of mepivacaine 2% with epinephrine 1:100,000 as inferior alveolar nerve block ( IANB ) supplemented with either articaine 4% with epinephrine 1:100,000 ( septocaine ) or mepivacaine 2% buccal infiltration ( BI ) injection on two visits .", "The effects of mepivacaine and the KATP channel inhibitor glibenclamide, alone or in combination, on levcromakalim-induced vasodilation were assessed in the isolated aortas.", "and the [ Ca(2+)]i increase evoked by mepivacaine . Verapamil attenuated the mepivacaine - induced [ Ca(2+)]i increment . Calcium - free solution almost abolished mepivacaine - induced", "Articaine and mepivacaine BIs were more comfortable than mepivacaine IANB injections .", "enhanced levcromakalim - induced vasodilation compared with pretreatment with mepivacaine alone . This vasodilation was attenuated in aortas precontracted with PDBu compared with those", "of mepivacaine in samples was measured with a commercial ELISA kit . RESULTS Mepivacaine concentrations in the DFTS samples , at both T15 ( 5077 mg / l ) and T60 ( 3503 mg / l ) ,", "above the threshold for toxicity ( 5 μg / mL ) . CONCLUSIONS Toxic levels of mepivacaine are possible , even when a submaximal dose is used . A twofold increase in the dose of mepivacaine", "CONCLUSIONS Toxic levels of mepivacaine are possible, even when a submaximal dose is used.", "For anesthetic solution deposition , 8% of the subjects reported moderate pain with the lidocaine solution and 12% reported moderate pain with the mepivacaine solution .", "2-APB and low calcium attenuated vasoconstriction and the [ Ca(2+)]i increase evoked by mepivacaine . Verapamil attenuated the mepivacaine - induced [ Ca(2+)]i increment . Calcium - free solution", "vasoconstriction or the [ Ca(2+)]i increment evoked by mepivacaine . CONCLUSIONS The mepivacaine - evoked [ Ca(2+)]i increment , which contributes to mepivacaine - evoked contraction , appears to", "testing for first molar teeth were significantly higher after articaine regimen than mepivacaine during 45 min postinjection ( 267 vs. 250 episodes , respectively , P < 0.001 ) , however , both", "or combined treatment with a protein kinase C ( PKC ) inhibitor , GF109203X , and mepivacaine on this vasodilation were also investigated . Levcromakalim concentration - response curves were", ") for first molar pulp anesthesia ( P < 0.001 ) . CONCLUSIONS Supplementary mepivacaine and articaine buccal infiltrations produced similar successful first molar pulp anesthesia", "tendon sheath ( DFTS ) in horses . OBJECTIVES To evaluate the degree of diffusion of mepivacaine from the equine DFTS to adjacent synovial structures . STUDY DESIGN Crossover experiment . METHODS", "Verapamil attenuated the mepivacaine - induced [ Ca(2+)]i increment .", "Calcium-free solution almost abolished mepivacaine-induced contraction and strongly attenuated the mepivacaineinduced [Ca(2+)]i increase. Gd(3+) had no effect on either vasoconstriction or the [Ca(2+)]i increment evoked by mepivacaine.", "An increase in the average dose of mepivacaine from 1.88 ± 0.12 mg/kg (group I) to 3.35 ± 0.17 mg/kg (group II) increased the mean mepivacaine peak plasma levels from 2.33 ± 0.58 to 4.01 ± 0.69 μg/mL, respectively.", "were prospectively randomized into one of four groups : mepivacaine 37.5 mg ( M37.5 ) ; mepivacaine 30 mg plus fentanyl 10 μg ( M30/F10 ) ; mepivacaine 27 mg plus fentanyl 10 μg ( M27/F10 ) ; and", "aortas , and to investigate the specific protein kinases involved . The effects of mepivacaine and potassium chloride on intracellular calcium concentrations ( [ Ca(2+)]i ) and tension in the", "The aim of this study was to examine spinal anesthesia of nisoxetine and its influence on the antinociceptive action of mepivacaine.", "In total , the number of no sensations to maximum pulp testing for first molar teeth were significantly higher after articaine regimen than mepivacaine during 45 min postinjection ( 267 vs. 250 episodes , respectively , P < 0.001 ) , however , both articaine and mepivacaine buccal infiltrations are equally effective in securing anesthetic success for first molar pulp anesthesia when supplemented to mepivacaine IANB injections ( P > 0.05 ) .", "A twofold increase in the dose of mepivacaine caused the mean peak plasma concentration to increase proportionally , indicating that they may be predicted based on the relation of dose per bodyweight .", "a crossover , randomized , double - blind study . Each subject received injections of mepivacaine 2% with epinephrine 1:100,000 as inferior alveolar nerve block ( IANB ) supplemented with either", "calcium on the mepivacaine - evoked contraction in isolated rat aorta and on the mepivacaine - evoked [ Ca(2+)]i increment in fura-2 loaded aortic strips . We assessed the effect of verapamil", "Spinal Anesthesia for Knee Arthroscopy Previous work indicates that 30 mg isobaric mepivacaine 1.5% plus 10 μg fentanyl produces reliable anesthesia for knee arthroscopy with a more rapid", "02 . Volunteers in articaine group recorded earlier lip and teeth numbness than those in mepivacaine group . There were significant differences between the mean pain scores for volunteers in the post", "of these drugs . We hypothesized that intraoral injection of submaximal doses of mepivacaine does not lead to toxic levels of this drug in blood . This study evaluated the plasma levels of", "This study evaluated the plasma levels of mepivacaine in third molars surgeries.", ", the objective of this in vitro study was to examine the mechanism responsible for the mepivacaine - evoked [ Ca(2+)]i increment in isolated rat aorta . METHODS Isometric tension was measured in", "To evaluate the degree of diffusion of mepivacaine from the equine DFTS to adjacent synovial structures .", "< 0.001 ) . Mepivacaine IANB injection was significantly more painful than articaine / mepivacaine buccal injection . CONCLUSIONS About 4% articaine was faster than 2% mepivacaine ( both with 1:100,", "Mepivacaine attenuates vasodilation induced by ATP-sensitive potassium channels in rat aorta.", "injection pain and speed of local anesthetic effect induced by tissue infiltration of mepivacaine 2% with epinephrine 1:100,000 versus articaine 4% with epinephrine 1:100,000 in securing", "METHODS Under general anaesthesia, the DFTS of one front and one hindlimb of 8 horses were injected simultaneously with mepivacaine.", "CONCLUSIONS About 4% articaine was faster than 2% mepivacaine (both with 1:100,000 adrenaline) in anesthetizing the pulps of lower molar teeth after BIs.", "Gd(3 + ) had no effect on either vasoconstriction or the [ Ca(2+)]i increment evoked by mepivacaine . CONCLUSIONS The mepivacaine - evoked [ Ca(2+)]i increment , which contributes to mepivacaine -", "Taken together, these results suggest that mepivacaine attenuates vasodilation induced by KATP channels, which appears to be partly mediated by PKC.", "/ mepivacaine buccal injection . CONCLUSIONS About 4% articaine was faster than 2% mepivacaine ( both with 1:100,000 adrenaline ) in anesthetizing the pulps of lower molar teeth after BIs .", "Cumulative mepivacaine concentration - response curves were generated in the presence or absence of the following inhibitors : Rho kinase inhibitor Y-27632 , protein kinase C ( PKC ) inhibitor GF 109203X , extracellular signal - regulated kinase ( ERK ) inhibitor PD 98059 , c - Jun NH2-terminal kinase ( JNK ) inhibitor SP600125 , and p38 mitogen - activated protein kinase ( MAPK ) inhibitor SB 203580 .", "Coadministration of nisoxetine with mepivacaine displayed an additive effect .", "MATERIALS AND METHODS A total of 23 healthy adult volunteers received two regimens with at least 1-week apart; one with 4% articaine buccal infiltration and 2% mepivacaine IANB (articaine regimen) and another with 2% mepivacaine buccal infiltration supplemented to 2% mepivacaine IANB (mepivacaine regimen).", "aortas precontracted with PDBu compared with those precontracted with phenylephrine . Mepivacaine and glibenclamide , alone or in combination , attenuated levcromakalim - induced membrane", "Twenty percent and 28% of the subjects had incisive papilla swelling or soreness with the lidocaine and mepivacaine solutions, respectively.", "another with 2% mepivacaine buccal infiltration supplemented to 2% mepivacaine IANB ( mepivacaine regimen ) . Pulp testing of first molar tooth was electronically measured twice at baseline , then", ". Articaine buccal infiltration produced faster onset and longer duration than mepivacaine buccal infiltration following mepivacaine IANB injections .", "those estimated sufficient to produce synovial analgesia ( 100 mg / l or 300 mg / l ) . Mepivacaine was found in all synovial structures adjacent to the injected DFTS and in the contralateral MCP /", "- induced hyperpolarization were assessed in rat aortic vascular smooth muscle cells . Mepivacaine attenuated levcromakalim - induced vasodilation , whereas it had no effect on this vasodilation in", "There were no significant differences ( P > .05 ) between the lidocaine and mepivacaine solutions .", "faster onset and longer duration than mepivacaine buccal infiltration following mepivacaine IANB injections .", "[ Ca(2+)]i - tension curve . Pretreatment with Y-27632 or GF 109203X shifted the mepivacaine - induced [ Ca(2+)]i - tension curve to the lower right . Pretreatment with Y-27632 , GF 109203X ,", "assigned into two groups : group I ( two unilateral third molars ; submaximal dose of mepivacaine 108 mg with epinephrine 54 μg ) and group II ( four third molars ; submaximal dose of mepivacaine 2", "in vivo and in vitro . The goals of this in vitro study were to determine whether mepivacaine - induced contraction involves calcium sensitization in isolated endothelium - denuded aortas ,", "The goals of this in vitro study were to determine whether mepivacaine-induced contraction involves calcium sensitization in isolated endothelium-denuded aortas, and to investigate the specific protein kinases involved.", "3 ± 0.58 to 4.01 ± 0.69 μg / mL , respectively . Four patients obtained plasma levels of mepivacaine above the threshold for toxicity ( 5 μg / mL ) . CONCLUSIONS Toxic levels of mepivacaine are", "opener levcromakalim in isolated endothelium - denuded rat aortas . The effects of mepivacaine and the KATP channel inhibitor glibenclamide , alone or in combination , on levcromakalim -", "calcium concentration ( [ Ca(2+)]i ) . However , the mechanism responsible for the mepivacaine - evoked [ Ca(2+)]i increase remains to be determined . Therefore , the objective of this in vitro", "I ) and from 2.36 - 7.72 μg / mL ( group II ) . An increase in the average dose of mepivacaine from 1.88 ± 0.12 mg / kg ( group I ) to 3.35 ± 0.17 mg / kg ( group II ) increased the mean", "MCP / MTP joints at T60 ( P<0.001 ) . Blood samples had significantly higher mepivacaine concentrations at T15 and T60 than at T0 ( P<0.001 ) . CONCLUSIONS Mepivacaine injected into the", "Mepivacaine IANB injection was significantly more painful than articaine/mepivacaine buccal injection.", "Nifedipine , 2-APB and low calcium attenuated vasoconstriction and the [ Ca(2+)]i increase evoked by mepivacaine ."], "par_relations": ["Mepivacaine", "Piperidines", "Anesthetics, Local", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine"], "chd_relations": ["Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "dexivacain"], "syn_relations": ["Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine", "Mepivacaine"], "sib_relations": ["Alphaprodine", "Anabasine", "Biperiden", "Clopamide", "Cyproheptadine", "Domperidone", "Fentanyl", "Flecainide", "Fluspirilene", "Indoramin", "Isonipecotic Acids", "Ketanserin", "Ketotifen", "Lobeline", "Loperamide", "Methylphenidate", "Minoxidil", "Nipecotic Acids", "Pempidine", "Penfluridol", "Perhexiline", "Phencyclidine", "Pipecolic Acids", "Piperidones", "Piperoxan", "Trihexyphenidyl", "Paroxetine", "Cisapride", "Terfenadine", "Ritanserin", "Betalains", "Imino Pyranoses"], "wiki_entities": ["Mepivacaine", "ATC code N01", "2,6-Xylidine", "Local anesthetic nerve block", "Corbadrine", "C15H22N2O", "Sufentanil", "Local anesthesia", "Procaine", "Anesthetic"], "mesh_synonynms": ["curasan brand of mepivacaine hydrochloride", "polocaine", "mepihexal", "mepivacain-injektopas", "novocol brand of mepivacaine hydrochloride", "scandonest", "astrazeneca brand of mepivacaine hydrochloride", "mepivacaine hydrochloride", "mepivastesin", "isogaine", "mepivacaine", "mepivacain injektopas", "pascoe brand of mepivacaine hydrochloride", "mecain", "3m brand of mepivacaine hydrochloride", "inibsa brand of mepivacaine hydrochloride", "carbocaïne", "mepivacaina braun", "braun brand of mepivicaine hydrochloride", "abbott brand of mepivacaine hydrochloride", "mepivacaine monohydrochloride", "meaverin", "carbocaine", "scandinibsa", "braun, mepivacaina", "astra brand of mepivacaine hydrochloride", "sanofi brand of mepivacaine hydrochloride", "aventis brand of mepivacaine hydrochloride", "hydrochloride, mepivacaine", "dentsply brand of mepivacaine hydrochloride", "scandicain", "scandicaine", "clarben brand of mepivacaine hydrochloride", "monohydrochloride, mepivacaine", "isocaine", "hexal brand of mepivacaine hydrochloride"], "dbpedia_synonyms": ["scandonest plain", "scandicaine", "scandicane", "atc code n01bb03", "scandicain", "mepivacaine hydrochloride", "arestocaine", "polocaine-mpf", "mepivacaine", "isocaine hcl", "polocaine", "carbocaine", "mepivacain", "arestocaine hcl", "carbocain", "scandonest", "atcvet code qn01bb03"]}, "target_ent": {"research_entity_id": "RXNORM:2021", "canonical_name": "Carbocaine", "aliases": ["carbocaine"], "definition": "Mepivacaine  is a local anesthetic of the amide type.", "other_contexts": ["Determination of the toxicological and pharmacological properties of carbocaine , lidocaine and procaine by means of simultaneous experiments .", "[ EMLA cream ( lidocaine / prilocaine ) versus infiltration analgesia with carbocaine ( mepivacaine ) in vasectomy ] .", "The effectivity of Carbocaine and Marcaine in oral surgery .", "A RECENT report from Scandinavia ( Dhuner et al . , 1956 ) describes a clinical trial of Carbocaine in which 652 cases were injected with results which the authors describe as raising \" expectations that Carbocaine may prove to be of great value as a local anaesthetic drug . \"", "Young rats received single or repeated injections of 2% mepivacaine ( Carbocaine ) into the tibialis anterior or extensor digitorum longus muscles .", "The analgesic efficacy of EMLA cream was compared with infiltration with 1% carbocaine in 13 bilateral vasectomies .", "The excreation of Scandicain in urine was tested at various times after anaesthesia .", "Carbocaine is d , 1-N - methyl - pipecolic acid 2 , 6-dimethylanilide and has the structural formula The base is poorly soluble , but the hydro - chloride is easily soluble in water and very resistant to acid and alkaline hydrolysis .", "Studies on mechanical actions of mepivacaine ( Carbocaine ) and its optically active isomers on isolated smooth muscle : role of Ca + + and cyclic AMP .", "Mepivacaine ( Carbocaine ) , a potent new local anesthetic .", "[ Experience with the new local Scandicaine ( Mepivacaine ) in otorhinolaryngology ] .", "Two per cent Carbocaine without adrenaline was first tried in 65 dental cases for both regional and infiltration anaesthesia in order to obtain some idea of the following factors : ( 1 ) Dosage .", "Myotoxicity of single and repeated injections of mepivacaine ( Carbocaine ) in the rat .", "Dental trial of carbocaine ; a new local anaesthetic .", "The chemical and physical properties of Scandicain ( Carbocain ) and its hydrochlorid were determined .", "A comparative clinical examination of Carbocaine 1 percent and Marcaine 0.25 percent .", "The local anaesthetics Xylonest 3% Octapressin and Scandicain have been clinically tested in a series of 220 consecutive patients .", "It was found that , when no adrenaline was used , anaesthesia lasted longer with Carbocaine than with lignocaine ( Xylocaine ) , for i , 1 and 2 per cent solutions .", "Scandicain is well suited for short interventions .", "[ Clinical comparison of Xylonest - Octapressin and Scandicain ] .", "Thin layer chromatography was used for qualitative analysis and for separation of Scandicain from other local anaesthetics ."], "par_relations": ["Mepivacaine", "Mepivacaine Hydrochloride"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Carbocaine 10 MG/ML Injectable Solution", "30 ML Carbocaine 15 MG/ML Injection", "Carbocaine 20 MG/ML Injectable Solution", "1.7 ML Carbocaine 30 MG/ML Cartridge", "Mepivacaine Injectable Solution [Carbocaine]", "Mepivacaine Hydrochloride 10 MG/ML [Carbocaine]", "Mepivacaine Hydrochloride 15 MG/ML [Carbocaine]", "Mepivacaine Hydrochloride 20 MG/ML [Carbocaine]", "Mepivacaine Hydrochloride 30 MG/ML [Carbocaine]", "Carbocaine Injectable Product", "Carbocaine 30 MG/ML Cartridge", "Mepivacaine Cartridge [Carbocaine]", "30 ML Carbocaine 10 MG/ML Injection", "Carbocaine 2 % per 20 ML Injection", "Carbocaine 15 MG/ML Injection", "Carbocaine 20 MG/ML Injection", "Carbocaine 10 MG/ML Injection", "Mepivacaine Injection [Carbocaine]"], "wiki_entities": ["Mepivacaine", "List of drugs: C-Ca", "List of local anesthetics", "Ehlers–Danlos syndromes", "AstraZeneca", "List of cocaine analogues", "List of compounds with carbon number 15"], "mesh_synonynms": ["curasan brand of mepivacaine hydrochloride", "polocaine", "mepihexal", "mepivacain-injektopas", "novocol brand of mepivacaine hydrochloride", "scandonest", "astrazeneca brand of mepivacaine hydrochloride", "mepivacaine hydrochloride", "mepivastesin", "isogaine", "mepivacaine", "mepivacain injektopas", "pascoe brand of mepivacaine hydrochloride", "mecain", "3m brand of mepivacaine hydrochloride", "inibsa brand of mepivacaine hydrochloride", "carbocaïne", "mepivacaina braun", "braun brand of mepivicaine hydrochloride", "abbott brand of mepivacaine hydrochloride", "mepivacaine monohydrochloride", "meaverin", "scandinibsa", "braun, mepivacaina", "astra brand of mepivacaine hydrochloride", "sanofi brand of mepivacaine hydrochloride", "aventis brand of mepivacaine hydrochloride", "hydrochloride, mepivacaine", "dentsply brand of mepivacaine hydrochloride", "scandicain", "scandicaine", "clarben brand of mepivacaine hydrochloride", "monohydrochloride, mepivacaine", "isocaine", "hexal brand of mepivacaine hydrochloride"], "dbpedia_synonyms": ["mepivacaine"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0012811", "canonical_name": "Wide nasal ridge", "aliases": ["broad nasal ridge", "wide nasal dorsum", "increased width of nasal ridge", "increased width of nasal dorsum", "broad nasal dorsum", "increased width of dorsum of nose", "wide dorsum of nose", "broad dorsum of nose", "wide nasal ridge", "nasal ridge, wide"], "definition": "The nasal helmet was a type of combat helmet characterised by the possession of a projecting bar covering the nose and thus protecting the centre of the face; it was of Western European origins and was used from the Early Middle Ages until the High Middle Ages.", "other_contexts": [], "par_relations": ["Abnormality of the nasal dorsum"], "chd_relations": [], "syn_relations": ["Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge", "Wide nasal ridge"], "sib_relations": ["Wide nasal ridge", "Wide nasal ridge", "Convex nasal ridge", "Concave nasal ridge", "Narrow nasal ridge", "Depressed nasal ridge", "Large beaked nose"], "wiki_entities": ["Nasal helmet", "Distinctive feature", "Flap consonant", "Augmentation pharyngoplasty", "Mongoloid", "Bulbasaurus", "Slovak Cuvac", "Negroid", "Cri du chat", "Voiceless alveolar affricate"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU052282", "canonical_name": "Wide nasal ridge", "aliases": ["wide nasal ridge"], "definition": "The nasal helmet was a type of combat helmet characterised by the possession of a projecting bar covering the nose and thus protecting the centre of the face; it was of Western European origins and was used from the Early Middle Ages until the High Middle Ages.", "other_contexts": [], "par_relations": ["Nose"], "chd_relations": [], "syn_relations": [], "sib_relations": ["AU-KLINE SYNDROME"], "wiki_entities": ["Nasal helmet", "Distinctive feature", "Flap consonant", "Augmentation pharyngoplasty", "Mongoloid", "Bulbasaurus", "Slovak Cuvac", "Negroid", "Cri du chat", "Voiceless alveolar affricate"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0001002", "canonical_name": "obsolete Decreased subcutaneous fat", "aliases": ["decreased fat below the skin", "obsolete decreased subcutaneous fat", "little subcutaneous fat", "sparse subcutaneous fat", "subcutaneous fat loss"], "definition": "Kuru is a very rare, incurable neurodegenerative disorder that was formerly common among the Fore people of Papua New Guinea.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["obsolete Decreased subcutaneous fat", "obsolete Decreased subcutaneous fat", "obsolete Decreased subcutaneous fat", "obsolete Decreased subcutaneous fat", "obsolete Decreased subcutaneous fat", "Reduced subcutaneous adipose tissue", "obsolete Decreased subcutaneous fat", "obsolete Decreased subcutaneous fat", "obsolete Decreased subcutaneous fat"], "sib_relations": [], "wiki_entities": ["Filariasis", "Female body shape", "Role of skin in locomotion", "Kuru (disease)", "Progesterone (medication)", "Eye surgery", "Multiple sclerosis", "Progesterone", "Morphine"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU017273", "canonical_name": "Decreased subcutaneous fat", "aliases": ["decreased subcutaneous fat"], "definition": "In biology, adipose tissue  ( listen), body fat, or simply fat is a loose connective tissue composed mostly of adipocytes.", "other_contexts": [], "par_relations": ["Skin", "MUSCLE SOFT, TISSUE"], "chd_relations": [], "syn_relations": [], "sib_relations": ["MARFAN SYNDROME", "FUMARASE DEFICIENCY", "PROGEROID SYNDROME, NEONATAL", "HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME", "SCHOLTE SYNDROME", "ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME"], "wiki_entities": ["Adipose tissue", "Abdominal obesity", "Body fat redistribution syndrome", "Marasmus", "Bioelectrical impedance analysis", "Classification of obesity", "Adiposopathy", "Congenital generalized lipodystrophy", "Barraquer–Simons syndrome", "MDP syndrome"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0006802", "canonical_name": "Abnormal anterior horn cell morphology", "aliases": ["anomaly of the anterior horn cells", "abnormal anterior horn cell morphology", "anterior horn cell disease", "abnormality of the anterior horn cells", "abnormality of the anterior horn cell"], "definition": "The hippocampus (named after its resemblance to the seahorse, from the Greek ἱππόκαμπος, \"seahorse\" from ἵππος hippos, \"horse\" and κάμπος kampos, \"sea monster\") is a major component of the brains of humans and other vertebrates.", "other_contexts": [], "par_relations": ["Abnormal anterior horn cell morphology", "Abnormal motor neuron morphology", "Abnormal peripheral nervous system morphology"], "chd_relations": ["Degeneration of anterior horn cells", "Abnormal anterior horn cell morphology"], "syn_relations": ["Abnormal anterior horn cell morphology", "Abnormal anterior horn cell morphology", "Abnormal anterior horn cell morphology", "Abnormal anterior horn cell morphology", "Abnormal anterior horn cell morphology", "Abnormal anterior horn cell morphology"], "sib_relations": ["Peripheral neuropathy", "Neoplasm of the peripheral nervous system", "Hypertrophic nerve changes", "Abnormality of the cranial nerves", "Abnormal lower motor neuron morphology", "Diffuse axonal swelling", "Paucity of anterior horn motor neurons", "Abnormality of peripheral nerves", "Motor neuron atrophy", "Decreased size of nerve terminals", "Abnormal peripheral myelination", "Enhanced neurotoxicity of vincristine", "Abnormal upper motor neuron morphology", "Peripheral axonal degeneration"], "wiki_entities": ["Hippocampus", "Pretectal area", "Chromatolysis", "Heterochromia iridum", "Group C nerve fiber", "Cervix", "Pachygyria", "Astrocyte", "Zona incerta", "Ovary"], "mesh_synonynms": ["primary lateral sclerosis", "motor neuron disease", "scleroses, primary lateral", "sclerosis, lateral", "secondary motor neuron disease", "upper motor neuron disease", "primary lateral scleroses", "motor neuron disease, upper", "motor neuron disease, familial", "motor system diseases", "lateral sclerosis", "motor neuron disease, lower", "neuron disease, motor", "lateral scleroses, primary", "motor neuron diseases", "neuron diseases, motor", "motor neuron disease, secondary", "motor system disease", "sclerosis, primary lateral", "familial motor neuron disease", "scleroses, lateral", "lateral scleroses", "lower motor neuron disease", "lateral sclerosis, primary"], "dbpedia_synonyms": ["amyotrophic lateral sclerosis"]}, "target_ent": {"research_entity_id": "MSH:D016472", "canonical_name": "Motor Neuron Disease", "aliases": ["scleroses, lateral", "motor neuron disease", "lateral sclerosis", "upper motor neuron disease", "motor neuron dis second", "familial motor neuron disease", "motor system disease", "motor neuron dis lower", "scleroses, primary lateral", "lower motor neuron dis", "lateral scleroses, primary", "familial motor neuron dis", "second motor neuron dis", "primary lateral sclerosis", "lateral sclerosis, primary", "motor neuron dis familial", "neuron disease, motor", "motor neuron dis upper", "sclerosis, primary lateral", "lower motor neuron disease", "motor neuron disease, familial", "secondary motor neuron disease", "lateral scleroses", "motor neuron diseases", "upper motor neuron dis", "neuron diseases, motor", "motor system dis", "motor neuron disease, lower", "primary lateral scleroses", "motor system diseases", "sclerosis, lateral", "motor neuron disease, secondary", "motor neuron dis", "motor neuron disease, upper", "anterior horn cell dis", "anterior horn cell disease"], "definition": "A motor neuron disease (MND) is any of several neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body.", "other_contexts": ["AIM To examine the relationship between place of death and underlying cause of death in Parkinson's disease, multiple sclerosis and motor neurone disease and the impact of coding rule changes on analysis of place of death.", "Our review shows that amyotrophic lateral sclerosis/motor neuron disease patients and their caregivers' supportive care needs were mentioned across all seven domains of the Supportive Care Needs Framework.", "Our objective was to address this by exploring the experience of hospitalisation following a diagnosis of motor neuron disease from the perspective of family carers of those diagnosed with the illness .", "Dementia as underlying cause of death increased likelihood of care home death in Parkinson's disease (PR: 1.25, 95% CI = 1.19-1.32), multiple sclerosis (PR: 1.73, 95% CI = 1.22-2.45) and motor neurone disease (PR: 2.36, 95% CI = 1.31-4.27).", "Methods We performed a retrospective case control study on patients seen at the King's Motor Neuron Disease Care and Research Centre.", "provide multidisciplinary care to amyotrophic lateral sclerosis / motor neuron disease patients and individualised care .", "DESIGN/PARTICIPANTS This article reports data from qualitative interviews with family carers and professionals following the death of patients with motor neurone disease who were using non-invasive ventilation in the final phase of the disease.", ") , hospice deaths ranged from 0.6% ( Parkinson 's disease ) to 11.2% ( motor neurone disease ) and hospital deaths ranged from 43.4% ( Parkinson 's disease ) to 55.8% ( multiple sclerosis ) .", "coding procedures . SETTING / PARTICIPANTS A total of 34 people with motor neurone disease were recruited from the Irish motor neurone disease population - based register . RESULTS We", "A total of 34 people with motor neurone disease were recruited from the Irish motor neurone disease population - based register . RESULTS We identified that control , reassurance , resignation and", "OBJECTIVES To determine if all cases of pathologically confirmed FTLD - MND have clinical evidence of frontotemporal dementia and motor neuron disease , and to determine the possible reasons for misdiagnosis", "AIMS AND OBJECTIVES To identify the supportive care needs of amyotrophic lateral sclerosis/motor neuron disease patients and their caregivers, categorise and summarise them into a Supportive Care Needs Framework and identify gaps in literature.", "RELEVANCE TO CLINICAL PRACTICE The Supportive Care Needs Framework has potential utility in the development of patient-centred support services or healthcare policies and serves as an important base for further studies; especially, specific examples of each supportive care needs domain can guide in clinical settings when healthcare professionals provide multidisciplinary care to amyotrophic lateral sclerosis/motor neuron disease patients and individualised care.", "The multifaceted nature of the problems faced by someone with motor neuron disease requires a knowledgeable multidisciplinary team approach .", "BACKGROUND Non - invasive ventilation improves quality and quantity of life in patients with motor neurone disease who have respiratory failure .", "in future care choices ; however , this approach has rarely been explored in motor neuron disease . AIM We aimed to investigate caregiver perspectives on the acceptability and impact of advance", "Proper clinical studies, electrophysiology, and neuroimaging are necessary before reaching a diagnosis of motor neuron disease.", "From the perspectives of amyotrophic lateral sclerosis/motor neuron disease patients and their caregivers, there is a significant need for more practical, social, informational, psychological, physical, emotional and spiritual support.", "included . Home deaths ranged from 9.7% ( Parkinson 's disease ) to 27.1% ( motor neurone disease ) , hospice deaths ranged from 0.6% ( Parkinson 's disease ) to 11.2% ( motor neurone disease )", "articles were included . Our review shows that amyotrophic lateral sclerosis / motor neuron disease patients and their caregivers ' supportive care needs were mentioned across all seven domains of", ") the population sample included patients of amyotrophic lateral sclerosis / motor neuron disease or their caregivers . RESULTS Thirty - seven articles were included . Our review shows that", "AIM To identify key psycho-social processes that underpin how people with motor neurone disease engage with healthcare services.", ", and its relation with underlying cause of death , in Parkinson 's disease , motor neurone disease , and multiple sclerosis : a population - based study . BACKGROUND Little is known about place of", "with healthcare professionals and approach end - of - life care . People with motor neurone disease exert control in care and meaningful relationships with healthcare professionals are important to", "Behavioural and cognitive changes appear to occur in a subset of patients with motor neurone disease , but the cause of this variability remains unclear .", "1993 - 2010 ) with any mention of Parkinson 's disease , multiple sclerosis or motor neurone disease as a cause of death , identified from national mortality data . RESULTS In this study , 125,242", "RESULTS From a total of 17 cases of pathologically confirmed FTLD-MND, all had clinical evidence of frontotemporal dementia, while only 10 (59%) had clinical evidence of motor neuron disease. Semiquantitative analysis of motor and extramotor pathological findings revealed a spectrum of pathological changes underlying FTLD-MND.", "To investigate this in motor neuron disease a retrospective case-control study has been carried out on 15 negroid African and 45 white patients with the disease seen over 8 years.", "It is concluded that race may influence the phenotype and progression of motor neuron disease .", "CONCLUSION This study identified new and important aspects of control, trust and reassurance which shed light on how people with motor neurone disease engage with healthcare professionals and approach end-of-life care.", ". OBJECTIVES The multifaceted nature of the problems faced by someone with motor neuron disease requires a knowledgeable multidisciplinary team approach . Where available , generally , such", "Only the articles which concentrated on the ventilation , nutrition , cognitive or multidisciplinary approaches for motor neuron disease were included .", "DATA SYNTHESIS Motor neuron disease is an adult-onset neurodegenerative disease that leads to weakness of limb, bulbar, and respiratory muscles.", "Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease.", "- of - life care , but there has been paucity of research on how people with motor neurone disease understand and use healthcare services . AIM To identify key psycho - social processes that", "of control , trust and reassurance which shed light on how people with motor neurone disease engage with healthcare professionals and approach end - of - life care . People with motor neurone", "Reviewing evidences on the management of patients with motor neuron disease.", "In this study , 125,242 patients with Parkinson 's disease , 23,501 with multiple sclerosis , and 27,030 with motor neurone disease were included .", "this by exploring the experience of hospitalisation following a diagnosis of motor neuron disease from the perspective of family carers of those diagnosed with the illness . METHOD This was a", "PURPOSE OF REVIEW Motor neurone disease has traditionally been considered a pure motor syndrome which spares aspects of cognition and behaviour, although in recent years it has been suggested that up to 50% of patients with motor neurone disease may develop frontal dysfunction which, in some cases, is severe enough to reach criteria for frontotemporal dementia.", "the supportive care needs perspective of amyotrophic lateral sclerosis / motor neuron disease patients or their caregivers and ( iv ) the population sample included patients of amyotrophic", "OBJECTIVE To review evidences on the management of patients with motor neuron disease.", "The chance of presenting with the \" flail arm \" variant of motor neuron disease was four times as high in the African group than the white group (odds ratio 4.33, p=0.05, 95% confidence interval 0.99–18.92).", "Detection of signs of clinical motor neuron disease is also difficult when motor neuron degeneration is mild and in patients with hippocampal sclerosis.", "( n = 8) . CONCLUSION From the perspectives of amyotrophic lateral sclerosis / motor neuron disease patients and their caregivers , there is a significant need for more practical , social ,", "To identify the supportive care needs of amyotrophic lateral sclerosis / motor neuron disease patients and their caregivers , categorise and summarise them into a Supportive Care Needs", "PARTICIPANTS AND SETTING Structured interviews were held with 18 former caregivers of deceased patients with motor neuron disease .", ". Tools and strategies for increasing the efficacy of advance care planning for motor neuron disease should be evaluated and implemented .", "BACKGROUND People with motor neurone disease access healthcare services from disease onset to end-of-life care, but there has been paucity of research on how people with motor neurone disease understand and use healthcare services.", "The ability to detect the clinical signs of dementia and motor neuron disease in pathologically confirmed FTLD-MND has not been assessed.", "carers and health - care professionals perceived that the terminal phase of motor neurone disease was unexpectedly rapid and that this often led to unplanned interactions with the emergency", "Hippocampal sclerosis , predominantly of the subiculum , was a significantly more frequent occurrence in the cases without clinical evidence of motor neuron disease ( P<.01 ) .", "in motor neurone disease : a qualitative study . BACKGROUND People with motor neurone disease access healthcare services from disease onset to end - of - life care , but there has been paucity", "People with motor neurone disease exert control in care and meaningful relationships with healthcare professionals are important to them.", "Each African was compared with three age and sex matched white patients with motor neuron disease.", "interviews were held with 18 former caregivers of deceased patients with motor neuron disease . A total of 10 patients had created a disease - specific advanced directive , ' Letter of Future", "Family carer perspectives of acute hospital care following a diagnosis of motor neuron disease: a qualitative secondary analysis.", "BACKGROUND Little is known about the supportive care needs of amyotrophic lateral sclerosis/motor neuron disease patients and their caregivers, and this subject has not previously been systemically reviewed.", "There is an increasing body of evidence suggesting that race can aVect the clinical phenotype and progression of certain neurodegen - erative diseases , including Parkinson 's disease and motor neuron disease .", "Cognition and behaviour in motor neurone disease.", "- invasive ventilation improves quality and quantity of life in patients with motor neurone disease who have respiratory failure . Use of non - invasive ventilation may , however , result in complex", "CONCLUSION Motor neuron disease is an incurable disease, for which a highly effective treatment is still pending.", "AIM We aimed to investigate caregiver perspectives on the acceptability and impact of advance care planning , documented in a letter format , for patients with motor neuron disease and caregivers .", "To test this hypothesis , we carried out a case - control study on the phenotype of motor neuron disease in patients of African and white origin .", "SETTING/PARTICIPANTS A total of 34 people with motor neurone disease were recruited from the Irish motor neurone disease population-based register.", "We identified 15 African patients originating from West Africa or the Caribbean, and matched each patient with three white motor neuron disease controls.", "CONCLUSIONS Patients with motor neuron disease have specialist needs that are not always met during hospital admission, particularly to non-specialist units.", "A multidisciplinary approach embracing advances in non-invasive ventilation and gastrostomy can improve quality of life and extend the survival of motor neuron disease patients.", "STUDY SELECTION Key words for literature search were \"motor neuron disease review (MND)\".", "Home deaths ranged from 9.7% (Parkinson's disease) to 27.1% (motor neurone disease), hospice deaths ranged from 0.6% (Parkinson's disease) to 11.2% (motor neurone disease) and hospital deaths ranged from 43.4% (Parkinson's disease) to 55.8% (multiple sclerosis).", "1–4 In evaluating patients with motor neuron disease in the King 's Motor Neuron Disease Care and Research Centre , we had the impression that a syndrome of predominant arm weakness , which we have termed the \" flail arm \" syndrome 5 ( also known as Vulpian - Bernhardt variant 6 7 ) was more common in people of African descent .", "The study involved interview data from 18 bereaved carers and 3 current carers of family members diagnosed with motor neuron disease in Northwest England .", "We review the cognitive and behavioural changes in motor neurone disease emphasizing the recent advances.", "All participants were classified according to the El Escorial World Federation of Neurology Criteria for motor neuron disease.", "PARTICIPANTS Deaths in England (1993-2010) with any mention of Parkinson's disease, multiple sclerosis or motor neurone disease as a cause of death, identified from national mortality data.", "with Parkinson 's disease , 23,501 with multiple sclerosis , and 27,030 with motor neurone disease were included . Home deaths ranged from 9.7% ( Parkinson 's disease ) to 27.1% ( motor neurone", "describe carer and health professional experiences of end - of - life care of motor neurone disease patients using non - invasive ventilation . DESIGN / PARTICIPANTS This article reports data from", ". AIM To identify key psycho - social processes that underpin how people with motor neurone disease engage with healthcare services . DESIGN Grounded theory approach comprising in - depth", "psycho - social processes underpinning engagement with services in motor neurone disease : a qualitative study . BACKGROUND People with motor neurone disease access healthcare services", "with healthcare professionals are important to them . Some people with motor neurone disease prefer to die without life - sustaining interventions .", "Some people with motor neurone disease prefer to die without life - sustaining interventions .", "The use of non-invasive ventilation at end of life in patients with motor neurone disease: a qualitative exploration of family carer and health professional experiences.", "Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. BACKGROUND Motor neuron disease is a fatal disease, characterised by progressive loss of motor function, often associated with cognitive deterioration and, in some, the development of frontotemporal dementia.", "Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.", "Participants questioned the benefit of life - sustaining interventions in motor neurone disease and few of them associated life - sustaining interventions with palliative care .", "Understanding psycho-social processes underpinning engagement with services in motor neurone disease: a qualitative study.", "with family carers and professionals following the death of patients with motor neurone disease who were using non - invasive ventilation in the final phase of the disease . RESULTS Ten of the 20", "neuron disease : A qualitative study of caregiver perspectives . BACKGROUND Motor neuron disease is a fatal disease , characterised by progressive loss of motor function , often associated with", "In addition, neuronal loss, gliosis, and corticospinal tract degeneration were less severe in the other 3 cases without clinical evidence of motor neuron disease.", "Non-invasive positive pressure ventilation prolongs life in motor neuron disease patients with respiratory failure.", "BACKGROUND Frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) is a pathological entity characterized by motor neuron degeneration and frontotemporal lobar degeneration.", "of advance care planning , documented in a letter format , for patients with motor neuron disease and caregivers . DESIGN This is a qualitative cross - sectional study . Data were analysed by a", "hospital admissions but also on carer bereavement . CONCLUSIONS Patients with motor neuron disease have specialist needs that are not always met during hospital admission , particularly to non -", "Longitudinal studies showed that progression of cognitive impairment over the course of motor neurone disease appears to be mild and occurs only in a proportion of motor neurone disease patients.", "underlying cause of death in Parkinson 's disease , multiple sclerosis and motor neurone disease and the impact of coding rule changes on analysis of place of death . DESIGN Population - based", "METHODS We conducted a scoping review from the MEDLINE, EMBASE, CINAHL and Cochrane databases for the period January 2000-July 2016, using the following inclusion criteria: (i) written in English only, (ii) published in peer-reviewed journals, (iii) at least part of the research considered the supportive care needs perspective of amyotrophic lateral sclerosis/motor neuron disease patients or their caregivers and (iv) the population sample included patients of amyotrophic lateral sclerosis/motor neuron disease or their caregivers.", "Tools and strategies for increasing the efficacy of advance care planning for motor neuron disease should be evaluated and implemented.", ". Participants questioned the benefit of life - sustaining interventions in motor neurone disease and few of them associated life - sustaining interventions with palliative care . Participants", "Place of death , and its relation with underlying cause of death , in Parkinson 's disease , motor neurone disease , and multiple sclerosis : a population - based study .", "RECENT FINDINGS A major advance in pathology has been the recent discovery of TDP-43 and FUS inclusions as the key components in cases of motor neurone disease, frontotemporal dementia-motor neurone disease and some cases with pure frontotemporal dementia.", "AIM This study aimed to describe carer and health professional experiences of end-of-life care of motor neurone disease patients using non-invasive ventilation.", "Phenotypic diVerences between African and white patients with motor neuron disease : a case - control study There is increasing evidence that race may aVect the phenotype in some neuro - degenerative diseases .", ", resignation and trust are key variables that shape how people with motor neurone disease engage with healthcare services . Participants exerted control in care to cope with loss . Most", "Timely commencement of 'Advance Care Planning' enables patients to participate in future care choices; however, this approach has rarely been explored in motor neuron disease.", "is known about the supportive care needs of amyotrophic lateral sclerosis / motor neuron disease patients and their caregivers , and this subject has not previously been systemically reviewed .", "Multidisciplinary care units are important in the management of motor neuron disease patients.", "Both carers and health - care professionals perceived that the terminal phase of motor neurone disease was unexpectedly rapid and that this often led to unplanned interactions with the emergency services .", "= 1.19 - 1.32 ) , multiple sclerosis ( PR : 1.73 , 95% CI = 1.22 - 2.45 ) and motor neurone disease ( PR : 2.36 , 95% CI = 1.31 - 4.27 ) . CONCLUSIONS Underlying cause of death has a marked effect", "RESULTS We identified that control, reassurance, resignation and trust are key variables that shape how people with motor neurone disease engage with healthcare services.", "from 18 bereaved carers and 3 current carers of family members diagnosed with motor neuron disease in Northwest England . RESULTS The findings reveal dissatisfaction with the inpatient care"], "par_relations": ["Neuromuscular Diseases", "Neurodegenerative Diseases", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease"], "chd_relations": ["Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Amyotrophic Lateral Sclerosis", "Muscular Atrophy, Spinal", "Bulbar Palsy, Progressive", "Neuropathy, Hereditary Sensorimotor, with Upper Motor Neuron, Visual Pathway and Autonomic Disturbance", "Motor Neuron Disease with Dementia and Ophthalmoplegia", "Primary lateral sclerosis juvenile", "Primary Lateral Sclerosis, Adult, 1", "Lethal Arthrogryposis With Anterior Horn Cell Disease"], "syn_relations": ["Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease", "Motor Neuron Disease"], "sib_relations": ["Motor Neurons", "Fatigue Syndrome, Chronic", "Muscular Diseases", "Parkinson Disease", "Peripheral Nervous System Diseases", "Poliomyelitis", "Postpoliomyelitis Syndrome", "Stiff-Person Syndrome", "Prion Diseases", "Subacute Combined Degeneration", "Multiple System Atrophy", "Heredodegenerative Disorders, Nervous System", "Paraneoplastic Syndromes, Nervous System", "Neuromuscular Junction Diseases", "Lewy Body Disease", "Tauopathies", "TDP-43 Proteinopathies", "Chronic Traumatic Encephalopathy"], "wiki_entities": ["Motor neuron disease", "Motor neuron", "Amyotrophic lateral sclerosis", "Madras motor neuron disease", "Lower motor neuron lesion", "Upper motor neuron lesion", "Alpha motor neuron", "Neuron", "Neuromuscular disease", "Parkinson's disease"], "mesh_synonynms": ["primary lateral sclerosis", "motor neuron disease", "scleroses, primary lateral", "sclerosis, lateral", "secondary motor neuron disease", "upper motor neuron disease", "primary lateral scleroses", "motor neuron disease, upper", "motor neuron disease, familial", "motor system diseases", "lateral sclerosis", "motor neuron disease, lower", "anterior horn cell disease", "neuron disease, motor", "lateral scleroses, primary", "motor neuron diseases", "neuron diseases, motor", "motor neuron disease, secondary", "motor system disease", "sclerosis, primary lateral", "familial motor neuron disease", "scleroses, lateral", "lateral scleroses", "lower motor neuron disease", "lateral sclerosis, primary"], "dbpedia_synonyms": ["amyotrophic lateral sclerosis", "primary lateral sclerosis", "motor neuron disease", "motor neuron diseases", "lower motor neuron lesion"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D020967", "canonical_name": "Myotonic Disorders", "aliases": ["myotonic myopathy", "myopathy, myotonic", "disorder, myotonic", "myotonic disorder", "von eulenberg's disease", "myotonia fluctuans", "myotonic myopathies", "disorders, myotonic", "paramyotonia congenita without cold paralysis", "eulenburg's disease", "von eulenberg disease", "paralysis periodica paramyotonia", "paramyotonia congenita of von eulenberg", "eulenburgs dis", "paramyotonia congenita", "myotonic disorders", "myopathies, myotonic", "paramyotonia congen", "eulenburg dis", "myotonic dis", "eulenburg disease"], "definition": "Myotonia (Myo from Greek; muscle, and Tonus from Latin; tension) is a symptom of a small handful of certain neuromuscular disorders characterized by delayed relaxation (prolonged contraction) of the skeletal muscles after voluntary contraction or electrical stimulation.", "other_contexts": ["We review the pathomechanisms of myotonia, the clinical features of the dystrophic and nondystrophic myotonic disorders, and the diagnostic approach and treatment options for patients with symptomatic myotonia.", "This mini-review describes proximal myotonic myopathy, a recently delineated, dominantly inherited disorder that is similar to but distinct from myotonic dystrophy.", "Myotonic disorders: A review article The myotonic disorders are a heterogeneous group of genetically determined diseases that are unified by the presence of myotonia, which is defined as failure of muscle relaxation after activation.", "Western blot analyses of the tau protein showed a triplet of isoforms (60, 64 and 69 kDa) in neocortical areas, and a doublet (64 and 69 kDa) in subcortical areas that distinguish our myotonic disorder from other's myotonic dystrophies.", "Proximal myotonic myopathy is not linked to the gene locus for myotonic dystrophy or to the loci of the genes of the muscle sodium and chloride channels associated with other myotonic disorders.", "Moreover, there have been few randomized controlled trials of treatment for myotonic disorders and consequently no standardized treatment regimens are available.", "The combination of myotonic myopathy and parkinsonism is so rare that it may appear to be just a coincidence.", "New classification and treatment for myotonic disorders.", "There are other myotonic disorders related to Na channelopathy which include three disorders : paramyotonia congenita , adynamia episodica hereditaria , and myotonia fluctuans .", "A patient with proximal myotonic myopathy and parkinsonism.", "Abstract History of Myotonia Research New Classification and Treatment for Myotonic Disorders Myotonia is repetitive firing of muscle action potentials causing prolonged muscle contractions even after mechanical stimulations to the muscles have ceased.", "In Japan, proximal myotonic myopathy, which is now called DM2 has not been reported.", "Proximal myotonic myopathy : mini - review of a recently delineated clinical disorder .", "We present a review of selected treatment trials in the myotonic disorders and in muscle channelopathies, and discuss, on the basis of our experience in the myotonic disorders, the limits and advantages of treatment trials in this field.", "Diseases that resemble the inherited myotonic disorders are now easier to identify , and as a result of genetic testing a new clinical disorder that is similar to but distinct from myotonic dystrophy has emerged .", "In this review, we describe the clinical features and pathophysiology of the different myotonic disorders, their laboratory and electrophysiologic findings and briefly review the currently available treatments.", "The purpose of this review is to discuss the clinical presentation , recent advances in understanding the disease mechanism with particular emphasis on myotonic dystrophies and potential therapy options in myotonic disorders .", "The majority of proximal myotonic myopathy syndromes reported so far have been related to the myotonic dystrophy (DM) type 2 (DM2) mutation, an expanded (CCTG)n repeat in the ZNF9 gene.", "INTRODUCTION There are two case reports of patients who had proximal myotonic myopathy (PROMM)/myotonic dystrophy (DM) Type 1 and parkinsonism.", "Research interest in the myotonic disorders continues to expand rapidly, which justifies a review of the scientific bases, clinical manifestations, and numerous therapeutic approaches associated with these disorders.", "This new disorder, proximal myotonic myopathy, does not appear to be linked to the genes for the sodium or chloride channels, and has cataracts, myotonia, weakness, and no abnormal expansion of the [CTG]n repeat in the gene for myotonic dystrophy.", "Despite the recent progress in molecular genetics of these myotonic disorders, the precise mechanisms responsible for myotonia and for permanent or episodic muscle weakness are still unclear.", "A non - DM1 , non - DM2 multisystem myotonic disorder with frontotemporal dementia : phenotype and suggestive mapping of the DM3 locus to chromosome 15q21 - 24 .", "The gene defect responsible for proximal myotonic myopathy awaits discovery.", "This review discusses the diagnosis and treatment of these myotonic disorders .", "We suggest that this may be a novel form of a neurodegenerative disorder, which we name 'Parkinsonism-Myotonic Myopathy-Complex'.", "This previously unreported multisystem myotonic disorder including findings resembling DM1, DM2 and frontotemporal dementia provides further evidence of the clinical and genetic heterogeneity of the myotonic dystrophies.", "However, previous neuropathological examinations of patients who had myotonic dystrophy showed that there were intracytoplasmic inclusion bodies in the nigra and striatum, which raises the possibility that myotonic myopathy may be associated with parkinsonism.", "Because of the clinical similarities between proximal myotonic myopathy and myotonic dystrophy, clarification of the genetic differences will not only shed light on the pathomechanism of proximal myotonic myopathy, but may also increase our understanding of myotonic dystrophy.", "Myotonic disorders.", "Therapy in myotonic disorders and in muscle channelopathies Myotonia and muscle weakness are cardinal features of myotonic disorders including the myotonic dystrophies and the non-dystrophic myotonias.", "The diagnosis and treatment of myotonic disorders.", "Key words : myotonic dystrophy type 1 ( DM1 ) , Thomsen 's disease , autosomal recessive generalized myotonia ( Becker type ) , paramyotonia congenita , adynamia episodica hereditaria , myotonia fluctuans If we quickly review the important investigations of myotonic disorders we can start out from Landau 's work in 1952 ( 1 ) , when he described that myotonia occurs even when we block the peripheral nerves , and neuromuscular junctions ; therefore , myotonia occurs due to an abnormality of the muscle membrane .", "Myotonic disorders in childhood : diagnosis and treatment .", "Myotonia is a defining clinical symptom and sign common to a relatively small group of muscle diseases, including the myotonic dystrophies and the nondystrophic myotonic disorders.", "Myotonic disorders include the myotonic dystrophies and nondystrophic myotonias .", "Most common myotonic disorder is myotonic dystrophy which is now termed DM1, myotonic dystrophy type 1.", "Here, we describe the phenotype and the histological features in muscle and brain of the first large pedigree with a non-myotonic dystrophy type 1 (DM1) non-DM2 multisystem myotonic disorder associated with severe frontotemporal dementia."], "par_relations": ["Myotonic Disorders", "Muscular Diseases", "Myotonic Disorders", "Myotonic Disorders"], "chd_relations": ["Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Dystrophy", "Myotonia Congenita", "Myotonic Myopathy with Cylindrical Spirals"], "syn_relations": ["Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders", "Myotonic Disorders"], "sib_relations": ["Arthrogryposis", "Compartment Syndromes", "Contracture", "Fatigue Syndrome, Chronic", "Fibromyalgia", "Muscle Cramp", "Muscle Rigidity", "Muscle Spasticity", "Musculoskeletal Pain", "Myofascial Pain Syndromes", "Myositis", "Paralyses, Familial Periodic", "Polymyalgia Rheumatica", "Rhabdomyolysis", "Craniomandibular Disorders", "Eosinophilia-Myalgia Syndrome", "Muscle Weakness", "Mitochondrial Myopathies", "Myalgia", "Isaacs Syndrome", "Muscle Neoplasms", "Myopathies, Structural, Congenital", "Muscular Disorders, Atrophic", "Tendinopathy", "Medial Tibial Stress Syndrome"], "wiki_entities": ["Myotonia", "Myotonic dystrophy", "Fainting goat", "List of neuromuscular disorders", "Muscular dystrophy", "Dystrophy", "Trinucleotide repeat disorder", "Anticipation (genetics)", "Myotonin-protein kinase", "RNA-dominant disease"], "mesh_synonynms": ["disorders, myotonic", "paramyotonia congenita without cold paralysis", "myotonic disorder", "myotonic myopathy", "paramyotonia congenita", "myotonia fluctuans", "von eulenberg disease", "paramyotonia congenita of von eulenberg", "eulenburg disease", "eulenburg's disease", "myopathy, myotonic", "paralysis periodica paramyotonia", "myotonic disorders", "disorder, myotonic", "von eulenberg's disease", "myotonic myopathies", "myopathies, myotonic"], "dbpedia_synonyms": ["paramyotonia congenita", "paramyotonia congenita of von eulenburg", "myotonia", "eulenburg disease", "paralysis periodica paramyotonia", "von eulenberg's disease"]}, "target_ent": {"research_entity_id": "OMIM:168300", "canonical_name": "PARAMYOTONIA CONGENITA OF VON EULENBURG", "aliases": ["paralysis periodica paramyotonica", "paramyotonia congenita without cold paralysis", "pmc", "paramyotonia congenita of von eulenburg"], "definition": "Paramyotonia congenita (PC), also known as paramyotonia congenita of von Eulenburg or Eulenburg disease, is a rare congenital autosomal dominant neuromuscular disorder characterized by “paradoxical” myotonia.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["PARAMYOTONIA CONGENITA OF VON EULENBURG", "PARAMYOTONIA CONGENITA OF VON EULENBURG", "PARAMYOTONIA CONGENITA OF VON EULENBURG", "PARAMYOTONIA CONGENITA OF VON EULENBURG"], "sib_relations": ["Muscle stiffness", "Muscle pain", "Muscle hypertrophy", "Autosomal dominant", "Percussion myotonia", "Onset in infancy or early childhood", "Highly variable phenotype", "Allelic disorder to hypokalemic periodic paralysis (HOKPP, 170400)", "Allelic disorder to potassium-aggravated myotonia (608390)", "Allelic disorder to hyperkalemic periodic paralysis (HYPP, 170500)", "Grip myotonia", "Paradoxical myotonia (myotonia increases with exercise)", "Decreased muscle action potential after warming affected muscle", "Episodic weakness may or may not occur independent of myotonia", "Usually no myopathic changes on biopsy", "Potassium sensitivity has been reported", "Patients may have a combination phenotype of PMC and HYPP (see 603967.0005)", "Affected females report aggravation of symptoms during menstrual periods and pregnancy, with alleviation after menopause", "Transient neonatal hypotonia (less common)", "Some patients may present with transient neonatal hypotonia, and then later develop classic PMC in childhood", "Alcohol may alleviate symptoms", "Myotonia, cold-sensitive, predominantly of face, tongue, forearm, and hand precipitated by muscle cooling or cold exposure or rest after exercise", "Muscle weakness after cooling or on warming affected muscle", "Caused by mutation in the alpha-subunit of the type IV voltage-gated sodium channel gene (SCN4A, 603967.0003)", "Poor feeding in early life", "Inspiratory stridor in early life"], "wiki_entities": ["Paramyotonia congenita", "Albert Eulenburg", "List of diseases (P)"], "mesh_synonynms": ["disorders, myotonic", "myotonic disorder", "myotonic myopathy", "paramyotonia congenita", "myotonia fluctuans", "von eulenberg disease", "paramyotonia congenita of von eulenberg", "eulenburg disease", "eulenburg's disease", "myopathy, myotonic", "paralysis periodica paramyotonia", "myotonic disorders", "disorder, myotonic", "von eulenberg's disease", "myotonic myopathies", "myopathies, myotonic"], "dbpedia_synonyms": ["paramyotonia congenita", "pmc (disambiguation)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C005034", "canonical_name": "hexafluorenium", "aliases": ["hexafluorenium", "hexamethylenebis(fluoren-9-yldimethylammonium) dibromide", "mylaxen", "hexafluorenium bromide", "hexafluronium bromide", "hexafluorenium dibromide salt"], "definition": "Hexafluronium (or hexafluorenium) is a muscle relaxant.", "other_contexts": ["Groups IV - VI were pretreated with hexafluorenium 0.3 mg kg-1 .", "The desensitizing interaction of hexafluorenium with the cholinergic receptor in the diaphragm of the rat . 1 .", "Arrowood and Kaplan ( 1956 ) reported on the combined use of hexafluorenium and suxa - methonium in thirty patients .", "It is concluded that , in man , hexafluorenium can modify the action of suxamethonium by two different mechanisms .", "They postulated that the \" blanket - ing \" of non - specific liphophflic sites ( fat depots , nervous tissue and cell membrane structures ) by anaesthetic agents possessing high lipoid affinities would lessen the attraction of these receptors for hexafluorenium , and thus enhance its action at the neuromuscular junction .", "Interaction of hexafluorenium with human plasma cholinesterase in comparison with hexamethonium 1 .", "The first report of serious complications resulting from the administration of hexafluorenium , was published by Selvin and Howland ( 1959 ) .", "They used a mixture of hexafluorenium and suxamethonium in six patients ; bronchospasm was observed in all cases and proved fatal …", "Hexafluorenium enhanced the desensitization by suxamethonium .", "Hexafluorenium extension of suxamethonium block .", "Hexafluorenium was prepared in 1954 by Caval - lito , Gray and Spinner , as one of a group of bis - fluorenyl - bis - quaternary ammonium compounds , and a preliminary account of its pharmacological actions was given by Macri ( 1954 ) .", "In the normal child , hexafluorenium produced a marked potentiation of suxamethonium block , while partially antagonizing the block in the atypical homozygote child .", "The influence of the 2 alkane - bis - onium compounds hexafluorenium ( HFl ) and hexamethonium ( C6 ) on human plasma cholinesterase ( ChE ) was studied with respect to the type of inhibition .", "The first report of the use of hexafluorenium to provide muscle relaxation during surgical operations was published by Cordaro and Arro - wood ( 1955 ) .", "Suxamethonium 1.0 mg kg-1 alone caused the serum potassium to increase to values greater than control ; hexafluorenium attenuated this effect .", "Potentiation of the neuromuscular effect of succinylcholine by hexafluorenium .", "The interaction of the bisquaternary ammonium compound hexafluorenium with the histaminic receptor in the guinea - pig ileum .", "They concluded that suxamethonium intensified the neuromuscular block produced by hexafluorenium .", "The serum potassium concentration decreased significantly after the induction of anaesthesia and also following the administration of hexafluorenium .", "Anesthesia was maintained by 0.5 micrograms / kg increments of fentanyl , muscle relaxation by increments of 0.15 mg / kg or less hexafluorenium and 0.2 mg / kg or less succinylcholine , depending on the surgical time requirements .", "In both situations , the hexafluorenium - suxamethonium block appeared to be antidepolarizing in nature as indicated by tetanic fade and post - tetanic facilitation .", "They utilized a continuous intravenous drip , containing 0.02 per cent hexafluorenium , and intermittent injections of suxamethonium ( 10 - 20 mg ) , to maintain apnoea .", "2 . Hexafluorenium inhibited acetylcholinesterase in the end - plate .", "Neither suxamethonium 0.2 mg nor 0.6 mg kg-1 with or without hexafluorenium restored the potassium concentration to the control value .", "Two important observations emerged from this study : that hexafluor - enium was more effective during ether and cyclo - propane anaesthesia than during nitrous oxide or thiopentone administration , and was practically ineffective in the unanaestherized human subject ; and that in two patients who received suxa - methonium 30 mg , following fractional doses of hexafluorenium , apnoea lasting 20 and 30 minutes respectively occurred .", "The combination of hexafluorenium and suxamethonium may be of benefit in patients who are anephric or are in chronic renal failure .", "For endotracheal intubation and further relaxation 0.3 mg / kg hexafluorenium , followed in 5 minutes by 0.2 mg / kg succinylcholine were given intravenously .", "Prevention of suxamethonium - induced changes in serum potassium concentration by hexafluorenium .", "SUMMARY Clinical trials of the effectiveness of hexafluorenium ( Mylaxen ) , as an extender of suxamethonium block , have been conducted in 645 administrations of halothane .", "The effect of hexafluorenium 0.3 mg / kg on the neuromuscular block of suxamethonium 0.1 mg / kg in a child with homozygote atypical plasma cholinesterase activity and in one of his normal brothers has been compared .", "The desensitizing interaction of hexafluorenium with the receptors may explain the non - competitive antagonism with depolarizing drugs with regard to the depolarization of the end - plate and the synergism with these drugs with regard to the paralysis of the indirectly stimulated muscle reported earlier .", "The potentiation of the neuromuscular blocking activity of hexafluorenium and d - tubocurarine by volatile anaesthetics .", "Effects of bisquaternary ammonium compound hexafluorenium on the cholinergenic system in the jejunum of the rat and the guinea - pig .", "The interaction of hexafluorenium with acetylcholine , carbachol and suxamethonium with regard to the depolarization of the end - plate of rat diaphragm was studied .", "Prevention of succinylcholine induced hyperkalemia by neurolept anesthesia and hexafluorenium in anephric patients ."], "par_relations": ["Fluorenes", "Hexamethonium Compounds", "hexafluorenium", "hexafluorenium", "hexafluorenium", "hexafluorenium"], "chd_relations": ["hexafluorenium", "hexafluorenium", "hexafluorenium", "hexafluorenium"], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Hexafluronium bromide"], "mesh_synonynms": [], "dbpedia_synonyms": ["mylaxen", "hexafluronium bromide", "milaxen", "atc code m03ac05", "hexafluronium", "atcvet code qm03ac05"]}, "target_ent": {"research_entity_id": "RXNORM:53017", "canonical_name": "HEXAFLUORENIUM BROMIDE", "aliases": ["hexafluorenium bromide"], "definition": "Hexafluronium (or hexafluorenium) is a muscle relaxant.", "other_contexts": ["The effectiveness of pretreatment with subparalyzing doses ( \" self - taming \" ) of SCC or with the cholinesterase inhibitor hexafluorenium bromide in preventing hyperkalemia was also studied .", "The differences in percentage inhibition by hexafluorenium bromide [ hexamethylene1,6-bis-(9-fluorenyldimethylammonium ) dibromide ( Mylaxa , Nessler , Mallinckrodt , Germany ) ] and in polyacrylamide - gel disc - electrophoretic pattern of the hydrolytic activity of acetylthiocholine iodide of different fractions of rat jejunum have been reported by Das & Sayer ( 1 975 ) ."], "par_relations": ["hexafluorenium"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Hexafluronium bromide"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D038261", "canonical_name": "Alexander Disease", "aliases": ["alexanders disease", "leukodystrophy with rosenthal fibers", "fibrinoid degeneration of astrocytes", "alexander's disease", "alexander disease", "dysmyelinogenic leukodystrophy", "demyelinogenic leukodystrophy"], "definition": "Alexander disease, also known as fibrinoid leukodystrophy, is a progressive and fatal neurodegenerative disease.", "other_contexts": ["detection of the gene mutation . Here we present six Polish children affected of Alexander disease with congenital ( 1 ) , infantile ( 4 ) and juvenile ( 1 ) form . Five of them were previously", "Unusual variants of Alexander's disease.", "To elucidate the genotype-phenotype correlation in Alexander's disease, molecular diagnosis and MRI examination are required for many patients and their families.", "considered as leukodystrophy - experience of an institution . Alexander Disease ( ALXDRD ) is an autosomal dominant leukodystrophy caused by mutation in one allele of GFAP gene , encoding", "In all the cases of Alexander's disease examined, strong immunolabeling of RF by the antibodies to 4-hydroxy-2-nonenal pyrrole adducts were noted.", "Quantitative Evaluation of Brain Stem Atrophy Using Magnetic Resonance Imaging in Adult Patients with Alexander Disease.", "Asymptomatic hereditary Alexander's disease caused by a novel mutation in GFAP.", "Recent identification of GFAP gene mutations in the sporadic infantile- and juvenile-onset Alexander's disease prompted us to examine the GFAP gene in two Japanese hereditary adult-onset Alexander's disease brothers with autopsy in one case.", "There are three clinical subtypes of ALXDRD: infantile, juvenile and adult form, but congenital form is also outlined.", "characterized by degeneration of the white matter in the central nervous system . Alexander disease is a leukodystrophy that is usually observed in early childhood but rarely in adults . It is", "The L331P mutation may be associated with the mild phenotype of Alexander's disease.", "Advanced lipid peroxidation end-products in Alexander's disease.", "acidic protein ( GFAP ) gene that causes Alexander disease . CONCLUSIONS Alexander disease should be considered in the differential diagnosis of infantile leukoencephalopathy , even when no", "Oblongata and Upper Cervical Cord on Magnetic Resonance Imaging Adult - onset Alexander disease ( AOAD ) has been increasingly recognized since the identification of the glial fibrillary acidic", "A Case of Adult-Onset Alexander Disease Featuring Severe Atrophy of the Medulla Oblongata and Upper Cervical Cord on Magnetic Resonance Imaging Adult-onset Alexander disease (AOAD) has been increasingly recognized since the identification of the glial fibrillary acidic protein gene mutation in 2001.", "Hereditary adult-onset Alexander's disease shows progressive spastic paresis, bulbar or pseudobulbar palsy, palatal myoclonus symptomatologically, and prominent atrophy of the medulla oblongata and upper spinal cord on magnetic resonance imaging.", ", both clinical and radiological , between mitochondrial leukoencephalopathies and Alexander disease , an astrogliopathy . Clinically , both can manifest with a myriad of symptoms and signs , arising", "Although most are sporadic, occasional familial Alexander's disease cases have been reported for each subtype.", "Identification of GFAP gene mutation in hereditary adult-onset Alexander's disease.", "In this study, we immunohistochemically examined three cases of Alexander's disease using antibodies to a lysine-derived pyrrole modification arising from 4-hydroxy-2-nonenal, a highly cytotoxic reactive aldehyde produced by lipid peroxidation.", "These results suggest the existence of a forme fruste of Alexander's disease.", "Rosenthal fibers (RF), intra-astrocytic hyaline inclusions, accumulate in various pathological conditions and are the histological hallmark of Alexander's disease.", "Furthermore, taken together with our previous data indicating advanced Maillard reaction end products in RF, it seems that post-translational modification of RF, initiated by oxidative stress, is critical for both the accumulation and the insolubility of RF, and therefore, by inference, in the pathogenesis of Alexander's disease.", "- astrogliopathy considered as leukodystrophy - experience of an institution . Alexander Disease ( ALXDRD ) is an autosomal dominant leukodystrophy caused by mutation in one allele of GFAP gene ,", "The proband, a 16-month-old boy, presented with megalocephaly and brain magnetic resonance imaging (MRI) showing the typical findings of Alexander's disease.", "We studied 10 patients who did not meet previously established magnetic resonance imaging (MRI) criteria for Alexander's disease, but for whom this diagnosis was considered because of Rosenthal fibers at histological examination or presence of some MRI features suggestive of Alexander's disease.", "This is the first report of identification of the causative mutation of the GFAP gene for neuropathologically proven hereditary adult-onset Alexander's disease, suggesting a common molecular mechanism underlies the three Alexander's disease subtypes.", "We report on a family with dominantly inherited asymptomatic Alexander's disease due to a novel Glial fibrillary acidic protein (GFAP) mutation.", "These results indicate that modification of protein by lipid peroxidation adducts may play an important role in the formation of RF as well as in the pathogenesis of Alexander's disease.", "In conclusion, DNA diagnostics is warranted in patients who display MRI features suggestive of Alexander's disease, even if they do not meet the full set of previously established MRI criteria.", "protein ( GFAP ) . Most cases occur due to de novo . There are three clinical subtypes of ALXDRD : infantile , juvenile and adult form , but congenital form is also outlined . The disease 's", "mutations in the glial fibrillary acidic protein ( GFAP ) gene that causes Alexander disease . CONCLUSIONS Alexander disease should be considered in the differential diagnosis of infantile", "spectroscopy may reveal elevation of lactate in the abnormal white matter in Alexander disease making the distinction even more challenging . PATIENT AND METHODS We present a child who was", "in Adult Patients with Alexander Disease . Brain MRI in adult patients with Alexander disease ( AxD ) mainly shows atrophy in the medulla oblongata . However , currently there is no", "- old patient . He had megalencephaly since birth . We use this case to discuss Alexander disease .", "of Brain Stem Atrophy Using Magnetic Resonance Imaging in Adult Patients with Alexander Disease . Brain MRI in adult patients with Alexander disease ( AxD ) mainly shows atrophy in the medulla", "They are the pathognomonic feature of the astrocyte pathology in Alexander Disease (AxD), a neurodegenerative disorder caused by heterozygous mutations in the GFAP gene, encoding glial fibrillary acidic protein (GFAP).", "Alexander's disease, a leukodystrophy characterized by Rosenthal fibers (RFs) in the brain, is categorized into three subtypes: infantile, juvenile, and adult.", "aggregates . They are the pathognomonic feature of the astrocyte pathology in Alexander Disease ( AxD ) , a neurodegenerative disorder caused by heterozygous mutations in the GFAP gene ,", "Juvenile alexander disease: a case report.", "The purpose of this study was to describe unusual variants of Alexander's disease.", "Alexander Disease (ALXDRD) is an autosomal dominant leukodystrophy caused by mutation in one allele of GFAP gene, encoding glial fibrillary acidic protein (GFAP)."], "par_relations": ["Heredodegenerative Disorders, Nervous System", "Hereditary Central Nervous System Demyelinating Diseases"], "chd_relations": ["Alexanders leukodystrophy"], "syn_relations": ["Alexander Disease", "Alexander Disease"], "sib_relations": ["Glial Fibrillary Acidic Protein", "Cockayne Syndrome", "Dystonia Musculorum Deformans", "Gerstmann-Straussler-Scheinker Disease", "Pantothenate Kinase-Associated Neurodegeneration", "Hepatolenticular Degeneration", "Huntington Disease", "Leukodystrophy, Globoid Cell", "Leukodystrophy, Metachromatic", "Myotonic Dystrophy", "Myotonia Congenita", "Neuronal Ceroid-Lipofuscinoses", "Hereditary Sensory and Motor Neuropathy", "Hereditary Sensory and Autonomic Neuropathies", "Optic Atrophies, Hereditary", "Spinocerebellar Degenerations", "Tourette Syndrome", "Tuberous Sclerosis", "Adrenoleukodystrophy", "Neurofibromatoses", "Pelizaeus-Merzbacher Disease", "Amyloid Neuropathies, Familial", "Canavan Disease", "Neuroacanthocytosis", "Spinal Muscular Atrophies of Childhood", "Lafora Disease", "Unverricht-Lundborg Syndrome", "Hereditary Central Nervous System Demyelinating Diseases", "Mental Retardation, X-Linked", "Bulbo-Spinal Atrophy, X-Linked"], "wiki_entities": ["Alexander disease", "Disease", "Death of Alexander the Great", "Amyotrophic lateral sclerosis", "Cardiovascular disease", "Leukodystrophy", "Coeliac disease", "Huntington's disease", "List of eponymously named diseases", "Genetic disorder"], "mesh_synonynms": ["alexanders disease", "demyelinogenic leukodystrophy", "leukodystrophy with rosenthal fibers", "dysmyelinogenic leukodystrophy", "fibrinoid degeneration of astrocytes", "alexander disease", "alexander's disease"], "dbpedia_synonyms": ["axd", "demyelinogenic leukodystrophy", "fibrinoid leukodystrophy", "hyaline panneuropathy", "leukodystrophy with rosenthal fibers", "megalencephaly with hyaline panneuropathy", "dysmyelinogenic leukodystrophy", "megalencephaly with hyaline inclusion", "dysmyelogenic leukodystrophy-megalobare", "dysmyelogenic leukodystrophy", "fibrinoid degeneration of astrocytes", "alexander disease", "infantile alexander's disease", "alexander's disease"]}, "target_ent": {"research_entity_id": "OMIM:137780", "canonical_name": "GLIAL FIBRILLARY ACIDIC PROTEIN", "aliases": ["glial fibrillary acidic protein", "gfap", "alexander disease"], "definition": "Glial fibrillary acidic protein (GFAP) is a protein that is encoded by the GFAP gene in humans.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["GLIAL FIBRILLARY ACIDIC PROTEIN", "GFAP, ARG239CYS", "GFAP, ARG239HIS", "GFAP, ARG416TRP", "GFAP, ARG79HIS", "GFAP, ARG79CYS", "GFAP, ARG88CYS", "GFAP, ARG88SER", "GFAP, LEU76PHE", "GFAP, ASN77TYR", "GFAP, GLU362ASP", "GFAP, ARG276LEU", "GFAP, LEU352PRO", "GFAP, ASP78GLU", "GLIAL FIBRILLARY ACIDIC PROTEIN"], "sib_relations": ["GFAP, ARG239CYS", "GFAP, ARG239HIS", "GFAP, ARG416TRP", "GFAP, ARG79HIS", "GFAP, ARG79CYS", "GFAP, ARG88CYS", "GFAP, ARG88SER", "GFAP, LEU76PHE", "GFAP, ASN77TYR", "GFAP, GLU362ASP", "GFAP, ARG276LEU", "GFAP, LEU352PRO", "GFAP, ASP78GLU"], "wiki_entities": ["Glial fibrillary acidic protein", "Neuroglia", "Radial glial cell", "Satellite glial cell", "Intermediate filament", "Nasal glial heterotopia", "Nestin (protein)", "Astrocyte", "Rosenthal fiber", "Pituicyte"], "mesh_synonynms": ["alexanders disease", "glial intermediate filament protein", "demyelinogenic leukodystrophy", "astroprotein", "leukodystrophy with rosenthal fibers", "dysmyelinogenic leukodystrophy", "gfa-protein", "glial fibrillary acid protein", "fibrinoid degeneration of astrocytes", "gfa protein", "alexander's disease"], "dbpedia_synonyms": ["axd", "demyelinogenic leukodystrophy", "fibrinoid leukodystrophy", "hyaline panneuropathy", "leukodystrophy with rosenthal fibers", "megalencephaly with hyaline panneuropathy", "gfap (gene)", "gfap (disambiguation)", "dysmyelinogenic leukodystrophy", "megalencephaly with hyaline inclusion", "dysmyelogenic leukodystrophy-megalobare", "dysmyelogenic leukodystrophy", "fibrinoid degeneration of astrocytes", "alexander disease", "infantile alexander's disease", "alexander's disease"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0007465", "canonical_name": "Honeycomb palmoplantar keratoderma", "aliases": ["honeycomb palmoplantar keratoderma"], "definition": "Many conditions affect the human integumentary system—the organ system covering the entire surface of the body and composed of skin, hair, nails, and related muscle and glands.", "other_contexts": [], "par_relations": ["Palmoplantar keratoderma"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Diffuse palmoplantar keratoderma", "Nonepidermolytic palmoplantar keratoderma", "Patchy palmoplantar keratoderma", "Congenital palmoplantar keratodermia"], "wiki_entities": ["List of cutaneous conditions", "List of diseases (D)", "List of genetic disorders"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU005662", "canonical_name": "Honeycomb palmoplantar keratoderma", "aliases": ["honeycomb palmoplantar keratoderma"], "definition": "Many conditions affect the human integumentary system—the organ system covering the entire surface of the body and composed of skin, hair, nails, and related muscle and glands.", "other_contexts": [], "par_relations": ["Skin"], "chd_relations": [], "syn_relations": [], "sib_relations": ["KERATOSIS LINEARIS WITH ICHTHYOSIS CONGENITA AND SCLEROSING KERATODERMA"], "wiki_entities": ["List of cutaneous conditions", "List of diseases (D)", "List of genetic disorders"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C545373", "canonical_name": "ponatinib", "aliases": ["ponatinib hydrochloride", "ap24534", "ap-24534", "ap 24534", "3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-n-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide", "iclusig", "ponatinib"], "definition": "Ponatinib (trade name Iclusig  eye-KLOO-sig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).", "other_contexts": ["These results suggest that caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily, from the 45 mg daily starting dose, could be considered.", "The exact mechanism of ponatinib in CML has been still unknown.", "Treatment with ponatinib for 72 h inhibited cell growth and induced apoptosis in K562 cells in a dose - dependent manner .", "The findings suggest that no dose adjustment is necessary when ponatinib is administered with drugs that increase gastric pH.", "Additionally , the intracellular signaling of ponatinib and vorinostat was examined .", "Because the EPIC trial was terminated early , efficacy of ponatinib in this setting remains to be established .", "We investigated the difference in the efficacy of ponatinib and vorinostat by using ponatinib - resistant Ba / F3 cells .", "Furthermore , most patients with prior history of bleeding or who are receiving anticoagulation and/or antiplatelet therapies did not experience any bleeding episodes while treated with ponatinib .", "– Mass Spectrometry / Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague – Dawley Rats INTRODUCTION By means of liquid - liquid extraction with ethyl acetate ,", "aimed to determine the potential mechanisms and structural metabolic changes activated by ponatinib treatment in imatinib - sensitive K562 human CML cell lines and 3 μM - imatinib - resistant K562/", "resistant or intolerant to prior TKIs . In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4 . The effects of CYP3A4 inhibition on the pharmacokinetics of", "CYP3A4 inducers should be avoided unless the benefit outweighs the possible risk of ponatinib underexposure , because the safety of ponatinib dose increases has not been studied in this", "Recently, in the Ponatinib Ph1 Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Evaluation (PACE) trial, ponatinib showed significant efficacy against Ph-positive leukemia in patients with multiresistant T315I mutations.", "Furthermore, cell cycle analyses revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase.", "The estimated mean ratios for AUC0-∞ , AUC0-t , and C(max ) indicated increased exposures to ponatinib of 78% , 70% , and 47% , respectively ; exposure to AP24567 decreased by 71% .", "A corresponding 25 % decrease in the geometric mean maximum plasma concentration ( C max ) of ponatinib was observed for ponatinib + lansoprazole versus ponatinib alone ( 40.67 vs. 53.96 ng / mL ) .", "Three patients had vaginal bleeding, one occurred while ponatinib was on hold for grade 3 thrombocytopenia (platelets recovering to 55 x10/L at the time of bleeding), one had grade 1 vaginal bleeding associated with a high grade squamous cervical intraepithelial lesion (CIN 3), and one experienced grade 1 menorrhagia with negative workup while simultaneously taking aspirin and rivaroxaban.", "Additionally , the effects of ponatinib on macromolecules and lipid profiles were also analyzed using Fourier transform infrared spectroscopy ( FTIR ) .", "Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat : A Potential Treatment for BCR - ABL - Positive Leukemia Resistance to imatinib ( Gleevec® ) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR - ABL .", "Twenty-five (31%) patients were receiving antiplatelet therapy while on ponatinib (19 aspirin alone, 5 aspirin and clopidogrel, one aspirin and plasugrel).", "± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5 , 15.0 and 30.0 mg / kg ponatinib in rats , respectively . After consecutive administration at 3.75 mg / kg for 7 days , there was", "Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated in a pivotal phase 2 clinical trial.", "In mice with orthotopic xenograft neuroblastoma tumors , treatment with ponatinib resulted in decreased growth and vascularity .", "and only 0.24 ± 0.10% in urine . CONCLUSION For the first time , the pharmacokinetics of ponatinib were systematically evaluated in rats , which facilitated the study and development of the", "21 - 1447x10/L ) . Seven ( 9% ) patients were receiving anticoagulation therapy while on ponatinib for atrial fibrillation ( n=3 ) , portal vein thrombosis , pulmonary embolism , lower extremity", "In contrast , Ba / F3 ponatinib - R cells were resistant to ponatinib ( Figure 1B ) .", "drug that is effective even in CML patients with T315I mutation . The exact mechanism of ponatinib in CML has been still unknown . In this study , we aimed to determine the potential mechanisms and", "Using orthotopic xenograft mouse models of human neuroblastoma , we analyzed tumors treated with ponatinib for growth , gross and histologic appearance , and vascularity .", "BACKGROUND Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment , although it is associated with arterial occlusion .", "in rats , which facilitated the study and development of the analogous candidates of ponatinib .", "Thus , combined administration of ponatinib and vorinostat may be a powerful strategy against BCR - ABL mutant cells and could enhance the cytotoxic effects of ponatinib in those BCR - ABL mutant cells .", ", sensitive , and specific LC - MS / MS method was developed and validated for assaying ponatinib and the internal standard , warfarin . METHODS The method was verified and successfully applied to", ") . These results suggest that caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily , from the 45 mg", "Although the lipid to protein ratio increased in imatinib - sensitive K562 cells with a little decrease in the K562/IMA-3 cells , ponatinib treatment indicated significant changes in the lipid composition such as a significant increase in the cellular cholesterol amounts much more in the K562/IMA-3 cells than the sensitive counterparts .", "We hypothesized that ponatinib would be effective against neuroblastoma in preclinical models.", "early release paper by Neelakantan et al . regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia ( CML ) resistant to multiple tyrosine kinase inhibitors", "However, in some patients, especially those with Ph-positive ALL, ponatinib-resistant clones were identified.", "Grade 3 or 4 adverse events observed in more than 5% of patients in the ponatinib group were increased lipase ( 22 [ 14% ] of 154 vs three [ 2% ] of 152 with imatinib ) , thrombocytopenia ( 19 [ 12% ] of 154 vs ten [ 7% ] of 152 with imatinib ) , rash ( ten [ 6% ] of 154 vs two [ 1% ] of 152 with imatinib ) .", "any bleeding episodes while treated with ponatinib . These findings suggest that ponatinib may be safely used even on patients with history of bleeding or receiving antiplatelet /", "concomitant use of anticoagulants or antithrombotic agents while patients are receiving ponatinib .", ". One patient experienced 2 episodes of hematuria related to urinary tract infection while ponatinib was on hold due to thrombocytopenia . One patient had a hematoma in the gluteal area and lower", "Z-VAD-fmk treatment inhibited OM-induced apoptosis but did not prevent the degradation of BCR-ABL, HSP90, and Bcl-2 in Ba/F3 ponatinib-R cells (supplemental Figure 1D).", "Dawley Rats INTRODUCTION By means of liquid-liquid extraction with ethyl acetate, a rapid, sensitive, and specific LC-MS/MS method was developed and validated for assaying ponatinib and the internal standard, warfarin.", "In the imatinib group, grade 3 or 4 adverse events observed in more than 5% of patients were neutropenia (12 [8%] of 152 vs five [3%] of 154 with ponatinib) and thrombocytopenia (ten [7%] of 152 vs 19 [12%] of 154 with ponatinib).", "Subjects ( N = 22 ) received two single doses ( orally ) of ponatinib 15 mg , once given alone and once coadministered with daily ( 5 days ) ketoconazole 400 mg , a CYP3A4 inhibitor .", "Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects .", "In vitro studies have demonstrated that the aqueous solubility of the tyrosine kinase inhibitor ponatinib decreases as pH increases.", "A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib Chronic myeloid leukemia (CML) is a type of hematological malignancy that is characterized by the generation of Philadelphia chromosome encoding BCR/ABL oncoprotein.", "We investigated the efficacy of OM against ponatinib-resistant Ph-positive cells.", "in imatinib - sensitive K562 cells with a little decrease in the K562/IMA-3 cells , ponatinib treatment indicated significant changes in the lipid composition such as a significant increase in", "Seventeen patients had a combined total of 23 surgical procedures performed during treatment with ponatinib; only 2 procedures had a bleeding complication in the same patient, as described above.", "regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia (CML) resistant to multiple tyrosine kinase inhibitors (TKI) therapy.", "Methods We evaluated the effects of ponatinib on survival and migration of human neuroblastoma cells in vitro.", "CONCLUSION For the first time, the pharmacokinetics of ponatinib were systematically evaluated in rats, which facilitated the study and development of the analogous candidates of ponatinib.", "The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia .", "Coadministration of ponatinib with strong CYP3A4 inducers should be avoided unless the benefit outweighs the possible risk of ponatinib underexposure, because the safety of ponatinib dose increases has not been studied in this context.", "Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects Ponatinib is a BCR - ABL tyrosine kinase inhibitor ( TKI ) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome - positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs .", "The mechanism of platelet dysfunction reported to occur with ponatinib is currently unknown .", "5 ) , and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h ( p < 0.05 ) . Analysis of ponatinib in various tissues revealed it was distributed widely in the body , highly exposed in the lung ,", "revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase . Moreover , ponatinib treatment created a more ordered nucleic acid structure in the resistant cells . Although the", "In our experience , a small minority of patients who received ponatinib experienced clinical bleeding and in none of these cases did the bleeding appear to be directly related to ponatinib .", "In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4.", "on day 1 , rifampin 600 mg alone on days 8 - 13 , 15 , and 16 , and rifampin 600 mg with ponatinib on day 14 . Rifampin decreased maximum plasma concentration ( Cmax ) and area under the plasma", "study in healthy volunteers . Subjects ( N = 22 ) received two single doses ( orally ) of ponatinib 15 mg , once given alone and once coadministered with daily ( 5 days ) ketoconazole 400 mg , a CYP3", "to AP24567 was marginal after ponatinib alone ( no more than 4% of the exposure to ponatinib ) . These results suggest that caution should be exercised with the concurrent use of ponatinib", "Importantly, lansoprazole did not decrease the overall ponatinib systemic exposure as assessed by the ponatinib area under the plasma concentration-time curve from time zero to infinity (AUC∞ 1,153 ng·h/mL for lansoprazole + ponatinib vs. 1,222 ng·h/mL for ponatinib alone).", "together , all these results showed powerful antiproliferative and apoptotic effects of ponatinib in both imatinib - sensitive and imatinib - resistant CML cells in a dose - dependent manner , and", "562/IMA3 CML cell lines generated at our lab . Apoptotic and antiproliferative effects of ponatinib on imatinib - sensitive and 3 μM - imatinib - resistant K562/IMA3 CML cells were determined by", "One patient experienced 2 episodes of hematuria related to urinary tract infection while ponatinib was on hold due to thrombocytopenia.", "Seven (9%) patients were receiving anticoagulation therapy while on ponatinib for atrial fibrillation (n=3), portal vein thrombosis, pulmonary embolism, lower extremity deep vein thrombosis, or stroke (one each).", "for primary hemostasis ) in 5 patients with CML resistant to TKI who had been receiving ponatinib for at least two weeks without interruption . Although none of these patients developed clinical", "It has been suggested that inhibition of several kinases such as SFK, LYN, and FYN, that play an important role in early platelet activation, may be responsible for the effect of ponatinib on platelet function.", "Subjects received a single oral dose of ponatinib 45 mg alone on day 1, an oral dose of lansoprazole 60 mg on day 14, and ponatinib 45 mg plus lansoprazole 60 mg on day 15.", "In this study , we aimed to determine the potential mechanisms and structural metabolic changes activated by ponatinib treatment in imatinib - sensitive K562 human CML cell lines and 3 μM - imatinib - resistant K562/IMA3 CML cell lines generated at our lab .", "Moreover , ponatinib treatment created a more ordered nucleic acid structure in the resistant cells .", "benefit outweighs the possible risk of ponatinib underexposure , because the safety of ponatinib dose increases has not been studied in this context .", "To define the clinical implication of this finding on the risk of bleeding among CML patients receiving ponatinib, we reviewed the medical records of 80 patients diagnosed with chronic phase CML (CML-CP) according to previously described criteria and treated with ponatinib on clinical trials conducted at The University of Texas, MD Anderson Cancer Center between August 25 2008 and December 21 2012.", "- dependent exposure in the circulation system , and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40% , 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5 , 15.", "phase CML ( CML - CP ) according to previously described criteria and treated with ponatinib on clinical trials conducted at The University of Texas , MD Anderson Cancer Center between August", "and once coadministered with daily ( 5 days ) ketoconazole 400 mg , a CYP3A4 inhibitor . Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration ( C(max ) ) and area under the", "with ponatinib for growth , gross and histologic appearance , and vascularity . Results Ponatinib treatment of neuroblastoma cells resulted in decreased cell viability and migration in vitro . In", "The antitumor effects of ponatinib suggest its potential as a novel therapeutic agent for neuroblastoma, and further preclinical testing is warranted.", "This open - label , nonrandomized , fixed - order crossover study evaluated the effect of multiple oral doses of rifampin , a strong CYP3A4 inducer , on the pharmacokinetics of ponatinib ( 45 mg , single dose ) .", "Exposure to AP24567 was marginal after ponatinib alone (no more than 4% of the exposure to ponatinib).", "in both K562 and K562/IMA-3 cells . Furthermore , cell cycle analyses revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase . Moreover , ponatinib treatment created a more", "The method was verified and successfully applied to evaluate the pharmacokinetics of ponatinib in Sprague - Dawley rats . RESULTS Ponatinib showed dose - dependent exposure in the circulation", "The trial was terminated early, on Oct 17, 2013, following concerns about vascular adverse events observed in patients given ponatinib in other trials.", "; exposure to AP24567 decreased by 71% . Exposure to AP24567 was marginal after ponatinib alone ( no more than 4% of the exposure to ponatinib ) . These results suggest that caution should", "The single-dose safety profile of ponatinib with and without coadministration of lansoprazole was also characterized.", "Ponatinib was eliminated primarily in feces at 26.17 ± 7.70% of its original form and only 0.24 ± 0.10% in urine.", "Analysis of ponatinib in various tissues revealed it was distributed widely in the body , highly exposed in the lung , thyroid , and lowly exposed in plasma , the brain , bone and the liver , indicating its potential action on lung cancer with lower system toxicity .", "Apoptotic and antiproliferative effects of ponatinib on imatinib - sensitive and 3 μM - imatinib - resistant K562/IMA3 CML cells were determined by proliferation and apoptosis assays .", "The authors have shown a prolonged closure time with PFA 100 (a sensitive measure for primary hemostasis) in 5 patients with CML resistant to TKI who had been receiving ponatinib for at least two weeks without interruption.", "administration at 3.75 mg / kg for 7 days , there was distinct accumulation of ponatinib ( AUC0-∞ = 5479.41 ± 757.07 μg h / L ) relative to that of a single dose ( AUC0-∞ = 2301.84 ± 787.1", "pharmacokinetics of ponatinib ( 45 mg , single dose ) . Twenty healthy adults received ponatinib on day 1 , rifampin 600 mg alone on days 8 - 13 , 15 , and 16 , and rifampin 600 mg with ponatinib", "be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily , from the 45 mg daily starting dose , could be considered .", "Activity of omacetaxine mepesuccinate against ponatinib - resistant BCR - ABL - positive cells .", "Combined treatment of ponatinib - resistant cells with ponatinib and vorinostat caused a significant increase in cytotoxicity .", "INTERPRETATION The efficacy of ponatinib treatment of newly diagnosed chronic-phase chronic myeloid leukaemia compared with imatinib could not be assessed due to trial termination, but preliminary data suggest there might be benefit, although with more arterial occlusive events than with imatinib at the doses studied.", "METHODS The method was verified and successfully applied to evaluate the pharmacokinetics of ponatinib in Sprague - Dawley rats .", "of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects . Ponatinib , an oral tyrosine kinase inhibitor with significant activity in", "in vitro and reduces tumor growth and vascularity in vivo . The antitumor effects of ponatinib suggest its potential as a novel therapeutic agent for neuroblastoma , and further preclinical", "the liver , indicating its potential action on lung cancer with lower system toxicity . Ponatinib was eliminated primarily in feces at 26.17 ± 7.70% of its original form and only 0.24 ± 0.10% in", "clinical implication of this finding on the risk of bleeding among CML patients receiving ponatinib , we reviewed the medical records of 80 patients diagnosed with chronic phase CML ( CML - CP )", "( C(max ) ) and area under the concentration - time curve ( AUC ) compared with ponatinib alone . The estimated mean ratios for AUC0-∞ , AUC0-t , and C(max ) indicated increased exposures", "Trial termination limited assessment of the primary endpoint of major molecular response at 12 months, as only 13 patients in the imatinib group and ten patients in the ponatinib group could be assessed at this timepoint; the proportion of patients achieving a major molecular response at 12 months did not differ significantly between the two groups (eight [80%] of ten patients given ponatinib and five [38%] of 13 patients given imatinib; p=0·074). 11 (7%) of 154 patients given ponatinib and three (2%) of 152 patients given imatinib had arterial occlusive events (p=0·052); arterial occlusive events were designated serious in ten (6%) of 154 patients given ponatinib and in one (1%) of 152 patients given imatinib (p=0·010).", "on platelet function . In our experience , a small minority of patients who received ponatinib experienced clinical bleeding and in none of these cases did the bleeding appear to be directly", "Previously established ponatinib-resistant Ba/F3 cells were also resistant to imatinib, nilotinib, and dasatinib.", "Attention should be given to other precipitating factors for bleeding such as low platelet count or concomitant use of anticoagulants or antithrombotic agents while patients are receiving ponatinib.", "estimated mean ratios for AUC0-∞ , AUC0-t , and C(max ) indicated increased exposures to ponatinib of 78% , 70% , and 47% , respectively ; exposure to AP24567 decreased by 71% . Exposure to AP24567", "Rifampin decreased maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration (AUC0-t ) and from time zero to infinity (AUC0-∞ ) of ponatinib by 42%, 59%, and 63%, respectively, with no effect on time to Cmax .", "and/or antiplatelet therapies did not experience any bleeding episodes while treated with ponatinib . These findings suggest that ponatinib may be safely used even on patients with history of", "OBJECTIVES The primary aim of this study was to assess the effects of the gastric proton pump inhibitor lansoprazole on the pharmacokinetics of ponatinib .", "Our findings suggest that OM may be beneficial in the treatment of leukemia patients with BCR-ABL mutant cells, helping in overcoming ponatinib resistance.", "The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.", "Ponatinib (AP24534) is a multitarget TKI.", "After consecutive administration at 3.75 mg / kg for 7 days , there was distinct accumulation of ponatinib ( AUC0-∞ = 5479.41 ± 757.07 μg h / L ) relative to that of a single dose ( AUC0-∞ = 2301.84 ± 787.10 μg h / L , p < 0.05 ) , and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h ( p", "of multiple oral doses of rifampin , a strong CYP3A4 inducer , on the pharmacokinetics of ponatinib ( 45 mg , single dose ) . Twenty healthy adults received ponatinib on day 1 , rifampin 600 mg", "patients developed clinical bleeding during the study period , the authors concluded that ponatinib may inhibit platelet function , suggesting that physicians should be vigilant when patients with", "doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects . Ponatinib , an oral tyrosine kinase inhibitor with significant activity in heavily pretreated patients with", "We then examined ponatinib-resistant primary Ph-positive ALL and chronic-phase CML samples.", "changes in imatinib - sensitive and imatinib - resistant K562 cells exposed to ponatinib Chronic myeloid leukemia ( CML ) is a type of hematological malignancy that is characterized by", "were considered related to ponatinib or required interruption or dose adjustment of ponatinib . Seventeen patients had a combined total of 23 surgical procedures performed during treatment", "Conclusions Ponatinib reduces neuroblastoma cell viability in vitro and reduces tumor growth and vascularity in vivo.", "Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects .", ", treatment with ponatinib resulted in decreased growth and vascularity . Conclusions Ponatinib reduces neuroblastoma cell viability in vitro and reduces tumor growth and vascularity in vivo .", "RESULTS Lansoprazole coadministration resulted in a 1-h increase in the time to maximum plasma concentration (t max) of ponatinib (6 vs. 5 h post-dose; P < 0.001).", "With 72 hours of OM treatment, the cell growth of Ba/F3 ponatinib-R and Ph-positive ALL cell lines was significantly reduced, even when treated with low concentrations of OM (Figure 1A and supplemental Figure 1A).", "We found that the growth of primary cells was not affected by ponatinib but was reduced after OM treatment.", "The safety profile was considered acceptable when ponatinib was administered alone or with lansoprazole .", "Ba/F3 ponatinib-resistant (Ba/F3 ponatinib-R) cells have 3 BCR-ABL point mutations (Y253H, E255K, and T315I; data not shown).", "The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite, AP24567, were evaluated in a single-center, randomized, two-period, two-sequence crossover study in healthy volunteers.", "experienced bleeding events . Three patients had vaginal bleeding , one occurred while ponatinib was on hold for grade 3 thrombocytopenia ( platelets recovering to 55 x10/L at the time of", "using Fourier transform infrared spectroscopy ( FTIR ) . Our results revealed that ponatinib inhibited cell proliferation and induced apoptosis as determined by loss of mitochondrial membrane", "The median platelet count at the start of ponatinib therapy was 256x10/L (range 21-1447x10/L).", "The limits of the 90% confidence intervals of the estimated geometric mean ratios of ponatinib Cmax , AUC0-t , and AUC0-∞ did not fall within the 80-125% margins for equivalence, suggesting a statistically significant interaction.", "Patients from 106 centres in 21 countries were randomly assigned ( 1:1 , with stratification by Sokal score at diagnosis ) using an interactive voice and web response system to receive oral ponatinib ( 45 mg ) or imatinib ( 400 mg ) once daily until progression , unacceptable toxicity , or other criteria for withdrawal were met .", "Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration (C(max)) and area under the concentration-time curve (AUC) compared with ponatinib alone.", "despite aggressive treatment , and novel therapies are needed to improve these outcomes . Ponatinib is a multi - tyrosine kinase inhibitor that targets many pathways implicated in neuroblastoma", "Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia : an international , randomised , open - label , phase 3 trial .", "Twenty healthy adults received ponatinib on day 1, rifampin 600 mg alone on days 8-13, 15, and 16, and rifampin 600 mg with ponatinib on day 14.", "against neuroblastoma in preclinical models . Methods We evaluated the effects of ponatinib on survival and migration of human neuroblastoma cells in vitro . Using orthotopic xenograft mouse", "rivaroxaban . Twenty - five ( 31% ) patients were receiving antiplatelet therapy while on ponatinib ( 19 aspirin alone , 5 aspirin and clopidogrel , one aspirin and plasugrel ) . A total of 9 ( 11% )", ", as described above . The mechanism of platelet dysfunction reported to occur with ponatinib is currently unknown . It has been suggested that inhibition of several kinases such as SFK , LYN ,", "Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague–", "an important role in early platelet activation , may be responsible for the effect of ponatinib on platelet function . In our experience , a small minority of patients who received ponatinib", "Our results revealed that ponatinib inhibited cell proliferation and induced apoptosis as determined by loss of mitochondrial membrane potential, increased caspase-3 enzyme activity, and transfer of phosphatidylserine to the plasma membrane in both K562 and K562/IMA-3 cells.", "Although none of these patients developed clinical bleeding during the study period, the authors concluded that ponatinib may inhibit platelet function, suggesting that physicians should be vigilant when patients with ponatinib are facing any hemostatic challenges.", "The resistance of Ba/F3 cells bearing these 3-point mutations to ponatinib is consistent with the high-level resistance conferred by compound mutations such as E255V/T315I, although Ba/F3 ponatinib-R cells did not display increased antiapoptotic proteins.", "platelet function , suggesting that physicians should be vigilant when patients with ponatinib are facing any hemostatic challenges . To define the clinical implication of this finding on the", "bleeding and in none of these cases did the bleeding appear to be directly related to ponatinib . Furthermore , most patients with prior history of bleeding or who are receiving anticoagulation", "None of these episodes were considered related to ponatinib or required interruption or dose adjustment of ponatinib.", "Results Ponatinib treatment of neuroblastoma cells resulted in decreased cell viability and migration in vitro.", "CONCLUSIONS Although coadministration of lansoprazole led to a modest, albeit statistically significant, reduction in ponatinib C max, overall systemic exposure to ponatinib did not change.", "These findings suggest that ponatinib may be safely used even on patients with history of bleeding or receiving antiplatelet /anticoagulation therapies .", "5 days ) ketoconazole 400 mg , a CYP3A4 inhibitor . Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration ( C(max ) ) and area under the concentration - time curve ( AUC )", "Serious adverse events that occurred in three or more patients given ponatinib were pancreatitis (n=5), atrial fibrillation (n=3), and thrombocytopenia (n=3).", "mediated by CYP3A4 . The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite , AP24567 , were evaluated in a single - center , randomized ,", "xenograft mouse models of human neuroblastoma , we analyzed tumors treated with ponatinib for growth , gross and histologic appearance , and vascularity . Results Ponatinib treatment of", "METHODS The Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia ( EPIC ) study was a randomised , open - label , phase 3 trial designed to assess the efficacy and safety of ponatinib , compared with imatinib , in newly diagnosed patients with chronic - phase chronic myeloid leukaemia .", "Ponatinib , an oral tyrosine kinase inhibitor with significant activity in heavily pretreated patients with chronic myeloid leukemia , is a CYP3A4 substrate .", "Combined treatment of Ba / F3 T315I mutant cells with vorinostat and ponatinib resulted in significantly increased cytotoxicity .", "RESULTS Ponatinib showed dose - dependent exposure in the circulation system , and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40% , 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5 , 15.0 and 30.0 mg / kg ponatinib in rats , respectively .", "were determined by proliferation and apoptosis assays . Additionally , the effects of ponatinib on macromolecules and lipid profiles were also analyzed using Fourier transform infrared", "patients had a combined total of 23 surgical procedures performed during treatment with ponatinib ; only 2 procedures had a bleeding complication in the same patient , as described above . The", "We found that ponatinib potently inhibited the growth of Ba / F3 cells ectopically expressing BCR - ABL T315I mutation .", "equivalence , suggesting a statistically significant interaction . Coadministration of ponatinib with strong CYP3A4 inducers should be avoided unless the benefit outweighs the possible risk of", "of last measurable concentration ( AUC0-t ) and from time zero to infinity ( AUC0-∞ ) of ponatinib by 42% , 59% , and 63% , respectively , with no effect on time to Cmax . The limits of the 90%", "The ponatinib-resistant primary cells had several BCR-ABL point mutations (eg, Q252H, E255K/V, and T315I).", "targets many pathways implicated in neuroblastoma pathogenesis . We hypothesized that ponatinib would be effective against neuroblastoma in preclinical models . Methods We evaluated the effects", "FINDINGS Between Aug 14, 2012, and Oct 9, 2013, 307 patients were randomly assigned to receive ponatinib (n=155) or imatinib (n=152).", "Ponatinib is a multi-tyrosine kinase inhibitor that targets many pathways implicated in neuroblastoma pathogenesis.", ". The limits of the 90% confidence intervals of the estimated geometric mean ratios of ponatinib Cmax , AUC0-t , and AUC0-∞ did not fall within the 80 - 125% margins for equivalence , suggesting", "and imatinib - resistant CML cells in a dose - dependent manner , and hence , the use of ponatinib for the treatment of TKI - resistant CML patients may be an effective treatment approach in the", "hematoma , and one retinal hemorrhage ) . The median platelet count at the start of ponatinib therapy was 256x10/L ( range 21 - 1447x10/L ) . Seven ( 9% ) patients were receiving", "Taken together, all these results showed powerful antiproliferative and apoptotic effects of ponatinib in both imatinib-sensitive and imatinib-resistant CML cells in a dose-dependent manner, and hence, the use of ponatinib for the treatment of TKI-resistant CML patients may be an effective treatment approach in the clinic.", "in vitro . In mice with orthotopic xenograft neuroblastoma tumors , treatment with ponatinib resulted in decreased growth and vascularity . Conclusions Ponatinib reduces neuroblastoma cell", "Caspase 3 and PARP activation increased after combination treatment with ponatinib and vorinostat .", "these TKIs in the patients bearing T315I mutation is a major obstacle in CML therapy . Ponatinib , the third - generation TKI , is novel drug that is effective even in CML patients with T315I", "applied to evaluate the pharmacokinetics of ponatinib in Sprague - Dawley rats . RESULTS Ponatinib showed dose - dependent exposure in the circulation system , and the absolute bioavailabilities of", "In the current study, we analyzed the efficacy of ponatinib and vorinostat treatment by using BCR-ABL-positive cell lines.", "10/L ) and concomitant use of aspirin . None of these episodes were considered related to ponatinib or required interruption or dose adjustment of ponatinib . Seventeen patients had a combined total", "Ponatinib, the third-generation TKI, is novel drug that is effective even in CML patients with T315I mutation."], "par_relations": ["ponatinib", "ponatinib", "Antineoplastic Agents", "Imidazoles", "Pyridazines", "Protein Kinase Inhibitors", "ponatinib"], "chd_relations": ["ponatinib", "ponatinib", "ponatinib"], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Ponatinib", "ARIAD Pharmaceuticals", "Bcr-Abl tyrosine-kinase inhibitor", "Antileukemic drug", "Chronic myelogenous leukemia", "ATC code L01", "List of antineoplastic agents", "Tyrosine kinase", "Protein kinase inhibitor", "Clonal hypereosinophilia"], "mesh_synonynms": [], "dbpedia_synonyms": ["atc code l01xe24", "iclusig", "ponatinib", "atcvet code ql01xe24", "ap24534", "c29h27f3n6o"]}, "target_ent": {"research_entity_id": "RXNORM:1364347", "canonical_name": "ponatinib", "aliases": ["ponatinib"], "definition": "Ponatinib (trade name Iclusig  eye-KLOO-sig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).", "other_contexts": ["The ponatinib - resistant primary cells had several BCR - ABL point mutations ( eg , Q252H , E255K / V , and T315I ) .", "These results suggest that caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily, from the 45 mg daily starting dose, could be considered.", "The exact mechanism of ponatinib in CML has been still unknown.", "Treatment with ponatinib for 72 h inhibited cell growth and induced apoptosis in K562 cells in a dose - dependent manner .", "We investigated the difference in the efficacy of ponatinib and vorinostat by using ponatinib - resistant Ba / F3 cells .", "In the imatinib group , grade 3 or 4 adverse events observed in more than 5% of patients were neutropenia ( 12 [ 8% ] of 152 vs five [ 3% ] of 154 with ponatinib ) and thrombocytopenia ( ten [ 7% ] of 152 vs 19 [ 12% ] of 154 with ponatinib ) .", "Because the EPIC trial was terminated early , efficacy of ponatinib in this setting remains to be established .", "The findings suggest that no dose adjustment is necessary when ponatinib is administered with drugs that increase gastric pH.", "Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs.", "– Mass Spectrometry / Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague – Dawley Rats INTRODUCTION By means of liquid - liquid extraction with ethyl acetate ,", "aimed to determine the potential mechanisms and structural metabolic changes activated by ponatinib treatment in imatinib - sensitive K562 human CML cell lines and 3 μM - imatinib - resistant K562/", "resistant or intolerant to prior TKIs . In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4 . The effects of CYP3A4 inhibition on the pharmacokinetics of", "CYP3A4 inducers should be avoided unless the benefit outweighs the possible risk of ponatinib underexposure , because the safety of ponatinib dose increases has not been studied in this", "Recently, in the Ponatinib Ph1 Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Evaluation (PACE) trial, ponatinib showed significant efficacy against Ph-positive leukemia in patients with multiresistant T315I mutations.", "Furthermore, cell cycle analyses revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase.", "The estimated mean ratios for AUC0-∞ , AUC0-t , and C(max ) indicated increased exposures to ponatinib of 78% , 70% , and 47% , respectively ; exposure to AP24567 decreased by 71% .", "RESULTS Lansoprazole coadministration resulted in a 1-h increase in the time to maximum plasma concentration ( t max ) of ponatinib ( 6 vs. 5 h post - dose ; P < 0.001 ) .", "Three patients had vaginal bleeding, one occurred while ponatinib was on hold for grade 3 thrombocytopenia (platelets recovering to 55 x10/L at the time of bleeding), one had grade 1 vaginal bleeding associated with a high grade squamous cervical intraepithelial lesion (CIN 3), and one experienced grade 1 menorrhagia with negative workup while simultaneously taking aspirin and rivaroxaban.", "It has been suggested that inhibition of several kinases such as SFK , LYN , and FYN , that play an important role in early platelet activation , may be responsible for the effect of ponatinib on platelet function .", "± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5 , 15.0 and 30.0 mg / kg ponatinib in rats , respectively . After consecutive administration at 3.75 mg / kg for 7 days , there was", "Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated in a pivotal phase 2 clinical trial.", "and only 0.24 ± 0.10% in urine . CONCLUSION For the first time , the pharmacokinetics of ponatinib were systematically evaluated in rats , which facilitated the study and development of the", "21 - 1447x10/L ) . Seven ( 9% ) patients were receiving anticoagulation therapy while on ponatinib for atrial fibrillation ( n=3 ) , portal vein thrombosis , pulmonary embolism , lower extremity", "Serious adverse events that occurred in three or more patients given ponatinib were pancreatitis ( n=5 ) , atrial fibrillation ( n=3 ) , and thrombocytopenia ( n=3 ) .", "Apoptotic and antiproliferative effects of ponatinib on imatinib-sensitive and 3 μM-imatinib-resistant K562/IMA3 CML cells were determined by proliferation and apoptosis assays.", "In contrast , Ba / F3 ponatinib - R cells were resistant to ponatinib ( Figure 1B ) .", "The antitumor effects of ponatinib suggest its potential as a novel therapeutic agent for neuroblastoma , and further preclinical testing is warranted .", "drug that is effective even in CML patients with T315I mutation . The exact mechanism of ponatinib in CML has been still unknown . In this study , we aimed to determine the potential mechanisms and", "BACKGROUND Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment , although it is associated with arterial occlusion .", "in rats , which facilitated the study and development of the analogous candidates of ponatinib .", ", sensitive , and specific LC - MS / MS method was developed and validated for assaying ponatinib and the internal standard , warfarin . METHODS The method was verified and successfully applied to", "early release paper by Neelakantan et al . regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia ( CML ) resistant to multiple tyrosine kinase inhibitors", ") . These results suggest that caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily , from the 45 mg", "Although none of these patients developed clinical bleeding during the study period , the authors concluded that ponatinib may inhibit platelet function , suggesting that physicians should be vigilant when patients with ponatinib are facing any hemostatic challenges .", "We investigated the efficacy of OM against ponatinib - resistant Ph - positive cells .", "concomitant use of anticoagulants or antithrombotic agents while patients are receiving ponatinib .", "any bleeding episodes while treated with ponatinib . These findings suggest that ponatinib may be safely used even on patients with history of bleeding or receiving antiplatelet /", ". One patient experienced 2 episodes of hematuria related to urinary tract infection while ponatinib was on hold due to thrombocytopenia . One patient had a hematoma in the gluteal area and lower", "Z-VAD-fmk treatment inhibited OM-induced apoptosis but did not prevent the degradation of BCR-ABL, HSP90, and Bcl-2 in Ba/F3 ponatinib-R cells (supplemental Figure 1D).", "Dawley Rats INTRODUCTION By means of liquid-liquid extraction with ethyl acetate, a rapid, sensitive, and specific LC-MS/MS method was developed and validated for assaying ponatinib and the internal standard, warfarin.", "A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib Chronic myeloid leukemia (CML) is a type of hematological malignancy that is characterized by the generation of Philadelphia chromosome encoding BCR/ABL oncoprotein.", "Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects .", "In vitro studies have demonstrated that the aqueous solubility of the tyrosine kinase inhibitor ponatinib decreases as pH increases.", "in imatinib - sensitive K562 cells with a little decrease in the K562/IMA-3 cells , ponatinib treatment indicated significant changes in the lipid composition such as a significant increase in", "RESULTS Ponatinib showed dose-dependent exposure in the circulation system, and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5, 15.0 and 30.0 mg/kg ponatinib in rats, respectively.", "Grade 3 or 4 adverse events observed in more than 5% of patients in the ponatinib group were increased lipase (22 [14%] of 154 vs three [2%] of 152 with imatinib), thrombocytopenia (19 [12%] of 154 vs ten [7%] of 152 with imatinib), rash (ten [6%] of 154 vs two [1%] of 152 with imatinib).", "We found that the growth of primary cells was not affected by ponatinib but was reduced after OM treatment .", "Seventeen patients had a combined total of 23 surgical procedures performed during treatment with ponatinib; only 2 procedures had a bleeding complication in the same patient, as described above.", "Methods We evaluated the effects of ponatinib on survival and migration of human neuroblastoma cells in vitro.", "Twenty - five ( 31% ) patients were receiving antiplatelet therapy while on ponatinib ( 19 aspirin alone , 5 aspirin and clopidogrel , one aspirin and plasugrel ) .", "Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL.", "CONCLUSION For the first time, the pharmacokinetics of ponatinib were systematically evaluated in rats, which facilitated the study and development of the analogous candidates of ponatinib.", "5 ) , and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h ( p < 0.05 ) . Analysis of ponatinib in various tissues revealed it was distributed widely in the body , highly exposed in the lung ,", "Coadministration of ponatinib with strong CYP3A4 inducers should be avoided unless the benefit outweighs the possible risk of ponatinib underexposure, because the safety of ponatinib dose increases has not been studied in this context.", "Attention should be given to other precipitating factors for bleeding such as low platelet count or concomitant use of anticoagulants or antithrombotic agents while patients are receiving ponatinib .", "revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase . Moreover , ponatinib treatment created a more ordered nucleic acid structure in the resistant cells . Although the", "In our experience , a small minority of patients who received ponatinib experienced clinical bleeding and in none of these cases did the bleeding appear to be directly related to ponatinib .", "In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4.", "on day 1 , rifampin 600 mg alone on days 8 - 13 , 15 , and 16 , and rifampin 600 mg with ponatinib on day 14 . Rifampin decreased maximum plasma concentration ( Cmax ) and area under the plasma", "However , in some patients , especially those with Ph - positive ALL , ponatinib - resistant clones were identified .", "study in healthy volunteers . Subjects ( N = 22 ) received two single doses ( orally ) of ponatinib 15 mg , once given alone and once coadministered with daily ( 5 days ) ketoconazole 400 mg , a CYP3", "to AP24567 was marginal after ponatinib alone ( no more than 4% of the exposure to ponatinib ) . These results suggest that caution should be exercised with the concurrent use of ponatinib", "together , all these results showed powerful antiproliferative and apoptotic effects of ponatinib in both imatinib - sensitive and imatinib - resistant CML cells in a dose - dependent manner , and", "Importantly, lansoprazole did not decrease the overall ponatinib systemic exposure as assessed by the ponatinib area under the plasma concentration-time curve from time zero to infinity (AUC∞ 1,153 ng·h/mL for lansoprazole + ponatinib vs. 1,222 ng·h/mL for ponatinib alone).", "562/IMA3 CML cell lines generated at our lab . Apoptotic and antiproliferative effects of ponatinib on imatinib - sensitive and 3 μM - imatinib - resistant K562/IMA3 CML cells were determined by", "One patient experienced 2 episodes of hematuria related to urinary tract infection while ponatinib was on hold due to thrombocytopenia.", "Seven (9%) patients were receiving anticoagulation therapy while on ponatinib for atrial fibrillation (n=3), portal vein thrombosis, pulmonary embolism, lower extremity deep vein thrombosis, or stroke (one each).", "for primary hemostasis ) in 5 patients with CML resistant to TKI who had been receiving ponatinib for at least two weeks without interruption . Although none of these patients developed clinical", "Subjects received a single oral dose of ponatinib 45 mg alone on day 1, an oral dose of lansoprazole 60 mg on day 14, and ponatinib 45 mg plus lansoprazole 60 mg on day 15.", "In this study , we aimed to determine the potential mechanisms and structural metabolic changes activated by ponatinib treatment in imatinib - sensitive K562 human CML cell lines and 3 μM - imatinib - resistant K562/IMA3 CML cell lines generated at our lab .", "Moreover , ponatinib treatment created a more ordered nucleic acid structure in the resistant cells .", "This open-label, nonrandomized, fixed-order crossover study evaluated the effect of multiple oral doses of rifampin, a strong CYP3A4 inducer, on the pharmacokinetics of ponatinib (45 mg, single dose).", "benefit outweighs the possible risk of ponatinib underexposure , because the safety of ponatinib dose increases has not been studied in this context .", "To define the clinical implication of this finding on the risk of bleeding among CML patients receiving ponatinib, we reviewed the medical records of 80 patients diagnosed with chronic phase CML (CML-CP) according to previously described criteria and treated with ponatinib on clinical trials conducted at The University of Texas, MD Anderson Cancer Center between August 25 2008 and December 21 2012.", "- dependent exposure in the circulation system , and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40% , 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5 , 15.", "phase CML ( CML - CP ) according to previously described criteria and treated with ponatinib on clinical trials conducted at The University of Texas , MD Anderson Cancer Center between August", "and once coadministered with daily ( 5 days ) ketoconazole 400 mg , a CYP3A4 inhibitor . Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration ( C(max ) ) and area under the", "with ponatinib for growth , gross and histologic appearance , and vascularity . Results Ponatinib treatment of neuroblastoma cells resulted in decreased cell viability and migration in vitro . In", "Conclusions Ponatinib reduces neuroblastoma cell viability in vitro and reduces tumor growth and vascularity in vivo .", "in both K562 and K562/IMA-3 cells . Furthermore , cell cycle analyses revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase . Moreover , ponatinib treatment created a more", "CONCLUSIONS Although coadministration of lansoprazole led to a modest , albeit statistically significant , reduction in ponatinib C max , overall systemic exposure to ponatinib did not change .", "The method was verified and successfully applied to evaluate the pharmacokinetics of ponatinib in Sprague - Dawley rats . RESULTS Ponatinib showed dose - dependent exposure in the circulation", "INTERPRETATION The efficacy of ponatinib treatment of newly diagnosed chronic - phase chronic myeloid leukaemia compared with imatinib could not be assessed due to trial termination , but preliminary data suggest there might be benefit , although with more arterial occlusive events than with imatinib at the doses studied .", "Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.", "; exposure to AP24567 decreased by 71% . Exposure to AP24567 was marginal after ponatinib alone ( no more than 4% of the exposure to ponatinib ) . These results suggest that caution should", "Taken together , all these results showed powerful antiproliferative and apoptotic effects of ponatinib in both imatinib - sensitive and imatinib - resistant CML cells in a dose - dependent manner , and hence , the use of ponatinib for the treatment of TKI - resistant CML patients may be an effective treatment approach in the clinic .", "The trial was terminated early, on Oct 17, 2013, following concerns about vascular adverse events observed in patients given ponatinib in other trials.", "The single-dose safety profile of ponatinib with and without coadministration of lansoprazole was also characterized.", "Analysis of ponatinib in various tissues revealed it was distributed widely in the body , highly exposed in the lung , thyroid , and lowly exposed in plasma , the brain , bone and the liver , indicating its potential action on lung cancer with lower system toxicity .", "The authors have shown a prolonged closure time with PFA 100 (a sensitive measure for primary hemostasis) in 5 patients with CML resistant to TKI who had been receiving ponatinib for at least two weeks without interruption.", "administration at 3.75 mg / kg for 7 days , there was distinct accumulation of ponatinib ( AUC0-∞ = 5479.41 ± 757.07 μg h / L ) relative to that of a single dose ( AUC0-∞ = 2301.84 ± 787.1", "pharmacokinetics of ponatinib ( 45 mg , single dose ) . Twenty healthy adults received ponatinib on day 1 , rifampin 600 mg alone on days 8 - 13 , 15 , and 16 , and rifampin 600 mg with ponatinib", "be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily , from the 45 mg daily starting dose , could be considered .", "In mice with orthotopic xenograft neuroblastoma tumors, treatment with ponatinib resulted in decreased growth and vascularity.", "The mechanism of platelet dysfunction reported to occur with ponatinib is currently unknown.", "METHODS The method was verified and successfully applied to evaluate the pharmacokinetics of ponatinib in Sprague - Dawley rats .", "of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects . Ponatinib , an oral tyrosine kinase inhibitor with significant activity in", "in vitro and reduces tumor growth and vascularity in vivo . The antitumor effects of ponatinib suggest its potential as a novel therapeutic agent for neuroblastoma , and further preclinical", "the liver , indicating its potential action on lung cancer with lower system toxicity . Ponatinib was eliminated primarily in feces at 26.17 ± 7.70% of its original form and only 0.24 ± 0.10% in", "clinical implication of this finding on the risk of bleeding among CML patients receiving ponatinib , we reviewed the medical records of 80 patients diagnosed with chronic phase CML ( CML - CP )", "( C(max ) ) and area under the concentration - time curve ( AUC ) compared with ponatinib alone . The estimated mean ratios for AUC0-∞ , AUC0-t , and C(max ) indicated increased exposures", "on platelet function . In our experience , a small minority of patients who received ponatinib experienced clinical bleeding and in none of these cases did the bleeding appear to be directly", "Previously established ponatinib-resistant Ba/F3 cells were also resistant to imatinib, nilotinib, and dasatinib.", "estimated mean ratios for AUC0-∞ , AUC0-t , and C(max ) indicated increased exposures to ponatinib of 78% , 70% , and 47% , respectively ; exposure to AP24567 decreased by 71% . Exposure to AP24567", "Subjects (N = 22) received two single doses (orally) of ponatinib 15 mg, once given alone and once coadministered with daily (5 days) ketoconazole 400 mg, a CYP3A4 inhibitor.", "Rifampin decreased maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration (AUC0-t ) and from time zero to infinity (AUC0-∞ ) of ponatinib by 42%, 59%, and 63%, respectively, with no effect on time to Cmax .", "and/or antiplatelet therapies did not experience any bleeding episodes while treated with ponatinib . These findings suggest that ponatinib may be safely used even on patients with history of", "regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia ( CML ) resistant to multiple tyrosine kinase inhibitors ( TKI ) therapy .", "Our findings suggest that OM may be beneficial in the treatment of leukemia patients with BCR-ABL mutant cells, helping in overcoming ponatinib resistance.", "Additionally, the effects of ponatinib on macromolecules and lipid profiles were also analyzed using Fourier transform infrared spectroscopy (FTIR).", "We hypothesized that ponatinib would be effective against neuroblastoma in preclinical models .", "of multiple oral doses of rifampin , a strong CYP3A4 inducer , on the pharmacokinetics of ponatinib ( 45 mg , single dose ) . Twenty healthy adults received ponatinib on day 1 , rifampin 600 mg", "patients developed clinical bleeding during the study period , the authors concluded that ponatinib may inhibit platelet function , suggesting that physicians should be vigilant when patients with", "A corresponding 25 % decrease in the geometric mean maximum plasma concentration (C max) of ponatinib was observed for ponatinib + lansoprazole versus ponatinib alone (40.67 vs. 53.96 ng/mL).", "doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects . Ponatinib , an oral tyrosine kinase inhibitor with significant activity in heavily pretreated patients with", "We then examined ponatinib-resistant primary Ph-positive ALL and chronic-phase CML samples.", "changes in imatinib - sensitive and imatinib - resistant K562 cells exposed to ponatinib Chronic myeloid leukemia ( CML ) is a type of hematological malignancy that is characterized by", "were considered related to ponatinib or required interruption or dose adjustment of ponatinib . Seventeen patients had a combined total of 23 surgical procedures performed during treatment", "Ponatinib ( AP24534 ) is a multitarget TKI .", ", treatment with ponatinib resulted in decreased growth and vascularity . Conclusions Ponatinib reduces neuroblastoma cell viability in vitro and reduces tumor growth and vascularity in vivo .", "Using orthotopic xenograft mouse models of human neuroblastoma, we analyzed tumors treated with ponatinib for growth, gross and histologic appearance, and vascularity.", "Furthermore, most patients with prior history of bleeding or who are receiving anticoagulation and/or antiplatelet therapies did not experience any bleeding episodes while treated with ponatinib.", "None of these episodes were considered related to ponatinib or required interruption or dose adjustment of ponatinib .", "With 72 hours of OM treatment, the cell growth of Ba/F3 ponatinib-R and Ph-positive ALL cell lines was significantly reduced, even when treated with low concentrations of OM (Figure 1A and supplemental Figure 1A).", "The safety profile was considered acceptable when ponatinib was administered alone or with lansoprazole .", "After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib (AUC0-∞ = 5479.41 ± 757.07 μg h/L) relative to that of a single dose (AUC0-∞ = 2301.84 ± 787.10 μg h/L, p < 0.05), and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h (p", "Ba/F3 ponatinib-resistant (Ba/F3 ponatinib-R) cells have 3 BCR-ABL point mutations (Y253H, E255K, and T315I; data not shown).", "The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite, AP24567, were evaluated in a single-center, randomized, two-period, two-sequence crossover study in healthy volunteers.", "Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.", "experienced bleeding events . Three patients had vaginal bleeding , one occurred while ponatinib was on hold for grade 3 thrombocytopenia ( platelets recovering to 55 x10/L at the time of", "The median platelet count at the start of ponatinib therapy was 256x10/L (range 21-1447x10/L).", "The novel kinase inhibitor ponatinib is an effective anti - angiogenic agent against neuroblastoma Background High - risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment , and novel therapies are needed to improve these outcomes .", "using Fourier transform infrared spectroscopy ( FTIR ) . Our results revealed that ponatinib inhibited cell proliferation and induced apoptosis as determined by loss of mitochondrial membrane", "Combined treatment of ponatinib-resistant cells with ponatinib and vorinostat caused a significant increase in cytotoxicity.", "The limits of the 90% confidence intervals of the estimated geometric mean ratios of ponatinib Cmax , AUC0-t , and AUC0-∞ did not fall within the 80-125% margins for equivalence, suggesting a statistically significant interaction.", "Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration (C(max)) and area under the concentration-time curve (AUC) compared with ponatinib alone.", "despite aggressive treatment , and novel therapies are needed to improve these outcomes . Ponatinib is a multi - tyrosine kinase inhibitor that targets many pathways implicated in neuroblastoma", "We found that ponatinib potently inhibited the growth of Ba/F3 cells ectopically expressing BCR-ABL T315I mutation.", "In the current study , we analyzed the efficacy of ponatinib and vorinostat treatment by using BCR - ABL - positive cell lines .", "Twenty healthy adults received ponatinib on day 1, rifampin 600 mg alone on days 8-13, 15, and 16, and rifampin 600 mg with ponatinib on day 14.", "Ponatinib is a multi - tyrosine kinase inhibitor that targets many pathways implicated in neuroblastoma pathogenesis .", "against neuroblastoma in preclinical models . Methods We evaluated the effects of ponatinib on survival and migration of human neuroblastoma cells in vitro . Using orthotopic xenograft mouse", "rivaroxaban . Twenty - five ( 31% ) patients were receiving antiplatelet therapy while on ponatinib ( 19 aspirin alone , 5 aspirin and clopidogrel , one aspirin and plasugrel ) . A total of 9 ( 11% )", ", as described above . The mechanism of platelet dysfunction reported to occur with ponatinib is currently unknown . It has been suggested that inhibition of several kinases such as SFK , LYN ,", "Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague–", "Our results revealed that ponatinib inhibited cell proliferation and induced apoptosis as determined by loss of mitochondrial membrane potential, increased caspase-3 enzyme activity, and transfer of phosphatidylserine to the plasma membrane in both K562 and K562/IMA-3 cells.", "The resistance of Ba/F3 cells bearing these 3-point mutations to ponatinib is consistent with the high-level resistance conferred by compound mutations such as E255V/T315I, although Ba/F3 ponatinib-R cells did not display increased antiapoptotic proteins.", "an important role in early platelet activation , may be responsible for the effect of ponatinib on platelet function . In our experience , a small minority of patients who received ponatinib", "OBJECTIVES The primary aim of this study was to assess the effects of the gastric proton pump inhibitor lansoprazole on the pharmacokinetics of ponatinib.", "FINDINGS Between Aug 14 , 2012 , and Oct 9 , 2013 , 307 patients were randomly assigned to receive ponatinib ( n=155 ) or imatinib ( n=152 ) .", "bleeding and in none of these cases did the bleeding appear to be directly related to ponatinib . Furthermore , most patients with prior history of bleeding or who are receiving anticoagulation", "platelet function , suggesting that physicians should be vigilant when patients with ponatinib are facing any hemostatic challenges . To define the clinical implication of this finding on the", "Results Ponatinib treatment of neuroblastoma cells resulted in decreased cell viability and migration in vitro.", "Ponatinib was eliminated primarily in feces at 26.17 ± 7.70% of its original form and only 0.24 ± 0.10% in urine .", "Exposure to AP24567 was marginal after ponatinib alone ( no more than 4% of the exposure to ponatinib ) .", "METHODS The Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia ( EPIC ) study was a randomised , open - label , phase 3 trial designed to assess the efficacy and safety of ponatinib , compared with imatinib , in newly diagnosed patients with chronic - phase chronic myeloid leukaemia .", "5 days ) ketoconazole 400 mg , a CYP3A4 inhibitor . Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration ( C(max ) ) and area under the concentration - time curve ( AUC )", "mediated by CYP3A4 . The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite , AP24567 , were evaluated in a single - center , randomized ,", "xenograft mouse models of human neuroblastoma , we analyzed tumors treated with ponatinib for growth , gross and histologic appearance , and vascularity . Results Ponatinib treatment of", "Ponatinib , an oral tyrosine kinase inhibitor with significant activity in heavily pretreated patients with chronic myeloid leukemia , is a CYP3A4 substrate .", "Additionally, the intracellular signaling of ponatinib and vorinostat was examined.", "Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.", "Combined treatment of Ba / F3 T315I mutant cells with vorinostat and ponatinib resulted in significantly increased cytotoxicity .", "Patients from 106 centres in 21 countries were randomly assigned (1:1, with stratification by Sokal score at diagnosis) using an interactive voice and web response system to receive oral ponatinib (45 mg) or imatinib (400 mg) once daily until progression, unacceptable toxicity, or other criteria for withdrawal were met.", "Although the lipid to protein ratio increased in imatinib-sensitive K562 cells with a little decrease in the K562/IMA-3 cells, ponatinib treatment indicated significant changes in the lipid composition such as a significant increase in the cellular cholesterol amounts much more in the K562/IMA-3 cells than the sensitive counterparts.", "were determined by proliferation and apoptosis assays . Additionally , the effects of ponatinib on macromolecules and lipid profiles were also analyzed using Fourier transform infrared", "patients had a combined total of 23 surgical procedures performed during treatment with ponatinib ; only 2 procedures had a bleeding complication in the same patient , as described above . The", "Trial termination limited assessment of the primary endpoint of major molecular response at 12 months , as only 13 patients in the imatinib group and ten patients in the ponatinib group could be assessed at this timepoint ; the proportion of patients achieving a major molecular response at 12 months did not differ significantly between the two groups ( eight [ 80% ] of ten patients given ponatinib and five [ 38% ] of 13 patients given imatinib ; p=0·074 ) . 11 ( 7% ) of 154 patients given ponatinib and three ( 2% ) of 152 patients given imatinib had arterial occlusive events ( p=0·052 ) ; arterial occlusive events were designated serious in ten ( 6% ) of 154 patients given ponatinib and in one ( 1% ) of 152 patients given imatinib ( p=0·010 ) .", "equivalence , suggesting a statistically significant interaction . Coadministration of ponatinib with strong CYP3A4 inducers should be avoided unless the benefit outweighs the possible risk of", "of last measurable concentration ( AUC0-t ) and from time zero to infinity ( AUC0-∞ ) of ponatinib by 42% , 59% , and 63% , respectively , with no effect on time to Cmax . The limits of the 90%", "targets many pathways implicated in neuroblastoma pathogenesis . We hypothesized that ponatinib would be effective against neuroblastoma in preclinical models . Methods We evaluated the effects", "These findings suggest that ponatinib may be safely used even on patients with history of bleeding or receiving antiplatelet /anticoagulation therapies.", ". The limits of the 90% confidence intervals of the estimated geometric mean ratios of ponatinib Cmax , AUC0-t , and AUC0-∞ did not fall within the 80 - 125% margins for equivalence , suggesting", "and imatinib - resistant CML cells in a dose - dependent manner , and hence , the use of ponatinib for the treatment of TKI - resistant CML patients may be an effective treatment approach in the", "Thus, combined administration of ponatinib and vorinostat may be a powerful strategy against BCR-ABL mutant cells and could enhance the cytotoxic effects of ponatinib in those BCR-ABL mutant cells.", "hematoma , and one retinal hemorrhage ) . The median platelet count at the start of ponatinib therapy was 256x10/L ( range 21 - 1447x10/L ) . Seven ( 9% ) patients were receiving", "in vitro . In mice with orthotopic xenograft neuroblastoma tumors , treatment with ponatinib resulted in decreased growth and vascularity . Conclusions Ponatinib reduces neuroblastoma cell", "Caspase 3 and PARP activation increased after combination treatment with ponatinib and vorinostat .", "these TKIs in the patients bearing T315I mutation is a major obstacle in CML therapy . Ponatinib , the third - generation TKI , is novel drug that is effective even in CML patients with T315I", "applied to evaluate the pharmacokinetics of ponatinib in Sprague - Dawley rats . RESULTS Ponatinib showed dose - dependent exposure in the circulation system , and the absolute bioavailabilities of", "The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.", "10/L ) and concomitant use of aspirin . None of these episodes were considered related to ponatinib or required interruption or dose adjustment of ponatinib . Seventeen patients had a combined total", "Ponatinib, the third-generation TKI, is novel drug that is effective even in CML patients with T315I mutation."], "par_relations": [], "chd_relations": ["ponatinib hydrochloride", "Iclusig"], "syn_relations": [], "sib_relations": ["ponatinib 15 MG", "ponatinib Oral Product", "ponatinib Pill", "ponatinib Oral Tablet", "ponatinib 45 MG", "ponatinib 30 MG"], "wiki_entities": ["Ponatinib", "ARIAD Pharmaceuticals", "Bcr-Abl tyrosine-kinase inhibitor", "Antileukemic drug", "Chronic myelogenous leukemia", "ATC code L01", "List of antineoplastic agents", "Tyrosine kinase", "Protein kinase inhibitor", "Clonal hypereosinophilia"], "mesh_synonynms": [], "dbpedia_synonyms": ["atc code l01xe24", "iclusig", "c29h27f3n6o", "ap24534", "atcvet code ql01xe24"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D018476", "canonical_name": "Hypokinesia", "aliases": ["bradykinesia", "hypokinesia, antiorthostatic", "antiorthostatic hypokinesia", "hypodynamia", "hypokinesia", "bradykinesias", "hypokinesias, antiorthostatic", "antiorthostatic hypokinesias"], "definition": "Hypokinesia refers to decreased bodily movement.", "other_contexts": [], "par_relations": ["Dyskinesias", "Hypokinesia", "Hypokinesia"], "chd_relations": ["Hypokinesia", "Hypokinesia", "German Syndrome"], "syn_relations": ["Hypokinesia", "Hypokinesia", "Hypokinesia", "Hypokinesia", "Hypokinesia", "Hypokinesia", "Hypokinesia", "Hypokinesia"], "sib_relations": ["Hypokinesia", "Immobilization", "Ataxia", "Athetosis", "Catalepsy", "Chorea", "Dyskinesia, Drug-Induced", "Dystonia", "Myoclonus", "Tremor", "Synkinesis", "Tics", "Hyperkinesis", "Psychomotor Agitation", "Hypokinesia"], "wiki_entities": ["Hypokinesia", "Cogwheel (disambiguation)", "Hemimotor neglect", "Movement disorders", "Micrographia (handwriting)", "Third heart sound", "Methyldopa", "Parkinsonian gait", "Direct pathway of movement", "Parkinson's disease"], "mesh_synonynms": ["hypokinesias, antiorthostatic", "bradykinesias", "antiorthostatic hypokinesia", "bradykinesia", "hypokinesia, antiorthostatic", "antiorthostatic hypokinesias", "hypodynamia", "hypokinesia"], "dbpedia_synonyms": ["bradykinesia", "lead-pipe rigidity", "hypokinetic", "cogwheeling", "hypokinesia", "rigidity (neurology)", "akinesia"]}, "target_ent": {"research_entity_id": "OMIM:MTHU001204", "canonical_name": "Hypokinesia", "aliases": ["hypokinesia"], "definition": "Hypokinesia refers to decreased bodily movement.", "other_contexts": [], "par_relations": ["Heart", "Central nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["DANON DISEASE", "GAUCHER DISEASE, PERINATAL LETHAL", "KUFOR-RAKEB SYNDROME", "PARKINSON DISEASE 1, AUTOSOMAL DOMINANT", "SEGAWA SYNDROME, AUTOSOMAL RECESSIVE", "EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 28", "STRIATAL DEGENERATION, AUTOSOMAL DOMINANT 1"], "wiki_entities": ["Hypokinesia", "Cogwheel (disambiguation)", "Hemimotor neglect", "Movement disorders", "Micrographia (handwriting)", "Third heart sound", "Methyldopa", "Parkinsonian gait", "Direct pathway of movement", "Parkinson's disease"], "mesh_synonynms": ["hypokinesias, antiorthostatic", "bradykinesias", "antiorthostatic hypokinesia", "bradykinesia", "hypokinesia, antiorthostatic", "antiorthostatic hypokinesias", "hypodynamia"], "dbpedia_synonyms": ["bradykinesia", "lead-pipe rigidity", "hypokinetic", "cogwheeling", "rigidity (neurology)", "akinesia"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0001686", "canonical_name": "Loss of voice", "aliases": ["loss of voice"], "definition": "Children Who Chase Lost Voices (星を追う子ども, Hoshi o Ou Kodomo, lit.", "other_contexts": [], "par_relations": ["Abnormality of the voice"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Hoarse voice", "Weak cry", "Cat cry", "Weak voice", "High pitched voice", "Nasal speech", "Dysphonia", "Speech articulation difficulties", "Hyponasal speech", "Abnormally low-pitched voice"], "wiki_entities": ["Hoarse voice", "Hearing loss", "Packet loss", "Magic and Loss", "Voice type", "Packet loss concealment", "Speech recognition", "Noise pollution", "Future Man (TV series)", "Auditory hallucination"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "MSH:D006685", "canonical_name": "Hoarseness", "aliases": ["voice hoarseness", "neurogenic hoarseness", "hoarseness", "hoarseness, neurogenic", "hoarseness of voice", "neurogenic hoarsenesses", "hoarsenesses", "hoarseness, voice"], "definition": "A hoarse voice, also known as hoarseness or dysphonia, is when the voice involuntarily sounds breathy, raspy, or strained, or is softer in volume or lower in pitch.", "other_contexts": ["Furthermore , child hoarseness may influence a child 's possibilities to pursue a musical interest .", "The incidence of hoarseness was observed to be more frequent in patients with left-lung carcinoma who had undergone a mediastinoscopy (p = 0.03).", "Chronic child hoarseness has also been reported to sometimes lead to organic voice disorders ( S6dlackov~5 , 1960 ) .", "This guideline applies to all age groups evaluated in a setting where hoarseness would be identified or managed.", "of this study is to study incidence , duration and sex predilection for hoarseness of voice . Also to study different etiological and predisposing factors for hoarseness of voice . After", "of more cases may lead to better survival of patients with glottic cancer without hoarseness compared to those with hoarseness . Checking the larynx of patients without hoarseness or", "reported in 24 patients ( 5.4% ) with VM procedures resulting in a higher incidence of hoarseness than did CM procedures ( 6.9% and 3.2% ) ( p = 0.08 ) . The incidence of hoarseness was observed", "CONCLUSIONS Older age , higher anxiety levels , female gender , and clinician - perceived dysphonia are associated with higher levels of patient - perceived hoarseness in SD patients .", "patients with left - lung carcinoma who had undergone a mediastinoscopy ( p = 0.03 ) . Hoarseness developed in 6% of the patients sampled at station 4L , whereas this ratio was 0% in patients who", "Hoarseness is very rarely a manifestation of internal medical illness .", "hypotensive attacks ( P=0.0001 ) , were associated with severe and moderate hoarseness . In the comparison of % change for systolic and diastolic blood pressure between the hoarseness", "of Hoarseness : Its Importance to an Otorhinolaryngologist INTRODUCTION Cardiovocal hoarseness ( Ortner 's syndrome ) is hoarseness of voice due to recurrent laryngeal nerve involvement", "RESULTS The panel made strong recommendations that 1) the clinician should not routinely prescribe antibiotics to treat hoarseness and 2) the clinician should advocate voice therapy for patients diagnosed with hoarseness that reduces voice-related QOL.", "The only entity causing hoarseness that can be treated pharmacologically is chronic laryngitis associated with gastro-esophageal reflux, which responds to treatment of the reflux disorder.", "Comparing hoarseness and time of teaching , it was observed that the percentage of hoarseness is lower in a time shorter or equal to 1 year , and it is higher in a time between 10 and 20 years .", "they were for CM ( n = 6.65 ± 1.79 and n = 4.14 ± 0.84 ) ( p < 0.001 and p = 0.06 ) . Hoarseness was reported in 24 patients ( 5.4% ) with VM procedures resulting in a higher incidence of", "complaint ( n=70 ) were included in the study , and the group of patients who suffered hoarseness ( subgroup 1 : severe , subgroup 2 : moderate , subgroup 3 : mild ) were compared with each other", "Three attempts at a definition have been made in studies of the prevalence of child hoarseness .", "BACKGROUND Hoarseness (dysphonia) is the reason for about 1% of all consultations in primary care.", "were significantly higher among patients without hoarseness than among those with hoarseness ( p = .0036 and p = .0004 , respectively ) , survival curves showed no significant differences", "\" Silver - mann & Zimmer ( 1974 ) , applying the definition of Moore ( 1971 ) , regarded hoarse - ness …", "and tobacco chewing in 33% of patients and both , also having . Most common cause for hoarseness was found out to be laryngeal neoplasms of which supraglottic growth being commonest ( 37% ) in", "Probably due to a wider area of dissection, VM can lead to more frequent hoarseness.", "Objective of this study is to study incidence , duration and sex predilection for hoarseness of voice .", "Other factors like in terms of noise and sound competition, air pollution, and in terms of causing stress and anxiety, besides habits and style/quality of life are related to the presence of hoarseness.", "According to Baynes ( 1966 ) hoarseness is \" a quality of voice that is rough , grating , harsh , more or less discordant , and lower in pitch than normal for the individual .", "Conclusion VM, the presence of a tumor in the left-lung, and 4L sampling via mediastinoscopy are risk factors for subsequent hoarseness.", "clinician - perceived dysphonia are associated with higher levels of patient - perceived hoarseness in SD patients . Hoarseness is a very personal symptom . Multiple factors determine its self -", "Hoarseness and Risk Factors in University Teachers .", "BACKGROUND Few studies have investigated the clinical characteristics of patients with glottic cancer without hoarseness.", "METHODS This review is based on literature retrieved by a selective search in PubMed employing the terms \"hoarseness,\" \"hoarse voice,\" and \"dysphonia,\" on the relevant guideline of the American Academy of Otolaryngology -Head and Neck Surgery, and on Cochrane reviews.", ". In the comparison of % change for systolic and diastolic blood pressure between the hoarseness subgroups , diastolic blood pressure change was not different ( P=0.521 ) , but systolic blood", "A stepwise multiple regression analysis revealed that breathiness , hyperfunction and roughness are good predictors of hoarseness .", "Factors Associated With Patient - perceived Hoarseness in Spasmodic Dysphonia Patients", "Theoretically , video - assisted mediastinoscopy ( VM ) should provide a decrease in the incidence of hoarseness in comparison with conventional mediastinoscopy ( CM ) .", "These factors were closely associated with hoarseness , pitch , and phonatoy effort .", "Percentage of hoarseness is lower in the maximum workload of one to three class hours per day compared with the other workloads.", "Profile of Patients of Hoarseness of Voice Presenting to Tertiary Care hospital . Hoarseness is subjective term used to describe abnormal voice quality which may occur due to many causes", "Clinical practice guideline: hoarseness (dysphonia). OBJECTIVE This guideline provides evidence-based recommendations on managing hoarseness (dysphonia), defined as a disorder characterized by altered vocal quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related quality of life (QOL).", "Ortner ’s Syndrome - A Rare Cause of Hoarseness : Its Importance to an Otorhinolaryngologist", "Checking the larynx of patients without hoarseness or encouraging internists to check the larynx when performing gastroscopic or respiratory examinations may lead to improvement of glottic cancer prognosis .", "CONCLUSION University teachers show high percentage of hoarseness.", "Also to study different etiological and predisposing factors for hoarseness of voice .", "A multivariate analysis showed that the presence of a tumor in the left lung is the only independent risk factor indicating hoarseness (p = 0.09).", "RESULTS Hoarseness can be caused by acute ( 42.1% ) and chronic laryngitis ( 9.7% ) , functional vocal disturbances ( 30% ) , and benign ( 10.7 - 31% ) and malignant tumors ( 2.2 - 3% ) , as well as by neurogenic disturbances such as vocal cord paresis ( 2.8 - 8% ) , physiologic aging of the voice ( 2% ) , and psychogenic factors ( 2 - 2.2 % ) .", "( 8.6% ) with glottic cancer first presented to hospitals with complaints other than hoarseness . Although proportions of stage I and T1 disease were significantly higher among patients without", "The patients who had this complaint (n=70) were included in the study, and the group of patients who suffered hoarseness (subgroup 1: severe, subgroup 2: moderate, subgroup 3: mild) were compared with each other and with the control group, which did not suffer hoarseness (n=51).", "Thus the patient was diagnosed as case of cardiovocal hoarseness (Ortner's syndrome) secondary to aortic intramural hematoma.", "The treatment of hoarseness has been studied in only a few randomized controlled trials , all of which were on a small scale .", "INTRODUCTION Cardiovocal hoarseness ( Ortner 's syndrome ) is hoarseness of voice due to recurrent laryngeal nerve involvement secondary to cardiovascular disease .", "Percentage of hoarseness is higher in females ( 51.8% ) than in males ( 32.6% ) .", "In the management of child hoarseness, there has often been a lack of consideration of psychological factors which are known to sometimes underlie the phenomenon (Toohill, 1975).", "on contrast computed tomography . Thus the patient was diagnosed as case of cardiovocal hoarseness ( Ortner 's syndrome ) secondary to aortic intramural hematoma . CONCLUSION A silent aortic", "It is intended for all clinicians who are likely to diagnose and manage patients with hoarseness .", "to aortic intramural hematoma . CONCLUSION A silent aortic intramural hematoma with hoarseness as the only presenting symptom is very rare . This particular case report holds lot of", "Hoarseness affects nearly one-third of the population at some point in their lives.", "be aware of this entity and should always consider it in the differential diagnosis of hoarseness .", "groups ( p = .1334 ) . CONCLUSION Patients with glottic cancer without complaints of hoarseness were diagnosed at an earlier stage than those with hoarseness . Accumulation of more cases may", "hoarseness of voice . Also to study different etiological and predisposing factors for hoarseness of voice . After taking detailed history of the patient , complete examination of ear , nose and", "variable , Voice Handicap Index-10 ( VHI-10 ) , was used to quantify patient - perceived hoarseness . Clinical data , Hospital Anxiety and Depression Scale ( HADS ) , and VHI-10 were collected .", "The duration of their hoarseness was minimum 1 to maximum 24 hours .", "of voice . Also to study different etiological and predisposing factors for hoarseness of voice . After taking detailed history of the patient , complete examination of ear , nose and throat has", "Perceptual analysis of child hoarseness using continuous scales Fifty - eight 10-year old children were recorded and judged by a panel of voice expert listeners , who rated the voices along 26 voice parameters represented by visual analogue ( continuous ) scales on a test form .", "Another complication concerning the phenomenon of child hoarseness has been that the term hoarseness itself has been considered to be vague and indistinct, being a varying conglomerate of several perceptual voice parameters.", "hoarseness . Probably due to a wider area of dissection , VM can lead to more frequent hoarseness .", "without complaints of hoarseness were diagnosed at an earlier stage than those with hoarseness . Accumulation of more cases may lead to better survival of patients with glottic cancer without", "Academy of Otolaryngology - Head and Neck Surgery Clinical Practice Guidelines on Hoarseness distinguishes between hoarseness , which is a symptom perceived by the patient , and dysphonia ,", "INTRODUCTION Child hoarseness has been studied rather extensively.", ", video - assisted mediastinoscopy ( VM ) should provide a decrease in the incidence of hoarseness in comparison with conventional mediastinoscopy ( CM ) . Methods An investigation of 448 patients", "This particular case report holds lot of significance to an otolaryngologist as he should be aware of this entity and should always consider it in the differential diagnosis of hoarseness.", "in the left - lung , and 4L sampling via mediastinoscopy are risk factors for subsequent hoarseness . Probably due to a wider area of dissection , VM can lead to more frequent hoarseness .", "nerve . However painless asymptomatic intramural hematoma of the aortic arch , causing hoarseness as the only symptom , is a rare presentation as in this case . CASE REPORT We report a case of", "A detailed history and thorough clinical examination could not reveal the pathology of hoarseness .", "Although proportions of stage I and T1 disease were significantly higher among patients without hoarseness than among those with hoarseness (p = .0036 and p = .0004, respectively), survival curves showed no significant differences between groups (p = .1334).", "The empirical treatment of hoarseness with antibiotics or corticosteroids is not recommended . CONCLUSION Voice therapy , vocal cord surgery , and drug therapy for appropriate groups of patients with hoarseness are well documented as effective by the available evidence .", "( P=0.029 ) . Dialysis - induced hypotension may be the main contributor of transient hoarseness . Especially elderly and cardiovascularly compromised patients , who are vulnerable to rapid", "Percentage of hoarseness is lower when the maximum number of students per classroom is less than 30 than when it is between 101 and 150 students .", "INTRODUCTION Cardiovocal hoarseness ( Ortner 's syndrome ) is hoarseness of voice due to recurrent laryngeal nerve involvement secondary to cardiovascular disease . Recurrent", "are associated with higher levels of patient - perceived hoarseness in SD patients . Hoarseness is a very personal symptom . Multiple factors determine its self - perception .", "Older age ( P=0.024 ) , coronary artery disease ( P=0.014 ) , autonomic neuropathy ( P=0.011 ) , and intradialytic hypotensive attacks ( P=0.0001 ) , were associated with severe and moderate hoarseness .", "Hoarseness was reported in 24 patients ( 5.4% ) with VM procedures resulting in a higher incidence of hoarseness than did CM procedures ( 6.9% and 3.2% ) ( p = 0.08 ) .", "The incidence of hoarseness after mediastinoscopy and outcome of video-assisted versus conventional mediastinoscopy in lung cancer staging.", "In the control group, coronary artery disease (P=0.056), congestive heart failure (P=0.049), autonomic neuropathy (P=0.001), severe intradialytic hypotensive attacks (P=0.000), heart valve abnormalities (P=0.000), and left ventricular diastolic dysfunction (P=0.000) were significantly lower than in hoarseness group.", "The hoarseness factor was found to have high loadings in gratings , breathiness , hyperfunction , roughness , instability , and voice breaks .", "PURPOSE The primary purpose of this guideline is to improve diagnostic accuracy for hoarseness (dysphonia), reduce inappropriate antibiotic use, reduce inappropriate steroid use, reduce inappropriate use of anti-reflux medications, reduce inappropriate use of radiographic imaging, and promote appropriate use of laryngoscopy, voice therapy, and surgery.", "hoarseness compared to those with hoarseness . Checking the larynx of patients without hoarseness or encouraging internists to check the larynx when performing gastroscopic or respiratory", "clinical examination could not reveal the pathology of hoarseness . The cause of hoarseness was diagnosed as aortic intramural hematoma on contrast computed tomography . Thus the patient was", "- Head and Neck Surgery Clinical Practice Guidelines on Hoarseness distinguishes between hoarseness , which is a symptom perceived by the patient , and dysphonia , which is a diagnosis made by the", "laryngeal neoplasms of which supraglottic growth being commonest ( 37% ) in our study . Hoarseness of voice may be present due to various underlying pathologies . So proper diagnosis , through", "Glottic cancer in patients without complaints of hoarseness .", "survival of patients with glottic cancer without hoarseness compared to those with hoarseness . Checking the larynx of patients without hoarseness or encouraging internists to check the larynx", "CONCLUSIONS Older age , higher anxiety levels , female gender , and clinician - perceived dysphonia are associated with higher levels of patient - perceived hoarseness in SD patients . Hoarseness is", "distinguishes between hoarseness , which is a symptom perceived by the patient , and dysphonia , which is a diagnosis made by the clinician . Our objective was to determine factors that are", "Anxiety and Depression Scale ( HADS ) , and VHI-10 were collected . Clinician - perceived dysphonia was measured by a speech - language pathologist with Consensus Auditory Perceptual Evaluation of", "Our objective was to determine factors that are associated with patient-perceived hoarseness in spasmodic dysphonia (SD) patients.", ". CASE REPORT We report a case of silent aortic intramural hematoma which manifested as hoarseness as the only presenting symptom . A detailed history and thorough clinical examination could not", "Hoarseness is subjective term used to describe abnormal voice quality which may occur due to many causes because it is just a symptom .", "CONCLUSION Patients with glottic cancer without complaints of hoarseness were diagnosed at an earlier stage than those with hoarseness .", "to determine factors that are associated with patient - perceived hoarseness in spasmodic dysphonia ( SD ) patients . STUDY DESIGN Retrospective study . METHODS Adductor SD patients who presented", ", and left ventricular diastolic dysfunction ( P=0.000 ) were significantly lower than in hoarseness group . Older age ( P=0.024 ) , coronary artery disease ( P=0.014 ) , autonomic neuropathy ( P=0.01", "The panel offered as options that 1 ) the clinician may perform laryngoscopy at any time in a patient with hoarseness , or may refer the patient to a clinician who can visualize the larynx ; 2 ) the clinician may prescribe anti - reflux medication for patients with hoarseness and signs of chronic laryngitis ; and 3 ) the clinician may educate / counsel patients with hoarseness about control / preventive measures . DISCLAIMER This clinical practice guideline is not intended as a sole source of guidance in managing hoarseness ( dysphonia ) .", "An overlooked complication of hemodialysis : hoarseness .", "Factors, such as time of teaching, females, work organization, workplace, in terms of noise and sound competition, air pollution, and in terms of causing stress and anxiety, besides habits and style/quality of life, are related to the presence of hoarseness in this group.", "Most common cause for hoarseness was found out to be laryngeal neoplasms of which supraglottic growth being commonest ( 37% ) in our study .", "days . Objective of this study is to study incidence , duration and sex predilection for hoarseness of voice . Also to study different etiological and predisposing factors for hoarseness of voice .", "Accumulation of more cases may lead to better survival of patients with glottic cancer without hoarseness compared to those with hoarseness.", "with each other and with the control group , which did not suffer hoarseness ( n=51 ) . Hoarseness was found in 15.2% of the hemodialysis patients . The duration of their hoarseness was minimum 1", "PURPOSE To characterize the presence of hoarseness and the risk factors in male and female university teachers in private institutions in the city of São Paulo, Brazil.", "CONCLUSION A silent aortic intramural hematoma with hoarseness as the only presenting symptom is very rare .", "In hemodialysis patients , some degree of transient hoarseness may occur at the end of the dialysis , and it may be a wearisome , recurrent , and severe state for some hemodialysis patients .", "The panel made recommendations that 1 ) the clinician should diagnose hoarseness ( dysphonia ) in a patient with altered voice quality , pitch , loudness , or vocal effort that impairs communication or reduces voice - related QOL ; 2 ) the clinician should assess the patient with hoarseness by history and/or physical examination for factors that modify management , such as one or more of the following : recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve , recent endotracheal intubation , radiation treatment to the neck , a history of tobacco abuse , and occupation as a singer or vocal performer ; 3 ) the clinician should visualize the patient 's larynx , or refer the patient to a clinician who can visualize the larynx , when hoarseness fails to resolve by a maximum of three months after onset , or irrespective of duration if a serious underlying cause is suspected ; 4 ) the clinician should not obtain computed tomography or magnetic resonance imaging of the patient with a primary complaint of hoarseness prior to visualizing the larynx ; 5 ) the clinician should not prescribe anti - reflux medications for patients with hoarseness without signs or symptoms of gastroesophageal reflux disease ; 6 ) the clinician should not routinely prescribe oral corticosteroids to treat hoarseness ; 7 ) the clinician should visualize the larynx before prescribing voice therapy and document / communicate the results to the speech - language pathologist ; and 8) the clinician should prescribe , or refer the patient to a clinician who can prescribe , botulinum toxin injections for the treatment of hoarseness caused by adductor spasmodic dysphonia .", "51 ) . Hoarseness was found in 15.2% of the hemodialysis patients . The duration of their hoarseness was minimum 1 to maximum 24 hours . In the control group , coronary artery disease ( P=0.056 ) ,", "neoplasms of which supraglottic growth being commonest ( 37% ) in our study . Hoarseness of voice may be present due to various underlying pathologies . So proper diagnosis , through detailed", "Hoarseness is a very personal symptom.", ". Our objective was to determine factors that are associated with patient - perceived hoarseness in spasmodic dysphonia ( SD ) patients . STUDY DESIGN Retrospective study . METHODS Adductor SD", ". OBJECTIVES / HYPOTHESIS The American Academy of Otolaryngology - Head and Neck Surgery Clinical Practice Guidelines on Hoarseness distinguishes between hoarseness , which is a symptom perceived by the patient , and dysphonia , which is a diagnosis made by the clinician .", "Medical College , Bhopal from April 2013 to September 2014 with complaint of hoarseness of voice for more than 15 days . Objective of this study is to study incidence , duration and sex", "have investigated the clinical characteristics of patients with glottic cancer without hoarseness . METHODS This retrospective clinical study investigated 371 patients with glottic cancer .", "of hoarseness than did CM procedures ( 6.9% and 3.2% ) ( p = 0.08 ) . The incidence of hoarseness was observed to be more frequent in patients with left - lung carcinoma who had undergone a", "Hoarseness developed in 6% of the patients sampled at station 4L , whereas this ratio was 0% in patients who were not sampled at 4L ( p = 0.07 ) .", "First , many voice experts assume that child hoarseness is harmless and automatically disappears during puberty ( Hskansson & Kitzing , 1984 ) .", "Hoarseness was found in 15.2% of the hemodialysis patients.", ", Gandhi Medical College , Bhopal from April 2013 to September 2014 with complaint of hoarseness of voice for more than 15 days . Objective of this study is to study incidence , duration and sex", "the presence of a tumor in the left lung is the only independent risk factor indicating hoarseness ( p = 0.09 ) . The sensitivity , NPV , and accuracy of VM were calculated as to be 0.87 , 0.95 ,", "RESULTS Prevalence of hoarseness in the sample is 39.6%.", "of hemodialysis : hoarseness . In hemodialysis patients , some degree of transient hoarseness may occur at the end of the dialysis , and it may be a wearisome , recurrent , and severe state", "RESULTS Thirty - two of the 371 patients ( 8.6% ) with glottic cancer first presented to hospitals with complaints other than hoarseness .", "Having a hoarse , dysfunctional voice might influence on the child 's self perception as well as the listeners ' evaluation of her / his personal traits and capacities ( Ruscello , Lass , & Podbesek , 1988 ) .", "Hoarseness-causes and treatments.", "In the comparison of % change for systolic and diastolic blood pressure between the hoarseness subgroups, diastolic blood pressure change was not different (P=0.521), but systolic blood pressure change was statistically lower in mild group than moderate (P=0.033) and severe subgroup (P=0.029).", ". A detailed history and thorough clinical examination could not reveal the pathology of hoarseness . The cause of hoarseness was diagnosed as aortic intramural hematoma on contrast computed", "The main outcome variable, Voice Handicap Index-10 (VHI-10), was used to quantify patient-perceived hoarseness.", "This prospective study was carried out in 100 patients presented in Department of ENT , Gandhi Medical College , Bhopal from April 2013 to September 2014 with complaint of hoarseness of voice for more than 15 days .", "In patients with risk factors , especially smokers , hoarseness should be immediately evaluated by laryngos - copy .", "Dialysis - induced hypotension may be the main contributor of transient hoarseness .", "an Otorhinolaryngologist INTRODUCTION Cardiovocal hoarseness ( Ortner 's syndrome ) is hoarseness of voice due to recurrent laryngeal nerve involvement secondary to cardiovascular disease .", "proportions of stage I and T1 disease were significantly higher among patients without hoarseness than among those with hoarseness ( p = .0036 and p = .0004 , respectively ) , survival curves", "However painless asymptomatic intramural hematoma of the aortic arch, causing hoarseness as the only symptom, is a rare presentation as in this case. CASE REPORT We report a case of silent aortic intramural hematoma which manifested as hoarseness as the only presenting symptom.", ": mild ) were compared with each other and with the control group , which did not suffer hoarseness ( n=51 ) . Hoarseness was found in 15.2% of the hemodialysis patients . The duration of their", "A Study of Clinicopathological Profile of Patients of Hoarseness of Voice Presenting to Tertiary Care hospital.", "The cause of hoarseness was diagnosed as aortic intramural hematoma on contrast computed tomography."], "par_relations": ["Respiration Disorders", "Signs and Symptoms, Respiratory", "Voice Disorders", "Hoarseness"], "chd_relations": ["Hoarseness", "Lipoid Proteinosis of Urbach and Wiethe", "Asrar Facharzt Haque syndrome"], "syn_relations": ["Hoarseness", "Hoarseness", "Hoarseness", "Hoarseness", "Hoarseness", "Hoarseness", "Hoarseness", "Hoarseness"], "sib_relations": ["Voice Quality", "Altitude Sickness", "Aphonia", "Apnea", "Cheyne-Stokes Respiration", "Cough", "Dyspnea", "Hemoptysis", "Hypercapnia", "Hyperventilation", "Meconium Aspiration Syndrome", "Mouth Breathing", "Respiratory Distress Syndrome, Newborn", "Respiratory Distress Syndrome, Adult", "Respiratory Insufficiency", "Respiratory Sounds", "Sneezing", "Hypocapnia", "Tachypnea", "Hypoxia", "Hyperoxia", "Acute Chest Syndrome", "Vocal Cord Dysfunction", "Dysphonia", "Respiratory Aspiration", "Infantile Apparent Life-Threatening Event", "Sarcoglycanopathies", "Hypoventilation"], "wiki_entities": ["Hoarse voice", "Laryngitis", "Croup", "English-language vowel changes before historic /r/", "Cancer signs and symptoms", "Pause for a Hoarse Horse", "Reinke's edema", "Hoarse (album)", "Pronunciation of English ⟨th⟩", "Laryngopharyngeal reflux"], "mesh_synonynms": ["hoarseness of voice", "hoarseness, neurogenic", "hoarseness, voice", "hoarseness", "neurogenic hoarsenesses", "neurogenic hoarseness", "hoarsenesses", "voice hoarseness"], "dbpedia_synonyms": ["dysphonia"]}, "label": 0}
{"source_ent": {"research_entity_id": "HPO:HP:0006574", "canonical_name": "Hepatic arteriovenous malformation", "aliases": ["hepatic arteriovenous malformation", "liver arteriovenous malformation"], "definition": "Arteriovenous malformation (AVM) is an abnormal connection between arteries and veins, bypassing the capillary system.", "other_contexts": ["Hepatic arteriovenous malformation with small intrahepatic bilomas were found.", "Hepatic Arteriovenous Malformation or Rapidly Involuting Congenital Hemangioma?", "Hepatic arteriovenous malformation in Rendu-Osler-Weber syndrome.", "Hepatic arteriovenous malformation with hyperammonemia in Rendu-Osler-Weber syndrome.", "Hepatic arteriovenous malformation associated with persistent pulmonary hypertension of the newborn has been reported in two cases in the literature."], "par_relations": ["Arteriovenous malformation", "Abnormality of the hepatic vasculature"], "chd_relations": [], "syn_relations": ["Hepatic arteriovenous malformation", "Hepatic arteriovenous malformation"], "sib_relations": ["Arteriovenous fistula", "Portal hypertension", "Nevus flammeus", "Spinal arteriovenous malformation", "Gastrointestinal arteriovenous malformation", "Cerebral arteriovenous malformation", "Pulmonary arteriovenous malformation", "Hepatic vascular malformations", "Anomalous splenoportal venous system"], "wiki_entities": ["Arteriovenous malformation", "Arteriovenous fistula", "Chiari malformation", "Vascular malformation", "Focal nodular hyperplasia", "Kawashima procedure", "Hereditary hemorrhagic telangiectasia", "Volume overload", "Fistula", "Liver tumor"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU015338", "canonical_name": "Hepatic arteriovenous malformation", "aliases": ["hepatic arteriovenous malformation"], "definition": "Arteriovenous malformation (AVM) is an abnormal connection between arteries and veins, bypassing the capillary system.", "other_contexts": ["Hepatic Arteriovenous Malformation or Rapidly Involuting Congenital Hemangioma ?", "Hepatic arteriovenous malformation in Rendu-Osler-Weber syndrome.", "Hepatic arteriovenous malformation with hyperammonemia in Rendu-Osler-Weber syndrome.", "Hepatic arteriovenous malformation associated with persistent pulmonary hypertension of the newborn has been reported in two cases in the literature .", "Hepatic arteriovenous malformation with small intrahepatic bilomas were found ."], "par_relations": ["Liver"], "chd_relations": [], "syn_relations": [], "sib_relations": ["TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER"], "wiki_entities": ["Arteriovenous malformation", "Arteriovenous fistula", "Chiari malformation", "Vascular malformation", "Focal nodular hyperplasia", "Kawashima procedure", "Hereditary hemorrhagic telangiectasia", "Volume overload", "Fistula", "Liver tumor"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0002558", "canonical_name": "Supernumerary nipple", "aliases": ["accessory nipple", "supernumerary nipples", "accessory nipples", "supernumerary nipple", "accessory mamillas", "accessory mamilla"], "definition": "A supernumerary nipple (also known as a third nipple, triple nipple, accessory nipple, polythelia or the related condition: polymastia) is an additional nipple occurring in mammals, including humans.", "other_contexts": [], "par_relations": ["Abnormality of the nipple"], "chd_relations": [], "syn_relations": ["Supernumerary nipple", "Supernumerary nipple", "Supernumerary nipple", "Supernumerary nipple"], "sib_relations": ["Supernumerary nipple", "Supernumerary nipple", "Supernumerary nipple", "Inverted nipples", "Low-set nipples", "Prominent nipples", "Aplasia/Hypoplasia of the nipples", "Abnormal intermamillary distance", "Supernumerary nipple", "Supernumerary nipple", "Supernumerary nipple"], "wiki_entities": ["Supernumerary nipple", "Nipple", "Supernumerary body part", "Accessory breast", "Supernumerary nipples–uropathies–Becker's nevus syndrome", "Miller syndrome", "Snub (disambiguation)", "Witches' mark", "Pallister–Killian syndrome", "Long-nosed caenolestid"], "mesh_synonynms": [], "dbpedia_synonyms": ["accessory nipple", "an extra nipple", "pseudomamma", "supernumerary nipple", "thripple", "polythelia", "nubbin", "extra nipple", "supplementary nipple", "witch's tit", "supernumerary nipples", "accessory nipples", "triple nipple", "thripples", "the triple nipple club", "triple nipple club", "third nipple"]}, "target_ent": {"research_entity_id": "OMIM:163700", "canonical_name": "NIPPLES, SUPERNUMERARY", "aliases": ["accessory nipples", "nipples, supernumerary", "polymastia", "polythelia, familial"], "definition": "A supernumerary nipple (also known as a third nipple, triple nipple, accessory nipple, polythelia or the related condition: polymastia) is an additional nipple occurring in mammals, including humans.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["NIPPLES, SUPERNUMERARY", "NIPPLES, SUPERNUMERARY", "NIPPLES, SUPERNUMERARY", "NIPPLES, SUPERNUMERARY", "NIPPLES, SUPERNUMERARY", "NIPPLES, SUPERNUMERARY"], "sib_relations": ["Accessory breast", "Supernumerary nipples (polythelia)", "Autosomal dominant"], "wiki_entities": ["Supernumerary nipple", "Supernumerary body part", "Accessory breast", "Nipple", "Supernumerary nipples–uropathies–Becker's nevus syndrome", "Miller syndrome", "Snub (disambiguation)", "Pallister–Killian syndrome", "Witches' mark", "Incontinentia pigmenti"], "mesh_synonynms": [], "dbpedia_synonyms": ["polymastia (disambiguation)", "polymastism", "supernumerary nipple"]}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:14891", "canonical_name": "DnaJ heat shock protein family (Hsp40) member B12", "aliases": ["flj20027", "dnajb12", "dnajb12 gene", "dj10", "dnaj heat shock protein family (hsp40) member b12"], "definition": "DnaJ heat shock protein family (Hsp40) member C12 is a protein that in humans is encoded by the DNAJC12 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["DnaJ heat shock protein family (Hsp40) member B12", "DnaJ heat shock protein family (Hsp40) member B12", "DnaJ heat shock protein family (Hsp40) member B12", "DnaJ heat shock protein family (Hsp40) member B12", "DnaJ heat shock protein family (Hsp40) member B12", "DnaJ heat shock protein family (Hsp40) member B12"], "sib_relations": [], "wiki_entities": ["Dnaj heat shock protein family (hsp40) member c12", "Dnaj (hsp40) homolog, subfamily c, member 9", "Auxilin", "DNAJB6", "DNAJC19", "DNAJC3", "DNAJB1", "DNAJA3", "DNAJA1", "DNAJC7"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:608376", "canonical_name": "DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12", "aliases": ["flj20027", "dnaj/hsp40 homolog, subfamily b, member 12", "dj10", "dnajb12"], "definition": "DnaJ (Hsp40) homolog, subfamily C, member 9 is a protein that in humans is encoded by the DNAJC9 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12", "DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12", "DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12", "DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12", "DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12", "DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12"], "sib_relations": [], "wiki_entities": ["Dnaj (hsp40) homolog, subfamily c, member 9", "Chromosome 10 (human)", "DNAJB9", "DNAJB1", "DNAJC14", "DNAJB6", "DNAJA1", "Auxilin", "DNAJA3", "DNAJA2"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D014717", "canonical_name": "Vertigo", "aliases": ["vertigos, brain stem", "spinning sensations", "central nervous system origin vertigo", "peripheral vertigo", "brain stem vertigos", "brainstem vertigos", "sensation, spinning", "brainstem vertigo", "subjective vertigo", "vertigo, intermittant", "intermittant vertigo", "peripheral vertigos", "origin vertigo, cns", "central origin vertigos", "vertigo", "essential vertigos", "vertigos, subjective", "paroxysmal vertigos", "vertigo, constant", "vertigos, paroxysmal", "constant vertigos", "vertigo, central origin", "vertigo, brain stem", "vertigo, peripheral", "spinning sensation", "vertigos, brainstem", "cns origin vertigos", "constant vertigo", "vertigo, essential", "positional vertigo", "central origin vertigo", "brain stem vertigo", "paroxysmal vertigo", "vertigos, intermittant", "vertigos, peripheral", "intermittant vertigos", "origin vertigos, central", "cns origin vertigo", "vertigo cns origin", "vertigo, positional", "vertigo, subjective", "origin vertigo, central", "vertigo, cns origin", "vertigo, brainstem", "sensations, spinning", "essential vertigo", "origin vertigos, cns", "vertigos, cns origin", "vertigos, constant", "vertigo, paroxysmal", "vertigos, essential", "vertigos, central origin", "vertigos", "vertigo, central nervous system origin", "subjective vertigos"], "definition": "Vertigo is a medical condition where a person feels as if they or the objects around them are moving when they are not.", "other_contexts": ["About 50% of students with spinning vertigo and swaying vertigo also report to have orthostatic dizziness.", "Introduction Vertigo and dizziness belong to the most common chief complaints when patients seek medical advice1.", "Vertigo and migraine: a more than two-fold connection.", "With a high lifetime prevalence and high burden of disease, vertigo and dizziness can be severely disabling symptoms because of their high impact on daily life.", "BACKGROUND Vertigo is a symptom in which individuals experience a false sensation of movement.", "During eating, dizziness and vertigo have been reported in relation to either mastication [2], swallowing or digestion [3].", "In contrast , prolonged mastication without swallowing did not induce vertigo or nystagmus .", "RESULTS We identified 52 ( 4.7% ) vascular events in patients with dizziness / vertigo and 454 ( 1.8% ) vascular events in patients without dizziness / vertigo .", "Furthermore, development of vertigo and DBN immediately after the Electronic supplementary material The online version of this article (doi:10.1007/s00415-014-7539-9) contains supplementary material, which is available to authorized users.", "Patients may describe their complaints as light-headedness, *Corresponding author Email: eva.grill@med.uni-muenchen.de 1 Institute for Medical Information Processing, Biometrics and Epidemiology, Ludwig-Maximilians-Universität-München, Munich, Germany 2 German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-UniversitätMünchen, Munich, Germany 3 Department of Neurology, Ludwig-Maximilians-UniversitätMünchen, Munich, Germany 4 Institute for Clinical Neuroscience, LudwigMaximilians-UniversitätMünchen, Munich, Germany", "In Germany , about 3.4% of all out - patient consultations are due to the symptom vertigo / dizziness : the 12-month prevalence for all types of vertigo is about 23% and for rotational vertigo about 5% ( 2 ) .", "The visual and the somatosensory systems contribute to postural stability . Impaired sensory functions or impaired interaction between sensory systems can cause vertigo and dizziness .", "However , vertigo as well as dizziness are symptoms present in a wide variety of disorders .", "The appearance of vertigo might be irrelevant to the range and extent of vestibular dysfunction .", "Vertigo is a kind of patients ' subjective feelings .", "Vertigo and dizziness as symptoms are difficult to describe and to standardize .", "The onset of the migraine seems to be years earlier than the onset of the vertigo and the duration of the vertigo is between 1–24 h in most attacks ( 8) .", "Although isolated vertigo has frequently been reported as the only symptom in case series of cerebellar infarcts, only one article discussed its incidence.", "CONCLUSION Psychological distress is an important mechanism in the process how vertigo symptoms lead to vertigo - related handicap .", "With very few exceptions, vertigo has been regarded in epidemiological studies as a symptom or consequence of some other underlying disease of cardiovascular or neurological origin and has hardly been the focus of epidemiological research.", "In face of the high period prevalence and clinical relevance of dizziness/vertigo in adolescents there is a need for prevention strategies.", "Vertigo is no less often the reason for clinical consultations .", "One study , at high risk of bias , included 72 people with benign paroxysmal positional vertigo ( BPPV ) and compared betahistine with placebo ; all patients also had particle repositioning manoeuvres .", "The abnormal rates of oVEMP, cVEMP and caloric test in SSHL patients without vertigo were similar to that of SSHL patients with vertigo.", "Caloric test was operated in 21 SSHL patients without vertigo and 29 patients with vertigo.", "5% ears with vertigo ( 40/62 ) , and 26 .", "But we are short of a well accepted quantitative evaluation method capable of accurately and comprehensively evaluating vertigo in clinics .", "In epidemiological studies , detailed diagnostic work - ups of vestibular and non - vestibular causes of vertigo may be impossible .", "Of those , 1,118 patients were discharged home with a diagnosis of vertigo or dizziness .", "Risk factors for dizziness / vertigo need to be assessed to allow for conception of an intervention programme .", "The vertigo and DBN lasted approximately 50 s after deglutition.", "Reducing the onset of vertigo, enhancing the re- covery of equilibrium function, and improving the quality of life of vertigo patients should be taken as the focus of evaluating therapeutic effects.", "At this point , all available evidence points to a related co - morbidity of migraine and some forms of vertigo .", "Secondly , we should analyze different reasons for vertigo , choose symptoms and signs in line with vertigo features as well as with Chinese medical theories , and formulate corresponding syndrome effectiveness standards according to different diseases .", "The severity of vertigo is closely related to many factors.", "OBJECTIVES (1) To present a case series of vertigo and dizziness without vertigo of probable vascular origin and (2) to perform an evidence-based review regarding the incidence of isolated vertigo and dizziness of vascular origin.", "A single study has determined that 52% of patients with isolated vertigo of unclear etiopathology have posterior circulation anomalies .", "Psychological distress longitudinally mediates the effect of vertigo symptoms on vertigo-related handicap. OBJECTIVE Vertigo symptoms can lead to more or less vertigo-related handicap.", "Most interesting are the findings that some well known ‘classic’ vertigo syndromes, namely Ménière’s disease and benign paroxysmal positional vertigo, can be found more often than expected in patients with migraine.", "Statistical significance was found in oVEMP and cVEMP rates between SSHL without vertigo and normal group (P<0.", "The most frequent cause of pathologic vertigo is an impairment of the vestibular system.", "As for establishing a Chinese medical effectiveness evaluation system for vertigo , we believe we should distinguish different \" diseases \" .", "Epidemiological data on vertigo and dizziness is scarce and inconsistent .", "Our patient contrasted with those patients in that the vertigo and DBN were specifically induced by swallowing, and not by prolonged mastication.", "ER patients discharged home with a diagnosis of vertigo or dizziness had 2-fold (95% confidence interval [CI], 1.35-2.96; p<0.001) higher risk of stroke or cardiovascular events after adjusting for patient characteristics, co-morbidities, urbanization level of residence, individual socio-economic status, and initially taking medications after the onset of dizziness or vertigo during the first year.", "Furthermore, how can the headache specialist differentiate between migrainous vertigo and migraine-associated vertigo?", "RESULTS We identified nine cases of vertigo and dizziness without vertigo of probable vascular origin.", "Normal sinus rhythm was maintained during the vertigo attack on electrocardiogram.", "Three month prevalence of dizziness / vertigo was estimated ; symptoms were categorized as orthostatic dizziness , spinning vertigo , swaying vertigo or unspecified dizziness .", "Vertigo or nystagmus was not induced by vibratory stimuli on mastoid process and brow, horizontal head-shaking, and positional maneuvers including lying down, head-turning to either side while supine, straight head-hanging, and Dix-Hallpike maneuver to either side.", "Sixty-two SSHL patients with vertigo and twenty-five age-and gender-matched normal subjects were recruited as controls to analyze the vestibular dysfunction in SSHL patients without.", "But for non - systemic vertigo , the efficacy of vertigo could be comprehensively evaluated by taking UCLA vertigo questionnaire or dizziness handicap inventory as main efficacy indices .", "Vertigo and dizziness : challenges for epidemiological research Introduction Vertigo and dizziness are among the most common chief complaints when patients seek medical advice and affect a considerable part of adults of working age .", "Mediation analyses with bootstrapping were performed to investigate the mediating role of anxiety, depression, and somatization in the relationship between vertigo symptoms and vertigo-related handicap.", "The vertigo tended to develop after the first swallowing.", "The vertigo lasted less than 5 min and did not accompany any pain, tinnitus, or hearing loss.", "However , no significant statistical difference was found in oVEMP , cVEMP rates and caloric test between SSHL without vertigo and SSHL with vertigo group ( P>0 .", "CONCLUSION Dizziness and vertigo in grammar school students appear to be as common as in adults.", "However, swallowing of bread immediately induced vertigo and DBN (Fig", "The aim of this review was to discuss the challenges for epidemiological research in vertigo and dizziness.", "RESULTS When the mediating role of anxiety , depression , and somatization was evaluated separately from each other in single mediation models , the effect vertigo symptoms at baseline exerted on vertigo - related handicap at 12-month follow - up was significantly mediated by depression at 6-month follow - up ( p<0.05 ) , by anxiety at 6-month follow - up ( p<0.05 ) , as well as by somatization at 6-month follow - up ( p<0.05 ) .", "Epidemiological data also vary depending on data collection procedures , study design Vertigo and dizziness : challenges for epidemiological research E Grill1,2 * , M Müller1,2 , T Brandt2,4 , K Jahn2,3 and sample .", "METHODS Forty - two cases of unilateral SSHL without vertigo were enrolled in the study from May 2012 to May 2014 .", "Beside the vestibular vertigo during migraine attacks, other mechanisms may also contribute to the sensation of dizziness.", "For systemic vertigo, the efficacy of vertigo could be comprehensively evaluated by UCLA vertigo questionnaire or dizziness handicap inventory combined with equilibrium function testing indices.", "CONCLUSIONS ER patients discharged home with a diagnosis of dizziness or vertigo were at a increased risk of developing subsequent vascular events than those without dizziness/vertigo after the onset of dizziness or vertigo.", "Isolated vertigo and dizziness of vascular origin.", "[Thinking about vertigo effectiveness evaluation methods in clinical research of Chinese medicine].", "Most vertigo / dizziness types were confined to less than one minute on average .", "Despite the frequency of these symptoms, there is a lack of epidemiological data for the following reasons: (1) in contrast to headache, lumbago or dyspnoea, patients have problems to describe their complaints; (2) disorders presenting with vertigo and dizziness fall in different medical subspecialties (e.g. general practice, otorhinolarngology, neurology, psychiatry, ophthalmology, cardiology); (3) diagnostic categories are not established across medicine; and (4) most syndromes are not represented in international classification systems (e.g. ICD-10).", "Further, psychogenic vertigo can develop following organic vestibular disorders, or might develop as a comorbid condition of phobia or panic attacks2.", "The vertigo decreased with carbamazepine 600 mg per day.", "A Cox proportional hazard model was performed to compare the three-year vascular event-free survival rates between the dizziness/vertigo patients and those without dizziness/vertigo after adjusting for confounding and risk factors.", "The studies varied considerably in terms of types of participants , their diagnoses , the dose of betahistine and the length of time it was taken for , the study methods and the way any improvement in vertigo symptoms was measured .", "This longitudinal study investigated whether depression , anxiety , and/or somatization mediate the relationship between vertigo symptoms and vertigo - related handicap .", "Conflicting data regarding the vascular event risk among the dizziness or vertigo patients have been reported.", "The period prevalence for the other types of vertigo were spinning vertigo : 11.6% , 95%-CI = [ 10.1 - 13.3 ] , N = 193 ; swaying vertigo : 12.2% , 95%-CI = [ 10.6 - 13.8 ] , N = 202 ; and unspecified dizziness : 15.2% , 95%-CI = [ 13.5 - 17.1 ] , N = 253 .", "Herein, we describe a patient with vertigo and DBN induced by swallowing.", "Abnormal caloric test was observed in 52.4% ( 11/21 ) SSHL patients without vertigo and 75 .", "Vertigo can be of peripheral origin , i.e. a problem of the labyrinth or the vestibular nerve , or of central origin , as a consequence of a lesion of the cerebellum or brain stem .", "OBJECTIVES To assess the effects of betahistine in patients with symptoms of vertigo from different causes.", "METHOD (1) All patients from a vertigo clinic found to have vertigo of potential vascular origin had a complete neuro-otologic examination and were investigated by magnetic resonance angiography.", "Betahistine for symptoms of vertigo.", "Few authors have considered that a vascular origin should be thought of in cases of positional vertigo or vertigo not associated with neurologic signs ( ie , isolated vertigo ) in patients with vascular disease risk factors .", "METHODS In 1661 students in 8th-10th grade in twelve grammar schools in Munich , Germany information on vertigo / dizziness was assessed by a questionnaire in the class room setting .", "4% ears with vertigo (30/62), and 14.", "Increased Risk of Vascular Events in Emergency Room Patients Discharged Home with Diagnosis of Dizziness or Vertigo : A 3-Year Follow - Up Study BACKGROUND Dizziness and vertigo symptoms are commonly seen in emergency room ( ER ) .", "4% affected ears without vertigo ( 22/42 ) , 48 .", "vertigo .", "However , in recent years , it has also become clear that this association between migraine and vertigo is not due to a single clinical entity but that several clinical vertigo syndromes are more often seen in migraine patients ( 8) .", "CONCLUSION Vestibular function could be damaged in SSHL patients without vertigo .", "The proportion of students with any dizziness / vertigo accounting for failure attending school , leisure activities or obliging them to stay in bed were more pronounced for spinning or swaying vertigo .", "Period Prevalence of Dizziness and Vertigo in Adolescents OBJECTIVES To assess the period prevalence and severity of dizziness and vertigo in adolescents.", "This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes .", "AUTHORS' CONCLUSIONS Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms.", "This study aims to determine the risk of developing stroke or cardiovascular events in ER patients discharged home with a diagnosis of dizziness or vertigo .", "METHODS N=111 patients with vertigo / dizziness provided complete data on the following measures : Vertigo symptoms at baseline , depression at 6-month follow - up , anxiety at 6-month follow - up , somatization at 6-month follow - up , and vertigo handicap at 12-month follow - up .", "Based on the available data, the life-time prevalence of migrainous vertigo is about 1%, when the following criteria were used: (i) recurrent vestibular vertigo (rotational or positional vertigo); (ii) history of migraine according the International Headache Society criteria, at least two attacks in which migraine and vertigo occurred together; and (iii) the vertigo was not explained by other disorders (6).", "OBJECTIVE To observe the vestibular dysfunction in sudden sensorineural hearing loss ( SSHL ) patients without vertigo .", "CONCLUSION Vascular origin should be considered in cases of positional vertigo and isolated vertigo or dizziness when the etiology remains unclear.", "A 67-year - old man reported transient vertigo for 6 months , which had been induced by deglutition , especially when he swallowed solid foods .", "Swallowing-induced vertigo and downbeat nystagmus Dear Sirs, Intermittent vertigo and downbeat nystagmus (DBN) have been reported in various disorders including rotational vertebral artery syndrome, basilar invagination, cardiac asystole, Chiari malformation, episodic ataxia and multiple systemic atrophy [1].", "Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).", "INTRODUCTION Vertigo of vascular origin is usually limited to migraine, transient ischemic attacks, and ischemic or hemorrhagic stroke.", "SELECTION CRITERIA We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings .", "Using the GRADE system , we judged the quality of evidence overall to be low for two outcomes ( proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group : risk ratio ( RR ) 1.30 , 95% confidence interval ( CI ) 1.05 to 1.60 ; 606 participants ; 11 studies ) .", "When statistically controlling for the other mediators in a multiple mediator model, only depression at 6-month follow-up mediated the effect of vertigo symptoms at baseline on vertigo-related handicap at 12-month follow-up (p<0.05).", "RESULTS 72.0% (95%-CI = [69.8-74.2]; N = 1196) of the students (mean age 14.5±1.1) reported to suffer from at least one episode of dizziness or vertigo in the last three months.", "9% (22/29) SSHL patients with vertigo respectively.", "Vertigo can be either a reaction to stimulus, e.g. following unaccustomed head movements as in a carrousel or on a ship, or the result of a discrepancy between visual and vestibular information, e.g. in a moving car or on an exposed mountain ridge.", "We could roughly identify it as systemic vertigo and non - systemic vertigo .", "Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families.", "8% affected ears without vertigo ( 23/42 ) , 64 ."], "par_relations": ["Neurologic Manifestations", "Vestibular Diseases", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo"], "chd_relations": ["Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Benign Paroxysmal Positional Vertigo", "Episodic Ataxia, Type 3"], "syn_relations": ["Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo", "Vertigo"], "sib_relations": ["Dizziness", "Urinary Bladder, Neurogenic", "Decerebrate State", "Dyskinesias", "Meningism", "Pain", "Paresis", "Psychophysiologic Disorders", "Pupil Disorders", "Reflex, Abnormal", "Seizures", "Sensation Disorders", "Voice Disorders", "Paralysis", "Neurobehavioral Manifestations", "Neurogenic Inflammation", "Gait Disorders, Neurologic", "Neuromuscular Manifestations", "Orthostatic Intolerance", "Susac Syndrome", "Cerebrospinal Fluid Leak", "Sleep Wake Disorders", "Bilateral Vestibulopathy"], "wiki_entities": ["Vertigo", "Vertigo (DC Comics)", "Vertigo (film)", "Benign paroxysmal positional vertigo", "Vertigo (disambiguation)", "The Sandman (Vertigo)", "Count Vertigo", "Vertigo 2005: Live from Chicago", "Vertigo Records", "Migraine-associated vertigo"], "mesh_synonynms": ["brain stem vertigos", "intermittant vertigos", "origin vertigo, central", "intermittant vertigo", "vertigo", "spinning sensations", "brainstem vertigos", "peripheral vertigos", "vertigos, brain stem", "vertigos, constant", "cns origin vertigo", "vertigos, peripheral", "sensation, spinning", "central origin vertigo", "vertigos, central origin", "paroxysmal vertigos", "vertigo, cns origin", "brain stem vertigo", "peripheral vertigo", "central origin vertigos", "cns origin vertigos", "vertigo, subjective", "subjective vertigo", "positional vertigo", "essential vertigos", "vertigo, brainstem", "spinning sensation", "vertigos, intermittant", "vertigo, positional", "vertigos", "vertigo, central origin", "origin vertigo, cns", "brainstem vertigo", "paroxysmal vertigo", "vertigos, cns origin", "vertigo, paroxysmal", "constant vertigos", "vertigos, subjective", "vertigo, essential", "central nervous system origin vertigo", "origin vertigos, central", "origin vertigos, cns", "vertigo, constant", "constant vertigo", "vertigos, brainstem", "vertigo, central nervous system origin", "sensations, spinning", "subjective vertigos", "vertigos, essential", "vertigo, intermittant", "vertigo, brain stem", "vertigo, peripheral", "vertigos, paroxysmal", "essential vertigo"], "dbpedia_synonyms": ["vertiginous syndromes", "virtigo", "💫", "benign paroxysmal positional vertigo", "unsteadiness", "spinning death", "list of argentine films of 1993", "vertiginous", "vertigo (medical)"]}, "target_ent": {"research_entity_id": "OMIM:MTHU001035", "canonical_name": "Vertigo", "aliases": ["vertigo"], "definition": "Vertigo is a medical condition where a person feels as if they or the objects around them are moving when they are not.", "other_contexts": ["About 50% of students with spinning vertigo and swaying vertigo also report to have orthostatic dizziness.", "Introduction Vertigo and dizziness belong to the most common chief complaints when patients seek medical advice1.", "Vertigo and migraine: a more than two-fold connection.", "With a high lifetime prevalence and high burden of disease, vertigo and dizziness can be severely disabling symptoms because of their high impact on daily life.", "BACKGROUND Vertigo is a symptom in which individuals experience a false sensation of movement.", "During eating, dizziness and vertigo have been reported in relation to either mastication [2], swallowing or digestion [3].", "In contrast , prolonged mastication without swallowing did not induce vertigo or nystagmus .", "RESULTS We identified 52 ( 4.7% ) vascular events in patients with dizziness / vertigo and 454 ( 1.8% ) vascular events in patients without dizziness / vertigo .", "Furthermore, development of vertigo and DBN immediately after the Electronic supplementary material The online version of this article (doi:10.1007/s00415-014-7539-9) contains supplementary material, which is available to authorized users.", "Patients may describe their complaints as light-headedness, *Corresponding author Email: eva.grill@med.uni-muenchen.de 1 Institute for Medical Information Processing, Biometrics and Epidemiology, Ludwig-Maximilians-Universität-München, Munich, Germany 2 German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-UniversitätMünchen, Munich, Germany 3 Department of Neurology, Ludwig-Maximilians-UniversitätMünchen, Munich, Germany 4 Institute for Clinical Neuroscience, LudwigMaximilians-UniversitätMünchen, Munich, Germany", "In Germany , about 3.4% of all out - patient consultations are due to the symptom vertigo / dizziness : the 12-month prevalence for all types of vertigo is about 23% and for rotational vertigo about 5% ( 2 ) .", "The visual and the somatosensory systems contribute to postural stability . Impaired sensory functions or impaired interaction between sensory systems can cause vertigo and dizziness .", "However , vertigo as well as dizziness are symptoms present in a wide variety of disorders .", "The appearance of vertigo might be irrelevant to the range and extent of vestibular dysfunction .", "Vertigo is a kind of patients ' subjective feelings .", "Vertigo and dizziness as symptoms are difficult to describe and to standardize .", "The onset of the migraine seems to be years earlier than the onset of the vertigo and the duration of the vertigo is between 1–24 h in most attacks ( 8) .", "Although isolated vertigo has frequently been reported as the only symptom in case series of cerebellar infarcts, only one article discussed its incidence.", "CONCLUSION Psychological distress is an important mechanism in the process how vertigo symptoms lead to vertigo - related handicap .", "With very few exceptions, vertigo has been regarded in epidemiological studies as a symptom or consequence of some other underlying disease of cardiovascular or neurological origin and has hardly been the focus of epidemiological research.", "In face of the high period prevalence and clinical relevance of dizziness/vertigo in adolescents there is a need for prevention strategies.", "Vertigo is no less often the reason for clinical consultations .", "One study , at high risk of bias , included 72 people with benign paroxysmal positional vertigo ( BPPV ) and compared betahistine with placebo ; all patients also had particle repositioning manoeuvres .", "The abnormal rates of oVEMP, cVEMP and caloric test in SSHL patients without vertigo were similar to that of SSHL patients with vertigo.", "Caloric test was operated in 21 SSHL patients without vertigo and 29 patients with vertigo.", "5% ears with vertigo ( 40/62 ) , and 26 .", "But we are short of a well accepted quantitative evaluation method capable of accurately and comprehensively evaluating vertigo in clinics .", "In epidemiological studies , detailed diagnostic work - ups of vestibular and non - vestibular causes of vertigo may be impossible .", "Of those , 1,118 patients were discharged home with a diagnosis of vertigo or dizziness .", "Risk factors for dizziness / vertigo need to be assessed to allow for conception of an intervention programme .", "The vertigo and DBN lasted approximately 50 s after deglutition.", "Reducing the onset of vertigo, enhancing the re- covery of equilibrium function, and improving the quality of life of vertigo patients should be taken as the focus of evaluating therapeutic effects.", "At this point , all available evidence points to a related co - morbidity of migraine and some forms of vertigo .", "Secondly , we should analyze different reasons for vertigo , choose symptoms and signs in line with vertigo features as well as with Chinese medical theories , and formulate corresponding syndrome effectiveness standards according to different diseases .", "The severity of vertigo is closely related to many factors.", "OBJECTIVES (1) To present a case series of vertigo and dizziness without vertigo of probable vascular origin and (2) to perform an evidence-based review regarding the incidence of isolated vertigo and dizziness of vascular origin.", "A single study has determined that 52% of patients with isolated vertigo of unclear etiopathology have posterior circulation anomalies .", "Psychological distress longitudinally mediates the effect of vertigo symptoms on vertigo-related handicap. OBJECTIVE Vertigo symptoms can lead to more or less vertigo-related handicap.", "Most interesting are the findings that some well known ‘classic’ vertigo syndromes, namely Ménière’s disease and benign paroxysmal positional vertigo, can be found more often than expected in patients with migraine.", "Statistical significance was found in oVEMP and cVEMP rates between SSHL without vertigo and normal group (P<0.", "The most frequent cause of pathologic vertigo is an impairment of the vestibular system.", "As for establishing a Chinese medical effectiveness evaluation system for vertigo , we believe we should distinguish different \" diseases \" .", "Epidemiological data on vertigo and dizziness is scarce and inconsistent .", "Our patient contrasted with those patients in that the vertigo and DBN were specifically induced by swallowing, and not by prolonged mastication.", "ER patients discharged home with a diagnosis of vertigo or dizziness had 2-fold (95% confidence interval [CI], 1.35-2.96; p<0.001) higher risk of stroke or cardiovascular events after adjusting for patient characteristics, co-morbidities, urbanization level of residence, individual socio-economic status, and initially taking medications after the onset of dizziness or vertigo during the first year.", "Furthermore, how can the headache specialist differentiate between migrainous vertigo and migraine-associated vertigo?", "RESULTS We identified nine cases of vertigo and dizziness without vertigo of probable vascular origin.", "Normal sinus rhythm was maintained during the vertigo attack on electrocardiogram.", "Three month prevalence of dizziness / vertigo was estimated ; symptoms were categorized as orthostatic dizziness , spinning vertigo , swaying vertigo or unspecified dizziness .", "Vertigo or nystagmus was not induced by vibratory stimuli on mastoid process and brow, horizontal head-shaking, and positional maneuvers including lying down, head-turning to either side while supine, straight head-hanging, and Dix-Hallpike maneuver to either side.", "Sixty-two SSHL patients with vertigo and twenty-five age-and gender-matched normal subjects were recruited as controls to analyze the vestibular dysfunction in SSHL patients without.", "But for non - systemic vertigo , the efficacy of vertigo could be comprehensively evaluated by taking UCLA vertigo questionnaire or dizziness handicap inventory as main efficacy indices .", "Vertigo and dizziness : challenges for epidemiological research Introduction Vertigo and dizziness are among the most common chief complaints when patients seek medical advice and affect a considerable part of adults of working age .", "Mediation analyses with bootstrapping were performed to investigate the mediating role of anxiety, depression, and somatization in the relationship between vertigo symptoms and vertigo-related handicap.", "The vertigo tended to develop after the first swallowing.", "The vertigo lasted less than 5 min and did not accompany any pain, tinnitus, or hearing loss.", "However , no significant statistical difference was found in oVEMP , cVEMP rates and caloric test between SSHL without vertigo and SSHL with vertigo group ( P>0 .", "CONCLUSION Dizziness and vertigo in grammar school students appear to be as common as in adults.", "However, swallowing of bread immediately induced vertigo and DBN (Fig", "The aim of this review was to discuss the challenges for epidemiological research in vertigo and dizziness.", "RESULTS When the mediating role of anxiety , depression , and somatization was evaluated separately from each other in single mediation models , the effect vertigo symptoms at baseline exerted on vertigo - related handicap at 12-month follow - up was significantly mediated by depression at 6-month follow - up ( p<0.05 ) , by anxiety at 6-month follow - up ( p<0.05 ) , as well as by somatization at 6-month follow - up ( p<0.05 ) .", "Epidemiological data also vary depending on data collection procedures , study design Vertigo and dizziness : challenges for epidemiological research E Grill1,2 * , M Müller1,2 , T Brandt2,4 , K Jahn2,3 and sample .", "METHODS Forty - two cases of unilateral SSHL without vertigo were enrolled in the study from May 2012 to May 2014 .", "Beside the vestibular vertigo during migraine attacks, other mechanisms may also contribute to the sensation of dizziness.", "For systemic vertigo, the efficacy of vertigo could be comprehensively evaluated by UCLA vertigo questionnaire or dizziness handicap inventory combined with equilibrium function testing indices.", "CONCLUSIONS ER patients discharged home with a diagnosis of dizziness or vertigo were at a increased risk of developing subsequent vascular events than those without dizziness/vertigo after the onset of dizziness or vertigo.", "Isolated vertigo and dizziness of vascular origin.", "[Thinking about vertigo effectiveness evaluation methods in clinical research of Chinese medicine].", "Most vertigo / dizziness types were confined to less than one minute on average .", "Despite the frequency of these symptoms, there is a lack of epidemiological data for the following reasons: (1) in contrast to headache, lumbago or dyspnoea, patients have problems to describe their complaints; (2) disorders presenting with vertigo and dizziness fall in different medical subspecialties (e.g. general practice, otorhinolarngology, neurology, psychiatry, ophthalmology, cardiology); (3) diagnostic categories are not established across medicine; and (4) most syndromes are not represented in international classification systems (e.g. ICD-10).", "Further, psychogenic vertigo can develop following organic vestibular disorders, or might develop as a comorbid condition of phobia or panic attacks2.", "The vertigo decreased with carbamazepine 600 mg per day.", "A Cox proportional hazard model was performed to compare the three-year vascular event-free survival rates between the dizziness/vertigo patients and those without dizziness/vertigo after adjusting for confounding and risk factors.", "The studies varied considerably in terms of types of participants , their diagnoses , the dose of betahistine and the length of time it was taken for , the study methods and the way any improvement in vertigo symptoms was measured .", "This longitudinal study investigated whether depression , anxiety , and/or somatization mediate the relationship between vertigo symptoms and vertigo - related handicap .", "Conflicting data regarding the vascular event risk among the dizziness or vertigo patients have been reported.", "The period prevalence for the other types of vertigo were spinning vertigo : 11.6% , 95%-CI = [ 10.1 - 13.3 ] , N = 193 ; swaying vertigo : 12.2% , 95%-CI = [ 10.6 - 13.8 ] , N = 202 ; and unspecified dizziness : 15.2% , 95%-CI = [ 13.5 - 17.1 ] , N = 253 .", "Herein, we describe a patient with vertigo and DBN induced by swallowing.", "Abnormal caloric test was observed in 52.4% ( 11/21 ) SSHL patients without vertigo and 75 .", "Vertigo can be of peripheral origin , i.e. a problem of the labyrinth or the vestibular nerve , or of central origin , as a consequence of a lesion of the cerebellum or brain stem .", "OBJECTIVES To assess the effects of betahistine in patients with symptoms of vertigo from different causes.", "METHOD (1) All patients from a vertigo clinic found to have vertigo of potential vascular origin had a complete neuro-otologic examination and were investigated by magnetic resonance angiography.", "Betahistine for symptoms of vertigo.", "Few authors have considered that a vascular origin should be thought of in cases of positional vertigo or vertigo not associated with neurologic signs ( ie , isolated vertigo ) in patients with vascular disease risk factors .", "METHODS In 1661 students in 8th-10th grade in twelve grammar schools in Munich , Germany information on vertigo / dizziness was assessed by a questionnaire in the class room setting .", "4% ears with vertigo (30/62), and 14.", "Increased Risk of Vascular Events in Emergency Room Patients Discharged Home with Diagnosis of Dizziness or Vertigo : A 3-Year Follow - Up Study BACKGROUND Dizziness and vertigo symptoms are commonly seen in emergency room ( ER ) .", "4% affected ears without vertigo ( 22/42 ) , 48 .", "vertigo .", "However , in recent years , it has also become clear that this association between migraine and vertigo is not due to a single clinical entity but that several clinical vertigo syndromes are more often seen in migraine patients ( 8) .", "CONCLUSION Vestibular function could be damaged in SSHL patients without vertigo .", "The proportion of students with any dizziness / vertigo accounting for failure attending school , leisure activities or obliging them to stay in bed were more pronounced for spinning or swaying vertigo .", "Period Prevalence of Dizziness and Vertigo in Adolescents OBJECTIVES To assess the period prevalence and severity of dizziness and vertigo in adolescents.", "This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes .", "AUTHORS' CONCLUSIONS Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms.", "This study aims to determine the risk of developing stroke or cardiovascular events in ER patients discharged home with a diagnosis of dizziness or vertigo .", "METHODS N=111 patients with vertigo / dizziness provided complete data on the following measures : Vertigo symptoms at baseline , depression at 6-month follow - up , anxiety at 6-month follow - up , somatization at 6-month follow - up , and vertigo handicap at 12-month follow - up .", "Based on the available data, the life-time prevalence of migrainous vertigo is about 1%, when the following criteria were used: (i) recurrent vestibular vertigo (rotational or positional vertigo); (ii) history of migraine according the International Headache Society criteria, at least two attacks in which migraine and vertigo occurred together; and (iii) the vertigo was not explained by other disorders (6).", "OBJECTIVE To observe the vestibular dysfunction in sudden sensorineural hearing loss ( SSHL ) patients without vertigo .", "CONCLUSION Vascular origin should be considered in cases of positional vertigo and isolated vertigo or dizziness when the etiology remains unclear.", "A 67-year - old man reported transient vertigo for 6 months , which had been induced by deglutition , especially when he swallowed solid foods .", "Swallowing-induced vertigo and downbeat nystagmus Dear Sirs, Intermittent vertigo and downbeat nystagmus (DBN) have been reported in various disorders including rotational vertebral artery syndrome, basilar invagination, cardiac asystole, Chiari malformation, episodic ataxia and multiple systemic atrophy [1].", "Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).", "INTRODUCTION Vertigo of vascular origin is usually limited to migraine, transient ischemic attacks, and ischemic or hemorrhagic stroke.", "SELECTION CRITERIA We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings .", "Using the GRADE system , we judged the quality of evidence overall to be low for two outcomes ( proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group : risk ratio ( RR ) 1.30 , 95% confidence interval ( CI ) 1.05 to 1.60 ; 606 participants ; 11 studies ) .", "When statistically controlling for the other mediators in a multiple mediator model, only depression at 6-month follow-up mediated the effect of vertigo symptoms at baseline on vertigo-related handicap at 12-month follow-up (p<0.05).", "RESULTS 72.0% (95%-CI = [69.8-74.2]; N = 1196) of the students (mean age 14.5±1.1) reported to suffer from at least one episode of dizziness or vertigo in the last three months.", "9% (22/29) SSHL patients with vertigo respectively.", "Vertigo can be either a reaction to stimulus, e.g. following unaccustomed head movements as in a carrousel or on a ship, or the result of a discrepancy between visual and vestibular information, e.g. in a moving car or on an exposed mountain ridge.", "We could roughly identify it as systemic vertigo and non - systemic vertigo .", "Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families.", "8% affected ears without vertigo ( 23/42 ) , 64 ."], "par_relations": ["Ears", "Central nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["VON HIPPEL-LINDAU SYNDROME", "CHIARI MALFORMATION TYPE I", "EPISODIC ATAXIA, TYPE 2", "DEAFNESS, AUTOSOMAL DOMINANT 9", "KANZAKI DISEASE", "DEAFNESS, AUTOSOMAL RECESSIVE 2", "EPISODIC ATAXIA, TYPE 3", "EPISODIC ATAXIA, TYPE 4", "EPISODIC ATAXIA, TYPE 7", "HYPOMAGNESEMIA 6, RENAL", "BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 5"], "wiki_entities": ["Vertigo", "Vertigo (DC Comics)", "Vertigo (film)", "Benign paroxysmal positional vertigo", "Vertigo (disambiguation)", "The Sandman (Vertigo)", "Count Vertigo", "Vertigo 2005: Live from Chicago", "Vertigo Records", "Migraine-associated vertigo"], "mesh_synonynms": ["brain stem vertigos", "intermittant vertigos", "origin vertigo, central", "intermittant vertigo", "spinning sensations", "brainstem vertigos", "peripheral vertigos", "vertigos, brain stem", "vertigos, constant", "cns origin vertigo", "vertigos, peripheral", "sensation, spinning", "central origin vertigo", "vertigos, central origin", "paroxysmal vertigos", "vertigo, cns origin", "brain stem vertigo", "peripheral vertigo", "central origin vertigos", "cns origin vertigos", "vertigo, subjective", "subjective vertigo", "positional vertigo", "essential vertigos", "vertigo, brainstem", "spinning sensation", "vertigos, intermittant", "vertigo, positional", "vertigos", "vertigo, central origin", "origin vertigo, cns", "brainstem vertigo", "paroxysmal vertigo", "vertigos, cns origin", "vertigo, paroxysmal", "constant vertigos", "vertigos, subjective", "vertigo, essential", "central nervous system origin vertigo", "origin vertigos, central", "origin vertigos, cns", "vertigo, constant", "constant vertigo", "vertigos, brainstem", "vertigo, central nervous system origin", "sensations, spinning", "subjective vertigos", "vertigos, essential", "vertigo, intermittant", "vertigo, brain stem", "vertigo, peripheral", "vertigos, paroxysmal", "essential vertigo"], "dbpedia_synonyms": ["vertiginous syndromes", "virtigo", "💫", "unsteadiness", "spinning death", "vertiginous", "vertigo (medical)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0002268", "canonical_name": "Paroxysmal dystonia", "aliases": ["paroxysmal dystonia", "episodic dystonia"], "definition": "Dystonia is a neurological movement disorder syndrome in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures.", "other_contexts": [], "par_relations": ["Dystonia"], "chd_relations": [], "syn_relations": ["Paroxysmal dystonia", "Paroxysmal dystonia"], "sib_relations": ["Torsion dystonia", "Oculogyric crisis", "Focal dystonia", "Limb dystonia", "Axial dystonia", "Generalized dystonia"], "wiki_entities": ["Dystonia", "Paroxysmal exercise-induced dystonia", "Paroxysmal sympathetic hyperactivity", "Paroxysmal kinesigenic choreoathetosis", "Paroxysmal dyskinesia", "Paroxysmal nonkinesigenic dyskinesia", "Gratification disorder", "Alternating hemiplegia of childhood", "Neuroacanthocytosis", "Movement disorders"], "mesh_synonynms": ["limb dystonia", "dystonia, muscle", "dystonia, limb", "dystonia", "diurnal dystonia", "muscle dystonia", "dystonia, paroxysmal", "dystonia, diurnal"], "dbpedia_synonyms": ["dystonia"]}, "target_ent": {"research_entity_id": "OMIM:MTHU003848", "canonical_name": "Dystonia, paroxysmal", "aliases": ["dystonia, paroxysmal"], "definition": "Dystonia is a neurological movement disorder syndrome in which sustained or repetitive muscle contractions result in twisting and repetitive movements or abnormal fixed postures.", "other_contexts": [], "par_relations": ["Central nervous system"], "chd_relations": [], "syn_relations": [], "sib_relations": ["GLUT1 DEFICIENCY SYNDROME 1", "CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS"], "wiki_entities": ["Dystonia", "Paroxysmal exercise-induced dystonia", "Paroxysmal sympathetic hyperactivity", "Paroxysmal kinesigenic choreoathetosis", "Paroxysmal dyskinesia", "Paroxysmal nonkinesigenic dyskinesia", "Gratification disorder", "Alternating hemiplegia of childhood", "Neuroacanthocytosis", "Movement disorders"], "mesh_synonynms": ["paroxysmal dystonia", "limb dystonia", "dystonia, muscle", "dystonia, limb", "dystonia", "diurnal dystonia", "muscle dystonia", "dystonia, diurnal"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:6157", "canonical_name": "integrin subunit beta 3 binding protein", "aliases": ["integrin subunit beta 3 binding protein", "centromere protein r", "cenpr", "tap20", "beta3-endonexin", "itgb3bp", "itgb3bp gene", "hsu37139", "nrif3"], "definition": "Integrins are transmembrane receptors that facilitate cell-extracellular matrix (ECM) adhesion.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein", "integrin subunit beta 3 binding protein"], "sib_relations": [], "wiki_entities": ["CD61", "Integrin", "Integrin alpha M", "Fibronectin", "Integrin, beta 6", "CD29", "Integrin, beta 5", "G protein–coupled receptor", "CD11c", "Transforming growth factor beta"], "mesh_synonynms": [], "dbpedia_synonyms": ["itgb3bp (gene)"]}, "target_ent": {"research_entity_id": "OMIM:605494", "canonical_name": "INTEGRIN, BETA-3, BINDING PROTEIN OF", "aliases": ["endonexin, beta-3, long form", "cenpr", "itgb3bp", "centromeric protein r", "nrif3", "endonexin, beta-3", "nuclear receptor-interacting factor 3", "integrin, beta-3, binding protein of"], "definition": "Integrins are transmembrane receptors that facilitate cell-extracellular matrix (ECM) adhesion.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF", "INTEGRIN, BETA-3, BINDING PROTEIN OF"], "sib_relations": [], "wiki_entities": ["Integrin", "CD61", "Integrin alpha M", "Integrin, beta 6", "Integrin, beta 5", "CD29", "CD18", "Fibronectin binding protein A", "Fibronectin", "Transforming growth factor beta"], "mesh_synonynms": [], "dbpedia_synonyms": ["itgb3bp (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "ICD10CM:H53.9", "canonical_name": "Unspecified visual disturbance", "aliases": ["unspecified visual disturbance"], "definition": "A vision disorder is an impairment of the sense of vision.", "other_contexts": [], "par_relations": ["Visual disturbances"], "chd_relations": [], "syn_relations": ["Unspecified visual disturbance", "Unspecified visual disturbance"], "sib_relations": ["Color blindness", "Diplopia", "Night blindness", "Amblyopia ex anopsia", "Subjective visual disturbances", "Other visual disturbances", "Other and unspecified disorders of binocular vision", "Vision sensitivity deficiencies", "Visual field defects"], "wiki_entities": ["Vision disorder", "Visual snow", "Palinopsia", "Visual agnosia", "Illusory palinopsia", "Hallucinatory palinopsia", "Retinal migraine", "Scintillating scotoma", "Akinetopsia", "Hallucination"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "LNC:LP32161-9", "canonical_name": "Surfactant.total", "aliases": ["surfactant.total"], "definition": "Surfactants are compounds that lower the surface tension (or interfacial tension) between two liquids or between a liquid and a solid.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": [], "sib_relations": ["Phosphatidylglycerol/Surfactant.total:MFr:Pt:Amnio fld:Qn", "Phosphatidylinositol/Surfactant.total:MFr:Pt:Amnio fld:Qn", "Dimethylphosphatidyl ethanolamine/Surfactant.total:MFr:Pt:Amnio fld:Qn", "Lecithin/Surfactant.total:MFr:Pt:Amnio fld:Qn", "Phosphatidylinositol+Phosphatidylserine/Surfactant.total:MFr:Pt:Amnio fld:Qn", "Sphingomyelin/Surfactant.total:MFr:Pt:Amnio fld:Qn", "Phosphatidylcholine.saturated/Surfactant.total:MFr:Pt:Amnio fld:Qn"], "wiki_entities": ["Surfactant", "Critical micelle concentration", "Infant respiratory distress syndrome", "Surfactants in paint", "Oil dispersants", "Pulmonary alveolus", "Thermodynamics of micellization", "Surfactant protein A1", "Emulsion polymerization", "Surfactant protein B"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "MSH:D019896", "canonical_name": "alpha 1-Antitrypsin Deficiency", "aliases": ["alpha 1 antitrypsin deficiency", "deficiencies, alpha 1-antitrypsin", "alpha 1-antitrypsin deficiency", "alpha antitrypsin deficiency 01", "alpha 1-antitrypsin deficiencies", "deficiency, alpha 1-antitrypsin", "alpha 1 antitrypsin defic"], "definition": "Alpha-1 antitrypsin deficiency (α1-antitrypsin deficiency, A1AD, or AATD) is a genetic disorder that causes defective production of alpha-1 antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells.", "other_contexts": ["Cases of AATD exist within every COPD or spirometry population but must be actively investigated .", "Deficiency : Disease Management and Learning from Studies . Alpha-1-antitrypsin deficiency ( AATD ) is one of the most frequent genetic causes of liver and lung diseases . Despite its known", "2 conditions . In addition , the data suggested a potential link between hypothyroidism and AATD .", "METHODS Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared between 131 AATD patients (106 with, 25 without augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the COSYCONET COPD cohort.", "diseases . Despite its known association with chronic obstructive pulmonary disease ( COPD ) , AATD is largely unrecognised and underdiagnosed . Cases of AATD exist within every COPD or spirometry", "The association of AATD ( with / without AT ) with costs or HRQL was examined using generalized linear regression modelling ( GLM ) adjusting for age , sex , GOLD grade , BMI , smoking status , education and comorbidities .", "tobacco smoke play a key role in the pathogenesis of early - onset emphysema . Differences in AATD - related chronic obstructive pulmonary disease stages imply the existence of modifying factors", "general population . The current study describes the prevalence of other co - morbidities in AATD with particular emphasis on inflammatory bowel disease . METHODS AND RESULTS The case notes of 651", "RESULTS Thirty - two A1ATD patients who had undergone lung transplant were identified .", "( 37.12 % ) carried at least one mutation . Of those , we identified 1835 patients with severe AATD ( 9.82 % of the total test population ) including 194 individuals with rare genotypes . Test", "In addition, ASO-mediated depletion of mouse AAT may offer a useful animal model for the investigation of AATD lung disease.", "The molecular basis for the accumulation of a substance which displays the immunological reactivity of alpha-1-antitrypsin within vesicles of liver parenchymal cells of individuals with hepatic cirrhosis and serum alpha-1-antitrypsin deficiency remains unclear.", "In the present report we have extended these studies to include serum from five additional patients with alpha-1-antitrypsin deficiency and juvenile hepatic cirrhosis as well as a liver specimen obtained at autopsy of one of these patients .", "that must be confirmed by a blood test . A number of clinical ' clues ' can raise suspicion of AATD , potentially facilitating earlier diagnosis and initiation of appropriate treatment . Alpha-1-", "AATD with AT was significantly associated with higher outpatient (+273%) but lower inpatient (-35%) and medication costs (-10%, disregarding AT) compared with COPD patients without AATD.", "pulmonary disease ( COPD ) , AATD is largely unrecognised and underdiagnosed . Cases of AATD exist within every COPD or spirometry population but must be actively investigated . AATD is a", "worse symptoms of AATD - related emphysema . Therefore , prevention against severe stage of AATD - related emphysema would include early identification of the risk gene variants , cessation or", "INTRODUCTION In addition to emphysema alpha-1-antitrypsin deficiency ( AATD ) has been shown to be associated with several inflammatory conditions , including bronchiectasis , vasculitis , ( in particular Wegener 's granulomatosis ) , and panniculitis , suggesting neutrophil proteinases also play a role in their pathophysiology .", "was to assess the usefulness of different instruments to evaluate the HRQoL in patients with AATD compared to non - AATD COPD . Observational , cross - sectional study in which all patients filled", "( LCOPD ) and the COPD Assessment Test ( CAT ) . A total of 96 patients were included , 35 with AATD ( mean age 56.5 yrs , 57.1% male and mean FEV1(% ) 48.7% and 61 non - AATD COPD ( 70.3 yrs , 80.3%", "BACKGROUND Lung transplantation is a therapeutic option for patients with end - stage lung disease and a survival benefit has been described in patients with alpha-1-antitrypsin deficiency ( A1ATD ) .", "Besides , we evaluated the impact of additional screening efforts and the changes of the detection rate over time , and analysed the relevance of clinical parameters in the prediction of severe AATD .", "in Alpha-1-Antitrypsin Deficient COPD patients BACKGROUND Alpha-1-Antitrypsin Deficiency ( AATD ) is an economically unexplored genetic disease . METHODS Direct and indirect costs ( based on", "Results from a large targeted screening program for alpha-1-antitrypsin deficiency : 2003 - 2015 BACKGROUND Alpha-1-antitrypsin deficiency ( AATD ) is an autosomal codominant inherited disease that is significantly underdiagnosed .", "treatment . Alpha-1-antitrypsin augmentation therapy has a clear role in patients with severe AATD and a FEV1 ≤65% predicted . Emerging evidence suggests that attenuating the decline in lung", "of life in Alpha-1-Antitrypsin Deficient COPD patients BACKGROUND Alpha-1-Antitrypsin Deficiency ( AATD ) is an economically unexplored genetic disease . METHODS Direct and indirect costs ( based", "stress - related gene variants and inflammation are associated with worse symptoms of AATD - related emphysema . Therefore , prevention against severe stage of AATD - related emphysema", "a candidate for predictive biomarker for routine assessment of the oxidative stress level in AATD patients .", "This study examined whether individuals with AATD-associated COPD differ from individuals with non-AATD COPD with regard to depression, anxiety, dyspnea, and health-related quality of life (HRQL).", "r = -0.502 , p < 0.001 for AATD and r = -0.304 , p < 0.05 for non - AATD COPD . Patients with AATD have a similar degree of HRQoL impairment as older subjects with non - AATD COPD and showed a", "However, serum from family members homozygous for alpha-1-antitrypsin deficiency but without hepatic cirrhosis, and serum from patients with a variety of other kinds of liver disease, failed to exhibit the marked sialytransferase deficiency.", "AATD patients with AT ( excluding costs for AT ) , and € 7,460 in COPD patients without AATD . AATD with AT was significantly associated with higher outpatient ( + 273% ) but lower inpatient ( -35% )", "to determine the survival and health benefits of lung transplantation in UK patients with A1ATD compared to carefully matched non - transplant patients . METHODS Patients with the PiZZ ( alpha-1-", "for alpha-1-antitrypsin deficiency : 2003 - 2015 BACKGROUND Alpha-1-antitrypsin deficiency ( AATD ) is an autosomal codominant inherited disease that is significantly underdiagnosed . We have", "of lung disease in patients with alpha-1 antitrypsin deficiency . Alpha-1-antitrypsin deficiency ( AATD ) is an inherited disorder responsible for early onset emphysema associated with a", "We present two male patients with emphysema caused by severe AATD (PiZZ genotype).", "METHODS Patients with the PiZZ (alpha-1-antitrypsin deficiency) genotype who had undergone lung transplantation between 1996 and 2011 were identified from the UK A1ATD registry.", "Therefore, prevention against severe stage of AATD-related emphysema would include early identification of the risk gene variants, cessation or never smoking, and treatment with anti-inflammatory and anti-oxidant drugs.", "We find the sialytransferase activity in serum from six patients with alpha-1-antitrypsin deficiency and hepatic cirrhosis to be 50% of healthy pediatric control values and 30% of pediatric patients with liver disease.", ", p < 0.05 for COPD ; LCOPD r = -0.502 , p < 0.001 for AATD and r = -0.304 , p < 0.05 for non - AATD COPD . Patients with AATD have a similar degree of HRQoL impairment as older subjects with non -", "Differences in AATD-related chronic obstructive pulmonary disease stages imply the existence of modifying factors associated with disease severity.", "FEV1(% ) 47% . The questionnaire scores were similar , with a tendency towards worse scores in AATD for the EQ-5D ( VAS ) ( 64.8 ( 20.2 ) vs. 71.6 ( 17.1 ) ; p = 0.08 ) . The correlations between", "matched non - transplant patients . METHODS Patients with the PiZZ ( alpha-1-antitrypsin deficiency ) genotype who had undergone lung transplantation between 1996 and 2011 were identified from the", "AATD lung disease is caused by loss-of-function of AAT and can be treated with plasma-derived AAT.", "Adjusted mean direct annual costs were € 6,099 in AATD patients without AT , € 7,117 in AATD patients with AT ( excluding costs for AT ) , and € 7,460 in COPD patients without AATD . AATD", "Individuals with AATD-associated COPD were more likely to be a member of a couple (rather than single) and had a higher level of education when compared to individuals with non-AATD COPD.", "The correlations between the different scores and FEV1(% ) were significant in both groups for COPDSS and LCOPD , but not for CAT and EQ-5D. In general , the correlations of scores with FEV1(% ) were stronger for AATD compared with non - AATD COPD patients : COPDSS r = -0.570 , p < 0.01 for AATD and r = -0.260 , p < 0.05 for COPD ; LCOPD r = -0.502 , p < 0.001 for AATD and r = -0.304 , p < 0.05 for non - AATD COPD .", "Of those , we identified 1835 patients with severe AATD ( 9.82 % of the total test population ) including 194 individuals with rare genotypes .", "Oxidative Stress and Polymorphism of Xenobiotic - Metabolizing Enzymes in Two Patients with Severe Alpha-1-Antitrypsin Deficiency Alpha-1-antitrypsin deficiency ( AATD ) and tobacco smoke play a key role in the pathogenesis of early - onset emphysema .", "In addition, the data suggested a potential link between hypothyroidism and AATD.", "who had undergone lung transplantation between 1996 and 2011 were identified from the UK A1ATD registry . Lung physiology , health status and survival were compared pre- and post - transplant", "general , the correlations of scores with FEV1(% ) were stronger for AATD compared with non - AATD COPD patients : COPDSS r = -0.570 , p < 0.01 for AATD and r = -0.260 , p < 0.05 for COPD ; LCOPD r", "AATD is a laboratory diagnosis that must be confirmed by a blood test .", "Resources available to persons with AATD-associated COPD, such as being in a serious relationship and having higher education, may offset the effect of age when considering symptoms of depression and anxiety in patients with COPD.", "We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of severely deficient AATD patients .", "Despite its known association with chronic obstructive pulmonary disease ( COPD ) , AATD is largely unrecognised and underdiagnosed .", "rate over time , and analysed the relevance of clinical parameters in the prediction of severe AATD . RESULTS Between 2003 and 2015 , 18,638 testing kits were analysed . 6919 ( 37.12 % ) carried at", "of different instruments to evaluate the HRQoL in patients with AATD compared to non - AATD COPD . Observational , cross - sectional study in which all patients filled out a series of", "of free diagnostic testing results in the detection of a relevant number of severely deficient AATD patients . The present study provides an update on the results of our targeted screening program (", "not for CAT and EQ-5D. In general , the correlations of scores with FEV1(% ) were stronger for AATD compared with non - AATD COPD patients : COPDSS r = -0.570 , p < 0.01 for AATD and r = -0.260 , p", "RESULTS Adjusted mean direct annual costs were € 6,099 in AATD patients without AT , € 7,117 in AATD patients with AT ( excluding costs for AT ) , and € 7,460 in COPD patients without AATD .", "The questionnaire scores were similar , with a tendency towards worse scores in AATD for the EQ-5D ( VAS ) ( 64.8 ( 20.2 ) vs. 71.6 ( 17.1 ) ; p = 0.08 ) .", ", University of Marburg ) covering a period from August 2003 to May 2015 . METHODS Diagnostic AATD detection test kits were offered free of charge . Dried blood samples were sent to our laboratory", "to increase awareness with cost - free diagnostic testing , resulted in a high rate of AATD detection . The clinical data suggest that testing should be primarily offered to patients with", "Individuals with AATD-associated COPD did not report more symptoms of depression or anxiety; however, they did report more dyspnea (B = 0.31, 95% CI = 0.16 to 0.47, p < 0.001) and impairment in HRQL (B = 4.75, 95% CI = 2.10 to 7.41, p < 0.001) than other individuals with COPD.", "Alpha-1-antitrypsin augmentation therapy has a clear role in patients with severe AATD and a FEV1 ≤65% predicted.", "parameters provide extra information helpful in decision making . Lung transplantation for A1ATD patients significantly improves quality - of - life but not survival .", "< included , 35 with AATD ( mean age 56.5 yrs , 57.1% male and mean FEV1(% ) 48.7% and 61 non - AATD COPD ( 70.3 yrs , 80.3% men and FEV1(% ) 47% . The questionnaire scores were similar , with a", "of AATD exist within every COPD or spirometry population but must be actively investigated . AATD is a laboratory diagnosis that must be confirmed by a blood test . A number of clinical ' clues '", ", though not significant , overall costs and similar HRQL compared to COPD patients without AATD . AT was not associated with lower costs or higher HRQL . TRIAL REGISTRATION NCT01245933 .", "and a survival benefit has been described in patients with alpha-1-antitrypsin deficiency ( A1ATD ) . The aims of the current study were to determine the survival and health benefits of lung", "We recently reported that serum from a patient with alpha-1-antitrypsin deficiency and hepatic cirrhosis was substantially deficient in sialyltransferease (EC 2.4.99.1) an enzyme which transfers sialic acid from cytidine 5'-monophosphate-N-acetylneuraminic acid to a variety of asialoglycoprotein acceptors.", "Lung Transplantation in Alpha-1-Antitrypsin Deficiency.", "CONCLUSION Apart from AT costs, AATD patients tended to have lower, though not significant, overall costs and similar HRQL compared to COPD patients without AATD.", "in Two Patients with Severe Alpha-1-Antitrypsin Deficiency Alpha-1-antitrypsin deficiency ( AATD ) and tobacco smoke play a key role in the pathogenesis of early - onset emphysema . Differences", "post - transplant using carefully matched non - transplant patients . RESULTS Thirty - two A1ATD patients who had undergone lung transplant were identified . Lung function decline pre -", "patients ( 106 with , 25 without augmentation therapy ( AT ) ) and 2,049 COPD patients without AATD participating in the COSYCONET COPD cohort . The medication costs of AT were excluded from all", "Disease associations in alpha-1-antitrypsin deficiency.", "Cross - sectional data were collected via self - report questionnaires completed by 480 individuals with non - AATD COPD and 578 individuals with AATD - associated COPD under protocols with IRB approval .", "A total of 96 patients were included , 35 with AATD ( mean age 56.5 yrs , 57.1% male and mean FEV1(% ) 48.7% and 61 non - AATD COPD ( 70.3 yrs , 80.3% men and FEV1(% ) 47% .", "Smokers who have severe alpha-1 antitrypsin deficiency (AATD) are at risk for developing COPD earlier in life than smokers without AATD, and are likely to experience challenges adjusting to their illness because they are in a highly productive life stage when they are diagnosed with COPD.", "Lung transplantation for A1ATD patients significantly improves quality-of-life but not survival.", "These data provide more evidence that oxidative stress - related gene variants and inflammation are associated with worse symptoms of AATD - related emphysema .", "Here we demonstrate that antisense oligonucleotides (ASOs) targeting human AAT efficiently reduce levels of both short and long human AAT transcript in vitro and in transgenic mice, providing a novel therapy for AATD liver disease.", "The aims of the current study were to determine the survival and health benefits of lung transplantation in UK patients with A1ATD compared to carefully matched non - transplant patients .", "AATD liver disease is due to the aggregation and retention of mutant AAT protein in the liver; the only treatment available for AATD liver disease is liver transplantation.", "METHODS Diagnostic AATD detection test kits were offered free of charge .", "with disease severity . We present two male patients with emphysema caused by severe AATD ( PiZZ genotype ) . Both are former smokers and have epoxide hydrolase low - activity phenotype .", "program for alpha-1-antitrypsin deficiency : 2003 - 2015 BACKGROUND Alpha-1-antitrypsin deficiency ( AATD ) is an autosomal codominant inherited disease that is significantly underdiagnosed . We", "Similar assays carried out on a homogenate of a liver sample from one patient with alpha-1-antitrypsin deficiency and hepatic cirrhosis indicated that the deficiency of sialyltransferase activity was not demonstrable in liver .", "Alpha-1-antitrypsin deficiency (AATD) is one of the most frequent genetic causes of liver and lung diseases.", "Additionally , urinary 8-oxodG could be a candidate for predictive biomarker for routine assessment of the oxidative stress level in AATD patients .", "METHODS AND RESULTS The case notes of 651 PiZZ or PiZnull patients attending the UK national centre for AATD between 1996 and 2011 were reviewed.", "-1-antitrypsin deficiency . INTRODUCTION In addition to emphysema alpha-1-antitrypsin deficiency ( AATD ) has been shown to be associated with several inflammatory conditions , including", "correlation between HRQoL measurements and lung function impairment compared with non - AATD COPD . This may be related to the characteristics of the disease in these patients who are usually", "Our aim was to assess the usefulness of different instruments to evaluate the HRQoL in patients with AATD compared to non - AATD COPD .", "These observations suggest that the serum sialyltransferase deficiency in such patients probably arises after chronic and extensive liver disease involving hepatic accumulation of alpha-1-antitrypsin rather than the enzyme deficiency being the primary cause of the hepatic cirrhosis and alpha-1-antitrypsin deficiency.", "A number of clinical ' clues ' can raise suspicion of AATD , potentially facilitating earlier diagnosis and initiation of appropriate treatment .", "scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency . Alpha-1-antitrypsin deficiency ( AATD ) is an inherited disorder responsible for early onset", ". However , it remains unknown whether other inflammatory diseases are also more prevalent in AATD than the general population . The current study describes the prevalence of other co - morbidities", "females and 1.3% of males ) . CONCLUSIONS The current study of the UK cohort of patients with AATD confirmed a higher prevalence of ulcerative colitis than would be expected in the general", "all analyses to reveal differences associated with morbidity profiles . The association of AATD ( with / without AT ) with costs or HRQL was examined using generalized linear regression", "Mutations in AAT are associated with α-1 antitrypsin deficiency (AATD), a rare genetic disease with two distinct manifestations: AATD lung disease and AATD liver disease.", "deficiency . INTRODUCTION In addition to emphysema alpha-1-antitrypsin deficiency ( AATD ) has been shown to be associated with several inflammatory conditions , including bronchiectasis ,", ". Patients with AATD have a similar degree of HRQoL impairment as older subjects with non - AATD COPD and showed a stronger correlation between HRQoL measurements and lung function impairment", "disease and a survival benefit has been described in patients with alpha-1-antitrypsin deficiency ( A1ATD ) . The aims of the current study were to determine the survival and health benefits of", "The current study describes the prevalence of other co-morbidities in AATD with particular emphasis on inflammatory bowel disease.", "Costs and health - related quality of life in Alpha-1-Antitrypsin Deficient COPD patients BACKGROUND Alpha-1-Antitrypsin Deficiency ( AATD ) is an economically unexplored genetic disease .", "Alpha-1-Antitrypsin Deficiency : Disease Management and Learning from Studies .", "Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. Alpha-1-antitrypsin deficiency (AATD)", "RESULTS The case notes of 651 PiZZ or PiZnull patients attending the UK national centre for AATD between 1996 and 2011 were reviewed . The prevalence of inflammatory bowel disease ( 1.5% ) was", "disease in patients with alpha-1 antitrypsin deficiency . Alpha-1-antitrypsin deficiency ( AATD ) is an inherited disorder responsible for early onset emphysema associated with a significant", "Enzymes in Two Patients with Severe Alpha-1-Antitrypsin Deficiency Alpha-1-antitrypsin deficiency ( AATD ) and tobacco smoke play a key role in the pathogenesis of early - onset emphysema .", "( -35% ) and medication costs ( -10% , disregarding AT ) compared with COPD patients without AATD . There were no significant differences between groups regarding indirect costs and HRQL .", "Furthermore , a comparative kinetic analysis of serum and liver sialytransferase in normal and afflicted individuals failed to detect differences in substrate affinities which might account for a decrease in functional sialyltransferase capacity in individuals with alpha-1-antitrypsin deficiency and hepatic cirrhosis .", ", education and comorbidities . RESULTS Adjusted mean direct annual costs were € 6,099 in AATD patients without AT , € 7,117 in AATD patients with AT ( excluding costs for AT ) , and € 7,460 in", "Multiple linear regression models were used to test whether individuals with non-AATD COPD differed from individuals with AATD-associated COPD with regard to depression, anxiety, dyspnea, and HRQL.", "between groups regarding indirect costs and HRQL . CONCLUSION Apart from AT costs , AATD patients tended to have lower , though not significant , overall costs and similar HRQL compared", "of Xenobiotic - Metabolizing Enzymes in Two Patients with Severe Alpha-1-Antitrypsin Deficiency Alpha-1-antitrypsin deficiency ( AATD ) and tobacco smoke play a key role in the pathogenesis of", "Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient ( AATD ) liver disease and to model AATD lung disease Alpha-1 antitrypsin ( AAT ) is a serum protease inhibitor that belongs to the serpin superfamily .", "Asialoglycoprotein sialic acid transferase activity in liver and serum of patients with juvenile hepatic cirrhosis and alpha-1-antitrypsin deficiency .", "0.570 , p < 0.01 for AATD and r = -0.260 , p < 0.05 for COPD ; LCOPD r = -0.502 , p < 0.001 for AATD and r = -0.304 , p < 0.05 for non - AATD COPD . Patients with AATD have a similar degree of HRQoL", "Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD.", ",117 in AATD patients with AT ( excluding costs for AT ) , and € 7,460 in COPD patients without AATD . AATD with AT was significantly associated with higher outpatient ( + 273% ) but lower inpatient (", "Patients with AATD have a similar degree of HRQoL impairment as older subjects with non - AATD COPD and showed a stronger correlation between HRQoL measurements and lung function impairment compared with non - AATD COPD .", "However , it remains unknown whether other inflammatory diseases are also more prevalent in AATD than the general population .", "stronger for AATD compared with non - AATD COPD patients : COPDSS r = -0.570 , p < 0.01 for AATD and r = -0.260 , p < 0.05 for COPD ; LCOPD r = -0.502 , p < 0.001 for AATD and r = -0.304 , p < 0.0", "CONCLUSION A targeted screening program , combining measures to increase awareness with cost - free diagnostic testing , resulted in a high rate of AATD detection .", "quality of life ( HRQL , as assessed by SGRQ , CAT , and EQ-5D-3 L ) were compared between 131 AATD patients ( 106 with , 25 without augmentation therapy ( AT ) ) and 2,049 COPD patients without", "CONCLUSIONS The current study of the UK cohort of patients with AATD confirmed a higher prevalence of ulcerative colitis than would be expected in the general population , providing further evidence of a potential link between these 2 conditions ."], "par_relations": ["Liver Diseases", "Lung Diseases", "Subcutaneous Emphysema", "Genetic Diseases, Inborn"], "chd_relations": ["alpha-1-Antitrypsin Deficiency, Autosomal Recessive"], "syn_relations": ["alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency", "alpha 1-Antitrypsin Deficiency"], "sib_relations": ["alpha 1-Antitrypsin", "Adrenal Hyperplasia, Congenital", "Pain Insensitivity, Congenital", "Anemia, Hemolytic, Congenital", "Ataxia Telangiectasia", "Pulmonary Atelectasis", "Cherubism", "Cholestasis, Intrahepatic", "Chromosome Disorders", "Cystic Adenomatoid Malformation of Lung, Congenital", "Cystic Fibrosis", "Camurati-Engelmann Syndrome", "Dwarfism", "Eye Diseases, Hereditary", "Fatty Liver", "Hemoglobinopathies", "Hemoptysis", "Hepatic Veno-Occlusive Disease", "Hepatitis", "Hepatolenticular Degeneration", "Hepatomegaly", "Hepatorenal Syndrome", "Angioedemas, Hereditary", "Hypertension, Portal", "Hypertension, Pulmonary", "Kartagener Syndrome", "Polycystic Kidney Diseases", "Liver Abscess", "Liver Cirrhosis", "Liver Diseases, Alcoholic", "Liver Diseases, Parasitic", "Liver Neoplasms", "Lung Abscess", "Lung Diseases, Fungal", "Lung Diseases, Parasitic", "Lung Neoplasms", "Marfan Syndrome", "Metabolism, Inborn Errors", "Muscular Dystrophies", "Nail-Patella Syndrome", "Neoplastic Syndromes, Hereditary", "Oculocerebrorenal Syndrome", "Orofaciodigital Syndromes", "Osteoarthropathy, Primary Hypertrophic", "Osteochondrodysplasias", "Osteogenesis Imperfecta", "Pelger-Huet Anomaly", "Peliosis Hepatis", "Pneumonia", "Pulmonary Alveolar Proteinosis", "Pulmonary Edema", "Pulmonary Embolism", "Pulmonary Eosinophilia", "Pulmonary Fibrosis", "Pulmonary Veno-Occlusive Disease", "Respiratory Distress Syndrome, Newborn", "Respiratory Distress Syndrome, Adult", "Scimitar Syndrome", "Skin Diseases, Genetic", "Tuberculosis, Hepatic", "Tuberculosis, Pulmonary", "Werner Syndrome", "Zellweger Syndrome", "Plasma Cell Granuloma, Pulmonary", "Alagille Syndrome", "Porphyrias, Hepatic", "Kallmann Syndrome", "Lung Diseases, Interstitial", "Yellow Nail Syndrome", "Lennox Gastaut Syndrome", "Pycnodysostosis", "Donohue Syndrome", "CHARGE Syndrome", "Hyper-IgM Immunodeficiency Syndrome", "Lung Injury", "Focal Nodular Hyperplasia", "Hyperthyroxinemia, Familial Dysalbuminemic", "Lung, Hyperlucent", "Costello Syndrome", "Lung Diseases, Obstructive", "Hepatopulmonary Syndrome", "Acute Chest Syndrome", "Hereditary Autoinflammatory Diseases", "CADASIL", "Heredodegenerative Disorders, Nervous System", "Myasthenic Syndromes, Congenital", "Blood Coagulation Disorders, Inherited", "Budd-Chiari Syndrome", "Hajdu-Cheney Syndrome", "Anemia, Hypoplastic, Congenital", "Cardiomyopathy, Hypertrophic, Familial", "Frasier Syndrome", "Genetic Diseases, X-Linked", "Brugada Syndrome", "Familial Multiple Lipomatosis", "Hepatic Insufficiency", "Autoimmune Lymphoproliferative Syndrome", "Genetic Diseases, Y-Linked", "Solitary Pulmonary Nodule", "Loeys-Dietz Syndrome", "Chemical and Drug Induced Liver Injury", "Ciliopathies"], "wiki_entities": ["Alpha 1-antitrypsin deficiency", "Alpha-1 antitrypsin", "Panniculitis", "Serum protein electrophoresis", "Alpha 1", "Health of Frédéric Chopin", "Protease inhibitor (biology)", "Brooke McCarter", "Alpha 1-antichymotrypsin", "List of A1 genes, proteins or receptors"], "mesh_synonynms": ["deficiency, alpha 1-antitrypsin", "alpha 1-antitrypsin deficiencies", "alpha 1-antitrypsin deficiency", "deficiencies, alpha 1-antitrypsin"], "dbpedia_synonyms": ["alpha 1-antitrypsin deficiency"]}, "target_ent": {"research_entity_id": "OMIM:613490", "canonical_name": "ALPHA-1-ANTITRYPSIN DEFICIENCY", "aliases": ["a1atd", "alpha-1-antitrypsin deficiency"], "definition": "Alpha-1 antitrypsin deficiency (α1-antitrypsin deficiency, A1AD, or AATD) is a genetic disorder that causes defective production of alpha-1 antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["ALPHA-1-ANTITRYPSIN DEFICIENCY", "ALPHA-1-ANTITRYPSIN DEFICIENCY"], "sib_relations": ["Chronic obstructive pulmonary disease", "Abnormal liver function tests", "Autosomal recessive", "Abnormal liver function tests (SGOT, SGPT)", "Caused by mutation in the protease inhibitor 1 gene (PI, 107400.0001)", "Hepatic intracellular inclusions in ZZ homozygotes", "Infantile liver abnormalities in <20% with deficiency", "Cirrhosis (rare)", "Increased hepatocellular carcinoma risk", "Small airways", "Alveolar wall destruction", "Emphysema especially at bases", "Secondary prevention, avoid smoking, alcohol, and oxidants", "Z allele most common, only in Caucasians", "Serum alpha-1-antitrypsin (Pi) deficiency", "Dyspnea (onset 35 years in smokers, 45 years in nonsmokers)"], "wiki_entities": ["Alpha 1-antitrypsin deficiency", "Alpha-1 antitrypsin", "Panniculitis", "Serum protein electrophoresis", "Alpha 1", "Brooke McCarter", "Health of Frédéric Chopin", "Protease inhibitor (biology)", "Alpha 1-antichymotrypsin", "Weber–Christian disease"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D019772", "canonical_name": "Topotecan", "aliases": ["skf104864a", "9-dimethylaminomethyl-10-hydroxycamptothecin", "nogitecan hydrochloride", "nsc 609699", "topotecan monohydrochloride, (s)-isomer", "nsc609699", "sk&f104864a", "hydrochloride, topotecan", "topotecan hydrochloride", "skf 104864 a", "topotecan", "sk&f-104864-a", "skf-104864-a", "hycamtamine", "9 dimethylaminomethyl 10 hydroxycamptothecin", "nsc-609699", "sk&f 104864 a", "hydrochloride, nogitecan", "hycamtin"], "definition": "Topotecan (trade name Hycamtin) is a chemotherapeutic agent that is a topoisomerase inhibitor.", "other_contexts": ["In addition , the type of prior chemotherapy was not statistically significant in influencing the topotecan treatment outcome .", "These hematologic toxicities do not by gest on A uust 7, 2017 http://thologist.alpham edpss.org/ D ow nladed from 12 Topotecan and Small Cell Lung Cancer appear to be cumulative [3].", "Ten patients with advanced ovarian cancer received topotecan , 1.5 mg / m2 for 5 days , as second - line therapy in an open phase - II study after previous platinum - containing first - line therapy .", "Topotecan is excreted in urine and also is concentrated in bile .", ", not bound to 8C2 ) topotecan exposure in plasma ( AUCf ) and a decrease in the extent of topotecan - induced weight - loss . Consistent with model predictions , toxicodynamic experiments showed", "The three economic evaluations included in the review comprised one cost - minimisation analysis ( CMA ) comparing topotecan with caelyx , one cost - consequences analysis ( CCA ) comparing topotecan with paclitaxel , etoposide and altretamine and one cost - effectiveness analysis ( CEA ) comparing topotecan with paclitaxel .", "Their preliminary conclusion was that the combination of topotecan and paclitaxel is highly active against untreated SCLC patients and yielded similar responses to current front-line chemotherapy agents.", "The dose of topotecan does not have to be adjusted for abnormal liver function as long as the bilirubin is less than 10 mg / dl [ 2 ] .", "topotecan respectively.", "OBJECTIVES OF THE REVIEW To examine the clinical effectiveness and cost - effectiveness of oral and intravenous topotecan ( Hycamtin , SmithKline Beecham , UK ) for the treatment of all stages of ovarian cancer .", "TOPOTECAN AS A SECOND-LINE AGENT Topotecan is an effective second-line agent in patients with SCLC.", "Jett et al . reported at the Eighth World Conference on Lung Cancer meeting in Dublin on the effectiveness of the combination of topotecan and paclitaxel to treat chemotherapy - naive patients with ED - SCLC [ 5 ] .", "In addition, an independent cohort of non-tumor bearing rabbits was employed to evaluate the clinical and retinal toxicity after four weekly injections of two different doses of intravitreal topotecan (Group A, 5 μg/dose; Group B, 0.5 μg/dose) to the right eye of each animal.", "topotecan was compared with either CAV or oral topotecan for overall response rate ( ORR ) .", "TOPOTECAN AS", "High and prolonged concentrations were achieved in the rabbit vitreous after 5 μg of intravitreal topotecan.", "Amifostine, 300 mg/m2, does not significantly affect the pharmacokinetics of topotecan and there are pronounced intra- and inter-individual variabilities in the topotecan pharmacokinetics.", "Phase I clinical trial of weekly combined topotecan and irinotecan.", "Animals were weekly evaluated for clinical and hematologic values and ocular evaluations were performed with an inverse ophthalmoscope to establish potential topotecan toxicity .", "A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.", "Topotecan Dosage 1.5 mg / m2/day i.v . over 30 min every 5 days", "Topotecan , pegylated liposomal doxorubicin hydrochloride and paclitaxel for second - line or subsequent treatment of advanced ovarian cancer : a systematic review and economic evaluation .", "Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.", "The clinical evidence came from three clinical trials comparing topotecan plus cisplatin with cisplatin monotherapy (GOG-0179), topotecan plus cisplatin with paclitaxel plus cisplatin (GOG-0169), and four cisplatin-based combination therapies: topotecan plus cisplatin, paclitaxel plus cisplatin, gemcitabine plus cisplatin, and vinorelbine plus cisplatin (GOG-0204).", "When the incremental cost - effectiveness ratios ( ICERs ) were estimated , topotecan was dominated by PLDH .", "The ICER for oral topotecan is at the upper extreme of the range conventionally regarded as cost-effective from an NHS decision-making perspective.", "One week after the last injection, topotecan concentrations were measured in vitreous of all eyes and samples for retinal histology were obtained.", "assessed topotecan as a second-line treatment for patients with SCLC, but divided the patients by having either previously sensitive disease or refractory disease [7].", "A cohort of rabbits was used to study topotecan disposition in the vitreous after a single dose of 0.5 μg of intravitreal topotecan .", "The model was linked to a toxicodynamic model for topotecan-induced weight-loss, and simulations were conducted to predict the effects of 8C2 on the toxicity of topotecan in mice.", "The investigators’ conclusion also confirmed that topotecan is associated with an encouraging response rate in patients who are sensitive to prior chemotherapy.", "It is a randomized phase three trial in ED-SCLC, comparing topotecan and G-CSF versus observation after prior treatment with cisplatin plus etoposide.", "Consistent with model predictions, toxicodynamic experiments showed substantial reduction in the percent nadir weight loss observed with 30 mg/kg IP topotecan after co-administration of 8C2 (20 ± 8% vs. 10 ± 8%).", "- loss , and simulations were conducted to predict the effects of 8C2 on the toxicity of topotecan in mice . Increasing the molar dose ratio of 8C2 to topotecan resulted in a dose - dependent", "Total quality-adjusted life-years (QALYs) were 0.2247 and 0.4077, for BSC and oral topotecan respectively, resulting in an incremental cost-effectiveness ratio (ICER) of 33,851 pounds per QALY gained.", "Topotecan is a relatively well - tolerated drug .", "Topotecan, paclitaxel monotherapy and PLDH were all dominated by platinum monotherapy (i.e. higher costs and lower QALYs).", "Plasma concentrations of total topotecan and its active lactone form were determined using high-performance liquid chromatography.", "of 8C2 on the toxicity of topotecan in mice . Increasing the molar dose ratio of 8C2 to topotecan resulted in a dose - dependent decrease in the unbound ( i.e. , not bound to 8C2 ) topotecan", "The pharmacokinetics of 8C2, a monoclonal anti-topotecan antibody, were assessed following IV and SC administration, and the data were characterized using a two compartmental model with nonlinear absorption and elimination.", "CONCLUSIONS RECOMMENDATIONS FOR RESEARCH: Further good quality RCTs and CEAs are required comparing topotecan with other licensed and potentially useful (soon to be licensed) second-line treatments for ovarian cancer.", "The MTD for concomitant topotecan ( 1.5 mg / m(2)/wk ) is 60% of the single - agent topotecan dose for the 5-day topotecan schedule ( at 2.5 mg / m(2)/wk ) but only 30% of the single - agent topotecan dose for the weekly schedule ( 5 mg / m(2)/wk ) .", "The review of the economic evidence from the literature and industry submissions identified a number of significant limitations in existing studies assessing the cost - effectiveness of PLDH , topotecan and paclitaxel .", "In this study of topotecan as second - line therapy in patients with SCLC , 74 patients received topotecan ; 36 patients were part of the sensitive group , while 38 patients were refractory to therapy .", "Only randomised controlled trials (RCTs) and full economic evaluations comparing topotecan to non-topotecan regimens were included.", ") model was developed and evaluated . The pharmacokinetics of 8C2 , a monoclonal anti - topotecan antibody , were assessed following IV and SC administration , and the data were characterized", "Both of the clinical effectiveness studies on which this evidence is based had methodological flaws, the most serious being the lack of a blinded assessor in the topotecan versus caelyx trial, which is important for unbiased assessment of response outcomes.", "resulted in a dose - dependent decrease in the unbound ( i.e. , not bound to 8C2 ) topotecan exposure in plasma ( AUCf ) and a decrease in the extent of topotecan - induced weight - loss .", "Response rates also showed an advantage with topotecan plus cisplatin compared with cisplatin monotherapy .", "In these trials topotecan was compared with BSC, CAV [cyclophosphamide, Adriamycin (doxorubicin) and vincristine] or amrubicin, or oral topotecan was compared with i.v.", "CAV was associated with significantly less grade 4 thrombocytopenia compared with IV topotecan ( risk ratio = 5.83 ; 95% CI , 2.35 to 14.42 ) .", ", 8C2 , and the topotecan-8C2 complex . The model was linked to a toxicodynamic model for topotecan - induced weight - loss , and simulations were conducted to predict the effects of 8C2 on the", "- compartment model for 8C2 , and the model was employed to predict the disposition of topotecan , 8C2 , and the topotecan-8C2 complex . The model was linked to a toxicodynamic model for", "As a first - line agent in chemotherapy - naive patients with extensive disease SCLC , topotecan has a 39% response rate .", "topotecan , compared with BSC , were high and suggest that it is unlikely to be a cost - effective option .", "The evidence suggests there were no statistically significant differences overall between topotecan and paclitaxel , or topotecan and caelyx in clinical outcomes .", "The Role of Topotecan in the Treatment of Small Cell Lung Cancer Topotecan is a chemotherapeutic agent that is active in the treatment of small cell lung cancer (SCLC).", "However , with G - CSF added , only 29% of 35 patients treated with topotecan developed grade 3 or 4 neutropenia .", "The patients with documented brain metastasis (seven patients) and who responded systemically to topotecan (five patients) also responded in the CNS sites.", "Patients were randomised to receive intravenous ( IV ) amifostine at a daily dose of 300 mg / m2 prior to topotecan in the first cycle and topotecan alone in the second cycle or vice versa .", "Topotecan was given as a 30-min IV infusion.", "Structural formula of topotecan .", "Oral topotecan and i.v.", "There was a statistically significant benefit in favour of oral topotecan compared with BSC (HR 0.61, 95% CI 0.43 to 0.87, p = 0.01).", "The best trial evidence for decision making , because it was tested versus best supportive care , exists for oral topotecan .", "The study demonstrates that topotecan is an excellent second-line chemotherapeutic agent in patients with sensitive disease.", "After intravitreal administration no topotecan could be detected in plasma during the follow - up period nor in the vitreous of treated and control animals after 1 week of the last injection .", "The model used survival analysis methods to derive estimates of mean survival for patients treated with topotecan or receiving BSC alone .", "Thus, we here study the pharmacokinetics of topotecan after 0.5 μg and the toxicity profile of intravitreal topotecan in the rabbit eye as a potential treatment of retinoblastoma.", "Topotecan was associated with increased incidences of haematological toxicities (including neutropenia, leukopenia, anaemia and thrombocytopenia), alopecia, nausea and vomiting.", "Where the hazard ratio derived from GOG-0169 was employed, paclitaxel plus cisplatin was dominated by topotecan plus cisplatin, but, where the hazard ratio from GOG-0204 was adopted, paclitaxel plus cisplatin was found to have an ICER of 13,260 pounds per QALY versus topotecan plus cisplatin.", "Drug acquisition costs for four cycles of treatment were estimated at 2550 pounds for oral topotecan and 5979 pounds for i.v.", "In patients with creatinine clearances of 20 - 39 ml / min , and 40 - 59 ml / min , the dose of topotecan should be reduced to 0.5 mg / m2/d and 1.0 mg / m2/d , respectively [ 3 ] .", "This aim of this study was to compare the pharmacokinetics of topotecan in the presence and absence of preceding amifostine to reduce the risk of side effects in patients with advanced ovarian cancer .", "Indirectly, because we have two head-to-head comparisons of oral versus intravenous topotecan, and one comparison of intravenous topotecan versus CAV in similar patients as in the trial against best supportive care, one might infer that IV topotecan and CAV could also be superior to best supportive care, and that oral topotecan has similar effects to CAV with possibly better symptom control.", "The objectives of this phase I study were 1 ) to determine in a phase trial design whether topotecan and irinotecan administered concomitantly on a weekly schedule can be delivered at the same dose intensity as that of single - agent topotecan or irinotecan delivery ; and 2 ) to determine whether hematologic and/or nonhematologic toxicity is increased with topotecan and irinotecan administered together as a prelude to a possible phase II trial in responsive tumor categories .", "Topotecan and irinotecan are two camptothecan analogues that are active in different human tumors (topotecan in ovary; irinotecan in colon) and in different experimental tumor systems.", "Further studies are warranted with topotecan used in combination with other agents, including radiation therapy in patients with SCLC.", "No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients Objective.", "In the cycles when the patients received topotecan alone, the plasma AUC of the lactone averaged 40% of the AUC of the total concentration compared with 39% in the cycles when topotecan was given after amifostine.", "Results from GOG-0179 showed greater median overall survival with topotecan plus cisplatin than with cisplatin monotherapy: 9.4 months versus 6.5 months.", "PK / TD modeling for prediction of the effects of 8C2 , an anti - topotecan mAb , on topotecan - induced toxicity in mice .", "However , direct comparisons of the cost findings between the two studies is difficult because they used different designs , different time horizons for the cost analyses and the findings were presented as costs per person for only patients who responded in one study ( topotecan versus paclitaxel ) and costs per person regardless of whether they responded in the other study ( topotecan versus caelyx ) .", "On day 1 of the first and second treatment cycles, venous blood samples were collected up to 24 h after the start of topotecan infusion.", "Other studies are looking to evaluate topotecan in combination with other chemotherapeutic agents .", "Topotecan offers additional benefit over BSC, but at increased cost.", "Our results indicate that topotecan shows non linear pharmacokinetics after a single intravitreal dose in the range of 0.5-5 μg in the rabbit.", "There was a rapid decline in total topotecan plasma concentrations after the end of the infusion followed by a slower decay .", "In general, with a few minor exceptions, there were no statistically significant differences between topotecan and paclitaxel, or topotecan and caelyx in survival, response rate, median time to response, median duration of response and quality of life.", "At present , it is difficult to make any decisions about topotecan and other drugs for second - line therapy without good quality direct comparisons .", "Topotecan proved to be a promising agent for retinoblastoma treatment due to its pharmacological activity and limited toxicity.", "Intravenous topotecan was at least as effective as CAV in the treatment of patients with recurrent small-cell lung cancer and resulted in improved quality-of-life with respect to several symptoms.", "showed substantial reduction in the percent nadir weight loss observed with 30 mg / kg IP topotecan after co - administration of 8C2 ( 20 ± 8% vs. 10 ± 8% ) . The investigation supports the use of", "The corresponding figure after topotecan and amifostine was 80% (P=0.11).", "The treatment options considered in this model comprised PLDH , topotecan , paclitaxel - monotherapy , CAP , paclitaxel / platinum combination therapy and platinum monotherapy .", "Forty-eight chemotherapy-naive patients with extensive SCLC were given topotecan as a single agent at 2.0 mg/m2/d for five days every 21 days.", "Patients receiving topotecan plus cisplatin experienced a greater number of adverse events and the ERG was concerned with some of the assumptions related to HRQoL. In the base-case direct comparison, the incremental cost-effectiveness ratio (ICER) of topotecan plus cisplatin versus cisplatin monotherapy was 17,974 pounds per QALY in the main licensed population, 10,928 pounds per QALY in the cisplatin-naive population (including stage IVB patients) and 32,463 pounds per QALY in sustained cisplatin-free interval patients.", "The trials with topotecan in lung cancer have mainly focused on the treatment of ED - SCLC ; the drug has been evaluated both in SCLC patients who were previously untreated as well as those who have received prior therapy .", "Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.", "Concerning topotecan both the oral and intravenous options have similar efficacy, and patient preference may be a decisive factor if the choice would be between the two formulations.", "Maximum tolerated dosage ( MTD ) for the topotecan and irinotecan combination was defined as that which permitted 4 weeks of topotecan and irinotecan administration with G - CSF at or near the dose intensity reported for each single agent .", "A hybrid PK model was constructed by combining a PBPK model for topotecan with the two-compartment model for 8C2, and the model was employed to predict the disposition of topotecan, 8C2, and the topotecan-8C2 complex.", "Life expectancy was 0.4735 , 0.7984 and 0.7784 years for BSC , oral topotecan and i.v .", "Comparative trials of single-agent topotecan and irinotecan versus the combination of topotecan and irinotecan would be necessary to provide the proof of principle that combining analogues can increase therapeutic effectiveness.", "Due to the limited number of studies included in the review and the fact that they compared topotecan with different comparators , the out - come data could not be pooled statistically .", "Of 97 patients treated with single-agent topotecan at 1.5 mg/m2/d for five days every 21 days, 2 of 47 refractory patients achieved a PR, and 1 of 47 achieved a CR.", "Women who have previously received cisplatin and are currently being treated with topotecan in combination with cisplatin for the treatment of cervical cancer should have the option to continue therapy until they and their clinicians consider it appropriate to stop .", "TOPOTECAN Topotecan is a drug originating from a family of chemotherapeutic agents that inhibit the DNA topoisomerase I enzyme ( Table 1 ) .", "Non - drug treatment costs accounted for an additional 1097 pounds for oral topotecan and 4289 pounds for i.v .", "To facilitate the development of an inverse targeting strategy, where anti-topotecan antibodies are administered to prevent systemic toxicity following intraperitoneal topotecan, a pharmacokinetic/toxicodynamic (PK/TD) model was developed and evaluated.", "A large intra-individual pharmacokinetic of topotecan between cycles 1 and 2 was also observed.", "CONCLUSIONS For participants with platinum - resistant disease there was a low probability of response to treatment with PLDH , topotecan or paclitaxel .", "Electroretinograms (ERGs) were recorded before and after topotecan doses.", "CONCLUSIONS Topotecan appeared to be better than BSC alone in terms of improved survival, and was as effective as CAV and less favourable than i.v.", "Total costs for the modelled time horizon of 5 years were 4854 pounds for BSC , 11,048 pounds for oral topotecan and between 16,914 pounds and 17,369 pounds for i.v .", "From the evidence discussed above , it is evident that oral topotecan has similar efficacy to IV topotecan ( direct comparison ) and CAV ( indirect comparison ) .", "topotecan (38% versus 13%, respectively, p = 0.039).", "topotecan were between 0.3875 and 0.4157 ( depending on assumptions regarding time progression ) resulting in an ICER between 74,074 pounds and 65,507 pounds per QALY gained .", "topotecan were similar in efficacy .", "8C2 , and the model was employed to predict the disposition of topotecan , 8C2 , and the topotecan-8C2 complex . The model was linked to a toxicodynamic model for topotecan - induced weight - loss ,", "OBJECTIVES To assess the clinical effectiveness and cost-effectiveness of topotecan as second-line treatment for small cell lung cancer (SCLC).", "Reference [4] [5] [6] [7] [8] [9] Patient Chemo-naive Chemo-naive Patients with Previously Previously Previously population patients with patients with resistant disease to treated patients treated patients treated patients extensive stage SCLC SCLC etoposide & cisplatin Dosage of 2.0 mg/m2/d 1 mg/m2/d 3 5 1.25 mg/m2/d 1.5 mg/m2/d 1.5 mg/m2/d 1.5 mg/m2/d topotecan for 5 days with paclitaxel for 5 days for 5 days for 5 days for 5 days every 21 days 135 mg/m2 i.v.", "In addition, topotecan has been combined with paclitaxel to treat patients with ED-SCLC.", "Topotecan is a water-soluble analog (Fig.", "In view of the ongoing studies identified, an update of the current review should be considered in approximately 18 months (Summer 2002) or possibly sooner if the recently commissioned National Institute for Clinical Excellence review of caelyx for ovarian cancer identifies additional data relevant to topotecan.", "Indirect evidence showed that oral topotecan was at least as good as or better than CAV on all outcomes (survival, response rates, toxicities, and symptoms) that allowed indirect comparisons, with the only exception being grade four thrombocytopenia which occurred less often on CAV treatment.", "Vitreous concentration of lactone topotecan was close to the concentration assumed to be therapeutically active after 5 h of 0.5 μg intravitreal administration.", "The manufacturer stated that topotecan plus cisplatin is the only combination regimen to date to have demonstrated a statistically significant survival advantage compared to cisplatin monotherapy in the licensed population .", "Toxicity data showed a significant difference in favour of oral topotecan for neutropenia ( pooled risk ratio = 0.65 ; 95% CI , 0.47 to 0.89 ) .", "This paper will review the studies of topotecan on the treatment of SCLC (Table 2).", "Oral topotecan plus BSC has advantages over BSC alone in terms of survival (hazard ratio = 0.61; 95% CI, 0.43 to 0.87) and quality of life (EQ-5 D difference: 0.15; 95% CI, 0.05 to 0.25).", "The comparators assessed in these trials were oxaliplatin versus paclitaxel, paclitaxel given weekly versus every 3 weeks, paclitaxel at two different dose levels and oral versus intravenous topotecan.", "These included one study comparing oral topotecan plus best supportive care ( BSC ) to BSC alone , one study comparing intravenous topotecan to cyclophosphamide , adriamycin and vincristine ( CAV ) , and two studies comparing oral topotecan with intravenous topotecan .", "of 8C2 ( 20 ± 8% vs. 10 ± 8% ) . The investigation supports the use of anti - topotecan mAb to reduce the systemic toxicity of IP topotecan chemotherapy .", "CONCLUSIONS This review indicates that there is little evidence in the form of RCTs on which to base an assessment of the effectiveness of topotecan as second - line therapy for advanced ovarian cancer .", "In this study , there was a correlation between the topotecan levels and myelosuppression .", "Increasing the molar dose ratio of 8C2 to topotecan resulted in a dose - dependent decrease in the unbound ( i.e. , not bound to 8C2 ) topotecan exposure in plasma ( AUCf ) and a decrease in the extent of topotecan - induced weight - loss .", "The peak plasma concentration (Cmax) of the lactone averaged 72% of the Cmax of the total topotecan concentration in the topotecan-only group.", "in mice . To facilitate the development of an inverse targeting strategy , where anti - topotecan antibodies are administered to prevent systemic toxicity following intraperitoneal topotecan , a", "The CCA (comparing topotecan with three comparators) was of poor quality and of little relevance to the UK NHS.", "These were combined with quality of life (QoL) weights to derive estimates of mean quality-adjusted life expectancy for patients receiving BSC alone or topotecan plus BSC.", "Overall, two international multicentre RCTs of effectiveness comparing topotecan with paclitaxel (trial 039) and topotecan with caelyx (trial 30-49) were included in the review.", "The clinical effectiveness and cost - effectiveness of topotecan for small cell lung cancer : a systematic review and economic evaluation .", "Analysis 1 assessed the cost - effectiveness of PLDH , topotecan and paclitaxel administered as monotherapies .", "The two remaining studies , comparing topotecan with paclitaxel ( CEA ) and topotecan with caelyx ( CMA ) , both used effectiveness data from multicentre RCTs and based their costs on 1999/2000 UK sources .", "This paper presents a summary of the evidence review group ( ERG ) report into the clinical effectiveness and cost - effectiveness of topotecan in combination with cisplatin for the treatment of recurrent and stage IVB carcinoma of the cervix , in accordance with the licensed indication , based upon the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence ( NICE ) as part of the single technology appraisal ( STA ) process .", "The guidance issued by NICE on 28 October 2009 as a result of the STA states that topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer, only if they have not previously received cisplatin.", "In terms of single - agent compounds , the evidence suggests that PLDH is more effective than topotecan .", "Perez - Soler et al . investigated the use of topotecan in patients with SCLC refractory to etoposide and cisplatin [ 6 ] .", "The treatment was topotecan (oral or intravenous, i.v.) compared with one another, best supportive care (BSC) or other chemotherapy regimens.", "The inter-individual variability was pronounced and the area under the plasma concentration–time curve from time zero to infinity (AUC0–∞) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.", "The comparators that were assessed in the three trials that included both subtypes of participants were PLDH versus topotecan, topotecan versus paclitaxel and PLDH versus paclitaxel.", "Although the ICER of PLDH compared with paclitaxel monotherapy was less favourable, PLDH was still cost-effective compared with topotecan and paclitaxel monotherapy.", "Survival (hazard ratio = 0.98; 95% CI, 0.77 to 1.25) and response (pooled risk ratio = 1.04; 95% CI, 0.58 to 1.85) data were similar for the oral and IV topotecan groups.", "OBJECTIVES To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer.", "Although treatment with PLDH may therefore be more beneficial than that with topotecan, patient and physician choice as to the potential toxicities associated with each of the comparators and the patient's ability and willingness to tolerate these are of importance.", "The present data shows that four weekly intravitreal injection of 5 μg of topotecan is safe for the rabbit eye .", "Assuming the NHS is willing to pay up to pound 20,000 - 40,000 per additional QALY , PLDH appears to be cost - effective compared with topotecan and paclitaxel monotherapy , in terms of the overall patient population and the main subgroups considered .", "antibodies are administered to prevent systemic toxicity following intraperitoneal topotecan , a pharmacokinetic / toxicodynamic ( PK / TD ) model was developed and evaluated . The", "Further trials , or the implementation of registries , are required to establish the efficacy and safety of topotecan plus cisplatin .", "REVIEW METHODS Seventeen databases were searched for randomised controlled trials (RCTs) and systematic reviews for the clinical effectiveness of PLDH, topotecan and paclitaxel and economic evaluations of the cost-effectiveness of PLDH, topotecan and paclitaxel.", "There were no significant histologic damage of the retinas exposed to topotecan treatments .", "topotecan.", "An independent economic model estimated the cost - effectiveness of topotecan ( oral or i.v . ) compared with BSC .", "The investigation supports the use of anti-topotecan mAb to reduce the systemic toxicity of IP topotecan chemotherapy.", "and elimination . A hybrid PK model was constructed by combining a PBPK model for topotecan with the two - compartment model for 8C2 , and the model was employed to predict the disposition", "Patients who have responded or have stable disease after four cycles of etoposide and cisplatin are randomized to either observations or receive topotecan 1.5 mg/m2 i.v.", "Weekly controls included topotecan quantitation in plasma of all rabbits .", "There is no further evidence base of direct or possible indirect comparisons for other comparators than CAV of either oral or IV topotecan .", "Despite multiple injections of 0.5 μg of topotecan are also safe to the rabbit eye, lactone topotecan vitreous concentrations were potentially active only after 5 h of the administration.", "Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer To undertake a systematic review of the available data for oral and intravenous topotecan in adults with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first line regimen is not considered appropriate.", "The combination of topotecan and paclitaxel exhibits a promising overall response rate of 92% in chemotherapy-naive patients with extensive disease SCLC.", "Topotecan is one of six drugs currently licensed in the UK for second-line therapy, and recent reviews suggest that it has modest efficacy in the treatment of advanced disease and performs favourably against paclitaxel.", "Eyes injected with four weekly doses of topotecan ( 0.5 or 5 μg / dose ) showed no significant differences in their ERG wave amplitudes and implicit times in comparison with control ( p > 0.05 ) .", "A FIRST-LINE AGENT A study done by the Eastern Cooperative Oncology Group (ECOG) investigated topotecan as an initial treatment of extensive stage SCLC [4].", "supports the use of anti - topotecan mAb to reduce the systemic toxicity of IP topotecan chemotherapy .", "Topotecan was administered for 30 minutes ( after irinotecan administration ) at two dose levels within each of the irinotecan dose levels ( 1.0 and 1.5 mg / m(2 ) ) .", "Topotecan for the second-line treatment of advanced ovarian cancer was shown to be more cost-effective than paclitaxel (32,513 GB pounds versus 46,186 GB pounds per person in terms of any response (complete or partial), incremental cost-effectiveness = 3065 GB pounds) in all respects except cost per time without toxicity or symptoms, but less cost-effective than caelyx (14,023 GB pounds versus 9979 GB pounds per person regardless of whether the patient responded).", "Overall , the effects of topotecan could at best be described as modest , but the alternative agents offer no real advantages except fewer side - effects and possibly improved cost - effectiveness .", "topotecan (depending on assumptions regarding time progression).", "At present there is a paucity of evidence available on the clinical effects of topotecan plus cisplatin and the effects of palliative treatment in general for women with advanced and recurrent carcinoma of the cervix .", "Thereafter all patients were given amifostine and topotecan for additional four cycles."], "par_relations": ["Camptothecin", "Topoisomerase I Inhibitors", "Topotecan", "Topotecan", "Topotecan", "Topotecan"], "chd_relations": ["Topotecan", "Topotecan", "Topotecan", "Topotecan", "N-desmethyltopotecan", "T 2153", "T 0128", "CAT combination", "TAM protocol", "TA protocol", "CPT protocol", "TMC regimen", "CAT-G protocol", "topotecan-20-O-(4-fluorophenoxyacetate)", "TVTG protocol"], "syn_relations": ["Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan", "Topotecan"], "sib_relations": [], "wiki_entities": ["Topotecan", "Plant sources of anti-cancer agents", "List of chemotherapeutic agents", "Brain stem tumor", "Camptotheca", "A23187", "Lurtotecan", "Veliparib", "Brainstem glioma", "Amrubicin"], "mesh_synonynms": ["9 dimethylaminomethyl 10 hydroxycamptothecin", "sk&f-104864-a", "sk&f104864a", "nsc-609699", "hycamtin", "nsc 609699", "skf-104864-a", "hydrochloride, topotecan", "skf104864a", "hydrochloride, nogitecan", "nsc609699", "9-dimethylaminomethyl-10-hydroxycamptothecin", "nogitecan hydrochloride", "topotecan monohydrochloride, (s)-isomer", "sk&f 104864 a", "hycamtamine", "skf 104864 a", "topotecan", "topotecan hydrochloride"], "dbpedia_synonyms": ["atcvet code ql01xx17", "hycamtin", "hycamptamine", "c23h23n3o5", "atc code l01xx17", "hycamptin", "topotecan", "topotecan hydrochloride"]}, "target_ent": {"research_entity_id": "RXNORM:266573", "canonical_name": "Topotecan Hydrochloride", "aliases": ["topotecan hydrochloride"], "definition": "Topotecan (trade name Hycamtin) is a chemotherapeutic agent that is a topoisomerase inhibitor.", "other_contexts": ["At the concentrations studied , topotecan hydrochloride was stable for up to 24 h at room temperature and for up to 7 days at 5 degrees C , in PVC and polyolefin infusion bags and glass bottles containing either 5% dextrose injection or 0.9% sodium chloride injection .", "Synthesis of novel 10-hydroxycamptothecin derivatives utilizing topotecan hydrochloride as ortho-quinonemethide precursor.", "The ultra performance liquid chromatographic assay procedure, which proved superior because of its greater sensitivity and relatively shorter (4 min) run time, should be an important tool for speedy future analysis of topotecan hydrochloride in bulk and its injection dosage form.", "Topotecan HCl trihydrate was hydrated with D(2)O vapor to confirm the nature and location of the channel water using (13)C and (2)H solid-state NMR.", "Additionally, the topotecan hydrochloride formulation was added to 50 ml PVC infusion bags containing either 5% dextrose injection or 0.9% sodium chloride injection at an initial nominal topotecan concentration of 0.025 mg ml-1.", "A study of variable hydration states in topotecan hydrochloride. Topotecan hydrochloride, a pharmaceutical compound developed as a treatment for cancer, exhibits variable hydration states in a crystalline solid form chosen for manufacturing.", "During simulated Y-site injection, topotecan hydrochloride was physically and chemically compatible with 15 of 18 drug products.", "Palonosetron hydrochloride is physically compatible and chemically stable with topotecan hydrochloride and with irinotecan hydrochloride during Y - site administration .", "A series of 9-(alkylthiomethyl)-10-hydroxycamptothecins and pyrano-fused camptothecin derivatives were synthesized via the reaction of topotecan hydrochloride with various thiols and alkyl vinyl ethers respectively.", "RP - Ultra performance liquid chromatographic Method for Quantification of Topotecan Hydrochloride in Bulk and Injection Dosage Form A simple , very fast , precise and accurate reverse phase ultra", "The stability and compatibility of topotecan hydrochloride with common infusion solutions and containers were studied.", "Topotecan hydrochloride effects on retinal vessels in newborn rats.", "[Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].", "In the reactions , topotecan hydrochloride was utilized as ortho - quinonemethide ( o - QM ) precursor .", "The concentration of topotecan hydrochloride dropped to 88.7% of the initial concentration after four hours when the drug was mixed with ticarcillin disodium and with clavulanate potassium in 5% dextrose injection .", "The interactions of topotecan hydrochloride ( THC ) , neutral red ( NR ) and thioglycolic acid ( TGA ) capped CdTe / CdS quantum dots ( QDs ) built a solid base for the controlling of the fluorescent reversible regulation of the system .", "method was developed for the determination and validation of topotecan hydrochloride in bulk and injection dosage form . A Waters BEH C18 , 50×2.1 mm , 1.7 μm particle size column in", "Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated y - site administration .", "The current study was designed to evaluate the efficacy and toxicity of single agent Topotecan hydrochloride in the patients with recurrent advanced ovarian cancer.", "The objective of this study was to evaluate the physical and chemical stabilty of undiluted palonosetron hydrochloride 50 micrograms/mL in combination with topotecan hydrochloride 0.1 mg/mL or irinotecan hydrochloride 1 mg/mL in 5% dextrose injection during simulated Y-site administration.", "A formulation of topotecan hydrochloride was added to 50 ml PVC infusion bags, polyolefin infusion bags and 150 ml glass bottles containing either 5% dextrose injection or 0.9% sodium chloride injection at an initial nominal topotecan concentration of 0.05 mg ml-1.", "Development and Validation of a RP-Ultra performance liquid chromatographic Method for Quantification of Topotecan Hydrochloride in Bulk and Injection Dosage Form A simple, very fast, precise and accurate reverse phase ultra performance liquid chromatographic method was developed for the determination and validation of topotecan hydrochloride in bulk and injection dosage form.", "Topotecan hydrochloride for metastatic ovarian cancer.", "Fluorescent reversible regulation based on the interactions of topotecan hydrochloride , neutral red and quantum dots .", "Stability and compatibility of topotecan hydrochloride with selected drugs.", "The presence of topotecan hydrochloride did not contribute to leaching of DEHP in the PVC infusion bags.", "With a few exceptions , the drug combinations exhibited no visible change in color or clarity initially or after four hours , and the concentration of topotecan hydrochloride and of the secondary drugs was 95% or more of the initial concentration .", "A vial of topotecan hydrochloride was reconstituted under aseptic conditions with sterile water for injection to yield a solution containing 1 mg of topotecan base per milliliter and further mixed with 0.9% sodium chloride injection or 5% dextrose injection .", "Triplicate test samples were prepared by admixing 5 mL of palonosetron hydrochloride with 5 mL of the topotecan hydrochloride or irinotecan hydrochloride admixture .", "Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers .", "High - performance liquid chromatographic analysis found that palonosetron hydrochloride , topotecan hydrochloride , and irinotecan hydrochloride remained stable throughout the 4-hour test .", "The palonosetron hydrochloride-topotecan hydrochloride samples were clear and pale yellow when viewed in normal fluorescent room light.", "4 min ) run time , should be an important tool for speedy future analysis of topotecan hydrochloride in bulk and its injection dosage form .", "An intense yellow color and a slight haze developed immediately after topotecan hydrochloride was mixed with dexamethasone sodium phosphate or with fluorouracil in 0.9% sodium chloride injection.", "hydrochloride , neutral red and quantum dots . The interactions of topotecan hydrochloride ( THC ) , neutral red ( NR ) and thioglycolic acid ( TGA ) capped CdTe / CdS quantum dots ( QDs )", "The samples were also analyzed by separate HPLC methods to detect the presence of DEHP and the hydrolyzed lactone ring form ( SKF 105992 ) of topotecan hydrochloride ."], "par_relations": ["Topotecan"], "chd_relations": ["Hycamtin"], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Topotecan", "List of GlaxoSmithKline products", "Kadmon Corporation", "Irinotecan", "Gemcitabine", "Doxorubicin", "Mitoxantrone", "SLC22A8", "Bendamustine", "Nitrogen mustard"], "mesh_synonynms": ["9 dimethylaminomethyl 10 hydroxycamptothecin", "sk&f-104864-a", "sk&f104864a", "nsc-609699", "hycamtin", "nsc 609699", "skf-104864-a", "hydrochloride, topotecan", "skf104864a", "hydrochloride, nogitecan", "nsc609699", "9-dimethylaminomethyl-10-hydroxycamptothecin", "nogitecan hydrochloride", "topotecan monohydrochloride, (s)-isomer", "sk&f 104864 a", "hycamtamine", "skf 104864 a", "topotecan"], "dbpedia_synonyms": ["topotecan"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:17889", "canonical_name": "apurinic/apyrimidinic endodeoxyribonuclease 2", "aliases": ["apurinic/apyrimidinic endodeoxyribonuclease 2", "zinc finger, grf-type containing 2", "ape2", "apex2 gene", "apex2", "zgrf2", "apexl2", "xth2"], "definition": "In enzymology, DNA-(apurinic or apyrimidinic site) lyase, also referred to as DNA-(apurinic or apyrimidinic site) 5'-phosphomonoester-lyase (systematic name) or DNA AP lyase (EC 4.2.99.18) is a class of enzyme that catalyzes the chemical reaction of the cleavage of the C3'-O-P bond 3' from the apurinic or apyrimidinic site in DNA via beta-elimination reaction, leaving a 3'-terminal unsaturated sugar and a product with a terminal 5'-phosphate.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2", "apurinic/apyrimidinic endodeoxyribonuclease 2"], "sib_relations": [], "wiki_entities": ["DNA-(apurinic or apyrimidinic site) lyase", "APEX1", "40S ribosomal protein S3", "List of MeSH codes (D08)"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:300773", "canonical_name": "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "aliases": ["ape2", "apex nuclease (apurinic/apyrimidinic endonuclease) 2", "apex2", "apex nuclease-like 2", "apurinic/apyrimidinic endonuclease like-2", "apexl2", "xth2"], "definition": "DNA-(apurinic or apyrimidinic site) lyase is an enzyme that in humans is encoded by the APEX1 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2", "APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2"], "sib_relations": [], "wiki_entities": ["APEX1", "Flap structure-specific endonuclease 1", "MUTYH", "Stress granule"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C567062", "canonical_name": "Fabry Disease, Cardiac Variant", "aliases": ["fabry disease, cardiac variant"], "definition": "Coral reefs are diverse underwater ecosystems held together by calcium carbonate structures secreted by corals.", "other_contexts": [], "par_relations": ["Fabry Disease"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Lysosomal storage disease", "Hypertrophic cardiomyopathy", "List of systemic diseases with ocular manifestations", "List of genetic disorders", "List of cutaneous conditions", "List of genes mutated in cutaneous conditions", "Multiple sclerosis drug pipeline"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:300644", "canonical_name": "GALACTOSIDASE, ALPHA", "aliases": ["fabry disease, cardiac variant", "reclassified - variant of unknown significance", "galactosidase, alpha", "gala", "alpha-galactosidase a", "gla", "fabry disease"], "definition": "Alpha-galactosidase is a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["GALACTOSIDASE, ALPHA", "GLA, ARG356TRP", "GLA, EX3DEL", "GLA, TRP44TER", "GLA, EX4DEL", "GLA, IVS6DS, G-T, +1", "GLA, PRO40SER", "GLA, GLY328ARG", "GLA, GLU66GLN AND ARG112CYS", "GLA, ASN34SER", "GLA, CYS56GLY", "GLA, PRO146SER", "GLA, ALA156THR", "GLA, TRP162ARG", "GLA, CYS202TRP", "GLA, ASN215SER", "GLA, ARG227GLN", "GLA, ARG227TER", "GLA, ASP264VAL", "GLA, ASP266VAL", "GLA, VAL269ALA", "GLA, TRP287TER", "GLA, SER297PHE", "GLA, ASP313TYR", "GLA, GLN327LYS", "GLA, GLY328ALA", "GLA, TRP340TER", "GLA, ARG342GLN", "GLA, ARG342TER", "GLA, GLY361ARG", "GLA, GLU398TER", "GLA, IVSDS, GT-GG, +2", "GLA, IVS5AS, DEL -2,-3", "GLA, EX1-2DEL", "GLA, EX3-4DEL", "GLA, EX3-7DEL", "GLA, EX6-7DEL", "GLA, EX2-6DUP", "GLA, TYR365TER", "GLA, ALA143PRO", "GLA, TYR222TER", "GLA, THR410ALA", "GLA, 2-BP DEL, 1277AA", "GLA, 4-BP DEL, 1284ACTT", "GLA, ASN272SER", "GLA, ARG301GLN", "GLA, MET296VAL", "GLA, GLN279GLU", "GLA, ALA143THR", "GLA, 13-BP DEL, NT125", "GLA, 1-BP DEL, NT716", "GLA, 2-BP DEL, NT773", "GLA, 5-BP INS, NT954", "GLA, 11-BP DEL, NT1016", "GLA, 1-BP INS, NT1040", "GLA, 53-BP DEL, NT1123", "GLA, 2-BP DEL, NT1176", "GLA, 3-BP DEL, 1208AAG", "GLA, MET296ILE", "GLA, ALA20PRO", "GLA, 3-BP DEL, PHE383DEL", "GLA, SER65THR", "GLA, IVS4, G-A, -4", "GALACTOSIDASE, ALPHA", "GALACTOSIDASE, ALPHA", "GALACTOSIDASE, ALPHA", "GALACTOSIDASE, ALPHA", "GALACTOSIDASE, ALPHA"], "sib_relations": ["GLA, ARG301GLN", "GLA, ARG356TRP", "GLA, EX3DEL", "GLA, TRP44TER", "GLA, EX4DEL", "GLA, IVS6DS, G-T, +1", "GLA, PRO40SER", "GLA, GLY328ARG", "GLA, GLU66GLN AND ARG112CYS", "GLA, ASN34SER", "GLA, CYS56GLY", "GLA, PRO146SER", "GLA, ALA156THR", "GLA, TRP162ARG", "GLA, CYS202TRP", "GLA, ASN215SER", "GLA, ARG227GLN", "GLA, ARG227TER", "GLA, ASP264VAL", "GLA, ASP266VAL", "GLA, VAL269ALA", "GLA, TRP287TER", "GLA, SER297PHE", "GLA, GLN327LYS", "GLA, GLY328ALA", "GLA, TRP340TER", "GLA, ARG342GLN", "GLA, ARG342TER", "GLA, GLY361ARG", "GLA, GLU398TER", "GLA, IVSDS, GT-GG, +2", "GLA, IVS5AS, DEL -2,-3", "GLA, EX1-2DEL", "GLA, EX3-4DEL", "GLA, EX3-7DEL", "GLA, EX6-7DEL", "GLA, EX2-6DUP", "GLA, TYR365TER", "GLA, ALA143PRO", "GLA, TYR222TER", "GLA, THR410ALA", "GLA, 2-BP DEL, 1277AA", "GLA, 4-BP DEL, 1284ACTT", "GLA, ASN272SER", "GLA, ALA143THR", "GLA, 13-BP DEL, NT125", "GLA, 1-BP DEL, NT716", "GLA, 2-BP DEL, NT773", "GLA, 5-BP INS, NT954", "GLA, 11-BP DEL, NT1016", "GLA, 1-BP INS, NT1040", "GLA, 53-BP DEL, NT1123", "GLA, 2-BP DEL, NT1176", "GLA, 3-BP DEL, 1208AAG", "GLA, 3-BP DEL, PHE383DEL", "GLA, SER65THR", "GLA, ARG301GLN", "GLA, MET296VAL", "GLA, GLN279GLU", "GLA, MET296ILE", "GLA, ALA20PRO", "GLA, IVS4, G-A, -4", "GLA, ASP313TYR"], "wiki_entities": ["Alpha-galactosidase", "Galactosidases", "Fabry disease", "Alpha-gal", "Globotriaosylceramide", "Glycoside hydrolase family 27", "Blue–white screen", "Beano (dietary supplement)", "Capsular-polysaccharide endo-1,3-alpha-galactosidase", "Glycoside hydrolase family 36"], "mesh_synonynms": ["angiokeratoma, diffuse", "deficiency, ceramide trihexosidase", "alpha-galactosidase a deficiency disease", "ceramide trihexosidase deficiency", "deficiency, gla", "fabry's disease", "lipidosis, hereditary dystopic", "angiokeratoma corporis diffusum", "alpha-galactosidase a deficiency", "anderson-fabry disease", "anderson fabry disease", "hereditary dystopic lipidosis", "deficiency, alpha-galactosidase a", "gla deficiency", "diffuse angiokeratoma", "angiokeratoma diffuse", "alpha galactosidase a deficiency disease", "alpha galactosidase a deficiency"], "dbpedia_synonyms": ["alpha-galactosidase a deficiency", "ceramide trihexosidase deficiency", "angiokeratoma corporis diffusum universale", "gala (disambiguation)", "angiokeratoma corporis diffusum of fabry", "gla (gene)", "fabry's disease", "fabrey's disease", "diffuse angiokeratosis", "angiokeratoma diffuse", "gala", "anderson–fabry disease", "anderson-fabry disease", "fabrys disease", "gla (disambiguation)", "diffuse anglokeratoma", "ceramide trihexosidosis", "anglokeratoma corporis diffusum universale", "angiokeratoma corporis diffusum", "fabray's disease", "diffuse angiokeratoma"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0004586", "canonical_name": "Biconcave vertebral bodies", "aliases": ["codfish vertebrae", "biconcave vertebral bodies", "biconcave 'codfish' vertebrae", "scalloping of vertebral bodies", "biconcave vertebrae", "fish vertebrae"], "definition": "Amphicoelias (, meaning \"biconcave\", from the Greek αμφι, amphi: \"on both sides\", and κοιλος, koilos: \"hollow, concave\") is a genus of herbivorous sauropod dinosaur.", "other_contexts": [], "par_relations": ["Abnormal form of the vertebral bodies"], "chd_relations": ["Biconcave flattened vertebrae", "Posterior scalloping of vertebral bodies", "Anterior scalloping of vertebral bodies"], "syn_relations": ["Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies", "Biconcave vertebral bodies"], "sib_relations": ["Hemivertebrae", "Vertebral wedging", "Disc-like vertebral bodies", "Vertebral arch anomaly", "Anterior concavity of thoracic vertebrae", "Platyspondyly", "Sandwich appearance of vertebral bodies", "Ovoid vertebral bodies", "Vertebral clefting", "Beaking of vertebral bodies", "Anisospondyly", "Hypoplastic vertebral bodies", "Increased vertebral height", "Biconvex vertebral bodies", "Pear-shaped vertebrae", "Cuboid-shaped vertebral bodies", "Bifid thoracic vertebrae", "Abnormality of the vertebral spinous processes", "Tongue-like lumbar vertebral deformities", "Trapezoidal shaped vertebral bodies", "Abnormality of the vertebral endplates", "Patchy distortion of vertebrae", "Irregularity of vertebral bodies", "Abnormality of spinal facet joint"], "wiki_entities": ["Amphicoelias", "Temporomandibular joint dysfunction", "List of Latin words with English derivatives"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU019729", "canonical_name": "Biconcave vertebrae", "aliases": ["biconcave vertebrae"], "definition": "Diplosaurus is an extinct genus of goniopholidid mesoeucrocodylian.", "other_contexts": [], "par_relations": ["Spine"], "chd_relations": [], "syn_relations": [], "sib_relations": ["HAJDU-CHENEY SYNDROME", "OSTEOGENESIS IMPERFECTA, TYPE V", "OSTEOGENESIS IMPERFECTA, TYPE XI"], "wiki_entities": ["Diplosaurus", "Halecomorphi", "Microhylidae", "Amphicoelias"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D050033", "canonical_name": "Thyroid Dysgenesis", "aliases": ["dysgenesis, thyroid", "thyroid agenesis", "thyroid hypoplasia", "thyroid dysgenesis", "agenesis, thyroid", "thyroids, ectopic", "ectopic thyroid", "hypoplasia, thyroid", "thyroid, ectopic", "ectopic thyroids"], "definition": "Thyroid dysgenesis or thyroid agenesis is a cause of congenital hypothyroidism where the thyroid is missing, ectopic, or severely underdeveloped.", "other_contexts": [". The most frequent cause of congenital hypothyroidism is thyroid dysgenesis . Thyroid dysgenesis summarizes a spectrum of developmental abnormalities of the embryonic thyroid ranging from", "- induced Thyroid Proliferative Lesions in Wistar Hannover GALAS Rats with Thyroid Dysplasia Incidences and morphological features of thyroid proliferative lesions induced by carcinogens in", "bioassay protocol ( called DMBDD treatment ) . In the DMBDD - treated rats , thyroid dysplasia was found in 9 out of 114 rats . Follicular cell adenomas were found in 5 out of 9 rats with", "clustering in patients with permanent congenital hypothyroidism ( CH ) caused by thyroid dysgenesis ( TD ) has been reported in developed countries . There is no information on familial TD from", "Thyroid dysgenesis ( TD ) is responsible for most cases of congenital hypothyroidism , a condition that affects about one in 4000 newborns .", "with PCNA - positive cells , were fundamentally similar to those of rats without thyroid dysplasia . On the other hand , the luminal colloid in adenomas of rats with thyroid dysplasia had a", "Wistar Hannover GALAS rats ( GALAS rats ) showing normal growth with or without thyroid dysplasia were examined . All thyroid tissue samples were obtained from our recently conducted study using", "rats with thyroid dysplasia were fundamentally similar to those of rats without thyroid dysplasia , except for the vacuoles and T(4 ) staining profile .", "Screening of HHEX Mutations in Chinese Children with Thyroid Dysgenesis OBJECTIVE Congenital hypothyroidism (CH) is a frequent neonatal endocrine disease with an incidence of about 1:2500 worldwide.", "development in humans . The most frequent cause of congenital hypothyroidism is thyroid dysgenesis . Thyroid dysgenesis summarizes a spectrum of developmental abnormalities of the embryonic thyroid", "with that in rats without thyroid dysplasia ( 6.7% ) . Adenomas in rats with thyroid dysplasia were observed as single or multiple nodules , well demarcated and composed of variously sized", "Thyroid dysgenesis and the dysplasia hypothesis in tuberous sclerosis.", "Thyroid dysgenesis summarizes a spectrum of developmental abnormalities of the embryonic thyroid ranging from complete absence of the thyroid gland ( athyreosis ) , to a normally located but too small thyroid ( hypoplasia ) , or an abnormally located thyroid gland ( ectopy ) .", "found in 5 out of 9 rats with thyroid dysplasia and in 7 out of 105 rats without thyroid dysplasia . The incidence of adenoma was significantly increased in rats with thyroid dysplasia ( 55.6% )", "dysplasia . On the other hand , the luminal colloid in adenomas of rats with thyroid dysplasia had a tendency to be poorly stained for T(4 ) compared with that of rats without thyroid dysplasia", "BACKGROUND Thyroid dysgenesis (TD) is the most frequent cause of congenital hypothyroidism (CH), but its pathogenesis remains unclear.", "dysplasia . The incidence of adenoma was significantly increased in rats with thyroid dysplasia ( 55.6% ) compared with that in rats without thyroid dysplasia ( 6.7% ) . Adenomas in rats with", ", clinical and genetic features of the different monogenetic forms of thyroid dysgenesis , the aspects relevant for diagnosis and counseling of affected families and current research", "CONTEXT Ectopic Thyroid Gland ( ETG ) is known to be the most common form of thyroid dysgenesis in children with permanent congenital hypothyroidism ( CH ) . Recent reports indicate that", "agenesis or hypoplasia of thyroid gland may be commoner as compared to ETG in thyroid dysgenesis ( TD ) . There is limited information available on the proportion of different variants of TD in", "Congenital and Juvenile Hypothyroidism Due to Thyroid Dysgenesis .", "considered a sporadic disease , distinct genetic forms of isolated or syndromic thyroid dysgenesis have been described in recent years . However , genetics of thyroid dysgenesis ( TD ) are mostly", "features of carcinogen - induced thyroid proliferative lesions in GALAS rats with thyroid dysplasia were fundamentally similar to those of rats without thyroid dysplasia , except for the vacuoles", "Thyroid dysgenesis ( TD ) is the most prevalent form of congenital hypothyroidism .", "PAX8 mutation in a Chinese child with congenital thyroid dysgenesis . BACKGROUND Thyroid dysgenesis ( TD ) is the most frequent cause of congenital hypothyroidism ( CH ) , but its pathogenesis", "had a tendency to be poorly stained for T(4 ) compared with that of rats without thyroid dysplasia . From these findings , it appears that dysplastic thyroids of rats showing normal growth are more", "in rats with thyroid dysplasia ( 55.6% ) compared with that in rats without thyroid dysplasia ( 6.7% ) . Adenomas in rats with thyroid dysplasia were observed as single or multiple nodules ,", "and developmental anomalies in first degree relatives of children with thyroid dysgenesis . BACKGROUND Familial clustering in patients with permanent congenital hypothyroidism ( CH )", "9 out of 114 rats . Follicular cell adenomas were found in 5 out of 9 rats with thyroid dysplasia and in 7 out of 105 rats without thyroid dysplasia . The incidence of adenoma was significantly", "thyroid dysgenesis have been described in recent years . However , genetics of thyroid dysgenesis ( TD ) are mostly not following simple Mendelian patterns , and beside monogenic , multigenic and"], "par_relations": ["Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Congenital Abnormalities", "Thyroid Diseases"], "chd_relations": ["Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Lingual Thyroid", "Hypothyroidism, Congenital, Nongoitrous, 2"], "syn_relations": ["Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis", "Thyroid Dysgenesis"], "sib_relations": ["Abnormalities, Drug-Induced", "Abnormalities, Multiple", "Abnormalities, Radiation-Induced", "Chromosome Disorders", "Euthyroid Sick Syndromes", "Eye Abnormalities", "Goiter", "Hyperthyroidism", "Hyperthyroxinemia", "Hypothyroidism", "Respiratory System Abnormalities", "Situs Inversus", "Skin Abnormalities", "Thyroid Neoplasms", "Thyroiditis", "Urogenital Abnormalities", "Musculoskeletal Abnormalities", "Aicardi Syndrome", "Hernias, Diaphragmatic, Congenital", "Cardiovascular Abnormalities", "Stomatognathic System Abnormalities", "Digestive System Abnormalities", "Lymphatic Abnormalities", "Nervous System Malformations", "Abnormalities, Severe Teratoid", "Congenital Microtia"], "wiki_entities": ["Thyroid dysgenesis", "Thyroid", "Dysgenesis (embryology)", "Endocrine disease", "Hypothyroidism", "Congenital hypothyroidism", "Bamforth–Lazarus syndrome", "Turner syndrome", "List of diseases (G)", "PAX8"], "mesh_synonynms": ["thyroid dysgenesis", "hypoplasia, thyroid", "ectopic thyroid", "thyroid, ectopic", "thyroid hypoplasia", "thyroids, ectopic", "dysgenesis, thyroid", "thyroid agenesis", "agenesis, thyroid", "ectopic thyroids"], "dbpedia_synonyms": ["lingual thyroid", "ectopic thyroid", "thyroid dysgenesis", "accessory thyroid", "thyroid agenesis", "ectopic thyroid tissue"]}, "target_ent": {"research_entity_id": "OMIM:MTHU053626", "canonical_name": "Ectopic thyroid", "aliases": ["ectopic thyroid"], "definition": "Thyroid dysgenesis or thyroid agenesis is a cause of congenital hypothyroidism where the thyroid is missing, ectopic, or severely underdeveloped.", "other_contexts": [], "par_relations": ["ENDOCRINE FEATURES"], "chd_relations": [], "syn_relations": [], "sib_relations": ["HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2"], "wiki_entities": ["Thyroid dysgenesis", "Thyroid", "Ectopia (medicine)", "Congenital hypothyroidism", "Thyroglossal cyst", "Ectopic salivary gland tissue", "Parathyroid gland", "Parathyroid adenoma", "Pentagastrin", "Palpitations"], "mesh_synonynms": ["thyroid dysgenesis", "hypoplasia, thyroid", "thyroids, ectopic", "thyroid, ectopic", "thyroid hypoplasia", "dysgenesis, thyroid", "thyroid agenesis", "agenesis, thyroid", "ectopic thyroids"], "dbpedia_synonyms": ["thyroid dysgenesis"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:15574", "canonical_name": "RB1 inducible coiled-coil 1", "aliases": ["kiaa0203", "fip200", "rb1 inducible coiled-coil 1", "ppp1r131", "dragou14", "rb1cc1 gene", "rb1cc1", "atg17", "cc1", "200 kda fak family kinase-interacting protein", "phosphatase 1, regulatory subunit 131"], "definition": "The RB engine is a 2.0–3.0 L straight-6 four-stroke petrol/gasoline engine from Nissan, produced from 1985-2004.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1", "RB1 inducible coiled-coil 1"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["cc1 (disambiguation)", "gnu compiler collection", "rb1cc1 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:606837", "canonical_name": "RB1-INDUCIBLE COILED-COIL 1", "aliases": ["kiaa0203", "fip200", "cc1", "rb1-inducible coiled-coil 1", "breast cancer, somatic", "fak family kinase-interacting protein, 200-kd", "rb1cc1"], "definition": "The RB engine is a 2.0–3.0 L straight-6 four-stroke petrol/gasoline engine from Nissan, produced from 1985-2004.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1CC1, EX3-24 DEL", "RB1CC1, EX9-23 DEL", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1", "RB1-INDUCIBLE COILED-COIL 1"], "sib_relations": ["RB1CC1, EX3-24 DEL", "RB1CC1, EX9-23 DEL"], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["cc1 (disambiguation)", "gnu compiler collection", "rb1cc1 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0002924", "canonical_name": "Decreased circulating aldosterone level", "aliases": ["decreased circulating aldosterone level", "decreased serum aldosterone", "decreased aldosterone"], "definition": "A decreased level of aldosterone in the blood. [HPO:probinson]", "other_contexts": [], "par_relations": ["Abnormal circulating aldosterone"], "chd_relations": [], "syn_relations": ["Decreased circulating aldosterone level", "Decreased circulating aldosterone level", "Decreased circulating aldosterone level", "Decreased circulating aldosterone level"], "sib_relations": [], "wiki_entities": ["Renin–angiotensin system", "Hyperaldosteronism", "Adrenal gland", "Blood pressure", "Glomerulonephritis", "Renin", "Feline hyperaldosteronism", "Hypokalemia", "Adrenocortical hormone", "Cortisol"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU000160", "canonical_name": "Decreased serum aldosterone", "aliases": ["decreased serum aldosterone"], "definition": "Aldosterone, the main mineralocorticoid hormone, is a steroid hormone produced by the zona glomerulosa of the adrenal cortex in the adrenal gland.", "other_contexts": [], "par_relations": ["LABORATORY ABNORMALITIES"], "chd_relations": [], "syn_relations": [], "sib_relations": ["CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY", "CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY", "APPARENT MINERALOCORTICOID EXCESS"], "wiki_entities": ["Aldosterone", "Hyperaldosteronism", "Hyperkalemia", "Aldosterone synthase", "Azotemia", "Diuretic", "Anion gap", "Glucocorticoid remediable aldosteronism", "Angiotensin", "Renin"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C565065", "canonical_name": "Ectrodactyly and Ectodermal Dysplasia without Cleft Lip-Palate", "aliases": ["ectrodactyly and ectodermal dysplasia without cleft lip-palate"], "definition": "Ectrodactyly–ectodermal dysplasia–cleft syndrome, or EEC, and also referred to as EEC syndrome (also known as \"Split hand–split foot–ectodermal dysplasia–cleft syndrome\") is a rare form of ectodermal dysplasia, an autosomal dominant disorder inherited as an genetic trait.", "other_contexts": [], "par_relations": ["Ectodermal Dysplasia", "Foot Deformities, Congenital", "Hand Deformities, Congenital"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:604292", "canonical_name": "ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3", "aliases": ["ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3", "eec3", "eec syndrome 3"], "definition": "Ectrodactyly–ectodermal dysplasia–cleft syndrome, or EEC, and also referred to as EEC syndrome (also known as \"Split hand–split foot–ectodermal dysplasia–cleft syndrome\") is a rare form of ectodermal dysplasia, an autosomal dominant disorder inherited as an genetic trait.", "other_contexts": ["Mutations in the human p63 gene are known to cause either isolated split hand / foot malformation ( SHFM1 , MIM 183600 ) or a number of syndromes such as ectrodactyly - ectodermal dysplasia - cleft lip / palate syndrome ( EEC3 , MIM 604292 ) , ankyloblepharonectodermal dysplasia - clefting syndrome ( AEC , MIM 106260 ) , acro - dermato - ungual - lacrimal - tooth syndrome ( ADULT , MIM 103285 ) , limb - mammary syndrome ( LMS , OMIM 603543 ) , and Rapp - Hodgkin syndrome ( RHS , MIM 129400 ) [ 1 ] ."], "par_relations": [], "chd_relations": [], "syn_relations": ["ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3", "ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3", "ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3", "ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3"], "sib_relations": ["Blepharitis", "Blepharophimosis", "Choanal atresia", "Cleft lip", "Cleft palate", "Cryptorchidism", "Dacryocystitis", "Caries", "Hydronephrosis", "Syndactyly", "Ureterocele", "Vesicoureteral reflux", "Xerostomia", "Photophobia", "Pitted nails", "Small ears", "Bladder diverticula", "Dystrophic nails", "Maxillary hypoplasia", "Microdontia", "Ectrodactyly", "Micropenis", "Growth hormone deficiency", "Hypogonadotropic hypogonadism", "Hypoplastic nipples", "Autosomal dominant", "Megaureter", "Renal agenesis", "Blue irides", "Central diabetes insipidus", "Malformed auricles", "Hyperkeratosis", "Hearing loss", "Sparse eyebrows", "Sparse eyelashes", "Light colored hair", "Transverse vaginal septum", "Sparse, thin scalp hair", "Malar hypoplasia", "Mental retardation (7%)", "Duplicated collecting system", "Lacrimal duct abnormalities", "Absence of Stensen duct", "Fair skin", "Sparse pubic hair", "Sparse axillary hair", "Caused by mutation in the tumor protein p63 gene (TP63, 603273.0001)", "Heterogeneous disorder", "Two loci described - EEC1 (129900) and EEC3 (604292)", "Majority of EEC cases appear to be secondary to TP63 mutations (603273)", "Flat nasal tip", "Selective tooth agenesis", "Allelic to ADULT syndrome (103285), split hand/foot malformation 4 (605289), Rapp-Hodgkin syndrome (129400), Hay-Wells syndrome (106260), and limb-mammary syndrome (603543)", "Renal dysplasia"], "wiki_entities": ["Ectrodactyly–ectodermal dysplasia–cleft syndrome", "Facial cleft", "Uncombable hair syndrome", "Hearing loss with craniofacial syndromes", "TP63", "List of diseases (H)", "List of diseases (S)", "List of diseases (A)", "List of diseases (T)", "List of diseases (E)"], "mesh_synonynms": [], "dbpedia_synonyms": ["tp63"]}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:1482", "canonical_name": "calpain 5", "aliases": ["adniv", "capn5 gene", "ncl-3", "calpain 5", "htra3", "capn5"], "definition": "A calpain (; EC 3.4.22.52, EC 3.4.22.53) is a protein belonging to the family of calcium-dependent, non-lysosomal cysteine proteases (proteolytic enzymes) expressed ubiquitously in mammals and many other organisms.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["calpain 5", "calpain 5", "calpain 5", "calpain 5", "calpain 5", "calpain 5", "calpain 5", "calpain 5"], "sib_relations": [], "wiki_entities": ["Calpain", "CAPN5", "Calpain-3", "CAPN10", "Calpastatin", "CAPNS1", "CAPN2", "CAPN9", "Maitotoxin", "Leupeptin"], "mesh_synonynms": [], "dbpedia_synonyms": ["calpain-5", "nitrogen trichloride", "capn5 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:602537", "canonical_name": "CALPAIN 5", "aliases": ["vitreoretinopathy, neovascular inflammatory", "htra3", "calpain 5", "capn5"], "definition": "A calpain (; EC 3.4.22.52, EC 3.4.22.53) is a protein belonging to the family of calcium-dependent, non-lysosomal cysteine proteases (proteolytic enzymes) expressed ubiquitously in mammals and many other organisms.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["CALPAIN 5", "CALPAIN 5", "CAPN5, ARG243LEU", "CAPN5, LEU244PRO", "CALPAIN 5", "CALPAIN 5"], "sib_relations": ["CAPN5, ARG243LEU", "CAPN5, LEU244PRO"], "wiki_entities": ["Calpain", "CAPN5", "Calpain-3", "CAPN10", "Calpastatin", "CAPNS1", "CAPN2", "CAPN9", "Maitotoxin", "Leupeptin"], "mesh_synonynms": [], "dbpedia_synonyms": ["calpain-5", "capn5 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:3796", "canonical_name": "FBJ murine osteosarcoma viral oncogene homolog", "aliases": ["fos gene", "c-fos", "fos", "ap-1", "fbj murine osteosarcoma viral oncogene homolog"], "definition": "In the fields of molecular biology and genetics, c-Fos is a proto-oncogene that is the human homolog of the retroviral oncogene v-fos.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["FBJ murine osteosarcoma viral oncogene homolog", "FBJ murine osteosarcoma viral oncogene homolog", "FBJ murine osteosarcoma viral oncogene homolog", "FBJ murine osteosarcoma viral oncogene homolog", "FBJ murine osteosarcoma viral oncogene homolog", "FBJ murine osteosarcoma viral oncogene homolog"], "sib_relations": [], "wiki_entities": ["C-Fos", "FOSB"], "mesh_synonynms": ["c-fos proto-oncogenes", "c fos proto oncogenes", "v-fos oncogene", "c-fos gene", "v-fos oncogenes", "fos genes", "c-fos genes", "v-fos genes", "genes, fos", "v fos genes", "c-fos proto-oncogene", "v-fos gene", "c fos genes", "v fos oncogenes"], "dbpedia_synonyms": ["ap1 (disambiguation)", "c-fos", "ap-1 (disambiguation)", "ap-1", "fos (disambiguation)", "a.p.1", "fos", "uc san diego health", "cfos (am)", "ap.1", "ap 1"]}, "target_ent": {"research_entity_id": "MSH:D016762", "canonical_name": "Genes, fos", "aliases": ["c fos proto oncogenes", "c fos genes", "fos genes", "v fos oncogenes", "fos gene", "v-fos gene", "v fos genes", "c-fos genes", "c-fos proto-oncogenes", "v-fos oncogenes", "v-fos genes", "c-fos gene", "v-fos oncogene", "c-fos proto-oncogene", "genes, fos"], "definition": "Retrovirus-associated DNA sequences (fos) originally isolated from the Finkel-Biskis-Jinkins (FBJ-MSV) and Finkel-Biskis-Reilly (FBR-MSV) murine sarcoma viruses. The proto-oncogene protein c-fos codes for a nuclear protein which is involved in growth-related transcriptional control. The insertion of c-fos into FBJ-MSV or FBR-MSV induces osteogenic sarcomas in mice. The human c-fos gene is located at 14q21-31 on the long arm of chromosome 14.", "other_contexts": [], "par_relations": ["Proto-Oncogenes", "Genes, fos", "Genes, fos"], "chd_relations": ["Genes, fos", "Genes, fos"], "syn_relations": ["Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos", "Genes, fos"], "sib_relations": ["Proto-Oncogene Proteins c-fos", "Oncogene Proteins v-fos", "Genes, myc", "Genes, ras", "Genes, src", "Genes, abl", "Genes, fms", "Genes, mos", "Genes, jun", "Genes, erbA", "Genes, erbB", "Genes, bcl-2", "Genes, bcl-1", "Genes, myb", "Genes, sis", "Genes, rel"], "wiki_entities": ["C-Fos", "FOSB", "Addiction", "Immediate early gene", "AP-1 transcription factor", "C-jun", "JUNB", "FOSL1", "ELK1", "C-fos-induced growth factor"], "mesh_synonynms": ["c-fos proto-oncogenes", "v-fos oncogene", "c fos proto oncogenes", "c-fos gene", "v-fos oncogenes", "fos genes", "c-fos genes", "v-fos genes", "genes, fos", "v fos genes", "fos gene", "c-fos proto-oncogene", "v-fos gene", "c fos genes", "v fos oncogenes"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D010840", "canonical_name": "Phytosterols", "aliases": ["phytosteroids", "plant sterols", "phytosterol", "steroid, plant", "plant steroids", "phytoteroid", "sterols, plant", "phytosterols", "sterol, plant", "plant sterol", "steroids, plant", "plant steroid"], "definition": "Phytosterols, which encompass plant sterols and stanols, are phytosteroids, similar to cholesterol, which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.", "other_contexts": ["Phytosterol oxidation products ( POP ) in foods with added phytosterols and estimation of their daily intake : A literature review 1To evaluate the content of phytosterol oxidation products ( POP ) of foods with added phytosterols , in total 14 studies measuring POP contents of foods with added phytosterols were systematically reviewed .", "and esterified forms reveals that heating temperature and time , the chemical form of phytosterols added and the food matrix itself are determinants of POP formation with heating temperature and", "The physico - chemical properties of phytosterols are ideal for penetration into deeper skin layers owing to their affinity with lipids of cellular membranes ( Sekiya et al .", "and phytosterolemic homozygotes patients . We speculate that the accumulation of phytosterols could contribute to their vulnerability to PNAC . CLINICAL TRIAL REGISTRY The Ethics Committee of", "1997; Marjukka Suhonen et al. 1999) and phytosterols and/or their metabolites can reach the systemic circulation as occurs for steroid hormones in transdermal delivery.", "During this study an extraction and detection method for the main free phytosterols ( β-sitosterol , campesterol , stigmasterol and brassicasterol ) was optimised using a fractional factorial design .", "Most of the interest has focused on the cholesterol-lowering properties of phytosterols, but they may also interfere with endogenous steroid hormone synthesis.", "Phytosterols are plant-derived sterols present in pulp and paper wastewater and have been implicated in the endocrine disruption of aquatic species.", "applications : Phytosterol oxidation products ( POP ) are formed in foods containing phytosterols especially when exposed to heat treatment . This review summarising POP contents in foods with", "We suggest that there is another route of intake of phytosterols which has not yet been considered: dermal absorption from cosmetics.", "Graphical Abstract An extraction and detection method for the main free phytosterols (β-sitosterol, campesterol, stigmasterol and brassicasterol) was optimised using a fractional factorial design.", "Serum phytosterols not only from dietary intake.", "emulsions used for parenteral nutrition are based on vegetable oils . As a result , phytosterol administration occurs during intravenous administration of lipid . Levels of phytosterols in the", "In fat-based foods with 8% of added free plant sterols (FPS), plant sterol esters (PSE) or plant stanol esters (PAE) pan-fried at 160-200°C for 5-10 min, median POP contents were 72.0, 38.1, and 4.9 mg/100 g, respectively, with a median ORP of 0.90, 0.48, and 0.06%.", "are scarce . During this study an extraction and detection method for the main free phytosterols ( β-sitosterol , campesterol , stigmasterol and brassicasterol ) was optimised using a fractional", "charge of the dispersed particles . DSC data demonstrated that , at the higher level of phytosterol addition , crystallization of milk fat was delayed , whereas , at the lower level , phytosterol", "bilirubin . CONCLUSION VLBW preterm infants on PN with LE had rather long plasma phytosterol half - lives similar to hypercholesterolemic adults and phytosterolemic homozygotes patients . We", "on the effect of added plant sterols on the properties of the system . In this study , phytosterols dispersed in milk fat at a level of 0.3 or 0.6% were homogenized with an aqueous dispersion of", "Phytosterols are ubiquitous in plants , as they play an important role in cell membrane stability and as signal transducers .", "Following the 7th day , the phytosterol removal rate markedly accelerated , suggesting two different mechanisms are involved in phytosterol biotransformation , more likely related to the production of enzyme(s ) involved in phytosterol degradation , induced under different cell growth conditions .", "nutrition - associated liver disease . In this review , mechanisms by which lipids and phytosterols may cause cholestasis are discussed . Human studies of the association of phytosterols with liver", "Phytosterols, abundant in CA but not in SO, can inhibit the absorption of cholesterol and also replace a part of cholesterol in cell membranes.", "per 100 mL ) . Graphical Abstract An extraction and detection method for the main free phytosterols ( β-sitosterol , campesterol , stigmasterol and brassicasterol ) was optimised using a fractional", "Investigation of the mRNA expression of ATP-binding cassette (ABC) transporters involved in intestinal phytosterol absorption indicated significant decreases in the intestinal mRNA expression of Abcg5 and Abcg8 in SHRSP and Wistar-Kyoto rats compared with Wistar rats.", "interfere with endogenous steroid hormone synthesis . Despite this dual interest in phytosterols , accurate and fully validated methods for the quantification of phytosterols in food and feed", "β-sitosterol was preferentially degraded , as compared to stigmasterol and campesterol , although all three phytosterols fell below detection limits by the 24th day of incubation .", "No characterization of plasma phytosterol half - lives has been done in very low birth weight ( VLBW ) preterm infants receiving parenteral nutrition ( PN ) with LE .", ". Most of the interest has focused on the cholesterol - lowering properties of phytosterols , but they may also interfere with endogenous steroid hormone synthesis . Despite this dual", "RESULTS Compared to the control diet, the phytosterol diet resulted in 3- to 4-fold increases in the levels of phytosterols in plasma, red blood cells, liver, aorta and kidney of WKY inbred rats (P < 0.05).", "source , with phytosterols and dextrin as an additional carbon source , and with phytosterols added with ethanol as an additional carbon source and solubilizing agent . Significant phytosterol", "However , a fivefold greater amount of phytosterol was required to produce an effect that was equivalent to the survival time - shortening effect of canola oil .", "This study suggests that the high concentration of phytosterols in CA and the addition of phytosterols to other fats make the cell membrane more rigid , which might be a factor contributing to the shortened life span of SHRSP rats .", "removal rate markedly accelerated , suggesting two different mechanisms are involved in phytosterol biotransformation , more likely related to the production of enzyme(s ) involved in phytosterol", "DSC data demonstrated that , at the higher level of phytosterol addition , crystallization of milk fat was delayed , whereas , at the lower level , phytosterol enrichment induced nucleation and emulsion crystallization .", "suggests that administration of high doses of intravenous lipids that are high in phytosterols contributes to the development of parenteral nutrition - associated liver disease . In this review", "CONCLUSION VLBW preterm infants on PN with LE had rather long plasma phytosterol half - lives similar to hypercholesterolemic adults and phytosterolemic homozygotes patients .", "with added free plant sterols and 47.7 mg / d for fat - based products with added plant sterol esters . Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products", "biotransformation , more likely related to the production of enzyme(s ) involved in phytosterol degradation , induced under different cell growth conditions . β-sitosterol was preferentially", "Levels of phytosterols in the blood and tissues may reach high levels during parenteral lipid administration and may be toxic to cells .", ", ranging from ( medians ) 0.03 - 3.6 mg/100 g with corresponding oxidation rates of phytosterols ( ORP ) of 0.03 - 0.06% . In fat - based foods with 8% of added free plant sterols ( FPS ) , plant", "of phytosterols ( ORP ) of 0.03 - 0.06% . In fat - based foods with 8% of added free plant sterols ( FPS ) , plant sterol esters ( PSE ) or plant stanol esters ( PAE ) pan - fried at 160 - 200°C", "with liver disease are reviewed . In addition , clinical studies of lipid / phytosterol reduction for reversing and/or preventing parenteral nutrition associated liver disease are", "At 30 - 32 d , the groups fed the high phytosterol oils had greater levels of phytosterols and significantly ( P<0.05 ) higher ratios of phytosterols / cholesterol in plasma , RBC , liver and kidney , and a significantly ( P<0.05 ) lower RBC membrane deformabilty index than the groups fed oils low in phytosterols ( SO , OO and CFM ) .", "With the increasing consumption of cosmetics , a rising use and hence dermal absorption of phytosterols is expected .", "Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products (POP).", "Phytosterols are plant-derived sterols that are structurally and functionally analogous to cholesterol in vertebrate animals.", "routine parenteral nutrition with vegetable oil - based lipid emulsions . BACKGROUND Phytosterols in vegetable oil ( VO)-based lipid emulsions ( LE ) likely contribute to parenteral nutrition -", "Six-week-old male SHRSP were fed a test diet prepared by the addition of canola oil (CA diet), soybean oil (SO diet), soybean oil plus 0.6% phytosterol (SO + 0.06P diet) or soybean oil plus 4.5% phytosterol (SO + 0.45P diet) as a 10% fat source.", "Additionally, the method was shown to perform well in liquid samples low in phytosterols such as concentrate-based juices, soft drinks and beers (<5 μg per 100 mL).", "Systolic blood pressure (SBP) increased in the SO + 0.06P and SO + 0.45P groups compared with the SO group and the increase was dependent on the amount of phytosterol added, indicating that the addition of phytosterol to soybean oil may promote an increase in SBP in salt-loaded SHRSP.", "To assess the effect of dietary phytosterol on stroke and the lifespan of salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP), we investigated the effects of the addition of phytosterol to soybean oil (phytosterol content: 0.3%) on stroke onset, lifespan following onset of stroke and overall lifespan compared with canola oil (phytosterol content: 0.9%).", "In conclusion , the addition of phytosterol to soybean oil elevated SBP and promoted the onset of stroke , which may cause a reduction in survival time .", "0 g and 0.02 - 0.10 mg per 100 g. This method allowed quantification of all main , free phytosterols in different grains ( oats , barley , corn , malt ) and it was shown that the method can be used", "added and the food matrix are determinants of POP formation in foods with added phytosterols , leading to an increase in POP contents . Practical applications : Phytosterol oxidation products", "In this study , phytosterols dispersed in milk fat at a level of 0.3 or 0.6% were homogenized with an aqueous dispersion of whey protein isolate ( WPI ) .", "as a carrier for phytosterols , but there is limited knowledge on the effect of added plant sterols on the properties of the system . In this study , phytosterols dispersed in milk fat at a level of", "sterols and 47.7 mg / d for fat - based products with added plant sterol esters . Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products ( POP ) . This review", "These differences were attributed to the formation of separate phytosterol crystals within the emulsions at the high phytosterol concentration , as characterized by Synchrotron X - ray measurements .", ") of 0.03 - 0.06% . In fat - based foods with 8% of added free plant sterols ( FPS ) , plant sterol esters ( PSE ) or plant stanol esters ( PAE ) pan - fried at 160 - 200°C for 5 - 10 min , median", "1To evaluate the content of phytosterol oxidation products ( POP ) of foods with added phytosterols , in total 14 studies measuring POP contents of foods with added phytosterols were systematically", "As nature has selected and conserved a mechanism to exclude phytosterols from dietary intake, we deem that the amount and effects of transdermal penetration of phytosterols should be seriously evaluated.", "are structurally and functionally analogous to cholesterol in vertebrate animals . Phytosterols are found in many foods and are part of the normal human diet . However , absorption of", ", STIGM and SITO was 13.5 ± 6.9 , 10.3 ± 4.5 and 10.3 ± 4.0 days , respectively . Plasma phytosterol half - lives did not correlate with gestational age , birth weight , cumulative phytosterol", "calorimetry ( DSC ) and Synchrotron X - ray scattering at both small and wide angles . Phytosterol enrichment influenced the particle size and physical appearance of the emulsion droplets , but did", "The aim of this study was to determine, in the absence of excess dietary salt, the individual effects of excess accumulation of dietary phytosterols and phytostanols on blood pressure in Wistar Kyoto (WKY) inbred rats that have a mutation in the Abcg5 gene and thus over absorb phytosterols and phytostanols.", "In patients with sitosterolaemia, who have elevated levels of plant sterols due to increased intestinal absorption and reduced biliary secretion of neutral sterols (Berge, 2003), the principal oxyphytosterols are 5a,6a-epoxysitostanol, 3b,5a,6b-sitostanetriol, 7-ketositosterol and 7b-hydroxysitosterol (Plat et al.", "Two possibilities have been suggested for the presence of oxyphytosterols in plasma : absorption of oxidized sterols present in food and ‘ in vivo’ oxidation of phytosterols in plasma .", "peas . Additionally , the method was shown to perform well in liquid samples low in phytosterols such as concentrate - based juices , soft drinks and beers ( < 5 μg per 100 mL ) . Graphical", "The total phytosterol removal rate was linear for the first six days before re - spiking , with a rate of 0.47 mg / L - d ( R(2 ) = 0.998 ) .", "The significant decrease in the intestinal mRNA expression of Abcg5 and Abcg8 in SHRSP may be responsible, at least in part, for the unfavourable effects observed following the addition of phytosterol.", "Oxyphytosterols are oxidized derivatives of phytosterols that have toxicity comparable to oxysterols ( Adcox et al .", "three separate conditions : with phytosterols as the sole added carbon source , with phytosterols and dextrin as an additional carbon source , and with phytosterols added with ethanol as an", "Human studies of the association of phytosterols with liver disease are reviewed.", "added with ethanol as an additional carbon source and solubilizing agent . Significant phytosterol removal was not observed in assays set up with phytosterol powder , either with or without an", "lower plasma total CAMP , STIGM and SITO concentrations . The decay of plasma phytosterol concentrations was monoexponential . Half - life of plasma total CAMP , STIGM and SITO was 13.5 ± 6", "Half-life of plasma phytosterols in very low birth weight preterm infants on routine parenteral nutrition with vegetable oil-based lipid emulsions.", ", and Liver Disease During Parenteral Nutrition . Phytosterols are plant - derived sterols that are structurally and functionally analogous to cholesterol in vertebrate animals .", "exposed to heat treatment . This review summarising POP contents in foods with added phytosterols in their free and esterified forms reveals that heating temperature and time , the chemical form", "administration occurs during intravenous administration of lipid . Levels of phytosterols in the blood and tissues may reach high levels during parenteral lipid administration and may be", "found in many foods and are part of the normal human diet . However , absorption of phytosterols from the diet is minimal . Most lipid emulsions used for parenteral nutrition are based on", "This review summarizes literature data regarding POP contents of foods with added phytosterols that were exposed to storage and heat treatments .", "Biotransformation of phytosterols under aerobic conditions.", "and as signal transducers . Over the last few decades , scientific interest in phytosterols has significantly increased . Most of the interest has focused on the cholesterol - lowering", "Accumulating scientific evidence suggests that administration of high doses of intravenous lipids that are high in phytosterols contributes to the development of parenteral nutrition - associated liver disease .", "Thus , under the experimental conditions of this study , the bioavailability of phytosterols was limited without the presence of a solubilizing agent .", "However, absorption of phytosterols from the diet is minimal.", "of phytosterols under aerobic conditions . Phytosterols are plant - derived sterols present in pulp and paper wastewater and have been implicated in the endocrine disruption of", "Oil - in - Water Milk Fat Emulsions . Milk has been used commercially as a carrier for phytosterols , but there is limited knowledge on the effect of added plant sterols on the properties of the", "The life span of SHRSP rats fed the high phytosterol oils (CA, CA + P, SO + P and CO) was significantly (P<0.05) shorter than that of CFM- and SO-fed rats.", ") . This review summarizes literature data regarding POP contents of foods with added phytosterols that were exposed to storage and heat treatments .", "Phytosterols are not fully metabolized by the human body and must be excreted through the hepatobiliary system .", "Estimated daily upper POP intake was 47.7 mg / d ( equivalent to 0.69 mg / kg BW / d ) for foods with added PSE and 78.3 mg / d ( equivalent to 1.12 mg / kg BW / d ) for foods with added FPS as calculated by multiplying the advised upper daily phytosterol intake of 3 g / d with the 90% quantile values of ORP .", "The phytosterol diet decreased cholesterol levels by 40%, 31%, and 19% in liver, aorta and kidney, respectively (P < 0.05).", "paper wastewater treatment system was examined under three separate conditions : with phytosterols as the sole added carbon source , with phytosterols and dextrin as an additional carbon source ,", "in longitudinal packing and system disorder . Understanding the consequences of adding phytosterols , on the physical and crystalline behavior of emulsions may enable the functional food industry to", "( β-sitosterol , stigmasterol and campesterol ) . The aerobic biotransformation of the phytosterol mixture by a mixed culture developed from a pulp and paper wastewater treatment system was", "The estimated upper daily intakes of POP is 78.3 mg/d for fat-based products with added free plant sterols and 47.7 mg/d for fat-based products with added plant sterol esters.", "Fractional factorial design - based optimisation and application of an extraction and UPLC - MS / MS detection method for the quantification of phytosterols in food , feed and beverages low in phytosterols .", "Phytosterols are common components of plant foods , especially vegetable oils , seeds , nuts and cereals .", "In contrast, all three phytosterols were aerobically degraded when added as a dissolved solution in ethanol.", "After the second spiking, the total phytosterol removal rate was linear for seven days, with a rate of 0.32 mg/L-d (R(2) = 0.968).", "As a result, phytosterol administration occurs during intravenous administration of lipid.", "Plasma phytosterol half-lives did not correlate with gestational age, birth weight, cumulative phytosterol intakes and plasma conjugated bilirubin.", "X - ray measurements . X - ray scattering patterns demonstrated the ability of the phytosterol to integrate within the milk fat triacylglycerol matrix , with a concomitant increase in", "Over the last few decades , scientific interest in phytosterols has significantly increased .", "phytosterols may cause cholestasis are discussed . Human studies of the association of phytosterols with liver disease are reviewed . In addition , clinical studies of lipid / phytosterol reduction", "Understanding the consequences of adding phytosterols , on the physical and crystalline behavior of emulsions may enable the functional food industry to design more physically and chemically stable products .", "( 2004b ) observe that sitostanetriol is not formed ‘ in vivo’ from sitosterol in rats fed a high level of phytosterols , and they conclude that the oxidation of phytosterols in plasma is not probable .", "Male, 35-d-old SHRSP rats (n = 28/group) were fed semipurified diets containing CA, SO, CA fortified with phytosterols (canola oil + phytosterols, CA + P), SO fortified with phytosterols (soybean oil + phytosterols, SO + P), corn oil (CO), olive oil (OO) or a fat blend that mimicked the fat composition of a representative Canadian diet (Canadian fat mimic, CFM; 10 g/100 g diet).", "of an extraction and UPLC - MS / MS detection method for the quantification of phytosterols in food , feed and beverages low in phytosterols . Phytosterols are ubiquitous in plants , as they", "Despite this dual interest in phytosterols , accurate and fully validated methods for the quantification of phytosterols in food and feed samples are scarce .", "/or solubilizing agent on the aerobic biotransformation of a mixture of three common phytosterols ( β-sitosterol , stigmasterol and campesterol ) . The aerobic biotransformation of the phytosterol", "Significant phytosterol removal was not observed in assays set up with phytosterol powder, either with or without an additional carbon source.", ", and stigmasterol ( STIGM ) . Plasma phytosterol half - lives were calculated from the phytosterol concentrations - decay curves by using a single - compartment model . RESULTS After the stop of", "Dietary phytosterols and phytostanols decrease cholesterol levels but increase blood pressure in WKY inbred rats in the absence of salt - loading BACKGROUND There are safety concerns regarding widespread consumption of phytosterol and phytostanol supplemented food products .", "It is generally assumed that all serum and tissue phytosterols are derived exclusively by intestinal absorption and therefore that serum levels of phytosterols reflect dietary plant sterol intake and intestinal absorption (Miettinen et al.", "The phytostanol diet also decreased phytosterol levels by 29% to 54% in plasma and tissues ( P < 0.05 ) .", "degraded , as compared to stigmasterol and campesterol , although all three phytosterols fell below detection limits by the 24th day of incubation .", "agent . Significant phytosterol removal was not observed in assays set up with phytosterol powder , either with or without an additional carbon source . In contrast , all three phytosterols", "METHODS Thirty 35-day old male WKY inbred rats (10/group) were fed a control diet or a diet containing phytosterols or phytostanols (2.0 g/kg diet) for 5 weeks.", "with a rate of 0.47 mg / L - d ( R(2 ) = 0.998 ) . After the second spiking , the total phytosterol removal rate was linear for seven days , with a rate of 0.32 mg / L - d ( R(2 ) = 0.968 ) .", "of phytosterols was limited without the presence of a solubilizing agent . The total phytosterol removal rate was linear for the first six days before re - spiking , with a rate of 0.47 mg / L -", "Consequently, the SO + 0.45P and CA groups showed marked lifespan shortening, indicating that a fivefold greater amount of phytosterol was required to produce an effect equivalent to that of canola oil.", "This study was performed to determine whether the high concentration of phytosterols in CA might account for its life-shortening effect on SHRSP rats.", "CONCLUSION These data suggest that excessive accumulation of dietary phytosterols and phytostanols in plasma and tissues may contribute to the increased blood pressure in WKY inbred rats in the absence of excess dietary salt .", "The mean survival times were correlated with RBC deformability index ( r(2 ) = 0.91 , P = 0.0033 ) and cholesterol concentration ( r(2 ) = 0.94 , P = 0.0016 ) , and inversely correlated with RBC phytosterol concentration ( r(2 ) = 0.58 , P = 0.0798 ) and phytosterols / cholesterol ( r(2 ) = 0.65 , P = 0.0579 ) , except in the OO group .", "powder , either with or without an additional carbon source . In contrast , all three phytosterols were aerobically degraded when added as a dissolved solution in ethanol . Thus , under the", "added phytosterols , in total 14 studies measuring POP contents of foods with added phytosterols were systematically reviewed . In non - heated or stored foods , POP contents were low , ranging", "the quantification of phytosterols in food , feed and beverages low in phytosterols . Phytosterols are ubiquitous in plants , as they play an important role in cell membrane stability and as signal", "upper daily intakes of POP is 78.3 mg / d for fat - based products with added free plant sterols and 47.7 mg / d for fat - based products with added plant sterol esters . Phytosterols in foods", "Therefore , even though phytosterols and phytostanols lower cholesterol levels , prospective clinical studies testing the net beneficial effects of dietary phytosterols and phytostanols on cardiovascular events for subgroups of individuals that have an increased incorporation of these substances are needed .", "In this review , mechanisms by which lipids and phytosterols may cause cholestasis are discussed .", "Rats that consumed the phytosterol or phytostanol diets displayed significant increases in systolic and diastolic blood pressure compared to rats that consumed the control diet ( P < 0.05 ) .", "In conclusion, heating temperature and time, chemical form of phytosterols added and the food matrix are determinants of POP formation in foods with added phytosterols, leading to an increase in POP contents.", "The phytosterol diet increased renal angiotensinogen mRNA levels of these rats.", "addition , crystallization of milk fat was delayed , whereas , at the lower level , phytosterol enrichment induced nucleation and emulsion crystallization . These differences were attributed to", "to the formation of separate phytosterol crystals within the emulsions at the high phytosterol concentration , as characterized by Synchrotron X - ray measurements . X - ray scattering patterns", "BACKGROUND Phytosterols in vegetable oil ( VO)-based lipid emulsions ( LE ) likely contribute to parenteral nutrition - associated cholestasis ( PNAC ) in preterm infants .", "The aerobic biotransformation of the phytosterol mixture by a mixed culture developed from a pulp and paper wastewater treatment system was examined under three separate conditions : with phytosterols as the sole added carbon source , with phytosterols and dextrin as an additional carbon source , and with phytosterols added with ethanol as an additional carbon source and solubilizing agent .", "This review summarising POP contents in foods with added phytosterols in their free and esterified forms reveals that heating temperature and time, the chemical form of phytosterols added and the food matrix itself are determinants of POP formation with heating temperature and time having the biggest impact.", "in phytosterols , accurate and fully validated methods for the quantification of phytosterols in food and feed samples are scarce . During this study an extraction and detection method for the", "and estimation of their daily intake : A literature review 1To evaluate the content of phytosterol oxidation products ( POP ) of foods with added phytosterols , in total 14 studies measuring POP", "Both the phytosterol and phytostanol diets produced significant decreases in the ratios of cholesterol to phytosterols and phytostanols in plasma , red blood cells , liver , aorta and kidney .", "half - lives did not correlate with gestational age , birth weight , cumulative phytosterol intakes and plasma conjugated bilirubin . CONCLUSION VLBW preterm infants on PN with LE had rather", "Phytosterols are found in many foods and are part of the normal human diet.", "contain a considerable quantity of phytosterols , from natural ingredients that often are not assessed for safety by the Cosmetic Ingredient Review board and that are considered safe on the basis of oral studies ( Anon . , 2004 ) .", "Phytosterol enrichment influenced the particle size and physical appearance of the emulsion droplets , but did not affect the stability or charge of the dispersed particles .", "Once they reach systemic circulation, skin-penetrated phytosterols and/or their metabolites enter a pool with dietary absorbed phytosterols and follow the same metabolic destiny.", ". Thus , under the experimental conditions of this study , the bioavailability of phytosterols was limited without the presence of a solubilizing agent . The total phytosterol removal rate was", "The limits of detection ( LODs ) and lower limits of quantification ( LLOQs ) in grain matrices were as low as 0.01 - 0.03 mg per 100 g and 0.02 - 0.10 mg per 100 g. This method allowed quantification of all main , free phytosterols in different grains ( oats , barley , corn , malt ) and it was shown that the method can be used for other solid food and feed samples as well , including new matrices such as straw , hay , mustard seeds , grass and yellow peas .", "added phytosterols , leading to an increase in POP contents . Practical applications : Phytosterol oxidation products ( POP ) are formed in foods containing phytosterols especially when exposed to", "days , with a rate of 0.32 mg / L - d ( R(2 ) = 0.968 ) . Following the 7th day , the phytosterol removal rate markedly accelerated , suggesting two different mechanisms are involved in", "Practical applications : Phytosterol oxidation products ( POP ) are formed in foods containing phytosterols especially when exposed to heat treatment .", "Phytosterol additives increase blood pressure and promote stroke onset in salt-loaded stroke-prone spontaneously hypertensive rats. 1.", "added plant sterol esters . Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products ( POP ) . This review summarizes literature data regarding POP contents of", "Milk has been used commercially as a carrier for phytosterols, but there is limited knowledge on the effect of added plant sterols on the properties of the system.", "method for the quantification of phytosterols in food , feed and beverages low in phytosterols . Phytosterols are ubiquitous in plants , as they play an important role in cell membrane", "- associated cholestasis ( PNAC ) in preterm infants . No characterization of plasma phytosterol half - lives has been done in very low birth weight ( VLBW ) preterm infants receiving parenteral", "X-ray scattering patterns demonstrated the ability of the phytosterol to integrate within the milk fat triacylglycerol matrix, with a concomitant increase in longitudinal packing and system disorder.", "crystallization . These differences were attributed to the formation of separate phytosterol crystals within the emulsions at the high phytosterol concentration , as characterized by", "Oxyphytosterols in healthy subjects could derive from the oxidation catalysed by UV light of skin phytosterols absorbed from cosmetic products .", "Bioassays were performed to assess the effect of an additional carbon source and/or solubilizing agent on the aerobic biotransformation of a mixture of three common phytosterols (β-sitosterol, stigmasterol and campesterol).", "Plasma phytosterol half - lives were calculated from the phytosterol concentrations - decay curves by using a single - compartment model .", "Vegetable oils high in phytosterols make erythrocytes less deformable and shorten the life span of stroke - prone spontaneously hypertensive rats .", "reach high levels during parenteral lipid administration and may be toxic to cells . Phytosterols are not fully metabolized by the human body and must be excreted through the hepatobiliary system .", "BW / d ) for foods with added FPS as calculated by multiplying the advised upper daily phytosterol intake of 3 g / d with the 90% quantile values of ORP . In conclusion , heating temperature and", "In addition, clinical studies of lipid/phytosterol reduction for reversing and/or preventing parenteral nutrition associated liver disease are discussed.", "values of ORP . In conclusion , heating temperature and time , chemical form of phytosterols added and the food matrix are determinants of POP formation in foods with added phytosterols ,", "of sitosterol ( SITO ) , campesterol ( CAMP ) , and stigmasterol ( STIGM ) . Plasma phytosterol half - lives were calculated from the phytosterol concentrations - decay curves by using a single -", "Effect of Phytosterols on the Crystallization Behavior of Oil - in - Water Milk Fat Emulsions .", "Phytosterols, Lipid Administration, and Liver Disease During Parenteral Nutrition.", "We speculate that the accumulation of phytosterols could contribute to their vulnerability to PNAC.", "The decay of plasma phytosterol concentrations was monoexponential.", "In non - heated or stored foods , POP contents were low , ranging from ( medians ) 0.03 - 3.6 mg/100 g with corresponding oxidation rates of phytosterols ( ORP ) of 0.03 - 0.06% ."], "par_relations": ["Sterols", "Phytochemicals"], "chd_relations": ["Sitosterols", "Stigmasterol", "Ecdysteroids", "Withanolides", "Brassinosteroids", "25-azacycloartanol", "25-azacycloartenol", "antheridiol", "brassicasterol", "campesterol", "cycloartenol", "cyclolaudenol", "cycloleucalenol", "phytoecdysones", "piascledine", "soysterol", "cycloartenol ferulic acid ester", "anguivine", "isoanguivine", "3-amino-5-spirosolene", "3-aminospirosolane", "Sitosterolemia", "IDS 89 Sabal serrulata extract", "29-methylisofucosterol", "campestanol", "cerevisterol", "itesmol", "4-alpha-methyl-5-alpha-cholesta-8,22-dien-3-beta-ol", "24-methylenepollinastanol", "lichesterol", "5 alpha-ergostane-3 beta,5,6 beta,7 beta-tetrol", "roxburghiadiol A", "24-methylene cycloartanol", "khasianine", "dietary supplement, SPORT", "RICOM-1013-J", "6-oxocampestanol", "6-deoxacastasterone", "dihydrobrasicasterol", "cabraleadiol monoacetate", "cyclolaudenyl formate", "tillandsinone", "3-O-(4-feruloyl)campestanol", "FM-VP4 compound", "cyclolaudenone", "pubamide", "9-hydroxycerevisterol", "29-norcycloartenol", "cyanosterone A", "methyl gardenolate A", "2-deoxyintegristerone A", "(20R,24R)-24,25-epxy-15-alpha-hydroxy-3-beta-(bet-D-xylpyranosyoxy)-9,19-cyclanost-7-ene-16,23-dione", "(20R,24R)-24,25-epoxy-3-beta-(beta-D-xylopyranosyloxy)-9,19-cyclolanost-7-ene-16,23-dione", "tetranor-cycloartane glycoside", "3beta,7beta,24beta,25,30-pentahydroxycycloartane-3-omicron-beta-D-glucopyranoside-24-omicron-beta-D-glucopyranoside", "dolichosterone", "spirosolan-3-ol", "spirosol-5-en-3-yl acetate", "16-29-dihydroxy, 20-ene cyclolaudenol", "beta-dauosterol", "cyclobranol", "leucisterol", "3-O-(13-hydroxy-9Z,11E,15E-octadecatrienoyl) cycloeucalenol", "polygonoide A", "polygonoide B", "26-O-beta-D-glucopyranosyl-(25R)-5 alpha-furostan-12-one-3beta,22 alpha,26-triol-3-O-beta-D-glucopyranosyl (1-2)-beta-D-glucopyranosyl(1-4)-beta-D-galactopyranoside", "26-O-beta-D-glucopyranosyl-(25S)-5 alpha-furostan-22-methoxy-2 alpha,3beta,26-triol-3-O-beta-D-glucopyranosyl(1-2)-beta-D-glucopyranosyl(1-4)-beta-D-galactopyranoside", "veramitaline", "veranigrine", "lygodiumsteroside A", "ponasteroside A", "qinyangshengenin-3-O-beta-D-oleandropyranosyl-(1-4)-beta-D-cymaropyranosyl-(1-4)-beta-D-digitoxopyranoside", "rostratamine-3-O-beta-D-oleandropyranosyl-(1-4)-beta-D-cymaropyranosyl-(1-4)-beta-D-cymaropyranoside", "qinyangshengenin-3-O-beta-D-cymaropyranosyl-(1-4)-beta-D-digitoxo-pyranoside", "3-keto-28-norcathasterone", "hesperidine methylchalcone, ruscus aculeatus, vitamin C", "qinyangshengenin-3-O-beta-D-oleandropyranosyl-(1-4)-beta-D-oleandropyranosyl-(1-4)-beta-D-cymaropyranoside", "qinyangshengenin-3-O-beta-D-oleandropyranosyl-(1-4)-beta-D-cymaropyranoside", "ophiopogonin H", "ophiopogonin I", "alkesterol A", "alkesterol B", "Poly-2p cream", "23R,24S-chiograsterol B", "bethoside C", "bethoside B", "(25S)-20,22-O-(R-ethylidene)inokosterone", "20,22-O-(R-3-methoxycarbonyl)propylidene-20-hydroxyecdysone", "sarsaparilloside B", "sarsaparilloside C", "24,25,26,27-tetranor-apotirucalla-(apoeupha)-1-senecioyloxy-3,7-dihydroxy-14,20,22-trien-21,23-epoxy", "chonglouoside SL-7", "chonglouoside SL-8", "2,3-acetonide-24-hydroxyecdysone", "11-hydroxy-20-deoxyshidasterone", "21-hydroxyshidasterone", "ophiopogonin K", "ophiopogonin J", "turranin A", "tenacissoside C", "4-carboxy-4-methyl-24-methylenecycloartanol", "furostan-3,22,26-triol", "quadrangularic acid M", "nymphayol", "ponasteroside D", "ponasteroside C"], "syn_relations": ["Phytosterols", "Phytosterols", "Phytosterols", "Phytosterols", "Phytosterols", "Phytosterols", "Phytosterols", "Phytosterols"], "sib_relations": ["Adosterol", "Cholecalciferol", "Cholesterol", "Ergocalciferols", "Fusidic Acid", "Lanosterol", "Solanine"], "wiki_entities": ["Phytosterol", "Sterol", "Stigmasterol", "Campesterol", "Sterol ester", "Bioactive compound", "Beta-Sitosterol", "Cycloartenol", "Lipid-lowering agent", "Cholesterol"], "mesh_synonynms": ["plant steroid", "phytosterol", "phytosteroids", "plant steroids", "steroids, plant", "phytosterols", "plant sterols", "sterols, plant", "steroid, plant", "phytoteroid", "plant sterol", "sterol, plant"], "dbpedia_synonyms": ["plant sterol", "phytosterol", "plant sterols", "phytosterols"]}, "target_ent": {"research_entity_id": "RXNORM:8310", "canonical_name": "Phytosterols", "aliases": ["phytosterols"], "definition": "Phytosterols, which encompass plant sterols and stanols, are phytosteroids, similar to cholesterol, which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.", "other_contexts": ["The physico - chemical properties of phytosterols are ideal for penetration into deeper skin layers owing to their affinity with lipids of cellular membranes ( Sekiya et al .", "Phytosterol oxidation products ( POP ) in foods with added phytosterols and estimation of their daily intake : A literature review 1To evaluate the content of phytosterol oxidation products ( POP ) of foods with added phytosterols , in total 14 studies measuring POP contents of foods with added phytosterols were systematically reviewed .", "and esterified forms reveals that heating temperature and time , the chemical form of phytosterols added and the food matrix itself are determinants of POP formation with heating temperature and", "and phytosterolemic homozygotes patients . We speculate that the accumulation of phytosterols could contribute to their vulnerability to PNAC . CLINICAL TRIAL REGISTRY The Ethics Committee of", "1997; Marjukka Suhonen et al. 1999) and phytosterols and/or their metabolites can reach the systemic circulation as occurs for steroid hormones in transdermal delivery.", "During this study an extraction and detection method for the main free phytosterols ( β-sitosterol , campesterol , stigmasterol and brassicasterol ) was optimised using a fractional factorial design .", "Significant phytosterol removal was not observed in assays set up with phytosterol powder , either with or without an additional carbon source .", "β-sitosterol was preferentially degraded, as compared to stigmasterol and campesterol, although all three phytosterols fell below detection limits by the 24th day of incubation.", "Phytosterols are plant-derived sterols present in pulp and paper wastewater and have been implicated in the endocrine disruption of aquatic species.", "We suggest that there is another route of intake of phytosterols which has not yet been considered: dermal absorption from cosmetics.", "applications : Phytosterol oxidation products ( POP ) are formed in foods containing phytosterols especially when exposed to heat treatment . This review summarising POP contents in foods with", "Bioassays were performed to assess the effect of an additional carbon source and/or solubilizing agent on the aerobic biotransformation of a mixture of three common phytosterols ( β-sitosterol , stigmasterol and campesterol ) .", "Graphical Abstract An extraction and detection method for the main free phytosterols (β-sitosterol, campesterol, stigmasterol and brassicasterol) was optimised using a fractional factorial design.", "emulsions used for parenteral nutrition are based on vegetable oils . As a result , phytosterol administration occurs during intravenous administration of lipid . Levels of phytosterols in the", "Serum phytosterols not only from dietary intake.", "In fat-based foods with 8% of added free plant sterols (FPS), plant sterol esters (PSE) or plant stanol esters (PAE) pan-fried at 160-200°C for 5-10 min, median POP contents were 72.0, 38.1, and 4.9 mg/100 g, respectively, with a median ORP of 0.90, 0.48, and 0.06%.", "However , absorption of phytosterols from the diet is minimal .", "are scarce . During this study an extraction and detection method for the main free phytosterols ( β-sitosterol , campesterol , stigmasterol and brassicasterol ) was optimised using a fractional", "bilirubin . CONCLUSION VLBW preterm infants on PN with LE had rather long plasma phytosterol half - lives similar to hypercholesterolemic adults and phytosterolemic homozygotes patients . We", "Estimated daily upper POP intake was 47.7 mg/d (equivalent to 0.69 mg/kg BW/d) for foods with added PSE and 78.3 mg/d (equivalent to 1.12 mg/kg BW/d) for foods with added FPS as calculated by multiplying the advised upper daily phytosterol intake of 3 g/d with the 90% quantile values of ORP.", "on the effect of added plant sterols on the properties of the system . In this study , phytosterols dispersed in milk fat at a level of 0.3 or 0.6% were homogenized with an aqueous dispersion of", "charge of the dispersed particles . DSC data demonstrated that , at the higher level of phytosterol addition , crystallization of milk fat was delayed , whereas , at the lower level , phytosterol", "nutrition - associated liver disease . In this review , mechanisms by which lipids and phytosterols may cause cholestasis are discussed . Human studies of the association of phytosterols with liver", "per 100 mL ) . Graphical Abstract An extraction and detection method for the main free phytosterols ( β-sitosterol , campesterol , stigmasterol and brassicasterol ) was optimised using a fractional", "Phytosterols, abundant in CA but not in SO, can inhibit the absorption of cholesterol and also replace a part of cholesterol in cell membranes.", "DSC data demonstrated that, at the higher level of phytosterol addition, crystallization of milk fat was delayed, whereas, at the lower level, phytosterol enrichment induced nucleation and emulsion crystallization.", "Investigation of the mRNA expression of ATP-binding cassette (ABC) transporters involved in intestinal phytosterol absorption indicated significant decreases in the intestinal mRNA expression of Abcg5 and Abcg8 in SHRSP and Wistar-Kyoto rats compared with Wistar rats.", "interfere with endogenous steroid hormone synthesis . Despite this dual interest in phytosterols , accurate and fully validated methods for the quantification of phytosterols in food and feed", "No characterization of plasma phytosterol half - lives has been done in very low birth weight ( VLBW ) preterm infants receiving parenteral nutrition ( PN ) with LE .", ". Most of the interest has focused on the cholesterol - lowering properties of phytosterols , but they may also interfere with endogenous steroid hormone synthesis . Despite this dual", "source , with phytosterols and dextrin as an additional carbon source , and with phytosterols added with ethanol as an additional carbon source and solubilizing agent . Significant phytosterol", "Human studies of the association of phytosterols with liver disease are reviewed .", "This study suggests that the high concentration of phytosterols in CA and the addition of phytosterols to other fats make the cell membrane more rigid , which might be a factor contributing to the shortened life span of SHRSP rats .", "removal rate markedly accelerated , suggesting two different mechanisms are involved in phytosterol biotransformation , more likely related to the production of enzyme(s ) involved in phytosterol", "Systolic blood pressure ( SBP ) increased in the SO + 0.06P and SO + 0.45P groups compared with the SO group and the increase was dependent on the amount of phytosterol added , indicating that the addition of phytosterol to soybean oil may promote an increase in SBP in salt - loaded SHRSP .", "CONCLUSION VLBW preterm infants on PN with LE had rather long plasma phytosterol half - lives similar to hypercholesterolemic adults and phytosterolemic homozygotes patients .", "suggests that administration of high doses of intravenous lipids that are high in phytosterols contributes to the development of parenteral nutrition - associated liver disease . In this review", "with added free plant sterols and 47.7 mg / d for fat - based products with added plant sterol esters . Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products", "Once they reach systemic circulation , skin - penetrated phytosterols and/or their metabolites enter a pool with dietary absorbed phytosterols and follow the same metabolic destiny .", "biotransformation , more likely related to the production of enzyme(s ) involved in phytosterol degradation , induced under different cell growth conditions . β-sitosterol was preferentially", "of phytosterols ( ORP ) of 0.03 - 0.06% . In fat - based foods with 8% of added free plant sterols ( FPS ) , plant sterol esters ( PSE ) or plant stanol esters ( PAE ) pan - fried at 160 - 200°C", ", ranging from ( medians ) 0.03 - 3.6 mg/100 g with corresponding oxidation rates of phytosterols ( ORP ) of 0.03 - 0.06% . In fat - based foods with 8% of added free plant sterols ( FPS ) , plant", "At 30 - 32 d , the groups fed the high phytosterol oils had greater levels of phytosterols and significantly ( P<0.05 ) higher ratios of phytosterols / cholesterol in plasma , RBC , liver and kidney , and a significantly ( P<0.05 ) lower RBC membrane deformabilty index than the groups fed oils low in phytosterols ( SO , OO and CFM ) .", "with liver disease are reviewed . In addition , clinical studies of lipid / phytosterol reduction for reversing and/or preventing parenteral nutrition associated liver disease are", "CONCLUSION These data suggest that excessive accumulation of dietary phytosterols and phytostanols in plasma and tissues may contribute to the increased blood pressure in WKY inbred rats in the absence of excess dietary salt.", "As nature has selected and conserved a mechanism to exclude phytosterols from dietary intake , we deem that the amount and effects of transdermal penetration of phytosterols should be seriously evaluated .", "With the increasing consumption of cosmetics , a rising use and hence dermal absorption of phytosterols is expected .", "Phytosterols are plant-derived sterols that are structurally and functionally analogous to cholesterol in vertebrate animals.", "routine parenteral nutrition with vegetable oil - based lipid emulsions . BACKGROUND Phytosterols in vegetable oil ( VO)-based lipid emulsions ( LE ) likely contribute to parenteral nutrition -", "We speculate that the accumulation of phytosterols could contribute to their vulnerability to PNAC .", "Six-week-old male SHRSP were fed a test diet prepared by the addition of canola oil (CA diet), soybean oil (SO diet), soybean oil plus 0.6% phytosterol (SO + 0.06P diet) or soybean oil plus 4.5% phytosterol (SO + 0.45P diet) as a 10% fat source.", "Additionally, the method was shown to perform well in liquid samples low in phytosterols such as concentrate-based juices, soft drinks and beers (<5 μg per 100 mL).", "To assess the effect of dietary phytosterol on stroke and the lifespan of salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP), we investigated the effects of the addition of phytosterol to soybean oil (phytosterol content: 0.3%) on stroke onset, lifespan following onset of stroke and overall lifespan compared with canola oil (phytosterol content: 0.9%).", "However, a fivefold greater amount of phytosterol was required to produce an effect that was equivalent to the survival time-shortening effect of canola oil.", "In conclusion , the addition of phytosterol to soybean oil elevated SBP and promoted the onset of stroke , which may cause a reduction in survival time .", "0 g and 0.02 - 0.10 mg per 100 g. This method allowed quantification of all main , free phytosterols in different grains ( oats , barley , corn , malt ) and it was shown that the method can be used", "added and the food matrix are determinants of POP formation in foods with added phytosterols , leading to an increase in POP contents . Practical applications : Phytosterol oxidation products", "as a carrier for phytosterols , but there is limited knowledge on the effect of added plant sterols on the properties of the system . In this study , phytosterols dispersed in milk fat at a level of", "sterols and 47.7 mg / d for fat - based products with added plant sterol esters . Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products ( POP ) . This review", ") of 0.03 - 0.06% . In fat - based foods with 8% of added free plant sterols ( FPS ) , plant sterol esters ( PSE ) or plant stanol esters ( PAE ) pan - fried at 160 - 200°C for 5 - 10 min , median", "1To evaluate the content of phytosterol oxidation products ( POP ) of foods with added phytosterols , in total 14 studies measuring POP contents of foods with added phytosterols were systematically", "Oxyphytosterols are oxidized derivatives of phytosterols that have toxicity comparable to oxysterols (Adcox et al.", "are structurally and functionally analogous to cholesterol in vertebrate animals . Phytosterols are found in many foods and are part of the normal human diet . However , absorption of", ", STIGM and SITO was 13.5 ± 6.9 , 10.3 ± 4.5 and 10.3 ± 4.0 days , respectively . Plasma phytosterol half - lives did not correlate with gestational age , birth weight , cumulative phytosterol", "calorimetry ( DSC ) and Synchrotron X - ray scattering at both small and wide angles . Phytosterol enrichment influenced the particle size and physical appearance of the emulsion droplets , but did", "The aim of this study was to determine, in the absence of excess dietary salt, the individual effects of excess accumulation of dietary phytosterols and phytostanols on blood pressure in Wistar Kyoto (WKY) inbred rats that have a mutation in the Abcg5 gene and thus over absorb phytosterols and phytostanols.", "Following the 7th day, the phytosterol removal rate markedly accelerated, suggesting two different mechanisms are involved in phytosterol biotransformation, more likely related to the production of enzyme(s) involved in phytosterol degradation, induced under different cell growth conditions.", "X - ray scattering patterns demonstrated the ability of the phytosterol to integrate within the milk fat triacylglycerol matrix , with a concomitant increase in longitudinal packing and system disorder .", "METHODS Thirty 35-day old male WKY inbred rats ( 10/group ) were fed a control diet or a diet containing phytosterols or phytostanols ( 2.0 g / kg diet ) for 5 weeks .", "In patients with sitosterolaemia, who have elevated levels of plant sterols due to increased intestinal absorption and reduced biliary secretion of neutral sterols (Berge, 2003), the principal oxyphytosterols are 5a,6a-epoxysitostanol, 3b,5a,6b-sitostanetriol, 7-ketositosterol and 7b-hydroxysitosterol (Plat et al.", "Two possibilities have been suggested for the presence of oxyphytosterols in plasma: absorption of oxidized sterols present in food and ‘in vivo’ oxidation of phytosterols in plasma.", "peas . Additionally , the method was shown to perform well in liquid samples low in phytosterols such as concentrate - based juices , soft drinks and beers ( < 5 μg per 100 mL ) . Graphical", "In this review, mechanisms by which lipids and phytosterols may cause cholestasis are discussed.", "three separate conditions : with phytosterols as the sole added carbon source , with phytosterols and dextrin as an additional carbon source , and with phytosterols added with ethanol as an", "Biotransformation of phytosterols under aerobic conditions .", "Vegetable oils high in phytosterols make erythrocytes less deformable and shorten the life span of stroke-prone spontaneously hypertensive rats.", "added with ethanol as an additional carbon source and solubilizing agent . Significant phytosterol removal was not observed in assays set up with phytosterol powder , either with or without an", "lower plasma total CAMP , STIGM and SITO concentrations . The decay of plasma phytosterol concentrations was monoexponential . Half - life of plasma total CAMP , STIGM and SITO was 13.5 ± 6", "Half-life of plasma phytosterols in very low birth weight preterm infants on routine parenteral nutrition with vegetable oil-based lipid emulsions.", "Oxyphytosterols in healthy subjects could derive from the oxidation catalysed by UV light of skin phytosterols absorbed from cosmetic products.", ", and Liver Disease During Parenteral Nutrition . Phytosterols are plant - derived sterols that are structurally and functionally analogous to cholesterol in vertebrate animals .", "These differences were attributed to the formation of separate phytosterol crystals within the emulsions at the high phytosterol concentration, as characterized by Synchrotron X-ray measurements.", "exposed to heat treatment . This review summarising POP contents in foods with added phytosterols in their free and esterified forms reveals that heating temperature and time , the chemical form", "administration occurs during intravenous administration of lipid . Levels of phytosterols in the blood and tissues may reach high levels during parenteral lipid administration and may be", "found in many foods and are part of the normal human diet . However , absorption of phytosterols from the diet is minimal . Most lipid emulsions used for parenteral nutrition are based on", "Most of the interest has focused on the cholesterol - lowering properties of phytosterols , but they may also interfere with endogenous steroid hormone synthesis .", "This review summarizes literature data regarding POP contents of foods with added phytosterols that were exposed to storage and heat treatments .", "and as signal transducers . Over the last few decades , scientific interest in phytosterols has significantly increased . Most of the interest has focused on the cholesterol - lowering", "The significant decrease in the intestinal mRNA expression of Abcg5 and Abcg8 in SHRSP may be responsible , at least in part , for the unfavourable effects observed following the addition of phytosterol .", "Thus , under the experimental conditions of this study , the bioavailability of phytosterols was limited without the presence of a solubilizing agent .", "of phytosterols under aerobic conditions . Phytosterols are plant - derived sterols present in pulp and paper wastewater and have been implicated in the endocrine disruption of", "Oil - in - Water Milk Fat Emulsions . Milk has been used commercially as a carrier for phytosterols , but there is limited knowledge on the effect of added plant sterols on the properties of the", ") . This review summarizes literature data regarding POP contents of foods with added phytosterols that were exposed to storage and heat treatments .", "Phytosterols are ubiquitous in plants, as they play an important role in cell membrane stability and as signal transducers.", "Phytosterols are not fully metabolized by the human body and must be excreted through the hepatobiliary system .", "In conclusion , heating temperature and time , chemical form of phytosterols added and the food matrix are determinants of POP formation in foods with added phytosterols , leading to an increase in POP contents .", "The phytosterol diet decreased cholesterol levels by 40%, 31%, and 19% in liver, aorta and kidney, respectively (P < 0.05).", "paper wastewater treatment system was examined under three separate conditions : with phytosterols as the sole added carbon source , with phytosterols and dextrin as an additional carbon source ,", "in longitudinal packing and system disorder . Understanding the consequences of adding phytosterols , on the physical and crystalline behavior of emulsions may enable the functional food industry to", "( β-sitosterol , stigmasterol and campesterol ) . The aerobic biotransformation of the phytosterol mixture by a mixed culture developed from a pulp and paper wastewater treatment system was", "The estimated upper daily intakes of POP is 78.3 mg/d for fat-based products with added free plant sterols and 47.7 mg/d for fat-based products with added plant sterol esters.", "Fractional factorial design - based optimisation and application of an extraction and UPLC - MS / MS detection method for the quantification of phytosterols in food , feed and beverages low in phytosterols .", "In contrast, all three phytosterols were aerobically degraded when added as a dissolved solution in ethanol.", "As a result, phytosterol administration occurs during intravenous administration of lipid.", "Plasma phytosterol half-lives did not correlate with gestational age, birth weight, cumulative phytosterol intakes and plasma conjugated bilirubin.", "Over the last few decades , scientific interest in phytosterols has significantly increased .", "X - ray measurements . X - ray scattering patterns demonstrated the ability of the phytosterol to integrate within the milk fat triacylglycerol matrix , with a concomitant increase in", "phytosterols may cause cholestasis are discussed . Human studies of the association of phytosterols with liver disease are reviewed . In addition , clinical studies of lipid / phytosterol reduction", "( 2004b ) observe that sitostanetriol is not formed ‘ in vivo’ from sitosterol in rats fed a high level of phytosterols , and they conclude that the oxidation of phytosterols in plasma is not probable .", "of an extraction and UPLC - MS / MS detection method for the quantification of phytosterols in food , feed and beverages low in phytosterols . Phytosterols are ubiquitous in plants , as they", "/or solubilizing agent on the aerobic biotransformation of a mixture of three common phytosterols ( β-sitosterol , stigmasterol and campesterol ) . The aerobic biotransformation of the phytosterol", "Milk has been used commercially as a carrier for phytosterols , but there is limited knowledge on the effect of added plant sterols on the properties of the system .", ", and stigmasterol ( STIGM ) . Plasma phytosterol half - lives were calculated from the phytosterol concentrations - decay curves by using a single - compartment model . RESULTS After the stop of", "Dietary phytosterols and phytostanols decrease cholesterol levels but increase blood pressure in WKY inbred rats in the absence of salt - loading BACKGROUND There are safety concerns regarding widespread consumption of phytosterol and phytostanol supplemented food products .", "It is generally assumed that all serum and tissue phytosterols are derived exclusively by intestinal absorption and therefore that serum levels of phytosterols reflect dietary plant sterol intake and intestinal absorption (Miettinen et al.", "The phytostanol diet also decreased phytosterol levels by 29% to 54% in plasma and tissues ( P < 0.05 ) .", "RESULTS Compared to the control diet , the phytosterol diet resulted in 3- to 4-fold increases in the levels of phytosterols in plasma , red blood cells , liver , aorta and kidney of WKY inbred rats ( P < 0.05 ) .", "degraded , as compared to stigmasterol and campesterol , although all three phytosterols fell below detection limits by the 24th day of incubation .", "agent . Significant phytosterol removal was not observed in assays set up with phytosterol powder , either with or without an additional carbon source . In contrast , all three phytosterols", "The limits of detection (LODs) and lower limits of quantification (LLOQs) in grain matrices were as low as 0.01-0.03 mg per 100 g and 0.02-0.10 mg per 100 g. This method allowed quantification of all main, free phytosterols in different grains (oats, barley, corn, malt) and it was shown that the method can be used for other solid food and feed samples as well, including new matrices such as straw, hay, mustard seeds, grass and yellow peas.", "of phytosterols was limited without the presence of a solubilizing agent . The total phytosterol removal rate was linear for the first six days before re - spiking , with a rate of 0.47 mg / L -", "with a rate of 0.47 mg / L - d ( R(2 ) = 0.998 ) . After the second spiking , the total phytosterol removal rate was linear for seven days , with a rate of 0.32 mg / L - d ( R(2 ) = 0.968 ) .", "In non-heated or stored foods, POP contents were low, ranging from (medians) 0.03-3.6 mg/100 g with corresponding oxidation rates of phytosterols (ORP) of 0.03-0.06%.", "The life span of SHRSP rats fed the high phytosterol oils ( CA , CA + P , SO + P and CO ) was significantly ( P<0.05 ) shorter than that of CFM- and SO - fed rats .", "This study was performed to determine whether the high concentration of phytosterols in CA might account for its life-shortening effect on SHRSP rats.", "The mean survival times were correlated with RBC deformability index ( r(2 ) = 0.91 , P = 0.0033 ) and cholesterol concentration ( r(2 ) = 0.94 , P = 0.0016 ) , and inversely correlated with RBC phytosterol concentration ( r(2 ) = 0.58 , P = 0.0798 ) and phytosterols / cholesterol ( r(2 ) = 0.65 , P = 0.0579 ) , except in the OO group .", "powder , either with or without an additional carbon source . In contrast , all three phytosterols were aerobically degraded when added as a dissolved solution in ethanol . Thus , under the", "added phytosterols , in total 14 studies measuring POP contents of foods with added phytosterols were systematically reviewed . In non - heated or stored foods , POP contents were low , ranging", "the quantification of phytosterols in food , feed and beverages low in phytosterols . Phytosterols are ubiquitous in plants , as they play an important role in cell membrane stability and as signal", "upper daily intakes of POP is 78.3 mg / d for fat - based products with added free plant sterols and 47.7 mg / d for fat - based products with added plant sterol esters . Phytosterols in foods", "Therefore , even though phytosterols and phytostanols lower cholesterol levels , prospective clinical studies testing the net beneficial effects of dietary phytosterols and phytostanols on cardiovascular events for subgroups of individuals that have an increased incorporation of these substances are needed .", "Despite this dual interest in phytosterols, accurate and fully validated methods for the quantification of phytosterols in food and feed samples are scarce.", "In this study, phytosterols dispersed in milk fat at a level of 0.3 or 0.6% were homogenized with an aqueous dispersion of whey protein isolate (WPI).", "Levels of phytosterols in the blood and tissues may reach high levels during parenteral lipid administration and may be toxic to cells.", "After the second spiking , the total phytosterol removal rate was linear for seven days , with a rate of 0.32 mg / L - d ( R(2 ) = 0.968 ) .", "Rats that consumed the phytosterol or phytostanol diets displayed significant increases in systolic and diastolic blood pressure compared to rats that consumed the control diet ( P < 0.05 ) .", "The total phytosterol removal rate was linear for the first six days before re-spiking, with a rate of 0.47 mg/L-d (R(2) = 0.998).", "The phytosterol diet increased renal angiotensinogen mRNA levels of these rats.", "Male , 35-d - old SHRSP rats ( n = 28/group ) were fed semipurified diets containing CA , SO , CA fortified with phytosterols ( canola oil + phytosterols , CA + P ) , SO fortified with phytosterols ( soybean oil + phytosterols , SO + P ) , corn oil ( CO ) , olive oil ( OO ) or a fat blend that mimicked the fat composition of a representative Canadian diet ( Canadian fat mimic , CFM ; 10 g/100 g diet ) .", "addition , crystallization of milk fat was delayed , whereas , at the lower level , phytosterol enrichment induced nucleation and emulsion crystallization . These differences were attributed to", "Consequently , the SO + 0.45P and CA groups showed marked lifespan shortening , indicating that a fivefold greater amount of phytosterol was required to produce an effect equivalent to that of canola oil .", "BACKGROUND Phytosterols in vegetable oil ( VO)-based lipid emulsions ( LE ) likely contribute to parenteral nutrition - associated cholestasis ( PNAC ) in preterm infants .", "The aerobic biotransformation of the phytosterol mixture by a mixed culture developed from a pulp and paper wastewater treatment system was examined under three separate conditions : with phytosterols as the sole added carbon source , with phytosterols and dextrin as an additional carbon source , and with phytosterols added with ethanol as an additional carbon source and solubilizing agent .", "This review summarising POP contents in foods with added phytosterols in their free and esterified forms reveals that heating temperature and time, the chemical form of phytosterols added and the food matrix itself are determinants of POP formation with heating temperature and time having the biggest impact.", "to the formation of separate phytosterol crystals within the emulsions at the high phytosterol concentration , as characterized by Synchrotron X - ray measurements . X - ray scattering patterns", "Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products ( POP ) .", "in phytosterols , accurate and fully validated methods for the quantification of phytosterols in food and feed samples are scarce . During this study an extraction and detection method for the", "and estimation of their daily intake : A literature review 1To evaluate the content of phytosterol oxidation products ( POP ) of foods with added phytosterols , in total 14 studies measuring POP", "Both the phytosterol and phytostanol diets produced significant decreases in the ratios of cholesterol to phytosterols and phytostanols in plasma , red blood cells , liver , aorta and kidney .", "half - lives did not correlate with gestational age , birth weight , cumulative phytosterol intakes and plasma conjugated bilirubin . CONCLUSION VLBW preterm infants on PN with LE had rather", "contain a considerable quantity of phytosterols , from natural ingredients that often are not assessed for safety by the Cosmetic Ingredient Review board and that are considered safe on the basis of oral studies ( Anon . , 2004 ) .", "Phytosterols are found in many foods and are part of the normal human diet.", ". Thus , under the experimental conditions of this study , the bioavailability of phytosterols was limited without the presence of a solubilizing agent . The total phytosterol removal rate was", "added phytosterols , leading to an increase in POP contents . Practical applications : Phytosterol oxidation products ( POP ) are formed in foods containing phytosterols especially when exposed to", "days , with a rate of 0.32 mg / L - d ( R(2 ) = 0.968 ) . Following the 7th day , the phytosterol removal rate markedly accelerated , suggesting two different mechanisms are involved in", "Practical applications : Phytosterol oxidation products ( POP ) are formed in foods containing phytosterols especially when exposed to heat treatment .", "Phytosterol additives increase blood pressure and promote stroke onset in salt-loaded stroke-prone spontaneously hypertensive rats. 1.", "added plant sterol esters . Phytosterols in foods are susceptible to oxidation to form phytosterol oxidation products ( POP ) . This review summarizes literature data regarding POP contents of", "method for the quantification of phytosterols in food , feed and beverages low in phytosterols . Phytosterols are ubiquitous in plants , as they play an important role in cell membrane", "- associated cholestasis ( PNAC ) in preterm infants . No characterization of plasma phytosterol half - lives has been done in very low birth weight ( VLBW ) preterm infants receiving parenteral", "crystallization . These differences were attributed to the formation of separate phytosterol crystals within the emulsions at the high phytosterol concentration , as characterized by", "Plasma phytosterol half - lives were calculated from the phytosterol concentrations - decay curves by using a single - compartment model .", "In addition, clinical studies of lipid/phytosterol reduction for reversing and/or preventing parenteral nutrition associated liver disease are discussed.", "BW / d ) for foods with added FPS as calculated by multiplying the advised upper daily phytosterol intake of 3 g / d with the 90% quantile values of ORP . In conclusion , heating temperature and", "reach high levels during parenteral lipid administration and may be toxic to cells . Phytosterols are not fully metabolized by the human body and must be excreted through the hepatobiliary system .", "values of ORP . In conclusion , heating temperature and time , chemical form of phytosterols added and the food matrix are determinants of POP formation in foods with added phytosterols ,", "Understanding the consequences of adding phytosterols, on the physical and crystalline behavior of emulsions may enable the functional food industry to design more physically and chemically stable products.", "of sitosterol ( SITO ) , campesterol ( CAMP ) , and stigmasterol ( STIGM ) . Plasma phytosterol half - lives were calculated from the phytosterol concentrations - decay curves by using a single -", "Effect of Phytosterols on the Crystallization Behavior of Oil - in - Water Milk Fat Emulsions .", "Phytosterols, Lipid Administration, and Liver Disease During Parenteral Nutrition.", "Phytosterol enrichment influenced the particle size and physical appearance of the emulsion droplets, but did not affect the stability or charge of the dispersed particles.", "Phytosterols are common components of plant foods, especially vegetable oils, seeds, nuts and cereals.", "The decay of plasma phytosterol concentrations was monoexponential.", "Accumulating scientific evidence suggests that administration of high doses of intravenous lipids that are high in phytosterols contributes to the development of parenteral nutrition-associated liver disease."], "par_relations": [], "chd_relations": ["Animi-3", "Mi-Omega", "Cholesterol Management", "Vanachol", "Animi-3 with Vitamin D"], "syn_relations": [], "sib_relations": ["Phytosterols 200 MG", "Phytosterols 250 MG", "Phytosterols / Saw palmetto extract Oral Capsule", "Phytosterols 400 MG", "Phytosterols Oral Tablet", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / Vitamin B 12 / Vitamin B6", "Phytosterols / Saw palmetto extract", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / Vitamin B 12 / Vitamin B6 Oral Capsule", "Phytosterols 75 MG", "Ascorbic Acid / Chromium Polynicotinate / Niacinamide / OAT BRAN / Phytosterols / pregna-4,17-diene-3,16-dione Oral Tablet", "Ascorbic Acid / Chromium Polynicotinate / Niacinamide / OAT BRAN / Phytosterols / pregna-4,17-diene-3,16-dione", "Phytosterols 100 MG", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / policosanol / Vitamin B 12 / Vitamin B6 Oral Capsule", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / policosanol / Vitamin B 12 / Vitamin B6", "Ascorbic Acid / Chromium Polynicotinate / Niacinamide / OAT BRAN / Phytosterols / pregna-4,17-diene-3,16-dione Oral Product", "Ascorbic Acid / Chromium Polynicotinate / Niacinamide / OAT BRAN / Phytosterols / pregna-4,17-diene-3,16-dione Pill", "Phytosterols / Saw palmetto extract Oral Product", "Phytosterols / Saw palmetto extract Pill", "Phytosterols Oral Product", "Phytosterols Pill", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / Vitamin B 12 / Vitamin B6 Oral Product", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / Vitamin B 12 / Vitamin B6 Pill", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / policosanol / Vitamin B 12 / Vitamin B6 Oral Product", "Docosahexaenoate / Eicosapentaenoate / Folic Acid / Phytosterols / policosanol / Vitamin B 12 / Vitamin B6 Pill", "Cholecalciferol / Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12 Oral Product", "Cholecalciferol / Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12 Pill", "Cholecalciferol / Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12 Oral Capsule", "Cholecalciferol / Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12", "Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12 Oral Product", "Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12 Pill", "Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12 Oral Capsule", "Folic Acid / Omega-3 Acid Ethyl Esters (USP) / Phytosterols / pyridoxine / Vitamin B 12", "Omega-3 Acid Ethyl Esters (USP) / Phytosterols Oral Product", "Omega-3 Acid Ethyl Esters (USP) / Phytosterols Pill", "Omega-3 Acid Ethyl Esters (USP) / Phytosterols Oral Capsule", "Omega-3 Acid Ethyl Esters (USP) / Phytosterols", "Docosahexaenoate / Eicosapentaenoate / Phytosterols Oral Product", "Docosahexaenoate / Eicosapentaenoate / Phytosterols Pill", "Docosahexaenoate / Eicosapentaenoate / Phytosterols Oral Capsule", "Docosahexaenoate / Eicosapentaenoate / Phytosterols"], "wiki_entities": ["Phytosterol", "Sterol", "Stigmasterol", "Campesterol", "Sterol ester", "Bioactive compound", "Beta-Sitosterol", "Cycloartenol", "Lipid-lowering agent", "Cholesterol"], "mesh_synonynms": ["plant steroid", "phytosterol", "phytosteroids", "plant steroids", "steroids, plant", "plant sterols", "sterols, plant", "steroid, plant", "phytoteroid", "plant sterol", "sterol, plant"], "dbpedia_synonyms": ["phytosterol"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:4805", "canonical_name": "hydroxyacylglutathione hydrolase", "aliases": ["hagh1", "hagh gene", "glo2", "hydroxyacylglutathione hydrolase", "hagh", "glxii"], "definition": "In enzymology, a Hydroxyacylglutathione hydrolase (EC 3.1.2.6) is an enzyme that catalyzes the chemical reaction\n(R)-S-lactoylglutathione + water \n  \n    \n      \n        ⇌\n      \n    \n    {\\displaystyle \\rightleftharpoons }\n   glutathione + a 2-hydroxy carboxylate\nHence, this enzyme has two substrates, (R)-S-lactoylglutathione and water, and two products, glutathione and a 2-hydroxy carboxylate.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase", "hydroxyacylglutathione hydrolase"], "sib_relations": [], "wiki_entities": ["Hydroxyacylglutathione hydrolase", "HAGH", "PNKD", "List of EC numbers (EC 3)"], "mesh_synonynms": [], "dbpedia_synonyms": ["hagh (gene)", "ec 3.1.2.6", "s-(2-hydroxyacyl)glutathione hydrolase", "ec 3.1.2.8", "glyoxalase іі", "glyoxalase ii"]}, "target_ent": {"research_entity_id": "OMIM:138760", "canonical_name": "HYDROXYACYL GLUTATHIONE HYDROLASE", "aliases": ["hydroxyacyl glutathione hydrolase", "glyoxalase ii", "hagh", "glo2"], "definition": "In enzymology, a Hydroxyacylglutathione hydrolase (EC 3.1.2.6) is an enzyme that catalyzes the chemical reaction\n(R)-S-lactoylglutathione + water \n  \n    \n      \n        ⇌\n      \n    \n    {\\displaystyle \\rightleftharpoons }\n   glutathione + a 2-hydroxy carboxylate\nHence, this enzyme has two substrates, (R)-S-lactoylglutathione and water, and two products, glutathione and a 2-hydroxy carboxylate.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["HYDROXYACYL GLUTATHIONE HYDROLASE", "HYDROXYACYL GLUTATHIONE HYDROLASE", "HYDROXYACYL GLUTATHIONE HYDROLASE", "HYDROXYACYL GLUTATHIONE HYDROLASE", "HYDROXYACYL GLUTATHIONE HYDROLASE", "HYDROXYACYL GLUTATHIONE HYDROLASE"], "sib_relations": [], "wiki_entities": ["Hydroxyacylglutathione hydrolase", "Hepoxilin", "List of genetic disorders", "List of EC numbers (EC 1)", "List of MeSH codes (D08)"], "mesh_synonynms": [], "dbpedia_synonyms": ["hydroxyacylglutathione hydrolase", "hagh (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "ICD10CM:I25.1", "canonical_name": "Atherosclerotic cardiovascular disease", "aliases": ["coronary (artery) sclerosis", "atherosclerotic heart disease of native coronary artery", "atherosclerotic cardiovascular disease", "coronary (artery) atherosclerosis", "coronary (artery) disease", "coronary (artery) atheroma"], "definition": "Coronary artery disease (CAD), also known as ischemic heart disease (IHD), is a group of diseases that includes: stable angina, unstable angina, myocardial infarction, and sudden cardiac death.", "other_contexts": [], "par_relations": ["Chronic ischemic heart disease"], "chd_relations": ["Atherosclerotic heart disease of native coronary artery without angina pectoris", "Atherosclerotic heart disease of native coronary artery with angina pectoris"], "syn_relations": ["Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease", "Atherosclerotic cardiovascular disease"], "sib_relations": ["Aneurysm of heart", "Old myocardial infarction", "Other forms of chronic ischemic heart disease", "Chronic ischemic heart disease, unspecified", "Silent myocardial ischemia", "Ischemic cardiomyopathy", "Coronary artery aneurysm and dissection", "Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris"], "wiki_entities": ["Coronary artery disease", "Cardiovascular disease", "Atherosclerosis", "Peripheral artery disease", "Atheroma", "National Cholesterol Education Program", "High-density lipoprotein", "Monckeberg's arteriosclerosis", "Testosterone and the cardiovascular system", "Cardiology"], "mesh_synonynms": [], "dbpedia_synonyms": ["coronary artery disease"]}, "target_ent": {"research_entity_id": "LNC:LA12725-0", "canonical_name": "Atherosclerotic coronary heart disease (complete questions 10, 11 and 12 only)", "aliases": ["atherosclerotic coronary heart disease (complete questions 10, 11 and 12 only)"], "definition": "Management of acute coronary syndrome is targeted against the effects of reduced blood flow to the afflicted area of the heart muscle, usually because of a blood clot in one of the coronary arteries, the vessels that supply oxygenated blood to the myocardium.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": [], "sib_relations": ["Multi-Ethnic Study of Atherosclerosis (MESA) classification of underlying cause of death:Type:Point in time:^Patient:Nominal"], "wiki_entities": ["Management of acute coronary syndrome", "Myocardial infarction", "Heart", "History of invasive and interventional cardiology", "Carotid endarterectomy", "Angiogenesis", "Statin", "Stroke", "Women's Health Initiative", "List of Autopsy: The Last Hours of... episodes"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "MSH:D000069058", "canonical_name": "Vardenafil Dihydrochloride", "aliases": ["vardenafil dihydrochloride", "vardenafil hydrochloride anhydrous", "trihydrate, vardenafil hydrochloride", "anhydrous, vardenafil hydrochloride", "hydrochloride trihydrate, vardenafil", "hydrochloride anhydrous, vardenafil", "vardenafil", "1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine", "vardenafil hydrochloride", "levitra", "hydrochloride, vardenafil", "dihydrochloride, vardenafil", "vardenafil hydrochloride trihydrate"], "definition": "The following is a list of phosphodiesterase inhibitors.", "other_contexts": [], "par_relations": ["Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Imidazoles", "Piperazines", "Vasodilator Agents", "Phosphodiesterase 5 Inhibitors", "Urological Agents"], "chd_relations": ["Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride"], "syn_relations": ["Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride", "Vardenafil Dihydrochloride"], "sib_relations": ["Almitrine", "Aminoimidazole Carboxamide", "Antazoline", "Biotin", "Buspirone", "Carbimazole", "Cimetidine", "Cinnarizine", "Clotrimazole", "Creatinine", "Cyclizine", "Dacarbazine", "Diethylcarbamazine", "Dimethylphenylpiperazinium Iodide", "Econazole", "Etimizol", "Etomidate", "Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide", "Flunarizine", "Flupenthixol", "Fluspirilene", "HEPES", "Histamine", "Histidinol", "Hydroxyzine", "Ketoconazole", "Levamisole", "Lidoflazine", "Meclizine", "Methimazole", "Miconazole", "Naphazoline", "Niridazole", "Nitroimidazoles", "Oxymetazoline", "Phentolamine", "Pipemidic Acid", "Pipobroman", "Piribedil", "Prospidium", "Quipazine", "Tetramisole", "Thiethylperazine", "Trazodone", "Trimetazidine", "Trimethaphan", "Urocanic Acid", "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine", "Diketopiperazines", "Ondansetron", "Idazoxan", "Impromidine", "Itraconazole", "Pipecuronium", "Ranolazine", "Dexmedetomidine", "Enoximone", "Fadrozole", "Medetomidine", "Losartan", "Delavirdine", "Aripiprazole", "Olmesartan Medoxomil", "Sildenafil Citrate", "Imatinib Mesylate", "4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone", "Eszopiclone", "Imidazolines", "Imidazolidines", "Prasugrel Hydrochloride", "Vilazodone Hydrochloride"], "wiki_entities": ["List of phosphodiesterase inhibitors", "List of drugs: V-Ve", "Para-Chlorophenylpiperazine", "Mepiprazole", "Azimilide"], "mesh_synonynms": ["vardenafil hydrochloride anhydrous", "hydrochloride anhydrous, vardenafil", "levitra", "hydrochloride, vardenafil", "vardenafil hydrochloride", "hydrochloride trihydrate, vardenafil", "vardenafil dihydrochloride", "dihydrochloride, vardenafil", "vardenafil hydrochloride trihydrate", "trihydrate, vardenafil hydrochloride", "anhydrous, vardenafil hydrochloride", "1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine", "vardenafil"], "dbpedia_synonyms": ["atcvet code qg04be09", "levitra", "verdanafil", "vardenafil hydrochloride", "staxyn", "bay 38-9456", "vardenafil", "atc code g04be09"]}, "target_ent": {"research_entity_id": "RXNORM:1309396", "canonical_name": "Vardenafil hydrochloride trihydrate", "aliases": ["vardenafil hydrochloride trihydrate"], "definition": "The following is a list of phosphodiesterase inhibitors.", "other_contexts": [], "par_relations": ["vardenafil"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["List of phosphodiesterase inhibitors"], "mesh_synonynms": ["vardenafil hydrochloride anhydrous", "hydrochloride anhydrous, vardenafil", "levitra", "hydrochloride, vardenafil", "vardenafil hydrochloride", "hydrochloride trihydrate, vardenafil", "vardenafil dihydrochloride", "dihydrochloride, vardenafil", "trihydrate, vardenafil hydrochloride", "anhydrous, vardenafil hydrochloride", "1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine", "vardenafil"], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:C566857", "canonical_name": "Ceroid Lipofuscinosis, Neuronal, 2", "aliases": ["ceroid lipofuscinosis, neuronal, 2", "ceroid lipofuscinosis, neuronal, 2, variable age at onset"], "definition": "Neuronal ceroid lipofuscinosis (NCL) is the general name for a family of at least eight genetically separate neurodegenerative disorders that result from excessive accumulation of lipopigments (lipofuscin) in the body's tissues.", "other_contexts": [], "par_relations": ["Neuronal Ceroid-Lipofuscinoses"], "chd_relations": [], "syn_relations": [], "sib_relations": [], "wiki_entities": ["Neuronal ceroid lipofuscinosis", "Batten disease", "Lipofuscin", "CLN3", "Palmitoyl protein thioesterase", "CLN5", "Northern epilepsy syndrome", "List of diseases (N)", "Tripeptidyl peptidase I", "Cerliponase alfa"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:607998", "canonical_name": "TRIPEPTIDYL PEPTIDASE I", "aliases": ["cln2 gene", "ceroid lipofuscinosis, neuronal, 2", "tpp1", "tripeptidyl peptidase i", "spinocerebellar ataxia, autosomal recessive 7", "cln2", "tpp i"], "definition": "A tripeptidyl peptidase is a type of enzyme.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["TRIPEPTIDYL PEPTIDASE I", "TRIPEPTIDYL PEPTIDASE I", "TRIPEPTIDYL PEPTIDASE I", "TPP1, CYS365ARG", "TPP1, CYS365TYR", "TPP1, ARG208TER", "TPP1, IVS5AS, G-C, -1", "TPP1, ARG447HIS", "TPP1, ARG206CYS", "TPP1, GLY284VAL", "TPP1, ASN286SER", "TPP1, IVS7AS, A-G, -10", "TPP1, VAL466GLY", "TPP1, GLU343ASP", "TRIPEPTIDYL PEPTIDASE I", "TRIPEPTIDYL PEPTIDASE I", "TRIPEPTIDYL PEPTIDASE I", "TRIPEPTIDYL PEPTIDASE I", "TRIPEPTIDYL PEPTIDASE I"], "sib_relations": ["TPP1, IVS5AS, G-C, -1", "TPP1, VAL466GLY", "TPP1, GLU343ASP", "TPP1, CYS365ARG", "TPP1, CYS365TYR", "TPP1, ARG208TER", "TPP1, IVS5AS, G-C, -1", "TPP1, ARG447HIS", "TPP1, ARG206CYS", "TPP1, GLY284VAL", "TPP1, ASN286SER", "TPP1, IVS7AS, A-G, -10"], "wiki_entities": ["Tripeptidyl peptidase", "Tripeptidyl-peptidase", "Tripeptidyl peptidase I", "Tripeptidyl peptidase II", "Xaa-Xaa-Pro tripeptidyl-peptidase", "Dipeptidyl peptidase", "Cerliponase alfa", "TRIANGLE disease", "Subtilase", "Jansky–Bielschowsky disease"], "mesh_synonynms": [], "dbpedia_synonyms": ["tpp1 (gene)", "tripeptidyl peptidase i", "ec 3.4.14.9", "tripeptidyl-peptidase i", "cln2", "tpp1"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D005886", "canonical_name": "Gingival Hypertrophy", "aliases": ["gingival hypertrophies", "hypertrophies, gingival", "hypertrophy, gingival", "gingival hypertrophy"], "definition": "Gingival enlargement, (also termed gingival overgrowth, hypertrophic gingivitis, gingival hyperplasia, or gingival hypertrophy, and sometimes abbreviated to GO), is an increase in the size of the gingiva (gums).", "other_contexts": ["Gingival hypertrophy (GH) is a well-known physical manifestation due to inflammatory conditions, pregnancy, vitamin C deficiency, systemic diseases like leukemia, Wegners granulomatosis, and various drugs like anticonvulsants, immunosuppresant, and calcium channel blockers (CCBs).We present here a case of a 45-year-old woman, who has been taking Amlodipine 10mg once a day together with Atenelol 50mg per day for one and half years, and has subsequently developed gum hypertrophy.", "Gingival hypertrophy improved 4 months later (Picture 2) and it was resolved 3 years after nifedipine withdrawal (Picture 3).", "with Atenelol 50 mg per day for one and half years , and has subsequently developed gum hypertrophy . This manifestation was reversed after stopping of Amlodipine . Though this case presentation is", "n engl j med 359;16 www.nejm.org october 16 , 2008 e21 A 46-year - old woman who was not taking any medications presented with anemia and gingival hypertrophy that had been progressing over a period of 3 months .", "Two cases of gingival hypertrophy in young Senegalese females undergoing orthodontic treatment with fixed appliances are described and treated by gingivectomy.", "Gingival hypertrophy ( GH ) due to acute myeloid leukemia ( AML ) in a child is extremely rare .", "[Gingival hypertrophy due to cyclosporine.", "Syndrome of gingival hypertrophy, hirsutism, mental retardation and brachymetacarpia in two sisters: specific entity or variant of a described condition?", "Gingival hypertrophy in a child : Expect the unexpected Acute leukemia is the most common malignant disorder of childhood .", "This case - report shows localized gingival hypertrophy in young Senegalese female undergoing orthodontic treatment with fixed appliances .", "Examination revealed severe gingival hypertrophy with bleeding ( Picture 1 ) .", "The physical examination revealed severe gingival hypertrophy , which obscured the patient ’s few remaining teeth except for the left inferior second molar ( Panels A and B ) .", "Gingival hypertrophy and leukemia.", "Gingival hypertrophy was observed in 52 subjects ( 63.4% ) 25 ( 30% ) patients underwent surgical operation , 6 of them ( 24% ) showed a relapse about 3 months after the first operation .", "marrow failure due to the replacement of marrow elements by leukemic blasts . Gingival hypertrophy ( GH ) due to acute myeloid leukemia ( AML ) in a child is extremely rare . Here , we report a", "Calcium channel blockers, phenytoin, and cyclosporin are known to cause gingival hypertrophy.", "Features in our patient , which were not noted in previous reports of the disease , include gingival hypertrophy , ankylosis of joints , skeletal hyperostosis , and lymphatic dilation of the ileal villi .", "[ Gingival hypertrophy during orthodontic treatment : contribution of external bevel gingivectomy", "Comfort and controlled haemostasis after periodontal surgery make this procedure a good choice for treatment of gingival hypertrophy.", "[Treatment of localized gingival hypertrophy induced by orthodontic appliances using modified Widman flap.", "Medication - induced gingival hypertrophy .", "Nifedipine - induced gingival hypertrophy .", "Two sisters born to consanguineous Lebanese parents had mental retardation and epilepsy, brachymetacarpalia, hirsutism, bulbous soft nose, thick floppy ears with abnormal configuration and gingival hypertrophy.", "An African case with gingival hypertrophy and other unusual features.", "Medication-Induced Gingival Hypertrophy", "Gingival enlargement is a condition that commonly develops during orthodontic treatment .", "Missing diagnosis: gingival hypertrophy due to amlodipine."], "par_relations": ["Gingival Overgrowth"], "chd_relations": ["Oculodental syndrome Rutherfurd syndrome"], "syn_relations": ["Gingival Hypertrophy", "Gingival Hypertrophy", "Gingival Hypertrophy", "Gingival Hypertrophy", "Gingival Hypertrophy", "Gingival Hypertrophy"], "sib_relations": ["Fibromatosis, Gingival", "Gingival Hyperplasia"], "wiki_entities": ["Gingival enlargement", "Gingivitis", "Overgrowth", "Infantile systemic hyalinosis", "Hereditary gingival fibromatosis", "Periodontal pathology", "Linear gingival erythema", "Hemifacial hypertrophy", "Hand, foot, and mouth disease", "Gingival disease"], "mesh_synonynms": ["gingival hypertrophies", "gingival hypertrophy", "hypertrophy, gingival", "hypertrophies, gingival"], "dbpedia_synonyms": ["gingival enlargement"]}, "target_ent": {"research_entity_id": "OMIM:MTHU009464", "canonical_name": "Gum hypertrophy", "aliases": ["gum hypertrophy"], "definition": "Gingival enlargement, (also termed gingival overgrowth, hypertrophic gingivitis, gingival hyperplasia, or gingival hypertrophy, and sometimes abbreviated to GO), is an increase in the size of the gingiva (gums).", "other_contexts": [], "par_relations": ["Mouth"], "chd_relations": [], "syn_relations": [], "sib_relations": ["HURLER SYNDROME", "MARSHALL-SMITH SYNDROME", "INFANTILE SIALIC ACID STORAGE DISEASE", "MACS SYNDROME", "CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa"], "wiki_entities": ["Gingival enlargement", "Hemifacial hypertrophy", "Masseter muscle", "Herpetic gingivostomatitis", "Periodontitis", "Ciclosporin", "Gingivitis", "Mouth breathing", "Jaw reduction", "Periodontal pathology"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "CPT:1021907", "canonical_name": "Rural Health Clinic", "aliases": ["rural health clinic"], "definition": "A rural health clinic (RHC) is a clinic located in a rural, medically under-served area in the United States that has a separate reimbursement structure from the standard medical office under the Medicare and Medicaid programs.", "other_contexts": [], "par_relations": ["Place of Service Codes for Professional Claims"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Community Mental Health Center", "Group Home", "Mobile Unit", "Pharmacy", "School", "Skilled Nursing Facility", "Birthing Center", "Hospice", "Home", "Office", "Homeless Shelter", "Assisted Living Facility", "Custodial Care Facility", "Intermediate Care Facility/Mentally Retarded", "Ambulance - Land", "Ambulatory Surgical Center", "Inpatient Hospital", "Nursing Facility", "Military Treatment Facility", "Public Health Clinic", "Indian Health Service Free-standing Facility", "Indian Health Service Provider-based Facility", "Tribal 638 Free-standing Facility", "Tribal 638 Provider-based Facility", "Prison/ Correctional Facility", "Temporary Lodging", "Walk-in Retail Health Clinic", "Off Campus-Outpatient Hospital", "Urgent Care Facility", "On Campus-Outpatient Hospital", "Emergency Room - Hospital", "Ambulance - Air or Water", "Independent Clinic", "Federally Qualified Health Center", "Inpatient Psychiatric Facility", "Residential Substance Abuse Treatment Facility", "Psychiatric Residential Treatment Center", "Non-residential Substance Abuse Treatment Facility", "Mass Immunization Center", "Comprehensive Inpatient Rehabilitation Facility", "Comprehensive Outpatient Rehabilitation Facility", "End-Stage Renal Disease Treatment Facility", "Independent Laboratory", "Other Place of Service", "Place of Employment- Worksite", "Psychiatric Facility-Partial Hospitalization"], "wiki_entities": ["Rural health clinic", "Clinic", "Rural health", "Marshall University Rural Health Clinic", "Healthcare in India", "Free clinic", "Action for Rural Rejuvenation", "Regina Benjamin", "Marshfield Clinic", "Primary Health Centre (India)"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "MSH:D012423", "canonical_name": "Rural Health", "aliases": ["health, rural", "rural health"], "definition": "In medicine, rural health or rural medicine is the interdisciplinary study of health and health care delivery in rural environments.", "other_contexts": [], "par_relations": ["Health"], "chd_relations": [], "syn_relations": ["Rural Health", "Rural Health"], "sib_relations": ["Agricultural Workers' Diseases", "Child Health", "Holistic Health", "Mental Health", "Oral Health", "Physical Fitness", "Public Health", "Urban Health", "Occupational Health", "Women's Health", "Infant Health", "Reproductive Health", "Suburban Health", "Family Health", "Global Health", "Men's Health", "Adolescent Health", "Minority Health", "Veterans Health", "Cardiorespiratory Fitness", "Social Determinants of Health"], "wiki_entities": ["Rural health", "National Rural Health Mission", "Rural area", "The Journal of Rural Health", "Healthcare in India", "Rural health clinic", "Rural health care in Australia", "Comprehensive Rural Health Project", "Texas A&M Health Science Center School of Public Health", "Rural poverty"], "mesh_synonynms": ["health, rural", "rural health"], "dbpedia_synonyms": ["rural healthcare", "rural health"]}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:895", "canonical_name": "arginine vasopressin receptor 1A", "aliases": ["avpr1a gene", "arginine vasopressin receptor 1a", "avpr1a"], "definition": "Vasopressin receptor 1A (V1AR), or arginine vasopressin receptor 1A (officially called AVPR1A) is one of the three major receptor types for vasopressin (AVPR1B and AVPR2 being the others), and is present throughout the brain, as well as in the periphery in the liver, kidney, and vasculature.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["arginine vasopressin receptor 1A", "arginine vasopressin receptor 1A"], "sib_relations": [], "wiki_entities": ["Vasopressin receptor 1A", "Vasopressin receptor", "Vasopressin receptor 2", "Vasopressin receptor antagonist", "Vasopressin receptor 1B", "Vasopressin", "Vasopressin (medication)", "Desmopressin", "Conivaptan", "1A"], "mesh_synonynms": [], "dbpedia_synonyms": ["v1a vasopressin receptor", "vasopressin 1a receptor", "vasopressin v1a receptor", "avpr1a", "arginine vasopressin receptor 1a", "vasopressin receptor v1a", "avpr1a (gene)"]}, "target_ent": {"research_entity_id": "OMIM:600821", "canonical_name": "ARGININE VASOPRESSIN RECEPTOR 1A", "aliases": ["arginine vasopressin receptor 1a", "avpr1a"], "definition": "Vasopressin receptor 1A (V1AR), or arginine vasopressin receptor 1A (officially called AVPR1A) is one of the three major receptor types for vasopressin (AVPR1B and AVPR2 being the others), and is present throughout the brain, as well as in the periphery in the liver, kidney, and vasculature.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["ARGININE VASOPRESSIN RECEPTOR 1A", "ARGININE VASOPRESSIN RECEPTOR 1A"], "sib_relations": [], "wiki_entities": ["Vasopressin receptor 1A", "Vasopressin receptor", "Vasopressin receptor 2", "Vasopressin receptor antagonist", "Vasopressin receptor 1B", "Vasopressin", "Vasopressin (medication)", "Desmopressin", "Conivaptan", "1A"], "mesh_synonynms": [], "dbpedia_synonyms": ["v1a vasopressin receptor", "vasopressin 1a receptor", "vasopressin v1a receptor", "avpr1a", "arginine vasopressin receptor 1a", "vasopressin receptor v1a", "avpr1a (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:4472", "canonical_name": "G protein-coupled receptor 18", "aliases": ["gpr18 gene", "gpr18", "g protein-coupled receptor 18"], "definition": "G protein–coupled receptors (GPCRs) which are also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein–linked receptors (GPLR), constitute a large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and, ultimately, cellular responses.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["G protein-coupled receptor 18", "G protein-coupled receptor 18"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["gpr18 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:602042", "canonical_name": "G PROTEIN-COUPLED RECEPTOR 18", "aliases": ["g protein-coupled receptor 18", "gpr18"], "definition": "G protein–coupled receptors (GPCRs) which are also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein–linked receptors (GPLR), constitute a large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and, ultimately, cellular responses.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["G PROTEIN-COUPLED RECEPTOR 18", "G PROTEIN-COUPLED RECEPTOR 18"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": ["gpr18 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D013469", "canonical_name": "Sulpiride", "aliases": ["vertigo neogama", "sulpor", "arminol", "vertigo meresa", "digton", "desisulpid", "vertigo-neogama", "vertigo-meresa", "sulperide", "deponerton", "guastil", "eglonyl", "sulp", "sulpitil", "dolmatil", "tepavil", "ekilid", "lebopride", "aiglonyl", "sulpiride", "sulpivert", "meresa", "synédil", "benzamide, 5-(aminosulfonyl)-n-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-", "dogmatil", "neogama", "psicocen", "pontiride"], "definition": "Sulpiride (brand names Dogmatil ( DE, HK, SG, PH), Dolmatil (IE, UK), Eglonyl (RU, ZA), Espiride (ZA), Modal (IL), Prometar (UY), Sulpor (UK) and others) is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.", "other_contexts": ["Further investigation is required to determine the usefulness of sulpiride as a chronic treatment of schizophrenia and its effectiveness in treating the negative symptoms of schizophrenia .", "Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat Administration of haloperidol ( 1.4–1.6 mg / kg / day ) for up to 12 months or sulpiride ( 102–109 mg / kg / day ) for between 6 and 12 months increased the frequency of purposeless chewing jaw movements in rats .", "Bmax for 3H-piflutixol binding was not alfered by chronic haloperidol or sulpiride treatment.", "Furthermore, while sulpiride did not antagonize the pressor effect of the alpha-adrenoceptor agonist phenylephrine, it significantly attenuated the increases in blood pressure produced by tramazoline.", "[Sulpiride in the management of gastroduodenal ulcers.", "To explore the mechanisms involved in this sex-dependent effect, we administered the dopamine antagonist sulpiride (20 mg/kg i.p.) or vehicle (0.1 N HCl) to adult male rats during 21 days and daily assessed bodyweight and food intake.", "Bmax for 3H - NPA binding was elevated only after 12 months of both haloperidol and sulpiride treatment .", "In addition, the accumulation of sulpiride in BeWo cells (a human choriocarcinoma cell line) was obviously affected by inhibitors of carnitine/organic cation transporter (OCTN) 2, MDR1 and BCRP.", "Clinical studies support sulpiride as being equally effective as active controls in the acute treatment of patients with schizophrenia .", "After 12 months , sterotypy induced by high doses of apomorphine ( 0.5–1.0 mg / kg ) was exaggerated in haloperidol- , but not sulpiride - treated rats .", "The effects of Sulpiride on the duodenum are similar through some hypotony may be seen.", "The author believes that the clinical effectiveness of Sulpiride in the treatment of gastro-duodenal ulcers is incontestable showing maximum results in ambulatory patients from the 20th day.", "The alpha 2-adrenoceptor blocking action of sulpiride lasted for approximately 15 min at 1.0 mg/kg adn for 90 min at 2.0 mg/kg.", ", we speculated that the transporters expressed in placenta might be involved in sulpiride uptake across the blood – placenta barrier . The aim of our study was to determine which", "The aim of our study was to determine which transporters contributed to the placental transfer of sulpiride.", "Sulpiride can be considered to be an atypical antipsychotic, considering its action on negative, defective symptoms, its partial activity against positive symptoms, and its low incidence of extrapyramidal adverse effects.", "Spectrophotofluorometric method for quantitative determination of sulpiride in human plasma and urine .", "A risk-benefit assessment of sulpiride in the treatment of schizophrenia.", "However , at doses of 1.0 mg / kg and higher , sulpiride facilitates sympathetic nerve function via a preferential antagonism of alpha 2-adrenoceptors .", "Considering the structure of sulpiride , we speculated that the transporters expressed in placenta might be involved in sulpiride uptake across the blood –", "Lastly , the dopamine metabolites dihydroxyphenylacetic acid ( DOPAC ) and homovanilic acid ( HVA ) in the lateral hypothalamus were assessed by in vivo microdialysis after acute systemic injections of sulpiride and vehicle .", "Sulpiride does not appear to have an extensive first-pass metabolism, nor is it extensively protein-bound.", "The effect of sulpiride, a dopamine receptor antagonist, on peripheral alpha-adrenoceptors and dopamine receptors was determined.", "38 cases ( 29 men and 9 women , aged between 21 and 70 years ) had duodenal ulcers , 18 were treated with Sulpiride , 20 with placebo .", "The oral bioavailability of sulpiride is poor, with estimates approximating 35%.", "Positive chronotropic responses to cardioaccelerator nerve stimulation in pentobarbital-anesthetized dogs were potentiated by 1.0 and 2.0 mg/kg but not by 0.5 mg/kg intravenous sulpiride.", "These studies establish that peripheral neuronal and vascular dopamine receptors may be antagonized by sulpiride without affecting alpha - adrenergic mechanisms .", "In additional experiments , it was determined that the dopamine receptor - mediated bradycardic and hypotensive effects of N , N - di - n - propyldopamine were antagonized for at least 2 h by 0.1 , 0.5 , and 1.0 mg / kg sulpiride .", "OBJECTIVE To review the pharmacology , pharmacokinetics , clinical investigations , and adverse effects of sulpiride as a treatment for schizophrenia .", "Two Sulpiril capsules ( 100 mg S ) gave significantly higher plasma sulpiride concentrations from 1 to 6 hours than 20 ml Sulpiril mixt .", "contributed to the placental transfer of sulpiride . Our results revealed that sulpiride was a substrate of human organic cation transporter ( hOCT ) 3 , human multidrug resistance", "of our study was to determine which transporters contributed to the placental transfer of sulpiride . Our results revealed that sulpiride was a substrate of human organic cation transporter ( hOCT )", "The effects of sulpiride and metoclopramide on pre- and postsynaptic dopamine receptors were investigated in the rat brain as antagonism of the apomorphine-induced inhibition of the dopamine synthesis in the absence of nerve impulses and as blockade of the apomorphine-induced rotation following unilateral inactivation of the corpus striatum, respectively.", "Early pharmacology reports hypothesized that sulpiride was selective for dopamine ( D)2 receptors only , but sulpiride also blocks D3 and D4 receptors .", "In another experiment , food intake and water intake were assessed after acute injections of sulpiride or vehicle into the perifornical lateral hypothalamus .", "Since the same sex-dependent effect on body weight and food intake in rats has been observed during administration of risperidone, which has a different pharmacological profile than sulpiride, future studies must evaluate other neurotransmitters involved in food intake regulation such as serotonin, noradrenaline and histamine.", "The reduction in stimulus - induced tachycardia caused by the alpha 2-adrenoceptor agonist tramazoline was significantly antagonized by sulpiride .", "It has been proven that a small amount of sulpiride could cross the human placenta using an ex vivo placental perfusion model.", "DATA SOURCES Information was selected from a MEDLINE search of English-language medical literature using \"sulpiride\" as the search term.", "Following unilateral inactivation of the corpus striatum, metoclopramide at a low dose, but not sulpiride turned the rats ipsilaterally, indicating that the release of dopamine was facilitated and that the presynaptic dopamine receptors are of physiological significance.", "The plasma concentrations ( 0 - -24 hours ) and renal excretions ( 0 - -48 hours ) of sulpiride were measured after Dogmatil forte ( Schürholtz ) , or Sulpiril ( Leiras ) tablets both containing 200 mg of sulpiride , after two Sulpiril capsules ( Leiras ) containing 50 mg of sulpiride in each capsule , and after 20 ml Dogmatil saft ( Schürholtz ) and 20 ml Sulpiril mixt .", "Sulpiride may cause extrapyramidal effects , autonomic effects , tardive dyskinesia , and the neuroleptic malignant syndrome .", "[ Effect of storax on concentration of sulpiride in brain and blood by MD - HPLC ] .", "The same values calculated from the sulpiride urine concentrations were 118%, 114%, 71%, and 67%, respectively.", "Chronic administration of sulpiride does not induce identical changes in striatal dopamine function to those caused by haloperidol .", "The accumulation of sulpiride in primary human trophoblast cells was obviously affected by inhibitors of OCT3, OCTN1 and OCTN2.", "maternal circulation , and hOCT3 probably is involved in the bidirectional transport of sulpiride between the placenta and fetal blood .", "DATA SYNTHESIS Sulpiride is a substituted benzamide with selective dopaminergic blocking activity .", "Acute sulpiride significantly increased food intake, water intake, DOPAC and HVA levels.", ", the placental transfer mechanism has not been elucidated . Considering the structure of sulpiride , we speculated that the transporters expressed in placenta might be involved in sulpiride uptake", "N , n - propylnorapomorphine ( NPA ) ( 0.25–2.0 mg / kg SC ) did not induce hypoactivity in haloperidol - treated rats at any time ; sulpiride treatment for 9 and 12 months caused a reduction in the ability of NPA to induce hypoactivity .", "Haloperidol , but not sulpiride , treatment enduringly inhibited low dose apomorphine effects ( 0.125 mg / kg SC ) .", "Sulpiride is known to induce prolactin elevation in both serum and CSF , which may be associated with impotence in men and diminished gonadal function in women ; these effects appear to be dosage - dependent .", "The above results indicate that hOCTN1 and hOCTN2 likely contribute to the sulpiride uptake from maternal circulation to trophoblast cells, while hMDR1 and hBCRP mediate the efflux from trophoblast cells to maternal circulation, and hOCT3 probably is involved in the bidirectional transport of sulpiride between the placenta and fetal blood.", "However , after prolonged administration , sulpiride did not affect body weight .", "Sulpiride was more potent in blocking post-than presynaptic dopamine receptors whereas the reverse was found for metoclopramide.", "This lack of effect may be related to the impairment of insulin sensitivity, which may prevent body weight gain, and counteract other effects of sulpiride that promote adiposity such as hyperprolactinemia.", "1 and OCTN2 . The above results indicate that hOCTN1 and hOCTN2 likely contribute to the sulpiride uptake from maternal circulation to trophoblast cells , while hMDR1 and hBCRP mediate the efflux", "Data have confirmed the efficacy of sulpiride in patients with acute or chronic schizophrenia during both short and long term treatment, but long term, placebo-controlled trials are still lacking.", "There were no significant differences in the sulpiride concentrations in plasma or cumulative urinary excretion of sulpiride after Dogmatil forte ( 200 mg S ) or Sulpiril tablet ( 200 mg S ) .", "UNLABELLED Sulpiride (Dogmatil) is a new type of drug acting on the hypothalamus resulting in a physiological increase in amplitude and frequency of gastric motor activity, reduction of signs of abnormal activity and pyloric spasm and an increase in the rate of gastric emptying.", "Multiple drug transporters mediate the placental transport of sulpiride Sulpiride is a typical antipsychotic drug for the treatment of schizophrenia , depression and other psychological disorders .", "Bmax for specific striatal 3H-spiperone binding was increased by haloperidol, but not sulpiride, treatment throughout the study.", "Sulpiride penetrates the blood - brain barrier poorly because of its low lipid solubility .", ", depression and other psychological disorders . It has been proven that a small amount of sulpiride could cross the human placenta using an ex vivo placental perfusion model . However , the", "The renal excretion of sulpiride after two Sulpiril capsules ( 100 mg S ) was significantly lower than after a Sulpiril tablet ( 200 mg S ) from 8 to 48 hours , and also significantly lower than after a Dogmatil forte tablet ( 200 mg S ) from 24 to 48 hours .", "These findings noticeably contrast with those observed in sulpiride-treated female rats that appear to display enhanced insulin sensitivity.", "OBJECTIVE To observe the effect of traditional Chinese medicine storax on the concentration of combined western medicine sulpiride in brain and blood , discuss the effect of storax in inducing resuscitation and increasing the permeability of the gastrointestinal barrier ( GB ) and the blood - brain - barrier ( BBB ) , and explore the interaction between storax and sulpiride .", "Sulpiride : an antipsychotic with selective dopaminergic antagonist properties .", "RESULT The sulpiride combined with storax group showed a significant higher concentration of sulpiride than the pure sulpiride group .", "Sulpiride was extremely well tolerated, though amenorrhea (1) or galactorrhea (2) were noted without causing inconvenience to the patient.", "Striatal acetylcholine content was increased after 3 and 12 months of treatment with haloperidol, but was not affected by sulpiride.", "Of the 64 patients, 26 (18 men, 8 women, aged from 21 to 80 years) had gastric ulcers, 14 were treated with Sulpiride, 12 with placebo.", "The inhibitory effects of the latter three drugs were counteracted by metoclopramide, but not by sulpiride.", "The motor effects of Sulpiride do not relate to its effectiveness in treatment of gastroduodenal ulceration and experiments have shown that this activity can be explained by the reduction of capillary vaso - constriction in local blood circulation at the site of experimentally - induced ulcers , producing a vaso - dilatation assisting healing .", "Positive chronotropic effects of intravenous norepinephrine were unchanged by sulpiride , suggesting that sympathetic nerve function was facilitated via a presynaptic mechanism .", "The plasma half - life of sulpiride measured after two Sulpiril capsules , 20 ml Dogmatil saft and 20 ml Sulpiril mixt .", "Striatal dopamine - stimulated adenylate cyclase activity was inhibited for the 1st month of haloperidol treatment , thereafter returning to control levels ; dopamine stimulation was increased after 12 months of sulpiride treatment .", "Our results revealed that sulpiride was a substrate of human organic cation transporter (hOCT) 3, human multidrug resistance protein (hMDR) 1 and human breast cancer resistance protein (hBCRP) using transfected cells expressing respective transporters.", "Since yohimbine prevented the facilitatory action of sulpiride , an analysis of the ability of sulpiride to antagonize alpha - adrenoceptors was made .", "A unique pharmacology does not appear to provide sulpiride with a greater effectiveness than the standard antipsychotics, but may provide it with minor safety advantages.", "At low dosages ( 50 to 150 mg / day ) , sulpiride produces a disinhibiting and antidepressant effect , which is probably related to its action on D2 presynaptic autoreceptors , thus facilitating dopaminergic neurotransmission .", "The changes in insulin sensitivity do not appear related to a decrease in androgenic activity, because testosterone and DHEA-S levels were not affected by sulpiride.", "The synthesis and the utilization of dopamine was stimulated by sulpiride and metoclopramide and was inhibited by atropine, prazosin and aminooxyacetic acid.", "A new spectorophotofluorometric method for the determination of sulpiride ( S ) in the human plasma and urine is described .", "Two Sulpiril capsules (100 mg S) gave significantly higher sulpiride urine concentrations from 8 to 24 hours than 20 ml Sulpiril mixt.", "The safety profile of sulpiride is similar to that of typical antipsychotics , although the frequency of adverse effects seems to be globally lower .", "Two Sulpiril capsules ( 100 mg S ) produced significantly lower plasma concentrations of sulpiride at 3 hours than a Sulpiril tablet ( 200 mg S ) and these were also lower at 4 and 6 hours than with either a Dogmatil forte ( 200 mg S ) or a Sulpiril tablet ( 200 mg S ) .", "The pure sulpiride group showed a concentration ratio between sulpiride in brain and blood of 1:0.2; while the sulpiride combined with storax group increased the concentration ratio between sulpiride in brain and blood to 1:0.3.", "The antipsychotic drug sulpiride does not affect bodyweight in male rats .", "Sulpiride is a substituted benzamide with a selective action on receptors of the dopamine D2-like family , and clinical and pharmacological data suggest that it could be considered to be an atypical antipsychotic .", "(Leiras) both containing 5 mg/ml of sulpiride.", "Sulpiride could find its specific therapeutic role in elderly patients with schizophrenia, as it shows a good margin of safety between therapeutic dosages and toxic concentrations.", "Data from clinical studies are controversial ; the majority of authors indicate that sulpiride produces a better recovery rate from negative than from positive symptoms at low doses , but it shows a similar efficacy either on negative and positive symptoms at higher doses .", "CONCLUSIONS Sulpiride is a safe and effective pharmacotherapeutic treatment for the acute management of schizophrenia.", "Evaluation of peripheral dopamine receptor and alpha - adrenoceptor blocking activity of sulpiride .", "Compared with the pure sulpiride group , the sulpiride combined with storax group showed an increase of concentration by 39% in brain and 69% in blood . CONCLUSION Storax can notably increase the concentration of sulpiride in rat brain and blood , indicating that it can increase the permeation of sulpiride through gastrointestinal barrier and BBB .", "RESULTS Highly significant differences in favour of Sulpiride were shown in both gastric and duodenal ulcer cases, maximum from the 20th day than less significative radiological results appeared.", "Chronic sulpiride administration did not affect bodyweight gain and food intake .", "This study objectively evaluates the activity of Sulpiride in gastro - duodenal ulcers .", "of Sulpiride or placebo for 12 days, followed by 3 capsules daily of 50 mgs of Sulpiride or placebo for 48 days.", "Autonomic effects occur less frequently with sulpiride than with typical antipsychotics, showing no clinically relevant influence on cardiovascular parameters and, on the whole, good tolerability in elderly patients.", "carnitine / organic cation transporter ( OCTN ) 2 , MDR1 and BCRP . The accumulation of sulpiride in primary human trophoblast cells was obviously affected by inhibitors of OCT3 , OCTN1 and OCTN2 .", "It is still doubtful whether sulpiride is more effective than typical antipsychotics for the treatment of negative symptoms .", "The acute effects of sulpiride show that this drug is active at the perifornical lateral hypothalamus , which is a brain area where blockade of dopamine receptors stimulates feeding .", "Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors 1.", "Sulpiride does not block D1, adrenergic, cholinergic, gamma-aminobutyric acid-ergic, histaminergic, or serotonergic receptors to an appreciable extent.", "transfected cells expressing respective transporters . In addition , the accumulation of sulpiride in BeWo cells ( a human choriocarcinoma cell line ) was obviously affected by inhibitors of"], "par_relations": ["Benzamides", "Antipsychotic Agents", "Dopamine Antagonists", "Antidepressive Agents, Second-Generation", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride"], "chd_relations": ["Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride", "DO 710", "iodosulpride", "RIV 2093", "sultopride", "veralipride", "levosulpiride", "dogmagel", "N-((1-ethyl-5-oxo-2-pyrrolidinyl)methyl)-5-sulfamoyl-2-anisamide", "ROL 1943", "4-azidosulpiride"], "syn_relations": ["Sulpiride", "Sulpiride", "Sulpiride", "Sulpiride"], "sib_relations": ["Acecainide", "Aminohippuric Acids", "Bezafibrate", "DEET", "Dinitolmide", "Hippurates", "Indoramin", "Metoclopramide", "Procainamide", "Procarbazine", "Moclobemide", "Cisapride", "Raclopride", "Remoxipride", "Tiapride Hydrochloride", "Imatinib Mesylate"], "wiki_entities": ["Sulpiride", "Levosulpiride", "List of psychiatric medications", "Benzamide", "Modal", "C15H23N3O4S", "Dopamine antagonist", "Amisulpride", "Tiapride", "Sultopride"], "mesh_synonynms": ["vertigo neogama", "ekilid", "desisulpid", "digton", "meresa", "eglonyl", "psicocen", "sulpivert", "dolmatil", "vertigo meresa", "pontiride", "tepavil", "sulpiride", "sulpor", "lebopride", "sulpitil", "deponerton", "guastil", "aiglonyl", "synédil", "arminol", "neogama", "sulp", "dogmatil", "vertigo-meresa", "vertigo-neogama", "sulperide"], "dbpedia_synonyms": ["eusulpid", "eclorion", "stamonevrol", "championyl", "eglonil", "alimoral", "sulpride", "isnamide", "valirem", "meresa", "splotin", "normum", "espiride", "coolspan", "mirbanil", "eglonyl", "levopraid", "psicocen", "dogmatyl", "abilit", "trilan", "desmenat", "calmoflorine", "misulvan", "dolmatil", "sernevin", "zemorcon", "nufarol", "omperan", "omiryl", "fardalan", "equilid", "sulpiride", "pyrkappl", "synedil", "fidelan", "levobren", "bosnyl", "miradol", "pyrikappl", "norestran", "lisopiride", "sulpitil", "guastil", "suprium", "dobren", "sursumid", "enimon", "aiglonyl", "neogama", "dogmatil", "dresent", "darleton", "atcvet code qn05al01", "kylistro", "atc code n05al01", "mariastel", "ozoderpin"]}, "target_ent": {"research_entity_id": "RXNORM:203636", "canonical_name": "Dogmatil", "aliases": ["dogmatil"], "definition": "Sulpiride (brand names Dogmatil ( DE, HK, SG, PH), Dolmatil (IE, UK), Eglonyl (RU, ZA), Espiride (ZA), Modal (IL), Prometar (UY), Sulpor (UK) and others) is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression.", "other_contexts": ["[ Long - term use of 200 mg Dogmatil .", "A retrospective study of the follow up in 13 patients under maintenance Dogmatil 200 mg treatment ( 1 to 12 years ) establishes the drug 's effectiveness and tolerance .", "However , in a non - negligible number of cases , the clinical effect of Dogmatil is clearly noticeable by the patient himself after 48 hours .", "[ Sulpiride ( Dogmatil ) .", "[ Long - term dogmatil therapy in major psychiatry ] .", "In most instances , Dogmatil is prescribed in a daily dose of 150 to 200 mg for 4 to 6 weeks , usually in the form of capsules .", "Clinical and pharmacological investigation of a new psychotropic drug sulpiride ( Dogmatil ) .", "Dogmatil , whose effectiveness on vertigo resulting from peripheral causes is well - documented , is just as potent in central vestibular disorders .", "[ Effect of dogmatil on postoperative depression ] .", "The observations of six patients , who were given dogmatil as the main psychopharmaceutical agent for 6 to 13 years , are studied .", "High performance liquid chromatographic determination of sulpiride ( Dogmatil ) in urine .", "[ Double blind test results on efficacy of the new antivertiginous drug sulpiride ( dogmatil ) ( author 's transl ) ] .", "[ Dogmatil and vertigo in the aged subject .", "Dogmatil is an advantageous alternative to incisive neuroleptics .", "Three or four days are usually needed for the effect of Dogmatil to become apparent .", "[ Clinical - neuroleptic investigation of N-((1-ethyl - pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl - benzamide - neuroleptic sulpiride ( Dogmatil ) in acutly ill schizophrenics ] .", "[ Study of the disinhibitory effect of Dogmatil in defectual psychosis ] .", "Dogmatil is remarkably well - tolerated by the elderly , whether it is given as the sole medication or associated with other drugs which can not be discontinued , such as those prescribed for cardiovascular or respiratory disorders ."], "par_relations": ["Sulpiride"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Sulpiride 400 MG [Dogmatil]", "Dogmatil 400 MG Oral Tablet", "Sulpiride Oral Tablet [Dogmatil]", "Dogmatil Oral Product", "Dogmatil Pill"], "wiki_entities": ["Sulpiride", "List of psychiatric medications by condition treated", "Antipsychotic"], "mesh_synonynms": ["vertigo neogama", "ekilid", "desisulpid", "digton", "meresa", "eglonyl", "psicocen", "sulpivert", "dolmatil", "vertigo meresa", "pontiride", "tepavil", "sulpiride", "sulpor", "lebopride", "sulpitil", "deponerton", "guastil", "aiglonyl", "synédil", "arminol", "neogama", "sulp", "vertigo-meresa", "vertigo-neogama", "sulperide"], "dbpedia_synonyms": ["sulpiride"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D000068580", "canonical_name": "Varenicline", "aliases": ["varenicline", "champix", "6,7,8,9-tetrahydro-6,10-methano-6h-pyrazino(2,3-h)benzazepine", "chantix", "tartrate, varenicline", "varenicline tartrate"], "definition": "Varenicline (trade name Chantix and Champix), is a prescription medication used to treat nicotine addiction.", "other_contexts": [], "par_relations": ["Benzazepines", "Quinoxalines", "Nicotinic Agonists", "Varenicline", "Varenicline", "Varenicline"], "chd_relations": ["Varenicline", "Varenicline", "Varenicline"], "syn_relations": ["Varenicline", "Varenicline"], "sib_relations": ["Tobacco Use Cessation Products", "Benzodiazepines", "Carbadox", "Diltiazem", "Echinomycin", "Galantamine", "Harringtonines", "Fenoldopam", "Brimonidine Tartrate", "6-Cyano-7-nitroquinoxaline-2,3-dione", "Tyrphostins", "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine"], "wiki_entities": ["Varenicline", "Cytisine", "Benzazepine", "Nicotinic agonist", "Persistent genital arousal disorder", "Alpha-3 beta-2 nicotinic receptor", "Respiratory Pharmacology", "Nicotine withdrawal", "Dianicline", "Jed Rose (scientist)"], "mesh_synonynms": ["varenicline tartrate", "champix", "tartrate, varenicline", "6,7,8,9-tetrahydro-6,10-methano-6h-pyrazino(2,3-h)benzazepine", "varenicline", "chantix"], "dbpedia_synonyms": ["atc code n07ba03", "atcvet code qn07ba03", "c13h13n3", "varenicline tartrate", "champix", "smoking pill", "varenicline", "chantix"]}, "target_ent": {"research_entity_id": "RXNORM:591622", "canonical_name": "varenicline", "aliases": ["varenicline"], "definition": "Varenicline (trade name Chantix and Champix), is a prescription medication used to treat nicotine addiction.", "other_contexts": ["β2 nAChR mechanisms . Separate groups of male C57BL/6J mice were trained to discriminate varenicline ( 3.2 mg / kg ) or nicotine ( 1 mg / kg ) . Test drugs included mecamylamine ; the nAChR agonists", "The pharmacokinetic parameters of varenicline were dose proportional over the dose range from 0.5 to 2 mg / d .", ". The purpose of this study was to characterize the discriminative stimulus effects of varenicline and nicotine using various nAChR agonists and antagonists to elucidate possible non-α4β2 nAChR", "effects of varenicline . Physicians should bear in mind the toxic effects of varenicline on the cardiovascular system when prescribing it for smoking cessation .", "RESULTS We identified 575 smokers among 690 patients ( 83.3% ) , and assessed 82 courses of varenicline treatment prescribed to 70 smokers .", "Varenicline is widely used worldwide to help smoking cessation, but some published studies have reported associated cardiovascular events.", "about serious adverse neuropsychiatric adverse events as implying a causal effect of varenicline . This warning does not reflect current scientific evidence accurately and should be revised . (", "The present study showed that varenicline produced a dose - dependent bidirectional cross - sensitization with nicotine .", "In conclusion, varenicline is an effective aid to smoking cessation.", ", induced lipid peroxidation , and reduced antioxidant activity . Both acute and chronic varenicline exposure caused impairment of mean oxygen saturation . QT interval was prolonged in the chronic", "higher success rates ( continuous abstinence rates at 52 weeks ) with combination varenicline and bupropion ( 55.0% ; compared to varenicline monotherapy ( 32.1% ) , p < 0.001 ) . Subgroup", "h/mL for varenicline 1 mg BID and 95.7 ng .", "These results suggest that α4β2 * nAChRs differentially mediate the discriminative stimulus effects of nicotine and varenicline , and suggest that varenicline has substantial non-α4β2 nAChR activity .", "by nicotine and varenicline in rats . Furthermore , it examined the influence of varenicline , a partial alpha4beta2 nicotinic receptor agonist , on nicotine - induced sensitization . To", "and expression of nicotine - induced sensitization of locomotor activity in the rat . Varenicline did not induce sensitization on its own . When varenicline and nicotine were repeatedly", "seen in the clinical setting , and whether such effects contribute to the actions of varenicline as a smoking cessation aid .", "Physicians should bear in mind the toxic effects of varenicline on the cardiovascular system when prescribing it for smoking cessation .", "Patients and clinicians are likely to interpret the FDA Black Box warning about serious adverse neuropsychiatric adverse events as implying a causal effect of varenicline.", "Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation.", ". In varenicline - trained mice , maximum varenicline - appropriate responding was 90% varenicline , 86% epibatidine , 74% cytisine , 80% RTI-102 , 50% cocaine , and 50% or less for nicotine , PNU-2", "The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice The extent to which non-α4β2 versus α4β2 * nAChRs contribute to the behavioral effects of varenicline and other nAChR agonists is unclear .", "Longitudinal studies would be needed to see if similar effects are seen in the clinical setting , and whether such effects contribute to the actions of varenicline as a smoking cessation aid .", "drugs included mecamylamine ; the nAChR agonists epibatidine , nicotine , cytisine , varenicline , and RTI-102 ; the β2-containing nAChR antagonist dihydro-β-erythroidine ( DHβE ) ; the α7 nAChR", "Among high - body - weight subjects , adverse events ( AEs ) were reported by 57.1% of subjects in both the high- and low - dose varenicline groups and by 14.3% of subjects in the placebo group ; among low - body - weight subjects , AEs were reported by 64.3% , 73.3% , and 12.5% of subjects in the high - dose varenicline , low - dose varenicline , and placebo groups , respectively .", "Anecdotal reports from popular press and internet sites , in addition to post - marketing case reports and reports to the FDA 's Adverse Event Reporting System ( AERS ) , suggested that some patients prescribed varenicline had experienced suicidal behaviour [ 2 ] .", "Varenicline in the management of smoking cessation : a single technology appraisal .", "h / mL for varenicline 0.5 mg BID , consistent with values reported previously in adult smokers at the equivalent doses .", "NRT with either varenicline or bupropion . However , recent studies have examined varenicline and bupropion in combination . OBJECTIVES A systematic review assessing the efficacy and safety of", "1193 total patients . RESULTS Combination therapy yielded greater efficacy than varenicline monotherapy in two randomized controlled trials and one retrospective outcomes study . One single -", "Some of these events may be associated with nicotine withdrawal, rather than varenicline, although neuropsychiatric events have been observed in individuals who continued to smoke whilst receiving varenicline.", ". The success rate of the 6-month smoking cessation was 63.6% in the group that received varenicline for 12 weeks or longer , which was higher than 41.1% of the group that early terminated the", "novel pharmacotherapy combination for smoking cessation . Combination bupropion SR and varenicline displayed greater efficacy in smoking cessation than varenicline monotherapy , though further", "The submission presented a state transition model to estimate the incremental cost-effectiveness of varenicline compared with bupropion, NRT and placebo.", "In nicotine-trained mice, maximum nicotine-appropriate responding was 95% nicotine, 94% epibatidine, 63% varenicline, 58% cytisine, and less than 50% for RTI-102, PNU-282987, midazolam, and cocaine.", "for 12 weeks , as recommended . This study analyzed the subjects who received varenicline and investigated the effect of varenicline treatment duration on the success rate of 6-month", "RESULTS Acute varenicline exposure resulted in loss of body weight , while chronic varenicline exposure caused heart weight loss and decreased mean blood pressure , induced lipid peroxidation , and reduced antioxidant activity .", "\" , \" bupropion combination \" , \" bupropion AND varenicline \" , and \" bupropion AND varenicline combination smoking cessation \" , yielding four studies including 1193 total patients . RESULTS", "Twenty-two subjects (28.2%) had varenicline treatment for 12 weeks or longer; 18 subjects (23.1%) for 8~12 weeks; 22 subjects (28.2%) for 4~8 weeks; and 16 subjects (20.5%) for less than 4 weeks.", "METHODS This study retrospectively analyzed 78 subjects, who received varenicline, out of the 105 smokers that had visited the smoking cessation clinic after medical examination from September 2007 to December 2009.", "Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.", "studies , which can suffer from residual confounding , could not prove that varenicline did not cause neuropsychiatric adverse events . Nevertheless , they …", "nicotine replacement therapy ( NRT ) using propensity scores . Patients prescribed varenicline were no more likely than those prescribed NRT to be hospitalized for psychiatric problems [ hazard", "locomotor activity , nor did it attenuate nicotine - induced sensitization . However , varenicline did cross - sensitize to the effects of nicotine , and vice versa . The present study showed that", "In conclusion, varenicline is likely to be clinically and cost-effective for smoking cessation assuming that each user makes a single quit attempt.", "Varenicline was also dominant or cost effective versus nicotine replacement therapy , and cost effective versus unaided cessation .", "As a result , in November 2007 the FDA announced that they were conducting two safety reviews of varenicline 's associations with suicidality and neuropsychiatric adverse events not related to suicidality [ 3 ] .", "the discriminative stimulus and rate - decreasing effects of nicotine but not varenicline in either the nicotine or varenicline discrimination assays . The discriminative stimulus , but", "2009 . RESULTS The subjects were all males . Twenty - two subjects ( 28.2% ) had varenicline treatment for 12 weeks or longer ; 18 subjects ( 23.1% ) for 8~12 weeks ; 22 subjects ( 28.2% )", "Observational studies , which can suffer from residual confounding , could not prove that varenicline did not cause neuropsychiatric adverse events .", "The effect of varenicline on the development and expression of nicotine - induced behavioral sensitization and cross - sensitization in rats .", "patients smoke cigarettes , yet few data exist on the prevalence and outcomes of varenicline treatment among smokers with comorbid substance use and psychiatric disorders . METHODS We", "Both cardiovascular risk factors and psychiatric illness were highly prevalent among those prescribed varenicline: hypertension, 51%; hyperlipidemia, 23%; diabetes, 20%; depression, 53%; anxiety, 30%; psychotic disorders, 10%; bipolar disorder, 8.6%.", "with nicotine . Taken together , these findings provide pre - clinical evidence that varenicline is able to attenuate the effects of nicotine , yet simultaneously ' substitutes ' for the effects", "The model suggests that varenicline dominates bupropion, NRT and placebo.", "two groups : 1 ) the control group ( given only distilled water orally , n=10 ) and the varenicline group ( given 9 μg / kg / day varenicline on days 1 - 3 , 9 μg / kg twice daily on days 4 - 7 ,", "morphological heart damage in both groups . CONCLUSION Adverse effects of chronic varenicline exposure on cardiovascular tissue were confirmed by our electrocardiographic , biochemical , and", "Acute varenicline blocked the expression of nicotine-induced sensitization in a dose-dependent manner.", "The success rate of the 6-month smoking cessation was 63.6% in the group that received varenicline for 12 weeks or longer, which was higher than 41.1% of the group that early terminated the varenicline treatment (p=0.074).", "using observational data from military veterans . Pfizer ( the manufacturer of varenicline ) was also instructed to undertake a large randomized trial : Evaluating Adverse Events in a", "The varenicline doses in the high-body-weight group were 1 mg BID and 0.5 mg BID; the varenicline doses in the low-body-weight group were 0.5 mg BID and 0.5 mg once daily.", "Varenicline was generally well tolerated during the 14-day treatment period.", "Combination bupropion SR and varenicline displayed greater efficacy in smoking cessation than varenicline monotherapy, though further safety analysis is warranted to rule out additive psychiatric adverse effects.", "(FDA) approved varenicline (Chantix, Champix) for use in smoking cessation; it was the first oral non-nicotine treatment licensed by the FDA since bupropion in 1997 [1].", "More data are needed regarding the potential for neuropsychiatric events in varenicline recipients.", "Two controlled trials of 12 weeks of varenicline versus sustained-release bupropion and placebo suggested that varenicline results in a statistically significant improvement in the odds of quitting at 12 weeks [odds ratio (OR) for quit rate during last 4 weeks of the study: 1.90-1.93 (p < 0.001) varenicline versus bupropion; 3.85 (p < 0.001) varenicline versus placebo).", "In modelled cost-effectiveness analyses based on data from clinical trials in participants receiving smoking cessation therapy, 12 weeks' treatment with varenicline was predicted to be cost effective from a healthcare payer perspective in numerous countries.", "Taken together, these findings provide pre-clinical evidence that varenicline is able to attenuate the effects of nicotine, yet simultaneously 'substitutes' for the effects of nicotine in the rat.", "was conducted . METHODS PubMed and Clinicaltrials.gov were searched using terms : \" varenicline combination \" , \" bupropion combination \" , \" bupropion AND varenicline \" , and \" bupropion AND", "12 weeks or longer , which was higher than 41.1% of the group that early terminated the varenicline treatment ( p=0.074 ) . The period of varenicline treatment was extended for one more week , the", "α4β2 * nAChRs differentially mediate the discriminative stimulus effects of nicotine and varenicline , and suggest that varenicline has substantial non-α4β2 nAChR activity .", ". METHODS We reviewed all patient charts of opioid - dependent smokers prescribed varenicline between May 2006 and December 2009 in two urban methadone clinics that also provide on - site", "Adherence to Varenicline and Abstinence Rates for Quitting Smoking in a Private Health Promotion Center - Based Smoking Cessation Clinic BACKGROUND Varenicline is an effective smoking cessation aid .", "Varenicline was generally well tolerated in clinical trials; nausea, the most commonly occurring adverse event, diminished over time.", "Varenicline did not induce sensitization on its own.", "Patients prescribed varenicline were no more likely than those prescribed NRT to be hospitalized for psychiatric problems [hazard ratio (HR) = 0.76; 95% confidence interval (95% CI) = 0.40–1.46] [3].", "Varenicline also reduced cravings, the reinforcing effects of smoking and some withdrawal symptoms.", "The apparent renal clearance ( CL / F ) and volume of distribution ( V / F ) of varenicline and the effect of body weight on these parameters were estimated using nonlinear mixed - effects modeling .", "Evaluation of the cardiovascular effects of varenicline in rats BACKGROUND Cardiovascular disease is an important cause of morbidity and mortality among tobacco users .", "We identified 575 smokers among 690 patients ( 83.3% ) , and assessed 82 courses of varenicline treatment prescribed to 70 smokers . Both cardiovascular risk factors and psychiatric illness were", "Separate groups of male C57BL/6J mice were trained to discriminate varenicline (3.2 mg/kg) or nicotine (1 mg/kg).", "However, varenicline did cross-sensitize to the effects of nicotine, and vice versa.", "will likely experience little harm and a great deal of benefit from treatment with varenicline for smoking cessation .", "CONCLUSIONS Varenicline steady - state exposure in study subjects weighing > 55 kg was similar to that observed previously in adults .", "Furthermore, it examined the influence of varenicline, a partial alpha4beta2 nicotinic receptor agonist, on nicotine-induced sensitization.", "and psychiatric care . We assessed prevalence , adverse events , and effectiveness of varenicline treatment in this cohort . RESULTS We identified 575 smokers among 690 patients ( 83.3% ) , and", "CONCLUSIONS Despite substantial comorbidity, opioid-dependent smokers receiving integrated substance abuse, medical and psychiatric care had few documented adverse events with varenicline treatment.", "Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.", "and clinical studies to evaluate the exact mechanism(s ) of the detrimental effects of varenicline . Physicians should bear in mind the toxic effects of varenicline on the cardiovascular system", ". RESULTS Acute varenicline exposure resulted in loss of body weight , while chronic varenicline exposure caused heart weight loss and decreased mean blood pressure , induced lipid peroxidation ,", "BACKGROUND Varenicline is approved as an aid to smoking cessation in adults aged > or =18 years.", "of behavioral sensitization and cross - sensitization induced by nicotine and varenicline in rats . Furthermore , it examined the influence of varenicline , a partial alpha4beta2 nicotinic", "This issue needs to be investigated with new experimental and clinical studies to evaluate the exact mechanism(s) of the detrimental effects of varenicline.", ", maximum nicotine - appropriate responding was 95% nicotine , 94% epibatidine , 63% varenicline , 58% cytisine , and less than 50% for RTI-102 , PNU-282987 , midazolam , and cocaine . In", "Methadone patients will likely experience little harm and a great deal of benefit from treatment with varenicline for smoking cessation.", "The FDA subsequently commissioned two large observational studies to investigate the potential neuropsychiat - ric effects of varenicline using observational data from military veterans .", "Varenicline was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events.", "Well designed clinical trials indicate that varenicline is an effective aid to smoking cessation.", "cessation aid . However , smokers prescribed with varenicline do not always receive varenicline for 12 weeks , as recommended . This study analyzed the subjects who received varenicline and", "Adverse events occurred in 30.8% of the subjects who received varenicline , but no serious adverse events were found .", "rates at 52 weeks ) with combination varenicline and bupropion ( 55.0% ; compared to varenicline monotherapy ( 32.1% ) , p < 0.001 ) . Subgroup analyses suggest that this combination may be more", "One patient initiated new psychiatric medications within six months of initiating varenicline, but did not discontinue varenicline.", "When varenicline and nicotine were repeatedly administered sequentially , varenicline blocked the development and expression of nicotine - induced sensitization .", "The costs associated with varenicline are offset by direct savings associated with the reduction in smoking - related diseases .", ". OBJECTIVES A systematic review assessing the efficacy and safety of combination varenicline and bupropion was conducted . METHODS PubMed and Clinicaltrials.gov were searched using terms : \"", "In the first, 14 311 patients prescribed varenicline were matched to similar patients prescribed nicotine replacement therapy (NRT) using propensity scores.", "blocked the development and expression of nicotine - induced sensitization . Acute varenicline blocked the expression of nicotine - induced sensitization in a dose - dependent manner . Acute", "world . Current cessation medications include nicotine replacement therapy ( NRT ) , varenicline , and bupropion , while combination therapy primarily entails NRT with either varenicline or", "caused impairment of mean oxygen saturation . QT interval was prolonged in the chronic varenicline group , while PR interval prolongation was statistically significant in both the control and acute", "Another well designed trial demonstrated that extending varenicline therapy by an additional 12 weeks helped maintain abstinence in individuals who had quit smoking .", "Therefore, an effort to improve drug compliance for varenicline in clinical practices could be helpful for the long-term success of smoking cessation.", "A placebo - controlled maintenance trial examined whether a further 12 weeks of varenicline would maintain the rate of abstinence among those successfully treated on one 12-week course [ OR = 2.48 at week 24 for varenicline versus placebo ( p < 0.001 ) ] .", "-102 , PNU-282987 , midazolam , and cocaine . In varenicline - trained mice , maximum varenicline - appropriate responding was 90% varenicline , 86% epibatidine , 74% cytisine , 80% RTI-102 , 50%", "PR interval prolongation was statistically significant in both the control and acute varenicline groups . Caspase-9 activity was also significantly increased by chronic exposure . Moreover ,", ". Findings from these reviews were published in 2008 , with the FDA concluding that ' [ varenicline ] may cause worsening of a current psychiatric illness even if it is currently under control and", "CONCLUSION Adverse effects of chronic varenicline exposure on cardiovascular tissue were confirmed by our electrocardiographic, biochemical, and histopathological analyses.", "There were no incident cardiac or vascular events within six months of varenicline prescription .", "Both acute and chronic varenicline exposure caused impairment of mean oxygen saturation .", ". One patient initiated new psychiatric medications within six months of initiating varenicline , but did not discontinue varenicline . There were no reports of suicidal ideation , agitation", "'s Adverse Event Reporting System ( AERS ) , suggested that some patients prescribed varenicline had experienced suicidal behaviour [ 2 ] . As a result , in November 2007 the FDA announced that", "studies were reported in October 2011 . In the first , 14 311 patients prescribed varenicline were matched to similar patients prescribed nicotine replacement therapy ( NRT ) using propensity", ", and bupropion , while combination therapy primarily entails NRT with either varenicline or bupropion . However , recent studies have examined varenicline and bupropion in combination .", "the group that early terminated the varenicline treatment ( p=0.074 ) . The period of varenicline treatment was extended for one more week , the odds ratio of the 6-month smoking cessation success", "Some ( 8.6% ) varenicline - treated smokers quit smoking , and cessation was significantly associated with varenicline treatment duration .", "The purpose of this study was to characterize the discriminative stimulus effects of varenicline and nicotine using various nAChR agonists and antagonists to elucidate possible non-α4β2 nAChR mechanisms .", "and rate - decreasing effects of nicotine but not varenicline in either the nicotine or varenicline discrimination assays . The discriminative stimulus , but not the rate - decreasing , effects of", "The body-weight effect on varenicline pharmacokinetics, which resulted in higher exposure in individuals of smaller body size (< or =55 kg), was adequately offset by administration of half the varenicline dose recommended in adults.", ", 53% ; anxiety , 30% ; psychotic disorders , 10% ; bipolar disorder , 8.6% . Of 82 varenicline courses , nine ( 11% ) were discontinued due to adverse events and two due to depressive symptoms .", "smoking cessation increases . Therefore , an effort to improve drug compliance for varenicline in clinical practices could be helpful for the long - term success of smoking cessation .", "interval ( 95% CI ) = 0.40–1.46 ] [ 3 ] . In the second , 10 814 patients prescribed varenicline were matched to patients prescribed NRT . This study also showed that patients prescribed", "This study analyzed the subjects who received varenicline and investigated the effect of varenicline treatment duration on the success rate of 6-month smoking cessation .", "risk factors and psychiatric illness were highly prevalent among those prescribed varenicline : hypertension , 51% ; hyperlipidemia , 23% ; diabetes , 20% ; depression , 53% ; anxiety , 30% ;", "In high-body-weight subjects, steady-state varenicline exposure, as represented by the AUC(0-24), was 197.0 ng .", "medications within six months of initiating varenicline , but did not discontinue varenicline . There were no reports of suicidal ideation , agitation prompting clinical intervention , or", "who received varenicline , but no serious adverse events were found . CONCLUSION If varenicline treatment period is extended , the odds ratio of the success rate for the 6-month smoking", "development of behavioral sensitization , rats were chronically treated with vehicle , varenicline ( 0.03 - 3.0 mg / kg ) , nicotine ( 0.4 mg / kg ) or combinations for 5 days and locomotor", "This study also showed that patients prescribed varenicline were no more likely to be hospitalized for psychiatric problems (HR = 1.14; 95% CI = 0.56–2.34) [6].", "A US decision-analytic model from the perspective of various US health insurance plans demonstrated that, after 2 years, varenicline was predicted to dominate bupropion SR, in terms of the incremental cost per additional smoking cessation.", "bupropion SR and varenicline displayed greater efficacy in smoking cessation than varenicline monotherapy , though further safety analysis is warranted to rule out additive psychiatric adverse", "in a Private Health Promotion Center - Based Smoking Cessation Clinic BACKGROUND Varenicline is an effective smoking cessation aid . However , smokers prescribed with varenicline do not", "Of 82 varenicline courses, nine (11%) were discontinued due to adverse events and two due to depressive symptoms.", "OBJECTIVE The goal of this study was to characterize the multiple - dose pharmacokinetics , safety , and tolerability of varenicline in adolescent smokers .", "Varenicline is an effective smoking cessation aid . However , smokers prescribed with varenicline do not always receive varenicline for 12 weeks , as recommended . This study analyzed the subjects", "acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice The extent to which non-α4β2 versus α4β2 * nAChRs contribute to the behavioral effects of", "However, recent studies have examined varenicline and bupropion in combination.", "We assessed prevalence, adverse events, and effectiveness of varenicline treatment in this cohort.", "CONCLUSION If varenicline treatment period is extended , the odds ratio of the success rate for the 6-month smoking cessation increases .", ", 1.052~1.305 ) . Adverse events occurred in 30.8% of the subjects who received varenicline , but no serious adverse events were found . CONCLUSION If varenicline treatment period is", "substance abuse , medical and psychiatric care had few documented adverse events with varenicline treatment . Methadone patients will likely experience little harm and a great deal of benefit from", "Subjects were randomized to receive 14 days of treatment with a high dose of varenicline , a low dose of varenicline , or placebo .", "Combination bupropion SR and varenicline for smoking cessation: a systematic review.", "Pfizer ( the manufacturer of varenicline ) was also instructed to undertake a large randomized trial : Evaluating Adverse Events in a Global Smoking Cessation Study ( EAGLES ) ( NCT:01456936 ) .", "To assess the development of behavioral sensitization , rats were chronically treated with vehicle , varenicline ( 0.03 - 3.0 mg / kg ) , nicotine ( 0.4 mg / kg ) or combinations for 5 days and locomotor activity was measured .", "Test drugs included mecamylamine; the nAChR agonists epibatidine, nicotine, cytisine, varenicline, and RTI-102; the β2-containing nAChR antagonist dihydro-β-erythroidine (DHβE); the α7 nAChR agonist PNU-282987; the α7 antagonist methyllycaconitine (MLA); the α3β4 antagonist 18-methoxycoronaridine (18-MC); and the non-nAChR drugs midazolam and cocaine.", "Moreover , in Swedish analyses that also included societal costs for production and consumption , the incremental cost per QALY gained for varenicline versus bupropion SR , and for an additional 12 weeks of varenicline therapy versus varenicline for 12 weeks only , was below commonly accepted thresholds of cost effectiveness .", "The meta-analysis suggested that varenicline was superior to placebo and bupropion at 1 year and 3 months.", "The present study focused on the evaluation of behavioral sensitization and cross-sensitization induced by nicotine and varenicline in rats.", ", in November 2007 the FDA announced that they were conducting two safety reviews of varenicline 's associations with suicidality and neuropsychiatric adverse events not related to suicidality [ 3", "cessation . METHODS This study retrospectively analyzed 78 subjects , who received varenicline , out of the 105 smokers that had visited the smoking cessation clinic after medical examination", "large observational studies to investigate the potential neuropsychiat - ric effects of varenicline using observational data from military veterans . Pfizer ( the manufacturer of varenicline ) was", "In varenicline-trained mice, maximum varenicline-appropriate responding was 90% varenicline, 86% epibatidine, 74% cytisine, 80% RTI-102, 50% cocaine, and 50% or less for nicotine, PNU-282987, and midazolam.", "the expression of nicotine - induced sensitization in a dose - dependent manner . Acute varenicline did not significantly increase locomotor activity , nor did it attenuate nicotine - induced", "illness to reoccur ' [ 4 ] . In July 2009 the FDA went further , mandating that varenicline carry a ' Black Box warning ' [ 5 ] . These warnings highlighted ' the risk of serious neuro -", ". There were no incident cardiac or vascular events within six months of varenicline prescription . Some ( 8.6% ) varenicline - treated smokers quit smoking , and cessation was", "The ORs for sustained abstinence ( weeks 9 - 52 ) for varenicline versus bupropion were 1.77 ( p = 0.004 ) and 1.46 ( p = 0.057 ) , and for varenicline versus placebo were 2.66 - 3.09 ( p < 0.01 ) .", "The period of varenicline treatment was extended for one more week, the odds ratio of the 6-month smoking cessation success increased to 1.172-folds (p=0.004; 95% confidence interval, 1.052~1.305).", "histopathological analyses ( including immunostaining ) were performed . RESULTS Acute varenicline exposure resulted in loss of body weight , while chronic varenicline exposure caused heart weight", "disease is an important cause of morbidity and mortality among tobacco users . Varenicline is widely used worldwide to help smoking cessation , but some published studies have reported", "Treatment efficacy was based on a pooled analysis of 1-year quit rates from the varenicline clinical trials .", "The retrospective study displayed higher success rates (continuous abstinence rates at 52 weeks) with combination varenicline and bupropion (55.0%; compared to varenicline monotherapy (32.1%), p < 0.001).", "- treated smokers quit smoking , and cessation was significantly associated with varenicline treatment duration . CONCLUSIONS Despite substantial comorbidity , opioid - dependent smokers", "In the second, 10 814 patients prescribed varenicline were matched to patients prescribed NRT.", "only distilled water orally , n=10 ) and the varenicline group ( given 9 μg / kg / day varenicline on days 1 - 3 , 9 μg / kg twice daily on days 4 - 7 , and 18 μg / kg twice daily on days 8 - 90 [", "RESULTS Combination therapy yielded greater efficacy than varenicline monotherapy in two randomized controlled trials and one retrospective outcomes study.", "or vascular events within six months of varenicline prescription . Some ( 8.6% ) varenicline - treated smokers quit smoking , and cessation was significantly associated with varenicline", "using terms : \" varenicline combination \" , \" bupropion combination \" , \" bupropion AND varenicline \" , and \" bupropion AND varenicline combination smoking cessation \" , yielding four studies", "During the last 4 weeks of treatment , carbon monoxide - confirmed continuous abstinence rates were generally significantly higher with varenicline than with placebo , bupropion sustained release ( SR ) or nicotine replacement therapy .", "Based on indirect comparisons, varenicline was reported to be superior to NRT when compared with placebo or all controls at 1 year and 3 months.", "h/mL for varenicline 0.5 mg BID and 60.1 ng .", "58% cytisine , and less than 50% for RTI-102 , PNU-282987 , midazolam , and cocaine . In varenicline - trained mice , maximum varenicline - appropriate responding was 90% varenicline , 86%", "Acute varenicline did not significantly increase locomotor activity, nor did it attenuate nicotine-induced sensitization.", "extent to which non-α4β2 versus α4β2 * nAChRs contribute to the behavioral effects of varenicline and other nAChR agonists is unclear . The purpose of this study was to characterize the", "Findings from these reviews were published in 2008 , with the FDA concluding that ' [ varenicline ] may cause worsening of a current psychiatric illness even if it is currently under control and may cause an old psychiatric illness to reoccur ' [ 4 ] .", "Current cessation medications include nicotine replacement therapy ( NRT ) , varenicline , and bupropion , while combination therapy primarily entails NRT with either varenicline or bupropion .", "matched to patients prescribed NRT . This study also showed that patients prescribed varenicline were no more likely to be hospitalized for psychiatric problems ( HR = 1.14 ; 95% CI = 0.56–2.34 )", "h / mL for varenicline 0.5 mg once daily , values at the lower end of the range observed previously in adults at doses of 1 mg BID and 0.5 mg BID , respectively .", "In July 2009 the FDA went further, mandating that varenicline carry a 'Black Box warning' [5].", "QT interval was prolonged in the chronic varenicline group, while PR interval prolongation was statistically significant in both the control and acute varenicline groups.", "OBJECTIVES A systematic review assessing the efficacy and safety of combination varenicline and bupropion was conducted .", "study analyzed the subjects who received varenicline and investigated the effect of varenicline treatment duration on the success rate of 6-month smoking cessation . METHODS This study", "Most drug treatment patients smoke cigarettes , yet few data exist on the prevalence and outcomes of varenicline treatment among smokers with comorbid substance use and psychiatric disorders . METHODS We reviewed all patient charts of opioid - dependent smokers prescribed varenicline between May 2006 and December 2009 in two urban methadone clinics that also provide on - site medical and psychiatric care .", "Pharmacokinetics , safety , and tolerability of varenicline in healthy adolescent smokers : a multicenter , randomized , double - blind , placebo - controlled , parallel - group study .", "Assuming a willingness-to-pay threshold range of 20,000-30,000 pounds per quality-adjusted life-year gained, the probabilistic sensitivity analysis suggests that the probability that varenicline produces the greatest amount of net benefit is 0.70.", "This paper presents a summary of the submission 's evidence for the clinical effectiveness and cost - effectiveness of varenicline for smoking cessation included four studies of varenicline ( one of which was commercial - in - confidence ) and a meta - analysis of varenicline versus nicotine replacement therapy ( NRT ) , bupropion and placebo .", "DHβE antagonized the discriminative stimulus and rate - decreasing effects of nicotine but not varenicline in either the nicotine or varenicline discrimination assays .", "activity in the rat . Varenicline did not induce sensitization on its own . When varenicline and nicotine were repeatedly administered sequentially , varenicline blocked the development and", "With regard to the incremental costs per QALY or life - year gained , 12 weeks ' treatment with varenicline consistently dominated bupropion SR and nicotine replacement therapy and was dominant over or considered cost effective relative to unaided cessation , regular brief counselling or nortriptyline in analyses based on Markov models .", "on its own . When varenicline and nicotine were repeatedly administered sequentially , varenicline blocked the development and expression of nicotine - induced sensitization . Acute varenicline", "METHODS PubMed and Clinicaltrials.gov were searched using terms : \" varenicline combination \" , \" bupropion combination \" , \" bupropion AND varenicline \" , and \" bupropion AND varenicline combination smoking cessation \" , yielding four studies including 1193 total patients .", "- sensitize to the effects of nicotine , and vice versa . The present study showed that varenicline produced a dose - dependent bidirectional cross - sensitization with nicotine . Taken together ,", "The guidance issued by the National Institute for Health and Clinical Excellence in July 2007 states that varenicline is recommended within its licensed indications as an option for smokers who have expressed a desire to quit smoking and that varenicline should normally be prescribed only as part of a programme of behavioral support .", "MATERIALS AND METHODS We randomly separated 34 rats into two groups: 1) the control group (given only distilled water orally, n=10) and the varenicline group (given 9 μg/kg/day varenicline on days 1-3, 9 μg/kg twice daily on days 4-7, and 18 μg/kg twice daily on days 8-90 [total 83 days], n=24).", "stimulus effects , but not the rate - decreasing effects , of nicotine and varenicline . DHβE antagonized the discriminative stimulus and rate - decreasing effects of nicotine but not", "the discriminative stimulus effects of nicotine and varenicline , and suggest that varenicline has substantial non-α4β2 nAChR activity .", "cardiovascular events . OBJECTIVE To determine the cardiovascular toxicity induced by varenicline in rats . MATERIALS AND METHODS We randomly separated 34 rats into two groups : 1 ) the control", "In low - body - weight subjects , varenicline exposure was 126.3 ng .", "In additional modelled analyses from a healthcare payer perspective , administering varenicline for an additional 12 weeks in participants who had successfully quit smoking was estimated to have acceptable incremental costs per QALY gained relative to varenicline for 12 weeks and to dominate other smoking cessation options .", "Mecamylamine antagonized the discriminative stimulus effects, but not the rate-decreasing effects, of nicotine and varenicline.", "OBJECTIVE To determine the cardiovascular toxicity induced by varenicline in rats .", "However, smokers prescribed with varenicline do not always receive varenicline for 12 weeks, as recommended.", "The estimated varenicline V / F was decreased in individuals of small body size , thus predicting a varenicline C(max ) approximately 30% greater in low - body - weight subjects than in high - body - weight subjects .", "reflect current scientific evidence accurately and should be revised . ( FDA ) approved varenicline ( Chantix , Champix ) for use in smoking cessation ; it was the first oral non - nicotine", "Despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking.", "The Food and Drug Administration and varenicline : should risk communication be improved ?"], "par_relations": [], "chd_relations": ["varenicline tartrate", "Chantix"], "syn_relations": [], "sib_relations": ["varenicline 0.5 MG", "varenicline Oral Tablet", "varenicline 1 MG", "varenicline Oral Product", "varenicline Pill"], "wiki_entities": ["Varenicline", "Cytisine", "Benzazepine", "Nicotinic agonist", "Persistent genital arousal disorder", "Alpha-3 beta-2 nicotinic receptor", "Respiratory Pharmacology", "Nicotine withdrawal", "Dianicline", "Jed Rose (scientist)"], "mesh_synonynms": ["varenicline tartrate", "champix", "tartrate, varenicline", "6,7,8,9-tetrahydro-6,10-methano-6h-pyrazino(2,3-h)benzazepine", "chantix"], "dbpedia_synonyms": ["atc code n07ba03", "atcvet code qn07ba03", "c13h13n3", "varenicline tartrate", "champix", "smoking pill", "chantix"]}, "label": 1}
{"source_ent": {"research_entity_id": "HGNC:HGNC:4662", "canonical_name": "general transcription factor IIIA", "aliases": ["general transcription factor iiia", "gtf3a", "gtf3a gene", "tfiiia", "ap2"], "definition": "The retinoblastoma protein (protein name abbreviated pRb; gene name abbreviated RB or RB1) is a tumor suppressor protein that is dysfunctional in several major cancers.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["general transcription factor IIIA", "general transcription factor IIIA", "general transcription factor IIIA", "general transcription factor IIIA", "general transcription factor IIIA", "general transcription factor IIIA"], "sib_relations": [], "wiki_entities": ["GTF3A", "Zinc finger", "Metallothionein", "Hepatitis A", "Protein–protein interaction", "Sumerian language", "Linear A", "Endometrial cancer", "Mitochondrion", "Zinc finger nuclease"], "mesh_synonynms": ["gtf3a protein", "5s gene-specific transcription factor", "transcription factor tfiiia", "transcription factor iiia", "5s rna gene transcription factor", "5s gene specific transcription factor"], "dbpedia_synonyms": ["ap-2", "gtf3a (gene)", "gtf3a", "ap2 (disambiguation)", "tfiiia"]}, "target_ent": {"research_entity_id": "OMIM:600860", "canonical_name": "GENERAL TRANSCRIPTION FACTOR IIIA", "aliases": ["general transcription factor iiia", "tfiiia", "gtf3a"], "definition": "The retinoblastoma protein (protein name abbreviated pRb; gene name abbreviated RB or RB1) is a tumor suppressor protein that is dysfunctional in several major cancers.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["GENERAL TRANSCRIPTION FACTOR IIIA", "GENERAL TRANSCRIPTION FACTOR IIIA", "GENERAL TRANSCRIPTION FACTOR IIIA", "GENERAL TRANSCRIPTION FACTOR IIIA"], "sib_relations": [], "wiki_entities": ["GTF3A", "Zinc finger", "Metallothionein", "Hepatitis A", "Protein–protein interaction", "Sumerian language", "Linear A", "Endometrial cancer", "Mitochondrion", "Zinc finger nuclease"], "mesh_synonynms": ["gtf3a protein", "5s gene-specific transcription factor", "transcription factor tfiiia", "transcription factor iiia", "5s rna gene transcription factor", "5s gene specific transcription factor"], "dbpedia_synonyms": ["gtf3a (gene)", "tfiiia", "gtf3a"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D001139", "canonical_name": "Arnold-Chiari Malformation", "aliases": ["arnold-chiari malformation", "arnold chiari malformation, type 3", "arnold-chiari malformation, type 1", "type iv arnold-chiari malformation", "type i arnold chiari malformation", "chiari malformation type 2", "arnold chiari malformation, type ii", "deformity, arnold-chiari", "arnold-chiari malformation, type 3", "chiari malformation type ii", "arnold-chiari malformation, type iv", "arnold chiari malformation, type 1", "arnold chiari malformation", "arnold-chiari malformation, type 4", "arnold chiari syndrome", "type iv arnold chiari malformation", "arnold chiari malformation, type iv", "arnold chiari malformation, type 2", "arnold-chiari malformation, type i", "syndrome, arnold-chiari", "arnold-chiari malformation, type ii", "arnold chiari malformation, type 4", "type ii arnold chiari malformation", "arnold-chiari syndrome", "arnold-chiari malformation, type 2", "arnold chiari malformation, type i", "type i arnold-chiari malformation", "type iii arnold-chiari malformation", "type ii arnold-chiari malformation", "arnold chiari deformity", "malformation, arnold-chiari", "type iii arnold chiari malformation", "chiari malformation type i", "arnold chiari malformation, type iii", "arnold-chiari deformity", "malformation, arnold chiari", "arnold-chiari malformation, type iii"], "definition": "Chiari malformations (CMs) are structural defects in the cerebellum.", "other_contexts": [], "par_relations": ["Neural Tube Defects", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation"], "chd_relations": ["Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Chiari Malformation Type I with Syringomyelia"], "syn_relations": ["Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation", "Arnold-Chiari Malformation"], "sib_relations": ["Platybasia", "Anencephaly", "Encephalocele", "Meningocele", "Meningomyelocele", "Spinal Dysraphism", "Pentalogy of Cantrell"], "wiki_entities": [], "mesh_synonynms": ["arnold chiari malformation, type 1", "arnold chiari syndrome", "arnold-chiari malformation, type 4", "arnold chiari malformation", "chiari malformation type i", "arnold-chiari deformity", "arnold-chiari malformation", "type i arnold-chiari malformation", "chiari malformation type 2", "arnold-chiari malformation, type iii", "arnold-chiari malformation, type 1", "type ii arnold chiari malformation", "arnold chiari malformation, type 2", "type iv arnold chiari malformation", "syndrome, arnold-chiari", "arnold chiari malformation, type i", "arnold-chiari malformation, type i", "arnold chiari malformation, type iv", "arnold-chiari malformation, type ii", "arnold-chiari syndrome", "arnold chiari malformation, type ii", "arnold-chiari malformation, type 2", "arnold-chiari malformation, type iv", "arnold chiari malformation, type 4", "deformity, arnold-chiari", "malformation, arnold chiari", "type iii arnold chiari malformation", "type i arnold chiari malformation", "malformation, arnold-chiari", "arnold-chiari malformation, type 3", "chiari malformation type ii", "type iv arnold-chiari malformation", "arnold chiari malformation, type iii", "type iii arnold-chiari malformation", "arnold chiari malformation, type 3", "arnold chiari deformity", "type ii arnold-chiari malformation"], "dbpedia_synonyms": ["arnold–chiari malformation"]}, "target_ent": {"research_entity_id": "OMIM:207950", "canonical_name": "CHIARI MALFORMATION TYPE II", "aliases": ["chiari malformation type ii", "cm2", "arnold-chiari malformation"], "definition": "Chiari malformations (CMs) are structural defects in the cerebellum.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["CHIARI MALFORMATION TYPE II", "CHIARI MALFORMATION TYPE II", "CHIARI MALFORMATION TYPE II", "CHIARI MALFORMATION TYPE II"], "sib_relations": ["Ataxia", "Choking", "Heterotopias", "Dysphagia", "Hydrocephalus", "Hypotonia", "Spasticity", "Nystagmus", "Cervical myelopathy", "Opisthotonos", "Headache, occipital", "Poor feeding", "Inspiratory stridor", "Multifactorial", "Bulbar signs", "Herniation and elongation of the cerebellar tonsils, cerebellar vermis, brainstem, and fourth ventricle through the foramen magnum", "Small, thin cerebellum", "Absent cisterna magna", "Polygyria", "Ventricular anomalies", "Partial or total agenesis of the corpus callosum (33%)", "Subnormal intelligence (62%)", "Open spina bifida (myelomeningocele, 182940)", "Associated with syringomyelia (186700)", "Symptom onset at birth or infancy Arnold-Chiari type II is uniquely associated with myelomeninogocele (182940)", "Upper limb weakness", "Expiratory apnea with cyanosis"], "wiki_entities": ["Chiari malformation", "Interthalamic adhesion", "Cerebral shunt", "List of neurological conditions and disorders", "Loeys–Dietz syndrome", "Aortic dissection", "Congenital disorder", "Spontaneous cerebrospinal fluid leak", "Hereditary hemorrhagic telangiectasia", "List of diseases (C)"], "mesh_synonynms": ["arnold chiari malformation, type 1", "arnold chiari syndrome", "arnold-chiari malformation, type 4", "arnold chiari malformation", "chiari malformation type i", "arnold-chiari deformity", "arnold-chiari malformation", "type i arnold-chiari malformation", "chiari malformation type 2", "arnold-chiari malformation, type iii", "arnold-chiari malformation, type 1", "type ii arnold chiari malformation", "arnold chiari malformation, type 2", "type iv arnold chiari malformation", "syndrome, arnold-chiari", "arnold chiari malformation, type i", "arnold-chiari malformation, type i", "arnold chiari malformation, type iv", "arnold-chiari malformation, type ii", "arnold-chiari syndrome", "arnold chiari malformation, type ii", "arnold-chiari malformation, type 2", "arnold-chiari malformation, type iv", "arnold chiari malformation, type 4", "deformity, arnold-chiari", "malformation, arnold chiari", "type iii arnold chiari malformation", "type i arnold chiari malformation", "malformation, arnold-chiari", "arnold-chiari malformation, type 3", "type iv arnold-chiari malformation", "arnold chiari malformation, type iii", "type iii arnold-chiari malformation", "arnold chiari malformation, type 3", "arnold chiari deformity", "type ii arnold-chiari malformation"], "dbpedia_synonyms": ["cm2 (disambiguation)", "cm2"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D018901", "canonical_name": "Peroxisomal Disorders", "aliases": ["peroxisomal dysfunctions, single", "peroxisomal dysfunctions, general", "peroxisomal disorder", "acidemias, hyperpipecolic", "general peroxisomal dysfunctions", "dysfunctions, general peroxisomal", "peroxisomal dis", "neonatal adrenoleukodystrophies", "peroxisomal dysfunction, general", "single peroxisomal dysfunctions", "neonatal adrenoleukodystrophy", "adrenoleukodystrophy, autosomal, neonatal form", "peroxisomal disorders", "peroxisomal dysfunctions, multiple", "multiple peroxisomal dysfunction", "adrenoleukodystrophies, neonatal", "hyperpipecolatemia", "dysfunction, general peroxisomal", "adrenoleukodystrophy, autosomal neonatal form", "general peroxisomal dysfunction", "hyperpipecolic acidemias", "peroxisomal dysfunction, single", "single peroxisomal dysfunction", "dysfunction, multiple peroxisomal", "dysfunctions, multiple peroxisomal", "dysfunctions, single peroxisomal", "hyperpipecolic acidemia", "multiple peroxisomal dysfunctions", "dysfunction, single peroxisomal", "adrenoleukodystrophy, neonatal", "peroxisomal dysfunction, multiple", "acidemia, hyperpipecolic"], "definition": "Peroxisomal disorders represent a class of medical conditions caused by defects in peroxisome functions.", "other_contexts": ["In plasma from patients with peroxisomal disorders very long-chain fatty acids (VLCFA), pipecolic acid (PIPA), bile acids, and pristanic (PrA) and phytanic (PhA) acids accumulate in varying degree.", "We demonstrate that clinical manifestations of peroxisomal disorders may be very mild or completely atypical , and therefore , peroxisomal disorders should be considered in a variety of clinical settings .", "Detection and Quantification of Free Radicals in Peroxisomal Disorders :", "Because peroxisomes are involved in the metabolism of lipids critical to the functioning of the nervous system, many of the peroxisomal disorders manifest with significant degrees of progressive psychomotor dysfunction.", "Based on the fact that very long - chain fatty acylcarnitines are elevated in tissues and plasma from patients with certain peroxisomal disorders , we investigated whether phytanoyl- and pristanoyl - carnitine are also present in plasma from patients with different peroxisomal disorders .", "Twenty patients presented with a phenotype corresponding either to Zellweger syndrome, neonatal adrenoleukodystrophy, or infantile Refsum disease, 3 of whom had a peroxisomal disorder due to a single enzyme defect.", "Patients with peroxisomal disorders were subdivided according to diagnosis into peroxisomal biogenesis disorders and single enzyme deficiency.", "Hyperpipecolic acidaemia : a diagnostic tool for peroxisomal disorders .", "Depending on the main presenting sign , peroxisomal disorders in neonates should be suspected in two categories of circumstances : polymalformative syndrome with craniofacial dysmorphism , and severe neurological dysfunction .", "Some peroxisomal disorders have unique and specific clinical phenotypes , which may be diagnostic .", "Peroxisomal disorders result either from deficiency of a single peroxisomal enzyme or protein, or from a defect in the complex mechanism of peroxisomal biogenesis, resulting in deficiency of several or multiple peroxisomal functions.", "These results strongly support a role of free radicals in the pathophysiology of peroxisomal disorders and strengthen the importance of oxidative stress phenomenon in peroxisomal disorders pathogenesis.", "METHODS A total of 20 patients with peroxisomal disorders , aged six months to 13 years ( mean age 5.9 ± 3.2 years ) , were compared to 14 healthy controls .", "OBJECTIVE The aim of the work is to detect free oxide radicals in blood of patients with peroxisomal disorders and to study their relation with various oxidative stress parameters .", "Most of the peroxisomal disorders present with severe neurological abnormalities like psychomotor retardation , hypotonia , seizures , hearing deficiencies and ocular involvement ( see Wanders et al ( 1988 ) for a review ) .", "Peroxisomal disorders : Concentrations of metabolites in cerebrospinal fluid compared with plasma Peroxisomes are the metabolic sites of a variety of substrates that are poorly oxidized in mitochondria .", "Our study shows that phytanoyl- and pristanoyl - carnitine are indeed present in plasma samples from patients with different types of peroxisomal disorders , but only when the total plasma levels of their corresponding fatty acids , phytanic acid and pristanic acid , are markedly elevated .", "MATERIALS AND METHODS Twenty patients with peroxisomal disorders and 14 age and sex matched healthy subjects were included in the study.", "INTRODUCTION Free radicals have been thought to participate in pathogenesis of peroxisomal disorders .", "Current knowledge of peroxisomal biochemical and enzymatic processes permits precise identification of particular disorders within the peroxisomal disorder grouping .", "Clinical approach to inherited peroxisomal disorders : a series of 27 patients .", "Finally, 5 patients presented with clinical manifestations that were either unusually mild or completely atypical, and initially did not arouse suspicion of a peroxisomal disorder.", "An effort should be made to identify the specific peroxisomal disorder to provide a precise explanation for neurodevelopmental deficits, to potentially prevent recurrence through genetic counseling, and to provide appropriate therapies when available.", "Phytanic acid is a branched - chain fatty acid , the level of which is elevated in patients with a variety of peroxisomal disorders , including Refsum disease , and Rhizomelic chondrodysplasia punctata type 1 and 5 .", "These can be assessed by a battery of biochemical assays , enabling a biochemical phenotype to be defined that is specific and diagnostic for each of the peroxisomal disorders .", "there was decrease in superoxide dismutase levels in patients compared with control subjects. CONCLUSION We concluded that there is excess free radicals production accompanied with decrease in antioxidant defenses in patients with peroxisomal disorders.", "INTRODUCTION Peroxisomal disorders are subdivided into peroxisome biogenesis disorders (PBDs) and single peroxisomal enzyme deficiency.", "New developments include the identification of several additional peroxisomal disorders, the discovery of the primary defect in several of these peroxisomal disorders, the recognition of novel peroxisomal functions and the application of complementation analysis to obtain information on the genetic relationship between the different peroxisomal disorders.", "CONCLUSION This study sheds more light on the link between oxidative stress and peroxisomal disorders , as oxidative stress may be a hallmark of peroxisomal disorders .", "The prototype of peroxisomal disorders is represented by ‘", "Peroxisomal disorders .", "Evidence of oxidative stress in peroxisomal disorders .", "Furthermore , we suggest performing extensive peroxisomal investigations in every patient suspected of suffering from a peroxisomal disorder , even when the clinical presentation is typical .", "For all patients, pipecolic acid proved to be a useful parameter in the biochemical classification of peroxisomal disorders.", "Peroxisomal disorders include a complex spectrum of diseases, characterized by a high heterogeneity from both the clinical and the biochemical points of view.", "For the diagnosis of peroxisomal disorders , a variety of metabolites can be measured in blood samples from suspected patients , including very long - chain fatty acids , phytanic and pristanic acid .", "The peroxisomal disorders recognized at present comprise 12 different diseases , with neurological involvement in 10 of them .", "Clinical approach to inherited peroxisomal disorders At least 21 genetic disorders have now been found that are linked to peroxisomal dysfunction.", "Phenotypic variability (heterogeneity) of peroxisomal disorders.", "In this paper we report the analysis of VLCFA, bile acids diand trihydroxycholestanoic acids (DHCA and THCA), PrA and PhA in CSF from healthy individuals and some patients with various peroxisomal disorders, and comparison is made with plasma levels.", "The importance of peroxisomes in cellular metabolism is stressed by the existence of a group of inherited diseases , the peroxisomal disorders , caused by an impairment in one or more peroxisomal functions .", "We conclude that the measurement of phytanoyl- and pristanoyl - carnitine is not sensitive and specific enough to use these acylcarnitines as conclusive diagnostic markers for peroxisomal disorders .", "Whatever the genetic defect might be, peroxisomal disorders should be considered in various clinical conditions, dependent on the age of onset.", "Pipecolic acid was increased in all generalized peroxisomal disorders , while normal pipecolic acid with abnormal very long chain fatty acid concentrations was strong evidence for a single peroxisomal enzyme deficiency .", "Other peroxisomal disorders (pseudo-Zellweger syndrome, neonatal adrenoleukodystrophy (NALD), pseudo-neonatal adrenoleukodystrophy, rhizomelic chondrodysplasia punctata (RCDP), and hyperpipecolic acidaemia) share some of these symptoms, but with varying organ involvement, severity of dysfunction, and duration of survival.", "In the last decade our knowledge about peroxisomes and peroxisomal disorders has progressed enormously and has been the subject of several reviews .", "Identification and diagnostic value of phytanoyl- and pristanoyl - carnitine in plasma from patients with peroxisomal disorders .", "The peroxisomal disorders represent a group of inherited metabolic disorders that derive from defects of peroxisomal biogenesis and/or from dysfunction of single or multiple peroxisomal enzymes.", "In six patients the suggestion of a peroxisomal disorder was raised by the fortuitous finding of a pipecolic acid peak in amino acid chromatography, routinely performed as a general metabolic screening.", "Independently of the clinical symptoms and age of onset, most peroxisomal disorders described so far can be clinically screened by recordings of electroretinogram, visual-evoked responses, and brain auditory-evoked responses, which are almost always abnormal.", "This study aimed to investigate various oxidative stress parameters in patients suffering from peroxisomal disorders.", "Nine of the 17 peroxisomal disorders with neurological involvement are associated with an accumulation of very long-chain fatty acids (VLCFA), which suggests that assay of plasma VLCFA should be used as a primary test.", "Little is known about the pathogenesis of neurological symptoms encountered in peroxisomal disorders .", "Peroxisomal disorders in neurology .", "To illustrate the clinical and biochemical heterogeneity of peroxisomal disorders , we report our experience with 27 patients seen personally between 1982 and 1997 .", "The clinical heterogeneity of peroxisomal disorders constitutes a diagnostic challenge demanding a high index of suspicion on the clinician's part."], "par_relations": ["Peroxisomal Disorders", "Peroxisomal Disorders", "Metabolism, Inborn Errors", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders"], "chd_relations": ["Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Refsum Disease", "Zellweger Syndrome", "Adrenoleukodystrophy", "Acatalasia", "Refsum Disease, Infantile", "Chondrodysplasia Punctata, Rhizomelic", "Mevalonate Kinase Deficiency", "Peroxisome biogenesis disorders", "Peroxisome Biogenesis Disorder, Complementation Group 4", "Peroxisome Biogenesis Disorder, Complementation Group 14", "Peroxisome Biogenesis Disorder, Complementation Group J", "Bile acid synthesis defect, congenital, 4", "Peroxisome Biogenesis Disorder, Complementation Group 9", "Peroxisome Biogenesis Disorder, Complementation Group D", "Peroxisome Biogenesis Disorder, Complementation Group 12", "Peroxisome Biogenesis Disorder, Complementation Group G", "Peroxisome Biogenesis Disorder, Complementation Group 7", "Peroxisome Biogenesis Disorder, Complementation Group 1", "Peroxisome Biogenesis Disorder, Complementation Group E", "Peroxisome Biogenesis Disorder, Complementation Group K", "Peroxisome Biogenesis Disorder, Complementation Group 13", "Peroxisome Biogenesis Disorder, Complementation Group H", "Peroxisome Biogenesis Disorder, Complementation Group 3", "Peroxisome Biogenesis Disorder, Complementation Group 11", "Peroxisome Biogenesis Disorder, Complementation Group R"], "syn_relations": ["Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders", "Peroxisomal Disorders"], "sib_relations": ["Peroxisomes", "Amino Acid Metabolism, Inborn Errors", "Carbohydrate Metabolism, Inborn Errors", "Hyperbilirubinemia, Hereditary", "Lipid Metabolism, Inborn Errors", "Metal Metabolism, Inborn Errors", "Progeria", "Purine-Pyrimidine Metabolism, Inborn Errors", "Renal Tubular Transport, Inborn Errors", "Lysosomal Storage Diseases", "Cytochrome-c Oxidase Deficiency", "Amyloidosis, Familial", "Amino Acid Transport Disorders, Inborn", "Brain Diseases, Metabolic, Inborn", "Steroid Metabolism, Inborn Errors"], "wiki_entities": ["Peroxisomal disorder", "Peroxisome", "Zellweger syndrome", "Infantile Refsum disease", "D-bifunctional protein deficiency", "Inborn error of metabolism", "Peroxin", "Beta oxidation", "Adrenoleukodystrophy", "Refsum disease"], "mesh_synonynms": ["multiple peroxisomal dysfunctions", "peroxisomal disorder", "peroxisomal disorders", "dysfunctions, multiple peroxisomal", "peroxisomal dysfunctions, single", "neonatal adrenoleukodystrophies", "multiple peroxisomal dysfunction", "peroxisomal dysfunctions, general", "dysfunction, multiple peroxisomal", "hyperpipecolatemia", "neonatal adrenoleukodystrophy", "peroxisomal dysfunction, general", "adrenoleukodystrophy, autosomal, neonatal form", "peroxisomal dysfunction, single", "adrenoleukodystrophies, neonatal", "acidemia, hyperpipecolic", "peroxisomal dysfunction, multiple", "peroxisomal dysfunctions, multiple", "dysfunction, single peroxisomal", "adrenoleukodystrophy, autosomal neonatal form", "general peroxisomal dysfunctions", "single peroxisomal dysfunction", "hyperpipecolic acidemia", "general peroxisomal dysfunction", "hyperpipecolic acidemias", "adrenoleukodystrophy, neonatal", "dysfunctions, single peroxisomal", "single peroxisomal dysfunctions", "dysfunctions, general peroxisomal", "dysfunction, general peroxisomal", "acidemias, hyperpipecolic"], "dbpedia_synonyms": ["peroxisomal disease", "peroxisomal diseases", "peroxisomal disorder", "peroxisomal disorders", "pipecolic acidemia", "adrenoleukodystrophy", "peroxisomal defects", "peroxisome biogenesis disorders", "peroxisome biogenesis disorder"]}, "target_ent": {"research_entity_id": "OMIM:MTHU015267", "canonical_name": "Cholelithiasis (19% of adults)", "aliases": ["cholelithiasis (19% of adults)"], "definition": "Childhood obesity is a condition where excess body fat negatively affects a child's health or well-being.", "other_contexts": [], "par_relations": ["Biliary tract"], "chd_relations": [], "syn_relations": [], "sib_relations": ["DIGEORGE SYNDROME"], "wiki_entities": ["Childhood obesity", "Gallbladder", "Biliary colic", "Fenofibrate", "Fever of unknown origin", "Obesity", "Inguinal hernia", "Non-alcoholic fatty liver disease", "Lactose intolerance", "Diverticulitis"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:17689", "canonical_name": "POP5 homolog, ribonuclease P/MRP subunit", "aliases": ["pop5", "pop5 homolog, ribonuclease p/mrp subunit", "pop5 gene"], "definition": "Ribonuclease P/MRP protein subunit POP5 is an enzyme that in humans is encoded by the POP5 gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["POP5 homolog, ribonuclease P/MRP subunit", "POP5 homolog, ribonuclease P/MRP subunit"], "sib_relations": [], "wiki_entities": ["POP5", "Chromosome 12 (human)", "POP4 (gene)", "POP1 (gene)", "POP7", "Heat-responsive protein 12", "Stress granule"], "mesh_synonynms": [], "dbpedia_synonyms": ["pop5 (gene)"]}, "target_ent": {"research_entity_id": "OMIM:609992", "canonical_name": "PROCESSING OF PRECURSOR 5, S. CEREVISIAE, HOMOLOG OF", "aliases": ["pop5", "processing of precursor 5, s. cerevisiae, homolog of", "hspc004"], "definition": "Mitochondrial-processing peptidase subunit beta is an enzyme that in humans is encoded by the PMPCB gene.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["PROCESSING OF PRECURSOR 5, S. CEREVISIAE, HOMOLOG OF", "PROCESSING OF PRECURSOR 5, S. CEREVISIAE, HOMOLOG OF", "PROCESSING OF PRECURSOR 5, S. CEREVISIAE, HOMOLOG OF", "PROCESSING OF PRECURSOR 5, S. CEREVISIAE, HOMOLOG OF"], "sib_relations": [], "wiki_entities": ["Exonuclease", "PMPCB", "PMPCA", "Translocase of the outer membrane", "NIP7", "MLH1", "Michael Rosbash", "RRS1", "POP7", "ALG13"], "mesh_synonynms": [], "dbpedia_synonyms": ["pop5 (gene)"]}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D003009", "canonical_name": "Clorazepate Dipotassium", "aliases": ["monopotassium, clorazepate", "4306-cb", "chlorazepate, dipotassium", "chlorazepate", "tranxilium", "clorazepate monopotassium", "clorazepate dipotassium", "1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (k(oh)) (1:1)", "dipotassium, clorazepate", "dipotassium chlorazepate", "tranxene"], "definition": "Clorazepate (marketed under the brand names Tranxene and Novo-Clopate), also known as clorazepate dipotassium, is a benzodiazepine.", "other_contexts": ["Clorazepate dipotassium (Tranxilium) is one of the benzodiazepines which is widely used for oral premedication.", "As primary premedication they received either zolpidem 8.03 mg or zolpidem 16.06 mg or dipotassium clorazepate 10 mg or dipotassium clorazepate 20 mg or placebo.", "Value of a single night-time dose of potassium clorazepate in anxiety: a controlled trial comparison with diazepam.", "The single-dose regime of potassium clorazepate was significantly better, both for clinical effectiveness and patient acceptance.", "In the potassium clorazepate treated group there were significantly fewer side-effects.", "[Optimizing anesthesiologic premedication with reference to biopsychological theories. Exemplified by the effect of dipotassium clorazepate and zolpidem in combination with promethazine].", "The premedication for group II consisted in clorazepate dipotassium, 50 mg on the evening before operation and 25 mg on the morning of the day of the operation.", "Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate .", "When given in single doses of 20 - 30 mg at night it has an equivalent effect to dipotassium clorazepate 15 mg .", "Divided into four groups according to different kind and cause of disorder, 240 patients showing psychosomatic disorders have been treated with chlorazepate dipotassium only or in combination with clomipramine and dihydroergotamine tartrate ambulant or in hospital, depending on the degree of severity of the disorder.", "A total of 29 patients with anxiety or anxiety/hysteria, participated in a double-blind, cross-over trial of two benzodiazepine anxiolytics, diazepam and potassium clorazepate.", "However , a better quality of sleep was seen under zolpidem and dipotassium clorazepate compared with placebo .", "The sedative effects also show qualitative differences: in patients who completed the assessment lorazepam caused mainly daylong sedation and potassium clorazepate mid-day sedation, and when asked for their opinion on the value of sedation, only the potassium clorazepate group considered it to be beneficial.", "Differential behavioral profile induced by the injection of dipotassium chlorazepate within brain areas that project to the nucleus accumbens septi.", "Pharmacokinetic investigations concerning possible interactions of an orally administered single dosage of 20 mg dipotassium clorazepate and ethanol were conducted with 14 male subjects.", "In the AMY injected group TSOA, OAE and EA were increased by the higher doses of dipotassium chlorazepate (p < 0.01).", "Effect of N-desmethyldiazepam (nordiazepam) and a precursor, potassium clorazepate, on sleep in man. 1", "[Comparison of the effectiveness of orally administered clorazepate dipotassium and nordiazepam on preoperative anxiety].", "[ The role of chlorazepate dipotassium ( Tranxilium ) in the therapy of psychosomatic syndromes ( author 's transl ) ] .", "With 101 clinically treated cases of cyclothymic depression good results were obtained with combined treatment with chlorazepate dipotassium while reducing the dose of the antidepressant.", "The combination of the usual dihydroergotamine tartrate medication with a chlorazepate dipotassium treatment over several months showed longlasting good therapeutic results, confirmed by follow-up examinations, in 31 out of 40 cases with migraine respectively vasomotor headache.", "[2] who used 50 mg of clorazepate dipotassium on the evening before and 25 mg on the morning of the day of the operation.", "METHODS Three rat groups received either saline or dipotassium chlorazepate ( 1 or 2 μg/1 μl solution ) 15 min before testing .", "[Oral premedication with clorazepate dipotassium.", "Patients who received premedication with clorazepate dipotassium are less anxious on the morning of the operation than patients given flunitrazepam the evening before the operation (P < 0.05); this, however, does not correspond to the VAS results.", "The intention of this study was to examine whether clorazepate dipotassium has the same sedative-hypnotic and anxiolytic effects as i.m.", "DISCUSSION Oral premedication with clorazepate dipotassium has the same sedative-hypnotic, anxiolytic and amnestic effects as i.m.", "Only 2 patients stopped treatment because of the sedative effect of potassium clorazepate.", "1 Forty - four clinically anxious patients entered a comparative double - blind trial of clobazam 20 mg , clobazam 30 mg and dipotassium clorazepate 15 mg , all drugs given as a single dose at night . 2 Assessment by the Hamilton Anxiety Scale , Morbid Anxiety Inventory ( Salkind ) and a Visual Analogue Scale showed a statistically significant improvement for all treatment groups after 2 weeks , with continued improvement after a further 2 weeks .", "Dosages were: clorazepate dipotassium: body weight < 55 kg: 10 mg; body weight > 55 kg: 20 mg; nordiazepam: 1 gtt/kg; 5 mg = 24 gtt).", "[Pharmacokinetic studies on interactions between dipotassium clorazepate and alcohol after oral application (author's transl)].", "There were four groups: 1) E no medication; M clorazepate dipotassium; 2) E no medication; M nordiazepam; 3) E clorazepate dipotassium; M clorazepate dipotassium, 4) E clorazepate dipotassium; M nordiazepam.", "The effect of N-desmethyldiazepam (nordiazepam, 5 and 10 mg) and potassium clorazepate (15 mg, a precursor of nordiazepam) on sleep was studied in six healthy adult males.", "We conclude that orally administered clorazepate dipotassium and nordiazepam have a similar effect on preoperative anxiety.", "CONCLUSION We conclude that the injection of dipotassium chlorazepate has a differential effect depending of the brain area , leading to facilitatory and inhibitory effects on anxiety processing .", "RESULTS No differing effects of zolpidem and dipotassium clorazepate on preoperative mood were found .", "Two new benzodiazepines, potassium clorazepate (15 mg. at night), and lorazepam (1 mg. t.d.s.) were compared in 50 patients presenting with anxiety in general practice.", "Patient acceptance as a factor in the effectiveness of treatment: an open assessment of potassium clorazepate ('Tranxene') and lorazepam in anxiety.", "Blood alcohol concentrations did not appear to be influenced by dipotassium clorazepate or its metabolites nordiazepam and oxazepam.", "The same result was obtained with 63 patients suffering from severe neurasthenic exhaustion and 13 patients with general neurodystonic symptoms treated with chlorazepate dipotassium only ."], "par_relations": ["Clorazepate Dipotassium", "Benzodiazepines", "Anticonvulsants", "Anti-Anxiety Agents", "GABA Modulators", "Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium"], "chd_relations": ["Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium", "Noctran"], "syn_relations": ["Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium", "Clorazepate Dipotassium"], "sib_relations": ["Clorazepate Dipotassium", "Alprazolam", "Benzodiazepinones", "Chlordiazepoxide", "Estazolam", "Medazepam", "Midazolam", "Triazolam", "Clorazepate Dipotassium"], "wiki_entities": ["Clorazepate", "Canine epileptoid cramping syndrome", "List of drugs: Df-Di", "California Proposition 65 list of chemicals", "Midazolam", "Drugs controlled by the German Betäubungsmittelgesetz", "List of MeSH codes (D03)"], "mesh_synonynms": ["tranxilium", "dipotassium chlorazepate", "chlorazepate", "clorazepate dipotassium", "tranxene", "chlorazepate, dipotassium", "4306-cb", "clorazepate monopotassium", "dipotassium, clorazepate", "monopotassium, clorazepate"], "dbpedia_synonyms": ["clorazepate"]}, "target_ent": {"research_entity_id": "RXNORM:2607", "canonical_name": "Clorazepate Dipotassium", "aliases": ["clorazepate dipotassium"], "definition": "Clorazepate (marketed under the brand names Tranxene and Novo-Clopate), also known as clorazepate dipotassium, is a benzodiazepine.", "other_contexts": ["Only 2 patients stopped treatment because of the sedative effect of potassium clorazepate .", "Clorazepate dipotassium (Tranxilium) is one of the benzodiazepines which is widely used for oral premedication.", "Patient acceptance as a factor in the effectiveness of treatment : an open assessment of potassium clorazepate ( ' Tranxene ' ) and lorazepam in anxiety .", "As primary premedication they received either zolpidem 8.03 mg or zolpidem 16.06 mg or dipotassium clorazepate 10 mg or dipotassium clorazepate 20 mg or placebo .", "The premedication for group II consisted in clorazepate dipotassium, 50 mg on the evening before operation and 25 mg on the morning of the day of the operation.", "[Optimizing anesthesiologic premedication with reference to biopsychological theories. Exemplified by the effect of dipotassium clorazepate and zolpidem in combination with promethazine].", "In the potassium clorazepate treated group there were significantly fewer side - effects .", "Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate .", "Divided into four groups according to different kind and cause of disorder, 240 patients showing psychosomatic disorders have been treated with chlorazepate dipotassium only or in combination with clomipramine and dihydroergotamine tartrate ambulant or in hospital, depending on the degree of severity of the disorder.", "When given in single doses of 20 - 30 mg at night it has an equivalent effect to dipotassium clorazepate 15 mg .", "However, a better quality of sleep was seen under zolpidem and dipotassium clorazepate compared with placebo.", "RESULTS No differing effects of zolpidem and dipotassium clorazepate on preoperative mood were found.", "Differential behavioral profile induced by the injection of dipotassium chlorazepate within brain areas that project to the nucleus accumbens septi.", "Effect of N-desmethyldiazepam (nordiazepam) and a precursor, potassium clorazepate, on sleep in man. 1", "In the AMY injected group TSOA, OAE and EA were increased by the higher doses of dipotassium chlorazepate (p < 0.01).", "[ Oral premedication with clorazepate dipotassium .", "[Comparison of the effectiveness of orally administered clorazepate dipotassium and nordiazepam on preoperative anxiety].", "With 101 clinically treated cases of cyclothymic depression good results were obtained with combined treatment with chlorazepate dipotassium while reducing the dose of the antidepressant.", "[ The role of chlorazepate dipotassium ( Tranxilium ) in the therapy of psychosomatic syndromes ( author 's transl ) ] .", "The single - dose regime of potassium clorazepate was significantly better , both for clinical effectiveness and patient acceptance .", "Value of a single night - time dose of potassium clorazepate in anxiety : a controlled trial comparison with diazepam .", "[ Pharmacokinetic studies on interactions between dipotassium clorazepate and alcohol after oral application ( author 's transl ) ] .", "[2] who used 50 mg of clorazepate dipotassium on the evening before and 25 mg on the morning of the day of the operation.", "The combination of the usual dihydroergotamine tartrate medication with a chlorazepate dipotassium treatment over several months showed longlasting good therapeutic results, confirmed by follow-up examinations, in 31 out of 40 cases with migraine respectively vasomotor headache.", "METHODS Three rat groups received either saline or dipotassium chlorazepate ( 1 or 2 μg/1 μl solution ) 15 min before testing .", "Patients who received premedication with clorazepate dipotassium are less anxious on the morning of the operation than patients given flunitrazepam the evening before the operation (P < 0.05); this, however, does not correspond to the VAS results.", "Pharmacokinetic investigations concerning possible interactions of an orally administered single dosage of 20 mg dipotassium clorazepate and ethanol were conducted with 14 male subjects .", "The intention of this study was to examine whether clorazepate dipotassium has the same sedative-hypnotic and anxiolytic effects as i.m.", "DISCUSSION Oral premedication with clorazepate dipotassium has the same sedative-hypnotic, anxiolytic and amnestic effects as i.m.", "1 Forty - four clinically anxious patients entered a comparative double - blind trial of clobazam 20 mg , clobazam 30 mg and dipotassium clorazepate 15 mg , all drugs given as a single dose at night . 2 Assessment by the Hamilton Anxiety Scale , Morbid Anxiety Inventory ( Salkind ) and a Visual Analogue Scale showed a statistically significant improvement for all treatment groups after 2 weeks , with continued improvement after a further 2 weeks .", "Dosages were: clorazepate dipotassium: body weight < 55 kg: 10 mg; body weight > 55 kg: 20 mg; nordiazepam: 1 gtt/kg; 5 mg = 24 gtt).", "The effect of N-desmethyldiazepam (nordiazepam, 5 and 10 mg) and potassium clorazepate (15 mg, a precursor of nordiazepam) on sleep was studied in six healthy adult males.", "CONCLUSION We conclude that the injection of dipotassium chlorazepate has a differential effect depending of the brain area , leading to facilitatory and inhibitory effects on anxiety processing .", "We conclude that orally administered clorazepate dipotassium and nordiazepam have a similar effect on preoperative anxiety.", "Two new benzodiazepines, potassium clorazepate (15 mg. at night), and lorazepam (1 mg. t.d.s.) were compared in 50 patients presenting with anxiety in general practice.", "The sedative effects also show qualitative differences : in patients who completed the assessment lorazepam caused mainly daylong sedation and potassium clorazepate mid - day sedation , and when asked for their opinion on the value of sedation , only the potassium clorazepate group considered it to be beneficial .", "There were four groups : 1 ) E no medication ; M clorazepate dipotassium ; 2 ) E no medication ; M nordiazepam ; 3 ) E clorazepate dipotassium ; M clorazepate dipotassium , 4 ) E clorazepate dipotassium ; M nordiazepam .", "A total of 29 patients with anxiety or anxiety / hysteria , participated in a double - blind , cross - over trial of two benzodiazepine anxiolytics , diazepam and potassium clorazepate .", "Blood alcohol concentrations did not appear to be influenced by dipotassium clorazepate or its metabolites nordiazepam and oxazepam.", "The same result was obtained with 63 patients suffering from severe neurasthenic exhaustion and 13 patients with general neurodystonic symptoms treated with chlorazepate dipotassium only ."], "par_relations": ["clorazepate"], "chd_relations": ["Tranxene", "Gen-xene"], "syn_relations": [], "sib_relations": ["Clorazepate Dipotassium 15 MG", "Clorazepate Dipotassium 22.5 MG", "Clorazepate Dipotassium 7.5 MG", "Clorazepate Dipotassium 3.75 MG", "Clorazepate Dipotassium 5 MG", "Clorazepate Dipotassium 20 MG", "Clorazepate Dipotassium 10 MG", "Clorazepate Dipotassium 50 MG", "Clorazepate Dipotassium 2.5 MG", "Clorazepate Dipotassium 11.3 MG"], "wiki_entities": ["Clorazepate", "Canine epileptoid cramping syndrome", "List of drugs: Df-Di", "California Proposition 65 list of chemicals", "Midazolam", "Drugs controlled by the German Betäubungsmittelgesetz", "List of MeSH codes (D03)"], "mesh_synonynms": ["tranxilium", "dipotassium chlorazepate", "chlorazepate", "tranxene", "chlorazepate, dipotassium", "4306-cb", "clorazepate monopotassium", "dipotassium, clorazepate", "monopotassium, clorazepate"], "dbpedia_synonyms": ["clorazepate"]}, "label": 1}
{"source_ent": {"research_entity_id": "HPO:HP:0008110", "canonical_name": "Equinovarus deformity", "aliases": ["equinovarus deformity"], "definition": "In orthopedics, a varus deformity is an inward angulation (medial angulation, that is, toward the body's midline) of the distal segment of a bone or joint.", "other_contexts": [], "par_relations": ["Abnormality of the foot"], "chd_relations": [], "syn_relations": [], "sib_relations": ["Pes planus", "Podagra", "Contractures involving the joints of the feet", "Split foot", "Long foot", "Narrow foot", "Pes cavus", "Valgus foot deformity", "Abnormality of the tarsal bones", "Broad foot", "Medial deviation of the foot", "Abnormality of toe", "Medial rotation of the medial malleolus", "Abnormality of the plantar skin of foot", "Abnormal foot bone ossification", "Abnormality of the Achilles tendon", "Abnormality of dorsoventral patterning of the limbs", "Foot asymmetry", "Structural foot deformity", "Synostosis involving bones of the feet", "Duplication involving bones of the feet", "Osteolysis involving bones of the feet", "Ankylosis of feet small joints", "Aplasia/Hypoplasia involving bones of the feet", "Positional foot deformity", "Osteomyelitis or necrosis, distal, due to sensory neuropathy (feet)", "Autoamputation of foot", "Abnormality of the metatarsal bones"], "wiki_entities": ["Varus deformity", "Clubfoot", "PES", "Varus", "Clubbing", "Singleton Merten syndrome", "Astragalectomy", "List of diseases (T)", "Index of trauma & orthopaedics articles", "Ehlers–Danlos syndromes"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:MTHU013305", "canonical_name": "Equinovarus deformity", "aliases": ["equinovarus deformity"], "definition": "In orthopedics, a varus deformity is an inward angulation (medial angulation, that is, toward the body's midline) of the distal segment of a bone or joint.", "other_contexts": [], "par_relations": ["Feet"], "chd_relations": [], "syn_relations": [], "sib_relations": ["DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE"], "wiki_entities": ["Varus deformity", "Clubfoot", "PES", "Varus", "Clubbing", "Singleton Merten syndrome", "Astragalectomy", "List of diseases (T)", "Index of trauma & orthopaedics articles", "Ehlers–Danlos syndromes"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
{"source_ent": {"research_entity_id": "HGNC:HGNC:28945", "canonical_name": "WD repeat domain 43", "aliases": ["kiaa0007", "utp5", "wdr43", "wdr43 gene", "net12", "utp5, small subunit (ssu) processome component, homolog (yeast)", "wd repeat domain 43"], "definition": "The WD40 repeat (also known as the WD or beta-transducin repeat) is a short structural motif of approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) dipeptide.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["WD repeat domain 43", "WD repeat domain 43", "WD repeat domain 43", "WD repeat domain 43", "WD repeat domain 43", "WD repeat domain 43", "WD repeat domain 43", "WD repeat domain 43"], "sib_relations": [], "wiki_entities": ["WD40 repeat", "Bromodomain and WD repeat-containing protein 3", "Apoptosome", "Joomyeong Kim", "APC/C activator protein CDH1", "FBXW2", "KIAA0090", "NBEAL1", "Chromosome 19 (human)", "CD18"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "target_ent": {"research_entity_id": "OMIM:616195", "canonical_name": "WD REPEAT-CONTAINING PROTEIN 43", "aliases": ["wd repeat-containing protein 43", "wdr43", "utp5", "kiaa0007"], "definition": "The WD40 repeat (also known as the WD or beta-transducin repeat) is a short structural motif of approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) dipeptide.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["WD REPEAT-CONTAINING PROTEIN 43", "WD REPEAT-CONTAINING PROTEIN 43", "WD REPEAT-CONTAINING PROTEIN 43", "WD REPEAT-CONTAINING PROTEIN 43", "WD REPEAT-CONTAINING PROTEIN 43", "WD REPEAT-CONTAINING PROTEIN 43"], "sib_relations": [], "wiki_entities": [], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 1}
{"source_ent": {"research_entity_id": "MSH:D003317", "canonical_name": "Corneal Dystrophies, Hereditary", "aliases": ["corneal dystrophy, hereditary", "corneal macular dystrophies", "dystrophies, corneal macular", "dystrophies, corneal granular", "macular dystrophies, corneal", "corneal stromal dystrophies", "corneal macular dystrophy", "dystrophies, hereditary corneal", "granular dystrophies, corneal", "corneal stromal dystrophy", "stromal dystrophies, corneal", "groenouw's dystrophies", "granular dystrophy, corneal", "corneal dystrophies, hereditary", "groenouw dystrophies", "hereditary corneal dystrophy", "stromal dystrophy, corneal", "groenouws dystrophies", "dystrophy, corneal stromal", "dystrophy, hereditary corneal", "corneal granular dystrophy", "dystrophies, corneal stromal", "macular dystrophy, corneal", "hereditary corneal dystrophies", "dystrophy, corneal macular", "dystrophies, groenouw's", "dystrophy, corneal granular", "corneal granular dystrophies"], "definition": "Corneal dystrophy is a group of rare hereditary disorders characterised by bilateral abnormal deposition of substances in the transparent front part of the eye called the cornea.", "other_contexts": [], "par_relations": ["Corneal Diseases", "Eye Diseases, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary"], "chd_relations": ["Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Fuchs' Endothelial Dystrophy", "Corneal Dystrophy, Juvenile Epithelial of Meesmann", "Corneal Dystrophy, Band-Shaped", "Corneal Dystrophy, Crystalline, of Schnyder", "Corneal dystrophy, gelatinous drop-like", "Corneal dystrophy of Bowman layer, type 1", "Corneal Dystrophy, Posterior Polymorphous, 1", "Macular Dystrophy, Retinal, 2", "Dermochondrocorneal dystrophy of François", "Macular dystrophy, retinal, 1, North Carolina type", "Oculodental syndrome Rutherfurd syndrome", "Ichthyosiform erythroderma, corneal involvement, deafness", "Corneal dystrophy Avellino type", "Corneal Dystrophy, Fleck", "Corneal dystrophy, Thiel-Behnke type", "Meretoja syndrome", "Corneal Dystrophy, Central Type", "Macular dystrophy, corneal type 1", "Groenouw type I corneal dystrophy", "Lattice corneal dystrophy type 1", "Macular Corneal Dystrophy, Type II", "Chorioretinal atrophy, progressive bifocal", "Macular Dystrophy, Fenestrated Sheen Type", "Corneal Dystrophy, Posterior Polymorphous, 3", "Congenital Corneal Opacities, Cornea Guttata, and Corectopia", "Corneal Dystrophy, Lattice Type IIIA", "Mousa Al din Al Nassar syndrome", "Corneal cerebellar syndrome", "Corneodermatoosseous syndrome", "Epithelial Recurrent Erosion Dystrophy", "Corneal Degeneration, Ribbonlike, with Deafness", "Corneal Dystrophy, Posterior Polymorphous, 2", "Endothelial Dystrophy, Congenital Hereditary, with Nail Hypoplasia", "Corneal endothelial dystrophy type 2", "Corneal dystrophy and perceptive deafness", "Bietti Crystalline Dystrophy", "Brachymesomelia renal syndrome", "Sveinsson Chorioretinal Atrophy", "Corneal Dystrophy, Congenital Stromal", "Spondyloepiphyseal Dysplasia With Punctate Corneal Dystrophy", "Corneal Dystrophy, Posterior Amorphous", "Corneal Dystrophy, Subepithelial Mucinous", "Corneal Dystrophy, Endothelial, X-Linked", "Corneal Dystrophy, Lisch Epithelial", "Pseudoinflammatory fundus dystrophy, Finnish type", "Sammartino De Crecchio Syndrome", "Judge Misch Wright syndrome", "O'Donnell Pappas syndrome", "Kuster Majewski Hammerstein syndrome", "Corneal Endothelial Dystrophy 1"], "syn_relations": ["Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary", "Corneal Dystrophies, Hereditary"], "sib_relations": ["Corneal Dystrophies, Hereditary", "Albinism", "Aniridia", "Choroideremia", "Corneal Edema", "Corneal Opacity", "Duane Retraction Syndrome", "Gyrate Atrophy", "Keratitis", "Keratoconus", "Optic Atrophies, Hereditary", "Retinal Dysplasia", "Retinitis Pigmentosa", "Trachoma", "Corneal Neovascularization", "Aicardi Syndrome", "Walker-Warburg Syndrome", "Weill-Marchesani Syndrome", "Graves Ophthalmopathy", "Corneal Injuries", "Vitelliform Macular Dystrophy", "Leber Congenital Amaurosis", "Iridocorneal Endothelial Syndrome", "Corneal Endothelial Cell Loss", "Corneal Wavefront Aberration", "Cone-Rod Dystrophies", "Corneal Dystrophies, Hereditary"], "wiki_entities": ["Corneal dystrophy", "Lattice corneal dystrophy", "Schnyder crystalline corneal dystrophy", "Congenital hereditary endothelial dystrophy", "Thiel–Behnke dystrophy", "Eye disease", "Keratoconus", "List of ICD-9 codes 360–389: diseases of the sense organs", "Primary juvenile glaucoma", "Descemet's membrane"], "mesh_synonynms": ["dystrophy, corneal macular", "granular dystrophies, corneal", "hereditary corneal dystrophies", "stromal dystrophy, corneal", "dystrophies, groenouw's", "groenouw's dystrophies", "corneal macular dystrophy", "dystrophy, corneal granular", "dystrophies, corneal granular", "hereditary corneal dystrophy", "corneal stromal dystrophy", "corneal dystrophies, hereditary", "macular dystrophy, corneal", "corneal granular dystrophy", "corneal macular dystrophies", "corneal dystrophy, hereditary", "corneal stromal dystrophies", "macular dystrophies, corneal", "corneal granular dystrophies", "groenouw dystrophies", "dystrophy, hereditary corneal", "dystrophy, corneal stromal", "groenouws dystrophies", "dystrophies, corneal stromal", "dystrophies, corneal macular", "stromal dystrophies, corneal", "granular dystrophy, corneal", "dystrophies, hereditary corneal"], "dbpedia_synonyms": ["corneal dystrophy"]}, "target_ent": {"research_entity_id": "OMIM:121900", "canonical_name": "CORNEAL DYSTROPHY, GROENOUW TYPE I", "aliases": ["cdgg1", "granular corneal dystrophy, type i", "corneal dystrophy, punctate or nodular", "corneal dystrophy, groenouw type i", "gcd1"], "definition": "Granular corneal dystrophy is a slowly progressive corneal dystrophy that most often begins in early childhood.", "other_contexts": [], "par_relations": [], "chd_relations": [], "syn_relations": ["CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I", "CORNEAL DYSTROPHY, GROENOUW TYPE I"], "sib_relations": [], "wiki_entities": ["Granular corneal dystrophy", "Macular corneal dystrophy", "Arthur Groenouw", "List of genetic disorders"], "mesh_synonynms": [], "dbpedia_synonyms": []}, "label": 0}
